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Abbreviations	   	  5-­‐HT	   5-­‐hydroxytryptamine;	  serotonin	  A	   adenine	  aa	   amino	  acid	  
Aass	   aminoadipate-­semialdehyde	  synthase	  
Abcb1a	   ATP-­binding	  cassette,	  sub-­family	  B	  (MDR/TAP),	  member	  1A	  
Actb	   beta	  actin	  ad	   autosomal	  dominant	  
Adm	   adrenomedullin	  
Agtrl1	   angiotensin	  receptor-­like	  1	  AMD	   age	  related	  macula	  degeneration	  
ApoD	   apolipoprotein	  D	  ar	   autosomal	  recessive	  ARVO	   Association	  for	  Research	  in	  Vision	  and	  Ophthalmology	  β-­‐ME	   2-­‐mercaptoethanol	  BCA	   bicinchoninic	  acid	  	  BLAST	   Basic	  Local	  Alignment	  Search	  Tool	  BLAT	   BLAST-­‐Like	  Alignment	  Tool	  
Bmp4	   bone	  morphogenetic	  protein	  4	  bp	   basepair/s	  BSA	   bovine	  serum	  albumin	  C	   cytosine	  
Ctnnb1	   β-­‐catenin	  CB	   ciliary	  body	  CD	   Coats’	  disease	  CDS	   coding	  sequence	  cDNA	   complementary	  DNA	  
Centd3	   centaurin,	  delta	  3	  ChAT	   choline	  acetyltransferase	  
Cldn5	   claudin	  5	  CNS	   central	  nervous	  system	  CNV	   copy	  number	  variation	  Ct	   cycle	  threshold	  ddH2O	   double	  distilled	  water	  ddNTP	   dideoxy	  nucleotide-­‐triphosphate	  DAPI	   4’,6-­‐diamidino-­‐2-­‐phenylindole	  (fluorescent	  dye	  labeling	  DNA)	  DEPC	   diethylpyrocarbonate	  DKK	   dickkopf	  DNA	   deoxyribonucleic	  acid	  DNase	   deoxyribonuclease	  dNTP	   deoxy	  nucleotide-­‐triphosphate	  DTT	   dithiothreitol	  /	  Cleland’s	  reagent	  EB	   elution	  buffer	  (10	  mM	  Tris-­‐HCl,	  pH	  8.5)	  ED	   Eales’	  disease	  EDTA	   ethylenediaminetetraacetic	  acid	  	  EGF	   epidermal	  growth	  factor	  EJN	   European	  Journal	  of	  Neuroscience	  EM	   electron	  microscope	  ENU	   N-­‐ethyl-­‐N-­‐nitrosourea	  (a	  potent	  mutagen)	  ERG	   electroretinography	  ESE	   exonic	  splice	  enhancer	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ESR	   exonic	  splicing	  regulatory	  elements	  EtBR	   ethidium	  bromide	  EtOH	   ethanol	  EVR	   exudative	  vitreoretinopathy	  FEVR	   familial	  exudative	  vitreoretinopathy	  FPLC	   fast	  protein	  liquid	  chromatography	  fwd	   forward	  FZD4	   frizzled	  homolog	  4	  G	   guanine	  Gapd	   glyceraldehyde-­‐3-­‐phosphate	  dehydrogenase	  gDNA	  	   genomic	  deoxyribonucleic	  acid	  HBM	   high	  bone	  mass	  HRP	   horseradish	  peroxidase	  IgG	   immunoglobulin	  G	  IHC	   immunohistochemistry	  IMAC	   immobilized	  metal	  ion	  affinity	  chromatography	  INL	   inner	  nuclear	  layer	  IOVS	   Investigative	  Ophthalmology	  and	  Vision	  Research	  IP	   Incontinentia	  pigmentii	  IPL	   inner	  plexiform	  layer	  IS	   inner	  segment	  kb	   kilobasepair/s	  kDa	   kilo	  Dalton	  ko	   knockout	  LB	   Luria-­‐Bertani	  broth,	  bacterial	  growth	  medium	  
Lef1	   lymphoid	  enhancer	  binding	  factor	  1	  LRP5	   low	  density	  lipoprotein	  receptor-­‐related	  protein	  5	  LRP5L	   low	  density	  lipoprotein	  receptor-­‐related	  protein	  5-­‐like	  M	   methionine	  or	  molar	  
MAOA/B	   mono	  amine	  oxidase	  A	  /	  B	  MAPK	   mitogen-­‐activated	  protein	  kinase	  MF	   manifesting	  female	  miRNA	   micro	  RNA	  min	   minutes	  MR	   mental	  retardation	  mRNA	   messenger	  RNA	  NCBI	   National	  Center	  for	  Biotechnology	  Information	  ND	   Norrie	  Disease	  
NDP	    Norrie	  disease	  pseudoglioma	  
Ndph	    Norrie	  disease	  pseudoglioma	  homolog	  NE	   norepinephrine	  NF	   neurofilament	  NFL	   nerve	  fiber	  layer	  NGS	   normal	  goat	  serum	  NMD	   nonsense-­‐mediated	  mRNA	  decay	  NSS	   non-­‐specific	  serum	  NV	   neovascularization	  OCT	   optimal	  cutting	  temperature	  OD562	   optical	  density	  at	  562nm	  OIR	   oxygen	  induced	  retinopathy	  OMIM	   Online	  Mendelian	  Inheritance	  in	  Man	  o/n	   over	  night	  ONL	   outer	  nuclear	  layer	  OPL	   outer	  plexiform	  layer	  OPPG	   osteoporosis	  pseudoglioma	  syndrome	  ORF	   open	  reading	  frame	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OS	   outer	  segment	  p7	   postnatal	  day	  7	  PAS	   polyadenylation	  signal	  PBS	   phospate	  buffered	  saline	  PBST	   phospate	  buffered	  saline	  with	  Tween®	  20	  PCR	   polymerase	  chain	  reaction	  pDNA	   plasmid	  DNA	  PI	   propidium	  iodide	  PFA	   paraformaldehyde	  
Pfu	   Pyrococcus	  furiosus	  PFV	   persistent	  fetal	  vasculature	  	  PHPV	   persistent	  hyperplastic	  primary	  vitreous	  	  Plvap	   plasmalemma	  vesicle	  associated	  protein	  
Pola2	   polymerase,	  alpha	  2	  	  
Prdm9	   VPR	  domain	  containing	  9	  PRDX	   primary	  retinal	  dysplasia,	  X-­‐linked	  PVDF	   polyvinyliden	  difluoride	  qRT-­‐PCR	  	   quantitative	  reverse	  transcription	  polymerase	  chain	  reaction	  RB	   retinoblastoma	  rev	   reverse	  RGC	   retinal	  ganglion	  cell	  layer	  RIN	   RNA	  integrity	  number	  RIPA	   radioimmunoprecipitation	  assay	  buffer	  RNA	   ribonucleic	  acid	  RNase	   ribonuclease	  ROP	   retinopathy	  of	  prematurity	  RP	   retinitis	  pigmentosa	  RPE	   retinal	  pigment	  epithelium	  rpm	   revolutions	  per	  minute	  rRNA	   ribosomal	  RNA	  RS	   retinoschisis	  RT	   room	  temperature	  RT-­‐PCR	   reverse	  transcription	  polymerase	  chain	  reaction	  SDS-­‐PAGE	   sodium	  dodecyl	  sulfate	  polyacrylamide	  gel	  electrophoresis	  
Slc38a5	   solute	  carrier	  family	  38,	  member	  5	  SNAT5	   amino	  acid	  transporter	  system	  N2	  (Slc38a5	  protein)	  SNP	   single	  nucleotide	  polymorphism	  T	   thymine	  or	  threonine	  TAE	   tris-­‐acetate	  /	  EDTA	  
Taq	   Thermus	  aquaticus	  polymerase	  
Tcf3	   transcription	  factor	  3	  (Tcf7l1)	  
Tcf7l2	   transcription	  factor	  7-­‐like	  2	  (Tcf4)	  TE	   tris-­‐EDTA	  TEMED	   tetramethylethylenediamine	  Tris	   2-­‐amino-­‐2-­‐hydroxymethyl-­‐propane-­‐1,3-­‐diol	  /	  (HOCH2)3CNH2	  U	   uracil	  UTR	   untranslated	  region	  (non-­‐coding	  part	  of	  an	  exon)	  VI	   venous	  insufficiency	  VPA	   valproic	  acid	  VRNI	   Neovascular	  inflammatory	  vitreoretinopathy	  
Vwf	   von	  Willebrand	  factor	  homolog	  WB	   Western	  blot	  WGA	   whole	  genome	  amplification	  
Wnt	   wingless-­‐related	  MMTV	  integration	  site	  family	  of	  genes	  wt	  	   wild	  type	  Xl	   X-­‐linked	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Summary	  	  Norrie	   disease	   (ND)	   is	   an	   X-­‐linked,	   recessive	   disorder	   that	   presents	   with	   congenital	  blindness,	  progressive	  deafness	  and,	  to	  a	  certain	  degree,	  mental	  retardation.	  It	  is	  caused	  by	   mutations	   in	   the	   Norrie	   disease	   pseudoglioma	   (NDP)	   gene,	   which	   has	   also	   been	  associated	   with	   a	   variety	   of	   other	   recessive	   and	   sporadic	   vitreoretinal	   diseases,	  including	   exudative	   vitreoretinopathy	   (EVR),	   retinopathy	   of	   prematurity	   (ROP,	   stages	  4b	  and	  5)	  and	  Coats’	  disease	  (CD).	  Mutations	  in	  norrin	  (the	  NDP–protein)	  cause	  a	  defect	  of	  vascular	  development	  in	  the	  retina,	  which	  secondarily	  leads	  to	  inner	  retinal	  hypoxia	  and	   the	  associated	  clinical	   features.	  Previously,	  norrin	  was	  shown	  to	  be	  a	  high	  affinity	  ligand	  of	  the	  receptor-­‐pair	  FZD4	  and	  LRP5,	  and	  to	  activate	  the	  canonical	  Wnt-­‐pathway	  in	  cell	  culture,	  eventually	  leading	  to	  transcriptional	  regulation	  of	  target	  genes.	  However,	   even	   though	   a	   possible	  molecular	  mechanism	   for	  Norrin	   signaling	  has	   been	  proposed,	  it	  is	  still	  unknown	  whether	  this	  pathway	  is	  actually	  affected	   in	  vivo,	  whether	  other	   pathways	  might	   be	   involved	   in	   the	   course	   of	   the	   pathogenesis,	   and	   how	  norrin	  contributes	   to	   the	  development	  of	   the	  retinal	  vasculature.	  To	  address	   these	  questions,	  several	   potential	   downstream	   target	   genes	   of	   norrin	   signaling	   were	   identified	   in	   the	  course	  of	  this	  thesis,	  differential	  Wnt-­‐signaling	  was	  investigated	  in	  a	  mouse	  model,	  and	  a	  small	  patient	  group	  was	  screened	  for	  mutations	  in	  candidate	  genes.	  The	  results	  confirm	  norrin’s	  role	   in	  blood	  vessel	  development,	  and	  help	  to	  explain	  not	  only	   the	  ocular,	  but	  also	   the	  brain	  phenotype.	  Expression	  of	   two	  genes,	  Plvap	   and	  Slc38a5,	   is	   considerably	  altered	  in	  retinal	  development	  of	  norrin	  knockout	  mice	  and	  may	  reflect	  or	  contribute	  to	  the	  pathogenesis	  of	   the	  disease.	   In	  particular,	  ectopic	  expression	  of	  Plvap	   is	  consistent	  with	   hallmark	   disease	   symptoms	   in	   mouse	   and	   man.	   Contrary	   to	   the	   cell	   culture	  findings,	   canonical	   Wnt-­‐signaling	   could	   not	   be	   shown	   to	   be	   prominently	   involved.	  Instead,	   involvement	   of	   other	   pathways,	   such	   as	   the	  mitogen-­‐activated	   protein	   kinase	  (MAPK)	   pathway	   and	   serotonin-­‐mediated	   signaling,	   are	   discussed.	   Several	   potential	  modifying	  genes	  for	  ND	  were	  identified,	  and	  recombinant	  norrin	  protein	  was	  produced	  in	  eukaryotic	  cells	  to	  facilitate	  functional	  and	  structural	  analyses	  in	  the	  future.	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Zusammenfassung	  Die	   Norrie	   Krankheit	   ist	   eine	   X-­‐chromosomal	   vererbte,	   rezessive	   Form	   angeborener	  Blindheit,	   die	   mit	   progressiver	   Schwerhörigkeit	   und	   in	   manchen	   Fällen	   mit	   geistiger	  Behinderung	   einhergeht.	   Sie	   wird	   durch	   Mutationen	   im	   NDP-­‐Gen	   (Norrie	   disease	  pseudoglioma)	  hervorgerufen,	  die	  auch	  mit	  einigen	  anderen	  rezessiven	  und	  spontanen	  Vitreoretinopathien	   assoziiert	  wurden,	   unter	   anderem	   exsudativer	   Vitreoretinopathie,	  Frühgeborenenretinopathie	   (Stadien	   4b	   und	   5)	   und	   Morbus	   Coats’.	   Mutationen	   in	  Norrin	   (dem	   NDP-­‐Protein)	   verursachen	   einen	   Defekt	   in	   der	   Entwicklung	   retinaler	  Blutgefässe,	   der	   sekundär	   zu	  Hypoxie	   in	   der	   inneren	  Netzhaut	   und	   den	   beobachteten	  klinischen	  Bildern	  führt.	  In	  Zellkulturexperimenten	  wurde	  zuvor	  gezeigt,	  dass	  Norrin	  ein	  hochaffiner	   Ligand	   für	   das	   Rezeptorenpaar	   FZD4	   und	   LRP5	   ist,	   und	   den	   kanonischen	  Wnt-­‐Signalweg	  aktivieren	  kann,	  was	  schliesslich	  zur	   transkriptionellen	  Regulation	  von	  Zielgenen	  führt.	  Doch	  obwohl	  ein	  möglicher	  molekularer	  Mechanismus	  für	  Norrin	  vorgeschlagen	  wurde,	  weiss	  man	   bisher	   nicht,	   ob	   dieser	   Signalweg	   auch	   tatsächlich	   in	   vivo	   betroffen	   ist,	   ob	  andere	  Kaskaden	   ebenfalls	   eine	  Rolle	   in	   der	   Pathogenese	   spielen,	   und	  wie	  Norrin	   zur	  Entwicklung	   des	   retinalen	   Gefässsystems	   beiträgt.	   Um	   diese	   Fragen	   zu	   beantworten,	  wurden	   im	   Laufe	   dieser	   Arbeit	   mehrere	   mögliche,	   durch	   Norrin	   regulierte	   Zielgene	  identifiziert,	  die	  Aktivität	  des	  Wnt-­‐Signalwegs	  in	  einem	  Mausmodell	  analysiert,	  und	  eine	  kleine	  Patientengruppe	  auf	  Mutationen	  in	  Kandidatengenen	  untersucht.	  Die	  Ergebnisse	  bestätigen	  Norrins	  Rolle	  in	  der	  Blutgefässentwicklung	  und	  helfen	  nicht	  nur	  den	  Augen-­‐,	  sondern	   auch	   den	   Gehirnphänotyp	   zu	   verstehen.	   Die	   deutlich	   veränderte	   Expression	  zweier	  Gene,	  Plvap	  und	  Slc38a5,	  während	  der	  Netzhautentwicklung	  in	  Norrin-­‐knockout	  Mäusen	  könnte	  den	  Krankheitsverlauf	  widerspiegeln	  oder	  sogar	  eine	  Beteiligung	  an	  der	  Pathogenese	   der	   Krankheit	   nahelegen.	   Speziell	   die	   ektopische	   Expression	   von	   Plvap	  stimmt	   mit	   Hauptsymptomen	   in	   Maus	   und	   Mensch	   überein.	   Im	   Gegensatz	   zu	   den	  Zellkulturresultaten	  konnte	  keine	  bedeutende	  Mitwirkung	  des	  Wnt-­‐Signalwegs	  gezeigt	  werden.	  Stattdessen	  wird	  die	  Beteiligung	  anderer	  Signalwege,	  wie	  z.B.	  der	  MAP-­‐Kinase-­‐	  Kaskade	   (mitogen-­‐activated	   protein)	   oder	   Serotonin-­‐vermittelter	   Signalübertragung,	  diskutiert.	   Mehrere	   mögliche	   Modifikatorgene	   für	   die	   Norrie	   Krankheit	   wurden	  identifiziert,	   und	   rekombinantes	   Norrin	   wurde	   in	   einem	   eukaryotischen	   Zellsystem	  hergestellt,	  um	  zukünftige	  funktionelle	  und	  strukturelle	  Analysen	  zu	  ermöglichen.	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1.	  Introduction	  
1.1	  The	  eye	  The	  eye	  probably	  is	  the	  most	  important	  sense	  organ	  for	  human	  beings.	  It	  enables	  us	  to	  detect	  light	  and	  provides	  us	  with	  rich	  and	  detailed	  vision,	  including	  the	  ability	  to	  detect	  location,	   size,	   shape,	   direction	   and	   speed	   of	   an	   object	   in	   our	   environment,	   to	  discriminate	  10	  million	  colors	  and,	  due	  to	  the	  binocular	  vision	  and	  the	  overlapping	  fields	  of	   sight,	   to	   perceive	   depth.	   Light	   enters	   the	   eye	   through	   the	   cornea,	   a	   specialized,	  transparent	  part	  of	  the	  sclera,	  which	  is	  the	  fibrous	  tissue	  that	  delineates	  and	  shapes	  the	  eyeball	   (Figure	   1).	   It	   then	   passes	   the	   pupil,	   an	   opening	   that	   can	   be	   adjusted	   in	   size	  through	  contraction	  of	  a	  circular	  muscle	  (the	  iris)	  to	  admit	  more	  or	  less	  light	  to	  enter	  the	  eye	  depending	  on	  environmental	  conditions.	  The	  light	  is	  then	  projected	  through	  the	  lens	  and	  the	  vitreous	  (the	  gel-­‐like	  content	  taking	  up	  most	  space	  in	  the	  eye)	  onto	  the	  retina,	  which	  is	  the	  sensory	  tissue	  lining	  the	  inner	  surface	  of	  the	  eye.	  Here,	  external	  light	  stimuli	  are	  translated	  into	  electrical	  pulses	  that	  are	  transmitted	  to	  the	  brain	  through	  the	  optic	  nerve.	  	  
	  
Figure	   1	   Schematic	  mid-­‐sagittal	   cross-­‐section	   of	   the	   human	   eye	   (Kolb,	   2003).	   The	   enlargement	   on	   the	  right	  side	  shows	  the	  layered	  structure	  of	  the	  retina.	  	  
1.1.1	  The	  retina	  The	  retina	  (including	  the	  optic	  nerve)	  develops	  from	  outgrowths	  of	  the	  embryonic	  brain	  and	  thus	   is	  considered	  part	  of	   the	  central	  nervous	  system	  (CNS).	   It	   is	  a	   thin	  structure,	  not	   thicker	   than	   0.5mm,	   which	   is	   organized	   in	   three	   neuronal	   and	   two	   synaptic	  (plexiform)	  layers.	  The	  outermost	  layer	  (outer	  nuclear	  layer;	  ONL)	  consists	  of	  two	  types	  of	  light	  sensitive	  photoreceptors:	  the	  rods	  and	  the	  cones.	  The	  ~120	  million	  rods	  in	  the	  human	   retina	   are	   responsible	   for	   dim	   light	   vision,	   while	   the	   ~7	   million	   cones	   are	  responsible	  for	  daylight	  and	  color	  vision.	  Curiously,	  the	  sensory	  cells	  in	  vertebrates	  are	  not	  located	  at	  the	  surface	  of	  the	  retina;	  in	  this	  inverted	  retina	  light	  has	  to	  pass	  through	  all	  downstream	  neurons	  before	  it	  reaches	  the	  light	  sensitve	  cells.	  One	  immediate	  reason	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is	  that	  the	  photoreceptors	  have	  to	  be	  in	  contact	  with	  the	  light	  absorbing	  retinal	  pigment	  epithelium	   (RPE),	   which	   restores	   the	   photopigment	   retinal.	   Retinal,	   or	   vitamin	   A	  aldehyde,	   is	   necessary	   for	   the	   conversion	   of	   electromagnetic	   radiation	   (light)	   into	  neuronal	   (electric)	   impulses.	  Without	   the	   direct	   contact	   between	   photoreceptors	   and	  pigment	   epithelium	   cells,	   the	   ablity	   to	   perceive	   light	   could	   not	   be	   maintained.	   The	  pigment	  granules	  of	  the	  RPE	  further	  prevent	  photoreceptors	  from	  radiation	  damage	  by	  absorbing	  excessive	  light.	  In	  the	  outer	  plexiform	  layer,	  visual	  information	  is	  then	  relayed	  through	   synapses	   between	   photoreceptors	   and	   interneurons	   located	   in	   the	   inner	  nuclear	   layer	   (INL),	   the	   bipolar	   cells.	   First	   stages	   of	   image	   processing	   are	   already	  performed	  at	  this	  synaptic	  level.	  In	  the	  inner	  plexiform	  layer	  (IPL),	  the	  bipolar	  cells	  then	  connect	   to	   retinal	   ganglion	   cells	   (RGC),	   whose	   axons	   constitute	   the	   optic	   nerve	   and	  transmit	  axon	  potentials	  to	  the	  visual	  centers	  in	  the	  brain.	  There	  are,	  however,	  about	  70	  different	   cell	   types	   in	   the	   retina,	   and	   the	   retinal	   circuitry	   is	   far	   more	   complex	   than	  described	  here.	  The	  retina	  has	   the	  highest	  oxygen	  demand	  of	  all	  human	   tissues	  and	   therefore	  needs	  a	  well-­‐developed	  blood	  supply	  (Yu	  et	  al.,	  2001).	  Therefore,	  the	  retina	  is	  supported	  by	  two	  blood	  vessel	  systems:	  the	  choroid	  and	  the	  retinal	  vasculature.	  The	  choroid	  vessel	  system	  lies	   between	   the	   RPE	   and	   the	   sclera	   and	   nourishes	   RPE	   and	   photoreceptor	   cells.	   The	  inner	   retina	   (ganglion	   cells	   and	  bipolar	   cells)	   is	   supplied	  by	   the	   retinal	   vasculature.	   It	  consists	   of	   three	   networks:	   A	   superficial	   network	   in	   the	   nerve	   fiber	   layer	   (above	   the	  ganglion	  cell	   layer);	  a	  deep	  network	  at	   the	  border	  from	  the	  INL	  to	  the	  outer	  plexiform	  layer;	  and	  an	   intermediate	  network	  at	   the	  border	   from	  the	   INL	   to	   the	   inner	  plexiform	  layer	  (Figure	  2).	  	  
	  
Figure	  2	  Schematic	  diagram	  of	  the	  development	  of	  the	  retinal	  vasculature	  (adapted	  from	  Xu	  and	  Wang	  et	  al.,	   2004).	   The	   superficial	   network	   emerges	   from	   the	   central	   artery/vein	   through	   radial	   outgrowth	   of	  vessels	  in	  the	  nerve	  fiber	  layer.	  Then,	  the	  deep	  vasculature	  starts	  to	  develop	  at	  the	  INL/OPL	  border	  after	  perpendicular	  sprouting	  of	  vessels	  into	  the	  retina.	  Finally,	  an	  intermediate	  plexus	  forms	  at	  the	  border	  of	  INL	  and	  IPL.	  OS:	  outer	  segment;	  IS:	   inner	  segment;	  ONL:	  outer	  nuclear	  (photoreceptor)	  layer;	  OPL:	  outer	  plexiform	  layer;	  INL:	   inner	  nuclear	  layer;	  IPL:	   inner	  plexiform	  layer;	  GCL:	  ganglion	  cell	   layer;	  NFL:	  nerve	  fiber	  layer	  	  
INTRODUCTION	   21	  	  
	  
1.2	  The	  brain	  The	  brain	  is	  the	  center	  of	  the	  nervous	  system	  and	  integrates	  sensory	  information	  with	  memory	   to	   generate	  behaviour	   in	   response	   to	   the	   environment.	  While	   the	   function	  of	  single	  nerve	  cells	  and	  their	  synapses	  is	  considerably	  understood,	  comprehension	  of	  the	  complex	   neural	   network	   of	   ~100	   billion	   neurons	   in	   the	   human	   is	   demanding,	   and	   is	  subject	   of	   uncounted	   studies	   investigating	   cognitive	   functions	   in	   development	   and	  disease.	   The	   brain	   can	   be	   divided	   in	   numerous	   areas	   that	   are	   morphologically	   and	  functionally	  distinct.	  In	  the	  following	  paragraph,	  I	  want	  to	  adress	  some	  selected	  regions	  that	  are	  of	  interest	  in	  this	  work	  (Figure	  3).	  The	   cortex	   is	   the	   outermost	   layer	   of	   the	   forebrain,	   and	   is	   important	   for	   awareness,	  consciousness,	  memory,	   thought,	   and	   language.	   It	   is	   the	   phylogenetically	  most	   recent	  part	   of	   the	   brain,	   and	   distinguishes	   mammals	   from	   lower	   vertebrates	   by	   facilitating	  enhanced	  cognitive	  functions.	  Further	  evolutionary	  gain	  of	  brain	  mass	  lead	  to	  folding	  of	  the	   cortex	   in	   higher	  mammals,	  which	   is	   a	   conspicuous	  difference	   between	   the	   human	  and	   the	  mouse	  brain.	  The	  hippocampus	   is	   a	  morphologically	  well	  defined	  structure	  of	  the	  forebrain,	  and	  is	  located	  beneath	  the	  cortical	  surface.	  It	  is	  primarily	  involved	  in	  long-­‐term	   memory	   and	   spatial	   navigation.	   The	   part	   of	   the	   brain	   mainly	   known	   to	   be	  important	   for	  motion	   control	   and	   integration	  of	   sensory	  perception	   is	   the	   cerebellum,	  although	  it	  has	  also	  been	  shown	  to	  be	  involved	  in	  attention	  and	  memory.	  The	  olfactory	  bulb,	  the	  most	  rostral	  part	  of	  the	  murine	  brain,	  relays	  sensory	  information	  about	  odors	  from	   the	   nose	   to	   the	   brain,	   and	   is	   necessary	   for	   smelling.	   The	   brain	   stem	   is	   the	  evolutionary	  oldest	  part	  of	   the	  brain	  and	   in	  mammals	   is	   important	   for	  controlling	  and	  maintaining	   basic	   body	   functions,	   like	   regulation	   of	   cardiac	   and	   respiratory	   function,	  consciousness	   and	   the	   sleep-­‐wake	   cycle.	   The	   pituitary	   gland	   is	   an	   endocrine	   gland	  located	   inferior	   to	   the	   hypothalamus,	   to	  which	   it	   is	   functionally	   linked,	   and	   regulates	  numerous	   body	   functions	   like	   growth	   or	   blood	   pressure	   through	   the	   production	   of	  hormones.	  	  
1.2.1	  The	  cerebellum	  The	  cerebellum	  receives	  input	  from	  the	  brainstem	  and	  engages	  in	  movement	  control	  by	  projecting	   to	  all	  upper	  motor	  neurons	  via	   the	  deep	  cerebellar	  nuclei.	  This	   information	  flow	  through	  the	  cerebellum	  is	  modulated	  by	  a	  feedback	  system	  located	  in	  the	  cerebellar	  cortex	   (Figure	   3	   D).	   In	   contrast	   to	   the	   cerebral	   neocortex,	   which	   is	   organized	   in	   six	  horizontal	   layers,	   the	   cerebellar	   cortex	   can	   be	   divided	   in	   three	   layers.	   The	   innermost	  layer	   is	   the	   granular	   layer,	   which	   contains	   granule	   and	   Golgi	   cells.	   The	   granule	   cells	  receive	  their	  excitatory	  input	  from	  Mossy	  fibers,	  which	  also	  signal	  on	  the	  deep	  cerebellar	  nuclei,	  and	  receive	  negative	  feedback	  through	  Golgi	  cells.	  Granule	  and	  Golgi	  cells	  project	  axons	   into	   the	   outermost	   cerebellar	   layer,	   the	  molecular	   layer.	   Projections	   of	   granule	  cells,	   also	   known	   as	   parallel	   fibers,	   form	   hundreds	   of	   thousands	   of	   glutamatergic	  synapses	   with	   Purkinje	   cell	   dendrites.	   These	   cells	   make	   up	   the	   middle	   layer	   of	   the	  cerebellar	  cortex,	  the	  Purkinje	  cell	  layer.	  They	  are	  exceptionally	  large	  and	  represent	  the	  main	   integrative	   neurons	   of	   the	   cerebellum,	   projecting	   back	   on	   the	   deep	   cerebellar	  nuclei	  to	  form	  inhibitory	  (GABAergic)	  synapses.	  Purkinje	  cells	  also	  receive	  direct	  input	  from	  the	  brain	  stem	  via	  climbing	  fibers,	  which	  in	  contrast	  to	  parallel	  fibers	  only	  contact	  a	   single	   Purkinje	   cell.	   Besides	   the	   enormous	   dendritc	   trees	   of	   the	   Purkinje	   cells,	   the	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Figure	  3	  The	  mouse	  brain.	  (A)	  Superior	  view	  of	  an	   isolated	  mouse	  brain	  (source:	  www.nervenet.org).	  Note	  the	  smooth	  appearance	  of	  the	  cortex,	  which	  in	  contrast	  is	  folded	  in	  humans.	  (B)	  Nissl-­‐stained	  sagittal	  section	   through	   a	   mouse	   brain.	   Rostral	   is	   on	   the	   left,	   superior	   is	   on	   top.	   (C)	   Scheme	   of	   the	   section	  presented	  in	  (B).	  Brain	  areas	  mentioned	  in	  this	  work	  are	  highlighted.	  BS:	  brain	  stem;	  CB:	  cerebellum;	  CO:	  cortex;	  HI:	   hippocampus;	  OB:	   olfactory	   bulb.	   (modified	   from	   Paxinos	   and	   Franklin,	   2001,	   and	   adapted	  from	  Masterthesis	  Hänseler,	  2008)	  (D)	  Neuronal	  circuitry	  scheme	  of	   the	  cerebellum.	  Movement	  related	  information	   is	   transferred	   from	   the	   brain	   stem	   to	   motor	   areas	   in	   the	   neocortex	   through	   the	   deep	  cerebellar	  nuclei.	  These	  signals	  are	  modulated	   in	   the	   three-­‐layered	  cerebellar	  cortex	   through	   inhibitory	  signals	   from	   Purkinje	   cells,	   which	   integrate	   sensorimotor	   information	   from	   hundreds	   of	   thousands	   of	  granule	   cells.	   This	   cell	   type	   is	   the	  most	   abundant	   in	   the	   CNS,	   accounting	   for	   about	   70%	  of	   all	   neurons	  (Source:	  Purves	  et	  al.,	  2004).	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1.3	  Norrie	  disease	  and	  allelic	  disorders	  	  
1.3.1	  Blindness	  	  	  Blindness	  (amaurosis)	  is	  a	  severe	  handicap	  that	  affects	  between	  0.3%	  (legally	  blind)	  and	  1.2%	   (low	   vision)	   of	   the	   European	   population	   (WHO	   report	   2008;	  http://www.who.int/mediacentre/factsheets/fs282/en).	   About	   10%	   of	   all	   blindness	  cases	   in	   industrial	  nations	  are	  congenital,	  mainly	  caused	  by	  hereditary	  retinochoroidal	  dystrophies.	   The	   incidence	   of	   these	   usually	   monogenic	   disorders	   has	   been	   estimated	  1:4000	   in	   Germany	   (Kellner	   et	   al.,	   2004).	   While	   most	   forms	   of	   blindness	   (cataract,	  glaucoma,	  corneal	  opacity,	  diabetic	  retinopathy,	  vitamin	  A	  deficiency,	   infectious	  causes	  like	  trachoma	  and	  onchocerciasis)	  can	  be	  treated	  or	  prevented,	  treatment	  of	  hereditary	  forms	   is	   limited.	   Thus,	   the	   primal	   mission	   for	   handling	   of	   these	   diseases	   is	   an	  unambiguous	   differential	   diagnosis	   through	   molecular	   genetic	   testing,	   followed	   by	  investigation	   of	   the	   pathophysiology.	   This	  may	   ultimately	   lead	   to	   the	   development	   of	  new	   therapeutic	   strategies	   like	   gene	   therapy	   (Bainbridge	   et	   al.,	   2008).	   At	   present,	  genetic	   counseling	   and	   follow-­‐up	   examinations	   is	   all	   that	   can	   be	   provided	   to	   patients	  immediately.	  	  	  
1.3.2	  Norrie	  disease	  and	  allelic	  disorders	  In	   this	   thesis,	   I	   aimed	   to	   add	   further	   knowledge	   to	   the	   understanding	   of	   the	  pathogenesis	  of	  a	  subgroup	  of	  hereditary	  retinal	  diseases	  that	  are	  caused	  by	  variants	  in	  the	   Norrie	   disease	   pseuoglioma	   (NDP)	   gene	   and	   that	   may	   be	   subsumed	   under	   the	  umbrella	   term	   “exudative	   vitreoretinopathies”	   (EVR).	   This	   group	   of	   diseases	   is	  characterized	  by	  a	  high	  phenotypic	  variability,	  which	  complicates	  the	  diagnosis	  and	  the	  prediction	  of	  the	  impact	  of	  the	  disease	  on	  the	  individual	  patient.	  The	   common	   feature	   of	   EVRs	   is	   retinal	   hypoxia,	   which	   secondarily	   leads	   to	   tissue	  damage.	   It	   is	   likely	  caused	  by	  a	  defect	  development	  of	   the	  retinal	  blood	  vessel	  system,	  ranging	   from	   symptom-­‐free,	   small	   avascular	   peripheral	   regions	   to	   nearly	   complete	  avascularity	  of	  the	  retina	  (Berger	  and	  Ropers,	  2001).	  The	  existing	  vessels	  become	  leaky,	  and	   intra-­‐	   and	   subretinal	   lipid	   accumulation	  may	   ultimately	   lead	   to	   exudative	   retinal	  detachment.	   In	   addition,	   regression	   of	   the	    hyaloid 	   vessel	   system,	   a	   transient	   network	  nourishing	   the	   developing	   lens,	   is	   often	   impaired.	   Remainders	   of	   these	   vessels	   may	  appear	  as	  retrolental	  structures	  that	  can	  exert	  tractional	  forces	  on	  the	  retina,	  which	  can	  lead	   to	   tractional	   retinal	  detachment.	  Many	  clinical	  descriptions	  of	  patients	  have	  been	  published	   with	   slightly	   different	   symptoms,	   often	   postulating	   a	   distinct	   disease,	  although	   it	   later	   could	  be	   shown	   that	  all	  patients	  harbour	  mutations	   in	   the	  NDP	   gene.	  However,	  exudative	  vitreoretinopathies	  are	  heterogenous.	  At	  present,	   two	  other	  genes	  have	   been	   associated	   with	   this	   group:	   the	   seven-­‐transmembrane-­‐domains	   receptor	  Frizzled-­‐4	  (FZD4),	  and	  the	  gene	  for	  the	  low-­‐density	  lipoprotein	  receptor-­‐related	  protein	  5	   (LRP5),	  while	  more,	  possibly	  disease-­‐modifying	  genes	  will	   likely	  be	   identified	   in	   the	  future.	  In	  the	  following	  paragraph,	  I	  want	  to	  address	  the	  different	  clinical	  pictures	  that	  are	  associated	  with	  NDP	  mutations.	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1.3.2.1	  Norrie	  disease	  (ND)	  Norrie	   disease	   (ND)	   first	   has	   been	   described	   by	   the	   Danish	   ophthalmologist	   Gordon	  Norrie	  in	  1927,	  who	  examined	  a	  pair	  of	  brothers	  who	  suffered	  from	  congenital	  blindness	  (Norrie,	  1927).	  The	  disease	  was	  given	  his	  name	  by	  Mette	  Warburg	   in	  1961	  (Warburg,	  1961),	   further	   reporting	   on	   a	   Danish	   family	   with	   7	   affected	   males	   suffering	   from	  pseudotumour	   of	   the	   retina.	   In	   contrast	   to	   the	   patients	   described	   by	   Norrie	   himself,	  Warburg	  found	  that	  5	  of	  her	  patients	  encountered	  progressive	  hearing	  loss	  in	  addition	  to	  their	  visual	  impairment,	  and	  4	  were	  also	  mentally	  retarded.	  Following	  her	  first	  report	  in	   1961,	   Warburg	   examined	   8	   more	   families	   in	   the	   years	   after	   (Warburg,	   1963;	  Warburg,	   1966;	   Warburg,	   1968),	   and	   showed	   that	   the	   disease	   is	   inherited	   X-­‐chromosomal	  recessive.	  She	  also	  noted	  a	  high	  variability	  of	  the	  clinical	  presentation.	  In	  1992,	   linkage	  analysis	  and	  subsequent	  positional	  cloning	   lead	  to	  the	   identification	  of	  a	  locus	   on	   the	   short	   arm	   of	   chromosome	   X	   that	   co-­‐segregated	   with	   the	   disease	   and	  henceforth	  was	  termed	  NDP	  –	  Norrie	  disease	  pseudoglioma	  (Berger	  et	  al.,	  1992;	  Chen	  et	  al.,	   1992).	   Prevalence	   of	   Norrie	   disease	   is	   rare,	   with	   only	   one	   in	   100’000	   individuals	  affected	  (Chen	  et	  al.,	  1992).	  The	  first	  visible	  symptom	  and	  hallmark	  feature	  of	  Norrie	  disease	  is	  bilateral	  leukocoria,	  which	  can	  be	  recognized	  by	  a	  yellowish,	  opaque	   pupillary	  reflex	  soon	  after	  birth	  (Figure	  4A).	   It	   is	  caused	  by	  retrolental	  masses	  of	   fibrovascular	  tissue,	  which	  at	   first	  glance	  are	  hard	   to	   differentiate	   from	   a	   retinal	   tumour	   and	   thus	   are	   commonly	   referred	   to	   as	  pseudoglioma	   (Figure	   4B).	   In	   a	   progressed	   stage	   of	   the	   disease,	   the	   eye	   becomes	  atrophic	  and	  the	  globe	  shrinks	  (Figure	  4C).	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Figure	   4	   Clinical	   presentation	   of	   the	   ocular	   ND	   phenotype.	   (A)	   The	   hallmark	   feature	   and	   first	   visible	  clinical	   sign	  of	  ND	   is	   leukocoria,	   a	   yellowish	  pupillary	   reflex	   (Chynn	  et	   al.,	   1995).	  The	   image	  shows	   the	  affected	  eye	  of	  an	  1-­‐month-­‐old	  patient.	  (B)	  The	  same	  eye	  as	  in	  (A)	  after	  it	  has	  been	  enucleated	  at	  the	  age	  of	  2	  months	  due	  to	  suspicion	  of	  retinoblastoma.	  (C)	  Eye	  of	  a	  10-­‐year-­‐old	  patient	  showing	  shrinkage	  of	  the	  eye	  bulb	  (phthisis	  bulbi)	  (Khan	  et	  al.,	  2004).	  	  In	   a	   less	   severe	   form,	   these	   retrolental	   masses	   can	   also	   resemble	   persistent	   fetal	  vasculature	   (PFV),	   which	   includes	   remaining	   hyaloid	   vessels	   and	   vitreoretinal	  hemorrhages.	  Additional	  ocular	  features	  include	  retinal	  folding	  and	  retinal	  detachment,	  which	   have	   been	   described	   in	   detail	   in	   a	   publication	   reporting	   on	   a	   histopathologic	  examination	   of	   an	   ND	   patient’s	   eye	   that	   has	   been	   enucleated	   at	   the	   age	   of	   6	  months	  (Schroeder	  et	  al.,	  1997).	  Fibrovascular	  proliferation	  in	  the	  vitreous,	  but	  not	  in	  the	  retina,	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seemed	  to	  cause	  progressive	  hypoplasia	  and	  disorganization	  of	  the	  inner	  retinal	  layers.	  	  The	   authors	   postulated	   that	   formation	   of	   rosette-­‐like	   structures	   in	   the	   photoreceptor	  cell	  layer,	  retinal	  folding,	  and	  retinal	  detachment	  resulted	  from	  tractional	  forces	  caused	  by	  these	  fibrovascular	  masses.	  Secondarily,	   a	   cataract	   may	   develop,	   and	   the	   cornea,	   iris,	   ciliary	   body,	   and	   retinal	  pigment	  epithelium	  also	  become	  involved.	  In	  addition	   to	   the	  hallmark	  ocular	   features,	  deafness	  and	  mental	   retardation	   (MR)	  are	  frequently	  noted.	  MR	  manifests	  in	  up	  to	  fifty	  percent	  of	  the	  patients	  early	  in	  childhood,	  whereas	   progressive	   hearing	   loss	   typically	   is	   first	   diagnosed	   in	   the	   second	   or	   third	  decade	  of	  life.	  Warburg	  estimated	  the	  prevalence	  of	  the	  latter	  in	  about	  one	  third	  of	  the	  patients	  (Warburg,	  1966),	  but	  a	  recent	  report	  suggests	  a	  (variable)	  penetrance	  of	  100%	  (Halpin	  et	  al.,	  2005).	  A	  possible	  explanation	  for	  this	  discrepancy	  could	  be	  the	  late	  on-­‐set	  of	  hearing	  impairment,	  and	  a	  lack	  of	  follow-­‐up	  studies	  on	  ND	  patients.	  	  
1.3.2.2	  Coats’	  disease	  (CD)	  Coats’	  disease	  (CD)	  first	  has	  been	  described	  by	  George	  Coats	  in	  1908.	  The	  classical	  form	  is	  defined	  through	  a	  sporadic,	  unilateral	  form	  of	  abnormal	  retinal	  vascular	  development	  (retinal	  telangiectasis)	  that	  results	  in	  exudative	  retinal	  detachment	  (Figure	  5).	  It	  almost	  exclusively	   affects	  males.	   An	   excellent	   review	   of	   the	   literature	   has	   been	   published	   by	  Muletarow	  who	  states,	  “The	  general	  assumption	  is	  that	  CD	  is	  a	  connatal	  ophthalmologic	  disease	  with	  no	  familial	  occurrence	  and	  no	  manifestation	  of	  vascular	  anomalies	  in	  other	  organs.”	   (Muletarow	   et	   al.,	   2004).	  However,	   192	   of	   283	  patients	   described	   until	   2004	  showed	  additional	  pathologic	   features.	  This	  group	  exhibited	  no	  gender	  predisposition,	  and	   further	   presented	   mainly	   with	   a	   bilateral	   eye	   phenotype.	   This	   suggests	   the	  conclusion	   that	  CD	   is	  often	  diagnosed	  only	  on	   the	  basis	  of	   the	  morphologic	  definition,	  and	   thus	   rather	  describes	   an	   eye	  phenotype,	   not	   a	   disease,	  with	  Coats’-­‐like	  unspecific	  alterations	  of	  the	  retinal	  vasculature.	  	  
	  
Figure	  5	  Coats’	  disease.	  (A)	  The	  fundus	  picture	  shows	  telangiectatic	  vessels	  and	  an	  avascular	  periphery.	  
(B)	  Retinal	  exudates	  in	  the	  proximity	  of	  abnormal	  vessels.	  (C)	  Leukocoria	  as	  a	  result	  of	  exudative	  retinal	  detachment.	  (Source:	  Muletarow	  et	  al.,	  2004)	  	  For	  example,	  CD	  has	  been	  diagnosed	  in	  patients	  who	  in	  addition	  to	  their	  eye	  phenotype	  exhibited	  alterations	  in	  the	  brain,	  such	  as	  calcifications	  of	  the	  white	  matter	  (Goutieres	  et	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al.,	   1999;	   Révész	   et	   al.,	   1992;	   Rossazza	   et	   al.,	   1983;	   Tolmie	   et	   al.,	   1988),	   cerebellar	  atrophy	  (Kajtár	  et	  al.,	  1994),	  cerebellar	  ataxia	  (Goutieres	  et	  al.,	  1999;	  Révész	  et	  al.,	  1992;	  Tolmie	  et	  al.,	  1988),	  palsy	  of	  the	  6th	  brain	  nerve	  (Gass	  et	  al.,	  1991),	  as	  well	  as	  changes	  in	  the	   cerebral	   vasculature,	   which	  were	   characterized	   by	   a	   reduced	   development	   of	   the	  deep	  venous	  system	  in	  favor	  of	  a	  prominent	  superficial	  venous	  plexus	  (Robitaille	  et	  al.,	  1996).	   Further,	   CD	   patients	   suffering	   from	   epileptic	   seizures	   (Blum	   et	   al.,	   1994;	  Goutieres	   et	   al.,	   1999;	   Rossazza	   et	   al.,	   1983;	   Scholz	   et	   al.,	   1997;	   Tolmie	   et	   al.,	   1988;	  Wilensky	  et	  al.,	  1976)	  and	  mental	  retardation	  have	  been	  described	  (Burch	  et	  al.,	  1980;	  Folk	  et	  al.,	  1981;	  Matsuzaka	  et	  al.;	  1986;	  Révész	  et	  al.,	  1992;	  Rossazza	  et	  al.,	  1983;	  Scholz	  et	  al.,	  1997;	  Skuta	  et	  al.,	  1987;	  Small,	  1968).	  Growth	  delay	  was	  described	  in	  6	  CD	  patients	  (reviewed	  in	  Muletarow	  et	  al.,	  2004).	  CD	  also	  has	  been	  proposed	  to	  be	  a	  secondary	  effect	  to	  retinitis	  pigmentosa	  (RP),	  which	  has	  been	  diagnosed	  in	  58	  of	  the	  283	  CD	  patients	  (Koshibu	  et	  al.,	  1979;	  Witschel,	  1974).	  This	   might	   be	   a	   direct	   effect	   of	   the	   degenerating	   retina	   on	   the	   vasculature	   through	  release	   of	   factors	   that	   trigger	   the	   increased	   vessel	   leakiness,	   or	   an	   indirect	   effect	  secondary	  to	  inflammation.	  Taken	   together,	   many	   of	   the	   patients	   diagnosed	   with	   CD	   who	   exhibit	   extraocular	  symptoms	   in	   the	   brain	   or	   ear	   could	   possibly	   also	   be	   described	   as	   ND	   patients.	   This	  hypothesis	  has	  been	  supported	  by	  the	  finding	  of	  an	  NDP-­‐mutation	  in	  the	  enucleated	  eye	  of	  a	  Coats’	  patient	  (Black	  et	  al.,	  1999).	  Linking	  the	  diagnosis	  of	  CD	  to	  the	  morphological	  features,	  those	  authors	  postulated	  that	  Coats’	  disease	  can	  be	  considered	  as	  a	  unilateral,	  non-­‐syndromic	  form	  of	  Norrie	  disease	  that	  is	  likely	  caused	  by	  a	  somatic	  NDP	  mutation	  in	  the	   affected	   eye	   (Black	   et	   al.,	   1999).	   In	   the	   case	   of	   patients	   without	   gender	  predisposition	   and	  with	   a	   bilateral	   phenotype,	   I	   suspect	   that	   FEVR	  would	   be	   a	   better	  diagnosis.	  	  
1.3.2.3	  Episkopi	  blindness	  A	  large	  greek	  family	  with	  an	  X-­‐linked	  form	  of	  blindness	   living	   in	  Episkopi,	  Cyprus,	  has	  been	   described	   in	   1959	   (Taylor	   et	   al.,	   1959).	  Warburg	   speculated	   already	   in	   her	   first	  publication	   about	  ND	   (Warburg,	   1961)	   that	   this	   clinical	   entity	   could	   be	   another,	   non-­‐syndromic	   presentation	   of	   Norrie	   disease.	   In	   1992,	   this	   presumption	   could	   be	  substantiated,	  when	  it	  was	  shown	  that	  Episkopi	  blindness	  and	  ND	  mapped	  to	  the	  same	  genomic	  region	  (Wolff	  et	  al.,	  1992).	  	  
1.3.2.4	  X-­‐linked	  recessive	  primary	  retinal	  dysplasia	  (PRDX)	  X-­‐linked	  recessive	  primary	  retinal	  dysplasia	  (PRDX)	  is	  another	  clinical	  description	  that	  has	  been	  linked	  to	  Norrie	  disease	  locus	  (Ravia	  et	  al.,	  1993;	  Zhu	  and	  Hussels-­‐Maumanee,	  1994).	   PRDX	   describes	   a	   condition	   characterized	   by	   abnormal	   proliferation	   of	   retinal	  tissue,	  most	  likely	  neurons	  or	  glial	  tissue,	  that	  leads	  to	  retinal	  folds	  or	  glioma,	  but	  has	  no	  extraocular	  symptoms.	   It	  was	  diagnosed	  in	  a	   family	  with	   five	  affected	  males,	  who	  only	  presented	   with	   an	   eye	   phenotype,	   and	   two	   carrier	   females	   with	   minimal	   symptoms.	  Because	  of	  the	  lack	  of	  extraocular	  features	  and	  the	  penetrance	  in	  the	  carrier	  females,	  ND	  was	   initially	   rejected	   as	   diagnosis	   (Godel	   and	   Goodman,	   1981).	   However,	   linkage	  analysis	   of	   the	   family	   later	   suggested	   that	   the	   PRDX	   gene	   and	  NDP	   map	   to	   the	   same	  genetic	  region	  (Ravia	  et	  al.,	  1993),	  suggesting	  that	  PRDX	  could	  be	  caused	  by	  mutations	  in	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NDP.	   In	   addition,	   the	   description	   of	   the	   retinal	   phenotype	   correlates	   well	   with	   the	  hypoplastic	   and	   disorganized	   inner	   retina	   found	   in	   a	   patient	   with	   an	   NDP	   mutation	  (Schroeder	  et	  al.,	  1997).	  	  
1.3.2.5	  Persistent	  hyperplastic	  primary	  vitreous	  (PHPV)	  /	  Persistent	  fetal	  vasculature	  (PFV)	  Persistent	  hyperplastic	  primary	  vitreous	  (PHPV)	  often	  has	  been	  described	  as	  a	  disease.	  However,	   it	  has	  been	   suggested	   that	   it	   rather	  describes	  a	   symptom,	  which	   in	  addition	  should	   more	   accurately	   be	   termed	   persistent	   fetal	   vasculature	   (PFV)	   (Figure	   6;	  Goldberg,	  1997).	  The	  classical	  description	   includes	  white,	  vascularized	   tissue	  covering	  all	   or	   part	   of	   the	   posterior	   part	   of	   the	   lens;	   centrally	   dragged	   ciliary	   processes;	  intravitreal	  hemorrhages;	  persistence	  of	  the	  hyaloid	  artery;	  secondary	  glaucoma	  caused	  by	   swelling	   of	   the	   lens;	   and	   retinal	   detachment.	   Corneal	   opacifications,	   cataract,	   and	  persistence	   of	   the	   papillary	   membrane	   are	   also	   often	   observed.	   PFV	   has	   often	   been	  mentioned	  in	  the	  clinical	  description	  of	  patients	  diagnosed	  with	  ND	  or	  similar	  diseases,	  and	   NDP,	   FZD4,	   and	   LRP5	   mutations	   have	   been	   found	   in	   patients	   diagnosed	   with	  PHPV/PFV	  (Gong	  et	  al.,	  2001;	  Wu	  et	  al.,	  2007;	  Aponte	  et	  al.,	  2009;	  Robitaille	  et	  al.,	  2009).	  	  
	  
Figure	  6	   Spectrum	  of	   clinical	   features	   summarized	  under	   the	   term	  „persistent	   fetal	  vasculature“	   (PFV).	  (Picture	  taken	  from	  Goldberg,	  1997)	  	  
1.3.2.6	  Familial	  exudative	  vitreoretinopathy	  (FEVR)	  Familial	   exudative	   vitreoretinopathy	   (FEVR),	   or	   Criswick-­‐Schepens	   syndrome,	   is	   a	  slowly	   progressive	   congenital	   blinding	   disorder	   characterized	   by	   an	   incomplete	  peripheral	   vascularization	   of	   the	   retina	   (Criswick	   and	   Schepens,	   1969)	   and	   vitreous	  abnormalities	  resembling	  ROP.	  This	  defect	  in	  blood	  vessel	  development	  entails	  a	  highly	  variable	   phenotype	   due	   to	   secondary	   complications	   like	   vitreoretinal	   traction,	   retinal	  folds,	  or	  hemorrhages,	  which	  can	  range	  from	  symptom-­‐free	  conditions	  to	  severe	  retinal	  detachment	  (Canny	  and	  Oliver,	  1976;	  Laqua	  et	  al.,	  1980).	  High	  phenotypic	  similarity	  of	  FEVR	  to	  mild	  forms	  of	  ND	  lead	  to	  the	  statement	  that	  „clinically,	  Norrie	  Disease	  and	  XEVR	  appear	  to	  be	  different	  progressed	  stages	  of	  the	  same	  disease“	  (Kellner	  et	  al.,	  1996).	  Most	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cases	  are	  autosomal	  dominant,	  but	  X-­‐linked	  recessive	  and	  sporadic	  cases	  have	  also	  been	  reported.	   Indeed,	   in	   case	   of	   X-­‐linked	   inheritance,	   FEVR	   can	  be	   synonymous	  with	  non-­‐syndromic	  ND,	  as	  mutations	  in	  NDP	  have	  been	  associated	  with	  FEVR	  (EVR2;	  Chen	  et	  al.,	  1993).	   In	   addition,	   two	   autosomal	   genes	   have	   been	   associated	  with	   FEVR:	   Frizzled-­‐4	  (FZD4;	   EVR1;	   Robitaille	   et	   al.,	   2002),	   and	   low-­‐density	   lipoprotein	   receptor-­‐related	  protein	   5	   (LRP5;	  EVR4;	   Toomes	   et	   al.,	   2004),	  while	   a	   fourth	   locus	   has	   been	   linked	   to	  11p13-­‐p12	  without	  knowing	  the	  gene	  involved	  (EVR3;	  Downey	  et	  al.,	  2001)	  (Figure	  21).	  In	  contrast	   to	  FZD4,	  mutations	   in	  NDP	   and	  LRP5	  have	  been	  associated	  with	  additional	  diseases	  and	  extra-­‐ocular	  symptoms.	  Mutations	  in	  NDP	  often	  present	  with	  defects	  in	  the	  brain	   and	   inner	   ear,	   and	   recessive	   mutations	   in	   LRP5	   have	   been	   associated	   with	  osteoporosis	   pseudoglioma	   syndrome	   (OPPG),	   further	   presenting	   with	   bone	  abnormalities	   (Gong	   et	   al.,	   2001;	   Ai	   et	   al.,	   2005).	   Thus,	   it	   is	   difficult	   to	   describe	  phenotypic	  differences	  between	  FEVR	  and	  ND,	  when	  part	  of	  the	  reported	  FEVR	  cases	  are	  in	   fact	   non-­‐syndromic,	   mild	   ND	   cases	   due	   to	   mutations	   in	   the	   NDP	   gene.	   The	   same	  applies	   to	   differences	   between	   FEVR	   and	   OPPG,	   because	   both	   are	   associated	   with	  mutations	  in	  LRP5.	  Concentrating	  only	  on	  the	  FEVR	  cases	  with	  dominant	  mutations	  in	  FZD4,	   the	  following	  clinical	  observations	  have	  been	  made:	  Peripheral	  retinal	  avascularity	  (mainly	  temporal),	  severe	  retinal	  exudates,	   retinal	  peripheral	  neovascularization,	  peripheral	   fibrovascular	  mass,	  macular	  ectopia,	  retinal	   fold,	  retinal	  detachment,	  and	  vitreal	  hemorrhage	  (Qin	  et	  al.,	  2005).	  In	  addition,	  stretched	  temporal	  vessels,	  myopia,	  vitreofoveal	  traction,	  mature	  cataract,	  secondary	  strabism,	  PFV	  or	  PFV-­‐like	  features,	  and	  microphthalmos	  have	  been	  noted	  (Robitaille	  et	  al.,	  2002;	  Müller	  et	  al.,	  2007;	  Robitaille	  et	  al.,	  2009)	  (Figure	  7).	  No	  extraocular	  symptoms	  like	  progressive	  hearing	  loss,	  mental	  retardation,	  or	  altered	  bone	  density	  have	  been	  reported	  so	  far.	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Figure	  7	  Cinical	  presentation	  of	  a	  female	  FEVR	  patient	  with	  a	  small	  deletion	  in	  FZD4	  (p.M493_W494del).	  
(A)	  The	  left	  eye	  is	  conspicuous	  with	  a	  hypoplastic	  iris	  with	  posterior	  synechiae	  (adherence	  of	  the	  iris	  to	  the	   lens)	   and	   leukocoria.	   (B)	   In	   the	   right	   eye,	   retinal	   vessels	   are	   prominently	   lacking	   in	   the	   dysplastic	  retina,	   and	   a	   fibrovascular	   stalk	   extends	   from	   the	   optic	   disc	   to	   the	   inferotemporal	   aspect	   of	   the	   lens,	  reminiscent	  of	  PFV.	  (Source:	  Robitaille	  et	  al.,	  2009)	  	  
INTRODUCTION	   29	  	  
	  
1.3.2.7	  Retinopathy	  of	  prematurity	  (ROP)	  Retinopathy	   of	   prematurity	   (ROP)	   is	   a	   major	   cause	   of	   blindness	   in	   children	   despite	  current	  surgical	  treatment	  in	  the	  late-­‐stage	  of	  the	  disease	  (Chen	  and	  Smith,	  2007).	  ROP	  was	   originally	   described	   in	   the	   1940s	   as	   retrolental	   ﬁbroplasia	   that	   occured	   in	  premature	   infants	   (Terry,	   1942;	   Terry,	   1944).	   Its	   hallmark	   feature	   is	   development	   of	  retinal	   neovascularization	   due	   to	   transient	   local	   ischemia,	   mainly	   in	   the	   temporal	  periphery	   of	   the	   eye.	   Secondary	   complications	   are	   highly	   variable,	   ranging	   from	   no	  effect	   on	   vision	   to	   bilateral,	   total	   blindness.	   The	   younger	   and	   smaller	   the	   premature	  children,	  the	  higher	  the	  risk	  of	  desastrous	  ROP	  (Ashton	  et	  al.,	  1953;	  Palmer	  et	  al.,	  1991).	  In	   the	   1950s,	   supplementary	   oxygen	   was	   suspected	   as	   cause	   for	   the	   development	   of	  ROP.	  It	  was	  soon	  found	  that	  only	  the	  incompletely	  vascularized	  retina	  is	  susceptible	  to	  oxygen,	  and	  the	  more	  immature	  the	  vasculature,	  the	  greater	  the	  pathologic	  response	  to	  oxygen	  (Ashton	  et	  al.,	  1954).	  Thus,	  the	  temporal	  retina	  is	  predisposed	  for	  ROP,	  because	  it	  is	  the	  last	  part	  of	  the	  retina	  that	  becomes	  vascularized.	  The	   pathogenesis	   of	   ROP	   can	   be	   divided	   into	   two	   phases.	   The	   primary	   stage	   is	  characterized	   by	   vasoconstriction	   of	   immature	   retinal	   vessels,	   which	   can	   progress	   to	  vascular	  occlusion.	   It	  has	  been	  proposed	  that	   this	  mechanism	  could	  protect	   the	  neural	  retina	   during	   phases	   of	   elevated	   oxygen	   pressure	   (Flower,	   1985).	   When	   the	   oxygen	  pressure	  normalizes,	  e.g.	  through	  return	  of	  the	  patient	  to	  ambient	  air,	  the	  disease	  enters	  phase	  2,	  which	  can	  be	   identified	  by	  retinal	  neovascularization	  through	  proliferation	  of	  endothelial	  cells	  that	  are	  adjacent	  to	  the	  areas	  of	  ablated	  retinal	  capillaries.	  These	  events	  become	   clinically	   relevant	   when	   the	   proliferating	   cells	   penetrate	   the	   inner	   limiting	  membrane	  and	  blood	  vessels	  start	  to	  grow	  on	  the	  retinal	  surface	  and	  into	  the	  vitreous,	  especially	  in	  the	  central	  part	  of	  the	  retina.	  Therefore,	  ROP	  is	  internationally	  classified	  by	  the	  retinal	  areas	  that	  are	  involved	  (anterioposterior	  zones	  I-­‐III,	  where	  I	  represents	  the	  center	  around	  the	  optic	  disc	  and	  the	  macula	  and	  III	  is	  the	  temporal	  periphery),	  and	  the	  grade	  of	  pathogenic	  progression.	  The	  extent	  of	  ROP	  can	  be	  classified	  in	  five	  stages	  (Figure	  8).	  The	  first	  visible	  sign	  is	  the	  appearance	   of	   a	   demarcation	   line,	   a	   sharp	   border	   between	   the	   vascularized,	   central	  retina	  and	  the	  avascular	  periphery	  (Stage	  1;	  Figure	  8A).	  When	  the	  disease	  progressed	  to	  stage	  2,	   this	  demarcation	   line	  appears	   elevated	   in	   centripetal	  direction	  within	   the	  eye	  globe;	   a	   ridge	   has	   formed	   (Figure	   8B).	   In	   stage	   3,	   extraretinal	   fibrovascular	   tissue	  proliferates	   from	   the	   ridge	   (Figure	   8C).	   The	  next	   stage	   of	   severity	   is	   characterized	  by	  partial	  retinal	  detachment.	  Depending	  on	  foveal	  involvement,	  this	  stage	  can	  be	  classified	  in	  4A	  (without	  foveal	  involvement)	  and	  4B	  (with	  foveal	  involvement)	  (Figure	  8D).	  Stage	  5	   finally,	   the	   most	   severe	   form	   of	   ROP,	   is	   characterized	   by	   total	   retinal	   detachment	  (Figure	  8E).	  The	  different	  stages	  of	  ROP	  bear	  similarities	  to	  other	  clinical	  entities.	  Classic,	  severe	  ND	  is	  similar	  to	  ROP	  stage	  5,	  PRDX	  has	  been	  suggested	  to	  characterize	  ROP	  grades	  3	  and	  4,	  and	   FEVR	   is	   similar	   to	   the	  milder	   ROP	   grades	   1	   and	   2	   (Table	   1;	   Mintz-­‐Hittner	   et	   al.,	  1996).	  An	  important	  differential	  diagnosis	  for	  stages	  4	  and	  5	  further	  is	  retinoblastoma,	  and	  atypical	  cases	  of	  Coats’	  disease	  (CD),	  Eales’	  disease	  (ED),	  and	  retinoschisis	  can	  also	  resemble	  the	  clinical	  picture	  of	  ROP	  (Palmer	  et	  al.,	  2001).	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Figure	  8	  Diagrams	  showing	  the	  classification	  of	  ROP	  stages.	  (A)	  Stage	  1.	  A	  demarcation	  line	  separates	  the	  mature,	   vascularized	   part	   of	   the	   retina	   (right)	   from	   the	   avascular	   periphery	   (left).	   (B)	   Stage	   2.	   The	  characteristic	  ridge	  becomes	  visible	  along	  the	  demarcation	  line.	  (C)	  Stage	  3.	  Along	  the	  ridge,	  proliferation	  of	   extraretinal	   fibrovascular	   tissue	   is	   evident.	   (D)	   Stage	   4A.	   Subtotal	   detachment	   of	   the	   retina	  without	  involvement	  of	  the	  fovea.	  (E)	  Stage	  5.	  Total	  retinal	  detachment	  with	  anterior	  and	  posterior	  open	  funnel.	  (modified	  after	  figures	  presented	  in	  Palmer	  et	  al.,	  2001)	  	  	  
ROP Stage Characteristic Corresponds to 
   
1 Demarcation line FEVR; CD; ED; RS 
2 Ridge FEVR; CD; ED; RS 
3 Ridge with extraretinal fibrovascular proliferation PRDX; CD; ED 
4A Subtotal retinal detachment (extrafoveal) PRDX; RB; PFV; ED 
4B Subtotal retinal detachment (including the fovea) PRDX; RB; PFV; ED 
5 Total retinal detachment ND; RB; PFV; ED 
	  
Table	  1	  Classification	  of	  ROP	  stages.	  A	  „plus“	  is	  added	  to	  each	  stage	  when	  marked	  vascular	  changes	  are	  present	   (enlargement	   of	   posterior	   veins,	   increased	   tortuosity	   of	   arterioles,	   iris	   vascular	   engorgement,	  pupillary	  rigidity,	  and	  vitreous	  haze).	  (Source:	  Palmer	  et	  al.,	  2001)	  	  While	  the	  oxygen-­‐based	  hypothesis	  commonly	  is	  the	  most	  accepted,	  the	  etiology	  of	  ROP	  is	   not	   clear	   and	   appears	   to	   be	   multifactorial.	   Prematurity,	   low	   birth	   weight,	   and	  prolonged	   oxygen	   supplementation	   have	   long	   been	   established	   as	   main	   risk	   factors.	  Recently,	   insulin-­‐like	   growth	   factor	   (IGF-­1)	   has	   been	   found	   to	   act	   indirectly	   as	   a	  permissive	   factor	   for	  vessel	  growth.	  Lack	  of	   IGF-­‐1	   in	  preterm	   infants	  prevents	  normal	  retinal	  vascular	  growth	   in	  phase	  I	  of	  ROP.	  Rising	   levels	  of	   IGF-­‐1	   in	  phase	  II	   then	  allow	  pathological	   neovascularization	   (Chen	   and	   Smith,	   2007).	   IGF	   serum	   levels	   in	   the	  developing	   child	   depend	   heavily	   on	   the	   mother’s	   serum	   levels,	   and	   low	   IGF-­1	   serum	  levels	   in	   the	   mother	   may	   pose	   another	   risk	   factor	   for	   ROP.	   However,	   no	   genetic	  variations	  in	  the	  IGF-­1	  gene	  have	  been	  associated	  with	  ROP	  so	  far.	  In	  contrast,	  mutations	  in	  NDP	  have	  been	  found	  to	  predispose	  for	  a	  higher	  risk	  to	  develop	  ROP	  (Shastry	  et	  al.,	  1997;	   Hiraoka	   et	   al.,	   2001).	   However,	   the	   occurence	   of	   these	   mutations	   and	   the	   low	  gestational	   age	   could	   be	   coincident,	   opening	   the	   question	   whether	   these	   patients	  suffered	  from	  ROP	  or	  were	  just	  pre-­‐term	  babies	  who	  suffered	  from	  ND.	  	  Although	   cryotherapy	   and	   laser	   photocoagulation	   of	   the	   avascular	   retina	   became	  available	   in	   the	   1980s	   and	   1990s,	   these	   ablation	   treatments	   reduce	   the	   incidence	   of	  blindness	   only	   by	   25%	   in	   infants	   with	   late-­‐stage	   disease.	   Understanding	   of	   the	  molecular	   basis	   of	   the	   disease	   would	   be	   the	   prerequisite	   for	   a	   better	   and	   more	  comprehensive	  treatment.	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1.3.3	  Differential	  diagnosis	  In	  addition	  to	  the	  clinical	  entities	  that	  have	  been	  associated	  with	  mutations	  in	  the	  NDP	  gene,	  several	  other	  conditions	  with	  a	  similar	  phenotype	  have	  been	  described	  that	  may	  be	  related	  through	  a	  common	  pathogenic	  molecular	  pathway.	  	  
1.3.3.1	  Osteoporosis	  pseudoglioma	  syndrome	  (OPPG)	  Osteoporosis	   pseudoglioma	   syndrome	   (OPPG)	   is	   an	   autosomal	   recessive	   disorder	  presenting	  with	  juvenile	  skeletal	  fragility	  and	  congenital	  or	  early-­‐onset	  visual	  loss.	  The	  ocular	   phenotype	   is	   variable	   and	   resembles	   ND	   and	   FEVR,	   including	   the	   presence	   of	  congenital	   retinal	   folds	   and	   exudates,	   avascular	   periphery,	   PFV,	   pseudoglioma,	   phtisis	  bulbi,	   and	   cataract	   (Figure	   9).	   The	   disease	   is	   usually	   bilateral,	   but	   unilateral	   eye	  involvement	   has	   been	   reported	   (Ai	   et	   al.,	   2005).	   In	   addition,	   muscular	   hypotonia,	  ligamentous	  laxity,	  and	  	  mental	  retardation	  were	  noted	  (Balemans	  and	  van	  Hul,	  2007).	  Cognitive	  impairment	  of	  varying	  degree	  has	  been	  estimated	  to	  occur	  in	  27%	  (8	  of	  30)	  of	  all	  OPPG	  patients	  (Ai	  et	  al.,	  2005).	  Importantly,	   skeletal	   disease	   often	  was	   not	   recognized	   during	   the	   first	   2	   years	   of	   life	  (only	   in	   less	   than	   half	   of	   the	   cases)	   (Ai	   et	   al.,	   2005).	   In	   several	   asymptomatic	   infants,	  skeletal	  anomalies	  were	   found	   incidentally	  when	  radiographs	  were	  obtained	   for	  other	  reasons.	   Thus,	   depending	   on	   the	   degree	   or	   diagnosis	   of	   bone	   involvement,	   patients	  suffering	   from	  OPPG	   can	   also	   be	   diagnosed	   as	   FEVR	   or	   ND	   patients	   (especially	  when	  mental	  retardation	  is	  evident).	  	  
	  
Figure	  9	  (A)	  Right	  leg	  of	  a	  40-­‐year-­‐old	  female	  OPPG	  patient	  with	  angular	  deformity	  of	  the	  tibia	  and	  fibula,	  the	  consequence	  of	  multiple	  fractures	  occurring	  during	  childhood.	  (B)	  Abnormal	  flattening	  and	  concavity	  of	  the	  lumbar	  vertebrae	  of	  a	  10-­‐year-­‐old	  male	  OPPG	  patient	  shown	  in	  a	  lateral	  radiograph.	  (C)	  The	  right	  eye	  of	  a	  3-­‐month-­‐old	  male	  patient	  presents	  with	  leukocoria.	  (Source:	  Gong	  et	  al.,	  2001)	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OPPG	   has	   been	   associated	   with	   mutations	   in	   the	   low-­‐density	   lipoprotein	   receptor-­‐related	  protein	  5	  (LRP5)	  (Gong	  et	  al.,	  2001),	  which	   later	  has	  also	  been	  associated	  with	  FEVR	  (Toomes	  et	  al.,	  2004),	  substantiating	  the	  close	  similarity	  of	  the	  ocular	  phenotype.	  	  
1.3.3.2	  Retinoblastoma	  The	  retrolental	  masses	  and/or	  pseudoglioma	  observed	   in	  ND	  and	  allelic	  disorders	  are	  often	  confused	  with	  a	  malignant	  tumor	  (Figure	  10).	  In	  a	  CT	  scan,	  retinoblastomas	  can	  be	  diagnosed	   by	   a	   high	   degree	   of	   calcifications,	   which	   are	   only	   rare	   in	   pseudogliomas.	  Further,	   pseudogliomas	   seen	   in	  ND	   and	   allelic	   diseases	   are	   usally	   not	   solid,	   as	   can	  be	  observed	  by	  MRT	  (Scholz	  et	  al.,	  1997).	  Finally,	  differentiation	  can	  be	  achieved	  by	  genetic	  analysis,	  since	  hereditary	  retinoblastoma	  has	  been	  shown	  to	  be	  caused	  by	  mutations	  in	  the	  tumor-­‐suppressor	  gene	  RB1	  located	  at	  13q14.2	  (Lee	  et	  al.,	  1987).	  	  
	  
Figure	   10	   Retinoblastoma	   in	   a	   patient	   aged	   3	   years	   and	   5	  months.	   Note	   the	   characteristic	   leukocoria.	  (Source:	  Meier	  et	  al.,	  2006)	  	  
1.3.3.3	  Reese	  retinal	  dysplasia	  Reese	  retinal	  dysplasia	   is	   the	  characteristic	  eye	  phenotype	  of	   trisomy	  13	  (Iwig,	  1969).	  The	  ocular	  presentation	   is	  similar	   to	  ND	  regarding	   the	  malformation	  of	   the	  retina	  and	  persistence	   of	   fetal	   vitreous	   vessels.	   However,	   it	   is	   accompanied	   by	   many	   visceral	  manifestions	  and	  other	  extra-­‐ocular	  symptoms	  like	  polydactyly	  and	  cleft	  lip	  and	  palate	  (Reese	  and	  Straatsma,	  1958)	  (Figure	  11).	  	  	  
   
A B C 
Figure	   11	   Trisomy	   13	   in	   a	   full-­‐term	   neonate.	   (A)	   Bilateral	   nasolabial	   cleft	   lip	   and	   palate.	   (B)	  Microphthalmos,	   corneal	   leukoma,	   and	   iris	   coloboma.	   (C)	   Section	   of	   the	   enucleated	   eye	   exhibiting	  cataract,	  PFV,	  retinal	  dysplasia	  and	  detachment.	  (Source:	  de	  Juan,	  Jr.	  et	  al.,	  2001)	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1.3.3.4	  Familial	  retinoschisis	  (RS)	  X-­‐linked	  retinoschisis	  (RS)	  is	  a	  common	  juvenile	  macular	  dystrophy	  diagnosed	  in	  boys.	  It	   is	   characterized	   by	   intraretinal	   splitting	   that	  may	   lead	   to	   bilateral	   retinal	   folds	   and	  detachment	  that	  can	  be	  difficult	  to	  differentiate	  from	  other	  causes	  of	  retinal	  detachment.	  X-­‐linked	  juvenile	  retinoschisis	  has	  been	  linked	  to	  the	  Xp22.2-­‐p22.1	  interval	  and	  lead	  to	  the	  discovery	  of	  the	  XLRS1	  gene	  (Sauer	  et	  al.,	  1997).	  RS	  typically	  occurs	  with	  hyperopia	  and	   is	   only	   slowly	   progressive.	   Further	   reduction	   of	   visual	   acuity	   only	   occurs	   in	   the	  infrequent	  case	  of	  intravitreal	  hemorrhages.	  However,	  RS	  mainly	  affects	  the	  central,	  not	  peripheral	   part	   of	   the	   retina,	   and	   is	   not	   associated	   with	   a	   defect	   in	   blood	   vessel	  development	  (Kellner	  et	  al.,	  2004)	  (Figure	  12).	  A	  possible	  pathogenic	  mechanism	  could	  be	   based	   on	   a	   developmental	   defect	   of	   retinal	   Müller	   cells.	   Concurrent	   presence	   of	  temporal	  retinoschisis	  cavities	  reminiscent	  of	  RS	  and	  nasal	  telangiectatic	  vessels	  typical	  for	   CD	   have	   been	   described	   in	   two	   unrelated	   patients.	   However,	   sequencing	   of	   the	  exonic	   regions	   of	   the	   NDP	   and	   XLRS1	   genes	   have	   not	   revealed	   any	   disease-­‐causing	  mutations	  (Berinstein	  et	  al.,	  2001),	  opening	  the	  possibility	  for	  yet	  another	  gene	  involved	  in	  a	  CD/RS-­‐like	  phenotype.	  	  
   
	  
Figure	   12	   Fundus	   images	   from	   an	   11-­‐year-­‐old	   RS	   patient.	   (A)	   Foveal	   retinoschisis	   produces	   the	  characteristic	  spoke-­‐like	  macular	  appearance.	  (B)	  Inferotemporal	  retinoschisis	  with	  a	  large	  inner	  leaf	  hole	  and	  vitreous	  veils.	  (C)	  Schematic	  drawing	  of	  (A)	  and	  (B)	  and	  their	  position	  in	  the	  retina.	  (Source:	  Sauer	  et	  al.,	  1997)	  	  
1.3.3.5	  Incontinentia	  pigmenti	  (IP)	  Familial	   incontinentia	   pigmenti	   (IP;	   Bloch-­‐Sulzberger	   syndrome)	   is	   an	   X-­‐linked	  dominant,	   bilateral,	   but	   asymmetric	   disorder	   of	   pigmentary	   skin	   abnormalities	   with	  associated	   ocular,	   central	   nervous,	   and	   dental	   abnormalities	   that	   has	   first	   been	  described	  in	  1926	  (Bloch,	  1926;	  Sulzberger,	  1927).	  It	  is	  caused	  by	  mutations	  in	  the	  NF-­‐kappa-­‐B	  essential	  modulator	  gene	  (NEMO/IKBKG)	  at	  Xq28	  (Smahi	  et	  al.,	  2000).	  	  	  Ocular	   findings	   are	   very	   similar	   to	  ND	   and	   allelic	   diseases.	   Proliferating	   fibrovascular	  material	   in	   the	   periphery	   can	   lead	   to	   tractional	   retinal	   detachment	   (Cole	   and	   Cole,	  1959).	   The	   vasculature	   is	   markedly	   impaired	   and	   presents	   with	   peripheral	  microaneurysms,	   arteriovenous	   shunts,	   neovascularization	   in	   a	   peripheral	   avascular	  zone	   (Francois,	   1984),	   dilated	   retinal	   and	   choroidal	   vessels	   (Laqua,	   1980),	   macular	  aneurysms	   (Jain	   and	  Willetts,	   1978),	   optic	   disc	   neovascularization	   (Shah	   et	   al.	   1997),	  persistence	   of	   fetal	   vasculature,	   and	   vitreous	   hemorrhage	   (Fard	   and	   Goldberg,	   1998)	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(Figure	  13).	  Further	  phenocopying	  ND,	   IP	  may	  occur	  with	  congenital	  cataract	  (Carney,	  1976)	  and	  corneal	  opacities	  (Cole	  and	  Cole,	  1959).	  Sporadic	  cases	  due	  to	  somatic	  mutations	  in	  NEMO/IKBKG	  only	  in	  ocular	  precursor	  cells	  would	  be	  difficult	  to	  differentiate	  ophthalmologically	  from	  ND	  and	  allelic	  diseases.	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Figure	  13	  Clinical	  findings	  of	  incontinentia	  pigmenti	  (IP).	  (A)	  Erythematous	  vesicles	  and	  papules	  in	  a	  3-­‐week-­‐old	   girl.	   (B)	   Avascular	   periphery,	   arteriovenous	   shunts,	   vessel	   dilations,	   neovascularization,	   and	  leakage	   of	   fluorescein	   seen	   in	   the	   angiogram	   of	   a	   10-­‐month-­‐old	   girl.	   (Source:	   de	   Juan,	   Jr.	   et	   al.,	   2001;	  pictures	  courtesy	  of	  Molton	  Goldberg)	  	  In	  two	  sporadic	  cases,	  a	  de	  novo	  X-­‐autosome	  translocation	  t(X;9)(p11;q34)	  was	  found,	  which	   suggested	   that	   another	   IP	   gene	   may	   be	   at	   Xp11	   (Hodgson	   et	   al.,	   1985;	  Gilgenkrantz	   et	   al.,	   1985).	  However,	   it	   has	   been	   argued	   that	   these	   and	   other	   sporadic	  cases	  are	  not	  confluent	  with	  incontinentia	  pigmenti	  at	  all,	  since	  none	  of	  them	  matched	  the	   (syndromic)	   diagnostic	   criteria	   (Sybert,	   1994).	   It	   could	   be	   possible,	   though,	   that	  these	  chromosomal	  rearrangements	  affected	  the	  NDP	  locus	  at	  Xp11.3,	  which	  thus	  could	  explain	  the	  ocular	  similarities	  to	  IP.	  The	   eponymous	   pigmentary	   disturbances	   of	   the	   RPE	   have	   been	   postulated	   to	   be	   the	  cause	  of	  the	  retinovascular	  changes	  (Mensheha-­‐Manhart	  and	  Rodrigues,	  1975).	  But	  also	  the	  opposite,	  namely	  a	  vascular	  basis	   for	  the	  disease,	  has	  been	  suggested	  (Watzke	  and	  Stevens,	   1976).	   So	   far,	   the	   exact	   pathogenetic	   mechanism	   is	   unknown,	   although	   a	  unifying	  hypothesis	  was	  formulated	  proposing	  that	  vascular	  abnormalities	  are	  the	  result	  of	   a	   generalized	   type	   II	   (antibody-­‐mediated)	   cytotoxic	   inflammatory	   response	   to	   an	  abnormal	  gene	  product	  (Catalano,	  1990).	  	  
1.3.3.6	  Eales’	  disease	  (ED)	  Eales’	  disease	  (ED)	  is	  named	  after	  Henry	  Eales,	  who	  first	  noted	  recurrent	  hemorrhages	  and	  abnormal	  retinal	  veins	   in	  otherwise	  healthy	  young	  men	  (Eales,	  1880).	  Today,	   it	   is	  described	  as	  a	  primary	  retinal	  periphlebitis	  (inflammation	  of	  the	  outer	  coat	  of	  a	  vein	  or	  the	   tissues	   surrounding	   it),	  which	   secondarily	   leads	   to	   retinal	   ischemia	   (mainly	   in	   the	  periphery),	   finally	   culminating	   in	   retinal	   neovascularization,	   recurrent	   haemorrhages,	  and	   retinal	   detachment	   (Biswas	   et	   al.,	   2002).	   It	   predominantly	   affects	   healthy	   young	  males	   (97.6%)	   in	   India	   and	   the	   Middle	   East	   with	   a	   mean	   age	   of	   onset	   of	   26	   years,	  
INTRODUCTION	   35	  	  
	  
although	  one	  study	  from	  North	  America	  did	  not	  detect	  any	  gender	  differences	  (reviewed	  by	  Biswas	  et	  al.,	  2002).	  Retinal	   nonperfusion	   can	   lead	   to	   tortuous	   veins	   that	   closely	   resemble	   the	   vascular	  phenotype	  seen	  in	  ND/CD	  patients.	  Vascular	  sheating	  can	  be	  seen	  in	  80%	  of	  the	  patients	  (Gieser	  and	  Murphy,	  2001;	  Figure	  14	  A).	  In	  addition,	  the	  border	  between	  perfused	  and	  nonperfused	  retina	  is	  sharply	  demarkated	  (Spitznas	  et	  al.,	  1975;	  Figure	  14	  B).	  The	  etiology	  of	  ED	  is	  unclear	  and	  appears	  to	  be	  multifactorial.	  The	  primary	  events	  seem	  to	   involve	   ocular	   inflammation	   associated	   with	   immunologic	   phenomena.	   Leukocyte	  antigen,	   retinal	   autoimmunity,	   mycobacterial	   tuberculosis,	   and	   free	   radical–mediated	  damage	   seem	   to	   influence	   the	  pathogenesis	   of	   the	  disease	   (reviewed	  by	  Biswas	   et	   al.,	  2002).	  However,	  no	  evidence	  for	  a	  genetic	  basis	  has	  been	  presented	  so	  far.	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Figure	   14	   Fluorescein	   angiograms	   of	   Eales’	   disease	   patients.	   (A)	   Venular	   sheathing.	   Note	   the	   thin,	  continous	   white	   lines	   encompassing	   the	   vein	   (arrows).	   (B)	   The	   junction	   of	   perfused	   and	   nonperfused	  retina	  is	  obvious.	  (Source:	  Gieser	  and	  Murphy,	  2001)	  	  
1.3.3.7	  Neovascular	  inflammatory	  vitreoretinopathy	  (VRNI)	  Neovascular	   inflammatory	   vitreoretinopathy	   is	   an	   autosomal	   dominant	   blinding	  disorder	  characterized	  by	  neovascularization,	  vitreous	  hemorrhage,	  retinal	  detachment,	  and	  symptoms	  of	  ocular	   inflammation.	   It	  has	  been	  mapped	  to	  chromosome	  11q13,	  the	  region	  containing	  FZD4	  and	  LRP5	  (Sheffield	  et	  al.,	  1992;	  Stone	  et	  al.,	  1992).	  Sheffield	  et	  al.	  argued	  against	  the	  hypothesis	  that	  FEVR	  and	  VRNI	  are	  allelic,	  mainly	  on	  the	  basis	  of	  phenotypic	  differences.	  However,	  these	  differences	  might	  not	  exist	  on	  second	  sight	  (e.g.,	  the	  authors	  claimed	  the	  presence	  of	  vitreous	  cells	  to	  be	  exclusive	  for	  VRNI;	  a	  statement	  that	   cannot	   be	   sustained	   with	   regard	   to	   the	   published	   findings	   of	   the	   last	   17	   years).	  Consistency	   with	   another	   retinal	   disease,	   Best	   vitelliform	   macular	   dystrophy	   (VMD),	  which	  also	  maps	  to	  11q13,	  has	  been	  dismissed,	  because	  VMD	  has	  been	  associated	  with	  a	  gene	  10cM	  apart,	  bestrophin	  1	  (BEST1)	  (Sheffield	  et	  al.,	  1992).	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1.3.4	  Animal	  models	  To	  elucidate	  the	  molecular	  pathogenic	  mechanisms	  of	  human	  diseases	  and	  to	  investigate	  the	   efficacy	   of	   therapeutic	   strategies,	   animal	   models	   are	   often	   used	   under	   the	  assumption	   that	   findings	   can	  be	  generalized	   to	  human	  biology.	  Mice	  have	  become	   the	  major	  model	   used	   in	  medical	   research,	   primarily	   due	   to	   the	   ability	   to	   selectively	   turn	  genes	   on	   or	   off	   in	   so-­‐called	   transgenic	   or	   knockout	   mice,	   respectively	   (recently	  recognized	  by	  the	  award	  of	  the	  Nobel	  prize	  in	  Physiology	  or	  Medicine	  for	  2007	  to	  M.R.	  Capecchi,	  M.J.	  Evans,	  and	  O.	  Smithies	  for	  the	  development	  of	  the	  knockout	  technology).	  In	   addition,	   murine	   organ	   development	   and	   morphology	   are	   highly	   comparable	   to	  humans.	   With	   regard	   to	   the	   eye,	   some	   differences	   have	   to	   be	   kept	   in	   mind,	   though:	  Typical	   for	   a	   nocturnal	   animal,	   the	   cornea,	   lens,	   and	   vitreous	   are	   relatively	   large.	   The	  retina	   is	  rod-­‐dominated,	  and	  only	  two	  cone-­‐types	  (in	  contrast	   to	  three	   in	  humans)	  are	  present.	  However,	  one	  of	  the	  cone	  pigments	  is	  maximally	  responsive	  to	  ultraviolet	  (UV)	  light,	   thereby	   shifting	   the	   spectrum	   of	   perceivable	   light	   to	   shorter	   wave	   lenghts.	  Although	  no	  fovea	  (the	  retinal	  region	  in	  humans	  with	  the	  highest	  density	  of	  cones	  and	  lack	   of	   rods	   or	   retinal	   neurons;	   responsible	   for	   sharp,	   central	   vision)	   is	   present,	   the	  functional	  organization	  of	  the	  retinal	  network	  is	  largely	  similar.	  Further,	  the	  timing	  of	  events	  in	  retinal	  development	  is	  comparable,	  although	  the	  retinal	  vasculature	   in	   humans	   develops	   around	   mid-­‐gestation,	   and	   only	   postnatally	   in	   mice.	  This	  is	  important	  concerning	  the	  use	  of	  mouse	  models	  in	  ND	  research,	  because	  it	  allows	  easy	   accessibility	   during	   retinal	   vessel	   development,	   and	   allows	   generalization	   to	  human	   physiology.	   The	  murine	   retinal	   vasculature	   is	   also	   organized	   in	   three	   distinct	  layers.	   The	   superficial	   plexus,	   located	   within	   the	   ganglion	   cell	   /	   nerve	   fiber	   layer	  (GCL/NFL),	   starts	   at	   the	  optic	  nerve	  head	  and	   spreads	   radially	   towards	   the	  periphery	  between	   postnatal	   days	   3	   (p3)	   and	   p17.	   Around	   p7,	   blood	   vessels	   start	   to	   sprout	  perpendicular	   into	   the	   retina	   to	   form	   the	  deep	  retinal	  network	  at	   the	  border	  between	  outer	   plexiform	   layer	   (OPL)	   and	   inner	   nuclear	   layer	   (INL).	   The	   third,	   intermediate	  plexus	  starts	  to	  develop	  at	  p12,	  forming	  between	  the	  superficial	  and	  the	  deep	  networks	  at	  the	  border	  between	  inner	  plexiform	  layer	  (IPL)	  and	  INL	  (Fruttiger,	  2007).	  	  
1.3.4.1	  The	  Ndph	  knockout	  mouse	  The	  human	  NDP	   gene	   and	   the	  murine	  orthologue	  Ndph	   (Norrie	  disease	  pseudoglioma	  homolog)	   are	   highly	   conserved	   (95%	   sequence	   identity	   on	   the	   amino	   acid	   level),	   and	  similar	  transcriptional	  activity	  in	  eye,	  brain,	  and	  ear	  suggested	  an	  Ndph	  knockout	  mouse	  as	   a	   suitable	   model	   to	   study	   ND.	   The	   ko	   mouse	   was	   generated	   through	   targeted	  replacement	   of	   the	   coding	   part	   of	   exon	   2	  with	   a	   reverse	   oriented	   neomycin	   cassette,	  resulting	   in	   the	   deletion	   of	   the	   first	   56	   aa	   from	   the	   gene,	   including	   the	   signal	   peptide	  (Berger	   et	   al.,	   1996).	   The	   initial	   phenotypic	   characterization	   revealed	   an	   obvious	  involvement	   of	   ocular	   tissues.	   The	   vitreous	   of	   hemizygous	   Ndphy/-­	   mice	   contained	   a	  fibrovascular	   mass,	   and	   the	   retina	   appeared	   to	   be	   dysmorphic,	   with	   prominent	  disorganization	   of	   the	   ganglion	   cell	   layer.	   Heterozygous	   female	   carriers	   were	  asymptomatic.	   Electroretinography	   (ERG)	   measurements	   conducted	   to	   investigate	  retinal	   function	   revealed	   a	   more	   severe	   involvement	   of	   the	   inner	   retina.	   The	   b-­‐wave	  amplitudes	  generated	  by	  second	  order	  neurons	  were	  markedly	  reduced	  in	  hemizygous	  
Ndphy/-­	  mice,	  while	   the	  a-­‐waves	   (generated	  by	   the	  photoreceptors	   in	   the	  outer	   retina)	  were	   indistinguishable	   at	   lower	   light	   intensities,	   and	   only	   became	   conspicuous	   with	  increasing	   stimulus	   strength	   (Rüther	   et	   al.,	   1997).	   This	   finding	   was	   supported	   by	   a	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global	   gene	   expression	   study	   investigating	   retinal	   transcription	   in	   older	   mice,	   which	  revealed	  late	  degeneration	  of	  photoreceptor	  cells	  (Lenzner	  et	  al.,	  2002).	  The	  primary	  event	  in	  the	  pathogenesis	  of	  ND	  in	  the	  mouse	  seems	  to	  be	  the	  development	  of	   the	   retinal	   vasculature,	   as	   abberant	   morphology	   has	   been	   reported	   several	   times	  (Richter	  et	  al.,	  1998;	  Rehm	  et	  al.,	  2002;	  Luhmann	  et	  al.,	  2005a,b).	  The	  superficial	  vessel	  growth	  is	  delayed	  and	  never	  completed,	  leaving	  the	  retinal	  periphery	  avascular,	  and	  the	  deeper	   networks	   entirely	   fail	   to	   develop	   (Figure	   15;	   Figure	   16;	   Figure	   50).	   Since	   the	  astrocytic	   scaffold,	   which	   precedes	   vascular	   development	   and	   is	   important	   for	   vessel	  guidance,	  appears	  to	  be	  intact,	  a	  primary	  effect	  of	  the	  Ndph	  ko	  allele	  on	  endothelial	  cells	  has	   been	   suggested,	   resulting	   in	   a	   defect	   in	   sprouting	   angiogenesis	   (Luhmann	   et	   al.,	  2005a).	   In	   addition,	   regression	   of	   the	   fetal	   hyaloid	   vessel	   system	   is	   delayed	   and	  incomplete,	   resembling	   PFV.	   Detailed	   analysis	   of	   the	   early	   retinal	   development	  specifically	   focused	  on	   the	  vasculature	   in	  Ndph	   knockout	  mice	   revealed	   two	  phases	  of	  disease	  progression	   in	  vivo	   (Luhmann	  et	  al.,	  2005a):	   In	  the	  early	  phase,	   the	  absence	  of	  functional	   Norrin	   (Ndph–protein)	   causes	   a	   defect	   in	   sprouting	   angiogenesis	   and	   thus	  leads	  to	  a	  delayed	  outgrowth	  of	  the	  superficial	  vessels	  and	  prevents	  the	  formation	  of	  the	  deep	  capillary	  networks	  in	  the	  retina.	  Then,	  in	  the	  later	  phase,	  the	  developmental	  lack	  of	  the	   deep	   vasculature	   leads	   to	   inner	   retinal	   hypoxia.	   This	   pathological	   hypoxia	   may	  explain	  the	  observed	  clinical	  features	  of	  Norrie	  disease	  and	  might	  also	  be	  responsible	  for	  the	  similarities	  of	  the	  clinical	  phenotypes	  of	  the	  allelic	  diseases	  (Luhmann	  et	  al.,	  2005a).	  	  
  
A B 
Figure	  15	   Sections	   of	   p21	  Ndph	  wt	   and	   knockout	   retinas.	   Vessels	   have	   been	   stained	  with	   an	   antibody	  against	   collagen	   IV	   (red),	   nuclei	   were	   labeled	   with	   DAPI	   (blue).	   (A)	   All	   three	   retinal	   networks	   have	  developed	   in	   the	   wt	   retina,	   located	   in	   the	   RGC	   and	   in	   both	   plexiform	   layers	   adjacent	   to	   the	   INL.	   A	  connective	  vessel	  between	  the	  superficial	  and	  the	  intermediate	  network	  is	  visible	  on	  the	  right.	  (B)	  In	  the	  
Ndphy/-­	  retina,	  the	  deep	  and	  the	  intermediate	  vasculature	  are	  lacking.	  The	  superficial	  vasculature	  appears	  to	  be	  enlarged	  and	  forms	  occasional	  vessel	  clumps	  that	  can	  infiltrate	  the	  inner	  plexiform	  layer	  (visible	  on	  the	  right).	  INL:	  inner	  nuclear	  layer;	  ONL:	  outer	  nuclear	  layer;	  RGC:	  retinal	  ganglion	  cell	  layer.	  	  
In	  situ	  hybridization	  revealed	  Ndph	  expression	  in	  the	  three	  nuclear	  layers	  of	  the	  retina	  (RGC,	  INL,	  ONL),	  in	  the	  cochlea,	  olfactory	  bulb,	  hippocampus,	  cortex,	  and	  in	  the	  granular	  and	  Purkinje	  cell	  layers	  of	  the	  cerebellum	  (Chen	  et	  al.,	  1995;	  Berger	  et	  al.,	  1996;	  Hartzer	  et	  al.,	  1999).	  Thus,	  Ndph	  is	  expressed	  in	  all	  organs	  or	  tissues	  affected	  in	  ND.	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Figure	  16	  Flatmounted	  retinas	  of	  p7	  Ndph	  wt	  mice	  in	  comparison	  to	  ko.	  Images	  compiled	  from	  a	  Z-­‐Stack	  of	   pictures	   acquired	  with	   a	   Zeiss	   ApoTome™.	   To	   visualize	   the	   retinal	   vasculature,	   an	   antibody	   against	  collagen	   IV	  was	   used.	   (A)	   Top	   view	   of	   the	  wt	   superficial	   vasculature.	   (B)	   Same	   image	   as	   a	   in	   (A),	   but	  rotated	   90°.	   The	   superficial	   vasculature	   is	   located	   at	   the	   top.	   Deeper	   networks	   start	   to	   develop	   from	  angiogenic	   sprouts,	   mainly	   from	   veins	   and	   capillaries.	   (C)	   Topview	   of	   the	   ko	   retina.	   Outgrowth	   of	   the	  superficial	  capillary	  network	  appears	  to	  be	  much	  sparser,	  and	  (D)	  no	  developing	  deeper	  network	  could	  be	  detected	  in	  the	  90°	  rotated	  view.	  	  neurons	  of	   the	   spiral	  ganglion.	  But	   in	   contrast	   to	   the	  developmental	  defect	   in	   the	  eye,	  vessels	  in	  the	  inner	  ear	  at	  first	  seemed	  to	  develop	  normally,	  and	  pathologic	  changes	  only	  occured	   progressively	   during	   the	   adult	   life,	   hinting	   at	   a	   defect	   in	   homeostasis.	   Thus,	  norrin	   probably	   has	   a	   different	   effect	   on	   vasculature	   in	   eye	   and	   ear,	   affecting	  development	  in	  the	  first,	  and	  maintenance	  in	  the	  latter.	  In	  addition,	  Ndph	   transcripts	  were	  also	  detected	  in	  the	  endometrium	  of	  pregnant	  mice	  and	   in	   human	   placenta	   (Luhmann	   et	   al.,	   2005b).	   A	   human	   phenotype	   in	   female	  reproduction	  has	  not	  been	  reported	  so	  far,	  but	  female	  mice	  homozygous	  for	  the	  Ndph	  ko	  allele	   are	   completely	   infertile	  due	   to	   a	  defect	   in	  decidualization,	   i.e.	   remodeling	  of	   the	  endometrium	   (the	   inner	   membrane	   of	   the	   uterus)	   upon	   implantation	   of	   the	   embryo,	  probably	   as	   a	   result	   of	   impaired	   angiogenesis	   similar	   to	   the	   defects	   in	   eye	   and	   ear	  (Luhmann	  et	  al.	  2005b).	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No	   brain	   phenotype	   in	   the	   Ndph	   ko	   mouse	   has	   been	   described	   so	   far.	   However,	   in	  contrast	  to	  the	  eye,	  ear,	  and	  reproduction	  anomalies,	  assessment	  of	  mental	  retardation	  or	   developmental	   delay	   is	   more	   complicated.	   Since	   impairment	   of	   angiogenic	  remodeling	  seems	  to	  be	  the	  common	  cause	  of	  the	  respective	  phenotypes,	  it	  is	  tempting	  to	   speculate	   that	   it	   is	   also	   affected	   in	   cerebral	   tissues,	   especially	   since	   Ndph	   mRNA	  expression	  has	  been	  shown	  in	  cortex,	  hippocampus,	  and	  cerebellum.	  The	   ocular	  Ndph	   knockout	   phenotype	   could	   be	   rescued	   by	   ectopic	   overexpression	   of	  norrin	  in	  the	  lens	  (Ohlmann	  et	  al.,	  2005).	  	  
1.3.4.2	  The	  Fzd4	  knockout	  mouse	  The	   human	   and	   murine	   Fzd4	   genes	   are	   highly	   homologous,	   sharing	   96%	   sequence	  identity	   on	   the	   amino	   acid	   level.	   The	   Fzd4	   knockout	   mouse	   was	   generated	   through	  targeted	  replacement	  of	   the	  coding	  region	  of	   the	  Fzd4	   locus	  with	  a	  knock-­‐in	  construct	  containing	   a	  β-­‐galactosidase	   reporter	   and	   a	   neomycin	   resistance	   cassette,	   resulting	   in	  the	   near-­‐complete	   deletion	   of	   the	   Fzd4	   coding	   sequence	   (CDS;	   excluding	   the	   3’-­‐most	  70bp)	   (Wang	   et	   al.,	   2001).	   Fzd4	   is	   widely	   expressed	   during	   development,	   and	   in	   the	  adult,	  LacZ	   activity	  of	   the	  knock-­‐in	   reporter	   revealed	  expression	   in	  many	  CNS	   tissues,	  including	   brain,	   retina,	   and	   inner	   ear.	   In	   the	   cerebellum,	   LacZ	   expressivity	   was	  constrained	  to	  the	  Purkinje	  cells,	  while	  in	  the	  retina,	  uniform	  staining	  was	  found	  in	  the	  photoreceptor	  layer,	  and	  punctate	  staining	  was	  found	  in	  the	  inner	  nuclear	  and	  ganglion	  cell	  layers	  (Figure	  17	  C).	  	  
   
    
	  
Figure	  17	  (A,	  B)	  Retinal	  sections	  from	  p17	  Fzd4	  wt	  and	  Fzd4-­/-­	  mice	  (Source:	  Xu	  and	  Wang	  et	  al.,	  2004).	  
(A)	  The	  astrocytic	  network	  in	  the	  ganglion	  cell	  layer	  (GCL),	  labeled	  with	  an	  antibody	  against	  GFAP	  (green),	  and	  the	  three	  retinal	  blood	  vessel	  networks,	  stained	  with	  lectin	  (red),	  appeared	  normal	  in	  the	  wt	  mouse.	  
(B)	  While	   the	   astrocytic	   network	  was	   similar	   to	   the	  wt,	   the	   Fzd4-­/-­	   retina	   obiously	   lacks	   the	   deep	   and	  intermediate	  vasculature,	  and	  vessels	  of	  the	  superficial	  plexus	  appeared	  sparser	  and	  enlarged.	  (C)	  Spatial	  expression	  of	  Fzd4	  was	  investigated	  by	  X-­‐Gal	  staining	  of	  the	  adult	  Fzd4+/-­	  retina.	  Intenese	  staining	  in	  the	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photoreceptor	   layer,	   with	   uniform	   staining	   especially	   in	   the	   inner	   segments,	   and	   scattered,	   punctate	  staining	   in	   the	   inner	   nuclear	   and	   ganglion	   cell	   layers	  was	   observed	   (Source:	  Wang	   et	   al.,	   2001).	   (D-­‐G)	  Retinal	  flatmounts	  of	  p10	  Fzd4	  wt	  and	  ko	  mice.	  Vessels	  were	  stained	  as	  in	  A	  &	  B	  (Source:	  Xu	  and	  Wang	  et	  al.,	  2004).	  (D)	  In	  the	  p10	  wt,	  the	  superficial	  vasculature	  has	  reached	  the	  retinal	  periphery.	  (E)	  In	  the	  Fzd4-­
/-­	  retina,	  the	  superficial	  vasculature	  is	  sparser,	  and	  a	  characteristical	  clustering	  of	  endothelial	  cells	  at	  the	  sprouting	   front	  has	   formed,	   reminiscent	  of	   the	   fibrovascular	   ridge	   seen	   in	  ROP	  patients,	   separating	   the	  vascularized	  retina	  from	  the	  avascular	  periphery.	  (F,	  G)	  Same	  pictures	  as	  D	  &	  E,	  but	  with	  additional	  GFAP	  staining	  (green).	  (F)	  In	  the	  wt	  retina,	  close	  association	  of	  the	  astrocytic	  scaffold	  and	  the	  vasculature	  can	  be	  seen	  (yellow).	  (G)	  The	  astrocytic	  network	  in	  the	  Fzd4-­/-­	  retina	  is	  similar	  to	  the	  wt,	  extending	  to	  the	  retinal	  periphery.	  	  Homozygous	  Fzd4-­/-­	  knockout	  mice	  exhibit	  several	  distinct	  defects	  that	  closely	  resemble	  that	   of	   the	  Ndph	   ko	   mouse	   (Wang	   et	   al.,	   2001;	   Xu	   and	   Wang	   et	   al.,	   2004).	   The	   two	  intraretinal	   vessel	   systems	   are	   not	   developed,	   and	   the	   capillary	   bed	   of	   the	   superficial	  vasculature	  is	  only	  sparse,	  while	  the	  major	  arteries	  and	  veins	  are	  enlarged	  and	  tortuous	  (Figure	  17).	  In	  further	  concordance	  with	  the	  Ndph	  ko	  phenotpye	  (Figure	  50),	  outgrowth	  of	  the	  superficial	  vasculature	  is	  delayed,	  and	  a	  clustering	  of	  endothelial	  cells	  reminiscent	  to	  the	  characteristic	  fibrovascular	  ridge	  in	  ROP	  patients	  (Figure	  8)	  forms	  at	  the	  front	  of	  the	  sprouting	  vessels	  (Figure	  16).	  Many	  vessels	  in	  the	  nerve	  fiber	  layer	  are	  fenestrated,	  correlating	  with	   frequently	   observed	   retinal	   hermorrhages,	   and	   the	  hyaloid	   vessels	   in	  the	   vitreous	   fail	   to	   regress	   (Xu	   and	   Wang	   et	   al.,	   2004).	   However,	   in	   contrast	   to	   the	  
Ndphy/-­	  mouse,	  no	  obvious	  disorganization	  or	  degeneration	  of	  retinal	  neurons	  was	  noted	  in	  early	  adulthood.	  In	  addition	  to	  the	  ocular	  phenotype,	  progressive	  deafness	  was	  found,	  caused	  by	  a	  defect	  in	  the	  peripheral	  auditory	  system.	  The	  stria	  vascularis	  presented	  with	  enlarged	  vessels,	  and	  loss	  of	  outer	  hair	  cells	  was	  noted	  at	  4.5	  months	  of	  age.	  In	  11-­‐month-­‐old	  Fzd4-­/-­	  mice,	  the	   stria	   vascularis	   was	   completely	   degenerated	   and	   no	   vessels	   remained.	  Concomitantly,	   nearly	   complete	   loss	   of	   outer	   and	   inner	   hair	   cells	   was	   noted.	  Importantly,	   initial	  development	  of	   the	   inner	  ear	   seems	   to	  be	  similar	   to	  wt,	   thus	  Fzd4	  may	  be	  necessary	  for	  cochlear	  maintenance	  and	  survival	  (Wang	  et	  al.,	  2001),	  similar	  to	  norrin	  (Rehm	  et	  al.,	  2002).	  Loss	  of	  normal	  vascular	  morphology	  was	   further	  observed	   in	   the	  cerebellum,	  where	   it	  seems	   to	   correlate	   with	   progressive	   cerebellar	   degeneration.	   Beginning	   in	   the	   third	  postnatal	  week,	  Fzd4-­/-­	  mice	   exhibit	   an	   anormal	   gait	   and	   characteristical	  wide	   stance,	  which	  is	  a	  sign	  of	  severe	  cerebellar	  ataxia	  (Wang	  et	  al.,	  2001).	  Vessels	  become	  sparser,	  and	   by	   6	   months	   of	   age,	   the	   network	   appears	   disturbed,	   with	   enlarged	   vessels	   and	  frequent	   small	  hemorrhages	   (Figure	  18),	  while	   the	  vasculature	  elsewhere	   in	   the	  brain	  seems	  to	  be	  normal	  (Xu	  and	  Wang	  et	  al.,	  2004).	  Like	  the	  Ndph	  ko	  homozygous	  females,	  Fzd4	  ko	  homozygous	  female	  mice	  were	  reported	  to	  be	  infertile.	  However,	  the	  defect	  seems	  to	  involve	  corpora	  lutea	  formation,	  causing	  a	  failure	  in	  implantation,	  in	  contrast	  to	  impaired	  decidualization	  in	  Ndph	  ko	  mice	  (Hsieh	  et	  al.,	  2005).	  In	  addition,	  growth	  delay,	  reduced	  viability,	  and	  the	  absence	  of	  a	  skeletal	  muscle	  sheath	  around	   the	   lower	   esophagus	   have	   been	   noted.	   Also,	   the	   coat	   color	   of	   homozygous	  knockout	   mice	   is	   lighter,	   suggesting	   that	   Fzd4	   may	   play	   a	   role	   in	   the	   expansion	   or	  migration	   of	   melanocyte	   precursors	   from	   the	   neural	   crest	   or	   the	   differentiation	   and	  survival	  of	  melanocytes	  (Wang	  et	  al.,	  2001).	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Figure	  18	  Cerebellar	  sections	  of	  Fzd4	  wt	  and	  ko	  mice	  stained	  with	  an	  antibody	  against	  collagen	  IV	  (green)	  and	  DAPI	   (blue).	   (A)	   Cerebellar	   vasculature	   in	   the	   p14	  wt	   is	   similar	   to	   (B)	   the	  Fzd4-­/-­	   vasculature.	   (C)	  Vessels	  in	  the	  cerebellum	  of	  a	  6-­‐month-­‐old	  wt	  present	  with	  a	  different	  pattern	  than	  (D)	  cerebellar	  vessels	  in	   the	  Fzd4-­/-­	  mouse.	  Vessels	  are	  sparser,	  enlarged,	  and	   irregularly	  patterned,	  and	   the	  granule	  cell	   layer	  (blue)	  appears	  thinner	  than	  in	  the	  wt.	  (Source:	  Xu	  and	  Wang	  et	  al.,	  2004)	  	  Taken	   together,	   the	   phenotypic	   similarity	   between	   Fzd4	   and	   Ndph	   knockout	   mice	   is	  striking.	  The	  auditory	  and	  cerebellar	  phenotypes	  of	  Fzd4-­/-­	  mice	  implicate	  Fzd4	  signaling	  in	  maintenance	  of	  viability	  and	  integrity	  of	  the	  nervous	  system,	  which	  is	  in	  constrast	  to	  the	  observed	  ocular	  developmental	  defect	  and	  the	  commonly	  presumed	  role	  associated	  with	   Wnts,	   early	   cell	   proliferation	   and	   patterning	   effects	   (Wang	   et	   al.,	   2001).	   An	  interesting	   difference	   to	   human	   patients	   with	   mutations	   in	   Fzd4	   is	   the	   observed	  heterozygous	   insufficiency.	  Only	  one	  (severe)	  FEVR	  case	  with	  a	  homozygous	  mutation	  has	   been	  published	   (Kondo	   et	   al.,	   2003;	  Kondo	   et	   al.,	   2007),	  while	   all	   other	   cases	   are	  heterozygous.	   Thus,	   mutations	   in	   Fzd4	   are	   considered	   to	   be	   dominant,	   while	   the	  heterozygous	   mouse	   apparently	   shows	   no	   differences	   to	   wt	   littermates.	   Further,	   no	  extraocular	   symptoms	   have	   been	   described	   in	   patients	   with	   FZD4	   mutations,	   which	  maybe	  only	  manifest	  in	  homozygous	  cases.	  	  
1.3.4.3	  The	  Lrp5	  knockout	  and	  r18	  mutant	  mice	  
Lrp5	   is	  a	  23	  exon	  gene	   that	   like	  norrin	  shares	  95%	  sequence	   identity	  between	  human	  and	  mouse	  on	  protein	   level	   (Hey	  et	  al.,	  1998).	  Lrp5	   is	  very	  broadly	  expressed	   in	  most	  mouse	  tissues	  (Kato	  et	  al.,	  2002).	  Two	  different	  knockout	  mice	  (Kato	  et	  al.,	  2002;	  Fujino	  et	   al.,	   2003),	   and	   a	   mouse	   with	   a	   frameshift	   mutation,	   derived	   through	   induced	  mutagenesis	  (Xia	  et	  al.,	  2008),	  have	  been	  established.	  The	   first	   Lrp5	   ko	  mouse	   was	   generated	   through	   insertion	   of	   an	   IRES-­‐LacZ-­‐Neomycin	  cassette	  at	  amino	  acid	  residue	  373	  in	  exon	  6	  (Kato	  et	  al.,	  2002).	  This	  deletion	  of	  exon	  6	  did	  not	  lead	  to	  exon	  skipping,	  and	  thus	  created	  a	  functional	  ko,	  although	  a	  truncated	  5’-­‐transcript	  and	  resulting	  N-­‐terminal	  peptide	  were	  detected.	  Heterozygous	   Lrp5+/-­	   mice	   were	   phenotypically	   normal.	   Lrp5-­/-­	   mice	   were	   viable	   and	  fertile,	   but	   had	   a	   higher	  mortality	   rate,	   presumably	   due	   to	   fractures.	   They	   presented	  with	   a	   failure	   of	   macrophage-­‐mediated	   apoptosis	   of	   the	   hyaloid	   vessels	   (Kato	   et	   al.,	  2002),	   although	   the	   number	   of	   macrophages	   associated	   with	   wt	   and	   Lrp5-­/-­	   hyaloid	  vessels	   did	   not	   differ.	   LacZ	   expression	   of	   the	   knock-­‐in	   construct	   was	   detected	   in	  macrophages	   (Kato	   et	   al.,	   2002)	   and	   closely	   associated	   vitreal	   microvasculature	  endothelial	   cells	   (Lobov	   et	   al.,	   2005).	   In	   addition	   to	   the	   persistance	   of	   the	   hyaloid	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vasculature,	  a	  mild	  delay	   in	  regression	  was	  noted	   for	   the	  pupillary	  membrane	  and	  the	  tunica	   vasculosa	   lentis.	   No	   delay	   in	   hyaloid	   vessel	   regression	  was	   detected	   in	   Lrp5+/-­	  (Kato	   et	   al.,	   2002).	   The	   retinal	   phenotype	   again	  was	   very	   similar	   to	   that	   observed	   in	  




Figure	  19	  Retinal	  vasculature	  in	  1-­‐month-­‐old	  Lrp5	  knockout	  mice.	  (A)	  Normal	  fluorescein	  angiogram	  of	  an	  Lrp5+/-­	  retina.	  (B)	  The	  angiogram	  of	  the	  Lrp5-­/-­	  retina	  reveals	  increased	  background	  fluorescent	  signals	  due	  to	  hyperpermeable	  vessels.	  (C)	  A	  normal,	  three-­‐layered	  vasculature	  was	  found	  in	  this	  Lrp5+/-­	  retinal	  section	  labeled	  with	  an	  antibody	  against	  CD31	  (PECAM;	  an	  endothelial	  cell	  marker;	  green).	  (D)	  In	  the	  Lrp5	  null	   retina,	   only	   the	   superficial	   network	  was	   labeled	   similarly.	   The	   deep	   plexus	   in	   the	   outer	   plexiform	  layer	  (OPL)	  was	  not	  developed,	  and	  vessels	  in	  the	  IPL	  were	  reduced.	  (Source:	  Xia	  et	  al.,	  2008)	  	  Another	   OPPG	   mouse	   model	   was	   generated	   through	   ENU	   (N-­‐ethyl-­‐N-­‐nitrosourea)-­‐induced	   mutagenesis	   (Xia	   et	   al.,	   2008).	   Whole-­‐genome	   linkage	   analysis	   of	   offspring	  presenting	  with	   an	   eye	   phenotype	   similar	   to	   FEVR	   lead	   to	   the	   localization	   of	   the	   r18	  mutant	   allele	   in	   the	   Lrp5	   gene.	   A	   single	   nucleotide	   insertion	   in	   exon	   23	   was	   found,	  causing	  a	  frame	  shift	  and	  resulting	  in	  the	  replacement	  of	  the	  C-­‐terminal	  39	  amino	  acid	  residues	  by	  20	  new	  amino	  acids.	  Hetero-­‐	  and	  homozygous	  r18	  mice	  were	  viable	  and	  fertile.	  Homozygous	  Lrp5r18/r18	  mice	  presented	   with	   pale,	   attenuated	   retinal	   arteries,	   hypopigmentation,	   and	   frequently	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Figure	   20	  Three	   dimensional	   images	   of	   fluorescent-­‐dye	   labeled	   retinal	   vessels	   in	   6-­‐week-­‐old	  Lrp5	   r18	  mutant	   hetero-­‐	   and	   homozygous	   littermates.	   (A)	   A	   normal,	   three-­‐layered	   vasculature	   is	   present	   in	   the	  heterozygous	  Lrp5+/r18	  retina.	  (B)	  The	  retinal	  blood	  vessel	  system	  of	  the	  homozygous	  Lrp5r18/r18	  mutant	  is	  disorganized	   and	   attenuated.	   (C,	  D)	  These	  panels	   correspond	   to	   the	   images	   above,	   but	   are	   rotated	  90°.	  (Source:	  Xia	  et	  al.,	  2008)	  
	  Instead,	  extensive	  analyses	  have	  concentrated	  on	  the	  bone	  phenotype.	  Decreased	  bone	  mass	   in	  Lrp-­/-­,	   but	   also	   to	   a	   lesser	   extent	   in	  Lrp5+/-­,	   were	   shown	   to	   be	   the	   result	   of	   a	  functional	  defect	  of	  osteoblasts	  (Kato	  et	  al.,	  2002).	  Decrease	  in	  osteoblast	  proliferation	  and	   subsequent	   reduction	   of	   bone	   matrix	   deposition	   resulted	   in	   impaired	   bone	  formation	  postnatally.	  Since	  this	  phenotype	  was	  also	  evident	  in	  heterozygotes,	  the	  bone	  phenotype	   was	   proposed	   to	   be	   a	   dominant	   effect	   of	   the	   mutation,	   while	   the	   ocular	  features	   are	   recessive	   (Kato	   et	   al.,	   2002).	   This	   observation	   correlates	   well	   with	   the	  description	  of	  OPPG	  patients	  (Gong	  et	  al.,	  2001;	  Ai	  et	  al.,	  2005).	  Another	  Lrp5	  deficient	  mouse	  was	  generated	  through	  insertion	  of	  a	  neomycin	  cassette	  in	  exon	  18,	  thereby	  disrupting	  a	  ligand	  binding	  repeat	  (Fujino	  et	  al.,	  2003).	  In	  contrast	  to	  the	  other	  Lrp5	  mouse	  models,	  no	  apparent	  histological	  anomalies	   in	  bone	  or	  eye	  were	  reported.	   However,	   Lrp5	   and	   canonical	  Wnt	   signaling	  were	   shown	   to	   be	   required	   for	  glucose-­‐induced	   insulin	   secretion.	   Thus,	   this	   finding	   may	   provide	   a	   link	   between	  exudative	   vitreoretinopathies	   (caused	   by	   mutations	   in	   NDP,	   FZD4,	   and	   LRP5)	   and	  diabetic	  retinopathy.	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1.3.5	  The	  molecular	  basis	  of	  Norrie	  disease	  and	  allelic	  disorders	  	  From	   a	   geneticist’s	   point	   of	   view,	   the	   definite	   diagnosis	   for	   a	   certain	   exudative	  vitreoretinopathy	  can	  only	  be	  made	  when	  a	  causative	  gene	  mutation	  has	  been	  found.	   I	  suggest	   the	  diagnosis	  of	  Norrie	  disease,	   if	  a	  mutation	   in	  NDP	  were	   found;	  OPPG,	   if	   the	  mutation	  in	  LRP5	  is	  recessive,	  and	  HBM,	  if	  it	  is	  dominant.	  A	  little	  complex	  and	  confusing	  is	  the	  diagnosis	  of	  FEVR,	  since	  mutations	  in	  FZD4,	  NDP,	  and	  LRP5	  have	  been	  described	  as	  causes	  for	  FEVR,	  maybe	  due	  to	  the	  high	  variability	  of	  the	  diseases	  and	  the	  difficulties	  to	  establish	  definite	  morphological	  and	  clinical	  definitions.	   I	  suggest	   that	   the	  diagnosis	  of	  FEVR	  is	  only	  used	  when	  mutations	  in	  FZD4	  have	  been	  found,	  although	  the	  term	  “familial	  exudative	   vitreoretinopathy”	   could	   equally	   apply	   to	   all	   disorders	   caused	   by	   inherited	  mutations	  in	  NDP,	  FZD4,	  and	  LRP5.	  Prompted	  by	  the	  similar	  symptoms	  in	  patients	  harboring	  mutations	  in	  either	  NDP,	  FZD4,	  or	   LRP5	   (Figure	   21),	   and	   the	   close	   phenotypic	   appearance	   of	   the	   respective	   mouse	  models,	  Norrin	  has	  been	   found	   to	  be	  a	  high-­‐affinity	   ligand	  of	   the	  FZD4/LRP5	  receptor	  pair	  (Xu	  and	  Wang	  et	  al.,	  2004).	  	  
  
Figure	  21	  Loci	  and	  phenotypes	  associated	  with	  familial	  exudative	  vitreoretinopathy.	  Mutations	  in	  3	  genes	  have	  been	  associated	  with	  FEVR	  so	  far,	  while	  evidence	  has	  been	  published	  for	  at	  least	  3	  additional	  loci.	  
	  
1.3.5.1	  Wnt-­‐signaling	  FZD4	  and	  LRP5	  are	  known	  receptors	  for	  wingless	  type	  (Wnt)	  proteins.	  Members	  of	  this	  family	   are	   highly	   conserved	   and	   play	   important	   roles	   in	   multiple	   developmental	  processes,	  including	  mesoderm	  induction,	  tissue	  patterning,	  cell	  fate	  determination,	  and	  cell	  proliferation	  (Logan	  and	  Nusse,	  2004).	  Wnt-­‐induced	  signaling	  generally	   is	   thought	  to	  be	  limited	  to	  the	  immediate	  vicinity	  of	  the	  site	  of	  synthesis	  and	  secretion,	  presumably	  as	  a	  consequence	  of	  the	  tight	  binding	  of	  Wnts	  to	  extracellular	  matrix	  molecules	  (Wang	  et	  al.,	  2001).	  Although	  norrin	  is	  not	  part	  of	  the	  Wnt-­‐family	  of	  proteins,	  it	  shares	  a	  number	  of	   common	   features,	   like	   asscociation	   with	   the	   extracellular	   matrix	   (Perez-­‐Villar	   and	  Hill,	   1997),	   and	   the	   ability	   to	   induce	   canonical	   Wnt-­‐signaling	   (Figure	   22)	   through	  binding	  to	  FZD4/LRP5	  (Xu	  and	  Wang	  et	  al.,	  2004).	  Canonical	   Wnt-­‐signaling	   (or	   “Wnt/β-­‐catenin	   signaling”)	   probably	   is	   the	   most	  investigated	   and	   best	   understood	  Wnt	   pathway	   (reviewed	   in	   Lad	   et	   al.,	   2008).	   In	   the	  absence	   of	  Wnt-­‐proteins,	   a	   destruction	   complex	   consisting	   of	   adenomatous	   polyposis	  coli	  (APC)	  and	  AXIN1	  causes	  casein	  kinase	  1	  and	  glycogen	  synthase	  kinase	  3	  (GSK3β)	  to	  phosphorylate	   β-­‐catenin,	   thereby	   targeting	   it	   for	   ubiquitination	   and	   subsequent	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degradation	   by	   the	   proteosome.	   Upon	   binding	   of	   Wnts	   to	   the	   Frizzled/LRP-­‐receptor	  complex,	  activation	  of	  the	  phosphoprotein	  disheveled	  (DVL)	  leads	  to	  translocation	  of	  the	  GSK3-­‐complex	   to	   the	   cell	   membrane,	   where	   AXIN1	   binds	   to	   LRP5/6	   and	   becomes	  degraded.	   As	   a	   result,	   the	   GSK3-­‐complex	   dissociates,	   stablizing	   cytoplasmic	   β-­‐catenin	  and	  allowing	  it	  to	  translocate	  to	  the	  nucleus.	  It	  then	  interacts	  with	  transcription	  factors	  of	  the	  TCF/LEF-­‐family	  and	  initiates	  the	  transcription	  of	  target	  genes	  (Figure	  22).	  	  
  
A   B 
Figure	   22	   Canonical	   Wnt-­‐pathway.	   (A)	   In	   absence	   of	   Wnts	   or	   norrin,	   cytoplasmic	   β-­‐catenin	   is	  phosphorylated	   by	   a	   GSK3β	   complex	   (containing	   GSK3β,	   Axin1,	   APC,	   and	   casein	   kinase	   1),	   leading	   to	  ubiquitination	  and	  degradation	  by	  the	  proteosome.	  (B)	  Binding	  of	  norrin	  or	  Wnt-­‐proteins	  to	  frizzled	  and	  LRP5/6	  receptors	  activates	  the	  phosphoprotein	  disheveled,	  which	  subsequently	  inhibits	  GSK3β,	  and	  leads	  to	  binding	  of	  Axin1	  to	  LRP5/6.	  As	  consequence,	  the	  GSK3β	  destruction	  complex	  is	  degraded,	  and	  β-­‐catenin	  becomes	  stabilized	  and	  is	  able	  to	  translocate	  to	  the	  nucleus,	  where	  it	  binds	  to	  transcription	  factors	  of	  the	  TCF/LEF	  family,	  leading	  to	  transcription	  of	  target	  genes	  (modified	  after	  Lad	  et	  al.,	  2008).	  	  Based	   on	   the	   finding	   that	   norrin	   activates	   canonical	   Wnt-­‐signaling,	   the	   most	   likely	  pathogenic	  molecular	  mechanism	  for	  NDP,	  FZD4,	  and	  LRP5-­‐associated	  diseases	  would	  be	  altered	   signaling	   activity.	   This	   hypothesis	   was	   supported	   by	   experiments,	   in	   which	  signaling	  efficacy	  was	  measured	  for	  18	  NDP	  missense	  mutations	  in	  cells	  co-­‐transfected	  with	  Fzd4,	  Lrp5,	  and	  a	  Luciferase	  reporter	  under	  the	  control	  of	  Wnt-­‐/β-­‐catenin	  signaling	  (the	   so	   called	   “Super	   TOP-­‐FLASH”	   reporter).	   For	   17	   mutations,	   reduced	   signaling	  efficacy	  was	  found	  (Table	  2).	  11	  mutations	  even	  show	  less	  than	  half	  of	  the	  wt	  activity.	  In	  contrast,	  one	  mutation	  (p.K58N)	  showed	  2-­‐fold	  enhanced	  activity	  in	  comparison	  to	  the	  wt	  construct	  (Xu	  and	  Wang	  et	  al.,	  2004).	  Thus,	   Wnt-­‐target	   genes	   affected	   by	   altered	   signaling	   activity	   of	   the	   NDP/FZD4/LRP5	  complex	  would	  be	  ideal	  candidates	  for	  further	  mutation	  screening	  in	  ND/EVR	  patients	  negative	  for	  mutations	  in	  the	  three	  known	  genes	  (Figure	  21).	  In	  the	  following	  paragraph,	  I	  want	  to	  give	  an	  overview	  over	  the	  known	  genetic	  basis	  of	  ND	  and	  allelic	  diseases	  by	  reviewing	  the	  molecular	  properties	  of	  NDP,	  FZD4,	  and	  LRP5,	  and	  all	  disease-­‐associated	  mutations	  reported	  so	  far.	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Figure	  23	   Sequence	   and	   structure	  of	   norrin.	   (A)	  Multiple	   alignment	   of	   human,	   cow,	   and	  mouse	  norrin	  shows	   strong	   conservation.	   Six	   cysteine	   residues	   are	   important	   for	   the	   cystine-­‐knot	   structure.	   Specific	  domains	   are	  highlighted:	  orange:	   amino	   acids	   encoded	  by	   exon	  2;	   red:	   signal	   peptide;	   	  green,	  magenta:	  intramolecular	   disulfide	   bridge-­‐forming	   cysteins;	   blue:	   cysteine	   involved	   in	   dimerisation	   or	  oligomerisation.	  (B)	  Putative	  NDP	  tertiary	  structure,	   forming	  a	  cystine-­‐knot	  (adapted	   from	  Meitinger	  et	  al.,	  1993).	  Color	  scheme	   is	  equal	   to	   the	  one	  used	   in	   (A).	  (C)	  3D	  model	  of	  monomeric	  Norrin.	  An	  α-­‐helix	  (“heel”)	  is	  shown	  instead	  of	  the	  v-­‐loop	  in	  (B),	  and	  the	  two	  anti-­‐parallel	  β-­‐sheets	  are	  designated	  as	  “fingers”	  (from	  Meitinger	  et	  al.,	  1993).	  (Figure	  adapted	  from:	  Masterthesis	  Zürcher,	  2007,	  and	  W.	  Berger,	  personal	  communication)	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factors	  that	  also	  include	  platelet-­‐derived	  growth	  factor-­‐β	  (PDGF-­‐β),	  nerve	  growth	  factor	  (NGF),	   vascular	   endothelial	   growth	   factor	   (VEGF),	   placental	   growth	   facor	   (PlGF),	   and	  von-­‐Willebrand-­‐factor	  (VWF)	  (McDonald	  and	  Hendrickson,	  1993).	  A	   total	   of	   116	   different	  NDP	   mutations	   have	   been	   described	   so	   far	   (Table	   2).	   These	  include	   16	   gross	   chromosomal	   aberrations	   leading	   to	   entire	   or	   partial	   deletion	   of	   the	  
NDP	  locus.	  The	  remaining	  mutations	  are	  small	  insertions,	  deletions,	  or	  point	  mutations.	  91	  different	  mutations	  lie	  inside	  the	  reading	  frame,	  5	  mutations	  are	  located	  in	  exon	  1,	  1	  mutation	  is	  in	  intron	  1,	  5	  mutations	  are	  in	  intron	  2,	  and	  1	  mutation	  has	  been	  located	  in	  the	  3’-­‐UTR.	   	  Point	  mutations	  alone	  account	   for	  an	  amino	  acid	  exchange	  at	  49	  different	  positions.	  All	  mutations	  have	  been	  associated	  with	  visual	  impairment,	  although	  Norrie	  disease	  was	  not	  always	  suspected.	  Due	  to	  the	  high	  variability	  of	  the	  clinical	  presentation,	  even	  within	  one	  family	  (Zaremba	  et	  al.,	  1998),	  diagnoses	  also	  included	  Coats’	  disease	  (CD),	  (familial)	  exudative	  vitreoretinopathy	   (F)EVR,	  persistent	   fetal	  vasculature	   (PFV/PHPV),	  X-­‐linked	  recessive	   primary	   retinal	   dysplasia	   (PRDX),	   retinopathy	   of	   prematurity	   (ROP),	  retinoblastoma	  (RB),	  and	  retinoschisis	  (RS).	  In	  the	  case	  of	  29	  mutations	  (25%),	  variable	  degrees	   of	   hearing	   impairment	   have	   been	   reported	   in	   addition.	   No	   mention	   about	  hearing	   impairment	   has	   been	  made	   for	   22%	  of	   the	  NDP	  mutations.	   	   In	   the	   remaining	  53%,	  signs	  of	  progressive	  deafness	  might	  have	  been	  missed,	  since	   late	  onset	  and	  slow	  progression	   of	   the	   hearing	   loss	   may	   mask	   its	   presence	   and	   thereby	   limit	   formal	  assessment	  (Schuhback	  et	  al.,	  1995).	  While	  Warburg	  initially	  estimated	  30%	  (Warburg,	  1966)	  of	  the	  patients	  suffer	  from	  deafness,	  Halpin	  and	  Rehm	  proposed	  that	  penetrance	  is	  100%	  (Rehm	  et	  al.,	  2002;	  Halpin	  et	  al.,	  2005),	  and	  nearly	  all	  patients	  have	  detectable	  hearing	  impairment	  after	  puberty.	  Although	  this	  might	  be	  technically	  right,	  it	  is	  of	  great	  importance	   to	   be	   aware	   what	   these	   numbers	   mean	   for	   the	   blind	   patients,	   and	   to	   be	  careful	  how	  to	  confront	  them	  with	  the	  diagnosis.	  Mental	   retardation	   has	   been	   described	   in	   association	  with	   40	  mutations	   (35%).	   Here	  again,	  high	  variability	  has	  been	  observed,	  ranging	  from	  low	  IQ	  and	  learning	  difficulties	  to	   severe	   MR,	   growth	   failure,	   autistic	   features,	   and	   seizures.	   In	   contrast	   to	   the	  progressive	   nature	   of	   the	   hearing	   impairment,	   mental	   features	   usually	   present	   very	  early	   in	   life,	   and	   thus	   the	   estimated	   value	   of	   35%	   may	   be	   a	   good	   estimate	   for	   the	  penetrance.	  However,	  it	  could	  be	  difficult	  to	  differentiate	  between	  an	  NDP-­‐related	  mild	  MR	  and	  a	  developmental	  delay	  that	   is	  often	  observed	   in	  congenitally	  blind	  patients.	   In	  addition	   to	   vision	   loss,	   blind	   patients	   often	   encounter	   problems	   with	   their	   circadian	  rhythm	  (depending	  on	  the	  severity	  of	  damage	  to	  their	  melanopsin-­‐containing	  ganglion	  cells).	   If	   learning	  depends	   on	   a	   regular	   sleep	   routine	   (which	   is	   a	   popular	   hypothesis),	  developmental	  delay	  could	  easily	  be	  explained	  with	  a	  disturbed	  sleep/wake	  cycle	  alone.	  Black	   et	   al.	   suggested	   that	   Coats’	   disease	   (CD)	   is	   caused	   by	   a	   somatic	  NDP	  mutation	  within	   cells	   of	   neuroectodermal	   origin	   at	   a	   stage	   of	   development	   that	   results	   in	   a	  segment	  of	  the	  retina	  carrying	  the	  mutant	  allele	  (Black	  et	  al.,	  1999).	  This	  hypothesis	  of	  a	  genetic	   mosaic	   could	   explain	   the	   typical	   unilateral	   appearance	   and	   high	   phenotypic	  variability	  of	  CD.	  Manifesting	   carriers	  have	  been	  described	   for	  8	  mutations	   (7%).	  One	  of	   those	  patients	  was	  diagnosed	  with	  Coats’	   disease	   as	  only	  one	  of	  her	   eyes	  was	   affected.	   Interestingly,	  she	  then	  gave	  birth	  to	  an	  affected	  son,	  who	  presented	  with	  a	  full	  ND	  phenotype.	  In	  this	  case,	  a	  possible	  explanation	  could	  be	  a	  non-­‐random	  X-­‐inactivation,	  or	  a	  second,	  somatic	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mutation	  in	  the	  NDP	  gene	  in	  the	  mother’s	  affected	  eye.	  Such	  a	  situation	  was	  found	  in	  an	  enucleated	   eye	   of	   another,	   unrelated	   CD	   patient	   (Black	   et	   al.,	   1999).	   In	   the	   case	   of	   a	  manifesting	   carrier	  with	   a	   p.C69S	  mutation	   (Chen	   et	   al.,	   1993),	   a	   70:30	  X-­‐inactivation	  ratio	  in	  favor	  of	  the	  mutant	  allele	  has	  been	  found.	  In	  another	  2	  cases,	  genetically	  healthy	  female	  offspring	  of	  an	  NDP	  mutation-­‐carrying	  mother	  presented	  with	  an	  ND	  phenotype,	  indicating	   a	   transplacental	   role	   of	   Norrin	   might	   affect	   penetrance	   in	   females	   (Mintz-­‐Hittner	  et	  al.,	  1996).	  	  Different	   attempts	   have	   been	   made	   to	   assign	   certain	   mutations	   to	   a	   specific	   clinical	  presentation.	  Gross	  deletions	  and	  nonsense	  mutations	  have	  been	  assigned	  exclusively	  to	  ND	   (first	   noted	   by	   Wong	   et	   al.,	   1993;	   Chynn	   et	   al.,	   1996).	   Further,	   more	   severe	  phenotypes	  have	  been	  described	  if	  one	  of	  the	  structurally	  relevant	  six	  cysteine	  residues	  (39,	  65,	  69,	  96,	  126,	  128)	  constituting	   the	  cystine-­‐knot-­‐motif	   is	   involved	   (Meitinger	  et	  al.,	  1993;	  Schuback	  et	  al.,	  1995).	   Initially,	   it	  was	  suggested	   that	  mutations	   in	  NDP	  only	  account	  for	  the	  ocular	  phenotype,	  since	  no	  signs	  of	  mental	  retardation	  (MR)	  were	  found	  in	   a	   patient	   with	   a	   150kb	   deletion	   encompassing	   the	   entire	   NDP	   gene,	   but	   not	   the	  neighboring	   MAO-­A	   and	   MAO-­B	   genes.	   In	   contrast,	   patients	   with	   gross	   deletions	  including	   these	   genes	   were	  mentally	   challenged	   (Berger	   et	   al,	   1992).	   However,	   since	  then	   many	   point	   mutations	   have	   been	   described	   in	   patients	   with	   features	   of	   ND	  including	  MR,	  substantiating	  a	  role	  for	  norrin	  in	  the	  development	  of	  MR	  (e.g.	  Joos	  et	  al.,	  1994;	  Lev	  et	  al.,	  2007;	  Table	  2).	  Further,	  it	  has	  been	  proposed	  that	  myoclonus	  epilepsy	  and	  growth	  retardation	  were	  never	  seen	   in	  association	  with	  point	  mutations	  and	   thus	  must	  be	  ascribed	  to	  functional	  defects	  in	  other	  genes	  or	  non-­‐genic	  factors	  (Berger	  et	  al.,	  1992).	   However,	   a	   patient	   with	   a	   p.S75P	   mutation	   has	   been	   described	   who	   suffered	  from	  tonic-­‐clonic	  epilepsy	  and	  frontal	  motor	  seizures,	  indicating	  that	  epilepsy	  is	  part	  of	  the	   phenotypic	   spectrum	   of	   ND,	   in	   the	   case	   concurrent	   non-­‐genic	   factors	   can	   be	  excluded	  (Yamada	  et	  al.,	  2001).	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Phenotype Exon cDNA Protein Reference Age Deafness MR MF 
         
Gross deletions including NDP: 
ND  4 different deletions (complete, partial, 4bp and single)  Zhu, 1994 ? ? ?  
ND / FEVR  xp11.4invq22  Pettenati, 1993 ~ + +  
ND 1-3 entire NDP deletion, as well as MAOA & MAOB; 2-2.5 Mb  Suarez-Merino, 2001 ~ ? seizures  
ND 2 partial NDP deletion, 4kb  Chen, 1993 ? ? ?  
ND 2 partial NDP deletion, 5kb  Chen, 1993 ? ? ?  
ND 2 partial NDP deletion, 2-10kb  Chen, 1993 2 - -  
ND 2 partial NDP deletion  Schuback, 1995 2 - -  
ND 2-3 partial NDP deletion  Schuback, 1995 5 - -  
ND 3 partial NDP deletion; MAOA/MAOB del >20kb  Chen, 1993 2 - 
microcephaly, 
seizures  
ND 3 partial NDP deletion; 7kb; part of exon 3  Chen, 1993 ? ? ?  
ND 3 partial NDP deletion  Schuback, 1995 <1 - -  
ND 3 partial NDP deletion  Schuback, 1995 36 + seizures  
ND 3 partial NDP deletion; 3’-UTR of ex3 incl. PAS  Rivera-Vega, 2005 ~ - 22%  
         
Small deletions, insertions, and point mutations in NDP: 
ROP 1 c.-391_-380delinsGTCTCTC 5´-UTR Talks, 2001 1 - - + 
ROP 1 c.-386_-310del 5´-UTR Talks, 2001 <1 ? ?  
ND, ROP 1 ins 12 bp (CT repeat) 5´-UTR Hiraoka, 2001; Wu, 2007 <1 - -  
ND 1 ins 10 bp (CT repeat) 5´-UTR Schuback, 1995 ~ + 50%  
ROP, RS 1 del 14 bp (CT repeat) 5´-UTR Hiraoka, 2001; Dickinson, 2006; Wu, 2007 <1 - -  
ND IVS 1 c.-208+1G>A  Fuchs, 1996 9 + +  
ND 2 c.1A>G p.M1V Isashiki, 1995; Gal, 1996; ZH, unpublished ~ 50% 50%  
ND 2 c.2_3delTG p.M1KfsX22 Caballero, 1996 10 - -  
ND 2 c.2T>G p.M1R Schuback, 1995 20 + autistic features  
ND? 2 c.27_28insATCC p.F10IfsX17 Berger, 1992 ~ - -  
ND 2 c.38T>G p.L13R* Fuchs, 1994 ~ 78% 45%  
ND 2 c.44T>G p.L15R Berger, 2008 11 ? ?  
ND 2 c.47T>C p.L16P Yamada, 2001 ~ - seizures (20%)  
ND 2 c.50_51insT p.V17fsX8 Gal, 1996 ~ ? seizures  
ND, FEVR 2 c.53T>A p.I18K Kondo, 2007; Shima, 2009 <1 - -  
ND 2 c.65delC p.T22KfsX9 Schuback, 1995 12 +/- -  
ND 2 c.86C>G p.S29X Meindl, 1992 ~ ? +  
ND 2 c.103delG p.D35TfsX6 Chynn, 1996 <1 - -  
ND 2 c.109C>T p.R37X Ott, 2000 6 - -  
ND, FEVR, 
PHPV 2 c.112C>T p.R38C 
Royer, 2003; Riveiro-Alvarez, 
2005 ~ - -  
ND 2 c.115T>C p.C39R Joos, 1994; Wu, 2007 ~ 50% microcephaly (50%)  
EVR 2 c.122G>A p.R41K* Shastry, 1997 ? - -  
PFV 2 c.123G>C p.R41S Wu, 2007 <1 - -  
PFV 2 c.123G>T p.R41S Dhingra, 2006 <1 - -  
FEVR, EVR 2 c.125A>G p.H42R* Shastry, 1997; Wu, 2007 ~ - -  
ND 2 c.128_129insA p.H43QfsX13 Caballero, 1996 <1 - -  
ND 2 c.128A>G p.H43R Dickinson, 2006 5 + -  
ND 2 c.129C>G p.H43Q Royer, 2003 ~ - +  
ND 2 c.131A>G p.Y44C Meindl, 1992 26 - ++  
ND, PHPV, 
sporadic 2 c.131_132insA p.Y44X Hatsukawa, 2002 ~ - -  
ND 2 c.133G>A p.V45M Royer, 2003 18 - +  
ND, MR 2 c.134T>A p.V45E Lev, 2007 <2 ? seizures  
ND 2 c.136delG p.D46IfsX58 Schuback, 1995 22 + -  
ND 2 c.142_145delATCA p.I48VfsX55 Zhu, 1994 Meeting abstract ? ? ?  
ND, FEVR 2 c.162G>C p.K54N Hoefsloot, 2000; Kondo, 2007; Boonstra, 2009 ~ - ? + 
ND 2 c.170C>G p.S57X Berger, 1992 ? + +  
ND, EVR 2 c.174G>T p.K58N† Fuentes, 1993; Shastry, 1997 ~ +/- 50%  
ND IVS 2 c.174+1G>T ? ZH, unpublished ? ? ?  
ND IVS 2 c.174+1G>C ?p.K58fsX49? Fuchs, 1996 2 - -  
ND IVS 2 c.174+5G>C ?p.K58fsX49? Berger, 1992; Fuchs, 1996 ? - +  
ND IVS 2 c.175-1G>C ? Royer, 2003 ~ + 40%  
ND, FEVR IVS 2 c.175-1G>A ? Kondo, 2007 1 - -  
ND 3 c.179T>A p.V60E* Meindl, 1992 11 - +/-  
ND, VI 3 c.181C>T p.L61F Berger, 1992; Rehm, 1997 ~ + -  
FEVR 3 c.181C>A p.L61I Wu, 2007 <1 - -  
ND 3 c.182T>C p.L61P* Schuback, 1995 14 - -  
ND 3 c.185T>C p.L62P Zhu, 1994 Meeting abstract ? ? ?  
ND 3 c.187G>T p.A63S Novelli, 1999 ? ? ?  
ND 3 c.188C>A p.A63D* Schuback, 1995 14 - -  
ND 3 c.194G>A p.C65Y Strasberg, 1995; Wu, 2007 ~ + +  
ND 3 c.195C>G p.C65W Schuback, 1995 ? ? ?  
PFV (unilateral) 3 c.196G>A p.E66K Aponte, 2009 <1 - -  
50	   INTRODUCTION	  	  
	  
Phenotype Exon cDNA Protein Reference Age Deafness MR MF 
ND 3 c.205delT p.C69AfsX35 Schuback, 1995 45 + +  
ND 3 c.206G>C p.C69S Chen, 1993 ~ + 66% + 
ND 3 c.218C>A p.S73X Walker, 1997 <1 - -  
ND, FEVR 3 c.220C>T p.R74C Berger, 1992; Fuchs, 1996; Allen, 2006 ? +/- -  
ND 3 c.223T>C p.S75P Yamada, 2001 ~ - seizures (40%)  
ND 3 c.224C>G p.S75C Berger, 1992 ? + +  
ND 3 c.226G>T p.E76X Hutcheson, 2005 ? ? ?  
ND 3 c.236_240delTGTCG p.V78fsX67 Riveiro-Alvarez, 2005 ? + +  
ND 3 c.267_268insCTC p.F89_R90insL Hutcheson, 2005 ? ? ?  
ND 3 c.268C>T p.R90C Royer, 2003 ~ - 75%  
ND 3 c.269G>C p.R90P* Berger, 1992 ? - -  
ND 3 c.282_286delinsATGCCTCG p.H94_C96delinsQCLG Schuback, 1995 17 + autistic features  
ND (severe) 3 c.283T>C p.C95R Isashiki, 1995 16 - -  
ND (severe) 3 c.284G>T p.C95F Khan, 2004 ~ - -  
ND (severe) 3 c.285C>A p.C95X Wu, 2007 <1 50% ?  
ND, EVR 3 c.287G>A p.C96Y Berger, 1992; Meindl, 1992; Shastry, 1999 ~ - + + 
ND, CD 3 c.288C>G p.C96W Black, 1999 ~ - - + 
ND 3 c.290delG p.R97RfsX6 Berger, 1992 ? ? +  
ND 3 c.290G>C p.R97P Rivera-Vega, 2005; Kondo, 2007 ~ - 33%  
ND, PHPV 
(mild) 3 c.302C>T p.S101F* Walker, 1997 ~ - -  
FEVR 3 c.307C>G p.L103V Dickinson, 2006 ? - -  
ND (mild) 3 c.310A>C p.K104Q* Meindl, 1995 3 ? -  
ND 3 c.312G>T p.K104N Riveiro-Alvarez, 2006 ? ? ?  
ND 3 c.313G>A p.A105T* Torrente, 1997 ~ - -  
ROP 3 c.323T>C p.L108P* Shastry, 1997 1 - -  
ND 3 c.325C>T p.R109X Schuback, 1995; Mintz-Hittner, 1996 ~ 50% 50% (+)* 
ND 3 c.328T>C p.C110R Zhu, 1993; Fuchs, 1996 ~ + -  
FEVR 3 c.328T>G p.C110G* Torrente, 1997 ~ - -  
ND 3 c.328T>A p.C110S ZH, unpublished  ? ?  
ND 3 c.330C>A p.C110X Berger, 1992 ? -/+ -  
ND 3 c.333delA p.S111fsX150 Hutcheson, 2005 ? ? ?  
FEVR (highly 
variable) 3 c.335G>A p.G112E Allen, 2006 ~ - -  
FEVR 3 c.344G>T p.R115L Kondo, 2007 21 - -  
ND 3 c.353C>A p.A118D Shastry, 1999 ~ + - + 
EVR 3 c.359A>G p.Y120C* Shastry, 1997 ? - -  
ND 3 c.360C>A p.Y120X Riveiro-Alvarez, 2005 ? + +/-  
ND 3 c.360_368delCCGGTACAT p.R121_I123del Schuback, 1995 1 - -  
ND, PRDX 3 c.361C>G p.R121G Zhu, 1994 Meeting Abstract ? ? ?  
ND, ND (mild), 
FEVR, ROP 3 c.361C>T p.R121W 
Meindl, 1995; Shastry, 1995; 
Kellner, 1996; Shastry, 1997; 
Wu, 2007 
~ - - + 
ND, ND (mild), 
FEVR 3 c.362G>A p.R121Q* 
Fuentes, 1993; Meindl, 1995; 
Riveiro-Alvarez, 2005; 
Boonstra, 2009 
~ - -  
FEVR (highly 
variable) 3 p.362G>T p.R121L* 
Johnson, 1996; Mintz-Hittner, 
1996 ~ - - (+)* 
ND 3 c.368T>A p.I123N* Schuback, 1995 ~ 50% seizures  
FEVR 3 c.370C>T p.L124F* Chen, 1993 ~ - -  
ND 3 c.377G>C p.C126S Gal, 1996 ~ + seizures  
ND 3 c.378T>A p.C126X Fuchs, 1996; Keller, 1996 ~ - - + 
ND 3 c.382T>C p.C128R Royer, 2003 3 - -  
ND 3 c.383_384delinsAA p.C128X Wong, 1993; Hutcheson, 2005 ~ - autistic features  
ND 3 c.384C>A p.C128X Schuback, 1995 <1 ? +  
ND 3 c.397delT p.S133PfsX129 Berger, 1992 ? ? +  
ND 3 c.399delC p.S133fsX128 Riveiro-Alvarez, 2008 ? ? ?  
FEVR 3 c.*716T>C 3´-UTR Wu, 2007 <1 - -  
	  
Table	   2	   List	   of	   all	   NDP	   mutations	   published	   so	   far.	   Numbering	   according	   to	   reference	   sequence	  NC_000023.9,	  GI:	  89161218.	  The	  A	  of	  the	  ATG	  start	  codon	  lies	  at	  position	  +1.	  Age:	  age	  at	  first	  examination;	  tilde	  symbol	  (~):	  varying,	  i.e.	  the	  same	  patient	  was	  examined	  at	  different	  ages,	  or	  several	  different	  patients	  have	  been	  described.	  Penetrance	  of	  the	  mutation	  is	  given	  in	  percent,	  where	  described.	  Mutations	  marked	  with	  *	  have	  been	  shown	  to	  have	  reduced	  efficacy	  to	  induce	  Wnt-­‐/β-­‐catenin	  signaling	  in	  cell	  culture,	  while	  the	  p.K58N	  mutation	  (†)	  has	  2-­‐fold	  increased	  efficacy	  (Xu	  and	  Wang	  et	  al.,	  2004).	  CD:	  Coats’	  disease;	  EVR:	  exudative	   vitreoretinopathy	   (sporadic);	   FEVR;	   familial	   exudative	   vitreoretinopathy;	   MF:	   manifesting	  female;	   MR:	   mental	   retardation;	   ND:	   Norrie	   disease;	   	   PAS:	   polyadenylation	   signal;	   PHPV:	   persistent	  hyperplastic	   primary	   vitreous;	   PFV:	   persistent	   fetal	   vasculature;	   PRDX:	   primary	   retinal	   dysplasia,	   X-­‐linked;	  ROP:	  retinopathy	  of	  prematurity;	  RS:	  retinoschisis;	  VI:	  venous	  insufficiency.	  *indicated	  manifesting	  females	   were	   genetically	   healthy	   (wt)	   offspring	   of	   a	   heterozygous	   mother;	   this	   may	   indicate	   a	  transplacental	  effect	  of	  NDP	  mutations.	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1.3.5.3	  FZD4	  The	   first	   locus	   for	   autosomal	   dominant	   FEVR	   has	   been	   mapped	   to	   the	   long	   arm	   of	  chromosome	   11	   at	   11q13-­‐q23	   (Li	   et	   al.,	   1992).	   Ten	   years	   later,	   the	   seven-­‐pass	  transmembrane	  receptor	  Frizzled-­‐4	  (FZD4;	  CD344)	  was	  identified	  as	  the	  disease-­‐causing	  gene,	   thereby	   associating	   a	   Wnt-­‐receptor	   with	   human	   disease	   for	   the	   first	   time	  (Robitaille	  et	  al.,	  2002).	  FZD4	   is	  a	  2-­‐exon	  gene	  consisting	  of	  7,382	  bps	  (separated	  by	  a	  2,330bps	   intron),	  producing	  a	  537aa	  protein,	  and	  spans	  a	  9,711bps	  genomic	  region	  at	  11q14.2	   (Figure	   24).	   FZD4	   is	   highly	   conserved,	   with	   96%	   identity	   on	   the	   amino	   acid	  level	  with	  rat	  and	  mouse.	  A	  total	  of	  27	  different	  mutations	  have	  been	  described	  so	  far	  (Figure	  24;	  Table	  3).	  Most	  common	   are	   missense	   mutations	   (18),	   followed	   by	   frameshift	   (5)	   and	   nonsense	   (3)	  mutations.	  Although	  mutations	  in	  the	  FZD4	  gene	  have	  been	  defined	  to	  follow	  dominant	  inheritance,	  which	  is	  in	  contrast	  to	  the	  mouse	  model	  (Wang	  et	  al.,	  2001),	  penetrance	  and	  phenotypic	  variablility	  are	  high.	  Kondo	  et	  al.	  (2003)	  described	  2	  families	  with	  a	  p.R417Q	  exchange	  in	  7	  members,	  yet	  only	  4	  were	  diagnosed	  with	  FEVR	  (58%).	  In	  the	  case	  of	  the	  p.M105V	  and	  p.G488D	  alterations,	  only	  one	  of	  two	  family	  members	  carrying	  one	  of	  the	  mutations	  was	  clinically	  affected	  (50%).	  The	  same	  applies	  to	  the	  p.M342V	  and	  p.W335C	  mutations,	  which	  only	  have	  been	  found	  in	  one	  of	  two	  mutation-­‐carrying	  family	  members	  (Yoshida	   et	   al.,	   2004;	   Qin	   et	   al.,	   2005).	   Penetrance	   of	   the	   p.W319CfsX5	   frameshift	  	  	  
	  
Figure	  24	  Amino	  acid	  sequence	  and	  schematic	  structure	  of	  FZD4.	  The	   first	  95aa	  are	  encoded	   in	  exon	  1	  (green	   box),	   the	   remaining	   442aa	   in	   exon	   2	   (orange	   box).	   All	   mutations	   known	   to	   date	   are	   depicted:	  Truncating	  nonsense	  or	  frameshift	  mutations	  (orange),	  missense	  mutations	  (blue),	  and	  the	  small	  deletion	  (purple)	  (adapted	  from	  Toomes	  et	  al.,	  2004).	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Phenotype Exon cDNA Protein Reference Age 
           
FEVR 1 c.97C>T p.P33S† MacDonald, 2005; Nallthambi, 2006; Boonstra, 2009 ~ 
FEVR 1 c.107G>A p.G36D Toomes, 2004  
FEVR 1 c.205C>T p.H69Y Omoto, 2004  
FEVR 1 c.244_251del8ins27 p.F82AfsX54 Nallathambi, 2006  
           
FEVR 2 c.313A>G p.M105V Kondo, 2003  
FEVR 2 c.314C>T p.M105T Toomes, 2004  
ND; FEVR; PFV 2 c.341T>C p.I114T Robitaille, 2009  
FEVR 2 c.471A>G p.M157V Toomes, 2004 ~ 
FEVR; PFV 2 c.541T>C p.C181R Omoto, 2004  
FEVR 2 c.610T>C p.C204R Nallathambi, 2006 ~ 
FEVR 2 c.668T>A p.M223K Boonstra, 2009  
ROP 2 c.766A>G p.I256V MacDonald, 2005 ? 
FEVR 2 c.957G>A p.W319X Kondo, 2003  
FEVR 2 c.957delG p.W319CfsX5 Toomes, 2004 <1 
FEVR 2 c.1005G>C p.W335C Qin, 2005  
FEVR 2 c.1024A>G p.M342V Yoshida, 2004  
PHPV/severe FEVR* 2 c.1250G>A p.R417Q Kondo, 2003 / 2007  
FEVR 2 c.1286_1290delAGTTA p.K428RfsX28 Müller, 2004 ~ 
FEVR 2 c.1333A>C p.T445P Boonstra, 2009  
FEVR 2 c.1463G>A p.G488D Kondo, 2003  
FEVR 2 c.1474C>G p.G492R Müller, 2004 ~ 
FEVR; PFV 2 c.1479_1484delGTGGAT p.M493_W494del Robitaille, 2002 / 2009  
FEVR 2 c.1488G>A p.W496X Boonstra, 2009  
FEVR 2 c.1490C>T p.S497F Toomes, 2004  
FEVR 2 c.1497delA p.K499fsX13 Toomes, 2004  
FEVR 2 c.1501_1502delCT p.L501SfsX33 Robitaille, 2002  
FEVR 2 c.1513C>T p.Q505X Toomes, 2004  
	  
Table	   3	   List	   of	   all	   FZD4	   mutations	   published	   so	   far.	   Numbering	   according	   to	   reference	   sequence	  NC_000011.8,	  GI:	  51511727.	  The	  A	  of	  the	  ATG	  start	  codon	  lies	  at	  position	  +1.	  Age:	  age	  at	  first	  examination;	  tilde	  symbol	  (~):	  varying,	  i.e.	  the	  same	  patient	  was	  examined	  at	  different	  ages,	  or	  several	  different	  patients	  have	   been	   described.	   FEVR:	   familial	   exudative	   vitreoretinopathy;	  ND:	   Norrie	   disease;	   PHPV:	   persistent	  hyperplastic	   primary	   vitreous;	  PFV:	   persistent	   fetal	   vasculature;	  ROP:	   retinopathy	   of	   prematurity.	   *The	  severe	  phenotype	  could	  be	  explained	  by	  the	  homozygousity	  of	  the	  mutation,	  the	  only	  one	  described	  so	  far.	  †	  Conflicting	   reports	  exist	  about	   the	  pathogenicity	  of	   this	  mutation,	   since	   it	  was	  not	   found	   to	   segregate	  with	  the	  disease	  in	  an	  FEVR	  family	  (Boonstra	  et	  al.,	  2009),	  but	  was	  found	  in	  a	  sporadic	  case	  (MacDonald	  et	  al.,	  2005)	  and	  in	  an	  Indian	  family	  (Nallathambi	  et	  al.,	  2006).	  	  mutation	  was	  determined	  to	  be	  33%	  (1/3).	  However,	  the	  patient’s	  father	  and	  sibling	  had	  not	   undergone	   fluorescein	   angiography,	   leaving	   the	  possibility	   of	   subclinical	   affection.	  The	  truncation	  mutation	  p.Q505X	  had	  a	  penetrance	  of	  75%	  (3/4)	  (Toomes	  et	  al.,	  2004).	  The	   mutations	   p.K428RfsX28	   and	   p.G492R	   have	   been	   reported	   to	   show	   100%	  penetrance,	   but	   variable	   expressivity	   (Müller	   et	   al.,	   2008),	   and	   non-­‐penetrance	   for	  mutations	  in	  p.W319X	  was	  53%	  (8/15)	  (Boonstra	  et	  al.,	  2009).	  The	  two	  variants	  p.P33S	  and	  p.P168S	  were	  found	  in	  cis	  in	  a	  sporadic	  EVR	  case	  (MacDonald	  et	  al.,	  2005).	  Since	  the	  p.P168S	   alteration	  was	   described	   as	   a	   benign	   rare	   sequence	   variant	   (p<0.3%)	   before	  (Toomes	  et	  al.	  2004),	  the	  authors	  concluded	  that	  only	  the	  p.P33S	  variation	  is	  pathogenic.	  However,	  both	  variations	  on	  the	  same	  allele	  did	  not	  co-­‐segregate	  with	  FEVR	  in	  a	  family	  recently	  described,	  further	  suggesting	  highly	  variable	  penetrance	  (Boonstra	  et	  al.,	  2009).	  Taken	  together,	  although	  mutations	  in	  FZD4	  are	  dominantly	  inherited,	  no	  prediction	  can	  be	   made	   on	   the	   expressivity	   of	   a	   clinical	   phenotype,	   suggesting	   the	   involvement	   of	  additional	  modifiers.	  One	  such	  possible	  non-­‐genic	  modifier	  was	  recently	  discussed	  in	  a	  family	  with	   4	  members	   carrying	   a	   p.I114T	   (Robitaille	   et	   al.,	   2009).	   The	   grandmother	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harbored	   the	  mutation,	   but	  was	   asymptomatic.	  The	  mother	   also	   carried	   the	  mutation,	  but	   the	   phenotype	   was	   mild,	   with	   no	   avascular	   retinal	   areas	   and	   a	   retinal	   tear	   and	  possible	  hole	  being	  the	  only	  signs.	  In	  contrast,	  her	  two	  boys	  presented	  with	  a	  full	  blown	  FEVR	  phenotype	  with	  retinal	  detachments	  and	  low	  visual	  acuity.	  Of	  interest,	  the	  mother	  was	   treated	   with	   valproic	   acid	   for	   juvenile	   myoclonic	   epilepsy	   during	   pregnancy.	  Valproic	   acid	   has	   been	   shown	   to	   up-­‐regulate	   genes	   in	   the	   Wnt-­‐pathway	   (Duenas-­‐Gonzales	   et	   al.,	   2008),	   and	   the	   authors	   thus	   speculated	   that	   development	   of	   a	   worse	  FEVR	  phenotype	  could	  in	  part	  be	  due	  to	  valproic	  acid	  in	  the	  presence	  of	  a	  FZD4	  mutation	  in	  the	  mother.	  	  	  In	   addition	   to	   co-­‐segregation	   with	   the	   disease,	   the	   effect	   of	   possible	   pathogenic	  alterations	   in	  FZD4	  was	  mainly	   supported	  with	   in	   silico	   analyses,	   e.g.	  by	  predicting	  an	  effect	   on	   the	   protein	   structure.	   In	   the	   case	   of	   the	   p.L501SfsX33	  mutation,	   it	   could	   be	  experimentally	  shown	  that	  the	  mutation	  in	  the	  cytoplasmic	  tail	  inhibited	  the	  protein	  to	  translocate	  to	  the	  plasmamembrane	  (Robitaille	  et	  al.,	  2002).	  Interestingly,	  and	  in	  contrast	  to	  NDP	  and	  LRP5,	  mutations	  in	  FZD4	  have	  been	  associated	  only	   with	   ocular	   features	   so	   far.	   This	   may	   be	   related	   to	   the	   almost	   exclusive	  heterozygous	   occurrence	   in	   FEVR	   patients.	   The	   homozygous	   Fzd4	   ko	  mouse,	   like	   the	  
Ndph	  ko	  mouse,	  presented	  with	  progressive	  hearing	  loss	  and	  in	  addition	  showed	  signs	  of	   cerebellar	   ataxia.	   The	   lack	   of	   reports	   on	   homozygous	   FZD4	   mutations	   in	   patients	  might	  of	  course	  be	  due	  to	  the	  rare	  prevalence	  of	  the	  mutated	  alleles,	  but	  it	  is	  tempting	  to	  speculate	   that	   some	   extraoccular	   features	   could	   manifest	   in	   patients	   harboring	   a	  homozygous	  mutation.	  In	  the	  only	  case	  report	  of	  a	  homozygous	  patient	  published	  so	  far,	  the	   eye	   phenotype	   was	   severe	   and	   worse	   than	   in	   the	   heterozygous	   parents,	   but	   no	  mention	  about	  extraocular	  features	  was	  made	  (Kondo	  et	  al.,	  2007).	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1.3.5.4	  LRP5	  Mutations	   in	   the	   low-­‐density	   lipoprotein	   receptor-­‐related	   protein	   5	   gene	   (LRP5)	   first	  have	   been	   associated	   with	   OPPG	   (Gong	   et	   al.,	   2001),	   then	   with	   high	   bone	   mass	  phenotypes	   (HBM;	   Little	   et	   al.,	   2002;	   Boyden	   et	   al.,	   2002),	   and	   later	   also	   with	   FEVR	  (Toomes	  et	  al.,	  2004).	  LRP5	  is	  located	  on	  11q13.2	  and	  spans	  a	  genomic	  region	  of	  136.63	  kb.	  The	  only	  known	  transcript	  (ENST00000294304)	  consists	  of	  5,124	  bps,	  is	  organized	  in	  23	  exons	  and	  codes	  for	  a	  1,615	  aa	  protein	  (Figure	  92).	  	  LRP5	  functions	  as	  a	  Wnt	  co-­‐receptor	  that	  can	  be	  divided	   into	  an	  extracellular,	  a	  single	  transmembrane,	   and	   a	   cytoplasmic	   domain.	   The	   large	   extracellular	   domain	   of	   LRP5	  consists	  of	  a	  signal	  peptide	  followed	  by	  four	  six-­‐bladed	  β-­‐propeller	  domains	  (containing	  six	  YWDT	  motifs)	  separated	  by	  an	  EGF-­‐like	  repeat	  each,	  and	  three	  LDL-­‐Receptor	  repeats	  (Figure	  25).	  WNT	  ligands	  bind	  to	  the	  first	  two	  β-­‐propellers.	  The	  intracellular	  domain	  has	  been	  shown	  to	  bind	  Axin	  (AXIN1)	  and	  FRAT1	  (frequently	  rearranged	  in	  advanced	  T-­‐cell	  lymphomas)	   (Balemans	   and	   van	  Hul,	   2006).	   The	  Wnt-­‐inhibitor	   family	   dickkopf	   (DKK)	  initially	  has	  been	  proposed	  to	  bind	  to	  the	  third	  β-­‐propeller	  (Mao	  et	  al.,	  2001),	  although	  additional	  evidence	  has	  been	  provided	  that	  DKK	  may	  bind	  to	  the	  first	  and	  second	  or	  the	  third	  and	   fourth	  β-­‐propeller	  motifs	   (Zhang	  et	  al.,	  2004).	  This	  would	  correlate	  with	   the	  finding	  that	  DKK	  inhibition	  (besides	   inhibition	  through	  Sclerostin)	   is	   impaired	   in	  HBM	  associated	  alleles,	  which	  cluster	  in	  the	  first	  β-­‐propeller	  (Semenov,	  2006).	  	  	  
	  
Figure	  25	  Illustration	  of	  the	  LRP5	  protein	  showing	  the	  clustering	  of	  mutations	  causing	  HBM	  in	  the	  first	  β-­‐propeller	   and	   the	   clustering	   of	  missense	  mutations	   causing	   OPPG	   in	   the	   second	   β-­‐propeller.	   (modified	  from	  Balemans	  and	  van	  Hul,	  2006)	  	  A	  total	  of	  85	  different	  LRP5	  mutations	  have	  been	  described	  so	  far	  (Table	  4).	  Two	  large	  deletions	   were	   reported:	   one	   gross	   deletion	   of	   8kb	   due	   to	   non-­‐homologous	  recombination	  between	  Alu	  repeats,	  leading	  to	  the	  removal	  of	  exons	  14-­‐16	  (Chung	  et	  al.,	  2009),	  and	  one	  large	  deletion	  of	  174bp	  involving	  parts	  of	  exon	  and	  intron	  11	  (Ai	  et	  al.,	  2005).	  The	  remaining	  mutations	  are	  small	   insertions,	  deletions,	  or	  point	  mutations.	  81	  different	  mutations	  lie	  inside	  the	  reading	  frame,	  2	  mutations	  are	  located	  in	  the	  5’-­‐UTR,	  3	  mutations	  are	  intronic.	  70	  mutations	  have	  been	  associated	  with	  an	  eye	  phenotype;	  the	  remaining	   15	   were	   only	   described	   in	   conjunction	   with	   bone	   anomalies.	   All	   10	   HBM	  associated	  mutations	  do	  not	  seem	  to	  have	  ocular	  effects	  (Boyden	  et	  al.,	  2002;	  Little	  et	  al.,	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2002;	  van	  Wesenbeek	  et	  al.,	  2003;	  Boyden	  in	  response	  to	  Whyte	  et	  al.,	  2004;	  Rickels	  et	  al.,	  2005;	  Balemans	  et	  al.,	  2007).	  	  Carriers	   of	   OPPG	   mutations	   show	   an	   increased	   incidence	   for	   osteoporotic	   fractures,	  indicating	  a	  dominant	  effect	  of	  LRP5	  on	  bone	  mass,	  but	  only	  a	  recessive	  influence	  on	  the	  ocular	   phenotype	   (van	   Wesenbeeck	   et	   al.,	   2003;	   Gong	   et	   al,	   1996).	   This	   hypothesis	  correlates	  with	  the	  published	  data:	  All	  15	  bone-­‐only-­‐related	  mutations	  follow	  dominant	  inheritance,	   and	  51	  of	   the	  70	  eye-­‐related	  mutations	  have	  been	  described	  as	   recessive.	  The	  cases	  of	  the	  divergent	  19	  mutations	  described	  as	  dominant	  have	  to	  be	  treated	  with	  care:	   In	   most	   cases,	   the	   respective	   mutation	   was	   also	   found	   heterozygously	   in	   non-­‐affected	  relatives	  (Gong	  et	  al.,	  2001;	  Toomes	  et	  al.,	  2004;	  Ai	  et	  al.,	  2005),	  and	  the	  term	  „dominant“	  was	  used	  to	  describe	  the	  effect	  on	  the	  skeletal	  system,	  but	  not	  the	  eye.	  Several	  compound	  heterozygous	  LRP5	  mutations	  were	  found	  (Gong	  et	  al.,	  2001;	  Ai	  et	  al.,	  2005;	   Cheung	   et	   al.,	   2006).	   Digenic	   inheritance	   of	   mutations	   in	   LRP5	   and	   FZD4	   was	  reported	   in	   one	   study,	   stating	   that	   the	   phenotype	   was	   more	   severe	   than	   with	   the	  dominant	  FZD4	  mutation	  alone	  (Qin	  et	  al.,	  2005).	  This	   finding	  opens	  up	  the	  possibility	  that	  digenic	   inheritance	  could	  have	  been	  missed	   in	  some	  of	   the	  cases	  with	  a	  supposed	  dominant	  effect	  of	  LRP5	  mutations	  on	  the	  eye.	  The	   reported	  mutations	  might	   have	   different	   functional	   aspects.	   The	  most	   conclusive	  effect	   of	   deletions,	   frameshift,	   or	   nonsense	  mutations	   in	   OPPG	   patients	   is	   the	   lack	   of	  protein,	   because	   transcripts	   truncated	   in	   all	   but	   the	   last	   exon	   are	   likely	   a	   target	   of	  nonsense-­‐mediated	  mRNA	  decay	  (NMD).	  Lack	  of	  LRP5	  protein	  then	  results	  in	  decreased	  bone	   mass	   due	   to	   reduced	   canonical	   Wnt-­‐signaling	   (Balemans	   and	   van	   Hul,	   2006).	  Missense	  mutations	  could	  lead	  to	  impaired	  LRP5	  function.	  In	  vitro	  studies	  showed	  that	  different	   mutated	   LRP5	   proteins	   (p.T390K,	   p.T244M,	   p.G404R,	   p.D.434N,	   p.G610R)	  reached	   the	   cell	   surface	   in	   different	   amounts	   and	   had	   different	   afﬁnities	   for	   the	  molecular	  chaperone	  MESD,	  which	  is	  important	  for	  folding	  and	  transportation	  (Ai	  et	  al.,	  2005).	  The	  mutants	  p.T244M,	  p.S356L,	  p.T390K,	  p.G520V	  were	  shown	  to	  be	  unable	   to	  transduce	   Wnt1,	   Wnt10b,	   or	   NDP	   signals,	   while	   the	   p.G404R	   p.D434N,	   and	   p.G610R	  variants	   had	   significantly	   reduced	   signaling	   activity	   (Ai	   et	   al.,	   2005).	   None	   of	   these	  mutants	  had	  a	  dominant	  negative	  effect	  on	  Wnt-­‐signaling	  when	  co-­‐expressed	  with	   the	  wt	  LRP5.	  These	  observations	   correlate	  with	   the	   finding	   that	  most	  missense	  mutations	  cluster	   in	   the	   second	   β-­‐propeller	   domain,	   which	   has	   been	   shown	   to	   be	   required	   for	  binding	  to	  MESD	  or	  Wnts.	  In	  contrast,	  nonsense,	  frameshift	  and	  splice	  site	  mutations	  are	  scattered	  over	  all	  domains	  (Balemans	  and	  van	  Hul,	  2006).	  All	  HBM	  mutations	  reside	  near	  the	  top	  surface	  and	  central	  region	  of	  the	  first	  β-­‐propeller	  domain.	  None	  of	  them	  was	  constitutively	  active	  in	  the	  absence	  of	  Wnts.	  However,	  HBM	  mutant	   LRP5	   proteins	   have	   been	   shown	   to	   have	   reduced	   affinity	   to	   DKK1,	   an	  endogenous	   Wnt-­‐inhibitor,	   and	   it	   was	   suggested	   that	   these	   mutations	   affect	   Wnt-­‐signaling	  through	  diminished	  regulation	  by	  DKK1	  (Boyden	  et	  al.,	  2002;	  Ai	  et	  al.,	  2005).	  In	  addition,	  some	  HBM	  mutations	  might	  selectively	  bind	  one	  Wnt-­‐ligand	  better	  than	  the	  other,	  thereby	  shifting	  the	  specificity	  of	  LRP5.	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Phenotype AD/AR Domain Exon cDNA Protein Reference 
       
OPPG AR signal peptide 1 c.29G>A p.W10X Gong, 2001 
OPPG AR signal peptide 1 c.43-60del p.Leu15_Leu20del Chung, 2009 
Osteoporosis AD signal peptide 1 c.85G>A p.A29T Hartikka, 2005 
OPPG AR β-propeller 1 2 c.209_210delinsAA p.F70X Ai, 2005 
Osteopetrosis AD β-propeller 1 2 c.331G>T p.D111Y van Wesenbeek, 2003 
FEVR, reduced BMD AD β-propeller 1 2 c.433C>T p.L145F Qin, 2005 
HBM AD β-propeller 1 2 c.461G>T p.R154M Rickels, 2005 
Osteopetrosis AD β-propeller 1 3 c.511G>C p.G171R van Wesenbeek, 2003 
HBM AD β-propeller 1 3 c.512G>T p.G171V Little, 2002; Boyden, 2002 
FEVR AD β-propeller 1 3 c.518C>T p.T173M Toomes, 2004 
HBM AD β-propeller 1 3 c.593A>G p.N198S Whyte, 2004 
OPPG AR β-propeller 1 3 c.607G>A p.D203N Ai, 2005 
Endosteal hyperostosis, 
HBM AD β-propeller 1 3 c.640G>A p.A214T van Wesenbeek, 2003 
Osteosclerosis AD β-propeller 1 3 c.641C>T p.A214V van Wesenbeek, 2003 
Endosteal hyperostosis, 
Osteopetrosis AD β-propeller 1 4 c.724G>A p.A242T van Wesenbeek, 2003 
OPPG AR β-propeller 1 4 c.731C>T p.T244M Ai, 2005 
Osteopetrosis AD β-propeller 1 4 c.758C>T p.T253I van Wesenbeek, 2003 
OPPG AR β-propeller 1 4 c.765G>A p.W255X Ai, 2005 
OPPG AR β-propeller 1 4 c.789C>A p.C263X Ai, 2005 
FEVR, reduced BMD AR β-propeller 1 4 c.803_812delGGGGGAAGAG p.G268_R271delfsX4 Qin, 2005 
HBM AD β-propeller 1 4 c.844A>G p.M282V Balemans, 2007 
OPPG AR EGF1 5 c.920C>T p.S307F Ai, 2005 
OPPG AR EGF1 5 c.1004_1005insAGGAC p.T335fsX50 Ai, 2005 
OPPG AR β-propeller 2 6 c.1042C>T p.R348W Ai, 2005 
OPPG AR β-propeller 2 6 c.1058G>A p.R353Q Ai, 2005 
OPPG AR β-propeller 2 6 c.1067C>T p.S356L Ai, 2005 
OPPG AD* β-propeller 2 6 c.1169C>A p.T390K Ai, 2005 
OPPG AR β-propeller 2 6 c.1199C>A p.A400E Ai, 2005 
OPPG AR β-propeller 2 6 c.1210G>A p.G404R Ai, 2005 
OPPG AR β-propeller 2 6 c.1225A>G P.T409A Streeten, 2008 
OPPG AR β-propeller 2 6 ? p.W425X Streeten, 2008 
OPPG AR β-propeller 2 6 c.1282C>T p.R428X Gong, 2001 
OPPG AR β-propeller 2 6 c.1300G>A p.D434N Ai, 2005 
FEVR, reduced BMD AD+ β-propeller 2 6 c.1330C>T p.R444C Qin, 2005 
Osteoporosis AD β-propeller 2 6 c.1364C>T p.S455L Crabbe, 2005 
OPPG AR β-propeller 2 6 c.1378G>A p.E460K Ai, 2005 
OPPG AR β-propeller 2 7 c.1432T>A p.W478R Cheung, 2006 
OPPG AD* β-propeller 2 7 c.1453G>T p.E485X Gong, 2001 
OPPG AR β-propeller 2 7 c.1468delG p.D490MfsX40 Gong, 2001 
OPPG AR β-propeller 2 7 c.1481G>A p.R494Q Gong, 2001 
OPPG AR β-propeller 2 7 c.1512G>T p.W504C Cheung, 2006 
FEVR AD β-propeller 2 7 c.1532A>C p.D511A Boonstra, 2009 
OPPG AR β-propeller 2 7 c.1559G>T p.G520V Ai, 2005 
FEVR / Osteoporosis AD β-propeller 2 7 c.1564G>A p.A522T Qin, 2005 
OPPG AR β-propeller 2 8 c.1592A>T p.N531I Barros, 2007 
FEVR AR β-propeller 2 8 c.1604C>T p.T535M Qin, 2005 
OPPG AR β-propeller 2 8 c.1708C>T p.R570W Gong, 2001 
FEVR AR β-propeller 2 8 c.1709G>A p.R570Q Jiao, 2004 
OPPG AR β-propeller 2 8 c.1750C>T p.Q584X Ai, 2005 
FEVR, reduced BMD AR EGF 2 9 c.1828G>A p.G610R Qin, 2005 
OPPG AD* EGF 2 9 c.1828G>C p.G610R Ai, 2005 
FEVR AR EGF 2 9 c.1850T>G p.F617C Qin, 2005 
reduced BMD AD β-propeller 3 9 c.1999G>A p.V667M Ferrari, 2004 
OPPG AR β-propeller 3 9 c.2047G>A p.D683N Ai, 2005 
OPPG AR β-propeller 3 10 c.2151_2152insT p.D718X Gong, 2001 
OPPG AR β-propeller 3 10 c.2197T>C p.Y733H Ai, 2005 
OPPG, reduced BMD AD β-propeller 3 10 c.2202G>A p.W734X Gong, 2001 
OPPG AR β-propeller 3 10 c.2246delG p.G749fsX48 Ai, 2005 
FEVR AR β-propeller 3 10 c.2254C>G p.R752G Jiao, 2004 
OPPG, reduced BMD AD β-propeller 3 10 c.2305delG p.D769IfsX29 Gong, 2001 
FEVR AD β-propeller 3 11 c.2392A>G p.T798A Qin, 2005 
OPPG AR β-propeller 3 11 c.2409_2503+79del (174bp) ? Ai, 2005 
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FEVR AD β-propeller 3 11 c.2413C>T p.R805W Boonstra, 2009 
OPPG AR β-propeller 3 12 c.2557C>T p.Q853X Gong, 2001 
OPPG AR EGF 3 12 c.2718_2721delTATG p.C906fsX52 Ai, 2005 
OPPG AR EGF 3 12 c.2737_2738insT p.C913LfsX73 Ai, 2005; Hartikka, 2005 
OPPG AR β-propeller 4 14-16 
chr11:g.(13871447_1387511)_(13879636_
13879700)del p.P1010QfsX38 Chung, 2009 
Osteoporosis AD β-propeller 4 14 c.3107G>A p.R1036Q Hartikka, 2005 
OPPG AR β-propeller 4 14 c.3232C>T p.R1078X Ai, 2005 
OPPG AD* β-propeller 4 15 c.3295G>T p.D1099Y Ai, 2005 
OPPG AR β-propeller 4 15 c.3337C>T p.R1113C Ai, 2005 
FEVR AD β-propeller 4 15 c.3361A>G p.N1121D Qin, 2005 
FEVR AD* β-propeller 4 16 c.3502T>C p.Y1168H Toomes, 2004 
OPPG AR LDLR repeat 17 c.3763+2T>C ? Ai, 2005 
OPPG AR LDLR repeat 18 c.3804delA p.T1268fsX170 Gong, 2001 
FEVR AD* LDLR repeat 19 c.4081T>G p.C1361G Toomes, 2004 
FEVR AR LDLR repeat 19 c.4099G>A p.Q1367K Jiao, 2004 
OPPG AD* LDLR repeat 19 c.4105_1406delAT p.M1369VfsX2 Ai, 2005 
FEVR AD LDLR repeat 20 c.4119_4120insC p.K1374QfsX176 Toomes, 2004 
OPPG AR transmembrane 20 c.4202G>A2 p.G1401D Ai, 2005 
FEVR AD Cytoplasmic 21 c.4488+2T>G ? Toomes, 2004 
OPPG AR Cytoplasmic 22 c.4512_4517delinsTGTACAACAT p.P1504fsX46 Ai, 2005 
OPPG AR Cytoplasmic 22 c.4586+2T>C ? Ai, 2005 
OPPG AR Cytoplasmic 23 c.4600C>T p.R1534X Ai, 2005 
Osteoporosis AD Cytoplasmic 23 c.4609G>A p.A1537T Crabbe, 2005 
	  
Table	   4	   List	   of	   all	   LRP5	   mutations	   published	   so	   far.	   Numbering	   according	   to	   reference	   sequence	  NM_002335.	   The	  A	   of	   the	  ATG	   start	   codon	   lies	   at	   position	  +1.	  AD:	   autosomal	   dominant;	  AR:	   autosomal	  recessive;	  BMD:	   bone	  mass	   density;	   FEVR:	   familial	   exudative	   vitreoretinopathy;	  HBM:	   high	   bone	  mass;	  
OPPG:	  osteoporosis	  pseudoglioma	  syndrome.	  *	  Heterozygous	  mutation	  not	  only	  in	  the	  patient,	  but	  also	  in	  clinically	  unconspicuous	  relatives.	  +	  patient	  is	  compound	  heterozygous	  with	  an	  additional	  FZD4	  mutation	  (p.R417Q),	  explaining	  the	  more	  severe	  phenotype.	  	  	  
1.4	  Aim	  of	  the	  thesis	  	  This	  thesis	  aimed	  to	  add	  further	  knowledge	  to	  the	  understanding	  of	  the	  pathogenesis	  of	  human	  blinding	  diseases	   caused	  by	   variants	   in	   the	  Norrie	   disease	  pseuoglioma	   (NDP)	  gene.	   To	   further	   elucidate	   the	   functional	   role	   of	   norrin	   (the	  NDP	   protein),	   the	  Ndph	  knockout	   mouse	   model	   was	   used,	   focussing	   on	   the	   early	   stages	   of	   postnatal	   eye	  development.	  I	  wanted	  to	  investigate	  norrin’s	  proposed	  role	  as	  transcriptional	  regulator,	  especially	   of	   Wnt/beta-­‐catenin	   target	   genes,	   and	   to	   investigate	   the	   activity	   of	   this	  pathway	  in	  vivo.	  I	  further	  aimed	  to	  identify	  and	  sequence	  potential	  candidate	  genes	  in	  ND/EVR-­‐patients,	  who	  were	  negative	  for	  mutations	  in	  NDP	  or	  its	  receptors	  FZD4	  and	  LRP5.	  To	  this	  end,	  I	  hypothesized	   that	   genes	   differentially	   transcribed	   in	   the	   retina	   of	   the	  Ndph	   ko	  mouse	  model	  would	  be	  attractive	  candidates.	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2.	  Material	  and	  Methods	  	  
2.1	  Animals	  The	  research	  presented	  in	  this	  work	  was	  approved	  by	  the	  Veterinary	  Service	  of	  the	  State	  of	  Zurich	  (Switzerland).	  
2.1.1	  Ndph	  knockout	  mouse	  The	   Ndph	   knockout	   mouse	   line	   has	   been	   established	   in	   1996	   by	   homologous	  recombination	  (Berger	  et	  al.,	  1996).	  Exon	  2	  of	  the	  Ndph	  gene	  has	  partially	  been	  replaced	  with	  a	   reverse	  oriented	  neomycin	  cassette,	   resulting	   in	  a	   loss	  of	  about	  half	   the	  coding	  sequence,	   including	   the	   signal	   peptide	   for	   protein	   secretion.	   The	   gene	   targeting	   was	  performed	   in	   embryonic	   stem	  cells	   from	   the	  129P2	   strain,	   but	   the	  mutation	  has	  been	  kept	  on	  a	  C57BL/6	  background.	  For	  all	  experimental	  work	  in	  this	  study,	  only	  males	  were	  used.	  
2.1.2	  BATgal	  reporter	  mouse	  A	  Wnt-­‐signaling	   reporter	  mouse,	   the	   so-­‐called	  BATgal	   reporter	   (Maretto	   et	   al.,	   2003),	  	  was	   obtained	   from	   the	   lab	   of	   Stefano	   Piccolo	   (Padua,	   Italy).	   The	   reporter	   was	  constructed	  by	  fusing	  seven	  TCF/LEF-­‐binding	  sites	  upstream	  of	  the	  minimal	  promoter–TATA	  box	  of	  the	  anuran	  siamois	  gene,	  a	  known	  Wnt	  target	  	  (Brannon	  et	  al.,	  1997),	  to	  the	  bacterial	   lacZ	   gene.	   This	   reporter	   mouse,	   which	   was	   maintained	   on	   a	   B6D2F1	  background,	  was	  subsequently	  crossed	  with	  the	  Ndph	  ko	  mouse	   line	  to	  create	  a	  cross-­‐breed	  termed	  NDxBATgal.	  
2.1.3	  Preparation	  and	  tissue	  isolation	  For	  tissue	  preparation,	  mice	  were	  deeply	  anaesthetized	  with	  CO2	  (when	  they	  were	  older	  than	  p10),	  and	  sacrificed	  by	  cervical	  dislocation	  and	  subsequent	  decapitation	  (directly,	  when	  they	  were	  younger).	  A	  tail	  biopsy	  was	  taken	  for	  genotyping.	  Eyes	  were	   enucleated	  by	   a	   forceps	  pull	   behind	   the	   eye,	   taking	   care	   to	   firmly	   grab	   the	  optic	   nerve	   to	   avoid	   any	   traction	   damage	   to	   the	   retina.	   Occasionally,	   especially	  when	  eyes	  were	   prepared	   from	   very	   young	   animals	   (p3,	   p5),	   which	   still	   have	   very	   delicate	  tissue	   structures,	   enucleation	  was	  performed	  with	  a	   scissor	   cut	  behind	   the	  eye.	  When	  eyes	   were	   prepared	   from	   stages	   with	   closed	   eyes	   (up	   to	   p14),	   eye	   lids	   were	   cut	   off	  before	  enucleation.	  Retinas	  were	  prepared	  by	  two	  different	  methods,	  depending	  on	  the	  purpose	  they	  were	  used	  for:	  A	  “quick-­‐and-­‐dirty”	  method	  for	  RNA	  and	  protein	  extraction,	  and	  a	  more	  careful	  method	  for	  whole-­‐mount	  preparations	  and	  microscopy.	  	  For	  quick	  retina	  isolation,	  the	  eye,	  still	  in	  situ,	  was	  fixed	  with	  a	  forceps	  at	  the	  exit	  point	  of	  the	  optic	  nerve.	  The	  cornea	  was	   then	  opened	  with	   fine	   spring	   scissors.	  Then	  pressure	  was	  applied	  from	  the	  forceps	  behind	  the	  eye,	  and	  the	  lens	  and	  vitreous	  were	  squeezed	  out.	  After	  cautious	  removal	  with	  the	  scissors,	  the	  retina	  was	  stripped	  out	  off	  the	  eye	  by	  pulling	  the	  forceps	  gently	  forward.	  The	  retina	  was	  then	  briefly	  cleaned	  from	  remaining	  vitreous	  or	  retinal	  pigment	  cells,	  and	  then	  quickly	  transferred	  to	  a	  micro	  centrifuge	  tube	  and	  snap-­‐frozen	  in	  liquid	  nitrogen.	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For	  retinal	  whole-­‐mount	  preparation,	  the	  eye	  was	  removed	  as	  described	  above.	  The	  eye	  was	  hold	  by	  the	  optic	  nerve	  remnant	  against	  the	  edge	  of	  a	  Petri	  dish	  lid,	  and	  the	  cornea	  was	   poked	   with	   a	   small,	   butterfly-­‐type	   syringe	   to	   reduce	   eye	   pressure.	   Then	   it	   was	  transferred	   into	  a	  PBS-­‐filled	  Petri	  dish.	  Beginning	   from	  the	  hole	   in	   the	  cornea,	   the	  eye	  was	  opened	  with	  spring	  scissors,	  cutting	  along	  the	  ora	  serrata.	  The	  cornea	  was	  removed,	  the	  spring	  scissors	  were	  inserted	  perpendicular	  to	  the	  corneal	  plane	  and	  4-­‐5	  cuts	  were	  made	  to	  separate	  the	  eye	  globe	  in	  4-­‐5	  sectors.	  Each	  of	  these	  sectors	  was	  then	  pulled	  to	  the	  bottom	  of	  the	  Petri	  dish,	  flattening	  the	  retina	  and	  sclera	  to	  a	  structure	  resembling	  a	  4-­‐5-­‐foil	  cloverleaf	  (Figure	  26).	  	  
	  
Figure	  26	  	  Cloverleaf-­‐like	  retinal	  flatmount	  of	  a	  p15	  BGND	  animal.	  
	  Then	  vitreous	  and	  lens	  were	  removed.	  Through	  gentle	  agitation	  of	  the	  tissue	  in	  the	  PBS,	  the	   retina	   was	   slowly	   dissociated	   from	   the	   retinal	   pigment	   epithelium.	   Occasionally,	  when	  the	  cut	  along	  the	  ora	  serrata	  was	  to	  precautious,	  the	  retina	  remained	  attached	  to	  the	  underlying	  sclera	  through	  the	  ciliary	  musculature.	  In	  this	  case,	  a	  fine	  cut	  between	  the	  peripheral	  retinal	  edge	  and	  the	  ciliary	  body	  was	  conducted.	  Finally,	  the	  spring	  scissors	  were	   carefully	   inserted	  between	   the	   retina	   and	   the	  pigment	   epithelium,	   and	   the	  optic	  nerve	  was	   cut	   directly	   beneath	   the	   optic	   disc,	  mostly	   resulting	   in	   a	   small	   hole	   in	   the	  middle	  of	   the	  retina.	  The	  retina	  now	  freely	   floated	  away	   from	  the	  pigment	  epithelium.	  After	   short	   cleaning	   of	   the	   retina	   from	   possible	   remainers	   of	   RPE,	   the	   retina	   was	  transferred	   into	  a	  micro	   centrifuge	   tube	   containing	  PBS	  or	  directly	  onto	  a	  microscope	  slide.	  The	  brain	  was	  also	  prepared	  from	  part	  of	  the	  animals.	  Skin,	  muscle	  and	  fat	  tissue	  were	  cut	  off	  /	  stripped	  off	  in	  rostral	  direction.	  Also	  lateral	  tissue	  (ears)	  was	  removed,	  until	  the	  skull	   was	   completely	   exposed.	   If	   adult	   mice	   were	   prepared,	   scissors	   were	   inserted	  carefully	   into	   the	   foramen	  magnum,	   taking	   care	   to	   guide	   the	   blade	   only	   superficial	   to	  avoid	   any	   damage	   to	   the	   brain,	   and	   the	   skull	   was	   cut	   along	   the	   sagittal	   suture	   from	  caudal	   to	   rostral.	   Subsequently,	   two	   other	   cuts	   were	   performed	   along	   the	   lambdoid	  suture,	  from	  the	  median	  to	  each	  lateral	  side.	  Each	  parietal	  portion	  of	  the	  skull	  was	  then	  broken	   apart	   with	   sturdy	   forceps,	   followed	   by	   the	   frontal	   and	   occipital	   parts.	   If	   the	  animals	  were	  in	  their	  first	  postnatal	  weeks,	  the	  skull	  was	  punctured	  at	  the	  lambda	  point,	  the	  intersection	  of	  the	  central	  and	  the	  lambdoid	  sutures,	  and	  cut	  open	  analogous	  to	  the	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procedure	   for	  adults,	   in	  order	   to	  avoid	  damage	   to	   the	  brain	  stem	  and	  cerebellum.	  The	  occipital	  part	  of	  the	  skull	  was	  then	  simply	  broken	  apart	  without	  a	  median	  cut.	  During	  the	  cutting	  and	  breaking	  procedure,	  great	  care	  had	  to	  be	  taken	  to	  avoid	  damage	  to	  the	  basis	  of	  skull.	  After	  the	  skull	  had	  been	  opened,	  the	  brain	  was	  lifted	  out	  of	  the	  skull,	  beginning	  at	   the	  olfactory	  bulbs,	  with	  a	  small	   spatula.	   In	  most	  cases,	   the	  brain	  was	  subsequently	  transferred	  in	  a	  Petri	  dish	  that	  was	  placed	  on	  ice,	  and	  sagitally	  cut	  into	  two	  halfs	  with	  a	  razor	  blade.	  	  
2.2	  DNA	  techniques	  
2.2.1	  DNA	  Isolation	  	  
2.2.1.1	  DNA	  isolation	  from	  mouse-­‐tail	  biopsies	  Mouse-­‐tail	  biopsies	  were	  used	  to	   isolate	  DNA	  for	  genotyping	  purposes.	  The	  tissue	  was	  digested	  by	  a	  proteinase	  K	  solution	  (Roche	  Diagnostics,	  Rotkreuz,	  Switzerland),	  and	  the	  nucleic	   acids	   were	   subsequently	   precipitated	   with	   isopropanol,	   washed	   with	   ethanol	  and	  resolved	  in	  TE	  buffer.	  	  	  The	  required	  digestion	  buffer	  volume	  should	  be	  thrice	  the	  amount	  of	  buffer	  that	  barely	  overcasts	  the	  tail	  biopsy	  in	  the	  micro	  centrifuge	  tube.	  Typically,	  500µl	  were	  used.	  	  	  	  
Proteinase K buffer Stock conc. Vol. Final conc. 
dH2O  365µl  
Tris HCl pH 7.5 1M 50µl 100mM 
EDTA pH 8.0 0.5M 5µl 5mM 
SDS-solution 10% 10µl 0.2% 
NaCl 5M 20µl 200mM 
Proteinase K 10mg/ml 50µl 1mg/ml 
    
Total:  500µl  
	  
Table	  5	  	  Proteinase	  K	  digestion	  buffer	  for	  mouse-­‐tail	  biopsies.	  
	  
• Tail	  biopsies	  were	  digested	  in	  a	  heating	  block	  for	  1-­‐3h	  @	  55°C,	  1200	  
• Tubes	  were	  centrifuged	  for	  1h	  @	  4°C,	  13000	  rpm	  	  
• Supernatant	  was	   transferred	   into	  a	  new	  micro	  centrifuge	   tube	  and	  mixed	  with	  one	  volume	  (500µl)	  of	  100%	  isopropanol	  
• Tubes	  were	  centrifuged	  for	  30min	  @	  4°C,	  13000	  rpm	  
• Supernatant	  was	   carefully	   decanted	   and	   remaining	   alcohol	   at	   the	   edge	  of	   the	   tube	  was	  removed	  by	  spotting	  the	  tube	  on	  kim	  wipes	  
• The	  nucleic	  acid	  pellet	  was	  washed	  with	  200µl	  70%	  ethanol	  
• Tubes	  were	  centrifuged	  for	  10min	  @	  4°C,	  13000	  rpm	  
• Supernatant	  was	   carefully	   removed	   by	   pipetting,	   and	   the	   pellet	  was	   air-­‐dried	   in	   a	  heating	  block	  for	  5-­‐10min	  @	  37°C	  
• Finally,	  the	  pellet	  was	  resolved	  in	  500μl	  TE	  buffer	  (pH	  8)	  for	  30	  min	  @	  37°C	  or	  o/n	  @	  4°C	  for	  complete	  dissolving	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2.2.1.2	  DNA	  isolation	  from	  patient’s	  blood	  or	  saliva	  All	  patients	  were	   referred	   to	   the	   Institute	  of	  Medical	  Genetics	   for	  diagnostic	  purposes	  and	  informed	  consent	  according	  to	  the	  declaration	  of	  Helsinki	  and	  applicable	  Swiss	  law	  was	  obtained	  from	  all	  subjects	  involved	  in	  genetic	  testing.	  DNA	  samples	  were	  extracted	  from	   EDTA	   blood	   in	   the	   diagnostics	   division	   of	   our	   institute,	   from	   saliva	   samples	  collected	  with	  the	  OraGene	  kit	  (DNA	  Genotek,	  Ottawa,	  Ontario,	  Canada),	  or	  sent	  to	  us	  by	   approved	   foreign	   diagnostic	   laboratories.	   All	   samples	   obtained	   a	   five-­‐digit	  identification	   (ID)	   number	   in	   order	   to	   anonymize	   personal	   patient	   data	   (Table	   6).	  Additionally,	   192	  DNAs	  of	   patients	  who	  were	   referred	   to	   us	   and	  diagnosed	  with	  non-­‐ND/EVR	  related	  diseases	  were	  used	  as	  internal	  controls	  to	  obtain	  allele	  frequencies	  for	  the	  new	  sequence	  variants	  found	  in	  the	  screening.	  	  	  
#	   DNA	   Sex	   Clinical	  diagnosis	   NDP	   FZD4	   LRP5	  
1 22277 m ND p.C110S - - 
2 23081 m ND p.C128X - - 
3 25775 m ND p.M1V - - 
4 27019 m ND c.174+1G>T - - 
5 27095 m ND; PHPV p.R74C - - 
6 27118 f CD, bilateral; FEVR none p.P33S, p.P168S - 
7 28786 f CD none none p.T672M 
       
8 22439 f CD, bilateral none none none 
9 24165 f CD; retinal telangiectasia none none none 
10 24536 m CD none none c.2178C>T and c.3764-30G>A 
11 25160 m ND none none none 
12 25649 m ND none none none 
13 27110 f ND; FEVR; PHPV none none none 
14 27111 ? ND none none none 
15 27112 ? ND; RB none none none 
16 27113 ? ND none none none 
17 27116 ? ND none none c.3427+10C>T 
18 27188 m ND none none - 
19 27735 m CD; retinal telangiectasia none none none 
20 28931 m ED none none none 
21 29550 f FEVR none none none 
22 29833 m ND none - - 
	  
Table	  6	  	  Patients	  screened	  in	  this	  study.	  The	  first	  five	  patients	  have	  been	  shown	  to	  have	  mutations	  in	  the	  
NDP	  gene	  by	  our	  diagnostic	  department,	  patient	  27118	  was	  shown	  to	  be	  heterozygous	  for	  2	  mutations	  in	  the	  FZD4	   gene	   (Masterthesis	   J.	   Zürcher,	   2007),	   and	   patient	   28786	   harbors	   a	  missense	  mutation	   in	   the	  
LRP5	   gene	   that	  may	  contribute	   to	   the	  disease	  phenotype	   (Masterthesis	  W.	  Hänseler,	  2008).	  All	  patients	  were	  screened	  for	  mutations	  in	  the	  LMO2,	  PLVAP,	  and	  SLC38A5	  genes.	  Patient	  DNAs	  27110	  –	  27118	  were	  referred	  to	  us	  from	  Susanne	  Kohl	  and	  Bernd	  Wissinger	  (Universitätsklinikum	  Tübingen,	  Department	  für	  Augenheilkunde,	   Forschungsinstitut	   für	   Augenheilkunde,	   Molekulargenetisches	   Labor,	   Tübingen,	  Germany),	  DNA	  29550	  from	  Tanya	  Bardakjian	  (Albert	  Einstein	  Medical	  Center,	  Philadelphia,	  PA,	  USA).	  CD:	  
Coats’	   disease;	  ED:	  Eales’	   disease;	   FEVR:	  Familial	   exudative	   vitreoretinopathy;	  ND:	  Norrie	  disease;	   	  PHPV:	  
Persistent	  hyperplastic	  primary	  vitreous;	  RB;	  Retinoblastoma	  	  DNA	   from	   patient’s	   blood	   was	   isolated	   with	   a	   semi-­‐automated	   DNA	   extraction	   robot	  	  (chemagic	   MSMI;	   Chemagen,	   Baesweiler,	   Germany;	   Figure	   27)	   in	   our	   diagnostic	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department.	  The	  extraction	  method	  is	  based	  on	  the	  usage	  of	  magnetic	  particles	  that	  bind	  to	  DNA.	  Isolation	  was	  performed	  according	  to	  the	  manufacturer’s	  protocol.	  
	  
Figure	  27	  	  Chemagic	  magnetic	  separation	  module	  I	  (MSM	  I).	  	  Patient’s	   DNA	   was	   also	   collected	   in	   form	   of	   saliva	   samples.	   For	   this	   purpose,	   the	  OraGene	   saliva	  DNA	  extraction	  kit	   (OG-­‐250,	  DNA	  Genotek,	  Ottawa,	  Ontario,	  Canada)	  was	   applied.	   The	   extraction	   method	   is	   based	   on	   alcohol	   precipitation	   and	   was	  performed	  according	  to	  the	  manufacturer’s	  protocol.	  	  
2.2.1.3	  DNA	  isolation	  from	  agarose	  gels	  DNA	   bands	   from	   electrophoresis	   gels	   were	   excised	   with	   a	   scalpel	   on	   a	   UV-­‐transilluminator	   (TFX-­‐20.M;	   Vilber	   Lourmat,	   Eberhardzell,	   Germany)	   and	   transferred	  into	   a	  microcentrifuge	   tube.	   After	  weighing	   of	   the	   sample,	  DNA	  was	   isolated	  with	   the	  column-­‐based	   QIAquick®	   gel	   extraction	   kit	   (#28706;	   Qiagen,	   Hilden,	   Germany)	  according	  to	  the	  manufacturer’s	  instructions.	  	  
2.2.1.4	  Plasmid	  DNA	  (pDNA)	  isolation	  from	  bacterial	  cells	  Plasmid	   DNA	   was	   isolated	   with	   a	   column-­‐based	   kit	   according	   to	   the	   manufacturer’s	  protocol.	  Depending	  on	  the	  amount	  of	  pDNA	  to	  be	  isolated,	  different	  kits	  were	  used:	  The	  QIAprep®	  Spin	  Miniprep	  Kit	  (Qiagen,	  Hilden,	  Germany;	  no.	  27104/27106)	  for	  pDNA	  up	  to	  20µg,	   ort	  h	  QIAGEN®	  Plasmid	  Maxi	  Kit	  (no.	  12163)	  for	  pDNA	  up	  to	  500µg.	  	  
2.2.1.5	  DNA	  isolation	  from	  the	  yeast	  Pichia	  pastoris	  DNA	   from	   Pichia	   pastoris	   was	   only	   needed	   for	   genotyping	   by	   PCR,	   so	   the	   extraction	  method	  was	   essentially	   only	   a	   break-­‐up	   of	   the	   cell	   pellet.	   A	   single	   colony	  was	   picked	  with	   a	   sterile	   pipette	   tip	   or	   an	   inoculation	   loop	   and	   dissolved	   in	   20µl	   TE/SDS-­‐buffer	  (Table	  7)	  by	  vortexing	  for	  a	  few	  seconds.	  The	  cell	  suspension	  was	  then	  heated	  to	  100°C	  for	   5min	   and	   vortexed	   again.	   After	   spin-­‐down	   of	   the	   cell	   debris	   (14’000rpm/10min),	  2.5µl	  of	  the	  supernatant	  were	  used	  as	  PCR	  template.	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Yeast cell breakage-buffer 
Tris-HCl 1M, pH 8.0 500µl 
EDTA 0.5M, pH 8.0 100µl 
SDS 10% 50µl 
ddH2O add 50ml 
	  
Table	  7	  TE/SDS-­‐buffer	  for	  DNA	  isolation	  from	  yeast.	  
	  
2.2.2	  DNA	  quantification	  DNA	   concentration	   was	   quantified	   with	   a	   NanoDrop®	   ND-­‐1000	   photospectrometer	  (NanoDrop	  Technologies/Thermo	  Scientific,	  Wilmington,	  DE,	  USA).	  	  
2.2.3	  Polymerase	  chain	  reaction	  (PCR)	  The	   polymerase	   chain	   reaction	   (PCR)	   at	   present	   is	   arguably	   the	   most	   important	   and	  often	  used	  technique	  in	  molecular	  biology	  (Mullis	  et	  al.,	  1986;	  Saiki	  et	  al.,	  1988).	  It	  was	  applied	  numerous	   times	  during	   the	  course	  of	  my	   thesis	   to	  amplify	  genomic	   regions	  of	  interest.	  A	  specific	  protocol	  is	  given	  in	  context	  with	  each	  respective	  experiment.	  Primers	  were	   designed	   with	   the	   web-­‐based	   tool	   Primer	   3	  (http://frodo.wi.mit.edu/primer3/input.htm),	   VectorNTI	   10.1.1	   (Invitrogen,	   Carlsbad,	  CA,	  USA),	  Oligo	  6.57	  (Molecular	  Biology	  Insights,	  Cascade,	  CO,	  USA),	  or	  Primer	  Express	  2.0	   (Applied	   Biosystems,	   Foster	   City,	   CA,	   USA)	   and	   were	   ordered	   from	   Microsynth	  (Balgach,	  Switzerland).	  Primer	  sequences	  are	  given	  in	  the	  appendix.	  PCR	  reagents	  used	  were	  mainly	  from	  Solis	  BioDyne	  (Tartu,	  Estonia;	  HOT	  FIRETaq	  Polymerase,	  buffer	  B,	  dNTPs,	   S-­‐solution)	   or	   Qiagen	   (Hilden,	   Germany;	  HotStarTaq®	   Polymerase,	   PCR-­‐buffer,	  MgCl2,	  Q-­‐solution).	  For	  generation	  of	  long	  fragments	  (P.	  pastoris	  expression	  constructs),	  the	  Phusion™	  High-­‐Fidelity	  PCR	  Kit	  was	  used	  (#F-­‐553S,	  New	  England	  Biolabs,	  Frankfurt	  am	   Main,	   Germany).	   The	   thermocyclers	   used	   in	   this	   study	   were	   from	   Applied	  Biosystems	  (Foster	  City,	  CA,	  USA;	  ABI	  2720)	  or	  MJ	  Research	  (Oldendorf,	  Germany;	  MJR	  PTC-­‐200,	  MJR	  PTC-­‐225;	  Figure	  28).	  	  
	  
Figure	  28	  MJR	  PTC-­‐225	  thermocycler.	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2.2.3.1	  Mouse	  genotyping	  The	  Ndph	  genotype	  was	  determined	  using	  a	  multiplex	  PCR	  (Berger	  et	  al.,	  1996;	  Table	  8).	  Primers	  179	  and	  180	  flank	  exon	  2	  of	  the	  Ndph	  gene	  and	  amplify	  a	  527bp	  product	  from	  the	  wild	  type	  allele.	  Primers	  177	  and	  178	  bind	  inside	  the	  neomycin	  cassette	  of	  the	  Ndph	  knockout	  allele	  and	  will	  yield	  2	  smaller	  PCR	  products	  in	  combination	  with	  primers	  179	  and	  180:	  a	  133bp	  product	  (178	  with	  180),	  and	  an	  amplicon	  of	  271bp	  (177	  with	  179).	  
Ndph Stock conc. Vol. Final conc. 
ddH2O  12.75µl  
Buffer B 10x 2.5µl 1x 
MgCl2 25mM 6µl 6mM 
dNTPs (each) 20mM 0.25µl 200µM 
DTT 100mM 1.25µl 5mM 
Primer 177 (SL 105) 10µM 0.25µl 100nM 
Primer 178 (SL 106) 10µM 0.25µl 100nM 
Primer 179 (SL 107) 10µM 0.25µl 100nM 
Primer 180 (SL 108) 10µM 0.25µl 100nM 
HotFire Polymerase 5u/µl 0.25µl 0.05u/µl 
DNA template 20ng/µl 1µl 0.8ng/µl 
    
Total:  25µl   
Cycling conditions 





72°C 10min  
10°C ∞   
	  
Table	  8	  PCR	  conditions	   ort	  he	  Ndph	  genotyping	  procedure.	  	  To	  distinguish	  females	  and	  males,	  a	  PCR	  amplifying	  the	  Sry	  gene	  was	  used,	  which	  is	  the	  sex-­‐determining	  region	  on	  the	  Y	  chromosome.	  Primers	  188	  and	  189	  generated	  a	  406bp	  product	  only	  from	  males	  (Table	  9).	  
Sry Stock conc. Vol. Final conc. 
ddH2O  16µl  
Buffer B 10x 2.5µl 1x 
MgCl2 25mM 3µl 3mM 
dNTPs (each) 20mM 0.25µl 200µM 
Primer 188 (SL 120) 10µM 1µl 400nM 
Primer 189 (SL 121) 10µM 1µl 400nM 
HotFire Polymerase 5u/µl 0.25µl 0.05u/µl 
DNA template 20ng/µl 1µl 0.8ng/µl 
    
Total:  25µl   
Cycling conditions 





72°C 10min  
10°C ∞   
	  
Table	  9	  	  PCR	  conditions	   ort	  he	  Sry	  genotyping	  procedure	  	  Presence	  of	  the	  BATgal	  reporter	  gene,	  the	  bacterial	  LacZ,	  was	  determined	  with	  primers	  54	  and	  55,	  resulting	  in	  a	  450bp	  amplicon	  (Table	  10).	  
LacZ Stock conc. Vol. Final conc. 
ddH2O  16.5µl  
Buffer B 10x 2.5µl 1x 
MgCl2 25mM 2.5µl 2.5mM 
dNTPs (each) 20mM 0.25µl 200µM 
Primer 54 (LacZ1L20) 10µM 1µl 400nM 
Primer 55 (LacZ1U20) 10µM 1µl 400nM 
HotFire Polymerase 5u/µl 0.25µl 0.05u/µl 
DNA template 20ng/µl 1µl 0.8ng/µl 
    
Total:  25µl   
Cycling conditions 





72°C 10min  
10°C ∞   
	  
Table	  10	  	  PCR	  conditions	   ort	  he	  LacZ	  genotyping	  procedure	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2.2.3.2	  Mutation	  analysis	  Six	   different	   (candidate)	   genes	   were	   amplified	   from	   patient’s	   DNA	   and	   sequenced	  afterwards.	  The	  PCR	  conditions	  for	  NDP	  (Table	  11)	  have	  been	  established	  before	  in	  our	  diagnostic	  division	  and	  our	  technician	  Silke	  Feil	  has	  performed	  sequencing	  mainly.	  The	  conditions	  for	  FZD4	  (Table	  12)	  were	  determined	  by	  Jurian	  Zürcher,	  who	  also	  did	  most	  of	  the	  FZD4	  screening,	  as	  part	  of	  his	  MSc	  thesis	  during	  the	  time	  of	  my	  thesis.	  Primer	  design	  for	  and	  sequencing	  of	  LRP5	  (Table	  13)	  were	  performed	  mainly	  by	  Walther	  Hänseler	  as	  part	   of	   his	   MSc	   thesis,	   which	   he	   wrote	   under	   my	   supervision.	   The	   conditions	   for	  
SLC38A5	   (Table	   16)	   were	   established	   mainly	   by	   Karin	   Schläpfer,	   who	   did	   a	   6-­‐week	  internship	   at	   the	   institute	   also	   under	   my	   supervision,	   during	   which	   time	   she	   also	  conducted	  most	  of	  the	  SLC38A5	  sequencing	  bench	  work.	  The	  PCRs	  for	  LMO2	  (Table	  14)	  and	   PLVAP	   (Table	   15),	   as	   well	   as	   the	   PCRs	   for	   the	   3’-­‐UTRs	   of	   NDP	   and	   FZD4,	   were	  exclusively	   designed	   by	   myself.	   Further,	   I	   did	   not	   only	   conduct	   sequencing	   of	   these	  genes,	  but	  did	  some	  sequencing	  of	  NDP,	  FZD4,	  LRP5,	  and	  SLC38A5	  by	  myself.	  	  
2.2.3.2.1	  NDP	  
NDP Stock conc. Vol. Final conc. 
ddH2O  13.35µl  
Buffer B 10x 2µl 1x 
MgCl2 25mM 1.2µl 1.5mM 
dNTPs (each) 20mM 0.25µl 250µM 
Primer fwd 10µM 1µl 500nM 
Primer rev 10µM 1µl 500nM 
HotFire Polymerase 5u/µl 0.2µl 0.05u/µl 
DNA template 100ng/µl 1µl 5ng/µl 
    
Total:  20µl   
Exon Primer Size [bp] 
1 581/582 369 
2 583/584 525 
3 585/586 442 
3.1 561/562 501 
3.2 563/590 850 
   
Cycling conditions 





72°C 10min  
10°C ∞   
	  
Table	  11	  	  PCR	  conditions	  for	  amplification	  of	  exons	  1,	  2,	  and	  3	  of	  the	  NDP	  gene.	  	  
2.2.3.2.2	  FZD4	  
FZD4 Stock conc. Vol. Final conc. 
ddH2O  17.55µl  
Buffer B 10x 2.5µl 1x 
MgCl2 25mM 1.5µl 1.5mM 
dNTPs (each) 20mM 0.25µl 200µM 
Primer fwd 10µM 1µl 400nM 
Primer rev 10µM 1µl 400nM 
HotFire Polymerase 5u/µl 0.2µl 0.04u/µl 
DNA template 100ng/µl 1µl 4ng/µl 
    
Total:  25µl   
Exon Primer Size [bp] 
1 465/429 437 
2a 430/450 440 
2b 443/444 425 
2c 445/447 473 
2e 446/439 448  
Cycling conditions Exon 1 





72°C 10min  
10°C ∞   
Cycling conditions Exon 2 





72°C 10min  
10°C ∞   
 
	  
Table	  12	  PCR	  conditions	  for	  amplification	  of	  exons	  1	  and	  2	  (fragments	  a-­‐e)	  of	  the	  FZD4	  gene.	  Fragment	  2d	  does	  not	  exist.	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2.2.3.2.3	  LRP5	  





ddH2O  16.5µl  
Buffer B 10x 2.5µl 1x 
MgCl2 25mM 2.5µl 2.5mM 
dNTPs (each) 20mM 0.25µl 200µM 
Primer fwd 10µM 1µl 400nM 
Primer rev 10µM 1µl 400nM 
HotFire Polymerase 5u/µl 0.2µl 0.04u/µl 
DNA template 50ng/µl 1µl 2.5ng/µl 
    




1.1 355/356 361 
(1.2)† 361/290 270 
2 291/292 613 
3 293/294 609 
4 295/296 468 
5 297/298 555 
6 299/300 789 
7 301/302 563 
8 303/304 428 
9 305/306 712 
10 344/345 438 




12 311/312 578 
13 313/314 477 
14 343/316 603 
15 317/318 522 
16 319/320 523 
17 321/322 396 
18 323/324 547 
19 325/326 327 
20 327/328 495 
21 329/330 388 
22 331/332 495 
23 333/341 603  






ddH2O  13.55µl  
PCR-buffer* 10x 2.5µl 1x 
Q-Solution™ 5x 5µl 1x 
MgCl2 25mM 0.5µl *2.0mM 
dNTPs (each) 20mM 0.25µl 200µM 
Primer fwd 10µM 1µl 400nM 
Primer rev 10µM 1µl 400nM 
HotFire Polymerase 5u/µl 0.2µl 0.04u/µl 
DNA template 50ng/µl 1µl 2.5ng/µl 
    
Total:  25µl   






ddH2O  14µl  
Buffer B 10x 2.5µl 1x 
S-Solution™ 10x 2.5µl 1x 
MgCl2 25mM 2.5µl 2.5mM 
dNTPs (each) 20mM 0.25µl 200µM 
Primer fwd 10µM 1µl 400nM 
Primer rev 10µM 1µl 400nM 
HotFire Polymerase 5u/µl 0.2µl 0.04u/µl 
DNA template 50ng/µl 1µl 2.5ng/µl 
    
Total:  25µl   
Cycling conditions exons 
2, 3, 6, 7, 11, 12, 14, 16, 17, 19, 21 





72°C 10min  
10°C ∞   
Cycling conditions exons 
4, 5, 8, 9, 10, 13, 15, 18, 20, 22, 23 





72°C 10min  
10°C ∞   
Cycling conditions exon 
1 





72°C 10min  
10°C ∞   
	  
Table	  13	  PCR	  conditions	  for	  amplification	  of	  exons	  1	  to	  23	  of	  the	  LRP5	  gene.	  *	  Qiagen	  PCR-­‐buffer	  contains	  15mM	  MgCl2.	   †Fragment	  1.2	   is	  designed	  as	  a	  nested	  PCR	  from	  amplicon	  1.1	  to	  reduce	  contamination	  by	  product	  derived	  from	  the	  highly	  similar	  LRP5L	  sequence	  from	  chromosome	  22.	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2.2.3.2.4	  LMO2	  
LMO2 exons 1, 2, 5, 6.1 Stock conc. Vol. Final conc. 
ddH2O  13.4µl  
Buffer B 10x 2µl 1x 
MgCl2 25mM 1.6µl 2mM 
dNTPs (each) 20mM 0.2µl 200µM 
Primer fwd 10µM 0.8µl 400nM 
Primer rev 10µM 0.8µl 400nM 
HotFire Polymerase 5u/µl 0.2µl 0.05u/µl 
DNA template 50ng/µl 1µl 2.5ng/µl 
    
Total:  20µl   
Exon Primer Size [bp] 
1 565/566 641 
2 567/568 359 
3-4 588/589 837 
5 600/601 389 
6.1 575/576 601  
LMO2 exon 3-4 Stock conc. Vol. Final conc. 
ddH2O  9.4µl  
Buffer B 10x 2µl 1x 
Q-Solution™ 5x 4µl 1x 
MgCl2 25mM 1.6µl 2mM 
dNTPs (each) 20mM 0.2µl 200µM 
Primer fwd 10µM 0.8µl 400nM 
Primer rev 10µM 0.8µl 400nM 
HotFire Polymerase 5u/µl 0.2µl 0.05u/µl 
DNA template 50ng/µl 1µl 2.5ng/µl 
    
Total:  20µl   
Cycling conditions 





72°C 10min  
10°C ∞   
	  
Table	  14	  	  PCR	  conditions	  for	  amplification	  of	  exons	  1-­‐6	  (only	  CDS-­‐containing	  part	  of	  exon	  6)	  of	  the	  LMO2	  gene.	  	  	  
2.2.3.2.5	  PLVAP	  
PLVAP Stock conc. Vol. Final conc. 
ddH2O  13.4µl  
Buffer B 10x 2µl 1x 
MgCl2 25mM 1.6µl 2mM 
dNTPs (each) 20mM 0.2µl 200µM 
Primer fwd 10µM 0.8µl 400nM 
Primer rev 10µM 0.8µl 400nM 
HotFire Polymerase 5u/µl 0.2µl 0.05u/µl 
DNA template 50ng/µl 1µl 2.5ng/µl 
    
Total:  20µl   
Exon Primer Size [bp] 
1.1 545/546 301 
1.2 547/548 432 
2 549/550 276 
3.1 551/552 502 
3.2 553/554 501 
4-5 555/556 551 
6.1 557/558 583 
6.2 559/560 556  
Cycling conditions exons 
1.1, 2, 3.2 





72°C 10min  
10°C ∞   
Cycling conditions exons 
1.2, 3.1, 4-5, 6.1, 6.2 





72°C 10min  
10°C ∞   
 
	  
Table	  15	  	  PCR	  conditions	  for	  amplification	  of	  exons	  1-­‐6	  of	  the	  PLVAP	  gene.	  	  









ddH2O  18µl  
Buffer B 10x 2.5µl 1x 
MgCl2 25mM 2µl 2mM 
dNTPs (each) 20mM 0.25µl 200µM 
Primer fwd 10µM 0.5µl 200nM 
Primer rev 10µM 0.5µl 200nM 
HotFire Polymerase 5u/µl 0.25µl 0.05u/µl 
DNA template 20ng/µl 1µl 0.8ng/µl 
    




1a 604/605 500 
1b 606/607 500 
1c 608/609 489 
2-3 610/611 499 
4-5 612/613 495 
6-7 614/615 548 
8 616/617 389 
   
Cycling conditions 
all exons Δ  9-10 





72°C 10min  




9-10 632/633 538 
11 620/621 363 
12 622/623 387 
13 624/625 398 
14-15 626/627 571 
16a 628/629 484 
16b 630/631 500 
   
Cycling conditions 
exon 9-10 





72°C 10min  
10°C ∞   
	  
Table	  16	  	  PCR	  conditions	  for	  amplification	  of	  exons	  1-­‐16	  of	  the	  SLC38A5	  gene.	  	  
2.2.3.3	  Verification	  of	  Pichia	  pastoris	  expression	  vector	  constructs	  To	  verify	   the	  presence	  of	   the	  correct	  constructs	   in	  Pichia	   clones	  used	   for	  recombinant	  protein	   expression,	   a	   PCR	   with	   primers	   against	   the	   AOX1	   gene	   was	   conducted	   (	  Table	   17).	   The	  wt	  AOX1	   gene	   has	   a	   size	   of	   2.2kb,	   and	   the	   expected	  C-­‐terminal	   tagged	  
NDP	   constructs	   placed	   under	   the	   control	   of	   the	  AOX1	   promoter	   have	   1017bp.	   	   Thus,	  through	   usage	   of	   the	   appropriate	   extension	   time,	   only	   a	   PCR	   product	   from	   the	  NDP	  constructs	  was	  received.	  	  
P. pastoris expression vector Stock conc. Vol. Final conc. 
ddH2O  14.5µl  
Buffer B 10x 2.5µl 1x 
MgCl2 25mM 3µl 3mM 
dNTPs (each) 20mM 0.25µl 200µM 
Primer 282 (AOX 5’) 10µM 1µl 400nM 
Primer 283 (AOX 3’) 10µM 1µl 400nM 
HotFire Polymerase 5u/µl 0.25µl 0.05u/µl 
DNA template ?* 2.5µl ?* 
    
Total:  25µl   
Product Primer Size [bp] 
wt AOX1 282/283 2200 
C-term construct 282/283 1017 
N-term construct 282/283 1071 
   
Cycling conditions 





72°C 10min  
10°C ∞   
	  
Table	   17	   PCR	   reaction	   mix	   for	   P.	   pastoris	   expression	   vector	   constructs.	   *Supernatant	   of	   a	   crude	   cell	  breakage	  suspension	  was	  used	  as	  the	  PCR	  template.	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2.2.4	  Gel	  electrophoresis	  The	  PCR	  products	  were	   separated	  by	   size	  using	  agarose	  gel	   electrophoresis.	  DNA	  was	  stained	  with	  ethidium	  bromide	  (EtBr;	  0.5μg/ml),	  which	  intercalates	  into	  the	  DNA	  double	  helix	  (Figure	  29),	  and	  was	  visualized	  on	  a	  UV	  transilluminator.	  	  
	    
Figure	   29	   (a)	   Chemical	   structure	   of	   ethidium	   bromide;	   (b)	   Process	   of	  intercalation,	  illustrating	  the	  lengthening	  and	  untwisting	  of	  the	  DNA	  helix.	   Figure	  30	  	  Band	  pattern	  of	  the	   Invitrogen	   1Kb	  PlusLadder	  in	  base	  pairs.	  




Glacial acetic acid 57.1ml 
EDTA 0.25M, pH 8.0 200ml 
Glycerol 12.5ml 
   
Loading-buffer 10x 
ddH2O add 50ml 
Ficoll® 400 7.5g 
Bromphenol blue 0.25mg 
EDTA 0.5M, pH 8.0 1ml 
  
Agarose gel 1.2% 
 Mini Midi Maxi 
Electrophoresis chamber Horizon® 58 Horizon® 11-14 Horizon® 20-25 
TAE-Buffer 1x 25ml 100ml 250ml 
Agarose 0.3g 1.2g 3.0g 
EtBr 10mg/ml 1.25µl 5µl 12.5µl 
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Gel electrophoresis equipment 
1Kb Plus Ladder™ Invitrogen, Carlsbad, CA, USA 
Acetic acid Merck, Darmstadt, Germany 
Agarose Eurogentech, Seraing, Belgium 
EDTA Brunschwig, Basel, Switzerland 
Ethidium bromide (EtBr) Fluka, Buchs, Switzerland 
Ficoll® 400 Pharmacia Biotech, Vienna, Austria 
Glacial acetic acid Merck, Darmstadt, Germany 
Glycerol Fluka, Buchs, Switzerland 
Horizon® 11-14 gel electrophoresis chamber GibcoBRL Life Technologies / Invitrogen 
Horizon® 20-25 gel electrophoresis chamber GibcoBRL Life Technologies / Invitrogen 
Horizon® 58 gel electrophoresis chamber GibcoBRL Life Technologies / Invitrogen 
Image Master® VDS UV transilluminator Pharmacia Biotech, Vienna, Austria 
Standard Power Pack P25 Power Adapter Biometra, Göttingen, Germany 
Tris-Base Merck, Darmstadt, Germany 
Video Graphic Printer UP-895CE Sony, Schlieren, Switzerland 
	  
Table	  18	  Gel	  electrophoresis	  equipment	  	  
2.2.5	  Cloning	  of	  DNA	  fragments	  The	  Taq-­‐based	  polymerases	  used	  in	  this	  study	  (HOT	  FIREPol®	  from	  Solis	  Biodyne,	  Tartu,	  Estonia,	  and	  HotStarTaq®	  from	  Qiagen,	  Hilden,	  Germany)	  add	  single	  deoxyadenosine	  (A)	  overhangs	   to	   the	   3’-­‐end	   of	   the	   PCR	   amplicons.	   If	   necessary,	   these	   amplicons	   were	  subcloned	   with	   the	   TOPO	   TA	   Cloning®	   Kit	   using	   the	   pCR®II-­‐TOPO®	   Dual	   promotor	  vector	  and	  OneShot®	  TOP10	  chemically	  competent	  cells	  (Invitrogen,	  Carlsbad,	  CA,	  USA).	  Amplicons	  generated	  with	  the	  Pfu-­‐based	  Phusion™	  DNA	  polymerase	  were	  blunt-­‐ended	  and	   have	   been	   cloned	   with	   the	   Zero	   Blunt®	   TOPO®	   PCR	   Cloning	   Kit	   (Invitrogen,	  Carlsbad,	   CA,	   USA).	   Reactions	   were	   performed	   according	   to	   the	   manufacturer’s	  instructions.	  Transformed	  TOP10	  E.	  coli	  cells	  were	  grown	  on	  LB	  agar	  plates	  (Table	  19)	  with	  50µg/ml	  ampicillin	  and	  clones	  were	  selected	  with	  X-­‐gal	  (32µl	  per	  plate/50mg/ml;	  only	   in	  case	  of	  pCR®II-­‐TOPO.	  The	  pCR®-­‐Blunt	  II-­‐TOPO®	  vector	   includes	  the	   lethal	  ccdB	  selection	  gene,	  and	  thus	  does	  not	  require	  X-­‐Gal	  selection).	  Positive	   clones	  were	   picked	  with	   a	   disposable	   inoculation	   loop	   (Nunc,	   Langenselbold,	  Germany)	   and	   incubated	   in	   12ml	   culture	   tubes	   (Sarstedt,	   Nümbrecht,	   Germany)	  with	  3ml	  LB	  medium	  (Table	  19)	  containing	  50µg/ml	  ampicillin	  at	  37°C	  o/n	  at	  220rpm	  in	  a	  lab	   incubator	   shaker	   (Innova™	  4400;	  New	  Brunswick	   Scientific,	   Edison,	  NJ,	   USA).	   The	  colonies	  were	  pelleted	  in	  a	  benchtop	  centrifuge	  (5810R;	  Eppendorf,	  Hamburg,	  Germany)	  for	  10min	  at	  4000rpm	  and	  the	  plasmid	  DNA	  was	  isolated	  (see	  page	  63).	  	  
2.2.5.1	  Restriction	  analysis	  of	  clones	  Clones	   were	   analyzed	   for	   constructs	   of	   the	   expected	   size	   with	   an	   EcoRI	   restriction	  enzyme	  digestion	  prior	  to	  sequencing.	  2µl	  of	  pDNA	  were	  digested	  in	  a	  10µl-­‐reaction	  (6µl	  ddH2O,	  1µl	  10x	  buffer,	  1µl	  EcoRI;	  Fermentas,	  St.-­‐Leon-­‐Rot,	  Germany)	  at	  37°C	  for	  at	  least	  1h,	  before	  DNA	  fragments	  were	  separated	  by	  size	  on	  an	  agarose	  gel	  (see	  page	  70).	  







Bacto Tryptone 10g 
Bacto Yeast Extract 5g 
dH2O 1000ml 
   
LB plates 
NaCl 10g 
Bacto Tryptone 10g 
Bacto Yeast Extract 5g 




5417R centrifuge Eppendorf, Hamburg, Germany 
5810R centrifuge Eppendorf, Hamburg, Germany 
Ampicillin Sigma-Aldrich, Buchs, Switzerland 
Bacto Agar Brunschwig, Basel, Switzerland 
Bacto Tryptone Brunschwig, Basel, Switzerland 
Bacto Yeast Extract Brunschwig, Basel, Switzerland 
Culture tubes / Snap-cap 12ml Sarstedt, Nümbrecht, Germany 
Disposable inoculation loops Nunc, Langenselbold, Germany 
EcoRI Fermentas, St. Leon-Rot, Germany 
Innova™ 4400 incubator shaker New Brunswick Scientific, Edison, NJ, USA 
One Shot® TOP10 competent cells Invitrogen, Carlsbad, CA, USA 
TOPO TA Cloning® Kit Invitrogen, Carlsbad, CA, USA 
X-Gal Promega, Madison, WI, USA 
Zero Blunt® TOPO® PCR Cloning Kit Invitrogen, Carlsbad, CA, USA 
	  
Table	  19	  Reagents	  and	  equipment	  for	  cloning.	  LB	  medium	  was	  autoclaved	  after	  mixing.	  1000ml	  LB	  Agar	  was	  sufficient	  for	  ~40	  LB	  plates.	  	  
2.2.6	  Sequencing	  DNA	  sequencing	  was	  performed	  through	  the	  Sanger	  chain-­‐termination	  method	  (Sanger	  et	   al.,	   1977).	  The	  principle	  behind	   it	   is	   random	   incorporation	  of	   fluorescently	  marked	  dideoxynucleotides	  (ddNTPs)	   into	   the	  DNA	  strand	  during	  amplification,	  which	   inhibits	  further	   elongation.	   When	   ddNTPs	   are	   mixed	   with	   an	   excess	   of	   dNTPs	   (1:100),	   a	  heterogenous	  population	  of	  fragments	  of	  all	  possible	  lengths	  is	  generated,	  one	  for	  each	  nucleotide	  of	   the	   sequence.	   Since	  each	  nucleotide	   is	   labeled	  with	  a	  unique	   fluorescent	  dye,	   it	   is	   possible	   to	   distinguish	   the	   different	   nucleotides	   and	   obtain	   the	   sequence	  information	  after	  size	  separation	  of	  the	  fragments	  by	  gel	  electrophoresis.	  The	  sequencing	  in	  this	  study	  was	  performed	  with	  the	  ABI	  PRISM®	  BigDye™	  Terminator	  v.3.1	  Cycle	  Sequencing	  kit	  and	  a	  capillary	  gel	  electrophoresis-­‐based	  sequencing	  machine	  (ABI	  PRISM®	  3100	  or	  ABI	  PRISM®	  3730	  Genetic	  Analyser;	  Applied	  Biosystems,	  Foster	  City,	  CA,	  USA).	  	  
2.2.6.1	  PCR	  product	  purification	  After	  PCR	  and	  before	  nucleotide	  labeling,	  small	  DNA	  fragments	  (<70bp)	  that	  otherwise	  could	   interfere	  with	   the	  sequencing	  reaction	  were	  removed	  through	  application	  of	   the	  ExoSAP-­‐IT®	  PCR	  Clean-­‐up	  method	  (#78200;	  USB,	  Cleveland,	  OH,	  USA).	  It	  is	  based	  on	  two	  enzymes:	   Exonuclease	   I	   (Exo)	   digests	   residual	   single-­‐stranded	   primers	   and	   any	  irrelevant	  single-­‐stranded	  DNA	  produced	  during	  the	  PCR	  reaction,	  and	  Shrimp	  Alkaline	  Phosphatase	  (SAP)	  removes	  unincorporated,	  remaining	  dNTPs.	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5	  µl	  of	  ExoSAP-­‐IT®	  mix	  (0.1µl	  ExoSAP,	  4.9µl	  EB	  buffer	  (Qiagen,	  Hilden,	  Germany))	  were	  added	   to	  0.6µl	  of	  PCR	  product	   and	  digested	   for	  15	  minutes	   at	  37°C.	  The	   reaction	  was	  stopped	  by	  15	  minutes	  incubation	  at	  80°C	  to	  inactivate	  the	  enzymes.	  	  
2.2.6.2	  Nucleotide	  labeling	  In	   contrast	   to	   a	   regular	   PCR,	   the	   cycle	   sequencing,	   as	   the	   the	   nucleotide	   labeling	  procedure	  is	  also	  called,	  only	  allows	  for	  one	  primer.	  To	  obtain	  the	  sequence	  information	  of	   both	   complementary	   strands,	   each	   PCR	   product	   was	   sequenced	   twiced,	   i.e.	   in	   the	  forward	   and	   the	   reverse	   direction.	   The	   reaction	   conditions	   are	   given	   in	   Table	   20.	  Typically,	  the	  primers	  that	  were	  used	  for	  amplification	  of	  the	  product	  were	  also	  used	  for	  cycle	  sequencing;	  exceptions	  are	  highlighted	  in	  Table	  21.	  	  The	  0.6µl	  PCR	  reaction	  in	  the	  protocol	  is	  a	  good	  standard	  volume	  for	  PCR	  products	  that	  works	  in	  most	  cases.	  However,	  standard	   recommendations	  were	   10ng/100bp	   PCR	   product	   or	   200ng	   pDNA	   per	   cycle	  sequencing	  reaction.	  	  
Cycle sequencing Vol. 
ddH2O 1.2µl 
Sequencing buffer 1.6µl 




Total: 10µl  
Cycling conditions 





10°C ∞   
	  





1 587 582 
2 583 584 
3 585 586 
3.1 561 562 





1 465 429 
2a 430 450 
2b 443 444 
2c 445 447 





(1.2)† 361 290 
2 291 292 
3 293 294 
4 295 296 
5 297 298 
6 336 300 
 337 338 
7 301 302 
8 303 304 
9 339 306 
10 350 345 





12 311 12 
13 313 13 
14 343 14 
15 317 15 
16 319 16 
17 321 17 
18 323 18 
19 325 19 
20 327 20 
21 329 21 
22 331 22 





1 565 566 
2 567 568 
3-4 588 589 
5 600 601 





1.1 545 546 
1.2 547 548 
2 549 550 
3.1 551 552 
3.2 553 554 
4-5 591 556 
6.1 557 558 





1a 604 605 
1b 606 607 
1c 608 609 
2-3 610 611 
4-5 612 613 
6-7 614 615 





9-10 632 633 
11 620 621 
12 622 623 
13 624 625 
14-15 626 627 
16a 628 629 
16b 630 631  
	  
Table	  21	  Primers	  used	    ort	  he	  cycle	  sequencing	  reaction.	  Special	   sequencing	  primers	  different	   from	  the	  PCR	  primers	  are	  highlighted.	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2.2.6.3	  Gel	  filtration	  To	   avoid	   signal	   interference	   with	   the	   labeled	   fragments	   during	   the	   capillary	   gel	  electrophorsis,	  excess	  ddNTPs	  were	  removed	  from	  the	  cycle	  sequencing	  reaction	  by	  gel	  filtration	  with	  Sephadex®	   columns	   (Sephadex®	  G-­‐50,	  no.	   S5897;	   Sigma-­‐Aldrich,	  Buchs,	  Switzerland).	  The	  Sephadex®	  powder	  was	  portioned	  with	  a	  96-­‐well	  molding	  tool	  and	  transferred	  into	  a	   96-­‐well	   filter	   plate.	   350	   µl	   ddH2O	  were	   added	   to	   each	  well	   and	   the	   Sephadex®	  was	  allowed	  to	  expand	  for	  3	  hours	  at	  room	  temperature	  (or	  at	  4°C	  o/n).	  Subsequently,	   the	  plate	  was	  centrifuged	  at	  1500g	  for	  1	  minute,	  170	  µl	  ddH2O	  were	  added	  and	  the	  plate	  was	  centrifuged	   for	   an	   additional	   5	   minutes	   at	   950g.	   The	   cycle	   sequencing	   reaction	   was	  applied	   directly	   onto	   the	   Sephadex®	   columns,	   and	   the	   plate	   was	   centrifuged	   for	   5	  minutes	   at	   910g.	   During	   this	   step,	   ddNTPs	   were	   retained	   in	   the	   pores	   of	   the	   the	  Sephadex®	   column,	   and	   the	   eluate	   was	   finally	   transferred	   into	   a	   96-­‐well	   sequencing	  plate.	  Prior	  to	  the	  capillary	  gel	  electrophoresis,	  the	  volume	  of	  the	  eluate	  was	  adjusted	  to	  30µl	  (through	  addition	  of	  ddH2O).	  	  
2.2.6.4	  Capillary	  gel	  electrophoresis	  The	  labeled	  DNA	  fragments	  were	  size-­‐separated	  by	  capillary	  gel	  eletrophoresis	  with	  an	  ABI	  PRISM®	  3100	  (16	  capillaries)	  or	  3730	  (48	  capillaries)	  Genetic	  Analyser	  (Figure	  31).	  The	   DNA	   sequence	   was	   determined	   by	   a	   laser	   detector,	   which	   measured	   the	   light	  emission	   of	   the	   fluorecently	   labeled	   fragments	   in	   dependence	   of	   run-­‐time	   of	   the	   gel	  electrophoresis.	  This	  way,	   the	  sequence	  data	  was	  obtained	  nucleotide	  after	  nucleotide,	  and	  the	  collected	  output	  data	  was	  saved	  in	  an	  electropherogram.	  	  
	  
Figure	  31	  ABI	  PRISM®	  3730	  48-­‐capillary	  DNA	  analyzer	  (image	  from	  http://www.appliedbiosystems.com).	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2.2.6.5	  Analysis	  of	  sequence	  data	  Analysis	   of	   the	   electropherograms	   was	   performed	   with	   the	   software	   Sequencing	  Analysis	   5.2,	   SeqScape	   2.6	   (both	   Applied	   Bioscience,	   Foster	   City,	   CA,	   USA),	   and/or	  Sequence	   Pilot	   3.1	   (JSI	   Medical	   Systems	   GmbH,	   Kippenheim,	   Germany).	   Reference	  sequences	   were	   downloaded	   from	   Ensembl	   (http://www.ensembl.org)	   or	   NCBI	  (http://www.ncbi.nlm.nih.gov)	  (Table	  22).	  	  	  
Gene NCBI reference Ensembl reference 
NDP NC_000023.9, GI:89161218  
FZD4 NC_000011.8, GI:51511727  
LRP5 NC_000011.8, GI:51511727  
LMO2  ENSG00000135363 
PLVAP  ENSG00000130300 
SLC38A5  ENSG00000017483 
	  
Table	  22	  Reference	  sequences	  of	  the	  investigated	  genes.	  	  	  
2.3	  RNA	  techniques	  
2.3.1	  RNA	  isolation	  Total	  RNA	  was	  extracted	  with	  the	  RNeasy®-­‐Kit	  (Qiagen,	  Hilden,	  Germany)	  according	  to	  the	  manufacturer’s	  instructions.	  Lysis	  buffer	  (at	  least	  100µl)	  was	  added	  to	  deep	  frozen	  (-­‐80°C)	  tissue,	  and	  the	  sample	  was	  homogenized	  immediately	  with	  an	  Ultra-­‐Turrax®	  high-­‐performance	   disperser	   (Ika-­‐Werke,	   Staufen,	   Germany).	   HEK293T	   cell	   pellets	   were	  homogenized	  with	  a	  shredder-­‐column	  (QIAshredder	  Kit;	  Qiagen,	  Hilden,	  Germany).	  Total	   RNA	   including	   small	   RNAs	   (e.g.	   miRNA)	   was	   extracted	   with	   the	  miRNeasy®-­‐Kit	  (Qiagen,	  Hilden,	  Germany)	  according	  to	  the	  manufacturer’s	  instructions.	  	  	  	  
2.3.2	  RNA	  quantification	  RNA	   quantity	   and	   quality	   was	   determined	   with	   a	   NanoDrop®	   ND-­‐1000	   (NanoDrop	  Technologies/Thermo	  Scientific,	  Wilmington,	  DE,	  USA)	  and	  a	  Bioanalyzer	  2100	  (Agilent	  Technologies,	  Santa	  Clara,	  CA,	  USA)	  according	   to	   the	  manufacturer’s	   instructions.	  Only	  samples	   with	   a	   260nm/280nm	   ratio	   between	   1.8–2.1	   and	   an	   RNA	   integrity	   number	  (RIN)	  higher	  than	  9.0	  were	  further	  processed.	  	  	  
2.3.3	  Reverse	  transcription	  PCR	  (RT-­‐PCR)	  To	   determine	   absolute,	   local,	   or	   temporal	   expression	   of	   a	   gene,	   RT-­‐PCR	   is	   applied.	   In	  contrast	  to	  a	  regular	  PCR,	  which	  amplifies	  specific	  DNA	  fragments,	  RT-­‐PCR	  uses	  RNA	  as	  template.	   The	   procedure	   is	   nearly	   identical	   –	   the	   only	   difference	   is	   an	   initial	   RNA-­‐to-­‐DNA	  conversion	  procedure	  facilitated	  by	  an	  enzyme	  with	  reverse	  transcriptase	  activity.	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2.3.3.1	  DNase	  Treatment	  of	  RNA	  samples	  To	  remove	  all	  possible	  remaining	  traces	  of	  DNA	  that	  would	  interfere	  with	  downstream	  applications	   such	   as	   quantitative	  RT-­‐PCR,	  DNase	  digestion	  was	   applied	   either	   directly	  on-­‐column	   during	   extraction	   with	   the	   RNeasy®-­‐Kit	   (RNase-­‐free	   DNase	   Set,	   cat.	   no.	  79254,	   Qiagen,	   Hilden,	   Germany),	   the	   TURBO	  DNA-­‐free™-­‐Kit	   (#1907;	   Ambion,	   Austin,	  TX,	   USA),	   or	   separately	   after	   RNA	   extraction	   (RQ1	   RNase-­‐free	   DNase,	   p/n	   M610A,	  Promega,	  Madison,	  WI,	  USA)	  according	  to	  the	  manufacturer’s	  instructions.	  	  
2.3.3.2	  Synthesis	  of	  cDNA	  1250ng	  total	  RNA	  were	  reverse	  transcribed	   in	  a	  20μl	  reaction,	  using	  random	  hexamer	  primers	   pd(n)6	   (Amersham	   Biosciences	   /	   GE	   Healthcare	   Europe,	   Otelfingen,	  Switzerland)	   and	   the	   reverse	   transcriptase	   SuperScript™	   III	   RT	   (Invitrogen,	   Carlsbad,	  CA,	   USA)	   according	   to	   the	  manufacturer’s	   instructions.	   Before	   addition	   of	   the	   reverse	  transcriptase,	   RNA	   samples	  were	   heated	   to	   65°C	   for	   5	  min	   to	   break	   down	   secondary	  structures.	   RNasin®	   Plus	   (#9PIN261;	   Promega,	   Madison,	   WI,	   USA)	   or	   RNaseOUT™	  (#10777-­‐019;	  Invitrogen,	  Carlsbad,	  CA,	  USA)	  RNase	  inhibitor	  was	  added	  to	  the	  reaction	  mix	   to	   prevent	   template	   degradation	  during	   the	   1h	   /	   50°C	   incubation	   step.	   For	   every	  RNA	  sample,	  a	  negative	  „-­‐RT“	  control	  reaction	  without	  reverse	  transcriptase	  was	  run.	  	  	  
2.3.4	  Microarrays	  	  
2.3.4.1	  Whole	  genome	  cDNA	  microarray	  Gene	  chip	  expression	  analysis	  has	  been	  carried	  out	  with	  RNA	  from	  p7	  retinae	  of	  the	  ND	  mouse	  strain	  (wt:	  n=5,	  ko:	  n=5)	  using	  the	  Affymetrix	  GeneChip®	  Mouse	  Genome	  430	  2.0	  array	  (Affymetrix	  Inc.,	  Santa	  Clara,	  CA,	  USA).	  On	  this	  chip,	  over	  34,000	  genes	  and	  ESTs	  are	   represented	   by	   ~45,000	   probe	   sets.	   The	   microarray	   experiment,	   from	   cDNA	  synthesis	   to	   raw	   data	   processing,	   was	   performed	   at	   the	   Functional	   Genomics	   Center	  Zurich	  (FGCZ)	  by	  Marzanna	  Künzli.	  A	  detailed	  description	  of	  the	  protocol	  is	  given	  in	  the	  IOVS	  publication.	  	  
2.3.4.2	  Whole	  genome	  miRNA	  microarray	  Total	  RNA	  including	  miRNA	  was	  isolated	  from	  Ndph	  wt	  (n=4)	  and	  ko	  (n=4)	  mice	  aged	  p5	  and	  p21.	  The	   actual	  microarray	   experiments	  were	   conducted	  by	  Andrea	  Patrignani	   at	  the	  FGCZ	  with	  an	  Agilent	  Mouse	  miRNA	  8	  x	  15K	  OligoMicroarray	  (#G4472A,	  Design	  ID	  019119;	  Agilent	  Technologies,	  Santa	  Clara,	  CA,	  USA).	  This	  array	  contains	  probes	  for	  567	  mouse	  and	  10	  viral	  microRNAs	  from	  the	  Sanger	  database	  v10.1	  (microrna.sanger.ac.uk).	  Fluorescent	   miRNA	   with	   a	   sample	   input	   of	   100ng	   of	   total	   RNA	   was	   generated.	   This	  method	   involves	   the	   ligation	   of	   one	   cyanine	   3-­‐pCp	   molecule	   to	   the	   3'	   end	   of	   a	   RNA	  molecule	   using	   a	   kit	   (miRNA	   Complete	   Labeling	   and	   Hyb	   Kit;	   #5190-­‐0456;	   Agilent,	  Waldbronn,	  Germany).	  The	  quality	  of	   	  Cy3-­‐RNA	  was	  determined	  using	  a	  NanoDrop	  ND	  1000.	  Only	  RNA	  samples	  with	  a	  dye	  incorporation	  rate	  >2	  pmol/μg	  were	  considered	  for	  hybridization.	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Cy3-­‐labeled	  RNA	  samples	  were	  mixed	  with	  the	  kit	  blocking	  solution	  and	  resuspended	  in	  hybridization	  buffer.	  Target	  RNA	  samples	  (45μl)	  were	  hybridized	  on	  to	  the	  microarray	  chip	  for	  20h	  at	  55°C.	  Arrays	  were	  then	  washed	  using	  GE	  wash	  buffers	  1	  and	  2	  (#5188-­‐5326;	   Agilent,	   Waldbronn,	   Germany)	   according	   to	   the	   manufacturer	   instructions	  (www.agilent.com).	  A	  microarray	  scanner	  (Agilent	  #G2565BA)	  was	  used	  to	  measure	  the	  fluorescent	  intensity	  emitted	  by	  the	  labeled	  target.	  Raw	   data	   processing	   was	   performed	   using	   the	   Agilent	   Scan	   Control	   and	   the	   Agilent	  Feature	  Extraction	  Software	  Version	  9.5.3.1.	  Quality	  control	  measures	  were	  considered	  before	   performing	   the	   statistical	   analysis.	   These	   included	   inspection	   of	   the	   array	  hybridization	  pattern	  (absence	  of	  scratches,	  bubbles,	  areas	  of	  non	  hybridization),	  proper	  grid	  alignment	  and	  number	  of	  green	  feature	  non	  uniformity	  outliers	  (below	  100	  for	  all	  samples).	   Expression	   values	   were	   imported	   and	   processed	   in	   the	   B-­‐fabric	   database	  (http://fgcz-­‐bfabric.uzh.ch/b-­‐fabric/welcome).	  Hubert	  Rehrauer	  of	  the	  FGCZ	  performed	  the	  statistical	  analyses	  with	  the	  free	  software	  package	  R	  (http://www.r-­‐project.org/).	  	  	  
2.3.5	  Quantitative	  RT-­‐PCR	  (qRT-­‐PCR)	  Quantitative	  RT-­‐PCR	  was	  carried	  out	  in	  five	  replicates	  in	  an	  ABI	  PRISM®	  7900HT	  system	  (Applied	  Biosystems,	  Foster	  City,	  CA,	  USA;	  Figure	  32)	  using	  the	  recommended	  standard	  cycling	   conditions:	   45	   cycles	   of	   denaturation	   (15s/95°C)	   and	   annealing/extension	  (1min/60°C).	  Relative	  expression	  was	  calculated	  by	  the	  ΔΔCt	  (cycle	  threshold)	  method	  in	  two	  subsequent	  normalization	  steps:	  1.) Normalization	  of	  target	  gene	  expression	  to	  endogenous	  control:	  Cttarget	  gene	  –	  Ctendogenous	  control	  =	  	  ΔCt	  2.) Normalization	  of	  an	  individual	  sample	  to	  an	  arbitrary	  (e.g.	  mean	  of	  wt	  samples)	  calibrator	  sample:	  ΔCtsample	  –	  ΔCtcalibrator	  sample	  =	  	  ΔΔCt	  With	  this	  method,	  fold	  change	  expression	  differences	  can	  be	  calculated	  with	  the	  formula:	  2-­‐ΔΔCt.	  Confidence	   intervals	   for	  wild	   type	  and	  knockout	  gene	  expression	   (or	   treated	  vs.	  untreated	  samples)	  were	  calculated	  on	  basis	  of	  the	  mean	  ΔΔ	  ct-­‐values	  at	  a	  significance	  level	  of	  95%	  using	  Student’s	  t-­‐test.	  Two	  different	  transcript	  detection	  methods	  were	  applied,	  using	  either	  
• two	   target-­‐recognizing	   primers	   and	   SYBR®-­‐Green	   (a	   fluorescent	   dye	   that	  intercalates	  in	  doublestranded	  DNA),	  
• or	   using	   a	   TaqMan®	   probe	   (a	   third,	   fluorescently	   labeled	   primer	   that	   is	   only	  detectable	  when	  a	  target	  amplicon	  is	  generated).	  For	  each	  target	  gene,	  the	  amount	  of	  template	  cDNA	  had	  to	  be	  empirically	  determined	  for	  each	  tissue.	  Ideally,	  Ct-­‐values	  were	  between	  25-­‐30,	  since	  Ct	  values	  lower	  than	  35	  could	  also	   occur	   sporadically	   by	   chance.	   Candidate	   genes	   defined	   by	   the	   microarray	  experiment	  were	  verified	  by	  probes/primer	  pairs	  binding	  in	  the	  area	  that	  is	  recognized	  by	  the	  Affymetrix	  probes.	  




Figure	  32	  ABI	  PRISM®	  7900HT	  qRT-­‐PCR	  system	  (image	  from	  http://www.appliedbiosystems.com).	  	  
2.3.5.1	  qRT-­‐PCR	  with	  SYBR®-­‐Green	  Transcriptional	  analysis	  of	  several	  target	  genes	  (Table	  23)	  was	  conducted	  using	  0.5μM	  of	   a	   forward/reverse	   primer	   pair	   and	   SYBR®-­‐Green	   PCR	   Mastermix	   (Applied	  Biosystems,	  Foster	  City,	  CA,	  USA)	   in	  a	  10µl	   reaction	  volume	  (Table	  24).	   In	  addition,	   in	  the	   case	   primers	   were	   not	   exon	   spanning,	   DNA	   contamination	   of	   the	   sample	   was	  checked	  by	  a	  –RT	  control	   reaction	  (a	  sample	  where	  no	  reverse	   transcription	  has	  been	  performed).	   Efficiency	   of	   the	   primer	   pair	  was	   tested	  with	   a	   cDNA	   dilution	   series	   and	  compared	  to	  the	  efficiency	  of	  several	  endogenous	  controls	  to	  determine	  the	  appropriate	  control	  for	  each	  target	  gene.	  	  
Gene Primer pair RNA 
Bmp4 220 / 221 10ng 
Isl-1 284 / 285 1ng 
LacZ 230 / 231 1ng 
Mdm2 (Int7) 200 / 201 10ng 
Slc38a5 198 / 199 100ng 
Syp 286 / 287 1ng 
   
Endogenous controls:   
28S rRNA 202 / 203 0.025-0.1ng 
Pol2ra 351 / 352 1ng 
	  
Table	  23	  SYBR®-­‐Green	  qRT-­‐PCR	  primer	  pairs	  used	  in	  this	  study.	  	  
SYBR®-Green reaction mix 
ddH2O 3.5µl 
Template 1.0µl 
Primer 5’ (10µM) 0.25µl 
Primer 3’ (10µM) 0.25µl 




Table	  24	  SYBR®-­‐Green	  reaction	  mix.	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2.3.5.2	  qRT-­‐PCR	  with	  TaqMan®	  probes	  TaqMan®	  probes	   and	  TaqMan®	  Universal	   PCR	  Mastermix	   (Applied	  Biosystems,	   Foster	  City,	  CA,	  USA)	  were	  also	  used	  for	  relative	  quantification	  of	  mRNA	  expression.	  Reactions	  with	   a	   volume	  of	  6µl	  were	  performed	   in	  384-­‐well	   plates	   (Table	  25).	  TaqMan®	  probes	  and	  appropriate	  cDNA	  amounts	  used	  in	  this	  study	  are	  listed	  in	  Table	  26.	  	  
TaqMan® reaction mix 
ddH2O 1.7µl 
Template 1.0µl 
Primer/Probe (20x) 0.3µl 




Table	  25	  TaqMan®	  reaction	  mix.	  	  
Gene TaqMan® probe RNA 
Aass Mm00497118_m1 10ng 
Abcb1a Mm00440761_m1 10ng 
Adm Mm00437438_g1 10ng 
Agtrl1 Mm00442191_s1 10ng 
ApoD Mm00431817_m1 10ng 
Centd3 Mm00551866_m1 10ng 
Cldn5 Mm00727012_s1 10ng 
Ifnb1 Mm00439546_s1 65ng 
Ndph Ex3 
probe: 6FAM – CTG AGC CCT TGG TGT C - MGBNFQ 
fwd: CAC TGC AGC CAG GCA TCA C 
rev: AGG AAC GGA AAG GTT GCT TGA 
1ng 
Plvap Mm00453379_m1 10ng 
Prdm9 Mm00522708_m1 10ng 
SLC38A5 Hs01012028_m1 10ng 
Vwf Mm00550376_m1 10ng 
   
Endogenous controls:   
18S rRNA p/n 4308329 0.1ng 
Gapdh p/n 4352339E 0.1ng 
GAPD Hs02786624_g1 0.1ng 
	  
Table	  26	  TaqMan®	  probes	  used	  in	  this	  study.	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2.4	  Protein	  techniques	  
2.4.1	  Protein	  isolation	  All	   protein	   working	   steps	   were	   performed	   on	   ice.	   Animal	   tissue	   or	   cell	   pellets	   were	  disrupted	  in	  freshly	  prepared	  RIPA	  buffer	  (Table	  27;	  1g	  tissue	  –	  3ml	  buffer).	  To	  this	  end,	  deep	  frozen	  (dry	  ice)	  retinae	  were	  transferred	  in	  either	  a	  glass	  homogenizer	  (FB56673;	  Fisher	  Scientific,	  Wohlen,	  Switzerland)	  or	  a	  special	  microcentrifuge	  tube	  that	  was	  part	  of	  a	   single-­‐use	   homogenizer	   kit.	   Without	   hesitation,	   the	   tissue	   was	   disrupted	   by	   up-­‐down/rotary	  movements	  of	  the	  pestle	  for	  30	  seconds.	  All	  retinal	  samples	  in	  this	  study,	  regardless	  of	  their	  weight,	  were	  extracted	  in	  100µl	  of	  buffer,	  since	  this	  was	  the	  minimal	  volume	  needed	  for	  proper	  functioning	  of	  the	  homogenizers.	  Cell	  pellets	  and	  brain	  tissue	  were	  disrupted	  by	  sonication	  in	  a	  minimal	  volume	  of	  200µl	  (Sonopuls	  HD	  2200	  with	  MS72	  tip;	  Bandelin,	  Berlin,	  Germany).	  Ten	  0.5s	  pulses	  with	  a	  maximum	  of	  25%	  power	  were	  applied	  over	  the	  course	  of	  10s.	  	  The	  tissue	  lysate	  was	  placed	  on	  ice	  for	  3h	  before	  it	  was	  centrifuged	  at	  20000g	  for	  30min	  at	   4°C.	   The	   supernatant	   was	   transferred	   into	   a	   new	  microcentrifuge	   tube	   and	   stored	  until	   further	   use	   at	   -­‐20°C	   together	   with	   the	   unsoluble	   pellet	   fractions	   (which	   could	  contain	  membrane	  proteins).	  	  
2.4.2	  Protein	  quantification	  Protein	  concentration	  was	  estimated	  with	  the	  bicinchoninic	  acid	  (BCA)	  protein	  assay	  kit	  (Sigma-­‐Aldrich,	  Buchs,	  Switzerland)	  at	  560nm.	  The	  assay	  was	  carried	  out	   in	  a	  96-­‐well	  optical	  plate	   (TechnoPlasticProducts,	  Trasadingen,	  Switzerland)	  with	  a	  protein	  sample	  volume	  of	  20µl	  and	  200µl	  of	  BCA	  solution	  (Table	  27).	  The	  samples	  were	  incubated	  for	  30min	   at	   37°C	   (Heraeus	   function	   line	   incubator;	   Kendro,	   Zurich,	   Switzerland)	   and	  absorption	  was	  measured	  at	  560nm	  with	  a	  96-­‐well	  microplate	   reader	   (ELx808™;	  Bio-­‐Tek®,	  Bad	  Friedrichshall,	  Germany).	  The	   protein	   amount	   of	   a	   sample	   was	   calculated	   through	   comparision	   to	   a	   series	   of	  bovine	   serum	   albumine	   (BSA)	   reference	   samples	   of	   known	   concentrations	   (50-­‐1000ng/µl).	  Since	  this	  relative	  quantification	  is	  only	  valid	  within	  the	  linear	  range	  of	  the	  standard	  curve	  (OD560nm	  between	  0	  and	  1),	   two	  different	  sample	  dilutions	  (1:10,	  1:20)	  were	  measured	  simultaneously.	  Each	  sample	  was	  run	  in	  duplicate.	  	  
2.4.3	  SDS-­‐Polyacrylamide	  gel	  electrophoresis	  (SDS-­‐PAGE)	  Proteins	   were	   separated	   by	   size	   with	   SDS-­‐PAGE	   using	   a	   Mini-­‐PROTEAN®	   3	  electrophoresis	   system	  (BioRad,	  Reinach,	   Switzerland;	  Figure	  33).	  To	   remove	  possible	  traces	  of	  greasy	  residues,	  glass	  plates,	  combs,	  and	  sealings	  were	  cleaned	  with	  EtOH,	  and	  the	  setup	  was	  assembled	  to	  the	  manufacturer’s	  instructions.	  The	  resolving	  gel	  solution	  was	  prepared	  dependent	  on	  the	  expected	  size	  of	  the	  proteins	  to	  be	  separated	  (Sambrook	  et	  al.,	  1989;Figure 34)	  and	  poured	  between	  the	  glass	  plates.	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Figure	   33	   Components	   of	   the	   Mini-­‐PROTEAN®	   Tetra	   system.	   (A)	   electrophoresis	   module,	   companion	  running	  module,	   tank,	   lid,	   and	   buffer	   dam;	   (B)	   glass	   plates	   and	   combs;	   (C)	   sample	   loading	   guides;	   (D)	  casting	  stand	  and	  casting	  frames	  (image	  from	  http://bio-­‐rad.com).	  	  To	  obtain	  a	  smooth	  and	  flat	  border,	  the	  gel	  was	  covered	  with	  0.5ml	  isopropanol,	  which	  was	  removed	  with	  whatman	  paper	  after	  polymerization	  of	  the	  gel.	  Then	  the	  stacking	  gel	  was	  poured	  onto	  the	  resolving	  gel	  and	  filled	  to	  the	  top.	  To	  create	  the	  sample	  pockets,	  a	  comb	  was	  placed	   into	   the	   yet	   non-­‐polymerized	   stacking	   gel.	   After	   polymerization,	   the	  comb	   was	   removed,	   and	   the	   gel	   was	   transferred	   into	   the	   electrophoresis	   chamber,	  which	  was	  filled	  with	  1x	  SDS-­‐PAGE	  running	  buffer	  (Table	  27).	  To	  remove	  perturbing	  gel	  strands	  that	  may	  have	  formed	  during	  the	  preparation,	  sample	  pockets	  were	  flushed	  with	  1x	   SDS-­‐PAGE	   running	   buffer	   several	   times	   by	   pipetting	   up	   and	   down	   several	   times.	  Protein	  samples	  were	  heated	  for	  5min	  at	  95	  °C	  with	  Lämmli	  loading	  buffer	  containing	  β-­‐mercaptoethanol,	   which	   reduced	   disulfide	   bonds	   („reducing	   conditions“).	   All	   samples	  were	  centrifuged	  for	  2	  min	  at	  10000	  rpm	  and	  equal	  amounts	  of	  protein	  were	  loaded	  into	  the	  gel	  pockets	  (ideally,	  the	  loading	  volume	  was	  also	  adjusted	  with	  RIPA	  buffer	  to	  ensure	  comparable	  running	  characteristics;	  max.	  20µl).	  Proteins	  were	  then	  separated	  for	  about	  60	  min	  at	  200	  V	  until	  the	  loading	  dye	  reached	  the	  bottom	  of	  the	  gel.	  Since	  protein	  mass	  can	  be	  determined	  only	  relatively	  by	  this	  method,	  a	  molecular	  mass	  marker	  was	  loaded	  in	   each	   gel	   in	   the	   first	   (and/or	   last)	   lane.	   Usually,	   the	   PageRuler™	   Prestained	   Protein	  Ladder	  Plus	  (#SM1811;	  Fermentas,	  St.	  Leon–Rot,	  Germany)	  was	  used	  (Figure 34).	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separation size range 
(kDa) 
% acrylamide in resolving 
gel 
10 – 60 15 % 
30 – 120 10 % 
50 – 200 8 %  
Resolving gel 10% (10ml) 
H2O 4.0 ml 
30% acrylamide mix 3.3 ml 
1.5M Tris (pH 8.8) 2.5 ml 
10% SDS 0.1 ml 
TEMED 5 µl 
10% Ammonium Persulfate 0.1 ml   
Stacking gel 5% (2ml) 
H2O 1.4 ml 
30% acrylamide mix 0.33 ml 
1M Tris (pH 6.8) 0.25 ml 
10% SDS 20 µl 
TEMED 2 µl 





Figure 34 (A)	  SDS-­‐PAGE	  protocols	  for	  resolving	  /	  stacking	  gels	  and	  (B)	  a	  8-­‐16%	  SDS-­‐PAGE	  showing	  the	  PageRuler™	  Protein	  Ladder	  #1811	  (Fermentas,	  St.Leon-­‐Rot,	  Germany).	  	  
2.4.4	  Western	  blot	  	  SDS-­‐PAGE	  separated	  proteins	  were	  electrotransferred	  onto	  a	  polyvinylidene	  difluoride	  (PVDF)	   membrane	   (Roche	   Diagnostics,	   Rotkreuz,	   Switzerland)	   in	   a	   semi-­‐dry	   blotting	  chamber	   (BioRad,	  Reinach,	   Switzerland).	  To	  make	   it	  hydrophilic,	   the	  PVDF	  membrane	  was	   soaked	   shortly	   in	   methanol,	   washed	   in	   ddH20	   for	   5min	   and	   then	   prepared	   in	  blotting	  buffer	   for	   another	  5min.	  The	   SDS-­‐PA	  gel	  was	   incubated	   for	  15min	   in	  blotting	  buffer.	   Three	   pieces	   of	   chromotography	   filter	   paper	   (Whatman®,	   GE	   Healthcare,	  Otelfingen,	  Switzerland)	  were	  soaked	  with	  blotting	  buffer	  and	  stacked	  on	  the	  anode	  of	  the	  blotting	  system,	   trying	   to	  avoid	  air	  bubbles	   in	  between.	  The	  PVDF	  membrane	  was	  put	  on	  top	  of	   the	  three	  filter	  papers,	  and	  the	  SDS-­‐PA	  gel	  was	  carefully	  placed	  above	   it.	  The	  blot	  sandwich	  was	  completed	  with	  an	  additional	  three	  pieces	  of	  filter	  paper,	  and	  the	  blot	  chamber	  was	  closed	  with	  the	  cathode	  (Figure	  35).	  Proteins	  were	  transferred	  for	  20	  min	  at	  15V.	  	  	  
	  
Figure	  35	  Blot	  sandwich	  setup.	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RIPA buffer (10ml) 
Tris HCl pH 7.5 1M 500µl 
NaCl 5M 300µl 
EDTA pH 8.0 0.5M 20µl 
Nonidet P40 20µl 
ddH2O 9160µl 




Lämmli Loading-buffer 5x 






Bromphenol blue solution 0.5ml 
2-Mercaptoethanol 2ml  
SDS running buffer 5x 
Tris/HCl pH 8.3 15.1g 
Glycin 72g 
SDS 5g 
ddH2O ad 1000ml  
BCA assay mix 
Solution A: BCA, Na2CO3, sodium 
tartrate, NaHCO3 in 0.1N NaOH 
196µl 
Solution B: Copper (II) sulfate 
pentahydrate solution 4% (w/v) 4µl  
Blotting buffer 5x 
Tris/HCl pH 8.3 29.1g 
Glycin 14.65g 
SDS 1.88g 
ddH2O ad 1000ml  
Bromphenol blue solution 
ddH2O 10ml 
Bromphenol blue 0.25mg  
Protein fixation buffer (for 5ml gel) 
Ethanol 7.5ml 
Glacial acetic acid 2.5ml 
ddH2O 15ml  
Blotting buffer 1x (with MeOH) 
Blotting buffer 5x 20ml 
Methanol 20ml 
ddH2O 60ml  
Silver stain fixation buffer (for 5ml gel) 
Na2CO3 2.5g 
Formaldehyde solution 37% 12.5µl 
ddH2O 25ml  
Silver stain solution (for 5ml gel) 
AgNO3 20% 125µl 
ddH2O 25ml  
  
SDS-PAGE / Western blot equipment 
2-Mercaptoethanol Merck, Darmstadt, Germany 
Ammonium Persulfate (#9592.3) Carl Roth, Karlsruhe, Germany 
BCA Protein Assay Kit Sigma-Aldrich, Buchs, Switzerland 
Bovine serum albumine (BSA) 1mg/ml protein standard (#P0914) Sigma-Aldrich, Buchs, Switzerland 
Bromphenol blue (#15375) Serva, Heidelberg, Germany 
Complete Protease Inhibitor Cocktail tablets (#04693116001) Roche Diagnostics, Rotkreuz, Switzerland 
Curix 60 film developer machine AGFA, Köln, Germany 
EDTA Brunschwig, Basel, Switzerland 
ELx808™ absorbance microplate reader Bio-Tek®, Bad Friedrichshall, Germany 
Gel dryer model 543 BioRad, Reinach, Switzerland 
Glacial acetic acid Merck, Darmstadt, Germany 
Glycerol Fluka / Sigma-Aldrich, Buchs, Switzerland 
Imperial™ protein stain (#24615) Pierce / Thermo Scientific, Rockford, IL, USA 
Laboratory shaker (#3006) GFL, Burgwedel, Germany 
Mini-PROTEAN® 3 electrophoresis system BioRad, Reinach, Switzerland 
Nonidet P40 (#1754599) Roche Diagnostics, Rotkreuz, Switzerland 
Powerpack 200 BioRad, Reinach, Switzerland 
PVDF Western blotting membrane (#03010040001) Roche Diagnostics, Rotkreuz, Switzerland 
Rotiphorese® Gel 30 acrylamide gel mix Carl Roth, Karlsruhe, Germany 
Roto-Torque® Heavy Duty rotator (#7637-10) Cole-Parmer instruments, London, UK 
Silver nitrate  Merck, Darmstadt, Germany 
Sodium azide NaN3 (#71290) Fluka / Sigma-Aldrich, Buchs, Switzerland 
TEMED (#87689) Fluka / Sigma-Aldrich, Buchs, Switzerland 
Trans-Blot® SD Semi-Dry Transfer Cell (Blotting chamber) BioRad, Reinach, Switzerland 
Tris-HCl Merck, Darmstadt, Germany 
Western Lightning™ Chemiluminescence Reagent Plus (NEL103) Perkin Elmer, Boston, MA, USA 
Whatman® Chromatography Paper 3mm, 46x57cm (#3030917) GE Healthcare, Otelfingen, Switzerland 
  
Table	  27	  Protein	  /	  SDS-­‐PAGE	  /	  Western	  blot	  reagents	  and	  equipment.	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2.4.5	  Visualization	  of	  proteins	  	  
2.4.5.1	  Antibody	  staining	  /	  chemiluminescence	  detection	  of	  proteins	  on	  PVDF	  membranes	  After	  the	  blotting	  procedure,	  the	  PVDF	  membrane	  was	  shortly	  rinsed	  in	  PBST,	  and	  then	  blocked	  with	  5	  %	  milk	  powder	  in	  PBST	  for	  1h	  at	  RT	  on	  a	  laboratory	  shaker	  (#3006;	  GFL,	  Burgwedel,	  Germany)	  to	  prevent	  unspecific	  antibody	  binding.	  The	  primary	  antibody	  was	  diluted	  (Table	  28)	  in	  the	  blocking	  solution	  and	  the	  membrane	  was	  incubated	  o/n	  at	  4°C	  on	  a	  laboratory	  rocker	  or	  rotator	  (Roto-­‐Torque®	  Heavy	  Duty	  rotator,	  No	  7637-­‐10;	  Cole-­‐Parmer	  instruments,	  London,	  UK).	  The	  blot	  was	  washed	  three	  times	  for	  5	  min	  in	  PBST	  at	  RT	  before	  it	  was	  incubated	  in	  the	  secondary	  antibody	  solution	  (Table	  29)	  for	  30min	  at	  RT.	  Unbound	   antibodies	  were	   removed	   thoroughly	   by	  washing	   three	   times	   for	   10min	  with	   PBST.	   The	   horse	   radish	   peroxidase	   (HRP)	   labeled	   secondary	   antibodies	   were	  detected	  with	  the	  Western	  Lightning™	  ECL	  plus	  system	  (NEL103;	  Perkin	  Elmer,	  Boston,	  MA,	  USA).	  With	   this	  method,	  membrane-­‐bound	  proteins	  are	  detected	  by	  an	  enzymatic	  reaction	  that	  catalyzes	  chemiluminescence	  detection	  substrates	  to	  emit	  light,	  which	  then	  produces	  an	   image	  on	  photosensitive	   film.	  The	  substrates	  were	  prepared	  according	   to	  the	   manufacturer’s	   protocol	   and	   added	   to	   the	   membrane,	   which	   was	   then	   placed	  between	   two	   transparent	   overhead	   sheets	   and	   transferred	   into	   a	   film	   cassette.	   A	  photosensitive	   film	   (Lumi-­‐film;	   Roche,	  Mannheim,	   Germany)	  was	   then	   exposed	   to	   the	  membrane	   for	   different	   time	   spans	   and	   subsequently	   processed	   in	   a	   photo	   developer	  machine	  (Curix	  60;	  AGFA,	  Köln,	  Germany).	  Usually,	  the	  blot	  was	  then	  incubated	  a	  second	  time	   to	   ensure	   equal	   loading	   through	   the	   detection	   of	   the	   household	   protein	   GAPDH.	  Before	  the	  second	  incubation	  round,	  the	  blot	  was	  „stripped“,	  i.e.	  the	  activity	  of	  the	  horse	  radish	  peroxidase	  was	   terminated	   through	   incubation	  of	   the	  membrane	   in	  0.1%	  NaN3	  (Fluka/Sigma-­‐Aldrich,	  Buchs,	  Switzerland)	  in	  PBST	  for	  1h	  at	  RT.	  	  
Antibody Host Company Order no. Dilution α-c-myc mouse Roche 1667149 1 : 500 α-mouse β-catenin mouse BD Biosciences 610153 1 : 1,000 α-mouse Plvap/MECA-32 rat Developmental Studies Hybridoma Bank - 1 : 100 α-rat SNAT5 / Slc38a5 guinea pig F. Zafra, Madrid custom 1 : 4,000 α-rabbit GAPDH	   mouse Chemicon MAB374 1 : 8,000 α-rat p44/42 MAP Kinase	   rabbit Cell Signaling 4695 1 : 1,000 α-human phospho p44/42 
(Thr202/Tyr204) MAP Kinase	   rabbit Cell Signaling 9101 1 : 250 
	  
Table	   28	   Primary	   antibody	   dilutions	   for	  Western	   blots	   used	   in	   this	   study.	   Antibodies	  were	   diluted	   in	  PBST	  pH	  7.2	  with	  5%	  milk	  powder.	  	  
Antibody Host Company Order no. Dilution α-chicken/turkey IgG-HRP rabbit Zymed / Invitrogen 61-3120 1 : 10,000 α-guinea pig IgG-HRP rabbit Zymed / Invitrogen 61-4620 1 : 2,000 α-mouse IgG-HRP	   goat Dianova 115035062 1 : 10,000 α-rat IgG-HRP mouse Zymed / Invitrogen 80-9520 1 : 2,000 
	  
Table	  29	  Secondary	  antibody	  dilutions	   for	  Western	  blots	  used	   in	  this	  study.	  Antibodies	  were	  diluted	   in	  PBST	  pH	  7.2	  with	  5%	  milk	  powder.	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2.4.5.2	  Ponceau	  staining	  of	  SDS-­‐PAGE	  separated	  proteins	  on	  PVDF	  membranes	  The	  membrane	  was	  washed	  shortly	  three	  times	  in	  PBS	  at	  RT.	   It	  was	  then	  incubated	  in	  0.1%	   Ponceau	   S	   solution	   (P7110;	   Sigma,	   Buchs,	   Switzerland)	   for	   a	   few	  minutes	   until	  protein	  bands	  became	  visible.	  The	  membrane	  was	  quickly	  rinsed,	  and	  photographs	  were	  taken.	  
	  
2.4.5.3	  Coomassie	  staining	  of	  SDS-­‐PAGE	  protein	  gels	  The	  gel	  was	  washed	  three	  times	  in	  ddH2O	  for	  5min	  at	  RT.	  It	  was	  then	  incubated	  in	  20ml	  staining	  solution	  (Imperial™	  protein	  stain	  #24615;	  Pierce,	  Rockford,	  IL,	  USA)	  for	  2h.	  The	  gel	   was	   washed	   in	   ddH2O	   for	   another	   2h	   before	   it	   was	   dried	   (Gel	   dryer	   model	   543;	  BioRad,	  Reinach,	  Switzerland).	  	  
2.4.5.4	  Silver	  staining	  of	  SDS-­‐PAGE	  protein	  gels	  Proteins	  were	   fixed	   through	   incubation	  of	   the	  gel	   in	   five	  volumes	  of	  an	  ethanol:glacial	  acetic	  acid:water	  (30:10:60)	  solution	  o/n	  at	  RT.	  After	  removal	  of	  the	  fixative,	  the	  gel	  was	  gently	  washed	  twice	  in	  five	  gel	  volumes	  of	  30%	  EtOH	  for	  30min	  at	  RT.	  The	  ethanol	  was	  removed	  and	  ten	  gel	  volumes	  of	  ddH2O	  were	  added.	  This	  washing	  step	  was	  conducted	  twice	  for	  10min	  at	  RT.	  After	  washing,	  the	  gel	  was	  stained	  in	  five	  gel	  volumes	  of	  a	  fresh	  0.1%	  AgNO3	  solution	  for	  30min	  at	  RT	  (gently	  shaking).	  The	  solution	  was	  discarded	  and	  both	  sides	  of	  the	  gel	  were	  washed	  under	  a	  stream	  of	  deionized	  water	  for	  20s	  each.	  The	  gel	   was	   protected	   from	   light	   and	   five	   volumes	   of	   a	   freshly	   made	   fixing	   solution	  containing	  2.5%	  sodium	  carbonate	  and	  0.02%	  formaldehyde	  were	  added.	  The	  gel	  was	  incubated	  for	  a	  few	  minutes	  at	  RT,	  until	  protein	  bands	  became	  visible.	  The	  reaction	  was	  stopped	   through	  washing	   of	   the	   gel	   in	   a	   1%	   acetic	   acid	   solution.	   Finally,	   the	   gel	   was	  washed	  in	  water	  three	  times	  for	  10min	  and	  subsequently	  preserved	  by	  drying.	  	  
2.5	  Histology	  
2.5.1	  Cryosections	  Eyes	  were	  dissected,	   fixed	   for	  1h	   in	  PBS	  /	  4%	  para-­‐formaldehyde,	  washed	   in	  PBS	  and	  cryo-­‐protected	   in	   succrose/PBS	   solution	   (30min	   in	   10%,	   then	   o/n	   in	   20%)	   at	   4°C.	  Occasionally,	  the	  fixation	  step	  was	  omitted	  or	  fixation	  time	  was	  reduced,	  and	  the	  cryo-­‐protection	  was	  also	  not	  performed	  during	  some	  experiments.	  The	  eyes	  were	  embedded	  in	   Tissue-­‐Tek®	   O.C.T.	   Compound	   (Sakura	   Finetek,	   Zoeterwoude,	   Netherlands),	  submersed	   in	   liquid	   nitrogen,	   cut	   into	   8μm	   sections	  with	   a	   Leica	   Cryostat	   CM	   3050S	  (Leica,	  Heerbrugg,	  Switzerland)	  and	  transferred	  onto	  microscope	  glass	  slides.	  	  
2.5.2	  Immunohistochemistry	  After	   drying	   the	   sections	   for	   at	   least	   3h,	   unspecific	   binding	   sites	   were	   blocked	   by	  incubation	  with	  5%	  non-­‐specific	  serum	  (goat,	  rabbit,	  or	  sheep,	  depending	  on	  the	  origin	  of	   the	   secondary	   antibody;	   Sigma	  Aldrich,	   Steinheim,	  Germany)	   in	  PBST	   for	  1h.	   Slides	  were	   incubated	   with	   primary	   antibodies	   in	   blocking	   solution	   (o/n,	   4°C)	   in	   a	   wet	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chamber.	  Antibodies	  and	  used	  antiserum	  concentrations	  are	  listed	  in	  Table	  30.	  Sections	  were	  washed	  and	  incubated	  with	  secondary	  antibodies	   in	  PBS	  (90min,	  RT);	  secondary	  antibodies	  and	  dilutions	  used	  are	  given	  in	  Table	  31.	  Slides	  were	  washed	  a	  last	  time	  and	  finally	   mounted	   in	   a	   DAPI-­‐containing	   medium	   (Vectashield®	   Mounting	   Medium	   for	  Fluorescence	  with	  DAPI	  H-­‐1200,	  Vector	  Laboratories,	  Burlingame,	  CA,	  USA).	  	  
Antibody Host Company Order no. Dilution α-mouse Plvap/MECA-32 rat Developmental Studies Hybridoma Bank - 1 : 16 α-mouse Collagen IV rabbit AbD Serotec 2150-1470 1 : 300 α-rat SNAT5 / Slc38a5 guinea pig F. Zafra, Madrid custom 1 : 250 α-mouse APJ / Agtrl1 chicken abcam ab15639 1 : 300 α-human APOD rabbit abcam ab24808 1 : 200 α-E.coli β-galactosidase	   rabbit Molecular Probes A-11132 1 : 500 	       
Antibodies used in L. Galli-Restas lab in Pisa: α-mouse Synaptophysin/p38	   mouse Boehringer/Roche; E. Strettoi ? 1 : 500 α-mouse Islet-1/4D5	   mouse Sigma; L. Galli-Resta ? 1 : 50 α-mouse Vimentin (very old!)	   mouse Boehringer/Roche; L. Galli-Resta ? 1 : 5 α-mouse ChAT	   goat Chemicon AB144P 1 : 200 α-mouse mGluR6	   rabbit E. Strettoi, Pisa custom 1 : 1,000 α-mouse NF150	   rabbit Chemicon AB1981 1 : 500 α-mouse calbindin 28kDa	   rabbit Swant; L. Galli-Resta ? 1 : 200 
	  
Table	   30	   Primary	   antibody	   dilutions	   for	   cryosections	   used	   in	   this	   study.	   Antibodies	   were	   diluted	   in	  blocking	  solution	  (PBST	  pH	  7.2	  with	  10%	  normal	  goat/sheep	  serum).	  	  
Antibody Host Company Order no. Dilution α-rabbit IgG Cy3™ goat Jackson ImmunoResearch Europe 111-165-003 1 : 300 α-rat IgG AF®488 goat Molecular Probes / Invitrogen A-11006 1 : 1’000 α-guinea pig IgG AF®488 goat Molecular Probes / Invitrogen A-11073 1 : 300 α-chicken IgY Cy3™ donkey Jackson ImmunoResearch Europe 703-166-155 1 : 300 
	  
Table	  31	  Secondary	  antibody	  dilutions	  for	  cryosections	  used	  in	  this	  study.	  Antibodies	  were	  diluted	  in	  blocking	  solution	  (PBST	  pH	  7.2	  with	  10%	  normal	  goat/sheep	  serum)	  	  
2.5.3	  X-­‐Gal	  staining	  After	  drying	  of	  the	  cryosections	  for	  2h,	  the	  microscope	  slides	  were	  washed	  three	  times	  shortly	  (2-­‐3min)	  with	  PBS.	  Then	  300µl	  X-­‐Gal	  staining	  solution	  (Table	  32)	  were	  applied	  to	  each	  slide.	  	  
X-Gal staining solution Stock Final conc. Volume 
    
BetaBlue™ buffer 1x  292µl 
X-Gal in DMSO 40µg/µl 1µg/µl 7.5µl 
NP-40 10% 0.02% 0.6µl 
    
Total per slide:   300µl 
	  
Table	  32	  Reaction	  mix	   for	   the	  X-­‐Gal	  staining	  solution	  sufficient	   for	  one	  microscope	  slide.	  Kit	   ingrdients	  were	  from	  the	  BetaBlue™	  Staining	  Kit	  (Novagen/Merck,	  Darmstadt,	  Germany).	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Microscope	   slides	   were	   then	   incubated	   o/n	   at	   37°C	   in	   a	   wet	   chamber.	   The	   staining	  solution	  was	   removed,	   and	   the	   slides	  were	  washed	   three	   times	   shortly	   (2-­‐3min)	  with	  PBS.	   Sections	   were	   postfixed	   for	   1h	   with	   4%	   PFA	   in	   PBS,	   and	   washed	   again	   in	   PBS	  (5x3min).	   Finally,	   the	   sections	  were	   embedded	   in	  DAPI-­‐containing	  mounting	  medium,	  or	  were	  further	  stained	  by	  immunohistochemistry.	  	  
2.5.4	  Whole	  mount	  preparations	  For	   retinal	   flatmounts,	   eyes	   were	   dissected	   and	   fixed	   for	   15min	   in	   PBS/4%	   para-­‐formaldehyde.	   Retinae	   were	   removed	   and	   post-­‐fixed	   for	   additional	   15min.	   After	  washing	  in	  PBS,	  unspecific	  binding	  was	  blocked	  by	  10%	  non-­‐specific	  serum	  in	  PBST	  for	  1h.	  Samples	  were	   then	   incubated	  o/n	  with	   the	  primary	  antibodies.	  They	  were	  washed	  six	   times	   for	   1h	   in	   PBST	   and	   incubated	   o/n	  with	   the	   secondary,	   fluorescently-­‐labeled	  antibodies.	   After	   repetition	   of	   the	   washing	   procedure,	   the	   retinae	   were	   finally	  flatmounted	  on	  microscope	  slides	  in	  a	  DAPI-­‐containing	  medium.	  	  
2.5.5	  Paraffin	  sections	  After	   dissection,	   tissue	  was	   fixed	   in	   Serras-­‐fixative	   (Table	   33)	   on	   ice	   for	   a	   few	   hours,	  during	  which	   time	   the	   liquid	  was	   agitated	   2-­‐3	   times,	   because	  water	   leaking	   from	   the	  tissue	  has	  a	  higher	  density	  than	  the	  fixative.	  The	  sample	  was	  then	  placed	  at	  4°C	  and	  fixed	  o/n.	  On	   the	   next	   day,	   the	   Serras-­‐solution	  was	   exchangend	  with	   ice-­‐cold	   70%	   isopropanol,	  and	  the	  tissue	  was	  dehydrated	  for	  about	  2h.	  The	  step	  was	  repeated	  three	  times,	  and	  the	  last	  step	  was	  conducted	  o/n.	  The	  70%	  solution	  was	  then	  changed	  to	  100%	  isopropanol,	  (3x	  2h),	  at	  which	  point	  the	  tissue	  could	  be	  stored	  at	  -­‐20°C.	  Corneas	  were	  removed,	  and	   the	  eyes	  were	   further	  dehydrated	  by	   ice-­‐cold	  chloroform,	  which	  was	  exchanged	  once	  after	  3h,	  before	  being	  placed	  at	  4°C	  o/n.	  The	  tissue	  was	  then	  immersed	   in	  paraffin	  oil	  and	  placed	   into	  an	   incubator	  at	  60°C.	   It	  was	   then	   transferred	  into	   liquid	  paraffin	   for	  2h,	  which	  was	  exchanged	   two	  more	   times.	  The	  second	  paraffin	  step	  was	   conducted	  o/n.	  The	   tissue	  was	   then	  embedded	   in	  paraffin	   in	  a	   casting	  mold,	  carefully	   adjusting	   the	   eye’s	   position	   in	   space	  with	   a	  micro-­‐forceps,	   and	   the	   paraffin-­‐block	  was	  stored	  o/n	  at	  4°C.	  The	  embedded	  tissue	  was	  then	  cut	  into	  7µm	  sections	  with	  a	  rotary	   microtome	   (RM2145;	   Leica,	   Heerbrugg,	   Switzerland).	   The	   sections	   were	  straightened	   in	  a	   flattening	  bath,	   transferred	  onto	  microscope	  slides,	   and	  dried	  o/n	  at	  42°C	  on	  a	  heated	  flattening	  table.	  	  




Formaldehyde solution 37% 30% 
Acetic acid 10%  
4% PFA fixation solution 
Formaldehyde 2g 
PBS buffer 50ml  
  
Histology solutions & equipment 
AxioCam HRc digital camera Carl Zeiss MicroImaging, Jena, Germany 
AxioCam MRm digital camera Carl Zeiss MicroImaging, Jena, Germany 
Axioplan 2 microscope Carl Zeiss MicroImaging, Jena, Germany 
Chloroform (#102445.1000) Merck, Darmstadt, Germany 
Cold plate (#EG1140 C) Leica, Heerbrugg, Switzerland 
Cryostat (#CM 3050S) Leica, Heerbrugg, Switzerland 
Eosin staining solution 3% (Eosin B; #E8017) Sigma Aldrich, Steinheim, Germany 
Ethanol 95% (#1.00983) Merck, Darmstadt, Germany 
Flattening bath (#HI1210) Leica, Heerbrugg, Switzerland 
Flattening table (#HI1220) Leica, Heerbrugg, Switzerland 
Isopropanol (#109634) Merck, Darmstadt, Germany 
Mayer’s hemalum solution (#1.09249) Merck, Darmstadt, Germany 
Microtome blades type N35H, disposable: 
extreme hard (#207500007); hard( #207500006) 
Leica, Heerbrugg, Switzerland 
Paraffin (Histowax; #14 037432123) Leica, Heerbrugg, Switzerland 
Paraffin dispensing module, heated (#EG1140H) Leica, Heerbrugg, Switzerland 
Paraffin oil (#9190) Carl Roth, Karlsruhe, Germany 
Rotary microtome (#RM2145) Leica, Heerbrugg, Switzerland 
Roti Histokitt (#6638) Carl Roth, Karlsruhe, Germany 
Rotihistol (#6640) (Xylol alternative) Carl Roth, Karlsruhe, Germany 
Stereo microscope (#MZ6) Leica, Heerbrugg, Switzerland 
Superfrost / Plus microscope slides (#H867.1) Carl Roth, Karlsruhe, Germany 
Vectashield® Mounting Medium with DAPI (#H-1200)  Vector Laboratories, Burlingame, CA, USA  
 
Table	  33	  Histology	  reagents,	  solutions,	  and	  equipment	  
	  
2.5.6	  Hematoxylin-­‐eosin	  staining	  Paraffin-­‐embedded	   sections	   were	   then	   stained	   with	   hematoxylin-­‐eosin.	   For	   that	  purpose,	   the	   sections	   were	   deparaffinized	   twice	   in	   Rotihistol	   (Carl	   Roth,	   Karlsruhe,	  Germany)	   for	  10min,	  and	  subsequently	  hydrated	   in	  a	  descending	  alcohol	   series	   (2min	  each	  in	  100%(2x),	  90%,	  70%,	  50%	  isopropanol,	  ddH2O).	  Then,	  staining	  of	  the	  cell	  nuclei	  was	  performed	  with	  hemalum	  solution	  (Mayer’s;	  Merck,	  Darmstadt,	  Germany)	  for	  5min.	  The	   sections	   were	   washed	   twice	   quickly	   in	   ddH2O,	   and	   were	   then	   subjected	   to	   an	  ascending	  alcohol	  series	  and	  eosin	  stain	  (which	  labels	  the	  cytoplasm):	  
• 50%	  EtOH	  (10	  dips)	  
• 70%	  EtOH	  +	  NH4OH	  (2	  drops/50ml)	  (30s)	  
• 70%	  EtOH	  (quick)	  
• 95%	  EtOH	  (quick)	  
• 95%	  EtOH	  +	  0.3%	  eosin	  (90s)	  
• 95%	  EtOH	  (quick)	  
• 95%	  EtOH	  (quick)	  After	  preparation	  through	  submersion	  in	  Rotihistol	  III	  (5min)	  and	  Rotihistol	  IV	  (5min),	  sections	  were	   embedded	  with	   the	  Roti	  Histokitt	   (Carl	  Roth,	  Karlsruhe,	   Germany),	   and	  the	  slides	  were	  dried	  o/n.	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2.5.7	  Microscopy	  Images	  were	  taken	  with	  an	  Axioplan	  2	  microscope	  equipped	  with	  AxioCam	  HRc	  (color)	  and	   MRm	   (monochrome)	   digital	   cameras	   (Carl	   Zeiss	   MicroImaging,	   Jena,	   Germany;	  Figure	   36).	   Three-­‐dimensional	   immunofluorescence	   images	   from	   retinal	   flatmounts	  were	  compiled	  from	  a	  Z-­‐Stack	  of	  pictures	  acquired	  with	  a	  Zeiss	  ApoTome™.	  During	   a	   10-­‐day	   internship	   in	   Lucia	   Galli-­‐Restas	   lab	   in	   Pisa	   (Istituto	   di	   Neuroscienze,	  Consiglio	   Nazionale	   delle	   Ricerche),	   cryosections	   and	   wholemounts	   were	   examined	  under	  a	  confocal	  microscope	  (Leica	  TCS	  NT;	  Leica	  Microsystems	  S.p.A.,	  Milano,	  Italy).	  	  
	  
Figure	  36	  ApoTome	  imaging	  system	  on	  the	  basis	  of	   the	   fluorescence	  microscope	  Axioplan	  2	  (Carl	  Zeiss	  MicroImaging,	  Jena,	  Germany.	  Source:	  www.zeiss.de)	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2.6	  Recombinant	  protein	  expression	  in	  yeast	  
	  Recombinant	  norrin	  was	  engineered	  with	  the	  Multi-­‐Copy	  Pichia	  expression	  kit	  (#K1750-­‐01;	  Invitrogen,	  Carlsbad,	  CA,	  USA).	  The	  NDP	  constructs	  were	  placed	  under	  control	  of	  the	  
AOX1	   promoter,	   which	   allows	   methanol-­‐inducible	   high-­‐level	   expression	   in	   Pichia	  
pastoris	   cells.	   In	   addition,	   the	   NDP	   fragment	   was	   cloned	   behind	   an	   α–factor	   signal	  sequence,	  which	  facilitates	  secretion	  of	  the	  desired	  protein	  into	  the	  medium.	  	  




Figure	  37	  Donor	  (pDONR221;	  left)	  and	  P.	  pastoris	  expression	  (pDEST-­‐PICZalpha	  A;	  right)	  vectors	  for	  the	  Invitrogen	  Gateway®	  system	  were	  provided	  by	  Rolf	  Jaussi	  (Paul-­‐Scherrer-­‐Institute,	  Villigen,	  Switzerland).	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2.6.1.1	  Generation	  of	  the	  attB-­‐flanked	  PCR	  product	  Gateway®	  attB	  recombination	  sites,	  tags,	  and	  flanking	  cleavage	  sites	  for	  thrombin	  (TCS)	  were	  introduced	  with	  elongated	  PCR	  primers	  (Figure	  38;	  Figure	  39).	  The	  inclusion	  of	  c-­‐myc	   and	   6xHis	   tags	   facilitates	   easy	   purification	   and	   antibody	   detection	   of	   the	  recombinant	   protein,	   and	   TCS	   sites	   allow	   for	   facultative	   removal	   of	   the	   tags,	   e.g.	   for	  structure	  crystallography.	  Plasmid	  DNAs	  nos.	  82	  and	  84	  containing	  the	  human	  wild	  type	  and	   C95R	   Norrin	   variant	   in	   the	   pBudCE4.1	  mammalian	   expression	   vector	   (#V53220;	  Invitrogen,	  Carlsbad,	  CA,	  USA),	  respectively	  (provided	  by	  Ulrich	  Luhmann;	  see	  also	  PhD	  thesis	   Luhmann,	   2005),	   served	   as	   template	   for	   the	   PCR.	   Phusion™	   High-­‐Fidelity	   DNA	  polymerase	   (#F-­‐530s;	  New	  England	  Biolabs	  GmbH,	  Frankfurt	  am	  Main,	  Germany)	  was	  used	  to	  reduce	  the	  possibility	  of	  misincorporated	  bases	  (Table	  34).	  A	   nested	   PCR	   strategy	   was	   applied	   for	   the	   N-­‐terminal	   constructs.	   Amplicons	   were	  excised	  from	  the	  gel	  after	  the	   first	  PCR,	  and	  DNA	  from	  the	  gel	  extractions	  was	  used	  as	  template	   for	   the	   nested	   PCR	   to	   create	   the	   N-­‐terminally	   tagged	   constructs.	   For	  downstream	  processing,	  only	  DNA	  from	  excised	  bands	  was	  used	  (Figure	  40).	  	  
hNDP – Constructs Stock conc. Vol. Final conc. 
ddH2O  16.5µl  
Phusion HF buffer 5x 5µl* 1x 
MgCl2 25mM 0µl* 1.5mM 
dNTPs (each) 20mM 0.25µl 200µM 
Primer fwd 10µM 1.25µl 500nM 
Primer rev 10µM 1.25µl 500nM 
Phusion Polymerase 2u/µl 0.25µl 0.02u/µl 
DNA template 20ng/µl 0.5µl 0.4ng/µl 
    
Total:  25µl   
Product Primer Size [bp] 
C-terminal 277/278 424 
1st N-terminal 279/280 425 
2nd N-terminal 281/280 478 
   
Cycling conditions 





72°C 10min  
10°C ∞   
Table	  34	  PCR	  reaction	  mix	  for	  C-­‐	  and	  N-­‐terminally	  tagged	  constructs.	  *Phusion	  HF	  buffer	  contains	  1.5mM	  MgCl2	  	  
	  
Gateway® recombination sites thrombin cleavage sites (TCS) mature human NDP wt/C95R variation 
	  
Figure	  38	  Sequence	  of	   the	  attB-­‐flanked	  PCR	  product	  of	   the	  C-­terminal	   tagged	  constructs.	  The	  c-­‐myc	  and	   6xHis	   tags	   were	   already	   present	   in	   the	   expression	   vector	   and	   had	   not	   to	   be	   added	   through	   PCR	  primers.	  Note	   that	   the	  endogenous	  Stop	   codon	  was	   removed	   from	   the	  NDP	   sequence.	  Primers	  277	  and	  278	   have	   been	   used	   to	   introduce	   the	   TCS	   sites	   and	   the	   attB	   sequences	   required	   for	   the	   Gateway®	  recombination	  reaction.	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Gateway® recombination sites thrombin cleavage sites (TCS) mature human NDP wt/C95R variation c-myc tag 6xHis tag Stop codon 
	  
Figure	  39	  Sequence	  of	  the	  attB-­‐flanked	  PCR	  product	  of	  the	  N-­terminal	  tagged	  constructs.	  Primers	  279	  and	  280	  have	  been	  used	  in	  a	  first	  PCR,	  and	  primers	  281	  and	  280	  in	  the	  following	  nested	  PCR	  to	  introduce	  TCS	   sites,	   attB	   sequences	   required	   for	   the	  Gateway®	   recombination	   reaction,	   and	   the	  N-­‐terminal	   c-­‐myc	  and	  6xHis	  tags.	  To	  ensure	  that	  no	  read-­‐through	  occurs	  at	  the	  end	  of	  the	  coding	  sequence,	  a	  second	  Stop	  codon	  was	  added.	  	  
	   	   	   	  
A	   B	   C	   D	  
	  
Figure	   40	   Generation	   of	   the	   attB-­‐flanked	   PCR	   products.	   (A)	   1st	   PCR	   for	   C-­‐	   and	   N-­‐terminally	   tagged	  constructs.	  (B)	  Same	  gel	  as	  in	  (A)	  showing	  the	  position	  of	  the	  excised	  bands.	  (C)	  2nd,	  nested	  PCR	  with	  DNA	  from	   the	   right	   two	   extractions	   (N-­‐terminal	   constructs)	   of	   the	   gel	   shown	   in	   (B).	   (D)	   Same	   gel	   as	   in	   (C)	  showing	  the	  position	  of	  the	  excised	  bands.	  
	  
2.6.1.2	   Generation	   of	   entry	   vectors	   through	   enzymatic	   recombination	   of	   the	   attB-­‐PCR	  
product	  and	  the	  donor	  vector	  DNA	   isolated	   from	   the	   electrophoresis	   gel	   was	   cloned	   into	   the	   Zero	   Blunt®	   TOPO®	  vector	   and	   constructs	   were	   verified	   by	   sequencing	   (clones	   no.	   219-­‐222).	   In	   a	   first	  attempt,	   this	   vector	   DNA	   was	   used	   as	   template	   for	   the	   Gateway®	   recombination	  reaction.	  However,	  as	   this	  vector	   features	   the	  same	  resistance	  genes	  as	   the	  donor	  and	  expression	   vectors	   (Kanamycin	   and	   Zeocin™),	   the	   recombined	   clones	   could	   not	   be	  obtained,	   and	   only	   the	   template	   Zero	   Blunt®	   vector	   was	   successfully	   selected.	   In	   a	  second	   attempt,	   Rolf	   Jaussi	   did	   a	   PCR	  on	   the	   Zero	  Blunt®	   template	  with	  M13	   primers	  (56/57)	   and	   lowered	   the	   background	   of	   the	   template	   vector	   through	   digestion	   with	  
DpnI	   (Fermentas/LabForce,	   Nunningen,	   Switzerland),	   which	   only	   cuts	   methylated,	  vector	   DNA.	   The	   BP	   recombination	   reaction	   was	   performed	   with	   the	   donor	   vector	  pDONR221	  according	  to	  the	  manufacturer’s	  instructions,	  and	  the	  Clonase™	  enzyme	  mix	  
MATERIAL	  AND	  METHODS	   93	  	  
	  
was	   digested	   with	   Proteinase	   K.	   DH10β	   cells	   (in	   100µl	   SOC	  medium	   containing	   10%	  glycerin)	   were	   transformed	   through	   electroporation	   (Gene	   Pulser™;	   BioRad,	   Reinach,	  Switzerland)	   at	   1.7kV/200µF/200Ω	   in	   a	   1mm	   cuvette	   (resulting	   in	   a	   time	   constant	  between	   4.2	   –	   4.8	   ms).	   Selection	   of	   positive	   entry	   vector	   clones	   (Figure	   41)	   was	  performed	   on	   LB	   plates	   with	   Kanamycin	   (50µg/ml).	   After	   verification	   through	  sequencing	  with	  M13	   primers,	   one	   clone	   each	  was	   selected	   for	   the	   generation	   of	   the	  expression	  vector.	  
  
	  
Figure	  41	  Entry	  vectors	  for	  the	  C-­‐terminal	  (left)	  and	  N-­‐terminal	  (right)	  tagged	  NDP	  constructs	  generated	  through	  enzymatic	  recombination	  of	  the	  attB-­‐PCR	  product	  and	  the	  donor	  vector	  (pDONR221).	  	  
2.6.1.3	  Generation	  of	  the	  expression	  vector	  through	  enzymatic	  recombination	  of	  the	  donor	  
vector	  and	  the	  expression	  vector	  The	   LR	   recombination	   reaction	   was	   performed	   with	   the	   expression	   vector	   pDEST-­‐PICZalpha	  according	  to	  the	  manufacturer’s	   instructions,	  and	  the	  Clonase™	  enzyme	  mix	  was	  digested	  with	  Proteinase	  K.	  DH10β	  cells	  were	  transformed	  through	  electroporation,	  and	   selection	  of	  positive	  expression	  vector	   clones	   (Figure	  42)	  was	  performed	  on	   low-­‐salt	  LB	  plates	  (5g/l	  NaCl)	  with	  Zeocin™	  (100µg/ml;	  #R250-­‐01;	  Invitrogen,	  Carlsbad,	  CA,	  USA).	  Four	  clones	  were	  picked	  for	  each	  construct	  and	  verified	  through	  sequencing	  with	  
AOX1	  primers	  (282/283).	  One	  clone	  each	  was	  selected	  for	  subsequent	  transformation	  of	  
Pichia	  cells	  (clones	  no.	  223-­‐226;	  Figure	  43;	  Figure	  44).	  
  
	  
Figure	   42	   P.	   pastoris	   expression	   vectors	   for	   the	   C-­‐terminal	   (left)	   and	   N-­‐terminal	   (right)	   tagged	   NDP	  constructs	  generated	  through	  enzymatic	  recombination	  of	  the	  donor	  and	  the	  expression	  vector.	  A	  double	  Stop-­‐codon	  was	   introduced	  between	   the	  NDP	   C-­‐terminus	  and	   the	  vector-­‐derived	   tags	   in	   the	  N-­‐terminal	  constructs	  (right).	  TCS:	  Thrombin	  cleavage	  site	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Figure	   43	   Sequence	   of	   the	   translated	   part	   of	   the	   C-­terminal	   tagged	   expression	   vector.	   Different	  domains	   are	   color-­‐coded.	   Enzymatic	   cleavage	   sites	   of	   KEX2	   (inside	   the	   alpha	   factor	   signal	   peptide	  sequence)	  and	  thrombin	  (inside	  the	  TCS	  sites)	  are	  indicated	  by	  black	  bars.	  Clone	  no.	  223	  contains	  the	  wt	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Figure	   44	   Sequence	   of	   the	   translated	   part	   of	   the	   N-­terminal	   tagged	   expression	   vector.	   Different	  domains	   are	   color-­‐coded.	   Enzymatic	   cleavage	   sites	   of	   KEX2	   (inside	   the	   alpha	   factor	   signal	   peptide	  sequence)	  and	  thrombin	  (inside	  the	  TCS	  site)	  are	  indicated	  by	  black	  bars.	  Clone	  no.	  225	  contains	  the	  wt	  
NDP	  variant,	  clone	  no.	  226	  contains	  the	  C95R	  mutation.	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2.6.2	  Recombinant	  protein	  expression	  in	  Pichia	  pastoris	  Transformation	   of	   yeast	   cells	   and	   expression	   of	   recombinant	   protein	   was	   performed	  according	  to	  the	  manufacturer’s	  instructions	  (Invitrogen	  #V195-­‐20	  and	  #K1750-­‐01).	  
2.6.2.1	  Transformation	  of	  Pichia	  cells	  To	   obtain	   sufficient	   amounts	   of	   DNA	   for	   transformation	   of	   Pichia	   pastoris	   X-­‐33	   cells,	  colonies	  of	   the	  selected	  clones	  were	  cultured	   in	  250ml	   low-­‐salt	  LB	  medium	  and	  pDNA	  was	  isolated.	  Prior	  to	  transformation,	  the	  vector	  was	  linearized	  by	  50-­‐fold	  overdigestion	  with	   SacI	   (Fermentas/LabForce,	   Nunningen,	   Switzerland)	   o/n	   at	   37°C	   (Table	   35).	  Complete	   digestion	   was	   verified	   by	   loading	   of	   1µl	   onto	   a	   0.9%	   agarose	   gel	   and	   the	  enzyme	  was	  heat-­‐inactivated	  at	  65°C	  for	  20min.	  	  
Vector linearization Stock conc. Vol. 
pDNA 0.17µg/µl 60µl 
Buffer Ecl136II 10x 7.78µl 
SacI 10u/µl 10µl 
   
Total:  77.78µl 
	  
Table	  35	  Reaction	  mix	  for	  vector	  linearization.	  	  Linearized	   vector	  DNA	  was	   then	   isolated	   by	   phenol-­‐chloroform	   extraction	   (Carl	   Roth,	  Karlsruhe,	  Germany)	   and	   subsequent	  EtOH	  precipitation	   (containing	  1/10	  volume	  3M	  sodium	  acetate).	  Pichia	  pastoris	   cells	  were	   transformed	  by	  Suzanne	  Kronenberg	  (Paul-­‐Scherrer-­‐Institute)	  by	  electroporation	  and	  4	  positive	  clones	  per	  construct	  were	  selected	  on	   YPDS	   plates	   containing	   100,	   200,	   500,	   and	   800µg/ml	   Zeocin™,	   and	   glycerol	   stocks	  were	  prepared	   for	  storage	  at	   -­‐80°C	  according	   to	   the	  manufacturer’s	  protocol	   (glycerol	  stock	  no.	  5-­‐20).	  
2.6.2.2	  Induction	  of	  recombinant	  protein	  expression	  Clones	   were	   incubated	   o/n	   in	   5ml	   BMGY	   medium	   in	   12ml	   culture	   tubes	   at	   30°C	   /	  180rpm.	  Cell	  number	  was	  estimated	  by	  photospectrometric	  measurement	  of	  the	  OD600,	  and	  cultures	  were	  all	  diluted	  to	  an	  OD600	  of	  0.8	  to	  ensure	  equal	  number	  of	  cells.	  Then,	  4ml	   of	   the	   cultures	   were	   used	   to	   inoculate	   46ml	   of	   BMGY	   medium	   in	   300ml	   shaker	  flasks	  with	  baffles	  (Vitaris,	  Baar,	  Switzerland).	  Cultures	  were	  incubated	  for	  24h	  at	  30°C	  /	  180rpm	   (growth	   phase).	   	   Then,	   cell	   numbers	   were	   normalized	   again	   through	   OD600	  measurement,	  equal	  amounts	  of	  cells	  were	  pelleted	  and	  the	  medium	  was	  exchanged	  to	  BMMY	  (Expression	  phase).	   Induction	  of	  protein	  expression	  was	  maintained	  every	  12h	  with	   0.5%	   (250µl)	   100%	   methanol	   over	   a	   total	   period	   of	   4	   days.	   Medium	   samples	  (500µl)	  were	  taken	  at	  each	  methanol-­‐induction	  time	  point.	  
2.6.2.3	  Concentration	  of	  recombinant	  protein	  Culture	   supernatant	   was	   concentrated	   with	   Amicon®	   Ultra-­‐4	   10K	   filter	   columns	  (Millipore,	   Billerica,	   MA,	   USA)	   according	   to	   the	   manufacturer’s	   instructions.	   These	  columns	  have	  a	  molecular	  weight	  cut-­‐off	  of	  10kDa,	  and	  concentrate	  4ml	  input	  volume	  to	  200µl	  elution	  volume	  (factor	  20).	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2.7	  Cell	  culture	  of	  mammalian	  cells	  	  A	   total	   of	   8	   HEK293T	   cell	   cultures	   were	   seeded	   in	   standard	   medium	   (DMEM;	  Sigma/Aldrich,	   Steinheim,	   Germany)	   and	   grown	   for	   2	   days	   in	   medium	   sized	   bottles	  (75cm2,	   12ml	   volume;	   TPP,	   Trasadingen,	   Switzerland)	   by	   Jurian	   Zürcher.	   Sodium	  chloride	  (control)	  or	  lithium	  chloride	  (induction	  of	  canonical	  Wnt-­‐signaling)	  were	  added	  to	   the	   medium	   of	   four	   colonies	   each	   to	   a	   final	   concentration	   of	   25mM.	   Cells	   were	  incubated	  o/n	  and	  harvested	  the	  next	  day	  by	  trypsination:	  After	  removal	  of	  the	  medium,	  cells	  were	  washed	  with	  4ml	  phosphate	  buffered	  saline	  (PBS)	  to	  remove	  cell	  debris	  and	  Mg2+.	   The	   cell	   monolayer	   was	   then	   enzymatically	   digested	   with	   trypsin	   (0.25%)	   for	  2min	   at	   37°C.	   The	   digest	   was	   stopped	   with	   the	   addition	   of	   12ml	   DMEM.	   Cells	   were	  transferred	  to	  a	  centrifuge	  tube	  and	  pelleted	  at	  300g	  for	  5min.	  After	  centrifugation,	   the	  cell	  pellets	  were	  split	   in	  order	   to	   isolate	  RNA	   for	  quantitative	  RT-­‐PCR	  from	  one	  portion	  and	  protein	  for	  Western	  blot	  experiments	  from	  the	  other.	  
RESULTS	   97	  	  
	  
3.	  Results	  
3.1	   Vascular	   changes	   in	   the	   cerebellum	   of	   Norrin	   ⁄	   Ndph	   knockout	   mice	  
correlate	  with	  high	  expression	  of	  Norrin	  and	  Frizzled-­‐4	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3.1.1	  Abstract	  	  X-­‐linked	  Norrie	  disease,	  familial	  exudative	  vitreoretinopathy	  (FEVR),	  Coats’	  disease	  and	  retinopathy	   of	   prematurity	   are	   severe	   human	   eye	   diseases	   and	   can	   all	   be	   caused	   by	  mutations	  in	  the	  Norrie	  disease	  pseudoglioma	  gene.	  They	  all	  show	  vascular	  defects	  and	  characteristic	   features	   of	   retinal	   hypoxia.	   Only	   Norrie	   disease	   displays	   additional	  neurological	  symptoms,	  which	  are	  sensorineural	  hearing	  loss	  and	  mental	  retardation.	  In	  the	  present	  study,	  we	  analysed	  transcript	  levels	  of	  the	  ligand	  Norrin	  (Ndph)	  and	  its	  two	  receptors	   Frizzled-­‐4	   (Fzd4)	   and	   LDL-­‐related	   protein	   receptor	   5	   (Lrp5)	   in	   six	   different	  brain	   regions	   (cerebellum,	   cortex,	   hippocampus,	   olfactory	   bulb,	   pituitary	   and	   brain	  stem)	  of	  6-­‐	  to	  8-­‐month-­‐old	  wild-­‐type	  and	  Ndph	  knockout	  mice	  by	  quantitative	  real-­‐time	  PCR.	   No	   effect	   of	   the	  Ndph	   knockout	   allele	   on	   Fzd4	   or	   Lrp5	   receptor	   expression	  was	  found.	   Furthermore,	   no	   alterations	   of	   the	   transcript	   levels	   of	   three	   hypoxia-­‐regulated	  angiogenic	   factors	   (Vegfa,	   Itgrb3	   and	   Tie1)	   were	   observed	   in	   the	   absence	   of	   Norrin.	  Interestingly,	   we	   identiﬁed	   signiﬁcant	   differences	   in	   Ndph,	   Fzd4	   and	   Lrp5	   transcript	  levels	  in	  brain	  regions	  of	  wild-­‐type	  mice	  and	  observed	  highest	  expression	  of	  Norrin	  and	  Frizzled-­‐4	   in	  cerebellum.	  Transcript	  analyses	  were	  correlated	  with	  morphological	  data	  obtained	   from	   cerebellum	   and	   immunohistochemical	   studies	   of	   blood	   vessels	   in	  different	  brain	  regions.	  Vessel	  density	  was	  reduced	  in	  the	  cerebellum	  of	  Ndph	  knockout	  mice	  but	   the	  number	  of	  Purkinje	  and	  granular	  cells	  was	  not	  altered.	  This	  provides	   the	  ﬁrst	   description	   of	   a	   brain	   phenotype	   in	   Ndph	   knockout	   mice,	   which	   will	   help	   to	  elucidate	  the	  role	  of	  Norrin	  in	  the	  brain.	  
Keywords:	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  Lrp5,	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  retardation,	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3.1.2	  Introduction	  	  Mutations	  in	  the	  Norrie	  disease	  pseudoglioma	  gene	  (NDP)	  cause	  a	  variety	  of	  human	  eye	  diseases	  including	  Norrie	  disease,	  X-­‐linked	  familial	  exudative	  vitreoretinopathy	  (FEVR),	  Coats’	  disease	  and	  severe	  retinopathy	  of	  prematurity	  (ROP)	  (Berger	  et	  al	  92a;Berger	  et	  al	  92b;Chen	  et	  al	  92;Shastry	  et	  al	  97b;Shastry	  et	  al	  97a;Black	  et	  al	  99).	  Among	  these,	  only	  Norrie	  disease	  can	  be	  accompanied	  by	  progressive	  hearing	  loss	  and	  mental	  retardation	  (for	  review	  see	  (Berger	  98),	  but	  all	  four	  diseases	  exhibit	  similar	  vascular	  defects	  in	  the	  eye.	  Thus	  it	  was	  suggested	  that	  Norrin,	  the	  protein	  encoded	  by	  the	  NDP	  gene,	  has	  a	  role	  in	  ocular	  vascular	  development.	  This	  was	  supported	  by	  data	  from	  the	  respective	  mouse	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model	   (Berger	   et	   al	   96),	   which	   showed	   malformation	   of	   the	   retinal	   and	   hyaloid	  vasculature	   and	   abnormal	   vessels	   in	   the	   inner	   ear	   (Richter	   et	   al	   98;Ohlmann	   et	   al	  04;Rehm	  et	  al	  02).	  Further	  examination	  of	   retinal	  vascular	  development	   revealed	   that	  Norrin	  plays	  a	  role	  in	  sprouting	  angiogenesis.	  Its	  absence	  causes	  the	  lack	  of	  deep	  retinal	  capillary	  networks	  and	  subsequent	  retinal	  hypoxia	  which	  is	  accompanied	  by	  a	  three-­‐	  to	  fivefold	   increase	   of	   expression	  of	   the	   angiogenic	   factors	  Vegfa,	   Itgb3	  and	  Tie1.	   Retinal	  hypoxia	  seems	  to	  be	  one	  major	  pathogenic	  mechanism	  in	  the	  eye	  and	  might	  explain	  the	  clinical	  similarities	  in	  patients	  with	  all	  four	  diseases	  (Luhmann	  et	  al	  05).	  Identification	  of	  FEVR	  causing	  mutations	  in	  the	  Wnt	  receptor	  Frizzled-­‐4	  (FZD4)	  and	  its	  co-­‐receptor	  LDL	  related	  protein	  5	  (LRP5)	  (Robitaille	  et	  al	  02;Toomes	  et	  al	  04),	  together	  with	   high	   phenotypic	   similarities	   of	   Ndph	   and	   Fzd4	   knockout	   mice	   in	   eye	   and	   ear	  (Berger	   et	   al	   96;Richter	   et	   al	   98;Rehm	   et	   al	   02;Wang	   et	   al	   01;Xu	   et	   al	   04)	   led	   to	   the	  finding	  that	  Norrin	  is	  a	  high	  affinity	  ligand	  of	  Fzd-­‐4	  and	  Lrp5	  and	  activates	  the	  canonical	  Wnt-­‐/beta-­‐catenin	   signalling	   pathway	   (Xu	   et	   al	   04).	   Furthermore,	   these	   studies	  suggested	  that	  defects	  in	  this	  signalling	  pathway	  are	  also	  responsible	  for	  the	  progressive	  hearing	   loss	  observed	   in	  both,	  mice	   and	  Norrie	  disease	  patients	   from	  early	   adulthood	  onwards	  (Berger	  et	  al	  96;Wang	  et	  al	  01;Halpin	  et	  al	  05;Rehm	  et	  al	  02;Richter	  et	  al	  98).	  Findings	  in	  the	  brain	  of	  homozygous	  Fzd4	  knockout	  mice	  indicated	  the	  requirement	  of	  the	   Wnt-­‐receptor	   Fzd4	   for	   normal	   neuronal	   development.	   Abnormal	   gait	   and	  progressive	   cerebellar	   ataxia	   with	   a	   dramatic	   loss	   of	   cerebellar	   granular	   cells	   and	   a	  progressive	  Purkinje	  cell	   loss	  have	  been	  found	  in	  this	  mouse	  line	  (Wang	  et	  al	  01).	  At	  6	  month	  of	  age,	   these	   	  mice	  also	  showed	  sparse,	  enlarged	  and	   irregular	  blood	  vessels	   in	  the	   cerebellum	   (Xu	   et	   al	   04),	   suggesting	   an	   additional	   role	   of	   Fzd4	   signalling	   for	   the	  brain	  vasculature.	  Here,	  we	  aim	  to	  complement	  the	  understanding	  of	  Norrin’s	  role	  as	  a	  ligand	   of	   the	   Fzd4/Lrp5	   receptor	   pair	   in	   the	   adult	   brain,	   and	   to	   identify	   potential	  pathogenic	   mechanisms	   for	   the	   mental	   retardation	   phenotype	   observed	   in	   Norrie	  disease	   patients.	   We	   therefore	   investigated	   the	   correlations	   between	   Norrin	   and	   its	  receptors	   by	   quantitative	   RT-­‐PCR	   in	   different	   brain	   regions	   and	   explored	   whether	  degenerative	  and	  vascular	  defects	  as	  described	  for	  Fzd4	  knockout	  mice	  and	  subsequent	  hypoxia	  occur	   in	   the	  adult	  brain	  of	  Ndph	  knockout	  mice.	  We	  found	  that	  Norrin	  and	   its	  receptors	   were	   widely	   distributed	   in	   the	   brain	   and	   observed	   differences	   in	   their	  expression	  levels	  between	  brain	  regions.	  Highest	  levels	  for	  Norrin	  and	  Frizzled-­‐4	  were	  detected	   in	  the	  cerebellum	  where	  we	  also	   found	  a	  slight	  reduction	   in	  vessel	  density	   in	  
Ndph	  knockout	  mice.	  	  We	  discuss	  a	  possible	  role	  of	  Norrin	  in	  maintenance	  of	  cerebellar	  blood	  vessels	  during	  adulthood.	  	  
	  
3.1.3	  Material	  and	  methods	  
3.1.3.1	  Animals	  The	  Ndph	  knockout	  mouse	  line	  and	  genotyping	  has	  been	  described	  previously	  (Berger	  et	  al	   96).	   Male	   animals	   were	   obtained	   by	   breeding	   of	   heterozygous	   female	   mice	   with	  C57Bl/6	   male	   mice.	   Whenever	   possible,	   siblings	   from	   the	   same	   litter	   were	   used	   for	  experimental	   procedures.	   The	   research	  was	   performed	   in	   accordance	   with	   the	   ARVO	  Statement	  for	  the	  Use	  of	  Animals	  in	  Ophthalmic	  and	  Vision	  Research.	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3.1.3.2	  Tissue	  preparation,	  fixation,	  histology	  and	  immunohistochemistry	  Total	   brain	   or	   brain	   regions	   (olfactory	   bulb,	   cortex,	   cerebellum,	   brain	   stem,	  hippocampus,	   and	   pituitary)	  were	   dissected	   from	  male	  Ndph	   knockout	  mice	   and	  wild	  type	   littermates	  at	   the	  age	  of	  6-­‐8	  months.	  For	  RNA	   isolation,	   tissue	  preparations	  were	  performed	  on	  ice	  and	  immediately	  frozen	  in	  liquid	  nitrogen.	  For	  immunohistochemistry	  the	   brain	   was	   embedded	   into	   O.C.T.	   compound	   (Tissue-­‐Tek/	   Sakura	   Finetek,	  Zoeterwoude,	  Netherlands)	  and	  frozen	  on	  dry	  ice.	  The	  brains	  were	  sagittally	  sectioned	  (8µm),	  transferred	  to	  SuperFrost	  slides	  (Roth,	  Reinach,	  Germany)	  and	  dried	  over	  night	  at	   room	   temperature	   for	   fixation.	   The	   brain	   sections	   were	   stained	   with	   a	   primary	  antibody	  against	  Collagen	  type	  IV	  (polyclonal	  Col	  IV	  antibody,	  rabbit	  anti-­‐mouse	  (1:250),	  no.2150-­‐1470,	  AbD	  Serotec/MorphoSys,	  Oxford,	  UK)	  and	  a	  secondary	  Cy-­‐3-­‐labeled	  anti	  rabbit	  antibody	  (1:200,	  no	  111-­‐165-­‐003;	  Dianova,	  Hamburg,	  Germany).	  For	  histological	  examination	  the	  tissue	  was	  transferred	  to	  Serra’s	  fixative	  (60%	  ethanol,	  11.1%	   (30%	   of	   37%)	   formaldehyde,	   10%	   acetic	   acid)	   and	   fixed	   over	   night	   at	   4°C.	  Subsequently,	   the	   tissue	  was	  dehydrated	   in	  70%	  and	  100%	  isopropanol,	  embedded	   in	  paraffin,	   sectioned	   (7μm),	   and	   transferred	  onto	  SuperFrost	  Plus	   slides	   (Roth,	  Reinach,	  Germany).	   Histological	   staining	   was	   performed	   by	   hematoxylin-­‐eosin	   staining	  procedure	   (Mayer's	   hemalum	   solution,	   Merck,	   Darmstadt,	   Germany).	   The	   slides	   were	  mounted	  with	  Rotihistokitt	   (Roth,	  Reinach,	  Germany)	  and	  observed	  under	  bright	   light	  illumination	   using	   a	   Zeiss	   Axioplan	   2	  microscope.	   Image	   collection	  was	   performed	   by	  using	  an	  AxioCam	  HRc	  digital	  camera	  (Carl	  Zeiss	  AG,	  Jena,	  Germany).	  	  
3.1.3.3	  Quantitative	  examination	  of	  hematoxylin-­‐eosin	  -­‐	  or	  ColIV-­‐stained	  sections	  To	  quantify	  the	  cell	  number	  in	  the	  cerebellum,	  hematoxylin-­‐eosin	  stained	  sagittal	  brain	  sections	  of	  five	  wild	  type	  (wt:	  n	  =	  5)	  and	  five	  Ndph	  knockout	  mice	  (Ndph-­‐ko:	  n	  =	  5)	  were	  used.	  Within	  an	  individual	  cerebellum	  two	  groups	  of	  three	  images	  each	  were	  taken	  from	  two	  different	  sectioning	  planes	  differing	  by	  at	   least	  140µm.	  The	  three	   images	  within	  a	  group	  were	   taken	   from	  the	  same	  sagittal	  section	  at	  defined	  positions.	  For	  quantitative	  analysis	   of	   cell	   numbers,	   all	   Purkinje	   cells	   per	   image	  were	   counted	   and	   granular	   cells	  were	  determined	  in	  two	  areas	  of	  250µm2.	  A	  mean	  value	  per	  image	  was	  calculated.	  Based	  on	  the	  mean	  values	  for	  both	  cell	  types	  in	  each	  animal,	  the	  mean	  cell	  number	  of	  Purkinje	  cells	  and	  the	  mean	  cell	  density	  for	  granular	  cells	  in	  the	  cerebellum	  were	  calculated.	  	  Col	   IV	   stains	   the	   extracellular	  matrix	   of	   endothelial	   cells	   and	  was	   used	   to	   label	   blood	  vessels	  in	  the	  brain.	  Col	  IV	  stained	  cryosections	  (wt:	  n	  =	  6;	  Ndph-­‐ko:	  n	  =	  6)	  were	  used	  to	  determine	   the	   vessel	   density	   in	   three	   different	   brain	   regions	   (cerebellum,	   cortex	   and	  hippocampus).	   The	   number	   of	   vessels	   was	   counted	   and	   normalized	   to	   the	   total	   area	  used	   for	   counting.	   Vessel	   density	   is	   given	   in	   number	   of	   blood	   vessels	   per	   500µm2	   for	  each	  brain	  region.	  	  
3.1.3.4	  RNA	  isolation,	  DNaseI	  treatment	  and	  quantitative	  RT-­‐PCR	  (Real–Time	  –PCR)	  Total	   RNA	  was	   isolated	   from	  dissected	   brain	   regions	   from	   animals	   of	   both	   genotypes	  (wt:	  n	  =	  6;	  Ndph-­‐ko:	  n	  =	  6)	  using	  RNA	  extraction	  kits	   (RNeasy	  Mini	  kit:	  olfactory	  bulb,	  pituitary;	  RNeasy	  Midi	  kit:	  cerebellum,	  cortex,	  hippocampus,	  brain	  stem;	  Qiagen,	  Hilden,	  Germany).	  The	  RNA	  was	   treated	  with	  RQ1	  RNAse-­‐Free	  DNase	   I	   (Promega,	  Mannheim,	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Germany)	   before	   concentration	   and	   integrity	  were	   checked	  on	   an	  Agilent	  Bioanalyzer	  2100	   (Agilent	   technologies,	   Basel,	   Switzerland).	   DNaseI-­‐treated	   RNA	   (0,5	   -­‐	   1	  µg)	  was	  reverse	   transcribed	  using	   SuperScript	   III	  RNase	  H–	  Reverse	  Transcriptase	   (Invitrogen,	  Basel,	   Switzerland)	   and	   random	   Hexamer	   Primers	   pd(N)6	   (Amersham	   Bioscience,	  Freiburg,	  Germany).	  Quantitative	  real-­‐time-­‐PCR	  in	  384-­‐well	  plate	  format	  was	  performed	  using	   a	   robotic	   aid	   for	   pipetting	   and	   the	  ABI	  PRISM	  7900	   Sequence	  Detection	   System	  with	   the	   published	   MGB-­‐TaqMan	   probes	   for	  Ndph,	   Fzd4,	   Lrp5,	   Itgb3,	   Tie1	   and	   Vegfa	  (Luhmann	  et	  al	  05).	  Five	  replicates	  for	  target	  genes	  and	  three	  replicates	  for	  the	  internal	  standard	   18S	   rRNA	   (TaqMan	   Ribosomal	   RNA	   Control	   Reagent,	   ABI,	   Rotkreuz,	  Switzerland)	  were	  included	  for	  each	  sample.	  The	  ΔCt-­‐method	  for	  relative	  quantification	  was	  used	  and	  data	  was	  normalized	  to	  the	  Norrin	  expression	  level	  in	  one	  individual	  wild	  type	  cortex.	  Data	  analysis	  was	  performed	  using	  the	  ABI	  Prism	  7900HT	  SDS2.2	  Software	  and	   a	   spreadsheet	   program.	   Based	   on	   the	   mean	   relative	   expression	   values	   for	   the	  technical	  replicates	  in	  each	  brain	  region,	  mean	  values	  for	  wild	  type	  and	  knockout	  groups	  were	  calculated	  and	  are	  shown	  with	  standard	  deviation	  (SD)	  error	  bars	   in	   the	  graphs.	  Since	  the	  technical	  reproducibility	  of	  the	  qRT	  results	  was	  very	  high,	  SD	  error	  bars	  reflect	  the	  inter-­‐individual	  variability.	  	  
3.1.3.5	  Statistical	  analysis	  For	  statistical	  analysis	  the	  software	  package	  SPSS	  14.0	  for	  Windows	  (SPSS	  inc.,	  Chicago,	  USA)	  was	  used.	  Real-­‐time	  expression	  data	  were	  statistically	  analyzed	  by	  using	  ANOVA	  for	   repeated	   measurements	   treating	   brain	   regions	   as	   repeated	   measurements	  (dependent	   within	   subject	   factor)	   and	   defining	   the	   two	   groups	   of	   wt	   and	   Ndph-­‐ko	  animals	  as	   independent	  between	  subject	  factors.	  For	  this	  test	  we	  used	  the	  ΔΔCt	  values	  for	  statistical	  analysis,	  as	   they	  are	  assumed	  to	  be	  normally	  distributed	  (Love	  et	  al	  06).	  Subsequently,	   pair	   wise	   comparisons	   were	   used	   to	   identify	   groups	   with	   significant	  differences.	  For	  within	  subject	  data	  (brain	  regions),	  the	  parametric	  paired	  t-­‐test	  or	  the	  non	  parametric	  Wilcoxon	  signed	  rank	  test	  was	  used,	  while	  for	  independent	  groups	  (wt	  versus	   Ndph	   knockout)	   either	   the	   parametric	   Student’s	   t-­‐test	   or	   the	   non	   parametric	  Mann	  Whitney	  U-­‐test	  was	  applied.	  As	  the	  ANOVA	  for	  repeated	  measurement	  analyses	  did	  not	  show	  significant	  differences	  between	   wild	   type	   and	   knockout	   animals	   for	   Fzd4,	   Lrp5,	   Itgrb3,	   Tie1	   and	   Vegfa	  expression	   in	   all	   brain	   regions	   (see	   results),	   the	   statistical	   analysis	   for	   the	   pair	   wise	  comparison	  of	  expression	  levels	  between	  different	  brain	  regions	  were	  based	  on	  pooled	  data	  sets	  from	  6	  wild	  type	  and	  6	  knockout	  animals	  (total	  n	  =	  12).	  	  
	  
3.1.4	  Results	  	  
3.1.4.1	   Expression	   studies	   for	   Ndph,	   Lrp5	   and	   Fzd4	   revealed	   differences	   in	   various	   brain	  
regions	  We	  evaluated	  the	  relative	  expression	   levels	  of	  Ndph,	  Frizzled-­4	   (Fzd4)	  and	  LDL	  related	  
protein	  5	  (Lrp5)	  in	  different	  brain	  regions	  by	  quantitative	  RT-­‐PCR	  (Figure	  45	  and	  Table	  36).	  When	  comparing	  the	  expression	  of	  all	  three	  genes	  in	  wild	  type	  and	  Ndph	  knockout	  animals,	  no	  significant	  differences	  were	  found,	  except	  the	  expected	  absence	  of	  the	  Ndph	  transcript	  in	  knockout	  animals	  [repeated-­‐measurements	  ANOVA:	  WT,	  n	  =	  6;	  Ndph-­‐KO,	  n	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=	  6	  (Ndph,	  P	  <	  0.01;	  Fzd4,	  P	  =	  0.950;	  Lrp5,	  P	  =	  0.397)].	  However,	  when	  comparing	  the	  expression	   levels	   in	   brain	   regions,	   significant	   differences	   were	   indicated	   for	   all	   three	  transcripts	   [Ndph	   (n	   =	   6),	  Fzd4	   and	  Lrp5	   (n	   =	   12):	  P	   <	   0.01;	   Figure	   45,	   Table	   36].	   To	  identify	   the	   differences	   in	   transcript	   levels	   in	   individual	   brain	   regions,	   both	   the	  parametric	   paired	   t-­‐test	   analysis	   of	   the	  ΔΔCt	   values	   and	   the	  non	  parametric	  Wilcoxon	  signed	  rank	  test	  analysis	  of	  the	  relative	  expression	  values	  (RQ)	  were	  used	  for	  pair	  wise	  comparison.	  	  For	  both	  tests	  significance	  was	  set	  to	  P	  <	  0.05.	  For	  Ndph,	  we	  observed	  the	  highest	  relative	  expression	  in	  the	  cerebellum	  (Figure	  45).	  It	  was	  significantly	  higher	  than	  in	  olfactory	  bulb	  and	  brain	  stem.	  The	  latter	  two	  were	  not	  significantly	   different	   from	   each	   other,	   but	   were	   higher	   than	   those	   in	   cortex	   and	  hippocampus.	   In	  pituitary,	   only	   traces	  of	  Ndph	   expression	  have	  been	  detected	   (Figure	  45,	  Table	  36).	  	  For	   Fzd4	   the	   highest	   level	   of	   expression	   was	   also	   found	   in	   cerebellum,	   which	   was	  significantly	  higher	  compared	  to	  all	  other	  brain	  regions	  (n	  =	  12,	  paired	  t-­‐test	  analysis	  of	  the	   ΔΔCt	   values:	   P	   <	   0.05;	   Figure	   45).	   In	   contrast	   to	   Ndph,	   Fzd4	   showed	   its	   lowest	  relative	   expression	   level	   in	   olfactory	   bulb	   (n	   =	   12,	   paired	   t-­‐test	   and	  Wilcoxon	   signed	  rank	  test:	  P	  <	  0.05).	  Other	  brain	  regions	  (cortex,	  hippocampus,	  pituitary	  and	  brain	  stem)	  showed	  intermediate	  transcript	  levels,	  which	  were	  statistically	  not	  distinguishable	  from	  each	  other	  (Figure	  45,	  Table	  36).	  Interestingly,	  pituitary	  was	  the	  only	  brain	  region	  where	  both	  receptors	  (Fzd4	  and	  Lrp5)	  were	  expressed,	  whereas	  their	  ligand	  (Ndph)	  was	  virtually	  absent.	  This	  might	  suggest	  a	  Norrin-­‐independent	  role	  of	  Fzd4	  in	  the	  pituitary.	  For	   Lrp5,	   the	   lowest	   amount	   of	   transcript	   was	   found	   in	   cortex	   and	   the	   highest	   in	  pituitary	   (Table	  36).	  Among	   the	  other	   regions,	   the	  expression	   level	   in	   cerebellum	  was	  significantly	  higher	  than	  that	  in	  hippocampus	  (n	  =	  12;	  paired	  t-­‐test	  and	  Wilcoxon	  signed	  rank	   tests	   P	   <	   0.05).	   Lrp5	   in	   comparison	   to	   Fzd4	   showed	   an	   about	   8-­‐9	   fold	   lower	  expression	  in	  cerebellum,	  cortex	  and	  hippocampus,	  while	  in	  olfactory	  bulb,	  pituitary	  and	  brain	  stem	  the	  reduction	  was	  only	  4-­‐5	  fold	  (Table	  36).	  This	  indicates	  that	  different	  brain	  regions	  express	  different	  Fzd4/Lrp5	  receptor	  transcript	  ratios.	  Our	  data	  also	  suggested	  variable	   receptor/ligand	   ratios	   in	   different	   brain	   regions	   and	   revealed	   overlapping	  expression	  of	  Ndph	  with	  its	  two	  receptors	  Lrp5	  and	  Fzd4	  in	  all	  but	  one	  brain	  region.	  	  
3.1.4.2	   Evaluation	   of	   hypoxia	   regulated	   angiogenic	   factors	   in	   brain	   regions	   of	   Ndph	  
knockout	  mice	  	  To	  assess	  potential	  hypoxic	  changes	  in	  the	  brain	  of	  Ndph	  knockout	  mice	  at	  the	  molecular	  level,	  we	  quantified	  the	  transcript	  levels	  of	  the	  three	  angiogenic	  factors	  integrin	  beta	  3	  (Itgb3),	   tyrosine	   kinase	   receptor	   1	   (Tie1)	   and	   vascular	   endothelial	   growth-­‐factor	   A	  (Vegfa)	  in	  the	  six	  brain	  regions	  by	  quantitative	  RT-­‐PCR	  (Figure	  46;	  Table	  37).	  We	  chose	  these	  three	  factors	  as	  they	  are	  known	  to	  be	  transcriptionally	  up-­‐regulated	  by	  hypoxia	  in	  Norrie	  disease	  mouse	  retinae	  (Luhmann	  et	  al	  05).	  Comparison	  of	  wild	  type	  (n	  =	  6)	  and	  
Ndph	  knockout	  mice	  (n	  =	  6)	  revealed	  no	  significant	  differences	  for	  the	  three	  angiogenic	  genes	   (ANOVA	   for	   repeated	  measurement	   analysis;	   Itgb3,	  P	   =	   0.764;	  Tie1,	  P	   =	   0.620;	  
Vegfa,	  P	  =	  0.868).	  Thus,	  we	  found	  no	  indication	  for	  hypoxia	  in	  Ndph	  knockout	  brains.	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Gene	   Brain	  region	   Relative	  Expression	  ±	  S.D.	  	   	   Wt	   Ndph	  ko	  
Ndph	   Cerebellum	   3.06	  ±	  0.81	   0.00	  ±	  0.00	  	   Cortex	   1.22	  ±	  0.39	   0.00	  ±	  0.00	  	   Hippocampus	   0.97	  ±	  0.47	   0.00	  ±	  0.00	  	   Olfactory	  bulb	   2.19	  ±	  0.41	   0.00	  ±	  0.00	  	   Pituitary	   0.03	  ±	  0.02	   0.01	  ±	  0.01	  	   Brain	  stem	   1.85	  ±	  1.23	   0.00	  ±	  0.00	  	   	   	   	  
Fzd4	   Cerebellum	   5.07	  ±	  1.32	   4.53	  ±	  1.10	  	   Cortex	   2.83	  ±	  0.75	   3.00	  ±	  1.18	  	   Hippocampus	   4.42	  ±	  2.47	   3.33	  ±	  0.88	  	   Olfactory	  bulb	   1.77	  ±	  0.38	   2.13	  ±	  0.49	  	   Pituitary	   3.45	  ±	  1.47	   3.27	  ±	  0.72	  	   Brain	  stem	   3.67	  ±	  2.14	   3.61	  ±	  1.51	  	   	   	   	  
Lrp5	   Cerebellum	   0.59	  ±	  0.33	   0.47	  ±	  0.30	  	   Cortex	   0.33	  ±	  0.21	   0.27	  ±	  0.14	  	   Hippocampus	   0.48	  ±	  0.29	   0.30	  ±	  0.11	  	   Olfactory	  bulb	   0.45	  ±	  0.10	   0.42	  ±	  0.16	  	   Pituitary	   0.83	  ±	  0.27	   0.64	  ±	  0.36	  	   Brain	  stem	   0.64	  ±	  0.51	   0.49	  ±	  0.20	  
	  
Table	  36	  Relative	  Expression	  of	  Ndph	  and	  its	  two	  receptors	  Fzd4	  and	  Lrp5	  in	  different	  brain	  regions	  of	  wt	  and	  Ndph	  ko	  mice.	  Data	  ±	  SD	  were	  normalized	  to	  Norrin	  expression	  in	  the	  cortex	  of	  an	  individual	  animal.	  	  
	  
Figure	   45	   Differential	   expression	   of	   Ndph,	   Lrp5	   and	   Fzd4	   in	   six	   brain	   regions	   of	   mice.	   The	   relative	  expression	   (±	   SD)	  of	   these	   genes	  was	  determined	  by	  quantitative	   real-­‐time	  PCR	   in	  Ndph	  wild-­‐type	   and	  knockout	  mice	  (WT,	  n	  =	  6;	  KO,	  n	  =	  6).	  All	  relative	  expression	  values	  were	  normalized	  to	  an	  individual	  Ndph	  expression	  level	  in	  WT	  cortex.	  	  	  	  
RESULTS	   103	  	  
	  
Gene	   Brain	  region	   Relative	  Expression	  ±	  S.D.	  	   	   Wt	   Ndph	  ko	  
Itgb3	   Cerebellum	   0.22	  ±	  0.10	   0.19	  ±	  0.06	  
	   Cortex	   0.46	  ±	  0.17	   0.45	  ±	  0.06	  
	   Hippocampus	   0.24	  ±	  0.10	   0.20	  ±	  0.03	  
	   Olfactory	  bulb	   0.24	  ±	  0.08	   0.24	  ±	  0.06	  
	   Pituitary	   0.28	  ±	  0.09	   0.26	  ±	  0.06	  
	   Brain	  stem	   0.40	  ±	  0.17	   0.38	  ±	  0.13	  
	   	   	   	  
Tie1	   Cerebellum	   2.96	  ±	  0.88	   2.41	  ±	  0.35	  
	   Cortex	   1.94	  ±	  0.45	   2.41	  ±	  0.63	  
	   Hippocampus	   1.73	  ±	  0.72	   1.83	  ±	  0.56	  
	   Olfactory	  bulb	   1.65	  ±	  0.54	   1.88	  ±	  0.47	  
	   Pituitary	   3.79	  ±	  1.00	   3.72	  ±	  0.73	  
	   Brain	  stem	   3.62	  ±	  1.72	   3.95	  ±	  1.76	  
	   	   	   	  
Vegfa	   Cerebellum	   13.49	  ±	  3.53	   12.70	  ±	  4.02	  	   Cortex	   6.98	  ±	  0.63	   7.88	  ±	  1.23	  	   Hippocampus	   6.32	  ±	  3.01	   5.92	  ±	  1.09	  	   Olfactory	  bulb	   9.70	  ±	  2.21	   8.97	  ±	  2.16	  	   Pituitary	   3.46	  ±	  0.92	   3.29	  ±	  1.51	  	   Brain	  stem	   9.74	  ±	  5.15	   9.62	  ±	  3.51	  
	  
Table	  37	  Relative	  Expression	  three	  angiogenic	  factors	  in	  six	  brain	  regions	  of	  wt	  and	  Ndph	  ko	  mice.	  Data	  ±	  SD	  were	  normalized	  to	  Norrin	  expression	  in	  the	  cortex	  of	  an	  individual	  animal.	  	  	  	  
	  
Figure	  46	   Expression	   of	   three	   hypoxia-­‐regulated	   angiogenic	   factors.	  Quantitative	   analysis	   of	   transcript	  levels	   of	   integrin	   beta	   3	   (Itgrb3)	   (A),	   tyrosine	   kinase	   receptor	   1	   (Tie1)	   (B)	   and	   vascular	   endothelial	  growth-­‐factor	  A	  (Vegfa)	  (C)	  in	  six	  brain	  regions.	  The	  mean	  relative	  expression	  is	  presented	  ±	  SD	  (WT,	  n	  =	  6;	  KO,	  n	  =	  6).	  Note	  the	  differences	  in	  the	  scale	  of	  the	  axes	  for	  the	  three	  transcripts.	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Nevertheless,	  when	  we	  analyzed	  transcript	  levels	  in	  different	  brain	  regions	  by	  using	  pair	  wise	   comparison	   on	   pooled	   data	   sets	   of	   wildtype	   and	   knockout	   data	   (n	   =	   12),	   a	  significant	  difference	  was	  found	  (ANOVA	  for	  repeated	  measurement;	  P	  <	  0.01).	  
Itgb3	  was	   highest	   expressed	   in	   cortex	   and	   brain	   stem,	  while	   pituitary,	   olfactory	   bulb,	  hippocampus	  and	  cerebellum	  showed	  significantly	  lower	  levels	  (Figure	  46A,	  Table	  37;	  P	  <	  0.05	  for	  paired	  t-­‐Test	  and	  Wilcoxon	  signed	  rank	  test).	  In	  contrast,	  Tie1	  mRNA	  showed	  highest	  amounts	  in	  pituitary	  and	  brain	  stem	  (Figure	  46B).	  	  The	   highest	   Vegfa	   expression	   level	   was	   found	   in	   the	   cerebellum,	   with	   successively	  decreasing	  levels	  in	  olfactory	  bulb,	  cortex,	  hippocampus,	  and	  pituitary	  (differences	  were	  significant	  in	  both,	  the	  Wilcoxon	  signed	  rank	  test	  and	  the	  paired	  t-­‐test	  P	  <	  0.05	  (Figure	  46C).	  While	  Vegfa	  expression	  in	  brain	  stem	  and	  olfactory	  bulb	  was	  at	  comparable	  levels,	  variability	  was	  less	  in	  the	  latter	  region.	  We	  note,	  that	  Vegfa	  and	  Norrin	  display	  a	  similar	  ratio	   of	   expression	   levels	   (approximately	   5:1)	   in	   the	   various	   brain	   regions	   with	   the	  exception	  of	  pituitary.	  	  In	  this	  brain	  region	  Norrin	  expression	  was	  virtually	  absent,	  while	  
Vegfa	  was	  found	  at	  considerable	  levels	  (Figure	  45	  and	  Figure	  46C).	  	  Taken	   together,	   our	   quantitative	   transcript	   analyses	   of	   angiogenic	   factors	   did	   not	  indicate	  hypoxia-­‐induced	  transcriptional	  upregulation	  in	  Ndph	  knockout	  mice.	  	  
	  
3.1.4.3	  Analysis	  of	  cerebellar	  morphology	  in	  Ndph	  knockout	  mice	  Because	   we	   observed	   highest	   Ndph	   and	   Fzd4	   expression	   in	   cerebellum	   we	   then	  examined	   the	  morphology	   of	   this	   brain	   region	   in	   6–8-­‐month-­‐old	  wild	   type	   and	  Ndph	  knockout	  mice	   using	  hematoxylin-­‐eosin	   stained	   sagittal	   sections	   (Figure	  47).	   Since	  no	  gross	  morphological	  changes	  were	  observed	  in	  Ndph	  knockout	  mice	  (Figure	  47A,B),	  we	  determined	   the	   number	   of	   cerebellar	   Purkinje	   and	   granular	   cells	   from	   five	   individual	  animals	  per	  genotype	  as	  an	   indicator	   for	  degenerative	  processes.	  Representative	  high-­‐magnification	   images	   from	  wild	   type	   and	   knockout	   sections	   are	   shown	   in	   Figure	   47C	  and	  D.	  No	  alterations	  were	  detected	  in	  the	  amount	  of	  Purkinje	  and	  granular	  cells	  (Mann	  Whitney	  U,	  P	  =	  0.138,	  P	  =	  0.249,	  respectively)	  (Figure	  47E).	  	  	  
3.1.4.4	  Characterization	  of	  the	  vasculature	  in	  cerebellum,	  hippocampus	  and	  cortex	  of	  wild	  
type	  and	  Ndph	  knockout	  mice	  To	   assess	   potential	   vascular	   changes	   in	   the	   brain	   of	  Ndph	   knockout	  mice,	  we	   applied	  immunohistochemistry.	  We	  stained	  for	  Collagen	  IV	  in	  sagittal	  sections	  of	  whole	  brains	  as	  a	   marker	   for	   the	   extracellular	   matrix	   of	   vascular	   endothelial	   cells	   (Figure	   48A).	   No	  obvious	  differences	   in	  vessel	  size	  and	  morphology	  were	  noted	   in	  hippocampus,	  cortex	  and	   the	   cerebellum	   (Figure	   48B).	   However,	   the	   distribution	   of	   blood	   vessels	   in	   the	  cerebellum	  of	  Ndph	   knockout	  mice	  occasionally	   seemed	   to	  be	   less	  dense	   compared	   to	  that	   in	   the	  wild	   type.	   Therefore,	   vessels	   in	   all	   three	  brain	   regions	   from	  wild	   type	   and	  
Ndph	   knockout	   animals	   (n	   =	   6)	   were	   counted	   and	   displayed	   as	   mean	   vessel	   density	  (Figure	   49A).	  We	   found	   a	   significant	   reduction	   of	   16.4%	   in	   the	   cerebellum,	   while	   an	  effect	  of	   the	  Ndph	   knockout	  on	   the	  vessel	  density	   in	  hippocampus	  and	  cortex	  was	  not	  detected	   (Figure	   49A,	   ANOVA	   for	   repeated	   measurement	   (P	   <	   0.05)	   and	   2-­‐tailed	  independent	  sample	  t-­‐test	  (P	  <	  0.05)).	  	  




Figure	  47	  Gross	  morphology	  and	  cell	  number	  of	  Purkinje	  and	  granular	  cells	  are	  not	  altered	  in	  Ndph-­‐KO	  mice.	  Haematoxylin–eosin	  stains	  of	  sagittally	  sectioned	  cerebellum	  from	  Ndph	  WT	  and	  knockout	  mice.	  A	  and	  C,	  wild-­‐type;	  B	  and	  D,	  Ndph-­‐KO;	  E,	  quantitative	  assessment	  of	  Purkinje	  and	  granular	  cell	  numbers	  in	  the	  cerebellum.	  Mean	  cell	  number	  (±	  SD)	  of	  Purkinje	  cells	  per	  section	  and	  granular	  cells	  per	  250µm2	  (n	  =	  5).	  Scale	  bars	  in	  A	  and	  B	  =	  200µm,	  in	  C	  and	  D	  =	  50µm.	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In	  addition,	  we	  found	  for	  both	  genotypes	  that	  the	  vessel	  density	  of	  the	  cerebellum	  was	  significantly	   higher	   than	   in	   cortex	   and	   hippocampus	   (Figure	   49A;	   ANOVA	   (P	   <	   0.01);	  paired	  t-­‐test	  and	  Wilcoxon	  signed	  rank	  test;	  n	  =	  6;	  P	  <	  0.05).	  
	  We	  attempted	   to	   localize	   the	   statistically	   significant	   reduction	   in	   the	  cerebellar	  vessel	  density	  to	  the	  layers	  of	  molecular,	  granular/Purkinje	  cell	  or	  white	  matter.	  We	  found	  that	  vessel	   density	   in	   the	   white	   matter	   layer	   (69.8%	   ±	   16.3	   %	   of	   Wt)	   was	   significantly	  reduced	   (2-­‐tailed	   independent	   sample	   t-­‐test	   (P	   =	  0.034)	   (Figure	  49B).	   In	   contrast,	   the	  trend	  of	  reduction	  in	  vessel	  densities	  of	  the	  molecular	  layer	  (86.0%	  ±	  15.9	  %	  of	  Wt)	  and	  the	  granular/Purkinje	  cell	  layer	  (86.8	  %	  ±	  22.8%	  of	  Wt)	  was	  not	  statistically	  significant	  (Figure	  49B).	  	  Taken	  together,	  our	  data	  suggested	  that	  the	  Ndph	  knockout	  had	  no	  general	  effect	  on	  the	  vascular	  system	  in	  the	  brain,	  but	  causes	  a	  mild	  reduction	  in	  vessel	  density	  in	  the	  white	  matter	  of	  the	  cerebellum.	  	  
3.1.5	  Discussion	  	  The	  data	  reported	  here	  expand	  our	  knowledge	  about	  the	  quantitative	  mRNA	  expression	  of	  Norrin	  and	  its	  two	  receptors	  Frizzled-­‐4	  and	  LDL	  related	  protein	  5	   in	  different	  brain	  regions	  of	  adult	  mice.	  Former	  studies	  located	  Ndph	  transcripts	  to	  retina	  and	  total	  brain.	  RNA	  in	  situ	  studies	  (Berger	  et	  al	  96)	  showed,	  in	  good	  accordance	  with	  our	  quantitative	  data,	   signals	   in	   the	   olfactory	   bulb	   and	   in	   Purkinje	   cells	   of	   the	   cerebellum,	   where	   we	  found	  highest	  Norrin	   transcript	   levels.	  Our	  data	  now	  provide	   additional	   evidence	   that	  Norrin	   is	  more	  widely	  expressed	  in	  brain	   including	  now	  also	  cortex,	  hippocampus	  and	  brain	  stem,	  while	  in	  pituitary	  only	  traces	  of	  Norrin	  were	  detected.	  Similarly,	  significant	  expression	  differences	  between	  the	  brain	  regions	  were	  found	  for	  Fzd4	  and	  Lrp5	  and,	  like	  
Ndph,	   the	  highest	  expression	  of	  Fzd4	  was	  detected	   in	  cerebellum.	  Fzd4	   and	  Lrp5	  were	  co-­‐expressed	   in	  all	  brain	   regions	   in	  which	  Ndph	  was	  present.	   In	   combination	  with	   the	  observation	   that	   Norrin	   activates	   the	  Wnt-­‐/beta-­‐catenin	   signalling	   pathway	   via	   FZD4	  and	  LRP5	  in	  cell	  culture	  assays	  (Xu	  et	  al.04),	  our	  expression	  data	  are	  consistent	  with	  the	  potential	  modulatory	  role	  of	  Norrin	  for	  the	  Wnt	  signalling	  pathway	  via	  FZD4	  and	  its	  co-­‐receptor	  LRP5	  in	  the	  brain.	  	  The	   expression	   patterns	   further	   suggest	   Norrin-­‐independent	   functions	   of	   FZD4	   and	  LRP5	   in	   the	   pituitary	   and	   raise	   the	   possibility	   of	   a	   regulation	   of	   Wnt-­‐signalling	   by	  changes	  in	  the	  expression	  levels	  of	  the	  ligand	  Norrin	  across	  different	  brain	  regions.	  	  	  As	  indicated	  by	  our	  results,	  a	  regulation	  of	  this	  signalling	  may	  also	  occur	  by	  changes	  in	  the	  ratio	  of	  FZD4	  to	  LRP5	  levels	  in	  different	  brain	  regions,	  which	  we	  either	  found	  to	  be	  8-­‐9	  in	   cerebellum,	   cortex	   and	   hippocampus	   or	   4-­‐5	   in	   olfactory	   bulb,	   pituitary	   and	   brain	  stem.	  Based	   on	   the	   similarity	   in	   expression	   patterns	   of	   Norrin	   and	   VEGFA	   across	   different	  brain	  regions,	  we	  hypothesize	   that	  concerted	  action	  of	  both	   factors	  may	  play	  a	   role	   in	  controlling	   brain	   angiogenesis.	   While	   the	   role	   of	   VEGFA	   and	   its	   signalling	   for	   this	  process	  is	  well	  established	  also	  in	  the	  cerebellum	  (Acker	  et	  al	  01;Zachary	  and	  Gliki	  01),	  the	  knowledge	  about	  Norrins	  role	  in	  angiogenesis	  is	  limited	  (Luhmann	  et	  al	  05;Berger	  et	  al	   96;Richter	   et	   al	   98).	  Whether	   an	   interaction	   between	  Norrin	   and	   VEGFA	   signalling	  exists,	  requires	  further	  investigations.	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Figure	   48	   Vessel	  morphology	   in	   different	   brain	   regions.	   (A)	   Collagen	   IV	   immunohistochemistry	   of	   the	  vasculature	  in	  cerebellum,	  hippocampus	  and	  cortex	  of	  wild-­‐type	  (WT)	  and	  Ndph-­‐KO	  (KO)	  mice.	  Counter-­‐staining	  was	  performed	  with	  DAPI.	  Representative	  haematoxylin–eosin-­‐stained	  images	  are	  shown	  in	  the	  left	   column.	   (B)	   Higher	   magniﬁcation	   of	   Col	   IV	   immunohistochemistry	   without	   counterstaining	   to	  visualize	   the	   vessel	   morphology.	   The	   white	   frames	   indicate	   the	   areas	   from	   which	   images	   of	   higher	  magniﬁcation	  for	  B	  have	  been	  taken.	  MCL:	  molecular	  cell	  layer;	  PCL:	  Purkinje	  cell	  layer;	  GCL:	  granular	  cell	  layer;	  WM:	  white	  matter,	  CA3-­‐1,	  CA3-­‐1	  region;	  DG:	  dentate	  gyrus;	  FC:	  frontal	  cortex.	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Figure	  49	  Quantitative	  assessment	  of	  vessel	  density	  in	  different	  brain	  regions	  and	  different	  layers	  of	  the	  cerebellum.	  (A)	  Col	   IV-­‐stained	  vessel	  sections	  were	  evaluated	   in	  deﬁned	  areas	   from	  six	  sections	  of	  each	  animal	   and	   brain	   region.	   The	  mean	   vessel	   density	   (±	   SD)	   per	   500µm2	   is	   shown.	   The	   asterisk	   indicates	  statistical	  signiﬁcance	  for	  the	  reduction	  in	  vessel	  density	  in	  Ndph-­‐KO	  mice	  based	  on	  parametric	  tests	  (*P	  <	  0.05,	  anova	  for	  repeated	  measurements;	  between-­‐subject	  test:	  P	  =	  0.037,	  Student’s	  t-­‐test:	  P	  =	  0.037).	  (B)	  Quantitative	  assessment	  of	  vessel	  density	  in	  the	  molecular	  layer,	  granular	  ⁄	  Purkinje	  cell	  layer	  and	  white	  matter.	  The	  number	  of	  Col	   IV-­‐stained	  vessels	   in	  each	   layer	  was	  counted	  and	  normalized	  to	   its	  area.	  The	  mean	   vessel	   density	   (±	   SD)	   per	   500µm2	   for	  WT	  and	  Ndph-­‐KO	   animals	   is	   shown.	  The	   asterisk	   indicates	  statistical	  signiﬁcance	   in	  vessel	  density	   found	  in	  the	  white	  matter	  of	  Ndph-­‐KO	  mice	  (Students	  t-­‐test,	  P	  =	  0.034).	  	  Homozygous	   Fzd4	   knockout	   mice	   show	   vascular	   defects	   in	   the	   retina,	   progressive	  hearing	  loss,	  growth	  retardation,	  abnormal	  gait	  and	  premature	  death	  (Xu	  et	  al	  04;Wang	  et	  al	  01).	  It	  was	  shown	  that	  these	  mice	  exhibit	  cerebellar	  degeneration,	  starting	  with	  a	  massive	  loss	  of	  granular	  cells	  between	  postnatal	  days	  p14	  and	  p19	  and	  a	  later	  reduction	  of	   Purkinje	   cells	   (Wang	   et	   al	   01).	   In	   contrast	   to	   this	   mouse	   model,	   we	   detected	   no	  numerical	   reduction	   of	   these	   cells	   in	   the	   cerebellum	   of	   six-­‐	   to	   eight-­‐month-­‐old	  Ndph	  knockout	  mice.	   This	   suggests	   that	   no	   degenerative	   changes	   leading	   to	   permanent	   cell	  loss	  are	  present	  up	  to	  this	  age	  although	  we	  can	  not	  exclude	  any	  transient	  changes	  during	  earlier	  development	  or	  age-­‐related	  manifestations	  (Figure	  47).	  We	  conclude	  that	  Norrin,	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despite	  its	  high	  expression	  in	  the	  cerebellum	  (Figure	  45),	  does	  not	  have	  a	  crucial	  role	  for	  the	  maintenance	   of	   neuronal	   cells,	   in	   particular	   the	   granular	   and	   Purkinje	   cells.	   This	  striking	   difference	   between	  Ndph	   and	   Fzd4	   knockout	  mouse	   lines	   suggests	   that	   Fzd4	  requires	  additional	  ligands	  other	  than	  Norrin.	  Most	  likely	  these	  ligands	  are	  members	  of	  the	  Wnt	   family,	   the	   conventional	   ligands	   for	   Frizzled	   receptors,	  which	   are	  widely	   and	  commonly	  expressed	  in	  the	  brain	  and	  play	  important	  roles	  in	  neuronal	  development	  and	  synapse	   formation	   as	   well	   as	   in	   control	   of	   neuronal	   apoptosis	   and	   neurotrophin	  expression	  (Ciani	  and	  Salinas	  05;Patapoutian	  and	  Reichardt	  00).	  	  However,	   we	   cannot	   exclude	   a	   direct	   effect	   of	   Norrin	   on	   neurons	   in	   different	   brain	  regions.	  During	   retinal	  development,	   the	  ectopic	  over-­‐expression	  of	  Norrin	   in	   the	   lens	  led	   to	   an	   increased	   number	   in	   retinal	   progenitor	   cells	   in	   vivo	   and	   suggested	   a	   pro-­‐proliferative	  effect	  on	  neuronal	  precursors	  of	  Norrin	  (Ohlmann	  et	  al	  05).	  While	  we	  did	  not	  observe	  any	  indications	  for	  such	  a	  role	  in	  the	  adult	  brain,	  it	  remains	  to	  be	  elucidated,	  whether	   a	   similar	  Norrin	   function	  might	   be	   important	   during	   the	   development	   of	   the	  brain.	  	  In	   addition	   to	   the	   neuronal	   degeneration	   of	   granular	   and	   Purkinje	   cells,	   progressive	  vascular	  enlargement	  and	  vascular	  disorganizations	  were	  described	  in	  the	  cerebellum	  of	  six-­‐month-­‐old	   homozygous	   Fzd4	   knockout	   mice.	   This	   vascular	   appearance	   was	  described	  as	  sparse,	  enlarged	  and	  irregular	  (Xu	  et	  al	  04).	  While	  our	  examination	  of	  the	  hippocampal,	  cortical	  and	  cerebellar	  vasculature	  of	  Ndph	  knockout	  mice	  at	  comparable	  age,	   using	   comparable	   methods,	   did	   not	   show	   obvious	   differences	   in	   vascular	  morphology	   and	   size	   even	   at	   higher	   magnifications.	   the	   significant	   16%	   reduction	   in	  vessel	   density	   in	   the	   cerebellum	   of	   Ndph	   knockout	   mice	   suggests	   a	   sparser	   vessel	  distribution.	  	  Furthermore,	  our	  data	  from	  the	  different	  cerebellar	  layers	  shows	  a	  general	  trend	   of	   reduced	   vessel	   density	   in	   all	   three	   layers,	   which	   reached	   significance	   in	   the	  white	  matter.	  	  This	  mild	   reduction	   in	   vessel	   density	  might	   indicate	   a	   potential	   role	   of	  Norrin	   for	   the	  maintenance	   of	   the	   vasculature	   in	   the	   cerebellum	   and	   revealed	   the	   first	   phenotypic	  alterations	  in	  brain	  of	  Ndph	  knockout	  mice.	  Supportively,	  Ndph	  and	  Fzd4	  expression	  was	  highest	  in	  this	  brain	  region.	  	  	  Norrin’s	   role	   for	   the	   vascular	   system	   in	   brain	   appears	   only	   modulatory,	   while	   it	   is	  essential	   in	   the	   retina.	   	   Thus,	   it	   seems	   that	   the	   function	   of	  Norrin	   for	   the	   vasculature	  shows	   a	   tissue-­‐specific	   effect.	   Tissue-­‐specificity	   has	   been	   reported	   in	   eye	   and	   ear	   of	  
Ndph	  knockout	  mice	  (Luhmann	  et	  al	  05;Rehm	  et	  al	  02).	  While	  the	  progressive	  hearing	  loss	   in	   Norrie	   disease	   patients	   and	   in	   Ndph	   knockout	   mice	   begins	   during	   early	  adulthood,	  	  the	  severe	  phenotype	  in	  the	  eye	  is	  already	  present	  shortly	  after	  birth	  (Rehm	  et	  al	  02;Halpin	  et	  al	  05;Warburg	  66;Luhmann	  et	  al	  05).	  Furthermore,	  the	  degeneration	  of	  the	  capillary	  network	  in	  the	  stria	  vascularis	  starts	  shortly	  after	  normal	  development	  suggesting	   a	   maintenance	   role	   for	   Norrin	   in	   the	   ear	   (Rehm	   et	   al	   02).	   In	   contrast,	  development	  rather	  than	  maintenance	  is	  affected	  in	  the	  retina	  (Luhmann	  et	  al	  05).	  	  Hypoxic	  pathogenic	  processes	  as	  seen	   in	  Ndph	  knockout	  retinae	  were	  not	   indicated	   in	  the	  brain,	  since	  we	  did	  not	  find	  up-­‐regulation	  of	  Itgrb3,	  Vegfa	  and	  Tie1.	  We	  chose	  these	  markers	  since	  they	  are	  significantly	  higher	  expressed	  in	  retinae	  of	  Ndph	  knockout	  mice	  under	   hypoxic	   conditions	   (Luhmann	   et	   al	   05).	   In	   addition,	   Vegfa	   is	   upregulated	   by	  hypoxia	  in	  brain	  (Marti	  and	  Risau	  98;Ozaki	  et	  al	  99).	   	  Since	  we	  did	  not	  find	  differences	  between	  wildtype	  and	  knockout	  animals	  for	  these	  three	  markers	  in	  the	  cerebellum,	  we	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conclude	  that	  the	  mild	  reduction	  in	  vessel	  density	  in	  Ndph	  knockout	  mice	  does	  not	  lead	  to	  a	  severe	  oxygen	  deficiency.	  Therefore,	  functional	  consequences	  of	  the	  reduced	  vessel	  density	   in	  the	  cerebellum	  remain	  uncertain	  at	   the	  molecular	   level.	  Future	  experiments	  will	   address	   Norrin’s	   role	   in	   hypoxia-­‐induced	   angiogenic	   responses	   and	   ischemic	  conditions	  in	  the	  brain.	  	  This	   study	   provides	   initial	   evidence	   for	   a	   mild	   vascular	   defect	   in	   the	   brain	   of	   Ndph	  knockout	  mice.	  The	  brain	  can	  also	  be	  affected	  in	  patients	  with	  Norrie	  disease	  (Warburg	  66)	   but	   the	   underlying	   processes	   are	   poorly	   characterized.	   The	   phenotypic	   features	  described	  in	  the	  brain	  vary	  and,	  consequently,	  it	  is	  difficult	  to	  understand	  the	  action	  of	  Norrin	   in	  the	  brain.	  The	  phenotype	  has	  often	  been	  described	  in	  general	  terms,	  such	  as	  “mental	  retardation”.	  For	  example,	  in	  a	  large	  Cuban	  kindred	  with	  46	  affected	  members,	  45%	   of	   the	   examined	   patients	   were	   described	   to	   show	   moderate	   or	   severe	   mental	  retardation	   (Fuchs	   et	   al	   94).	   In	   other	   families	   severe	   developmental	   delay	   has	   been	  described,	  with	  some	  patients	  showing	  hypotonia	  or	  epileptic	  seizures	  (Schuback	  et	  al	  95;Yamada	  et	  al	  01;Lev	  et	  al	  04;Fuentes	  et	  al	  93).	  The	  observations	  suggest	   that	   these	  clinical	  symptoms	  can	  occur	  in	  Norrie	  disease	  and	  probably	  reflect	  a	  pleiotropic	  function	  of	   Norrin	   also	   in	   the	   brain.	   It	   is	   tempting	   to	   speculate	   that	  mild	   vascular	   changes,	   as	  observed	   in	   the	   Ndph	   knockout	   mouse	   model,	   might	   also	   occur	   in	   Norrie	   disease	  patients	   and	   lead	   to	   a	   higher	   susceptibility	   to	   seizures.	   This	   idea	   is	   supported	   by	   the	  findings	   that,	   in	   a	   rodent	   model,	   hypoxia	   has	   been	   shown	   to	   be	   epileptogenic	   in	  immature	   animals,	   but	   not	   in	   adults	   (Jensen	   et	   al	   91).	   Therefore,	   the	   concept	   that	  absence	  of	  Norrin	  leads	  to	  vascular	  defects	  and	  to	  hypoxic	   insults	   in	  respective	  organs	  could	  be	  applicable	  not	  only	  to	  retina	  but	  also	  to	  the	  brain,	  although	  we	  cannot	  exclude	  the	  possibility	  that	  the	  function	  of	  Norrin	  may	  differ	  between	  mice	  and	  human.	  Therefore,	  further	  clinical	  examinations	  in	  patients	  with	  Norrie	  disease,	  FEVR,	  ROP	  and	  Coats’	   disease,	   especially	   addressing	   extra	   ocular	   vessel	  manifestations,	   could	   help	   to	  clarify	   the	   role	   of	   the	   Norrin/Frizzled-­‐4/Lrp5	   signaling	   for	   vascular	   development	   or	  maintenance	  of	  vasculature	  in	  different	  tissues.	  To	  the	  best	  of	  our	  knowledge,	  e.g.	  FEVR	  patients	   show	   no	   clinical	   symptoms	   in	   brain	   or	   ear,	   which	   is	   in	   contrast	   to	   Norrie	  disease	   patients	   and	   to	   findings	   in	   the	   Fzd4-­‐deficient	   mice	   (Xu	   et	   al	   04).	   To	   further	  characterize	   these	   differences	   in	   phenotype	   between	   mouse	   and	   human	   and	   to	  understand	   pathogenic	   mechanisms,	   a	   more	   thorough	   examination	   especially	   in	   the	  cerebellum	  might	  be	  worth	  considering.	  	  	  Although	  our	  study	  only	  showed	  a	  mild	  effect	  of	  the	  Ndph	  knockout	  on	  the	  vasculature	  in	  cerebellum,	  it	  might	  be	  worthwhile	  to	  examine	  different	  brain	  regions	  of	  patients	  for	  pathogenic	   changes.	   Vascular	   alterations	   might	   potentially	   help	   to	   explain	   the	  phenotypic	  variability	  of	  mental	  retardation	  seen	  in	  Norrie	  disease	  patients	  (Fuchs	  et	  al	  94).	  	  In	  this	  context	  it	  is	  interesting	  to	  note	  that	  the	  cerebellum	  has	  been	  shown	  not	  only	  to	  be	   involved	   in	  motor	   function	  but	   also	   in	   certain	   aspects	   of	   cognition	   and	   affective	  functioning,	   including	  emotional	   reactivity	  and	  mood	  (Gordon	  07).	   It	  was	  documented	  that	   patients	  with	   isolated	   cerebellar	   hypoplasia	   (incomplete	   or	   underdevelopment	   of	  the	   cerebellum)	  were	   predisposed	   to	   psychomotor	   delays	   and	   cognitive	   impairments,	  occasionally	  including	  epileptic	  seizures	  (Ventura	  et	  al	  06).	  Furthermore,	  patients	  with	  cerebellar	  lesions	  in	  the	  posterior	  inferior	  artery	  showed	  deficits	  in	  mainly	  visual-­‐spatial	  working	   and	  episodic	  memory	   as	  well	   as	   emotional	  withdrawal	   (Exner	   et	   al	   04).	  This	  might	   suggest	   that	   any	   potential	   defect	   in	   the	   Norrin-­‐Fzd4-­‐Lrp5	   signaling	   pathway	  affecting	  the	  cerebellum	  could	  possibly	  contribute	  to	  the	  mental	  retardation	  phenotype	  in	  Norrie	  disease	  patients.	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3.2.1	  Abstract	  
PURPOSE.	   Mutations	   in	   the	   NDP	   gene	   impair	   angiogenesis	   in	   the	   eyes	   of	   patients	  diagnosed	   with	   a	   type	   of	   blindness	   belonging	   to	   the	   group	   of	   exudative	  vitreoretinopathies.	   With	   this	   study,	   we	   aimed	   to	   investigate	   differential	   gene	  expression	  caused	  by	  the	  absence	  of	  Norrin	  (the	  NDP	  protein)	  in	  the	  developing	  mouse	  retina	  to	  elucidate	  early	  pathogenic	  events.	  
METHODS.	  A	  comparative	  gene	  expression	  analysis	  was	  performed	  on	  p7	  (postnatal	  day	  7)	   retinae	   from	   a	   knockout	   mouse	   model	   for	   Norrie	   disease	   using	   Affymetrix	  microarrays.	  Subsequently,	  results	  were	  verified	  by	  quantitative	  real-­‐time	  PCR	  analyses.	  Immunohistochemistry	   was	   performed	   for	   the	   vascular	   permeability	   marker	  Plasmalemma	  vesicle-­‐associated	  protein	  (Plvap).	  
RESULTS.	  Our	  study	  identified	  expression	  differences	  in	  Ndphy/-­	  vs.	  wild	  type	  mice	  retinae	  at	  p7.	  Gene	  transcription	  of	  the	  neutral	  amino	  acid	  transporter	  Slc38a5,	  apolipoprotein	  D	   (ApoD)	   and	   angiotensin	   II	   receptor-­‐like	   1	   (Agtrl1)	   was	   decreased	   in	   the	   knockout,	  whereas	   transcript	   levels	   of	   adrenomedullin	   (Adm)	   and	   of	   the	   plasmalemma	   vesicle	  associated	  protein	   (Plvap)	  were	   increased	   in	  comparison	   to	   the	  wild	   type.	   In	  addition,	  we	   found	   ectopic	   expression	   of	   Plvap	   in	   the	   developing	   retinal	   vasculature	   of	   Norrin	  knockout	  mice	  on	  the	  protein	  level.	  
CONCLUSIONS.	   These	   data	   provide	   molecular	   evidence	   for	   a	   role	   of	   Norrin	   in	   the	  development	  of	   the	  retinal	  vasculature.	  Expression	  of	   two	  genes,	  Plvap	   and	  Slc38a5,	   is	  considerably	  altered	  in	  retinal	  development	  of	  Norrin	  knockout	  mice	  and	  may	  reflect	  or	  contribute	  to	  the	  pathogenesis	  of	  the	  disease.	  In	  particular,	  ectopic	  expression	  of	  Plvap	  is	  consistent	  with	  hallmark	  disease	  symptoms	  in	  mouse	  and	  man.	  
Key	  words:	  Vitreoretinopathy	  •	  Angiogenesis	  •	  Gene	  expression	  •	  Norrie	  Disease	  •	  Ndph	  •	  Plvap	  
	  
3.2.2	  Introduction	  Norrie	  Disease	  (OMIM	  310600;	  ND)	  is	  an	  X-­‐linked,	  recessive	  neurological	  disorder	  that	  presents	  with	  congenital	  blindness,	  progressive	  deafness	  and	  mental	  retardation1,	  and	  is	  caused	   by	   mutations	   in	   the	   Norrie	   disease	   pseudoglioma	   (NDP)	   gene2,3,4.	   The	   high	  phenotypic	  variability	  even	  within	  one	   family	  carrying	   the	  same	  mutation5,6,7	   suggests	  the	   involvement	  of	  modifier	  genes	  or	  other	   factors,	  which	  might	  explain	  why	  no	  clear	  genotype-­‐phenotype	  correlation	  has	  been	  described	  so	  far.	  In	  addition,	  mutations	  in	  this	  gene	   have	   also	   been	   associated	   with	   a	   variety	   of	   other	   recessive	   and	   sporadic	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vitreoretinal	   diseases,	   including	   exudative	   vitreoretinopathy	   (OMIM	   133780;	   EVR),	  retinopathy	   of	   prematurity	   (ROP,	   stages	   4b	   and	   5)	   and	   Coats’	   disease	   (OMIM	  300216)8,9,10,11.	  These	  allelic	  clinical	  entities	  show	  remarkable	  similarities	  in	  their	  ocular	  phenotype	  especially	  with	  regard	  to	  abnormalities	  in	  the	  retinal	  vasculature.	  	  The	   human	   disease	   phenotype	   is	   strongly	   resembled	   by	   the	   Norrie	   disease	  pseudoglioma	  homolog	  (Ndph)	  knockout	  mouse12,13.	  Although	  the	  retinal	  vasculature	  in	  humans	   develops	   around	   mid-­‐gestation,	   and	   only	   postnatally	   in	   mice,	   the	   timing	   of	  events	  is	  comparable.	  In	  mice,	  retinal	  blood	  vessels	  start	  to	  develop	  around	  birth	  at	  the	  optic	  disc	  and	  spread	   radially	   inside	   the	  nerve	   fiber	   layer	  across	   the	   retina,	  until	   they	  reach	  the	  periphery	  around	  postnatal	  day	  9	  (p9).	  In	  addition,	  vessels	  start	  to	  sprout	  into	  the	  deeper	   layers	  of	   the	  retina	  at	  p7	  to	   form	  two	  additional	  networks	   in	  the	  plexiform	  layers,	   parallel	   to	   the	   superficial	   plexus.	   Contrary	   to	   the	   development	   of	   the	   retinal	  vasculature,	   the	   hyaloid	   vessel	   system,	   a	   transient	   developmental	   vasculature	  nourishing	   the	   developing	   lens,	   regresses.	   This	   process	   starts	   after	   its	   peak	   extension	  around	   p5	   and	   lasts	   until	   p15,	   around	  which	   time	   the	  mice	   open	   their	   eyes	   and	   eye	  development	  is	  more	  or	  less	  complete14.	  In	  the	  Ndph	  knockout	  mouse,	  the	  inner	  retinal	  vessel	  development	  is	  severely	  impaired.	  The	  outgrowth	  of	  the	  superficial	  retinal	  vessel	  plexus	   is	   delayed	   and	   remains	   sparse,	   deep	   retinal	   vessels	   do	   not	   develop,	   and	   the	  regression	   of	   the	   hyaloid	   vasculature	   is	   delayed	   and	   incomplete.	   Furthermore,	  disorganization	  of	  the	  retinal	  ganglion	  cell	  layer	  and	  a	  reduction	  of	  retinal	  ganglion	  cells	  have	   been	   described12,15,13.	   However,	   proliferation	   of	   fibrovascular	   material	   in	   the	  vitreous	   cavity	   is	   not	   as	  massive	   as	   the	   pseudoglioma	   described	   in	   patients	   suffering	  from	  severe	  ND.	  Different	  hypotheses	  have	  been	  postulated	  about	  the	  etiology	  of	  these	  symptoms.	  It	  has	  been	   discussed	   that	   the	   extended	   presence	   of	   hyaloid	   vessels	   might	   impair	   the	  development	  of	   the	  retinal	  vasculature16,17.	  However,	  blockage	  of	   the	  placental	  growth	  factor	  (PlGF)	  during	  early	  postnatal	  stages	  in	  the	  eye	  leads	  to	  delayed	  regression	  of	  the	  hyaloid	   vessel	   system,	   but	   not	   to	   changes	   in	   the	   retinal	   vasculature18,	   indicating	   that	  persistence	   of	   the	   hyaloidea	   does	   not	   necessarily	   lead	   to	   defects	   in	   or	   lack	   of	   retinal	  vascularization.	   Another	   hypothesis	   was	   provided	   by	   a	   detailed	   analysis	   of	   the	   early	  development	   of	   the	   retinal	   vasculature	   in	  Ndph	   knockout	  mice,	   which	   suggested	   two	  phases	   of	   disease	   progression	   in	   vivo15:	   In	   the	   early	   phase,	   the	   absence	   of	   functional	  Norrin	   (Ndph–protein)	   causes	   a	   defect	   in	   sprouting	   angiogenesis,	   which	   leads	   to	   a	  delayed	   outgrowth	   of	   the	   superficial	   vessels	   and	   prevents	   the	   formation	   of	   deep	  capillary	  networks	  in	  the	  retina.	  Then,	  in	  the	  later	  phase,	  the	  developmental	  lack	  of	  the	  deep	  vasculature	  leads	  to	  inner	  retinal	  hypoxia.	  This	  pathologic	  hypoxia	  may	  explain	  the	  observed	   clinical	   features	   of	   Norrie	   disease	   and	   might	   also	   be	   responsible	   for	   the	  similarities	   of	   the	   clinical	   phenotypes	   of	   the	   aforementioned	   diseases15.	   In	   another	  study,	  the	  knockout	  phenotype	  could	  be	  completely	  rescued	  by	  ectopic	  overexpression	  of	   Norrin	   in	   the	   lens19.	   Their	   authors	   suggested	   a	   direct	   effect	   of	   Norrin	   on	   vascular	  proliferation,	   since	  proliferation	  of	  microvascular	  endothelial	   cells	  was	   increased	  after	  co-­‐cultivation	  with	  the	  Norrin-­‐expressing	  lenses19.	  Further,	   autosomal	   dominant	   and	   recessive	   forms	   of	   FEVR	   (familial	   exudative	  vitreoretinopathy),	  which	  are	  caused	  by	  mutations	  in	  Frizzled-­‐	  4	  (FZD4)	  and	  LDL	  related	  protein	  5	  (LRP5)	  in	  approximately	  35%	  of	  the	  patients20,21,	  resemble	  the	  clinical	  pictures	  of	   the	   X-­‐linked	   diseases12,13,22.	   Prompted	   by	   these	   findings	   and	   the	   phenotypic	  similarities	  between	  Ndph	  and	  Fzd4	  knockout	  mice,	  Xu	  et	  al.	  could	  provide	  the	  first	  hint	  for	   a	   possible	   cellular	   function	   of	   Norrin.	   They	   showed	   that	   Norrin	   is	   a	   high	   affinity	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ligand	   of	   Frizzled-­‐4	   and	   activates	   the	   canonical	   Wnt/beta-­‐catenin	   pathway	   in	   the	  presence	   of	   LRP5	   in	   cell	   culture23.	   This	   pathway	   eventually	   leads	   to	   transcriptional	  regulation	  of	  target	  genes	  under	  the	  control	  of	  TCF/Lef-­‐binding	  sites.	  In	  summary,	  these	  data	   suggest	   that	   Norrin	   has	   an	   influence	   on	   transcriptional	   regulation	   of	  Wnt-­‐target	  genes,	  is	  required	  for	  early	  angiogenic	  sprouting	  in	  the	  retina	  and	  the	  regression	  of	  the	  hyaloid	   vessel	   system,	   and	   is	   necessary	   for	   the	   formation	   of	   deep	   retinal	   capillary	  networks	  around	  postnatal	  day	  7	  (p7)15.	  The	  main	   purpose	   of	   the	   experiment	   reported	   here	  was	   to	   find	   differently	   expressed	  genes	   in	   retinae	   of	   p7	  Ndph	   knockout	   mice	   that	   are	   involved	   in	   the	   process	   of	   deep	  plexus	  formation	  and	  that	  could	  confirm	  Norrin’s	  hypothesized	  role	  on	  Wnt	  target	  genes	  
in	  vivo.	  Our	  findings	  support	  a	  role	  of	  Norrin	  in	  blood	  vessel	  development	  and	  provide	  evidence	  for	  a	  potential	  regulation	  of	  new	  target	  genes	  that	  were	  not	  considered	  so	  far.	  However,	  involvement	  of	  the	  Wnt/beta-­‐catenin	  pathway	  could	  not	  be	  demonstrated	  by	  our	   experiments.	   One	   gene,	   the	   plasmalemma	   vesicle	   associated	   protein	   (Plvap),	   has	  been	   characterized	   in	   more	   detail.	   This	   gene	   was	   described	   as	   a	   major	   structural	  component	  of	  fenestrated	  blood	  vessels24,	  and	  here	  was	  found	  to	  be	  up-­‐regulated	  in	  the	  retinal	  vasculature	  in	  the	  absence	  of	  Norrin.	  Thus,	  we	  discuss	  the	  question	  whether	  or	  not	   Norrin	   could	   also	   be	   involved	   in	   blood	   vessel	   integrity	   and	   the	   formation	   or	  maintenance	  of	  the	  blood-­‐retina-­‐/blood-­‐brain-­‐barrier.	  
	  
3.2.3	  Materials	  And	  Methods	  
3.2.3.1	  Animals	  The	  Ndph	  knockout	  mouse	  line	  has	  been	  described	  before	  by	  Berger	  et	  al.12.	  Briefly,	  exon	  2	   of	   the	  Ndph	   gene	   has	   partially	   been	   replaced	   by	   homologous	   recombination	  with	   a	  reverse	  oriented	  neomycin	  cassette,	  resulting	  in	  a	  loss	  of	  about	  half	  the	  coding	  sequence,	  including	   the	   signal	  peptide	   for	  protein	   secretion.	  The	  mutation	   is	  kept	  on	  a	  C57BL/6	  background.	  Genotyping	  was	  performed	  by	  PCR	  analysis	  of	  tail	  DNA12.	  The	  research	  was	  performed	  in	  accordance	  with	  the	  ARVO	  Statement	  for	  the	  Use	  of	  Animals	  in	  Ophthalmic	  and	  Vision	  Research	  and	  was	  approved	  by	  the	  Veterinary	  Service	  of	  the	  State	  of	  Zurich	  (Switzerland).	  
3.2.3.2	  Tissue	  isolation	  and	  RNA	  preparation	  Wild	   type	   and	  Ndphy/-­‐	  mice	   of	   different	   developmental	   stages	   (p5,	   p7,	   p10,	   p15,	   p21)	  were	   sacrificed	   by	   cervical	   dislocation.	   Five	   animals	   of	   each	   genotype	  were	   prepared	  and	   the	   retinae	   were	   frozen	   in	   liquid	   nitrogen.	   Total	   RNA	   was	   extracted	   using	   the	  RNeasy®-­‐Kit	   (Qiagen,	   Hilden,	   Germany)	   according	   to	   the	   manufacturer’s	   instructions.	  DNase	  digestion	  was	  applied	  either	  directly	  on-­‐column	  (p7	  samples,	  RNase-­‐free	  DNase	  Set,	  cat.	  no.	  79254,	  Qiagen,	  Hilden,	  Germany),	  or	  separately	  after	  RNA	  extraction	  (RQ1	  RNase-­‐free	  DNase,	  p/n	  M610A,	  Promega,	  Madison,	  WI,	  USA).	  Both	  retinae	  of	  one	  animal	  were	  pooled	  into	  one	  tube	  of	  lysis	  buffer	  and	  homogenized	  with	  an	  Ultra-­‐Turrax®	  high-­‐performance	   disperser	   (Ika-­‐Werke,	   Staufen,	   Germany).	   RNA	   quality	   was	   determined	  with	  a	  NanoDrop	  ND	  1000	  (NanoDrop	  Technologies,	  Delaware,	  USA)	  and	  a	  Bioanalyzer	  2100	  (Agilent	  Technologies,	  Santa	  Clara,	  CA,	  USA).	  RNA	  Integrity	  number	  of	  all	  samples	  was	  greater	  or	  equal	  to	  9.3.	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3.2.3.3	  Microarray	  experiment	  Gene	  chip	  expression	  analysis	  has	  been	  carried	  out	  with	  RNA	  from	  p7	  retinae	  (wt:	  n=5,	  ko:	  n=5),	  using	  the	  Affymetrix	  GeneChip®	  Mouse	  Genome	  430	  2.0	  array	  (Affymetrix	  Inc.,	  Santa	   Clara,	   CA,	   USA).	   On	   this	   chip,	   over	   34,000	   genes	   and	   ESTs	   are	   represented	   by	  ~45,000	   probe	   sets.	   The	  Microarray	   experiment,	   from	   cDNA	   preparation	   to	   raw	   data	  processing,	  was	  performed	  at	  the	  Functional	  Genomics	  Center	  Zurich.	  Briefly,	  total	  RNA	  samples	   (2μg	   each)	   were	   reverse-­‐transcribed	   without	   additional	   amplification	   (one-­‐cycle	   protocol),	   purified,	   labeled	   and	   hybridized	   to	   the	   chip	   according	   to	   the	  manufacturer’s	   instructions.	   An	   Affymetrix	   GeneChip	   Scanner	   3000	   was	   used	   to	  measure	  the	  fluorescence	  intensity	  emitted	  by	  the	  labeled	  target.	  	  
Statistical	  analysis	  Raw	  data	  processing	  was	  performed	  using	  the	  Affymetrix	  GCOS	  1.2	  software	  (Affymetrix	  Inc.,	  Santa	  Clara,	  CA,	  USA).	  After	  hybridization	  and	  scanning,	  probe	  cell	  intensities	  were	  calculated	  and	  summarized	  for	  the	  respective	  probe	  sets	  by	  means	  of	   the	  MAS5	  algorithm25.	  To	   compare	   the	   expression	  values	  of	   the	   genes	   from	  chip	   to	  chip,	  global	  scaling	  was	  performed,	  which	  resulted	  in	  the	  normalization	  of	  the	  trimmed	  mean	  of	  each	  chip	  to	  a	  target	   intensity	  (TGT	  value)	  of	  500	  as	  detailed	  in	  the	  statistical	  algorithms	  description	  document	  of	  Affymetrix	   (2002).	  Quality	  control	  measures	  were	  considered	  before	  performing	  the	  statistical	  analysis.	  Differently	  expressed	  genes	  were	  calculated	   with	   the	   GeneSpring	   7.2	   software	   (Agilent	   Technologies,	   Santa	   Clara,	   CA,	  USA),	   filtered	   for	   presence	   (per	   Affymetrix	   presence/absence	   flags)	   in	   four	   of	   five	  samples	  in	  either	  one	  condition	  (wt	  or	  ko)	  and	  then	  subjected	  to	  a	  non-­‐parametric	  test	  for	   differential	   expression	   (Mann-­‐Whitney	   test	   without	   multiple	   testing	   correction	  (p<0.01),	  or	  with	  Benjamini-­‐Hochberg	  multiple	  testing	  correction	  (p<0.1)).	  
Pathway	   analysis	   Pathway	   analysis	   was	   conducted	   with	   the	   online	   tool	   “Pathway	  express”,	   which	   is	   part	   of	   the	   “Onto-­‐Tools”,	   hosted	   by	   the	   Wayne	   State	   University,	  Detroit,	  USA,	  using	  the	  default	  options26.	  
Gene	  ontology	  annotations	  Gene	  ontology	  (GO)	  annotations	  are	  used	  to	  describe	  e.g.	  biological	   process	   or	   cellular	   component	   of	   a	   given	   gene	  product.	   Annotations	   for	   the	  top	   differently	   expressed	   genes	   (Table	   40)	   were	   obtained	   from	   the	   Database	   for	  Annotation,	  Visualization	  and	  Integrated	  Discovery	  (DAVID)	  from	  the	  National	  Institute	  of	  Health27.	  	  
3.2.3.4	  Quantitative	  reverse	  transcription-­‐PCR	  Quantitative	   RT-­‐PCR	   was	   performed	   not	   only	   to	   investigate	   differential	   expression	  during	  development,	  but	  also	  to	  verify	  the	  microarray	  results.	  For	  p7,	  the	  same	  samples	  as	  in	  the	  array	  experiment	  were	  used.	  Generation	  of	  cDNA	  was	  accomplished	  as	  follows:	  1250ng	  total	  RNA	  were	  reverse	  transcribed	  in	  a	  20μl	  reaction,	  using	  random	  hexamers	  pd(n)6	   (Amersham	   Biosciences	   /	   GE	   Healthcare	   Europe,	   Otelfingen,	   Switzerland)	   and	  SuperScript	   III	   RT	   (Invitrogen,	   Carlsbad,	   CA,	   USA).	   For	   expression	   analysis	   of	   Slc38a5	  and	   Mdm2,	   quantitative	   RT-­‐PCR	   was	   conducted	   using	   0.5μM	   of	   a	   forward/reverse	  primer	   pair	   (binding	   in	   the	   area	   that	   is	   recognized	   by	   the	   Affymetrix	   probes)	   and	  SYBR®-­‐Green	   PCR	   Mastermix	   (Applied	   Biosystems,	   Foster	   City,	   CA,	   USA).	   TaqMan®	  probes	   and	   TaqMan®	   Universal	   PCR	  Mastermix	   (Applied	   Biosystems,	   Foster	   City,	   CA,	  USA)	  were	  used	   for	  quantification	  of	  Aass,	  Centd3,	  ApoD,	  Cldn5,	  Agtrl1,	  Adm	   and	  Plvap	  expression	  (Table	  38).	   In	  each	  reaction,	  10ng	  of	   transcribed	  total	  RNA	  were	  employed	  (except:	  Slc38a5	  /	  100ng).	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Quantitative	  RT-­‐PCR	  was	  carried	  out	  in	  five	  replicates	  in	  an	  Applied	  Biosystems	  PRISM®	  7900HT	   system	   using	   the	   recommended	   standard	   cycling	   conditions:	   45	   cycles	   of	  denaturation	   (15s/95°C)	   and	   annealing/extension	   (1min/60°C).	   Gapdh	   and	   18S	  (TaqMan®)	  or	  28S	  (SYBR®-­‐Green)	  rRNA	  were	  used	  as	  endogenous	  controls.	  Confidence	  intervals	   for	  wild	   type	   and	   knockout	   gene	   expression	  were	   calculated	   on	   basis	   of	   the	  mean	  ΔΔ	  ct-­‐values	  at	  a	  significance	  level	  of	  95%	  using	  Student’s	  t-­‐test.	  	  
Gene 5' Primer   3' Primer 
Mdm2 AAG ACA GGC TCT CAC TAT TAG CTA TGG TGG GAG TTA AAG GTC TGC CTG AT 
Slc38a5 CGA CCT TTG GAT ACC TCA CCT T TGG GTG TAC ATT TCC AGC ATC T 
28S rRNA TTG AAA ATC CGC GGG AGA G ACA TTG TTC CAA CAT GCC AG 
Gapdh AAC GAC CCC TTC ATT GAC TCC ACG ACA TAC TCA GCA C 
        
Gene TaqMan® probe Gene TaqMan® probe 
Aass Mm00497118_m1 Adm Mm00437438_g1 
Agtrl1 Mm00442191_s1 Plvap Mm00453379_m1 
ApoD Mm00431817_m1 18S rRNA p/n 4308329 
Centd3 Mm00551866_m1 Gapdh p/n 4352339E 
Cldn5 Mm00727012_s1     
	  
Table	  38	   Primers	   for	   SYBR®-­‐Green	  assays	  and	  part	  no.	   of	  TaqMan®	  assays	  used	   in	   this	   study	   (Applied	  Biosystems,	  Foster	  City,	  CA,	  USA).	  
	  
3.2.3.5	  Immunohistochemical	  staining	  and	  histology	  	  Cryosections	  were	  prepared	   from	  male	  wt	   and	  Ndphy/-­‐	  mice	  aged	  p3,	  p5,	  p7,	  p10,	  p15	  and	  p21.	  Eyes	  were	  dissected,	   fixed	  for	  1h	   in	  PBS	  /	  4%	  para-­‐formaldehyde,	  washed	  in	  PBS	  and	  cryo-­‐protected	  in	  Succrose	  (30min	  in	  10%,	  then	  o/n	  in	  20%)	  at	  4°C.	  They	  were	  embedded	   in	   Tissue-­‐Tek®	   O.C.T.	   Compound	   (Sakura	   Finetek,	   Zoeterwoude,	  Netherlands),	  submersed	  in	  liquid	  nitrogen,	  cut	  into	  8μm	  sections	  with	  a	  Leica	  Cryostat	  CM	  3050S	  (Leica,	  Heerbrugg,	  Switzerland)	  and	  transferred	  onto	  microscope	  glass	  slides.	  After	   drying	   the	   sections	   for	   at	   least	   3h,	   unspecific	   binding	   sites	   were	   blocked	   by	  incubation	  with	  5%	  normal	  sheep	  serum	  (Sigma	  Aldrich,	  Steinheim,	  Germany)	  in	  PBST	  for	  1h.	  Slides	  were	  incubated	  with	  primary	  antibodies	  in	  blocking	  solution	  (o/n,	  4°C)	  in	  a	   wet	   chamber.	   Antiserum	   concentrations	   were	   1μg/ml	   for	   anti-­‐Plvap/MECA-­‐32	   (rat	  anti-­‐mouse,	  Developmental	   Studies	  Hybridoma	  Bank)	   and	  7μg/ml	   for	   anti-­‐Collagen	   IV	  (polyclonal	  Col	  IV	  antibody,	  rabbit	  anti-­‐mouse,	  no.	  2150-­‐1470,	  AbD	  Serotec/MorphoSys,	  Oxford,	   UK).	   Sections	   were	   washed	   and	   incubated	   with	   secondary	   antibodies	   in	   PBS	  (90min,	  RT).	  Cy3™-­‐conjugated	  anti-­‐rabbit	  IgG	  serum	  (Jackson	  ImmunoResearch	  Europe,	  Newmarket,	   Suffolk,	   UK)	   was	   used	   at	   a	   concentration	   of	   5μg/ml,	   Alexa	   Fluor®	   488-­‐labelled	  anti-­‐rat	   IgG/M	  (no.	  A11006,	  Molecular	  Probes,	  Leiden,	  Netherlands)	  was	  used	  at	   2μg/ml.	   Slides	   were	   washed	   a	   last	   time	   and	   finally	   mounted	   in	   a	   DAPI-­‐containing	  medium	   (Vectashield®	  Mounting	  Medium	   for	   Fluorescence	  with	   DAPI	   H-­‐1200,	   Vector	  Laboratories,	  Burlingame,	  CA,	  USA).	  Images	  were	  taken	  with	  an	  Axioplan	  2	  microscope	  equipped	   with	   an	   AxioCam	   HRc	   digital	   camera	   (Carl	   Zeiss	   MicroImaging,	   Jena,	  Germany).	   Contrast	   in	   Plvap/AF	   488	   images	   was	   enhanced	   after	   acquisition	   with	   a	  photo-­‐editing	  program.	  For	   retinal	   flatmounts,	   eyes	   were	   dissected	   and	   fixed	   for	   15min	   in	   PBS/4%	   para-­‐formaldehyde.	   Retinae	   were	   removed	   and	   post-­‐fixed	   for	   additional	   15min.	   After	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washing	  in	  PBS,	  unspecific	  binding	  was	  blocked	  by	  10%	  normal	  sheep	  serum	  in	  PBST	  for	  1h.	  Samples	  were	  then	  incubated	  o/n	  with	  the	  Collagen	  IV	  antibody.	  They	  were	  washed	  six	   times	   for	  1h	   in	  PBST	  and	   incubated	  o/n	  with	   the	   secondary	  Cy3-­‐labeled	   antibody.	  After	   repetition	   of	   the	   washing	   procedure,	   the	   retinae	   were	   finally	   flatmounted	   on	  microscope	  slides.	  Sections	  (8μm)	  of	  paraffin-­‐embedded	  eyes	  were	  hematoxylin-­‐eosin	  stained	  as	  described	  elsewhere15	  and	  observed	  under	  bright-­‐light	  illumination.	  	  
3.2.4	  Results	  In	   this	   study,	   we	   used	   the	  Ndph	   knockout	   mouse	   to	   investigate	   molecular	   pathways	  involved	   in	   early	   angiogenic	   sprouting	   in	   the	   retina	   and	   the	   formation	  of	   deep	   retinal	  capillary	   networks	   at	   around	   postnatal	   day	   7	   (p7)15.	  We	   hypothesized	   that	   Norrin	   is	  required	   for	   these	   processes,	   probably	   by	   transcriptional	   regulation	   of	   Wnt/beta-­‐catenin	  target	  genes	  and/or	  other	  pathways.	  	  
3.2.4.1	  Retinal	  morphology	  at	  p7	  At	  p7,	   conventional	  microscopy	  of	  HE	  stained	   retinal	   sections	  did	  not	   reveal	   apparent	  differences	   in	   the	   retinal	   morphology	   of	   wild	   type	   and	   Ndph	   knockout	   mice	   (Figure	  50a,b).	  In	  contrast,	  ColIV	  immunohistochemistry	  revealed	  that	  the	  retinal	  vasculature	  of	  the	  Ndph	  knockout	  was	  strikingly	  altered,	  showing	  an	  intermediate	  phenotype	  to	  what	  we	   earlier	   observed	   at	   p5	   and	   p1015.	   The	   superficial	   vessel	   system	   appeared	   much	  sparser	  than	  in	  the	  wild	  type,	  its	  outgrowth	  was	  delayed,	  and	  missing	  vascular	  sprouts	  indicated	  a	   lacking	  development	  of	  deep	  retinal	  vessels	  (Figure	  50c-­‐e).	  Since	  we	  argue	  that	  the	  vascular	  phenotype	  is	  the	  earliest	  and	  most	  obvious	  retinal	  defect	  caused	  by	  the	  absence	  of	  Ndph,	  we	  used	  this	  developmental	  stage	  to	  investigate	  the	  initial	  pathologic	  events	  on	  the	  molecular	  level,	  i.e.	  to	  identify	  genes	  involved	  in	  the	  initiation	  of	  the	  deep	  retinal	  capillary	  network	  by	  sprouting	  angiogenesis,	  which	  may	  be	  regulated	  by	  Norrin	  directly	  or	  indirectly.	  
	  
3.2.4.2	  Microarray	  gene	  expression	  analysis	  To	  identify	  differently	  expressed	  genes	  in	  the	  retina	  of	  Ndph	  knockout	  mice,	  we	  took	  a	  global	  gene	  expression	  approach	  using	  microarrays.	  The	  gene	  chip	  experiment	  resulted	  in	  26’817	  expressed	  probe	  sets	  in	  p7	  retinae.	  Differences	  in	  the	  overall	  expression	  levels	  between	  Ndphy/-­	  and	  wild	  type	  retinae	  were	  rather	  moderate,	  both	  in	  absolute	  number	  and	   fold-­‐change.	   In	  microarray	   studies,	   usually	   an	   arbitrary	   fold-­‐change	   cut-­‐off	   of	   2.0	  has	  been	  applied28,	  still	  resulting	  in	  dozens	  or	  hundreds	  of	  differently	  expressed	  genes.	  Yet,	   expression	   changes	   of	   highly	   expressed	   genes	   may	   still	   be	   biologically	   relevant	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Figure	  50	  Retinae	  of	  p7	  Ndphy/-­	  mice	  in	  comparison	  to	  wild	  type.	  (A,B)	  Hematoxylin-­‐eosin	  (HE)	  stained	  central	   sections	   of	   paraffin	   embedded	   retinae.	   No	   obvious	   difference	   in	   retinal	   organization	   could	   be	  detected.	  (C,D)	   Immunofluorescence	  images	  from	  retinal	   flatmounts.	   Images	  compiled	  from	  a	  Z-­‐Stack	  of	  pictures	   acquired	   with	   a	   Zeiss	   ApoTome™.	   To	   visualize	   the	   retinal	   vasculature,	   an	   antibody	   against	  Collagen	   IV	   was	   used.	   In	   the	   wild	   type	   p7	   retina,	   deeper	   networks	   start	   to	   develop	   from	   veins	   and	  capillaries,	  but	  not	  arteries,	  as	  has	  been	  shown	  by	  other	  authors14	  (arrowheads).	  In	  contrast,	  outgrowth	  of	  the	   superficial	   capillary	   network	   in	   the	   knockout	   is	   delayed,	   appears	   to	   be	   much	   sparser,	   and	   no	  developing	  deeper	  network	  could	  be	  detected.	  (E,F)	  Higher	  magnification	  of	  ApoTome™	  images	  from	  c,d.	  Superficial	   vasculature	   is	   shown	   in	   red,	   deep	   vasculature	   in	   green.	  GCL:	   ganglion	   cell	   layer;	   IPL:	   inner	  
plexiform	  layer;	  INL:	  inner	  nuclear	  layer;	  OPL:	  outer	  plexiform	  layer;	  ONL:	  outer	  nuclear	  layer;	  A:	  artery;	  V:	  
vein	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despite	   a	   fold-­‐change	   lower	   than	  2.0,	  while	  weakly	   expressed	   transcripts	  may	   show	  a	  fold-­‐change	  higher	  than	  2.0	  due	  to	  their	  greater	   inherent	  measurement	  error28.	   In	  this	  study,	  we	  reasoned	  that	  a	  cut-­‐off	  of	  1.6	  might	  still	  be	  valid	  considering	  our	  use	  of	   five	  biological	   replicates	   (instead	   of	   the	   standard	   three)	   while	   giving	   us	   a	   decent	   list	   of	  differently	  expressed	  genes.	  The	  list	  of	  expressed	  probe	  sets	  was	  subjected	  to	  a	  non-­‐parametric	  Mann-­‐Whitney	  test	  with	  multiple	   testing	  correction	  (Benjamini-­‐Hochberg,	  p<0.1).	  This	  resulted	   in	  a	   list	  of	  450	   probe	   sets	   (with	   10%	   =	   45	   false	   positives),	   thirty-­‐four	   of	   which	   showed	   a	   fold-­‐change	   of	   at	   least	   1.6.	   Each	   of	   the	   thirty-­‐four	   represents	   a	   different	   gene	   (Table	   40),	  including	   five	   currently	   unknown	   cDNAs.	   Sixteen	   transcripts	   show	   an	   elevated	  expression	  in	  the	  knockout,	  while	  levels	  of	  eighteen	  genes	  are	  decreased.	  Since	  only	  one	  of	   these	  34	  genes	  (Apcdd1)	  has	  been	  associated	  with	  the	  Wnt-­‐signaling	  pathway	   so	   far,	   we	   attempted	   to	   find	   evidence	   for	   its	   involvement	   with	   a	   pathway	  analysis.	  Because	  the	   list	  of	  34	  genes	  was	  too	  small	   for	   this	  purpose,	  we	  subjected	  the	  list	  of	  expressed	  probe	  sets	   to	  a	  non-­‐parametric	  Mann-­‐Whitney	   test	   (p<0.01),	  but	   this	  time	  without	  multiple	  testing	  correction	  and	  fold-­‐change	  cut-­‐off.	  This	  resulted	  in	  a	  list	  of	  872	  probe	  sets	  (730	  genes	  or	  ESTs)	  to	  be	  considered	  differently	  expressed	  between	  wild	  type	  and	  knockout.	  We	  then	  performed	  a	  pathway	  analysis	  based	  on	  these	  730	  genes	  by	  utilizing	  the	  online	  tool	  “Pathway	  express”26.	  Also	  here,	  an	  involvement	  of	  Wnt-­‐signaling	  was	   not	   striking.	   The	   five	   most	   prominent	   affected	   pathways	   were:	   the	   MAP-­‐Kinase	  pathway,	  focal	  adhesion,	  calcium-­‐signaling,	  tight	  junction,	  and	  only	  then,	  Wnt-­‐signaling	  (	  Table	  39).	  Due	  to	  the	  low	  statistical	  power	  of	  this	  analysis,	  these	  results	  must	  be	  treated	  with	  caution.	  While	  they	  might	  provide	  clues	  for	  future	  research	  activities,	  they	  have	  to	  be	  verified	  first	  by	  independent	  experiments.	  In	  the	  study	  presented	  here,	  we	  decided	  to	  concentrate	  on	  the	  list	  of	  the	  34	  most	  differently	  expressed	  genes	  (Table	  40).	  	  
Rank Pathway Name Impact Factor 
Genes in 
Pathway 




% Input Genes in 
Pathway 
1 MAPK signaling pathway 23.79 233 11 231 1.51 
2 Focal adhesion 20.00 156 7 143 0.96 
3 Calcium signaling pathway 18.93 180 8 172 1.10 
4 Tight junction 13.67 125 7 114 0.96 
5 Wnt signaling pathway 12.77 141 6 139 0.82 
              
  Genes mapped to pathways: 75         
  cDNAs: 868         
	  
Table	   39	   Top	   5	   involved	   pathways.	   Results	   of	   a	   pathway	   analysis	   performed	   with	   the	   online	   tool	  “Pathway	  express”,	  which	  is	  part	  of	  the	  “Onto-­‐Tools”,	  hosted	  by	  the	  Wayne	  State	  University,	  Detroit,	  USA26.	  Only	  10%	  of	  the	  input	  genes	  could	  be	  mapped	  to	  a	  pathway	  based	  on	  the	  KEGG	  Pathway	  Database.	  	  As	  expected	  for	  a	  knockout,	  the	  Ndph	  gene	  appears	  in	  the	  list	  of	  lower	  expressed	  genes.	  However,	  its	  expression	  is	  only	  decreased	  by	  the	  factor	  of	  two.	  One	  possible	  explanation	  could	  be	  the	  general	  low	  retinal	  Ndph	  expression	  in	  the	  wild	  type,	  so	  the	  indicated	  fold-­‐change	   could	   be	   the	   result	   of	   a	   measurement	   error.	   Second,	   the	   knockout	   is	   not	   a	  complete	  null-­‐allele,	  but	  rather	  lacks	  most	  of	  exon	  2,	  resulting	  in	  the	  loss	  of	  about	  half	  its
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Table	  40	  Genes	  with	  the	  most	  change	  in	  expression.	  GO	  terms	  listed	  may	  not	  include	  all	  annotations	  for	  each	   gene,	   but	   rather	   only	   parent	   or	  main	   annotations	   to	   facilitate	   a	   ﬁrst	   impression	   of	   possible	   gene	  function.
Gene Ontology (GO) 
Increased Symbol Name 
Biological Process (BP) Cellular Component (CC) 
Affymetrix ID 
3.06 Mdm2 Transformed mouse 3T3 cell double minute 2 
traversing start control point of 
mitotic cell cycle, protein 
ubiquitination 
cytoplasm, nucleus 1457929_at 
2.79 Wdr67 WD repeat domain 67     1442286_at 
2.47 Seh1l SEH1-like (S. Cerevisiae)     1441857_x_at 
2.03 Adm Adrenomedullin   extracellular space 1447839_x_at 
2.00 Lilrb4 Glycoprotein 49 B     1420394_s_at 
1.95 Arhgap10 Rho GTPase activating protein 10 cytoskeleton organization and biogenesis   1442967_at 
1.88 Iqsec2 IQ motif and Sec7 domain 2     1448063_at 
1.86 Plvap Plasmalemma vesicle associated protein   integral to membrane 1418090_at 
1.84 Foxp1 Forkhead box P1 regulation of transcription nucleus 1446280_at 
1.81 A2m Alpha-2-macroglobulin protease inhibitor activity (MF)   1434719_at 
1.80 Gabarapl2 GABA-A receptor-associated protein-like 2 
intra-Golgi vesicle-mediated 
transport Golgi, cytoskeleton 1459477_at 
1.76 Sync Syncoilin intermediate filament-based process 
cytoplasm, intermediate 
filament, Z-disc, synapse 1432350_at 
1.67 Acta2 Actin, alpha 2, smooth muscle, aorta 




            
    Unknown genes       
2.30   A130078K24Rik     1444482_at 
2.04   E330034G19Rik     1433798_a_at 
1.66   AW492805     1457729_at 
            
Gene Ontology (GO) 
Decreased Symbol Name 
Biological Process (BP) Cellular Component (CC) 
Affymetrix ID 
14.03 Slc38a5 Solute carrier family 38, member 5 amino acid transport, oxygen transport integral to membrane 1454622_at 
2.57 Panx2 Pannexin 2   gap junction, integral to membrane 1440350_at 
2.44 Mfsd2 major facilitator superfamily domain containing 2   integral to membrane 1428223_at 
2.13 Aass Aminoadipate-semialdehyde synthase 
response to oxidative stress, 
electron transport mitochondrion 1423523_at 
2.06 Apod Apolipoprotein D transport extracellular space 1416371_at 
2.05 Centd3 Centaurin, delta 3 
regulation of cell shape and 
GTPase activity, negative 





2.03 Cldn5 Claudin 5 cell-cell adhesion tight junction, integral to membrane 1417839_at 
2.01 Ndph Norrie disease homolog   extracellular space 1449251_at 
1.92 Agtrl1 Angiotensin receptor-like 1  G-protein coupled receptor protein signaling pathway integral to membrane 1438651_a_at 
1.85 Plekhh1 
Pleckstrin homology domain 
containing, family H (with MyTH4 
domain) member 1 
cell adhesion cytoskeleton 1435053_s_at 
1.85 Sh2d3c SH2 domain containing 3C intracellular signaling cascade cytoplasm 1430098_at 
1.76 Zfp206 Zinc finger protein 206     1438787_at 
1.72 Eltd1 
EGF, latrophilin seven 
transmembrane domain containing 
1 
G-protein coupled receptor protein 
signaling pathway, neuropeptide 
signaling pathway 
integral to membrane 1418059_at 
1.67 Vwa1 von Willebrand factor A domain containing 1   extracellular space 1426399_at 
1.66 Apcdd1 Adenomatosis polyposis coli down-regulated 1     1418383_at 
1.62 Slc7a1 Solute carrier family 7 (cationic aa transporter, y+ system), 1 amino acid transport integral to membrane 1454992_at 
            
    Unknown genes       
1.89   6230424C14Rik     1441972_at 
1.88   2310015A05Rik     1436104_a_at 
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coding	   region.	   Since	   the	   probes	   of	   the	   Affymetrix	   Mouse	   Genome	   430	   2.0	   array	  predominantly	   target	   the	   3’-­‐region	   and	   a	   signal	   was	   detected	   in	   the	   knockout,	   it	   is	  possible	  that	  a	  transcript	  including	  this	  region	  is	  present	  in	  the	  retina	  of	  Ndphy/-­	  mice.	  In	  fact,	   a	   ko-­‐allele	   derived,	   low	  expressed	   artificial	   transcript	   has	   been	   isolated	   from	   the	  brain	  of	  Ndphy/-­	  mice.	  Partial	   sequencing	  of	   this	   transcript	   revealed	   that	  no	   functional	  Norrin	   can	   be	   translated	   from	   this	   RNA,	   as	   almost	   half	   of	   the	   open	   reading	   frame,	  including	   the	   signal	   peptide,	   is	  missing	   and	   no	   start	   codon	   is	   present	   in	   the	   relevant	  transcript	  area	  (data	  not	  shown29).	  	  
3.2.4.3	  Verification	  of	  differential	  expression	  by	  qRT-­‐PCR	  To	   validate	   the	   microarray	   results,	   qRT-­‐PCR	   was	   performed	   for	   three	   of	   the	   most	  upregulated	   and	   six	   of	   the	  most	   downregulated	   transcripts	   using	   the	   same	   p7	   retina	  RNA	   samples	   that	  were	   used	   for	   the	   array	   experiment.	   Relative	   quantification	   values	  were	  determined	  with	  18S	  or	  28S	  rRNA	  and	  Gapdh	  (not	  shown)	  as	  endogenous	  controls.	  Expression	   values	   in	   general	   seemed	   to	   correlate	  with	   the	  microarray	   results	   (Figure	  51).	   Five	   genes	   were	   proven	   to	   be	   significantly	   differentially	   expressed.	   Three	   genes	  showed	   a	   decreased	   expression	   in	   the	   knockout:	   The	   neutral	   amino	   acid	   transporter	  
Slc38a5	  (24x	  less),	  apolipoprotein	  D	  (ApoD;	  2.4x	  less)	  and	  angiotensin	  II	  receptor-­‐like	  1	  (Agtrl1;	   2x	   less).	   Increased	   expression	   was	   found	   for	   the	   plasmalemma	   vesicle-­‐associated	  protein	  (Plvap;	  4.2x	  higher)	  and	  adrenomedullin	  (Adm;	  2.7x	  higher).	  	  Despite	  the	  low	  fold-­‐change	  threshold	  of	  1.6	  for	  our	  microarray	  statistical	  analysis,	  we	  were	  able	  to	  confirm	  differential	  expression	  of	  more	  than	  half	  the	  genes	  examined.	  	  
	  
Figure	  51	  Transcriptional	  analysis	  of	  selected	  genes	   in	  retinae	  of	  Ndphy/-­	  knockout	  (n=5)	  and	  wild	  type	  (n=5)	  mice.	   The	   average	   expression	   value	   of	   the	  wild	   type	   group	  was	   set	   to	   1.	   Error	   bars	   indicate	   the	  confidence	   interval	  at	  a	  significance	   level	  of	  95%	  (p<0.05).	  Quantitative	  RT-­‐PCR	  results	   from	  p7	  retinae	  for	  genes	  that	  showed	  increased	  or	  decreased	  expression	  in	  the	  array	  experiment	  are	  depicted	  in	  (A)	  or	  (B),	   respectively.	   (A)	   Expression	   of	   Adrenomedullin	   (Adm;	   2.7x)	   and	   the	   gene	   for	   the	   Plasmalemma	  vesicle	   associated	   protein	   (Plvap;	   4.2x)	   is	   significantly	   increased	   at	   p7.	   (B)	   The	   neutral	   amino	   acid	  transporter	  Slc38a5	   (25x),	  Apolipoprotein	  D	  (ApoD;	  2.4x)	  and	  Angiotensin	  II	  receptor-­‐like	  1	  (Agtrl1;	  2x)	  show	   significantly	   decreased	   expression	   at	   p7.	   Significant	   difference	   in	   Claudin	   5	   (Cldn5)	   expression	   is	  borderline.	  18S	  /	  28S	  rRNA	  were	  used	  as	  endogenous	  controls.	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3.2.4.4	  Expression	  during	  development	  We	   further	   investigated	   expression	   for	   the	   two	   most	   differently	   expressed	   verified	  genes,	  Plvap	  and	  Slc38a5,	  during	  postnatal	  retinal	  development.	  In	  addition	  to	  p7,	  qRT-­‐PCR	  was	  conducted	  on	  retinal	  cDNA	  from	  p5,	  p10,	  p15	  and	  p21	  (Figure	  52).	  
Plvap	   expression	   in	   the	   knockout	   was	   significantly	   increased	   at	   every	   developmental	  stage	   in	   comparison	   to	   the	   wild	   type.	   The	   difference	   increased	   about	   one	   order	   of	  magnitude	   in	   later	   stages	   (p15/p21)	   when	   compared	   to	   the	   earlier	   stages	   (p5-­‐p10)	  (Figure	  52a).	  
Slc38a5	   expression	   was	   significantly	   decreased	   at	   every	   developmental	   stage	   in	   the	  
Ndph	   knockout	   (Figure	   52b).	   Fold-­‐change	   was	   about	   ten	   times	   lower	   at	   p5	   and	   p15,	  about	  twenty-­‐five	  times	  lower	  at	  p7	  and	  p10	  and	  about	  three	  times	  lower	  at	  p21.	  Since	  the	  Slc38a5	  locus	  is	  located	  within	  8.6	  Mb	  from	  the	  Ndph	  locus,	  we	  investigated	  whether	  the	   observed	   difference	   was	   caused	   by	   a	   different	   genetic	   background,	   because	   the	  knockout	  Ndph	   allele	   is	   derived	   from	   the	   129P2	   mouse	   strain,	   which	   has	   then	   been	  backcrossed	  to	  the	  C57BL/6	  background.	  We	  could	  not	  exclude	  a	  background	  effect	  by	  analysis	  of	  a	  genetic	  marker	  inside	  the	  Slc38a5	  locus	  (rs13483703),	  since	  it	  indicated	  the	  129P2	  allele	  at	   this	  position.	  Thus,	  we	  studied	   the	  expression	  of	  Slc38a5	  by	  additional	  qRT-­‐PCR	   on	   p7	   retinae	   of	   129P2	   wild	   type	   males	   and	   found	   similar	   levels	   as	   in	   the	  C57BL/6	  wild	  type	  group	  (data	  not	  shown).	  Consequently,	  we	  excluded	  an	  influence	  of	  the	  genetic	  background	  on	  the	  expressivity	  of	  Slc38a5.	  In	  summary,	  these	  developmental	  studies,	  which	  were	  performed	  on	  array-­‐experiment	  independent	   RNA	   samples,	   added	   additional	   proof	   to	   the	   obtained	   microarray	   gene	  expression	  data.	  	  	  
	  
Figure	   52	   Transcriptional	   analysis	   of	   the	   two	   most	   differently	   expressed	   verified	   genes	   in	   retinae	   of	  
Ndphy/-­	   knockout	   (n=5)	  and	  wild	   type	   (n=5)	  mice.	  The	  average	  expression	  value	  of	   the	  wild	   type	  group	  was	  set	  to	  1.	  Error	  bars	  indicate	  the	  confidence	  interval	  at	  a	  significance	  level	  of	  95%	  (p<0.05).	  (A)	  Plvap	  expression	   is	   significantly	   increased	   at	   every	   developmental	   stage	   from	  p5	   to	   p21.	   Difference	   between	  wild	  type	  and	  knockout	  increases	  about	  one	  order	  of	  magnitude	  in	  later	  stages	  (p15/p21)	  when	  compared	  to	   the	  earlier	  stages	   (p5-­‐p10).	   Insert	  shows	  expression	  data	   for	  p5-­‐p10	   in	  a	  different	  scale.	  (B)	  Slc38a5	  expression	  is	  significantly	  decreased	  at	  every	  developmental	  stage.	  	  Variability	  of	  wild	  type	  expression	  is	  higher	  in	  later	  stages	  (p10-­‐p21)	  than	  in	  early	  stages	  (p5,	  p7).	  Following	  endogenous	  controls	  were	  used:	  (A):	  18S	  rRNA	  (B):	  Gapd	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3.2.4.5	  Immunohistological	  staining	  of	  Plvap	  As	  gene	  expression	  differences	  do	  not	  always	  reflect	  consequences	  at	  the	  protein	  level,	  immunohistochemistry	  was	   also	   performed	   for	   Plvap	   at	   all	   developmental	   stages	   that	  have	  been	  investigated	  on	  the	  transcript	  level	  (plus	  p3	  in	  addition).	  Eye	  cryosections	  of	  




3.2.5.1	  Norrin	  and	  the	  role	  of	  Wnt-­‐signaling	  When	  Norrin	  has	  been	   shown	   to	  bind	   to	   the	  Wnt-­‐receptors	   Frizzled-­‐4	   and	  LRP-­‐523,	   it	  was	  suggested	   that	   signaling	  occurs	   through	   the	  canonical	  Wnt/beta-­‐catenin	  pathway.	  Surprisingly,	  our	  study	  suggested	  only	  one	  gene	  among	  the	  most	  differently	  transcribed	  genes	   besides	  Ndph	   to	   be	   associated	  with	   this	   pathway:	   Adenomatosis	   polyposis	   coli	  down-­‐regulated	  1	  (Apcdd1).	  This	  does	  not	  necessarily	  mean	  that	  Norrin	  is	  not	  exerting	  its	  function	  over	  binding	  to	  Wnt-­‐receptors	  –	  but	  it	  may	  imply	  that	  Norrin	  does	  not	  work	  primarily	   as	   a	   transcriptional	   regulator	   via	   the	   canonical	  Wnt/beta-­‐catenin	   signaling.	  However,	   this	   conclusion	   relies	  heavily	  on	   the	  number	  of	   currently	  known	  Wnt	   target	  genes,	  and	  on	  the	  assumption	  that	   this	  signaling	  actually	  occurs	   in	  p7	  retinae	  -­‐	  so	   it	   is	  still	   possible	   that	   this	   pathway	   is	   more	   prominent	   at	   another	   developmental	   stage.	  Furthermore,	   since	   we	   were	   not	   able	   to	   detect	   expression	   differences	   of	   two	   major	  angiogenesis-­‐related	   genes	   albeit	   they	   have	   been	   shown	   to	   be	   regulated	   by	   Wnt-­‐signaling	   (Tie-­2/Tek31	   and	   Vegfa32),	   it	   is	   possible	   that	   Norrin	   has	   a	   direct	   role	   in	  controlling	   expression	   of	   Wnt-­‐target	   genes	   in	   a	   spatially	   and	   temporally	   restricted	  manner	  which	  was	  not	  detectable	  by	  our	  experimental	  approach.	  On	  the	  other	  hand,	  we	  were	  able	  to	  confirm	  differential	  expression	  of	  five	  genes	  that	  so	  far	  were	  not	  shown	  to	  be	  Wnt-­‐targets.	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Figure	  53	  Immunofluorescence	  images	  of	  retinal	  cryosections	  of	  Ndphy/-­	  mice	  in	  comparison	  to	  wild	  type.	  For	  each	  one	  of	   the	   indicated	  developmental	   stages	   (p3,	  p5,	  p7,	  p10,	  p15	  and	  p21),	   co-­‐immunolabeling	  with	   antibodies	   directed	   against	   Plvap	   (AF488;	  green)	   and	   Collagen	   IV	   (Cy3;	   red)	   has	   been	   performed.	  Collagen	   IV	   localizes	   to	   the	   extracellular	   matrix	   of	   endothelial	   cells	   and	   serves	   as	   a	   marker	   for	   blood	  vessels.	  In	  all	  stages	  investigated,	  staining	  has	  been	  observed	  in	  the	  choroid	  (CV,	  below	  the	  RPE)	  and	  the	  superficial	  retinal	  vasculature	  (RV,	  inside	  the	  RGC/nerve	  fibre	  layer).	  From	  p10	  onwards,	  blood	  vessels	  of	  the	  secondary,	  deep	  retinal	  vasculature	  were	  detected	  in	  the	  OPL	  in	  the	  wild	  type,	  but	  not	  the	  knockout	  retina.	  In	  addition,	  at	  p15	  and	  p21,	  the	  tertiary,	  intermediate	  vessel	  system	  in	  the	  IPL	  can	  be	  seen	  in	  the	  wild	   type.	   Plvap	   localizes	   to	   the	   choroid	   vessel	   system	   (CV)	   in	   both	   wild	   type	   and	   knockout	   at	   all	  developmental	   stages.	   Interestingly,	   Plvap	   expression	   has	   also	   been	   detected	   in	   the	   retinal	   vasculature	  (RV)	   of	   the	   knockout	   animals	   beginning	   at	   p3	   and	   more	   intense	   over	   time.	   In	   contrast,	   the	   retinal	  vasculature	  of	  the	  wild	  type	  is	  not,	  or	  only	  very	  weakly,	  labeled	  by	  the	  Plvap	  antibody.	  In	  the	  superficial	  vessel	  network,	  staining	  in	  the	  wild	  type	  could	  only	  be	  detected	  at	  p3	  (arrow),	  but	  not	  in	  later	  stages.	  At	  p10,	   slight	   staining	   of	   the	   deep	   vessel	   system	   was	   observed	   (arrows).	   RV:	   superficial	   /	   deep	   retinal	  vasculature;	  CV:	   Choroid;	  RGC:	   retinal	   ganglion	   cell	   layer;	   IPL:	   inner	  plexiform	   layer;	   INL:	   inner	  nuclear	  layer;	  OPL:	  outer	  plexiform	  layer;	  ONL:	  outer	  nuclear	  layer;	  RPE:	  retinal	  pigment	  epithelium.	  
	  
3.2.5.2	  Plvap	  as	  an	  early	  indicator	  for	  vascular	  permeability	  Our	   results	   suggest	   an	   early	   involvement	   of	   Plvap	   (plasmalemma	   vesicle-­‐associated	  protein)	   in	   the	   pathogenesis	   of	  NDP-­‐related	   retinopathies.	  We	   found	   increased	  mRNA	  expression	   of	   Plvap	   throughout	   development	   (Figure	   52a)	   and	   also	   conclusive	  differences	  between	  immuno-­‐stained	  cryosections	  of	  wild	  type	  and	  Ndphy/-­	  mice	  (Figure	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53).	   Plvap	   is	   endothelial	   cell	   specific,	   and	   has	   been	   described	   as	   integral	   membrane	  glycoprotein	   associated	   with	   the	   stomatal	   diaphragms	   of	   caveolae,	   transendothelial	  channels,	  vesiculo-­‐vacuolar	  organelles	  and	  the	  diaphragms	  of	  endothelial	  fenestrae24,33.	  Enhanced	  prevalence	  of	  endothelial	  fenestrae	  might	  result	  in	  reduced	  vascular	  integrity.	  Both	  have	  been	  observed	  in	  retinae	  of	  Ndphy/-­	  mice	  as	  soon	  as	  p1413,15.	  Plvap	  expression	  further	  has	  been	  shown	  to	  be	  negatively	  correlated	  with	  the	  differentiation	  of	  the	  blood-­‐brain-­‐barrier30.	   Hence,	   elevated	   expression	   of	   Plvap	   may	   indicate	   enhanced	   vascular	  permeability	   and	   break-­‐down	   of	   the	   blood-­‐retina-­‐barrier.	   It	   has	   previously	   been	  proposed	   that	   blood	   vessel	   leakiness	   is	   a	   result	   of	   hypoxia-­‐driven	   VEGF	   (vascular	  endothelial	   growth	   factor	  A)	   upregulation15	   and	   thus	   is	   a	   secondary	   effect	   due	   to	   low	  oxygen	   supply.	   Interestingly,	   Plvap	   itself	   has	   been	   suggested	   to	   be	   a	   VEGF	   target34,	  rendering	  a	  correlation	  between	  vessel	  leakiness	  and	  Plvap	  more	  likely.	  Thus,	  elevated	  expression	  of	  Plvap	  in	  later	  developmental	  stages	  (p15	  onwards;	  Figure	  52a,	  Figure	  53),	  when	  a	  malformed/underdeveloped	  vasculature	  causes	  a	  pathologic	  hypoxic	  condition	  in	  the	  retina,	  was	  not	  surprising.	  Development	  of	  the	  superficial	  vessel	  system,	  however,	  is	  driven	  by	  a	  physiological	  hypoxia	  through	  induction	  of	  a	  periphery-­‐to-­‐center	  gradient	  of	   VEGF14.	   Noteworthy,	   this	   hypoxia-­‐driven	   VEGF	   expression	   does	   not,	   or	   only	  marginally,	  yield	  visible	  Plvap	  expression	  in	  the	  wild	  type	  situation	  that	  is	  detectable	  by	  immunohistochemistry.	  Therefore,	  we	  think	  that	  an	  increased	  Plvap	  expression	  in	  early	  developmental	  stages	  (p3-­‐p10;	  Figure	  52a;	  Figure	  53)	  of	  Ndphy/-­	  mice	  is	  not	  secondary	  due	  to	  low	  oxygen	  supply	  and	  subsequent	  VEGF	  upregulation,	  but	  rather	  due	  to	  a	  lack	  of	  Norrin	   that	   may	   have	   an	   important	   influence	   on	   vascular	   development.	   This	   is	  supported	   by	   the	   observation	   that	   Plvap	   upregulation	   is	   not	   solely	   dependent	   on	  hypoxia	   or	   VEGF,	   but	   is	   also	   triggered	   by	   other	   activation	   of	   the	   Erk1/2	   MAPK	  pathway35.	   In	   addition,	   also	   fenestrae	   induction	   has	   been	   shown	   to	   be	   VEGF-­‐independent,	   as	   it	   is	   regulated	   through	   cytoskeletal	   remodeling	   by	   actin	  depolymerization36.	   However,	   we	   could	   not	   detect	   differences	   in	   total-­‐	   and	  phosphorylated	   ERK1/2	   MAP-­‐kinase	   levels	   on	   Western	   blots	   with	   retinal	   protein	  extracts	   from	   p7	   Ndphy/-­	   wild	   type	   and	   knockout	   animals	   so	   far	   (data	   not	   shown).	  Additionally,	  differences	  in	  Plvap	  expression	  may	  be	  due	  to	  a	  mechanism	  of	  endothelial	  cells	  to	  compensate	  the	  impaired	  blood	  vessel	  development,	  because	  evidence	  has	  been	  provided	  before	  that	  Plvap	  might	  have	  a	  role	  in	  angiogenesis37.	  Thus,	   it	   remains	   to	   be	   shown	  whether	   a	   possible	   mode	   of	   action	   for	   Norrin,	   besides	  transcriptional	  regulation	  via	  the	  Wnt/β-­‐catenin	  pathway,	  might	  be	  a	  direct	  modulation	  of	   the	   microtubule	   cytoskeleton38	   or	   Plvap	   itself.	   While	   we	   are	   aware	   of	   these	  alternatives,	   we	   hypothesize	   that	   transient	   Plvap	   expression	   and	   fenestration	   occur	  during	   maturation	   of	   the	   retinal	   vasculature	   and	   that	   Norrin	   signaling	   is	   possibly	  required	   for	   its	   suppression.	   This	   might	   be	   indicated	   by	   the	   faint	   staining	   of	   the	  superficial	  and	  deep	  vasculature	  in	  the	  wild	  type,	  which	  was	  only	  observed	  during	  early	  development	  of	  the	  respective	  network	  (p3	  &	  p10),	  and	  the	  retinal	  expression	  pattern	  in	  the	  Ndphy/-­	  knockout.	  Since	  mRNA	  and	  protein	  levels	  in	  the	  knockout	  have	  been	  higher	  at	   each	   developmental	   stage	   examined,	   Norrin	   might	   act	   as	   a	   suppressor	   of	   Plvap	  expression,	   and	   thus	   may	   be	   involved	   in	   sprouting	   angiogenesis	   as	   well	   as	   in	   the	  formation	  and	  maintenance	  of	  the	  blood-­‐retina-­‐	  or	  blood-­‐brain-­‐barrier.	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3.2.5.3	  Differential	  gene	  expression	  reflects	  impaired	  blood	  vessel	  development	  Besides	  Plvap,	  we	  were	  able	   to	   confirm	  differential	   expression	  of	   four	  more	  genes.	  All	  but	   one	   of	   them	   seem	   to	   emphasize	   Norrin’s	   hypothetical	   role	   in	   blood	   vessel	  development.	  Agtrl1	  (angiotensin	  II	  receptor-­‐like	  1)	  is	  a	  venous	  marker39	  that	  has	  been	  shown	   to	   be	   important	   for	   retinal	   angiogenesis40.	   Therefore,	   its	   two	   fold	   reduction	  correlates	   well	   with	   the	   observed	   retinal	   phenotype	   of	   the	   Ndph	   knockout	   mouse.	  However,	  we	  cannot	  exclude	   that	   this	  decreased	  expression	   is	  merely	  an	   indicator	   for	  the	  already	  reduced	  overall	  vessel	  density	  or,	  considering	  the	  venous/capillary	  nature	  of	  the	   deep	   vessel	   system14,	   a	   lack	   of	   development	   of	   this	   particular	   network.	   The	   same	  applies	   to	   the	  2.4x	  reduction	  of	  ApoD	   (apolipoprotein	  D).	  Nevertheless,	  ApoD	   could	  be	  implicated	   in	   the	   observed	   angiogenic	   defect	   of	   Ndphy/-­	   mice,	   because	   it	   has	   been	  reported	   to	   stimulate	   proliferation	   and	   migration	   of	   vascular	   smooth	   muscle	   cells41,	  probably	  through	  modulation	  of	  the	  cellular	  response	  to	  Pdgf-­‐bb42.	  ApoD	  expression	  was	  suggested	  to	  be	  induced	  by	  PDGF-­‐BB	  itself43.	  Interestingly,	  Pdgfb	  and	  Pdgfrb	  expression	  have	   been	   shown	   to	   be	   decreased	   in	  Ndphy/-­	   mice	   in	   early	   stages	   (p5/p10)	   before15,	  which	  could	  indicate	  reduced	  angiogenic	  activity.	  Although	  Pdgfb	  has	  been	  shown	  to	  be	  regulated	   by	   VEGF43,	  Vegfa	   levels	   were	   not	   different	   at	   p5	   and	   even	   higher	   at	   p1015,	  suggesting	   an	   alternative,	   VEGF-­‐independent	   transcriptional	   regulation	   of	   Pdgfb,	   and	  thus	  ApoD,	  in	  Ndph	  knockout	  mice.	  The	  possibility	  of	  a	  functional	  relationship	  between	  Norrin	  and	  ApoD	  might	  be	  supported	  by	  the	  finding	  of	  co-­‐expression	  of	  these	  two	  genes	  in	   disease-­‐affected	   organs.	   APOD	   has	   been	   shown	   to	   be	   upregulated	   in	   human	  endometrium	  during	  implantation44,	  a	  process	  that	   is	  disturbed	  in	  female	  homozygous	  Norrin	  knockout	  mice45.	   Further,	  ApoD	   expression	  was	   also	   reported	   in	   the	   inner	   ear,	  another	   affected	   organ	   in	   Norrie	   disease	   patients	   and	   mice46,	   where	   it	   has	   been	  suggested	  to	  be	  implicated	  in	  cochlear	  fluid	  homeostasis47.	  Taken	  together,	  Norrin	  may	  influence	  angiogenesis	  either	  by	  direct	  transcriptional	  regulation	  of	  ApoD,	  or	  indirectly	  via	  Vegfa-­‐independent	  regulation	  of	  Pdgf-­‐β.	  Nearly	   three	   times	   elevated	   transcript	   levels	   in	   the	   knockout	   were	   observed	   for	  adrenomedullin	   (Adm)	   by	   quantitative	  RT-­‐PCR.	   It	   has	   been	   described	   to	   be	   a	   hypoxia	  induced	   vasodilating	   peptide48	   that	   might	   have	   a	   vascular	   protective	   function49.	   Adm	  probably	   exerts	   its	   protective	   role	   through	   a	   reduction	   of	   oxidative	   stress50	   and	   has	  further	   been	   shown	   to	   inhibit	   vascular	   remodeling51.	   It	   is	   tempting	   to	   speculate	   that	  elevated	  expression	  of	  Adm	   itself	   could	   lead	   to	  a	  developmental	  defect	  due	   to	   its	  anti-­‐angiogenic	  properties,	  and	  that	  improper	  transcriptional	  regulation	  might	  be	  the	  cause	  for	   it.	   Hence,	   also	   differential	   expression	   of	   Adm	   correlates	   well	   with	   the	   Ndphy/-­	  phenotype.	  Surprisingly,	  and	  in	  contrast	  to	  the	  other	  genes	  discussed	  here,	  the	  gene	  most	  differently	  expressed	  has	  not	  directly	  been	   linked	   to	  angiogenesis.	  Slc38a5	   (solute	   carrier	   familiy	  38,	  member	  5),	  which	  showed	  a	  twenty-­‐five	  times	  decreased	  expression	  at	  p7	  in	  Ndphy/-­	  mice	   (Figure	   52b),	   has	   been	   reported	   to	   be	   a	   main	   glutamine	   transporter	   in	   retinal	  Müller	   cells	   (system	   N2)52.	   It	   therefore	   may	   play	   an	   important	   role	   for	   the	   neuronal	  signal	   transduction	   through	   regulation	   of	   the	   glutamate/glutamine	   household.	   Its	  decreased	  expression	  in	  Ndphy/-­	  mice	  may	  indicate	  an	  involvement	  of	  Müller	  glia	  cells	  as	  a	  target	  of	  Norrin	  signaling.	  This	  may	  be	  reflected	  by	  the	  reduced	  synaptic	  activity	  that	  has	   been	   observed	   by	   ERG	  measurements	   in	   later	   stages53	   and	   is	   consistent	  with	   our	  observation	   that	   Slc38a5	   expression	   is	   decreased	   at	   every	   developmental	   stage	  investigated,	  including	  the	  rather	  mature	  p21	  (Figure	  52b).	  Besides	  their	  importance	  for	  neural	   function,	  Müller	  cells	  also	  play	  a	  role	  as	  guidance	  structures	   for	   the	  developing	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deep	   retinal	   vasculature14.	   As	   such,	   one	   could	   speculate	   that	   communication	   between	  Müller	  cells	  and	  blood	  vessels	  might	  be	  disturbed	  in	  Norrin	  knockout	  mice.	  Interestingly,	  it	  has	  been	  reported	  earlier	  that	  blood	  vessels	  of	   the	  ganglion	  cell	   layer	  are	   frequently	  not	  surrounded	  by	  glia	  in	  p14	  Ndphy/-­	  mice13.	  However,	  another	  possible	  explanation	  for	  reduced	  Slc38a5	   expression	  could	  be	  a	   secondary,	  neuroprotective	   response	  of	  Müller	  cells	   to	   oxidative	   stress.	  While	   this	   seems	   to	   be	   a	   likely	   mechanism	   at	   later,	   hypoxic	  stages	  in	  development	  (p15/p21),	  we	  think	  a	  ten-­‐fold	  decreased	  expression	  of	  Slc38a5	  at	  p5	  is	  unlikely	  to	  be	  exclusively	  the	  result	  of	  hypoxia-­‐induced	  neuroprotection	  (Figure	  52b).	  Besides	  this,	  no	  evidence	  for	  hypoxia	  at	  p5	  has	  been	  provided	  so	  far:	  Western	  blots	  for	  the	  glial	  stress	  marker	  GFAP	  and	  the	  hypoxia-­‐inducible	  factor	  1-­‐alpha	  (Hif1a)	  were	  shown	   to	   be	   similar	   up	   to	   p15	   and	   p10,	   respectively,	   and	   no	   significant	   expression	  differences	  could	  be	  found	  for	  VEGF15	  at	  this	  stage.	  But	  Slc38a5	  is	  not	  only	  expressed	  in	  the	  retina:	  it	  is	  also	  abundant	  in	  astrocytic	  end	  feet	  in	  the	  brain,	  the	  highest	  levels	  being	  found	  in	  neocortex,	  hippocampus,	  striatum	  and	  the	  cerebellum54.	  Thus,	  differential	  expression	  of	  this	  molecule	  might	  be	  a	  hint	  for	  a	  possible	  pathogenic	  mechanism	   also	   in	   the	   brain	   that	   could	   be	   associated	   with	   the	   mental	   retardation	  phenotype	  of	  ND.	  Noteworthy	  in	  this	  context,	  a	  microdeletion	  including	  SLC38A5	  and	  the	  neighboring	   FTSJ1	   has	   been	   found	   in	   three	   brothers	  with	  moderate	   to	   severe	  mental	  retardation55.	  	  
3.2.5.4	  Conclusion	  Consistent	  with	  data	  obtained	  from	  other	  developmental	  stages15,	  our	  examination	  of	  p7	  
Ndph	  knockout	  mice	  showed	  insufficient	  retinal	  capillarization	  and	   lack	  of	  deep	  vessel	  formation.	  For	  the	  first	  time,	  vascular	  permeability	  has	  not	  been	  observed	  only	  in	  later,	  nearly	   adult	   stages,	   but	  was	   noted	   throughout	   development,	   as	   indicated	   by	   elevated	  mRNA	  and	  protein	  expression	  data	  for	  Plvap.	  Because	   of	   the	   early	   developmental	   stage	   investigated	   here	   and	   the	   lack	   of	  neovascularization	  in	  later	  stages,	  we	  tend	  to	  consider	  a	  role	  of	  VEGF	  itself	  in	  the	  early	  pathogenesis	   of	  NDP-­‐related	   diseases	   rather	   unlikely	   and	   ask	  whether	  Norrin	   instead	  might	   modulate	   the	   cellular	   response	   to	   VEGF.	   Norrin’s	   hypothetical	   role	   as	   a	  transcriptional	   regulator	   of	  Wnt/β-­‐catenin	   target	   genes	   is	   not	   obvious	   from	   the	   array	  experiment.	  However,	  our	  recent	  and	  previous	  studies	  suggest	  that	  Norrin	  is	  important	  for	   retinal	   angiogenesis.	   Here,	  we	   could	   identify	   several	   genes	   probably	   implicated	   in	  blood	  vessel	  development	  that	  may	  be	  transcriptionally	  regulated	  by	  Norrin,	  directly	  or	  indirectly.	  These	  genes	  include	  Agtrl1,	  ApoD,	  and	  Adm,	  while	  Slc38a5	  might	  represent	  an	  interesting	  candidate	  with	  regard	  to	  future	  research	  of	  aberrant	  neuronal	  development	  and	   the	   massive	   reactive	   gliosis	   that	   may	   be	   the	   basis	   for	   the	   often	   described	  pseudogliomas	  in	  ND	  patients56.	  Finally,	  due	  its	  proposed	  role	  in	  angiogenesis	  and	  blood	  vessel	   integrity24,37,	   our	   findings	   suggest	   an	   important	   contribution	   of	   Plvap	   to	   the	  pathogenesis	  of	  Norrin-­‐associated	  diseases.	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3.2.8	   Contributions	   of	   authors	   to	   the	  manuscript	   „Differential	   gene	   expression	   in	  
Ndph	  knockout	  mice	  in	  retinal	  development”	  	  N.F.S.:	  Planning	   and	   administration	   of	   mouse	   breedings,	   preparation	   of	   animals,	  preparation	   of	   cryosections	   and	   flat-­‐mounts,	   selection	   of	   target	   genes,	  immunohistochemistry	  (IHC),	  morphometric	  analyses,	  preparation	  of	  RNA,	  qRT-­‐PCR,	  Western	  blots	  (WB),	  interpretation	  of	  data,	  writing	  of	  the	  manuscript	  U.F.L.:	  Conceptualization	  of	  the	  experiment,	  supervision	  of	  the	  initial	  experiments	  of	  the	  study,	  editing	  of	  the	  manuscript	  S.F.:	   Technical	  assistance	  with	  mouse	  genotyping,	  HE	  staining,	  IHC	  W.B.:	   Principal	   investigator	   (PI),	   conceptual	   planning,	   design	   and	   supervision	   of	   the	  entire	  study,	  interpretation	  of	  data,	  editing	  of	  the	  manuscript	  	  M.K.:	   Technical	  assistance	  with	  the	  microarray	  experiment,	  from	  reverse	  transcription	  to	  raw	  data	  processing	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3.3	  Further	  experiments	  on	  differential	  expression	  in	  Ndph	  knockout	  mice	  	  
3.3.1	  Whole	  genome	  cDNA	  microarray	  In	  addition	  to	  the	  results	  published	  in	  the	  IOVS	  paper	  (Table	  39;	  Table	  40),	  the	  complete	  list	   of	   differentially	   expressed	   genes	  without	   fold-­‐change	   cut-­‐off	   and	  without	  multiple	  testing	  correction	  at	  p<0.01	  can	  be	  found	  in	  the	  appendix	  (this	  list	  was	  the	  basis	    of	  the	  pathway	  analysis	  referenced	  in	  the	  publication).	  	  
3.3.2	  Analysis	  of	  microarray	  candidate	  genes	  
3.3.2.1	  Plasmalemma	  vesicle	  associated	  protein	  (Plvap)	  Retinal	  mRNA	  transcripts	  of	   the	  plasmalemma	  vesicle	  associated	  protein	   (Plvap)	  were	  increased	   in	   the	   microarray	   experiment	   (p7;	   Table	   40),	   and	   retinal	   expression	   was	  shown	  to	  be	  increased	  throughout	  postnatal	  retinal	  development	  from	  p5	  to	  p21	  (Figure	  52	  A),	  especially	  at	  more	  advanced	  stages.	  In	  retinal	  cryosections,	  ectopic	  expression	  in	  the	  retinal	  vasculature	  of	  the	  Ndph	  ko	  was	  detected	  (Figure	  53).	  	  
3.3.2.1.1	  Western	  blots	  from	  retinal	  protein	  extracts	  Specificity	   of	   the	   Plvap	   antibody	   was	   supported	   by	   Western	   blots,	   which	   did	   show	  several	  bands,	  but	  most	  prominently	  stained	  a	  protein	  at	  the	  expected	  size	  between	  50-­‐55kDa.	  These	  presumptive	  Plvap	  protein	  levels	  appeared	  to	  be	  higher	  in	  the	  ko	  than	  in	  the	  wt	  (Figure	  54),	  but	  not	  as	  high	  as	  the	  transcript	  levels	  (Figure	  52	  A).	  	  
	   	  
	  
A	  Plvap	  Western	  blot	   B	  Plvap	  WB	  quantification	  
Figure	   54	   Western	   blot	   and	   corresponding	   densitometric	   quantification	   of	   22µg	   p7	   retinal	   protein	  extracts	  of	  Ndph	  wt	  and	  ko	  mice	  stained	  with	  an	  antibody	  against	  Plvap.	  For	  densitometric	  quantification,	  density	  values	  have	  been	  normalized	  to	  Gapdh	  expression	  and	  calibrated	  on	  the	  wild	  type	  mean.	  (A)	  The	  most	  prominent	  bands	  in	  the	  Western	  blot	  are	  in	  the	  range	  of	  the	  predicted	  ~50-­‐55	  kDa	  band.	  Plvap	  levels	  in	   the	   knockout	   appear	   to	   be	   marginally	   higher	   in	   the	   knockout,	   which	   could	   be	   confirmed	   by	   the	  densitometric	  analysis	  (B).	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3.3.2.1.2	  Immunohistology	  on	  retinal	  flatmounts	  In	   addition	   to	   sections,	   immunohistology	   was	   also	   performed	   on	   retinal	   flatmount	  preparations	  (Figure	  55).	  Plvap	  immunoreactivity	  was	  ectopically	  detected	  in	  all	  blood	  vessels	  of	  the	  superficial	  network.	  Expression	  was	  especially	  prominent	  in	  veins,	  while	  it	  appeared	  reduced	  in	  arteries.	  However,	  this	  result	  could	  not	  be	  confirmed	  in	  subsequent	  experiments.	  
   
A Collagen IV B Plvap C Merge 
Figure	  55	  Retinal	  flatmount	  preparation	  from	  a	  p7	  Ndph	  ko.	  (A)	  An	  antibody	  against	  Collagen	  IV	  was	  used	  to	  label	  the	  extracellular	  matrix	  of	  the	  vasculature.	  (B)	  Plvap	  expression	  was	  ectopically	  detected	  in	  every	  retinal	   blood	   vessel.	   (C)	   The	   overlay	   picture	   reveals	   predominant	   Plvap	   labeling	   of	   the	   capillaries	   and	  veins.	  The	  major	  arteries	  (arrows)	  appear	  to	  be	  less	  stained.	  	  
3.3.2.2	  Solute	  carrier	  family	  38,	  member	  5	  (Slc38a5)	  The	  solute	  carrier	  Slc38a5	  was	  the	  transcript	  with	  the	  most	  decreased	  expression	  in	  the	  microarray	  experiment	  (Table	  40),	  and	  retinal	  expression	  was	  shown	  to	  be	  reduced	  in	  norrin	  ko	  mice	  throughout	  postnatal	  retinal	  development	  from	  p5	  to	  p21	  (Figure	  52	  B).	  Slc38a5,	  a	  neutral	  amino	  acid	  transporter,	  has	  been	  shown	  to	  be	  an	  important	  glutamine	  transporter	  in	  the	  retina	  (Umapathy	  et	  al.,	  2005).	  	  	  
3.3.2.2.1	  Western	  blots	  from	  retinal	  protein	  extracts	  To	  further	  investigate	  differential	  expression,	  I	  obtained	  a	  custom	  antibody	  against	  the	  rat	  Slc38a5	  protein	   from	  Francisco	  Zafra,	  Madrid	   (Cubelos	  et	  al.,	  2005).	  Western	  blots	  with	  p7	  retinal	  protein	  extracts	  showed	  the	  expected	  specific	  staining	  pattern	  (Cubelos	  et	   al.,	   2005)	   and	   could	   confirm	   high	   specificity	   of	   the	   antiserum	   also	   in	   mouse.	   Two	  bands	   of	   the	   predicted	   size	   of	   50kDa	   for	   the	   monomer	   and	   ~200kDa	   for	   a	   possible	  tetramer	  were	  detected	  (Figure	  56).	  The	  200kDa	  band	  was	  higher	  expressed	  in	  the	  Ndph	  knockout	   samples.	   However,	   densitometric	   quantification	   confirmed	   the	   impression	  that	  protein	  levels	  of	  the	  50kDa	  band	  were	  similar	  in	  wt	  and	  ko.	  	  
3.3.2.2.2	  Immunohistology	  of	  retinal	  cryosections	  Staining	  of	  retinal	  cryosections	  showed	  a	  strong	  signal	  in	  the	  outer	  plexiform	  layer	  at	  p7	  (Figure	   57).	   Since	   Slc38a5	   has	   been	   described	   as	   Müller	   cell	   specific	   glutamine-­‐transporter	   (Umapathy	   et	   al.,	   2005),	   this	   localization	   to	   a	   synaptic	   region	  was	   in	   line	  with	  my	   expectations.	   However,	   no	   differences	   could	   be	   observed	   between	  wild	   type	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Figure	  56	   Slc38a5	  Western	  blot	  and	  densitometric	  quantification	  of	  22µg	  p7	  retinal	  protein	  extracts	  of	  
Ndph	  wt	  (+;	  green)	  and	  ko	  (-­‐;	  red)	  mice.	  Density	  values	  have	  been	  normalized	  to	  Gapdh	  expression	  and	  calibrated	  on	  the	  wild	  type	  mean.	  (A)	  Western	  blot	  stained	  with	  anti-­‐Slc38a5	  serum	  detects	  two	  bands	  of	  the	  predicted	  size	  of	  50kDa	  for	  the	  monomer	  and	  ~200kDa	  for	  a	  possible	  tetramer	  (Cubelos	  et	  al.,	  2005).	  
(B)	   Densitometric	   quantification	   verified	   stronger	   expression	   of	   the	   200kDa	   band	   in	   the	   knockout	  samples.	   (C)	   However,	   densitometric	   quantification	   of	   the	   smaller	   band	   confirmed	   the	   impression	   that	  protein	  levels	  between	  wt	  and	  ko	  are	  comparable.	  	  
  
A	   B	  
Figure	   57	   Immunofluorescence	   images	   of	   p7	   retinal	   cryosections	   of	   Ndph	   wt	   (A)	   in	   comparison	   to	  knockout	   mice	   (B).	   The	   antibody	   against	   Slc38a5	   (detected	   with	   a	   2nd	   antibody	   labeled	   with	   AF488;	  
green)	  detects	  a	  strong	  signal	   in	   the	  outer	  plexiform	  layer	  (OPL).	  No	  differences	  between	  wild	   type	  and	  knockout	  could	  be	  observed.	  RGC:	  retinal	  ganglion	  cell	  layer;	  IPL:	  inner	  plexiform	  layer;	  INL:	  inner	  nuclear	  layer;	  OPL:	  outer	  plexiform	  layer;	  ONL:	  outer	  nuclear	  layer;	  RPE:	  retinal	  pigment	  epithelium	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and	  knockout	  specimen,	  which	  is	  in	  contrast	  to	  the	  significant	  difference	  on	  mRNA	  level	  that	   is	   about	   20-­‐fold	   lower	   in	   the	   knockout	   at	   p7	   (Figure	   52	   B).	   Since	   this	   Slc38a5	  antibody	   has	   been	   raised	   against	   a	   rat-­‐peptide,	   a	   possible	   cross-­‐reactivity	   with	   other	  epitopes	  in	  the	  mouse	  cannot	  be	  excluded.	  	  
3.3.2.2.3	  Expression	  of	  Slc38a5	  in	  the	  cerebellum	  Slc38a5	  was	  also	  found	  in	  astrocytes	  of	  the	  cerebellum	  (Cubelos	  et	  al.,	  2005).	  If	  norrin	  regulates	  expression	  of	  Slc38a5	   in	  the	  retina,	  it	  is	  possible	  that	  it	  also	  controls	  it	  in	  the	  cerebellum,	   where	  Ndph	   is	   expressed	   the	   most	   among	   all	   investigated	   brain	   regions	  (Table	  36).	  To	   test	   this	  hypothesis,	  qRT-­‐PCR	  analyses	  with	  RNA	  extracts	   from	  p21	  cerebella	  were	  conducted	   by	   Walther	   Hänseler	   (as	   part	   of	   his	   Masterthesis	   under	   my	   supervision).	  Indeed,	  reduced	  Slc38a5	  expression	   in	  the	  cerebellum	  of	  p21	  Ndph	  ko	  mice	  was	  found	  (Figure	  58;	  Hänseler,	  Masterthesis,	  2008).	  
  
A   B 
Figure	  58	  Transcriptional	  analysis	  of	  Slc38a5	   in	  cerebella	  of	  p21	  Ndphy/-­	  knockout	  (n=5)	  and	  wild	   type	  (n=5)	  mice.	   The	   average	   expression	   value	   of	   the	  wild	   type	   group	  was	   set	   to	   1.	   Error	   bars	   indicate	   the	  confidence	  interval	  at	  a	  significance	  level	  of	  95%	  (p<0.05).	  (A)	  Slc38a5	  mRNA	  expression	  of	  the	  individual	  animals.	   (B)	   Decrease	   of	  Slc38a5	   expression	   is	   significant	  when	   calculated	   for	   the	   biological	   replicates.	  
Pol2a	  was	  used	  as	  endogenous	  control.	  (Source:	  Masterthesis	  Hänseler,	  2008)	  	  
3.3.2.2.4	  Immunohistology	  on	  cerebellar	  cryosections	  We	   then	   also	   conducted	   immunohistochemistry	   with	   the	   Slc38a5	   antibody	   on	   brain	  sections.	  Staining	  intensity	  was	  generally	  weak,	  but	  appeared	  to	  be	  stronger	  in	  sections	  from	  norrin	  wt	  mice	  (Figure	  59).	   In	   the	  cerebellum,	   labeling	  was	  most	   intense	  around	  the	  Purkinje	  cells.	  	  
3.3.2.2.5	  Western	  blots	  from	  cerebellar	  protein	  extracts	  Walther	  Hänseler	  also	  performed	  a	  Western	  blot	  with	  cerebellar	  protein	  extracts	   from	  p21	   norrin	  wt	   and	   ko	  mice.	   Again,	   like	   in	   the	  WB	  with	   retinal	   samples,	   staining	  was	  specific,	   producing	   the	   two	   monomeric	   and	   tetrameric	   bands	   (Figure	   60	   A).	  Densitometric	  quantification	  suggested	  a	  stronger	  expression	  of	  the	  200kDa	  band	  in	  the	  ko	   samples,	   although	   not	   as	   clear	   as	   in	   the	   retina	   (Figure	   60	   B).	   No	   differences	  were	  observed	  for	  the	  monomeric	  band	  (Figure	  60	  C).	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Figure	   59	   Cerebellar	   cryosections	   stained	   for	   Slc38a5.	   Four	   p21	   animals	   were	   examined,	   2	   wild	   type	  
(A,B)	  and	  2	  Ndph	  knockout	  (C,D).	  Staining	  generally	  appears	  more	  intense	  in	  the	  wt	  samples.	  Strongest	  staining	  was	   found	   in	   (A),	   labeling	   areas	   around	   the	  Purkinje	   cells.	  M:	  molecular	   layer;	  P:	   Purkinje	   cell	  layer;	  G:	  granular	  cell	  layer.	  (Source:	  Masterthesis	  Hänseler,	  2008)	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Figure	   60	   Slc38a5	  Western	   blot	   and	   densitometric	   quantification	   of	   p21	   cerebellar	   protein	   extracts	   of	  
Ndph	   wt	   (green)	   and	   ko	   (red)	   mice.	   Density	   values	   have	   been	   normalized	   to	   Gapdh	   expression	   and	  calibrated	  on	  the	  wild	  type	  mean.	  (A)	  Western	  blot	  stained	  with	  anti-­‐Slc38a5	  serum	  detects	  two	  bands	  of	  the	  predicted	  size	  of	  50kDa	  for	  the	  monomer	  and	  ~200kDa	  for	  a	  possible	  tetramer	  (Cubelos	  et	  al.,	  2005).	  
(B)	   Densitometric	   quantification	   suggests	   a	   trend	   to	   stronger	   expression	   of	   the	   200kDa	   band	   in	   the	  knockout	   samples.	   (C)	   Densitometric	   quantification	   of	   the	   smaller	   band	   confirmed	   the	   impression	   that	  protein	  levels	  between	  wt	  and	  ko	  are	  comparable.	  (Source:	  Masterthesis	  Hänseler,	  2008)	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3.3.2.3	  Apolipoprotein	  D	  (ApoD)	  Retinal	  mRNA	  expression	  of	  apolipoprotein	  D	  (ApoD)	  revealed	  lower	  expression	  in	  the	  
Ndph	  ko	  not	  only	  at	  p7	  (as	  published	  in	  the	  IOVS	  publication),	  but	  also	  at	  p5	  (Figure	  61).	  
	  
3.3.2.3.1	  Immunohistology	  of	  retinal	  cryosections	  Cryosections	   treated	   with	   an	   antibody	   against	   ApoD	   resulted	   in	   weak	   labeling	   of	  presumably	   amacrine	   and	   horizontal	   cells,	   although	   no	   differences	   could	   be	   detected	  between	   norrin	   wild	   type	   and	   knockout	   (Figure	   62).	   No	   protein	   at	   the	   expected	  molecular	  weight	  of	  about	  21	  kDa	  was	  labeled	  on	  Western	  blots	  with	  p7	  retinal	  protein	  extracts.	  Only	  multiple	  bands	  of	  a	  different	  molecular	  weight	  were	  detected,	   indicating	  that	  the	  antibody	  probably	  is	  unspecific.	  	  
	  
Figure	  61	  Transcriptional	  analysis	  of	  apolipoprotein	  D	  (ApoD)	   in	  retinae	  of	  Ndphy/-­	  knockout	  (n=5;	  red)	  and	   wild	   type	   (n=5;	   green)	   mice.	   Postnatal	   time	   points	   p5	   and	   p7	   were	   investigated.	   The	   average	  expression	   value	   of	   the	   wild	   type	   group	  was	   set	   to	   1.	   Error	   bars	   indicate	   the	   confidence	   interval	   at	   a	  significance	   level	   of	   95%	   (p<0.05).	   Transcript	   expression	   of	  ApoD	   was	   significantly	   lower	   in	   the	  Ndph	  knockout	  at	  both	  p5	  (2.3x)	  and	  p7	  (2.4x)	  .	  18S	  rRNA	  was	  used	  as	  endogenous	  control.	  	  	  
	   	  
A	   B	  
Figure	  62	  Immunofluorescence	  images	  of	  p10	  retinal	  cryosections	  of	  Ndphy/-­	  mice	  (B)	  in	  comparison	  to	  wild	   type	   (A).	   The	   antibody	   against	  ApoD	   (detected	  with	   a	   2nd	   antibody	   labeled	  with	  Cy3;	   red)	   detects	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signals	  in	  the	  inner	  nuclear	  layer	  (INL)	  at	  the	  border	  to	  the	  plexiform	  layers,	  as	  well	  as	  cells	  in	  the	  retinal	  ganglion	   cell	   layer.	   These	   cells	   could	   be	   horizontal	   (at	   the	   border	   to	   the	   OPL)	   and	   amacrine	   cells.	  Counterstaining	   with	   DAPI	   (blue).	   No	   differences	   between	  wild	   type	   and	   knockout	   could	   be	   observed.	  
RGC:	  retinal	  ganglion	  cell	  layer;	  IPL:	  inner	  plexiform	  layer;	  INL:	  inner	  nuclear	  layer;	  OPL:	  outer	  plexiform	  layer;	  ONL:	  outer	  nuclear	  layer;	  RPE:	  retinal	  pigment	  epithelium	  	  
3.3.2.4	  Angiotensin	  receptor-­‐like	  1	  (Agtrl1)	  Transcript	   analysis	   of	   angiotensin	   receptor-­‐like	   1	   (Agtrl1)	   revealed	   significant	   lower	  expression	  in	  the	  Ndph	  ko	  retina	  at	  p7	  (as	  published	  in	  the	  IOVS	  publication),	  but	  not	  at	  p5	   (Figure	   63	   A),	   although	   a	   trend	   to	   lower	   expression	   was	   observed.	   This	   was	   in	  contrast	  to	  my	  hypothesis:	  I	  expected	  reduced	  expression	  of	  Agtrl1	  also	  earlier	  than	  p7,	  because	  it	  has	  been	  shown	  to	  be	  important	  for	  retinal	  angiogenesis	  (Kasai	  et	  al.,	  2004),	  the	  process	  impaired	  in	  the	  Ndph	  ko	  mouse	  retina.	  	  
	  
3.3.2.4.1	  Immunohistology	  of	  retinal	  cryosections	  Unfortunately,	  no	  specific	  staining	  could	  be	  obtained	  with	  the	  antibody	  against	  Agtrl1	  on	  eye	   or	   brain	   cryosections,	   or	   on	   Western	   blots	   with	   p7	   retinal	   extracts,	   which	   only	  showed	  many	  unspecific	  bands.	  	  
3.3.2.5	  Adrenomedullin	  (Adm)	  Adrenomedullin	  (Adm)	  has	  been	  described	  to	  be	  a	  hypoxia	  induced	  vasodilating	  peptide	  (Ogita	   et	   al.,	   2001)	   that	   might	   have	   a	   vascular	   protective	   function	   (Ando	   and	   Fujita,	  2003).	   At	   p21,	   hypoxia	   in	   the	   norrin	   ko	   retina	   is	   evident	   due	   to	   the	   under-­‐developed	  retinal	   vasculature	   (Luhmann	   et	   al,	   2005a).	   Thus,	   in	   addition	   to	   p7,	   p21	   retina	   was	  analyzed	  by	  qRT-­‐PCR.	  Indeed,	  retinal	  mRNA	  expression	  of	  Adm	  was	  elevated	  even	  more	  in	  the	  Ndph	  ko	  at	  p21	  (10x)	  than	  at	  p7	  (2.7)	  (Figure	  63	  B).	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Figure	   63	   Transcriptional	   analysis	   of	   angiotensin	   receptor-­‐like	   1	   (Agtrl1),	   adrenomedullin	   (Adm),	   and	  claudin	  5	  (Cldn5)	  in	  retinae	  of	  Ndphy/-­	  knockout	  (n=5;	  red)	  and	  wild	  type	  (n=5;	  green)	  mice.	  Postnatal	  time	  points	  p5	  and	  p7	  (Agtrl1)	  or	  p7	  and	  p21	  (Adm,	  Cldn5)	  were	  investigated.	  The	  average	  expression	  value	  of	  the	  wild	  type	  group	  was	  set	  to	  1.	  Error	  bars	  indicate	  the	  confidence	  interval	  at	  a	  significance	  level	  of	  95%	  (p<0.05).	  (A)	  Transcript	  expression	  of	  Agtrl1	  was	  significantly	  lower	  in	  the	  Ndph	  knockout	  at	  p7,	  but	  not	  at	  p5.	  (B)	  Expression	  of	  Adm	  mRNA	  was	  significantly	  higher	  in	  the	  Ndph	  knockout	  at	  p7	  and	  especially	  at	  p21.	  (C)	  No	  significant	  differences	  were	  detected	  in	  Cldn5	  expression.	  However,	  there	  is	  a	  trend	  to	  lower	  mRNA	  levels	  in	  the	  Ndph	  ko	  at	  both	  time	  points,	  and	  significance	  is	  borderline	  at	  p7.	  18S	  rRNA	  was	  used	  as	  endogenous	  control.	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3.3.2.6	  Claudin	  5	  (Cldn5)	  Significance	   of	   claudin	   5	   (Cldn5)	   transcript	   expression	   between	  Ndph	   wt	   and	   ko	   was	  only	   borderline	   at	   p7.	   Since	   claudin	   5	   plays	   a	   major	   role	   in	   tight	   junction-­‐specific	  obliteration	   of	   the	   intercellular	   space	   in	   CNS	   endothelial	   cells	   (Nitta	   et	   al.,	   2003),	  differential	  expression	  of	  Cldn5,	   in	  addition	  to	  Plvap,	  could	  explain	  leakiness	  of	  vessels.	  Thus,	   Cldn5	   appeared	   as	   an	   attractive	   candidate	   gene,	   and	   expression	   was	   analyzed	  additionally	   at	   p21,	   when	   the	   vasculature	   in	   the	   norrin	   ko	   is	   leaky.	   However,	   no	  significant	  difference	  at	  the	  transcript	  level	  was	  detected,	  although	  the	  mean	  expression	  value	  was,	  like	  in	  the	  p7	  retina,	  reduced	  two	  fold	  (Figure	  63	  C).	  	  
3.3.2.7	  Abcb1a,	  Prdm9,	  and	  Vwf	  ATP-­‐binding	   cassette,	   sub-­‐family	   B	   (MDR/TAP),	   member	   1A	   (Abcb1a),	   PR	   domain	  containing	  9	  (Prdm9),	  and	  von	  Willebrand	  factor	  homolog	  (Vwf)	  were	  on	  the	  long	  list	  of	  differentially	  expressed	  genes,	  exhibiting	  a	  considerable	   fold-­‐change	  (see	  complete	   list	  in	  the	  appendix),	  but	  were	  excluded	  through	  the	  multiple	  testing	  correction	  procedure	  from	   the	  published	   table	   (Table	  40).	  Nonetheless,	   transcript	   analysis	  by	  qRT-­‐PCR	  was	  performed,	   but	   no	   significant	   expression	   differences	   were	   observed,	   confirming	   the	  microarray	  results	  (Figure	  64).	  	  
	  
Figure	   64	   Transcriptional	   analysis	   of	   ATP-­‐binding	   cassette,	   sub-­‐family	   B	   (MDR/TAP),	   member	   1A	  (Abcb1a),	   PR	   domain	   containing	   9	   (Prdm9),	   and	   von	  Willebrand	   factor	   homolog	   (Vwf)	   in	   retinae	   of	   p7	  
Ndphy/-­	   knockout	   (n=5;	   red)	   and	  wild	   type	   (n=5;	  green)	  mice.	  The	  average	  expression	  value	  of	   the	  wild	  type	  group	  was	  set	  to	  1.	  Error	  bars	  indicate	  the	  confidence	  interval	  at	  a	  significance	  level	  of	  95%	  (p<0.05).	  No	  significant	  differences	   in	  gene	  expression	  were	  observed,	  verifying	   the	  microarray	  results.	  18s	  rRNA	  was	  used	  as	  endogenous	  control.	  	  
3.3.2.8	  Expression	  of	  microarray	  candidate	  genes	  in	  cerebellum	  As	  part	  of	  his	  Master	   thesis,	  Walther	  Hänseler	  also	  performed	  qRT-­‐PCR	  analyses	  with	  cerebellar	  mRNA	  of	   the	   target	  genes	   I	  have	  analyzed	   in	   the	  p7	  retina.	  Besides	   the	  p21	  results	  for	  Slc38a5,	  no	  significant	  differences	  were	  found	  for	  Abcb1a,	  Aass,	  Adm,	  Agtrl1,	  
ApoD,	  Centd3,	  Cldn5,	  Plvap,	  Prdm9,	  and	  Vwf	  expression	  in	  either	  adult	  or	  p21	  cerebellum.	  (Masterthesis	  Hänseler,	  2008)	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Figure	  65	  Retinal	  expression	  of	  ERK1/2	  mitogen-­‐activated	  protein	  kinases.	  (A)	  Western	  blot	  with	  40μg	  p7	  retinal	  protein	  extract	  (supernatant)	  loaded	  in	  each	  lane	  from	  ND	  p7	  animals.	  Two	  prominent	  bands	  at	  ~42kDa	   and	  ~44kDa	   are	   visible	   that	   correspond	   to	   the	  Erk1/2	  products.	   Total	  MAPK	   also	   served	   as	   a	  loading	  control.	  No	  obvious	  difference	  between	  Ndph	  wt	  and	  ko	  bands	  was	  noted.	  (B)	  The	  densitometric	  analysis	  of	  ERK1	  confirmed	  this	   impression.	  Expression	  of	   the	  phosphorylated	  ERK1	  was	  normalized	  to	  total	  ERK1	  expression.	  The	  mean	  of	   the	  wt	   samples	  was	   set	   to	  1.	  Reduced	  expression	  of	   the	   second	  ko	  sample	   is	   likely	  due	   to	   an	  experimental	   artifact.	   (C)	  Densitometric	   analysis	  of	  ERK2	  analog	   to	   (B).	  Also	  here,	  no	  differences	  were	  observed.	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3.3.4	  Analysis	  of	  whole	  genome	  microRNA	  (miRNA)	  expression	  MicroRNAs	  (miRNAs)	  are	  a	  small	  RNA	  species	  involved	  in	  gene	  suppression	  (Hamilton	  and	   Baulcombe,	   1999),	   and	   miRNA	   encoding	   genes	   are	   distributed	   all	   over	   the	  eukaryotic	   genome.	   Their	   transcripts	   are	   cleaved	   into	   60–70	   nucleotide	   microRNA	  precursors	   (pre-­‐microRNAs)	   by	   a	   microprocessor	   complex	   containing	   the	   nuclear	  RNaseIII	   Drosha	   and	   DiGeorge	   syndrome	   critical	   region	   8	   protein	   (Denli	   et	   al.,	   2004;	  Gregory	   and	   Yan	   et	   al.,	   2004;	   Han	   and	   Lee	   et	   al.,	   2004).	   Pre-­‐microRNAs	   are	   then	  exported	   from	   the	  nucleus	   and	   are	   cleaved	  by	   a	   cytoplasmic	  RNase	   III	   and	  Dicer.	  The	  resulting	   mature	   22bp	   microRNAs	   are	   incorporated	   into	   an	   RNA-­‐induced	   silencing	  complex	   to	   act	   as	   target	   recognition	   sequences	   (Gregory	   et	   al.,	   2005).	   Many	   mRNAs	  contain	  target	  sequences	  for	  miRNAs	  and,	  as	  a	  consequence	  of	  binding	  to	  the	  silencing	  complex,	  can	  undergo	  cleavage	  or	  translational	  repression	  (reviewed	  in	  Bartel,	  2004).	  	  
3.3.4.1	  Micro	  RNAs	  in	  angiogenesis	  and	  ocular	  vascular	  development	  Several	   studies	   suggest	   a	   potential	   role	   of	  microRNAs	   in	   angiogenesis.	   Migration	   and	  tube	   formation	   of	   cultured	   vascular	   endothelial	   cells	   (HUVECs)	   are	   reduced	   by	  transfection	   of	   miR-­‐221/-­‐miR-­‐222	   (Poliseno	   et	   al.,	   2006)	   or	   global	   changes	   in	  microRNAs	   induced	  by	  knockdown	  of	  Dicer	   (Suárez	  et	  al.,	  2007).	  Dicer	  knockout	  mice	  die	  during	  the	  embryonic	  stage	  because	  of	  disruption	  of	  the	  vascular	  development	  (Yang	  et	  al.,	  2005),	  indicating	  that	  microRNAs	  play	  a	  critical	  role	  in	  this	  process.	  A	  microarray	  analysis	   with	   ischemic	   murine	   retinas	   (using	   the	   oxygen	   induced	   retinopathy	   (OIR)	  technique)	  revealed	  3	  miRNAs	  (miR-­‐31,	  -­‐150,	  and	  -­‐184)	  that	  are	  downregulated	  during	  ischemia-­‐induced	   neovascularization	   (NV)	   (Shen	   et	   al.,	   2008).	   Intraocular	   injection	   of	  pre-­‐miR-­‐31,	   -­‐150,	   or	   -­‐184	   significantly	   reduced	   ischemia-­‐induced	   retinal	   NV,	   and	   the	  authors	  could	  further	  show	  that	  miR-­‐31	  and	  -­‐184	  are	  constitutively	  highly	  expressed	  in	  cornea	  and	  lens,	  two	  completely	  avascular	  tissues.	  	  
3.3.4.2	  Global	  miRNA	  expression	  in	  the	  developing	  Ndph	  ko	  retina	  Thus,	   miRNAs	   seem	   to	   play	   a	   crucial	   role	   in	   ocular	   vascular	   development.	   Since	   we	  hypothesized	   that	   norrin	   could	   act	   as	   a	   transcriptional	   regulator	   of	   target	   genes,	   and	  vascular	   development	   is	   impaired	   in	   the	   Ndph	   ko	   mouse	   and	   in	   ND	   patients,	   I	   also	  investigated	  differential	  miRNA	  expression	  in	  the	  Ndph	  ko	  mouse	  retina.	  Two	   developmental	   stages	   were	   investigated,	   p5	   and	   p21.	   Since	   miRNA	   microarrays	  became	  first	  available	  just	  during	  the	  course	  of	  my	  thesis,	  I	  wanted	  to	  perform	  the	  first	  experiment	   with	   a	   developmental	   stage	   that	   already	   exhibits	   large-­‐scale	   differences	  between	  the	  genotypes.	  This	  way,	  I	  could	  expect	  to	  see	  several	  differentially	  expressed	  miRNAs,	  even	   if	   the	  microarray	  should	   turn	  out	   to	  be	   insensitive.	  At	  p21,	   the	  Ndph	  ko	  retina	  has	  been	  shown	  to	  be	  severely	  hypoxic,	  just	  like	  the	  retina	  of	  the	  OIR-­‐model	  Shen	  et	   al.	   used	   for	   their	   experiments.	   Thus,	   similar	   results	   could	   be	   expected.	   Potential	  miRNA	   expression	   differences	   at	   p5	   may	   then	   be	   clearly	   attributable	   to	   the	   Ndph	  knockout	   genotype,	   because	   pathologic	   retinal	   hypoxia	   has	   not	   yet	   developed	   at	   this	  stage.	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3.3.4.3	  P21	  retina	  The	  total	  number	  of	  murine	  miRNAs	  known	  at	  the	  time	  point	  of	  the	  experiment	  was	  547	  (human:	  706).	  40%	  of	   them	  (219)	  were	  expressed	   in	   the	  p21	  retina.	  35	  miRNAs	  were	  significantly	  differentially	   expressed	   in	   the	  Ndph	   ko	   (p<0.01),	   of	  which	  12	   exhibited	   a	  fold	  change	  over	  1.3	  (Figure	  66).	  As	  expected,	  comparison	  of	  my	  results	  with	   the	  data	  generated	   in	   the	   OIR	   model	   suggested	   that	   the	   Ndph	   ko	   retina	   is	   in	   a	   similar	  (presumably	  hypoxic)	  condition	  as	  in	  the	  OIR	  model	  (see	  discussion;	  Figure	  113).	  	  
3.3.4.4	  P5	  retina	  After	  the	  miRNA	  chip	  has	  been	  validated	  with	  the	  p21	  experiment,	  the	  second	  run	  with	  p5	   retinas	   was	   performed.	   Technical	   requirements	   (RNA	   quality,	   chip	   readout)	   were	  fulfilled:	   46%	   (250)	   of	   all	   known	   murine	   miRNAs	   were	   expressed	   in	   the	   p5	   retina.	  Expression	   profiles	   of	   the	   individual	   samples	   clustered	   into	   two	   groups.	   However,	   no	  significant	   differences	   between	  Ndph	  wt	   and	   ko	   samples	  were	   observed.	   The	   samples	  instead	  clustered	  into	  two	  groups	  according	  to	  their	  belonging	  to	  one	  of	  two	  litters,	  with	  one	  exception	  (Figure	  67).	  This	  exception	  most	   likely	  was	  due	  to	  a	  confusion.	  Because	  both	  samples	  were	  Ndph	  ko,	  no	  effect	  on	  the	  comparison	  between	  norrin	  wt	  and	  ko	  had	  to	  be	  assumed.	  The	  litter-­‐specific	  differences	  were	  surprising,	  because	  all	  tested	  animals	  were	   offspring	   of	   the	   same	   parents.	   The	   only	   possible	   explanation	   for	   the	   significant	  expression	   differences	   between	   the	   litters	   would	   be	   a	   different	   developmental	   stage,	  although	  both	  were	  prepared	  5	  days	  after	  birth.	  	  
Increased Entrez Gene ID ProbeName 
2.15 mmu-miR-322 A_54_P2504 
2.09 mmu-miR-210 A_54_P1444 
1.75 mmu-miR-126-3p A_54_P2285 
1.53 mmu-miR-27a A_54_P4385 
1.42 mmu-miR-142-3p A_54_P2308 
1.38 mmu-miR-132 A_54_P1054 
1.33 mmu-miR-23a A_54_P1311 
1.29 mmu-miR-223 A_54_P2629 
1.29 mmu-miR-326 A_54_P1366 
1.25 mmu-miR-34c A_54_P1247 
1.22 mmu-miR-34b-5p A_54_P2446 
1.20 mmu-miR-140 A_54_P1075 
1.17 mmu-miR-335-3p A_54_P2691 
1.17 mmu-miR-24 A_54_P1143 
1.11 mmu-miR-21 A_54_P1307  
Decreased Entrez Gene ID ProbeName 
1.45 mmu-miR-129-3p A_54_P1337 
1.43 mmu-miR-129-5p A_54_P2343 
1.40 mmu-miR-375 A_54_P1511 
1.39 mmu-miR-211 A_54_P1466 
1.30 mmu-miR-7a A_54_P2659 
1.27 mmu-miR-135b A_54_P2589 
1.25 mmu-miR-33 A_54_P2637 
1.19 mmu-miR-149 A_54_P2321 
1.18 mmu-miR-218 A_54_P1458 
1.15 mmu-miR-137 A_54_P1069 
1.14 mmu-miR-30a A_54_P4363 
1.11 mmu-miR-106b A_54_P1263 
1.10 mmu-miR-29c* A_54_P3467 
1.10 mmu-miR-219 A_54_P1459 
1.10 mmu-miR-138 A_54_P1073 
1.09 mmu-miR-92a A_54_P2496 
1.07 mmu-miR-183* A_54_P3334 
1.07 mmu-miR-361 A_54_P1499 
1.05 mmu-miR-376b A_54_P2716 
1.03 mmu-miR-384-5p A_54_P2696  
	  
Figure	  66	   Global	  miRNA	   expression	   expression	   analysis	   of	   p21	   retinas	   revealed	   35	  miRNAs	   that	  were	  significantly	  differentially	  expressed	  in	  the	  Ndph	  ko	  (p<0.01).	  Expression	  of	  12	  transcripts	  was	  different	  by	  more	  than	  1.3	  fold	  change:	  7	  were	  increased,	  and	  5	  were	  decreased.	  	  





Figure	  67	  Sample	  correlation	  plots	  based	  on	  all	  miRNAs	  that	  were	  present	  at	  p5.	  White	  color	  relates	  to	  high	   correlation,	   black	   to	   low	   correlation	   of	   miRNA	   expression.	   (A)	   The	   sample	   correlation	   plot	   was	  strongly	  mixed	  when	  groups	  were	  arranged	  according	  to	  the	  Ndph	  genotype	  (green:	  Ndph	  wt;	  red:	  Ndph	  ko).	  (B)	  However,	   the	  samples	  clearly	  clustered	   in	   two	  groups.	  With	   the	  exception	  of	  samples	  ND	  2293	  and	  ND	  2393,	  the	  specimens	  arranged	  according	  to	  their	  belonging	  to	  one	  of	  the	  two	  litters	  from	  which	  the	   retinas	  were	   prepared.	   Litter	   1	   included	   samples	   no.	   ND	   2293,	   2295,	   2296,	   and	   2298	   (light	   blue).	  Litter	  no.	  2	  included	  ND	  2392,	  2393,	  2396,	  and	  2400	  (dark	  blue).	  This	  clustering	  suggests	  that	  samples	  ND	  2293	   and	   ND	   2393	   (orange)	   were	   likely	   confused	   with	   each	   other,	   and	   that	   differences	   in	   miRNA	  expression	  at	  p5	  were	  higher	  between	  different	  litters	  than	  between	  the	  Ndph	  genotypes.	  
	  
3.3.4.5	  Possible	  effects	  on	  target	  genes	  Nonetheless,	   since	   it	   is	   evident	   that	  miRNAs	  play	  an	   important	   role	   in	  ocular	  vascular	  development	   and	   remodeling,	   further	   studies	   concentrating	   on	   the	   differentially	  regulated	  miRNAs	  may	   reveal	   valuable	   insight	   into	   the	  molecular	  pathogenesis	   of	  ND.	  For	  this	  purpose,	  in	  silico	  analyses	  regarding	  the	  miRNAs	  already	  known	  to	  affect	  blood	  vessel	   development	   and	   those	   presented	   in	   Figure	   113	   were	   performed.	   A	   database	  search	  investigating	  which	  targets	  are	  recognized	  by	  these	  miRNAs	  revealed	  that	  some	  could	  influence	  expression	  of	  angiogenic	  genes	  (Table	  41).	  18	  of	  the	  39	  representatively	  selected,	   putative	   angiogenesis-­‐related	   genes	   harbor	   a	   binding	   site	   for	   at	   least	   one	   of	  these	  miRNAs.	   Four	   genes	   (Igf1,	  Notch3,	  Dvl3,	   and	   Slc38a5)	   are	   recognized	  by	   several	  miRNAs.	   The	   miRNA	   recognizing	   the	   most	   of	   the	   selected	   genes	   is	   mmu-­‐miR-­‐27a	   (5	  targets:	   Igf1,	  Cldn5,	  Dvl2,	  Notch2,	  and	  Notch4).	   Interestingly,	  none	  of	   these	  39	  genes	   is	  recognized	  by	  the	  miRNA	  with	  the	  highest	  differential	  expression:	  mmu-­‐miR-­‐322	  (2.2x).	  
3.3.4.6	  Synopsis	  Taken	   together,	  differential	   expression	  of	  miRNAs	   in	   the	  Ndph	  ko	   retina	  was	  detected	  with	   the	   microarray	   approach	   at	   p21,	   but	   not	   at	   p5.	   Although	   this	   does	   not	   exclude	  differences	   at	   p5,	   it	   could	   indicate	   that	   differential	   expression	   of	   miRNAs	   is	   not	   a	  primary	  event	  in	  the	  pathogenesis	  of	  ND,	  but	  rather	  mirrors	  secondary	  changes	  like	  the	  establishment	   of	   chronic	   hypoxia.	   Some	   of	   the	   miRNAs	   are	   predicted	   to	   regulate	  angiogenic	  factors,	  and	  it	  may	  be	  interesting	  to	  investigate	  their	  role	  in	  ND.	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Target effect  increased expression  decreased expression  literature 














































































































































Igf1 +/-   x x        x  x       
Notch3 +          x x      x    
Dvl3 +/-     x     x           
Slc38a5 -       x         x    x 
                      
VegfC -       x           x   
Angpt2 +            x         
Cldn5 -   x                  
Dll4 -     x                
Dvl2 -   x                  
Itgav -      x               
Lrp5 -  x                   
Notch2 -   x                  
Notch4 -   x                  
Nrp-1 +             x        
VegfA -    x                 
VEGFR2/Kdr +            x         
Fzd4                  x    
Tie1                 x     
                      
Adm                      
Agtrl1                      
Angpt1                      
ApoD                      
Ctnnb1                      
Dvl1                      
Efnb2                      
EphB4                      
Hif1a                      
Igf2                      
Itgb3                      
Jag1                      
Ndph                      
Notch1                      
Pdgfb                      
PdgfRb                      
Plvap                      
Tie2/Tek                      
VegfB                      
VEGFR1/Flt1                      
VEGFR3/Flt4                      
	  
Table	  41	  Representative	  selection	  of	  39	  genes	  that	  are	  (likely)	  involved	  in	  blood	  vessel	  development.	  18	  of	   these	   genes	   include	   a	   recognition	   site	   in	   the	   3’-­‐UTR	   for	   at	   least	   one	   of	   the	   differentially	   regulated	  miRNAs	  found	  in	  p21	  Ndph	  retinas,	  or	  for	  the	  miRNAs	  already	  described	  blood	  vessel	  regulating.	  4	  genes	  are	  recognized	  by	  more	  than	  1	  miRNA.	  The	  miRNAs	  recognizing	  the	  most	  of	  these	  selected	  angiogenesis-­‐related	  genes	  are	  miR-­‐27a	  (5	  targets)	  and	  miR-­‐129-­‐5p	  (3	  targets).	  The	  miRNA	  with	  the	  highest	  differential	  expression	   (mmu-­‐miR-­‐322)	   has	   no	   predicted	   target	   genes	   amongst	   this	   selection.	   The	   +/-­‐	   sign	   in	   the	  „effect“	  column	  indicates	  the	  impact	  of	  differential	  miRNA	  expression	  in	  p21	  Ndph	  ko	  retina	  on	  the	  target	  gene.	  Data	  have	  been	  retrieved	  from	  the	  miRBase	  hosted	  by	  the	  Sanger	  institute	  (microrna.sanger.ac.uk).	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3.3.5	  Analysis	  of	  neuronal	  markers	  in	  the	  retina	  	  Most	   data	   from	   the	   analysis	   of	   the	   norrin	   ko	   mouse	   support	   the	   hypothesis	   that	  impairment	  of	  the	  retinal	  vascular	  development	  is	  the	  first	  pathogenic	  event,	  and	  effects	  on	  the	  neural	  retina	  occur	  only	  secondarily	  (Luhmann	  et	  al.	  2005a;	  this	  work).	  Because	  of	   this,	   Dr.	   Lucia	   Galli-­‐Resta	   from	   the	   Institute	   of	   Neuroscience	   at	   the	   Consiglio	  Nazionale	  delle	  Ricerche	  (CNR)	  in	  Pisa	  has	  approached	  us	  with	  the	  idea	  that,	  if	  Norrin	  in	  the	   first	  place	   is	   essential	   for	   the	  development	  of	   the	   retinal	   vasculature,	   the	  Ndph	   ko	  mouse	   could	   serve	   as	   a	   model	   to	   investigate	   neuronal	   development	   under	   hypoxic	  conditions.	  This	  is	  what	  she	  was	  interested	  in,	  and	  so	  we	  started	  a	  collaboration,	  where	  I	  prepared	   retinas	   from	   the	   norrin	   ko	   breed,	   and	   Dr.	   Galli-­‐Resta	   and	   her	   co-­‐workers,	  mainly	  her	  PhD	  student	  Paola	  Leone,	  performed	  a	  series	  of	  immunohistological	  studies	  on	  them.	  During	  this	  collaboration,	  I	  had	  the	  opportunity	  to	  visit	  Dr.	  Galli-­‐Resta’s	  lab	  for	  a	   10-­‐day	   internship,	   and	   worked	   together	   with	   Paola	   Leone	   to	   analyze	   differential	  expression	  of	   neuronal	  markers	   in	   the	  Ndph	   ko	  mouse	  by	   immunohistochemistry	   and	  confocal	  microscopy.	  This	  set	  of	  antibodies	  contained	  markers	  for	  retinal	  ganglion	  cells	  (Islet-­‐1,	  beta-­‐tubulin	  (processes),	  Neurofilament	  150kDa	  (axons)),	  amacrine	  cells	  (Islet-­‐1,	   ChAT),	   bipolar	   cells	   (PKC-­‐α	   (rod	   bipolars),	  mGluR6	   (ON	   bipolars)),	   horizontal	   cells	  (calbindin	   28kd),	   Müller	   cells	   (vimentin),	   and	   synapses	   (SNAP	   25,	   synaptophysin,	  mGluR6).	  Two	  markers,	  synaptophysin	  (Syp)	  and	  Islet-­‐1	  (Isl-­‐1),	  were	  also	  investigated	  on	  the	  mRNA	  level	  after	  my	  return.	  	  
3.3.5.1	  Synaptophysin	  (Syp)	  Synaptophysin	   (Syp)	   is,	   together	   with	   synaptobrevin	   (Syb),	   the	   most	   abundantly	  expressed	  protein	  in	  synaptic	  vesicles,	  and	  thus	  is	  used	  as	  a	  synaptic	  marker	  (Calhoun	  et	  al.,	   1996).	   It	   probably	   modifies	   the	   release	   of	   synaptic	   vesicles	   through	   binding	   to	  synaptobrevin,	  which	  is	  central	  to	  the	  exocytotic	  SNARE	  complex,	  and	  thereby	  decreases	  vesicle	   release	   (Edelmann	   et	   al.,	   1995).	   As	   a	  marker,	   it	   is	   frequently	   used	   for	   density	  determination	   of	   synapses	   in	   brain	   disorders,	   as	   well	   as	   for	   the	   diagnosis	   of	  neuroendocrine,	  neuroectodermal,	  and	  CNS	  tumours	  (Morrison	  &	  Prayson,	  2000;	  Wick,	  2000).	  The	   staining	   pattern	   of	   synaptophysin	   was	   different	   between	   the	   Ndph	   wt	   and	   ko	  sections,	  especially	  at	  p21	  (Figure	  68).	  A	  typical	  pattern	  of	  small	  spots	  was	  visible	  in	  the	  plexiform	   layers	   of	   the	   wild	   type,	   indicating	   numerous	   synapses.	   In	   the	   knockout,	  labeling	  was	  weaker	  and	  more	  diffuse.	  Because	  of	  unspecific	   labeling	  of	   the	  secondary	  anti-­‐mouse	   IgG	   antibody,	   blood	   vessels	   were	   also	   visible.	   In	   the	   samples	   from	   p5	  animals,	   only	   very	   faint	   staining	  was	  detected	   in	   the	  wt,	   and	  no	   immunoreactivity	   for	  Syp	  could	  be	  observed	  in	  the	  ko.	  To	  further	  investigate	  differential	  expression	  of	  Syp,	  quantitative	  RT-­‐PCR	  with	  5	  wt	  and	  5	  ko	  retinas	  was	  performed.	  At	  both	  investigated	  time	  points,	  p5	  and	  p21,	  no	  significant	  differences	  in	  mRNA	  expression	  could	  be	  detected	  (Student’s	  t-­‐test;	  p<0.05)	  (Figure	  69).	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Figure	  68	  Confocal	  microscopy	  images	  of	  p5	  &	  p21	  retinal	  cryosections	  stained	  with	  an	  antibody	  against	  synaptophysin	  (Syp),	  a	  synaptic	  marker.	  The	  staining	  pattern	  of	  Syp	  was	  different	  between	  the	  Ndph	  wt	  and	   ko	   sections,	   especially	   at	   p21.	   (A,	   B)	   At	   p5,	   the	   most	   prominently	   labeled	   structures	   were	   blood	  vessels,	  which	  is	  due	  to	  the	  unspecific	  labeling	  by	  the	  secondary	  anti-­‐mouse	  IgG	  antibody	  (arrowheads).	  Besides	  very	  faint	  staining	  in	  the	  wt	  (A;	  arrow),	  no	  immunoreactivity	  for	  Syp	  could	  be	  observed	  at	  p5.	  (C)	  In	  the	  p21	  wt	  a	  typical	  pattern	  of	  small	  spots	  was	  visible	  in	  the	  plexiform	  layers.	  (D)	  A	  weaker	  and	  more	  uniform	   labeling	  was	   seen	   in	   the	  p21	  ko.	  (E,F)	  Higher	  magnification	   images	  of	   (C,D)	   showing	   the	   inner	  plexiform	  layer	  of	  the	  p21	  wt	  (E)	  and	  p21	  ko	  (F).	  RGC:	  retinal	  ganglion	  cell	  layer;	  IPL:	  inner	  plexiform	  layer;	  
OPL:	  outer	  plexiform	  layer.	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Figure	  69	  Transcriptional	  analysis	  of	  synaptophysin	  (Syp)	  in	  retinae	  of	  Ndphy/-­	  knockout	  (n=5;	  red)	  and	  wild	  type	  (n=5;	  green)	  mice.	  Postnatal	  time	  points	  p5	  (C,D)	  and	  p21	  (A,B)	  were	  investigated.	  The	  average	  expression	   value	   of	   the	   wild	   type	   group	  was	   set	   to	   1.	   Error	   bars	   indicate	   the	   confidence	   interval	   at	   a	  significance	   level	   of	   95%	   (p<0.05).	   (A)	  Quantitative	   RT-­‐PCR	   results	   of	   the	   individual	   p21	   samples.	   (B)	  Mean	  values	  of	  the	  five	  wt	  and	  5	  ko	  samples.	  (C)	  Results	  of	  the	  individual	  p5	  samples.	  (D)	  Mean	  values	  of	  the	  p5	  samples.	  No	  significant	  differences	  were	  found	  between	  the	  wild	  type	  and	  the	  knockout	  group.	  28S	  
rRNA	  was	  used	  as	  endogenous	  control.	  
	  
3.3.5.2	  Islet-­‐1	  (Isl-­‐1)	  A	  subset	  of	  RGCs,	  amacrine,	  and	  bipolar	  cells	  can	  be	  stained	  with	  an	  antibody	  against	  the	  transcription	   factor	   islet-­‐1,	   which	   has	   been	   shown	   to	   control	   the	   differentiation	   and	  maturation	  of	  these	  cell	  types	  (Elshatory	  et	  al.,	  2007;	  Pan	  et	  al.,	  2008).	  At	   p5,	   immunoreactivity	   was	   comparable	   between	   Ndph	   wt	   and	   ko	   (Figure	   70	   A,B).	  However,	  the	  number	  of	  amacrine	  cells	  appeared	  to	  be	  reduced	  in	  the	  knockout,	  and	  the	  intensity	  of	  bipolar	  cell	   labeling	  seemed	  to	  be	  higher.	  This	   impression	  might	  be	  due	  to	  the	   exact	   position	   of	   the	   section,	   since	   a	   clear	   center-­‐to-­‐periphery	   gradient	   was	  observed	  in	  sections	  from	  p5	  ko	  specimens	  for	  immunoreactive	  bipolar	  cells	  (Figure	  71).	  Multiple	   sections	   would	   have	   to	   be	   analyzed	   to	   adequately	   quantify	   a	   possible	  difference.	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Contrary,	   a	   clear	   difference	   was	   observed	   in	   sections	   and	   flatmounts	   of	   p21	   retinas	  (Figure	  70	  C-­‐F).	  Almost	  no	  Isl-­‐1	  labeling	  was	  detected	  in	  the	  Ndph	  ko.	  When	  present,	  it	  rather	  appeared	   in	   the	  cytoplasm	  than	   in	   the	  cell	  nucleus	  (Figure	  70	  F).	  Similar	   to	   the	  synaptophysin	  staining	  (Figure	  68),	  also	  here	  unspecific	  labeling	  of	  blood	  vessels	  due	  to	  the	  murine	  origin	  of	  the	  antibody	  occured.	  	  Background	   staining	  of	   the	  plexiform	   layers	   appeared	   to	  be	  higher	   in	   the	  ko,	  possibly	  due	  to	  increased	  permeability	  and	  leakage	  of	  the	  vasculature,	  and	  thus	  presence	  of	  IgGs	  in	  those	  areas.	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Figure	   70	   Confocal	  microscopy	   images	   of	   p5	  &	   p21	   retinas	   stained	  with	   an	   antibody	   against	   islet-­‐1,	   a	  transcription	  factor	  that	  serves	  as	  a	  marker	  for	  bipolar	  and	  amacrine	  cells.	  The	  different	  staining	  pattern	  of	  islet-­‐1	  between	  Ndph	  wt	  and	  ko	  was	  striking	  at	  p21,	  but	  not	  obvious	  at	  p5.	  Unspecific	  labeling	  of	  all	  3	  blood	  vessel	   layers	  occured	  due	  to	  the	  specificity	  of	  the	  secondary	  antibody	  (arrowheads).	  (A,	  B)	  At	  p5,	  amacrine	  (hollow	  arrows)	  and	  bipolar	  cells	  (arrows)	  were	  labeled	  in	  both	  the	  Ndph	  wt	  (A)	  and	  the	  ko	  (B)	  sections.	  However,	  the	  number	  of	  immunoreactive	  amacrine	  cells	  appeared	  to	  be	  reduced	  in	  the	  ko.	  (C)	  In	  p21	  wt	  cryosections,	  bipolar	  cells	  mostly	  accumulating	  near	  the	  border	  to	  the	  OPL	  were	  immunoreactive	  (arrow).	   Somata	   and	   processi	   of	   amacrine	   cells	   on	   both	   sides	   of	   the	   IPL	  were	   labeled	   as	  well	   (hollow	  arrows).	  (D)	  In	  p21	  ko	  cryosections,	  only	  the	  superficial	  vasculature	  was	  present,	  albeit	  it	  appeared	  to	  be	  dilated	   and	   was	   protruding	   into	   the	   retina	   at	   some	   places	   (arrowheads).	   Specific	   staining	   of	   islet-­‐1	  positive	  cells	  was	  only	  observed	  very	  weakly	  in	  the	  INL	  (arrows).	  Virtually	  no	  staining	  of	  amacrine	  cells	  could	  be	  detected.	  Background	  staining	  of	  the	  plexiform	  layers	  appeared	  to	  be	  higher	  in	  the	  ko,	  possibly	  due	  to	  increased	  permeability	  and	  leakage	  of	  the	  vasculature,	  and	  thus	  presence	  of	  IgGs	  in	  those	  areas.	  (E)	  Wholemounts	  of	  wt	  retinas	  correlated	  with	  the	  findings	  made	  with	  the	  cryosections.	  This	  confocal	  image	  focused	  on	  the	  superficial	  retina	  shows	  specific	  staining	  of	  amacrine	  cells	  (hollow	  arrows)	  and	  unspecific	  labeling	  of	   the	  superficial	  vessel	  network	  (arrowheads).	  (F)	  No	  staining	  (or	  only	  diffuse	  background)	  of	  amacrine	   cells	   was	   found	   in	   the	   ko	   wholemounts.	   RGC:	   retinal	   ganglion	   cell	   layer;	   IPL:	   inner	   plexiform	  
layer;	  INL:	  inner	  nuclear	  layer;	  OPL:	  outer	  plexiform	  layer;	  ONL:	  outer	  nuclear	  layer.	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Figure	  71	  Merged	  confocal	  microscopy	   images	  of	  Ndph	  ko	  p5	  retinal	  sections	  stained	  with	  an	  antibody	  against	   islet-­‐1.	   Note	   the	   center-­‐to-­‐periphery	   maturation	   gradient:	   Staining	   for	   bipolar	   cells	   (arrows)	  diminishes	  with	  increasing	  distance	  to	  the	  center	  (bottom	  left).	  Amacrine	  cells	  (hollow	  arrows)	  and	  blood	  vessels	  (arrowheads)	  are	  also	  immunoreactive.	  RGC:	  retinal	  ganglion	  cell	  layer;	  IPL:	  inner	  plexiform	  layer;	  





Figure	  72	  Transcriptional	  analysis	  of	  islet-­‐1	  (Isl-­1)	  in	  retinae	  of	  Ndphy/-­	  knockout	  (n=5;	  red)	  and	  wild	  type	  (n=5;	  green)	  mice.	  Postnatal	  time	  points	  p5	  and	  p21	  were	  investigated.	  The	  average	  expression	  value	  of	  the	  wild	  type	  group	  was	  set	  to	  1.	  Error	  bars	  indicate	  the	  confidence	  interval	  at	  a	  significance	  level	  of	  95%	  (p<0.05).	  (A)	  Quantitative	  RT-­‐PCR	  results	  of	   the	   individual	  p21	  samples.	  (B)	  Mean	  values	  of	   the	   five	  wt	  and	   5	   ko	   samples.	   (C)	   Results	   of	   the	   individual	   p5	   samples.	   (D)	   Mean	   values	   of	   the	   p5	   samples.	   No	  significant	  differences	  were	  found	  between	  the	  wild	  type	  and	  the	  knockout	  group.	  28S	  rRNA	  was	  used	  as	  endogenous	  control.	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Differential	   expression	   of	   Isl-­1	  was	   subsequently	   analyzed	   by	   qRT-­‐PCR.	  No	   significant	  differences	  between	  Ndph	  wt	  and	  ko	  were	  found	  at	  both	  investigated	  time	  points	  (p5	  &	  p21;	   Student’s	   t-­‐test;	   Figure	   72).	   However,	   inter-­‐individual	   expression	   could	   differ	   by	  factor	  4,	  suggesting	  substantial	  individual,	  but	  not	  genotype-­‐related,	  mRNA	  differences.	  
	  
3.3.5.3	  Vimentin	  (Vim),	  metabotropic	  glutamate	  receptor	  6	  (mGluR6)	  Immunohistochemistry	   with	   antibodies	   against	   vimentin	   (Vim),	   a	   Müller	   cell	   marker	  (Lemmon	  and	  Rieser,	  1983),	  and	  metabotropic	  glutamate	  receptor	  6	  (mGluR6),	  labeling	  ON	  bipolars	   (Nomura	   et	   al.,	   1994),	   did	   not	  work,	   probably	   because	   the	   antibody	   sera	  were	  too	  old.	  
	  
3.3.5.4	  Neurofilament	  (NF150)	  Neurofilaments	   (NF)	   are	   neuron-­‐specific	   intermediate	   filaments	   (reviewed	   by	   Shea,	  2000).	  Based	  on	  their	  molecular	  weight,	  different	  NF	  families	  have	  been	  defined.	  In	  the	  retina,	  antibodies	  against	  the	  NFs	  of	  medium	  weight	  (~150kDa)	  label	  axons	  of	  ganglion	  and	  horizontal	  cells.	  Confocal	   microscopy	   revealed	   no	   obvious	   differences	   between	   Ndph	   wild	   type	   and	  knockout	   retinas	   at	   p5	   and	  p21	   (Figure	  73).	   This	   suggested	   the	  presence	   of	   a	   normal	  nerve	   fiber	   layer	   in	  norrin	  ko	  mice.	   Further,	   also	   the	  network	  of	  horizontal	   cell	   axons	  was	  comparable	  (Figure	  73).	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Figure	  73	  Confocal	  microscopy	  images	  of	  p5	  &	  p21	  retinal	  flatmount	  preparations	  (A-­‐L)	  and	  sections	  (M-­‐P)	   stained	   with	   an	   antibody	   against	   Neurofilament	   150kDa,	   which	   labeles	   retinal	   ganglion	   cell	   (RGC)	  axons	   and	   horizontal	   cells	   (HC).	   Flatmount	   images	   in	  A-­D	   are	   composed	   of	   several	   pictures	   of	   higher	  magnifications.	  (A)	  Retinal	   flatmount	  from	  a	  p5	  Ndph	  wild	  type.	  RGC	  axons	  are	  clearly	  visible	  as	  stripes	  extending	   radially	   over	   the	   retina,	   merging	   at	   the	   optic	   disc. (B)	   Retinal	   flatmount	   from	   a	   p5	   Ndph	  knockout.	  No	  obvious	  differences	  to	  the	  wild	  type	  are	  apparent.	  On	  the	  left	  side	  of	  the	  image,	  where	  the	  flattened	  retina	  is	  reverted,	  axons	  of	  HCs	  are	  visible.	  (C)	  P21	  retinal	   flatmount	  from	  an	  Ndph	  wt.	  At	  this	  age,	  staining	  of	  the	  RGCs	  is	  better	  visible	  than	  at	  p5.	  	  (D)	  P21	  retinal	  flatmount	  from	  an	  Ndph	  ko.	  Also	  here,	  no	   obvious	   differences	   could	   be	   detected.	   (E-­H)	   Higher	   magnification	   images	   of	   A-­‐D,	   focussed	   on	   the	  nerve	  fiber	  layer	  (NFL).	  (E)	  In	  the	  p5	  wt,	  numerous	  RGC	  axon	  bundles	  are	  visible.	  (F)	  The	  p5	  ko	  NFL	  was	  comparable	  to	  the	  wt.	  (G)	  Wt	  p21	  NFL	  morphology	  appears	  similar	  to	  the	  p5	  samples. (H)	  Also	  in	  the	  p21	  
Ndph	   ko	  NFL,	  no	  obvious	  differences	   to	   the	  wt	  nerve	   fibers	  were	  detected.	  (I-­L)	   Images	   from	   the	   same	  position	  as	  in	  (E-­‐H),	  but	  focussed	  on	  the	  horizontal	  cells	  (HC).	  (I)	  At	  p5,	  the	  outer	  plexiform	  layer	  (OPL)	  is	  not	  developed,	  as	  can	  be	  seen	  by	  the	  lack	  of	  HC	  axons	  in	  the	  p5	  wt.	  However,	  HC	  somata	  are	  visible.	  (J)	  In	  the	  p5	  ko,	  no	  obvious	  differences	  were	  apparent.	  (K)	  A	  dense	  network	  of	  HC	  processi	  was	  detected	  in	  the	  p21	  wt	  OPL.	  (L)	  The	  p21	  ko	  OPL	  was	  similarly	  stained.	  (M-­N)	  Retinal	  sections,	  showing	  staining	  of	  NFL	  and	  HCs.	   (M)	  Ndph	  wt	  p5	   section.	   (N)	   The	  Ndph	   ko	  p5	   section	   showed	  no	  differences.	   (O)	   The	  p21	  wt	  inner	  plexiform	  layer	  (IPL)	  appears	  to	  be	  less	  immunoreactive	  than	  at	  p5.	  (P)	  The	  same	  applies	  to	  the	  p21	  ko.	   In	   addition,	   higher	  background	   staining	   in	   the	  plexiform	   layers	  was	  noted.	   INL:	   inner	   nuclear	   layer;	  	  
IPL:	  inner	  plexiform	  layer;	  NFL:	  nerve	  fiber	  layer;	  ONL:	  outer	  nuclear	  layer;	  OPL:	  outer	  plexiform	  layer;	  RGC:	  
retinal	  ganglion	  cell	  layer.	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3.3.5.5	  Choline	  acetyltransferase	  (ChAT)	  Cholinergic	   acetyltransferase	   (ChAT)	   catalyzes	   the	   synthesis	   of	   the	   neurotransmitter	  acetylcholine,	   through	   joining	   Acetyl-­‐CoA	   to	   choline.	   Thus,	   ChAT	   can	   be	   used	   as	   a	  marker	   for	  cholinergic	  neurons.	   In	  the	  retina,	  antibodies	  against	  ChAT	  effectively	   label	  cholinergic	  amacrine	  cells	  (Galli-­‐Resta,	  2002).	  Retinal	   immunohistology	  analyzed	  with	  confocal	  microscopy	  revealed	  two	  populations	  of	   immunoreactive	   cells:	   one	   was	   located	   in	   the	   inner	   nuclear	   layer,	   and	   the	   other	  formed	   in	   the	  ganglion	  cell	   layer.	  Both	  were	  adjacent	   to	   the	   inner	  plexiform	   layer	  and	  formed	  two	  parallel	  lines	  of	  dendritic	  connections.	  However,	  no	  difference	  at	  p5	  and	  p21	  could	   be	   observed	   between	   norrin	   wt	   and	   ko	   mice	   (Figure	   74),	   indicating	   an	   equal	  number	  and	  distribution	  of	  these	  cells	  in	  both	  genotypes.	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Figure	   74	   Cholinergic	   acetyltransferase	   (ChAT)	   immunohistology	   analyzed	   with	   confocal	   microscopy.	  
(A,D)	  Cholinergic	  amacrine	  cells	  located	  in	  the	  inner	  nuclear	  layer	  (INL;	  arrow)	  and	  the	  retinal	  ganglion	  cell	  layer	  (RGC;	  hollow	  arrow)	  were	  clearly	  visible	  in	  p5	  sections	  of	  Ndph	  wild	  type	  (A)	  and	  knockout	  (D)	  mice.	  (B,C,E,F)	  Spacing	  and	  immunoreactivity	  of	  these	  two	  cell	  layers	  was	  also	  comparable	  between	  p21	  wt	  and	  ko	  retinal	  wholemount	  preparations.	  (B)	  Amacrine	  cells	  in	  the	  INL	  of	  the	  wt	  and	  (E)	  the	  ko	  retina.	  
(C)	  Same	  position	  as	  in	  (B),	  but	  focused	  on	  the	  RGC,	  showing	  a	  second	  layer	  of	  cholinergic	  amacrine	  cells.	  
(F)	   Same	   position	   as	   in	   (E),	   showing	   the	   RGC	   layer	   of	   cholinergic	   amacrine	   cells	   in	   the	   ko.	   INL:	   inner	  
nuclear	  layer;	  IPL:	  inner	  plexiform	  layer;	  RGC:	  retinal	  ganglion	  cell	  layer	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Figure	  75	  Confocal	  microscopy	   images	   from	  retinas	   stained	  with	  an	  antibody	  against	  Calbindin	  28kDa.	  
(A,B)	   In	   p5	   retinal	   sections,	   immunoreactive	   cells	   were	   found	   in	   the	   forming	   outer	   plexiform	   layer	  (horizontal	  cells;	  arrows),	   framing	  the	   inner	  plexiform	  layer	  (amacrine	  cells;	  hollow	  arrows),	  and	   in	  the	  ganglion	  cell	  layer	  (RGCs;	  arrowheads).	  (A)	  Retinal	  section	  from	  a	  p5	  Ndph	  wt.	  (B)	  Section	  from	  a	  p5	  Ndph	  ko.	  No	  differences	  were	  observed.	  (C)	  At	  p21,	  the	  antibody	  only	  labeled	  horizontal	  cells	  in	  the	  wt	  (arrows).	  
(D)	  In	  the	  p21	  ko,	  the	  only	  specific	  staining	  was	  also	  detected	  in	  the	  OPL,	  and	  no	  obvious	  difference	  was	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detected.	   However,	   as	   has	   been	   described	   before	   in	   other	   immunohistologic	   experiments,	   a	   higher	  background	  of	  unspecific	  staining	  occured,	  especially	  in	  the	  IPL	  and	  around	  the	  superficial	  blood	  vessels.	  
INL:	  inner	  nuclear	  layer;	   	  IPL:	  inner	  plexiform	  layer;	  NFL:	  nerve	  fiber	  layer;	  ONL:	  outer	  nuclear	  layer;	  OPL:	  
outer	  plexiform	  layer;	  RGC:	  retinal	  ganglion	  cell	  layer	  	  
3.3.5.7	  Beta-­‐tubulin,	  PKC-­‐alpha,	  SNAP	  25	  In	  addition	  to	  the	  already	  presented	  neuronal	  markers,	  Paola	  Leone	  further	  investigated	  differential	  expression	  of	  β–tubulin	  (that	  labels	  the	  IPL,	  RGCs,	  and	  Müller	  cell	  processes),	  protein	  kinase	  C	  alpha	  (PKCα;	  marker	   for	  rod	   	  bipolar	  cells),	  and	  SNAP	  25	  (one	  of	   the	  SNARE	  proteins	  mediating	  vesicle	  relase).	  The	   antibody	   against	   β-­‐tubulin	   labeled	   the	   radially	   processing	  Müller	   cells,	   the	   inner	  plexiform	   layer,	   and	  also	   intensely	   the	   retinal	   ganglion	   cell	   layer.	  However,	  wt	  and	  ko	  sections	  were	  not	  different	  (Figure	  76	  A).	  PKC-­‐α	   positive	   cells,	   i.e.	   rod	   bipolars,	   were	   found	   on	   both	   sides	   of	   the	   inner	   nuclear	  layer.	  Also	  here,	  wt	  and	  ko	  stainings	  did	  not	  differ,	  maybe	  with	  the	  exception	  of	  a	  slightly	  higher	   background	   stain	   in	   the	   ko	   (Figure	   76	   B).	   Co-­‐staining	   with	   propidium	   iodide	  (labeling	   cell	   nuclei)	   showed	   dislocation	   of	   rod	   bipolar	   cell	   terminals	   in	   the	   inner	  plexiform	  layer	  by	  aberrantly	  invading	  vessels	  (Figure	  76	  C).	  SNAP	   25	   strongly	   labeled	   the	   outer	   plexiform	   layer,	   with	   no	   apparent	   difference	  between	   norrin	  wt	   and	   ko.	   Also	   the	  weaker	   SNAP	   25	   staining	   of	   the	   inner	   plexiform	  layer	  (IPL)	  was	  comparable	  between	  the	  genotypes	  (Figure	  76	  D).	  	  	  	  
	   	   	   	  
A β-tubulin B PKC-α C PKC-α D SNAP 25 
Figure	  76	  Additional	   immunostainings	  of	  p21	  retinal	  sections	  performed	  by	  Paola	  Leone.	  No	  significant	  differences	  between	  norrin	  wt	  and	  ko	  samples	  were	  detected.	  (A)	  The	  antibody	  against	  β-­‐tubulin	  equally	  labeled	   the	  Ndph	  wt	   and	  ko	   sections	   for	  Müller	   cells	   and,	  more	  diffusely,	   the	   IPL.	   Strong	   response	  was	  observed	  from	  cells	   in	  the	  RGC.	  (B)	  Rod	  bipolars	  were	  labeled	  by	  an	  antibody	  against	  PKC-­‐α.	  Unspecific	  background	  staining	  was	  higher	  in	  the	  ko.	  (C)	  Co-­‐staining	  of	  PKC-α with propidium iodide (red). A vessel	  clump	  dislocates	  bipolar	  cell	  terminals	  (green)	  and	  alters	   inner	  retinal	  morphology. (D)	  Synapses	  in	  the	  plexiform	  layers	  were	  labeled	  with	  a	  SNAP	  25	  antibody.	  Staining	  was	  stronger	  in	  OPL,	  but	  Ndph	  wt	  and	  ko	  sections	  were	  comparable.	   INL:	   inner	  nuclear	   layer;	   	   IPL:	   inner	  plexiform	   layer;	  ONL:	  outer	  nuclear	   layer;	  
OPL:	  outer	  plexiform	  layer;	  RGC:	  retinal	  ganglion	  cell	  layer	  
156	   RESULTS	  	  
	  
3.4	  Norrin’s	  role	  in	  Wnt/β-­‐catenin	  signaling	  
3.4.1	  Analysis	  of	  known	  Wnt-­‐signaling	  mediators	  and	  target	  genes	  	  Upon	   activation	  of	   the	   canonical	  Wnt-­‐signaling	  pathway,	  β-­‐catenin	   accumulates	   in	   the	  cytoplasm,	  translocates	  into	  the	  nucleus	  and	  forms	  a	  complex	  with	  transcription	  factors	  of	  the	  lymphoid	  enhancer	  (Lef)	  or	  transcription	  factor	  (Tcf)	  families	  to	  drive	  target	  gene	  expression.	   (reviewed	   by	   Willert	   and	   Jones,	   2006)	   Since	   norrin	   has	   been	   shown	   to	  activate	   this	  pathway	   in	   cell	   culture	   (Xu	  and	  Wang	  et	   al.,	   2004),	  mediators	   and	   target	  genes	  of	  canonical	  Wnt-­‐signaling	  were	  investigated	  in	  the	  Ndph	  knockout	  mouse	  retina.	  Most	   of	   the	   transcript	   expression	   experiments	  were	  performed	  by	  Bohdan	  Mikolasek,	  while	  I	  repeated/added	  some	  qRT-­‐PCRs,	  performed	  β-­‐catenin	  Western	  blots,	  and	  did	  the	  statistical	  analysis.	  
	  






Figure	  77	  Western	  blots	  with	  retinal	  protein	  extracts	  from	  Ndph	  wt	  and	  ko	  mice	  labeled	  with	  an	  antibody	  against	   β-­‐catenin.	   Densitometric	   quantification	   values	   for	   β-­‐catenin	   were	   normalized	   to	   Gapdh	   and	  calibrated	  to	  the	  wt	  mean.	  (A)	  Beta-­‐catenin	  was	  strongly	  expressed	  at	  every	  investigated	  developmental	  stage	  (p5-­‐p21)	  with	  no	  obvious	  differences	  between	  norrin	  wt	  and	  ko.	  Protein	  levels	  of	  Gapdh	  increased	  over	  time.	  Gapdh	  expression	  appeared	  to	  be	  weak	  in	  the	  first	  sample	  (p5	  wt).	  (B)	  When	  the	  Western	  blot	  was	  repeated	  with	  protein	   from	  p5	  retinas,	  no	  differences	  between	   the	  Ndph	   genotypes	  could	  be	   found	  (wt:	  n=4;	  ko:	  n=3).	  (C)	  Densitometric	  quantification	  of	  the	  blot	  presented	  in	  (A).	  Due	  to	  normalization	  of	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the	  β-­‐catenin	  levels	  to	  Gapdh,	  it	  appears	  as	  if	  β-­‐catenin	  protein	  levels	  decrease	  over	  time.	  They	  also	  seem	  to	   be	   reduced	   in	   the	   Ndph	   ko.	   (D)	   However,	   this	   impression	   could	   not	   be	   verified	   for	   p5.	   The	  densitometric	  analysis	  of	  (B)	  suggests	  equal,	  if	  not	  higher	  expression	  of	  β-­‐catenin	  in	  the	  norrin	  ko.	  Because	  norrin	  activates	  canonical	  Wnt-­‐signaling,	  I	  hypothesized	  that	  β-­‐catenin	  protein	  levels	   should	  be	   reduced	   in	  norrin-­‐responsive	   cells	   in	   the	  Ndph	   ko	   retina.	  To	   test	   this	  hypothesis,	  Western	  blots	  with	  retinal	  protein	  extracts	  of	  norrin	  wt	  and	  ko	  mice	  were	  labeled	  with	  an	  antibody	  against	  β-­‐catenin	  (Figure	  77).	  Beta-­‐catenin	  protein	  levels	  were	  strong	  at	  every	  investigated	  developmental	  stage	  (p5-­‐p21).	   No	   differences	   between	   norrin	  wt	   and	   ko	  were	   obvious	   at	   first	   sight,	   but	  when	  normalized	  to	  protein	  levels	  of	  Gapdh,	  β-­‐catenin	  appeared	  to	  be	  slightly	  reduced	  in	  the	  ko	  samples,	  thus	  tending	  to	  support	  the	  hypothesis	  (Figure	  77	  C).	  Since	  the	  Gapdh	  signal	  of	   the	  p5	  wt	   sample	  was	   suspiciously	   low	   in	   the	   first	  WB	  (Figure	  77	  A),	   a	   second	  WB	  with	   several	   norrin	   wt	   and	   ko	   samples	   was	   performed	   (Figure	   77	   B,D).	   Here,	   no	  difference	  in	  β-­‐catenin	  protein	  levels	  was	  observed.	  Due	  to	  normalization	  of	  β-­‐catenin	  to	  Gapdh,	   it	   appears	   as	   if	  β-­‐catenin	   protein	   levels	   decrease	   over	   time.	   This	  would	   imply	  that	  Wnt-­‐signaling	   is	  more	  active	  during	   the	  early	  phases	  of	   retinal	  development,	   and	  declines	  when	  the	  retina	  matures.	  However,	  it	  is	  mainly	  Gapdh	  expression	  that	  increases	  over	   time	   (Figure	   77	  A),	  making	   it	   difficult	   to	   estimate	   the	   actual	   protein	   levels	   of	  β-­‐catenin.	  	  
3.4.1.2	  Bone	  morphogenetic	  protein	  4	  (Bmp4)	  
Bmp4,	  a	  transforming	  growth	  factor-­‐β	   family	  member,	  was	  shown	  to	  be	  overexpressed	  in	   human	   colon	   cancer	   cells	   in	   response	   to	   oncogene-­‐activated	   β-­‐catenin	   expression.	  (Kim	  et	  al.,	  2002)	  Thus,	  this	  study	  provided	  evidence	  for	  regulatory	  interaction	  of	  WNT	  and	  TGF-­‐β	  signaling	  pathways.	  Since	  norrin	  has	  been	  described	  as	  a	  growth	  factor	  with	  high	  homology	  to	  TGF-­‐β	  (Meitinger	  et	  al.,	  1993),	  and	  further	  has	  been	  shown	  to	  activate	  canonical	   Wnt-­‐signaling	   (Xu	   and	   Wang	   et	   al.,	   2004),	   we	   chose	   to	   investigate	   Bmp4	  expression	  in	  Ndph	  knockout	  mice.	  Expression	   of	   Bmp4	   was	   more	   than	   four-­‐fold	   elevated	   in	   the	   p5	   ko	   retina,	   and	   was	  reduced	  two-­‐fold	  at	  p15	  (Figure	  78	  A).	  Although	  differences	  were	  not	  significant	  at	  p10	  and	  p21,	  the	  data	  indicated	  two	  disease	  phases:	  An	  early	  phase	  (including	  p5	  and	  p10),	  when	   expression	   of	  Bmp4	   is	   increased,	   and	   a	   late	   phase	   (consisting	   of	   p15	   and	   p21),	  when	   Bmp4	   expression	   is	   reduced.	   This	   observation	   is	   consistent	   with	   the	   disease	  phases	  proposed	  by	  Luhmann	  et	  al.	  (Luhmann	  et	  al.,	  2005a).	  	  
3.4.1.3	  Lymphoid	  enhancer	  binding	  factor	  1	  (Lef1)	  Lymphoid	  enhancer	  binding	   factor	  1	   (Lef1)	  has	  been	  shown	  to	  drive	   the	  expression	  of	  Wnt/β-­‐catenin	   target	   genes,	   while	   its	   own	   expression	   is	   negatively	   regulated	   by	  canonical	  Wnt-­‐signaling,	  providing	  a	  negative	  feedback	  loop	  (Hovanes	  et	  al.,	  2001).	  Transcript	  levels	  of	  Lef1	  were	  significantly	  reduced	  in	  the	  retina	  of	  p15	  Ndph	  ko	  mice	  by	  factor	  1.8	  (Figure	  78	  B).	  Expression	  differences	  were	  not	  statistically	  significant	  at	   the	  other	  investiated	  stages,	  but	  the	  same	  trend	  observed	  for	  Bmp4	  was	  also	  noted	  for	  Lef1:	  Higher	  expression	  in	  the	  ko	  at	  p5	  and	  p10,	  and	  lower	  expression	  at	  p15	  and	  p21.	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3.4.1.4	  Transcription	  factor	  3	  (Tcf3/Tcf7l1)	  Transcription	   factor	   3	   (Tcf3/Tcf7l1)	   forms	   a	   complex	   with	   β-­‐catenin	   upon	   Wnt-­‐stimulation	   and	   mediates	   signaling	   through	   binding	   to	   canonical	   Tcf	   DNA	   motifs	   of	  target	  genes.	  (Korinek	  et	  al.,	  1998)	  In	   the	   Ndph	   ko	   retina,	   expression	   of	   Tcf3	   did	   not	   show	   significant	   differences	   at	   all	  investigated	  time	  points	  (Figure	  78	  C).	  	  
3.4.1.5	  Transcription	  factor	  7-­‐like	  2	  (Tcf7l2/Tcf4)	  Transcription	  factor	  7-­‐like	  2	  (Tcf7l2/Tcf4)	  is	  another	  member	  of	  the	  Tcf	  family	  that	  can	  act	  as	  repressor	  of	  Wnt-­‐target	  genes	  in	  the	  absence	  of	  β-­‐catenin,	  and	  as	  activator	  in	  its	  presence.	  (reviewed	  by	  Brantjes	  et	  al.,	  2002)	  Like	  Tcf3,	  Tcf7l2	  mRNA	   levels	  were	  not	   significantly	  different	   in	   the	  norrin	  ko	   retinas	  (Figure	  78	  D).	  	  
  
A Bmp4 expression B Lef1 expression 
  
C Tcf3 expression D Tcf7l2 expression 
Figure	  78	  Transcriptional	  analysis	  of	  Wnt-­‐target	  genes	  in	  retinae	  of	  Ndphy/-­	  knockout	  (n=5;	  red)	  and	  wild	  type	   (n=5;	   green)	   mice.	   Postnatal	   time	   points	   p5,	   p10,	   p15,	   and	   p21	   were	   investigated.	   The	   average	  expression	   value	   of	   each	  wild	   type	   group	  was	   set	   to	   1.	   Error	   bars	   indicate	   the	   confidence	   interval	   at	   a	  significance	   level	   of	   95%	   (p<0.05).	  Gapdh	  was	   used	   as	   endogenous	   control.	   (A)	  Bmp4	   transcript	   levels	  were	  significantly	  higher	   in	  the	  Ndph	  knockout	  at	  p5	  (4.5x)	  and	  significantly	   lower	  at	  p15	  (2.2x).	  At	  p5,	  one	  wt	  and	  one	  ko	  sample	  were	  determined	  as	  outliers	  and	  removed	  from	  the	  statistical	  analysis	  (wt:	  n=4;	  ko:	  n=4).	  (B)	  Lef1	  expression	  was	  decreased	  significantly	  at	  p15	  (1.8x).	  As	  has	  been	  observed	   for	  Bmp4	  (A),	  there	  appears	  to	  be	  a	  trend	  of	  higher	  transcripts	  in	  the	  ko	  at	  p5	  and	  p10,	  and	  lower	  transcripts	  at	  p15	  and	   p21	   (yet	   statistically	   not	   significant).	   (C)	   Expression	   of	  Tcf3	   was	   not	   different	   in	  Ndph	   wt	   and	   ko	  samples	   at	   all	   4	   time	   points.	   (D)	   The	   same	   applies	   to	   Tcf7l2,	   were	   no	   significant	   alterations	   could	   be	  observed.	  
RESULTS	   159	  	  
	  
3.4.2	  Expression	  of	  SLC38A5	  in	  HEK	  cells	  in	  response	  to	  canonical	  Wnt-­‐signaling	  	  Canonical	  Wnt-­‐signaling	  in	  vivo	  and	  in	  cell	  culture	  can	  be	  activated	  with	  lithium	  chloride	  (LiCl),	   which	   inhibits	   the	   enzyme	   glycogen	   synthase	   kinase-­‐3β	   (GSK-­‐3β)	   (Klein	   and	  Melton,	   1996;	   Hedgepeth	   et	   al.,	   1997).	   GSK-­‐3β	   phosphorylates	   β-­‐catenin	   in	   the	  cytoplasm,	   targeting	   it	   for	   ubiquitination	   and	   degradation.	   Thus,	   LiCl	   increases	   the	  amount	  of	  β-­‐catenin	  protein	  in	  the	  cytoplasm,	  which	  then	  translocates	  into	  the	  nucleus,	  where	  it	  regulates	  Wnt-­‐signaling-­‐induced	  expression	  of	  target	  genes	  through	  binding	  to	  transcription	  factors.	  Several	   candidate	   genes	   have	   been	   determined	   by	   the	   microarray	   experiment	   and	  subsequent	  qRT-­‐PCRs.	  Since	  Slc38a5	  was	  so	  clearly	  lower	  expressed	  at	  all	   investigated	  time	   points	   and	   norrin	   has	   been	   shown	   to	   activate	   Wnt/β-­‐catenin	   signaling	   in	   cell	  culture	   (Xu	   and	   Wang	   et.	   al,	   2004),	   it	   could	   be	   possible	   that	   Slc38a5	   is	   under	  transcriptional	   control	   of	   canonical	   Wnt-­‐signaling.	   To	   test	   this	   hypothesis,	   human	  embryonic	  kidney	   cells	   (HEK293T)	  were	   treated	  with	   either	  LiCl	   or	  NaCl	   (as	  negative	  control),	  and	  protein	  and	  mRNA	  expression	  of	  SLC38A5	  were	  examined.	  	  
3.4.2.1	  Expression	  of	  β-­‐catenin	  in	  LiCl-­‐treated	  HEK	  cells	  In	   a	   first	   experiment,	   protein	   levels	   of	  β-­‐catenin	  were	   shown	   to	   be	   enhanced	   in	   LiCl-­‐treated	  HEK	  cells,	  confirming	  previous	  observations	  (Figure	  79).	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  A	  
	   	  
B	   C	  
Figure	  79	  Expression	  of	  β-­‐catenin	  is	  enhanced	  in	  LiCl-­‐treated	  HEK293T	  cells.	  (A)	  Western	  blot	  with	  50μg	  HEK	  cell	  pellet	  protein	  extract	  loaded	  in	  each	  lane.	  A	  band	  at	  ~92kDa	  is	  visible	  in	  each	  of	  the	  8	  samples	  (4	  treated	  with	   NaCl,	   4	   treated	  with	   LiCl)	   corresponding	   to	   the	   predicted	   size	   of	   beta-­‐catenin.	   Bands	   are	  stronger	  in	  the	  4	  LiCl-­‐treated	  samples.	  (B,C)	  Densitometric	  quantification	  of	  the	  β-­‐catenin	  Western	  blot.	  Values	  were	  normalized	   to	  GAPD	  expression	  and	  calibrated	   to	   the	  mean	  value	  of	   the	  NaCl-­‐treated	  cells.	  
(B)	   Individual	  densitometric	  values	  of	   the	  eight	  HEK	  samples.	  (C)	  The	  mean	  β-­‐catenin	   level	  of	   the	  LiCl-­‐treated	  cells	  was	  significantly	  higher	  (2.5x)	  than	  that	  of	  the	  control	  samples	  (Student’s	  t-­‐test;	  p<0.05).	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3.4.2.2	  Expression	  of	  SLC38A5	  in	  β-­‐catenin-­‐stabilized	  HEK	  cells	  Expression	   of	   SLC38A5	   mRNA	   was	   generally	   low	   (Ct≅31	   with	   10ng	   cDNA),	   but	  technically	   reproducible	   (Figure	   80	   A).	   It	   was	   varying	   considerably	   between	   the	  separate	   cell	   cultures.	   However,	   no	   significant	   difference	   was	   observed	   between	   the	  LiCl-­‐	  and	  the	  NaCl-­‐treated	  control	  group	  (Figure	  80).	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Figure	   80	   Transcriptional	   analysis	   of	   SLC38A5	   in	   HEK293T	   cells	   treated	  with	  NaCl	   (n=4;	  blue)	   or	   LiCl	  (n=4;	  orange).	  The	  average	  expression	  value	  of	   the	  NaCl-­‐treated	  group	  was	  set	   to	  1.	  Error	  bars	   indicate	  the	   confidence	   interval	   at	   a	   significance	   level	   of	   95%	   (p<0.05).	   (A)	  Quantitative	   RT-­‐PCR	   results	   of	   the	  individual	  HEK	  cell	  culture	  samples.	  (B)	  Mean	  values	  of	  the	  NaCl-­‐	  and	  LiCl-­‐treated	  cells.	  Expression	  varied	  significantly	  between	  the	   individual	  samples,	  but	  no	  significant	  difference	  was	   found	  between	  the	  NaCl-­‐	  and	  the	  LiCl-­‐treated	  group.	  POL2RA	  was	  used	  as	  endogenous	  control.	  	  The	   picture	   was	   a	   little	   bit	   different	   on	   the	   protein	   level.	   A	   Western	   blot	   from	   HEK	  cultures	  stained	  with	  a	  rat-­‐antibody	  against	  Slc38a5	  revealed	  two	  distinct	  bands:	  one	  at	  the	  predicted	  molecular	  weight	  around	  50kDa,	  and	  a	  band	  around	  200kDa,	  which	  may	  resemble	   a	   tetramer	   of	   the	   protein	   (Figure	   81	  A).	   Expression	   of	   the	   50kDa	   band	  was	  similar	  at	   first	   glance,	   and	   indicated	  a	   slight	   reduction	  of	  Slc38a5	   (50kDa)	   in	   the	  LiCl-­‐treated	  samples	  only	  when	  analyzed	  by	  densitometry	  (down	  to	  an	  average	  of	  0.8	  of	  the	  control	  group;	  Figure	  81	  B,	  C).	  	  The	   tetrameric	   band	   appeared	   to	   be	   drastically	   reduced	   in	   3	   out	   of	   4	   LiCl-­‐treated	  samples	   (Figure	   81	   D).	   However,	   the	   fourth	   sample	   turned	   out	   to	   express	   Slc38a5	  (200kDa)	  the	  most,	  more	  than	  every	  control	  sample	  (this	  resulted	  in	  a	  mean	  reduction	  to	  0.6	  of	  the	  NaCl	  control	  group,	  or	  0.36	  when	  sample	  LiCl	  was	  excluded;	  Figure	  81	  E).	  	  
3.4.2.3	  Synopsis	  Taken	   together,	   Slc38a5	   expression	   was	   not	   significantly	   altered	   in	   response	   to	   LiCl	  treatment	   /	   canonical	   Wnt-­‐signaling	   in	   HEK293T	   cells.	   On	   protein	   level,	   a	   slight	  reduction	  in	  the	  LiCl-­‐treated	  samples	  could	  be	  discussed,	  although	  it	  obviously	  does	  not	  fit	   the	  hypothesis	  of	  norrin	  positively	  regulating	  Slc38a5	  expression	  through	  canonical	  Wnt-­‐signaling.	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Figure	  81	  Protein	  expression	  of	  SLC38A5	  appears	   to	  be	  slightly	  reduced	   in	  LiCl-­‐treated	  HEK293T	  cells.	  
(A)	  Western	  blot	  with	  50μg	  HEK	  cell	  pellet	  protein	  extract	  loaded	  in	  each	  lane.	  Two	  prominent	  bands	  at	  ~50kDa	  and	  ~200kDa	  are	  visible	  that	  correspond	  to	  the	  expected	  mono-­‐	  and	  tetramer.	  Bands	  at	  ~50kDa	  seem	   to	   be	   comparable	   between	   NaCl	   and	   LiCl	   treated	   samples,	   while	   bands	   at	   ~200kDa	   seem	   to	   be	  weaker	   in	   the	   LiCl-­‐treated	   samples.	   (B-­E)	   Densitometric	   quantification	   of	   the	   SLC38A5	   Western	   blot.	  Values	  have	  been	  normalized	  to	  GAPD	  expression	  and	  calibrated	  on	  the	  NaCl	  mean.	  Values	  for	  LiCl4	  were	  excluded	  from	  the	  average.	  (B)	  Individual	  densitometric	  values	  for	  the	  50kDa	  band.	  (C)	  The	  mean	  protein	  levels	  for	  the	  50kDa	  tetramer	  band	  are	  similar	  in	  NaCl-­‐	  and	  LiCl-­‐treated	  cells.	  (D)	  Individual	  densitometric	  values	   for	   the	   200kDa	   band.	   The	   control	   protein	   levels	   are	   higher,	   with	   the	   exception	   of	   LiCl1,	   which	  showed	   the	   strongest	   signal.	  (E)	  The	  mean	  protein	   level	   for	   the	  200kDa	  monomer	   is	   lower	   in	   the	  LiCl-­‐treated	  cells	  (1.6x;	  2.8x	  without	  sample	  LiCl1).	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3.4.3	  Examination	  of	  the	  Wnt/β-­‐catenin	  pathway	  in	  vivo	  	  It	   has	   been	   shown	   in	   cell	   culture	   (Xu	   and	  Wang	   et	   al.,	   2004)	   that	  Norrin	   can	   activate	  transcription	   via	   the	   Wnt/β-­‐catenin	   signaling	   pathway.	   To	   study	   the	   activity	   of	   this	  pathway	  under	  the	  suggested	  control	  of	  Norrin	  in	  vivo	  through	  identification	  of	  Norrin-­‐responding	   cells	   in	   the	   retina	   and	   other	   tissues,	   I	   (with	   the	   generous	   help	   of	   Ulrich	  Luhmann)	   obtained	   a	   Wnt-­‐signaling	   reporter	   mouse,	   the	   so-­‐called	   BATgal	   reporter,	  from	  Dr.	   Stefano	   Piccolo,	   Padova,	   Italy.	   Although	   this	   reporter	  was	   not	   used	   to	   study	  Wnt-­‐signaling	  in	  the	  retina,	  it	  was	  successfully	  used	  to	  analayze	  it	  in	  the	  brain	  (Maretto	  et	   al.,	   2003).	   The	   Norrie	   Disease	   mouse	   line	   was	   crossed	   with	   this	   reporter	   mouse	  (NDxBATgal),	   which	   expresses	   the	   bacterial	   lacZ	   gene	   under	   the	   control	   of	   Wnt/β-­‐catenin	   signaling.	   Litters	   of	   mice	   aged	   p5,	   p7,	   p10,	   p15,	   p21,	   and	   also	   adult,	   were	  prepared	  and	  eyes	  and	  brains	  were	  collected.	  Because	   these	  animals	  were	  hold	  under	  quarantine	  conditions,	  which	  is	  rather	  expensive,	  it	  was	  decided	  to	  re-­‐establish	  the	  line	  from	  SPF-­‐conditions	  in	  my	  second	  PhD	  year.	  	  
3.4.3.1	  X-­‐Gal	  staining	  of	  the	  NDxBATgal	  retina	  Again,	   litters	   from	   the	   different	   developmental	   stages	   were	   prepared,	   and	   reporter	  activity	  in	  the	  eye	  was	  detected	  by	  X-­‐Gal	  staining,	  showing	  reproducible	  and	  consistent	  labeling	  of	  the	  ciliary	  body	  (Figure	  82).	  	  In	  addition,	  Wnt-­‐signaling	  was	  detected	  in	  cells	  inside	  the	  vitreous	  and	  adjacent	  to	  the	  lens	  in	  Ndph	  wt	  and	  ko	  in	  early	  stages	  (p5:	  Figure	  85;	  p7:	  Figure	  82,	  Figure	  87)	  and	  only	  in	  the	  ko	  in	  later	  stages	  (p21:	  Figure	  88).	  These	  cells	   highly	   likely	   are	   part	   of	   the	   hyaloid	   vasculature	   and	   the	   tunica	   vasculosa	   lentis,	  which	   are	   transient	   vessel	   networks	   during	   ocular	   development	   and	   nourish	   the	  evolving	   lens.	   In	   the	   wt,	   these	   vessels	   regress	   after	   p10,	   but	   it	   has	   been	   shown	   that	  regression	   of	   these	   systems	   is	   delayed	   in	   the	   Ndph	   ko	   (Richter	   et	   al.,	   1998).	   Further,	  hyaloid	  regression	  was	  shown	  to	  be	  Wnt-­‐signaling	  dependent,	  and	   is	   impaired	   in	  Lrp5	  ko	  mice	  (Lobov	  et	  al.,	  2005).	  Thus,	  X-­‐Gal	  positive	  cells	  could	  be	  expected	  in	  the	  hyaloid	  vasculature,	  and	  notably,	  although	  regression	  is	  impaired	  in	  the	  Ndph	  ko,	  Wnt-­‐signaling	  is	  active	  in	  this	  system.	  	  However,	   staining	   of	   the	   retina,	   i.e.	   in	   the	   retinal	   ganglion	   cell	   or	   inner	   nuclear	   layer,	  only	  appeared	  occasionally	  (Figure	  84;	  Figure	  86;	  Figure	  87;	  Figure	  88),	  contrary	  to	  my	  expectations	   due	   to	   published	   data	   of	   a	   similar	   reporter	   mouse	   (Liu	   et	   al.,	   2006).	  Further,	   staining	   was	   not	   Norrin	   genotype-­‐specific.	   Sometimes	   delineation	   of	   X-­‐Gal	  positive	  cells	  in	  the	  ganglion	  cell	  layer	  or	  the	  vitreous	  was	  not	  clear	  without	  ambiguity:	  
LacZ	  staining	  highly	  likely	  located	  to	  blood	  vessels	  in	  the	  section	  with	  the	  most	  abundant	  X-­‐Gal	   labeling	   I	   produced	   during	  my	   thesis,	   although	   at	   first	   glance	   it	   appeared	   to	   be	  located	  inside	  the	  ganglion	  cell	  layer	  (Figure	  85).These	  co-­‐localization	  experiments	  were	  performed	   with	   an	   antibody	   against	   collagen	   IV,	   an	   extracellular	   matrix	   protein	   of	  endothelial	  cells.	  Co-­‐localization	  of	  X-­‐Gal	  staining	  and	  collagen	  IV	  immunoreactivity	  was	  also	  observed	  in	  the	  outer	  plexiform	  layer	  of	  a	  p21	  Ndph	  wt	  (Figure	  86).	  However,	  the	  already	   cited	   study	   that	   revealed	  Wnt/β-­‐catenin	   activity	   in	   the	   retina	   located	   it	   to	   a	  subset	   of	   retinal	   ganglion	   cells,	   amacrine	   cells	   and	   the	   ciliary	   margin	   (and	   thereby	  probably	  neural	  progenitor	  cells),	  but	  not	  to	  the	  vasculature	  (Liu	  et	  al.	  2006).	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Figure	  82	  Central	  ocular	  sections	  of	  p7	  Ndph	  wt	  and	  ko	  Wnt-­‐reporter	  mice.	  Activity	  of	  the	  reporter	  LacZ	  gene	  was	  detected	  with	  X-­‐Gal	  staining.	  (A,	  B)	  Wnt-­‐signaling	  was	  detected	  in	  cells	  located	  in	  the	  vitreous	  (arrows),	  the	  cornea,	  and	  very	  strongly	  inside	  the	  ciliary	  body	  (CB).	  It	  was	  also	  found	  in	  cells	  adjacent	  to	  the	  lens,	  especially	  in	  the	  ko	  (arrowheads).	  (C,	  D)	  The	  blue	  staining	  was	  masked	  in	  some	  sections	  because	  of	  the	  pigmentation	  of	  the	  ciliary	  body,	  but	  could	  be	  seen	  always	  at	  higher	  magnifications.	  CB:	  ciliary	  body;	  
R:	  retina	  	  
3.4.3.2	  X-­‐Gal	  staining	  of	  NDxBATgal	  brain	  tissue	  In	   an	   effort	   to	   better	   visualize	   reporter	   gene	   expression,	   I	   tried	   different	   protocols	  (fixation	   type	   and	   time;	   post-­‐fixation;	   cryoprotection)	   without	   avail	   and	   also	  alternatively	   detection	   with	   a	   beta-­‐galactosidase	   antibody.	   Unfortunately,	   signals	   in	  immunostained	   cryosections	   were	   only	   unspecific.	   I	   therefore	   decided	   to	   re-­‐establish	  the	  X-­‐gal	  staining	  procedure	  on	  brain	  tissue,	  because	  Wnt-­‐activity	   in	  the	  brain	  is	  more	  widespread.	  And	   indeed,	  LacZ	   activity	  was	  reproducibly	  detected	  with	  X-­‐gal	  detection.	  Brain	   sections	   from	   different	   postnatal	   stages	   were	   prepared	   and	   wild	   type	   and	  knockout	   littermates	  were	   compared	   (Figure	  83).	  Expression	   intensity	  of	   the	   reporter	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Figure	   83	   Brain	   cryosections	   (8μm)	   showing	   the	   cerebellar	   region	   of	   Norrin	   wild	   type	   and	   knockout	  littermates	   of	   different	   developmental	   stages	   (p5,	   p7,	   p10,	   p15,	   p21).	   All	   sections	   were	   cut	   sagittally,	  except	  for	  p21,	  which	  was	  cut	  horizontally.	  Sections	  were	  stained	  with	  X-­‐Gal	  to	  visualize	  the	  Wnt-­‐signaling	  
Age	   Ndph	  wild	  type	   Ndph	  knockout	   RQ	  LacZ	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reporter.	  Staining	  was	  most	  prominent	  at	  the	  border	  between	  molecular	  and	  granular	  layer,	  presumably	  in	   Purkinje	   cells,	   although	   cells	   located	   in	   the	   granular	   layer	   and	   white	   matter	   were	   also	   frequently	  labeled.	   Almost	   no	   staining	   has	   been	   observed	   in	   the	  molecular	   layer.	   Differences	   in	   staining	   intensity	  correlated	  with	  relative	  genomic	  abundance	  of	  the	  reporter	  gene,	  but	  not	  with	  the	  Ndph	  genotype.	  For	  this	  purpose,	  Ct-­‐values	  of	  the	  LacZ	  amplicons	  were	  calculated	  relative	  to	  the	  copy	  number	  of	  the	  3rd	  exon	  of	  the	  
Ndph	  gene,	  which	  only	   is	  present	  once	   in	  each	  male	  genome	  (in	  wt	  and	   in	  ko).	  The	  copy	  number	  of	   the	  reporter	   gene	   allele	   in	   the	  Ndph	   wt	   was	   set	   to	   1.	   The	   yellow	   area	   indicates	   the	   technical	   confidence	  interval	  of	   the	  qRT-­‐PCR	  system	  of	  1	   ct.	  M:	  Molecular	   layer,	  G:	  Granular	   layer,	  P:	  Purkinje	   cells,	  W:	  White	  
matter	  	  varied:	  In	  one	  case	  (p5)	  it	  was	  higher	  in	  the	  knockout,	   in	  other	  cases	  (p10,	  p15)	  in	  the	  wild	  type,	  and	  similar	  in	  other	  investigated	  stages	  (p7,	  p21).	  This	  led	  me	  to	  question	  the	  validity	  of	  this	  experimental	  approach.	  If	  the	  hypothesis	  of	  norrin	   regulating	   canonical	  Wnt-­‐signaling	  was	   valid,	   I	  would	   expect	   genotype-­‐specific	  differences	   of	   reporter	   activity.	   Since	   the	   used	  mice	  were	   from	   an	  F2	   generation,	   and	  under	   the	   assumption	   that	   the	   transgene	   integrated	   just	   once	   into	   the	   genome,	   there	  was	  a	  25%	  possibility	  that	  they	  received	  the	  transgene	  from	  both	  parents.	  Hence,	  it	  was	  possible	  that	  the	  observed	  expression	  differences	  are	  due	  to	  different	  copy	  numbers	  of	  the	   reporter-­‐gene	   in	   the	  different	   animals,	   and	  not	   due	   to	   the	  presence	   or	   absence	   of	  norrin.	   To	   address	   this	   question,	   a	   qRT-­‐PCR	   assay	   was	   established	   to	   measure	   the	  relative	   quantity	   of	   LacZ.	   Indeed,	   the	   observed	   expression	   differences	   could	   be	  correlated	  with	  the	  relative	  amount	  of	  transgene	  copies	  (Figure	  83).	  	  
3.4.3.3	  X-­‐Gal	  staining	  of	  the	  NDxBATgal	  retina	  (revised)	  Follwing	  that	  experiment,	  X-­‐Gal	  staining	  of	  ocular	  cryosections	  was	  repeated	  with	  eyes	  from	   animals	   with	   comparable	   allele	   frequencies	   to	   ensure	   equal	   detection	   of	   Wnt-­‐signaling.	   In	   addition,	   thicker	   sections	   were	   cut	   (30µm	   instead	   of	   8µm)	   to	   maximize	  detetion	  of	  LacZ	  positive	  cells.	  The	  examined	  p7	  (Figure	  87)	  and	  p21	  (Figure	  88)	  eyes	  were	  from	  the	  same	  animals	  as	  the	  brains	  displayed	  in	  Figure	  83.	  In	  the	  p7	  sections,	  X-­‐Gal	   positive	   cells	  were	   detected	   in	   the	   optic	   nerve,	   in	   cells	   inside	   the	   vitreous,	   and	   in	  cells	   attached	   to	   the	   posterior	   border	   of	   the	   lens	   (Figure	   87).	   The	   latter	   two	   most	  probably	  again	  were	  cells	  of	  the	  transient	  hyaloid	  vasculature.	  No	  significant	  differences	  between	   the	   genotypes	  were	   observed.	   Peripheral	   sections	   of	   the	   same	   eyes	   revealed	  numerous	   cells	   inside	   the	   anterior	   vitreous,	   close	   to	   the	   ciliary	   body,	   which	   likely	  represent	  cells	  of	  the	  hyloidea	  as	  well.	  In	  the	  wild	  type,	  one	  single	  blue	  cell	  was	  observed	  in	  the	  ganglion	  cell	   layer.	  In	  the	  p21	  sections,	  two	  X-­‐Gal	  positive	  cells	  were	  detected	  in	  the	  inner	  nuclear	  layer	  of	  the	  wild	  type,	  which	  otherwise	  lacked	  any	  LacZ	  activity.	  In	  the	  knockout,	  no	  cells	  were	  stained	  inside	  the	  retina.	  Instead,	  Wnt-­‐signaling	  was	  detected	  in	  remainders	  of	  the	  hyaloid	  vasculature.	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Figure	  84	  Retinal	  sections	  from	  p10	  Ndph	  wt	  and	  ko	  Wnt-­‐reporter	  mice.	  Reporter	  activity	  was	  visualized	  with	  X-­‐Gal	  staining	  (A,D),	  and	  blood	  vessels	  were	  labeled	  with	  an	  antibody	  against	  collagen	  IV	  (B,	  E).	  (A-­C)	  In	  the	  Ndph	  wt,	  blood	  vessels	  were	  detected	  in	  all	  3	  retinal	  networks	  (B).	  A	  single	  cell	  in	  the	  ganglion	  cell	  layer	  was	  X-­‐Gal	  positive	  (A;	  arrow)	  that	  did	  not	  co-­‐localize	  with	  blood	  vessels	  (C;	  arrow).	  (D-­E)	  The	  Ndph	  ko	  presented	  only	  with	  a	  dilated	  superficial	  vasculature	  (E).	  X-­‐Gal	  staining	  of	  this	  section	  labeled	  3	  cells	  (D).	  One	  cell	   (arrow)	  situated	   in	   the	  ganglion	  cell	   layer	  did	  not	  co-­‐localize	  with	  blood	  vessels,	  while	   the	  other	   two	   (arrowheads)	   were	   located	   inside	   the	   vasculature	   (F).	   INL:	   inner	   nuclear	   layer;	   IPL:	   inner	  
plexiform	  layer;	  ONL:	  outer	  plexiform	  layer;	  OPL:	  outer	  plexiform	  layer;	  RGC:	  retinal	  ganglion	  cell	  layer	  	  
	  
Figure	  85	  Retinal	  section	   from	  a	  p5	  Ndph	  ko	  Wnt-­‐reporter	  mouse.	  (A)	  This	  section	   is	   the	  one	  with	   the	  most	  abundant	  X-­‐Gal	  staining	   I	  was	  able	   to	  produce	  during	  my	  experiments.	  At	   first	  glance,	   it	  appeared	  that	  the	  string-­‐of-­‐pearls	  like	  stained	  cells	  (dark	  blue)	  are	  located	  inside	  the	  retinal	  ganglion	  cell	  layer.	  (B)	  Co-­‐localization	  with	  cells	  immunoreactive	  for	  collagen	  IV	  (red)	  suggested	  that	  these	  Wnt-­‐signaling	  active	  cells	  are	  part	  of	  the	  vasculature.	  From	  this	  section,	   it	   is	  nearly	   impossible	  to	  decide	  whether	  the	  vessels	  are	  part	  of	  the	  superficial	  retinal	  network	  or	  of	  the	  hyaloid	  vasculature,	  because	  the	  lens	  is	  located	  directly	  adjacent	  to	  the	  retina.	  This	  could	  be	  a	  result	  of	  the	  cryoprotection	  procedure,	  which	  likely	  has	  drained	  H2O	  from	  the	  vitreous.	  However,	  the	  superficial	  vasculature	  at	  p5	  is	  still	  developing	  and	  is	  not	  present	  in	  the	  retinal	  periphery.	  Thus,	  vessels	  adjacent	  to	  the	  retina	  in	  this	  area	  are	  likely	  of	  hyaloid	  origin	  (see	  right	  side	  of	  the	  picture,	  near	  the	  ciliary	  body).	  CB:	  ciliary	  body;	  INL:	  inner	  nuclear	  layer;	  IPL:	  inner	  plexiform	  layer	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Figure	  86	  Retinal	  section	  from	  a	  p21	  Ndph	  wt	  Wnt-­‐reporter	  mouse.	  (A)	  Two	  cells	  inside	  the	  retina	  were	  
LacZ	  positive.	  (B)	   Immunostaining	  with	  collagen	  IV	   labeled	  all	  3	  retinal	  vessel	  systems.	  (C)	  The	  overlay	  picture	  revealed	  co-­‐staining	  of	  the	  two	  Wnt-­‐signaling	  active	  cells	  with	  vessels	  of	  the	  deep	  network,	  located	  at	  the	  border	  of	  the	  inner	  nuclear	  and	  outer	  plexiform	  layers.	  INL:	  inner	  nuclear	  layer;	  IPL:	  inner	  plexiform	  





Figure	  87	  Ocular	  cryosections	  (30µm)	  of	  p7	  Ndph	  wt	  and	  ko	  Wnt-­‐reporter	  mice	  were	  treated	  with	  X-­‐Gal	  to	  detect	  activity	  of	  Wnt-­‐signaling.	  No	  significant	  differences	  between	  the	  genotypes	  were	  observed.	  (A)	  Central	  section	  through	  an	  Ndph	  wt	  eye.	  X-­‐Gal	  positive	  cells	  (blue)	  were	  detected	  in	  the	  optic	  nerve	  (ON),	  in	  cells	  inside	  the	  vitreous	  (arrow),	  and	  in	  cells	  attached	  to	  the	  posterior	  border	  of	  the	  lens	  (arrowheads).	  
(B)	  Central	  section	  through	  an	  Ndph	  ko	  eye.	  Similar	   to	   the	  wt	  staining	  (A),	  blue	  cells	  were	   found	   in	   the	  vitreous	   (arrow;	   attached	   to	   the	   optic	   nerve)	   and	   adjacent	   to	   the	   lens	   (arrowheads).	   In	   addition,	   X-­‐Gal	  positive	  cells	  were	  observed	  in	  the	  cornea.	  (C)	  Peripheral	  wt	  section	  of	  the	  same	  eye	  as	  in	  (A).	  Numerous	  cells	  inside	  the	  anterior	  vitreous	  were	  labeled,	  close	  to	  the	  ciliary	  body	  (arrows).	  In	  the	  retina,	  one	  single	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blue	  blue	  cell	  was	  observed	  in	  the	  ganglion	  cell	  layer	  (hollow	  arrow).	  (D)	  Peripheral	  ko	  section	  of	  the	  eye	  presented	  in	  (B).	  As	  in	  the	  wt,	  numerous	  cells	  in	  the	  anterior	  part	  of	  the	  vitreous,	  close	  to	  the	  ciliary	  body,	  were	  labeled	  (arrows).	  No	  staining	  was	  observed	  in	  the	  retina.	  CB:	  ciliary	  body;	  ON:	  optic	  nerve	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Figure	  88	  Ocular	  cryosections	  (30µm)	  of	  p21	  Ndph	  wt	  and	  ko	  Wnt-­‐reporter	  mice	  were	  treated	  with	  X-­‐Gal	  to	  detect	  activity	  of	  Wnt-­‐signaling.	  (A)	  Central	  section	  through	  an	  Ndph	  wt	  eye.	  X-­‐Gal	  positive	  cells	  (blue)	  were	  detected	  in	  the	  optic	  nerve,	  the	  cornea,	  and	  inside	  the	  retina,	  at	  the	  borders	  of	  the	  inner	  nuclear	  to	  the	  inner	  and	  outer	  plexiform	  layers	  (hollow	  arrows).	  No	  cells	  were	  labeled	  inside	  the	  vitreous	  or	  adjacent	  to	   the	   lens.	   (B)	   Central	   section	   through	   an	  Ndph	   ko	   eye.	   Stained	   cells	   were	   found	   in	   the	   cornea,	   the	  vitreous	   (arrow),	   and	   adjacent	   to	   the	   lens	   (arrowheads).	   No	   X-­‐Gal	   positive	   cells	  were	   found	   inside	   the	  retina.	  CB:	  ciliary	  body;	  ON:	  optic	  nerve	  	  
3.4.3.4	  Synopsis	  After	   all,	   detection	   of	   retinal	   Wnt-­‐signaling	   activity	   was	   not	   successful.	   Since	   X-­‐Gal	  staining	  did	  work	  in	  other	  parts	  of	  the	  eye	  and	  also	  in	  the	  brain,	  the	  results	  suggest	  that	  my	   experimental	   procedures	   were	   suited	   to	   detect	   LacZ	   activity,	   but	   that	   the	   used	  reporter	  mouse	  may	  not	   allow	   investigation	  of	  Wnt-­‐signaling	   in	   the	   retina.	  This	   could	  not	  be	  expected,	  because	  a	  study	  conducted	  with	  a	  similar	  reporter	  mouse	  did	  work	  well	  (Liu	  et	  al.,	  2006).	  In	  addition,	  the	  use	  of	  this	  reporter	  mouse	  may	  further	  not	  be	  qualified	  for	  quantitative	  investigation	  of	  Wnt-­‐activity,	  since	  X-­‐Gal	  staining	  intensity	  varied	  with	  the	  number	  of	  LacZ	  alleles	  present	  in	  each	  animal.	  This	  necessitates	  the	  establishment	  of	  a	  homozygous	  breed	  or	  the	  quantification	  of	   the	  LacZ	  copy	  number	   in	  every	  animal	   in	  the	  experiment.	  However,	   my	   studies	   led	   to	   some	   qualitative	   results:	   It	   could	   be	   shown	   that	   Wnt-­‐signaling	   was	   active	   in	   the	   remaining	   hyaloid	   vessel	   system	   of	   the	   norrin	   ko	   mouse,	  although	   Wnt-­‐signaling	   usually	   facilitates	   the	   regression	   of	   this	   transient	   structure	  (Lobov	   et	   al.,	   2005).	   Thus,	   X-­‐Gal	   positive	   cells	   could	   be	   expected	   in	   the	   hyaloid	  vasculature	  of	  the	  wild	  type,	  and	  notably,	  impaired	  regression	  in	  the	  Ndph	  ko	  is	  not	  due	  to	  a	  lack	  of	  Wnt-­‐signaling	  in	  this	  system.	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3.5	  Candidate	  gene	  screening	  in	  patients	  	  
3.5.1	  Clinical	  description	  of	  patients	  	  A	  total	  of	  22	  patient	  DNAs	  referred	  to	  our	  diagnostic	  division	  was	  available	  for	  screening	  of	   candidate	  genes	   (Table	  6).	  Clinical	   suspicion	  of	  Norrie	  disease	  was	   stated	  14	   times,	  Coats’	  disease	  6	  times,	  FEVR	  3	  times,	  PHPV	  2	  times,	  and	  retinoblastoma	  was	  suspected	  once.	  For	  some	  patients,	  more	  than	  one	  clinical	  diagnosis	  was	  suggested.	  	  
3.5.2	  NDP	  screening	  	  All	   patients	   mentioned	   above	   were	   screened	   for	   mutations	   in	   the	   Norrie	   disease	  pseudoglioma	   (NDP)	   gene	   in	   our	   diagnostic	   division.	   All	   3	   exons	   were	   sequenced,	  including	  the	  5’-­‐	  and	  3’-­‐UTRs	  (Figure	  89).	  	  
	  
Figure	   89	   The	   NDP	   transcript	   consists	   of	   1,923	   bp	   coding	   a	   133	   aa	   protein.	   The	   gene	   is	   located	   on	  chromosome	   Xp11.3,	   spans	   24.82kb	   and	   is	   organized	   in	   3	   exons,	   2	   of	   them	   coding.	   (Source:	  
www.ensembl.org)	  	  Five	   patients	   (22277,	   23081,	   25775,	   27019,	   and	   27095)	   were	   found	   to	   harbour	  mutations	  in	  NDP	  prior	  to	  this	  study	  (Table	  6).	  Since	  miRNA	  recognition	  site	  mutations	  in	   the	   3’UTR	   have	   been	   discussed	   in	   association	   with	   human	   disease	   (Abelson	   et	   al.,	  2005;	  Clop	  et	  al.,	  2006;	  Sethupathy	  et	  al.,	  2007;	  Jensen	  et	  al.,	  2008),	  and	  the	  diagnostic	  routine	   at	   the	   institute	   did	   not	   include	   sequencing	   of	   the	   1kb	   3’UTR,	   this	   region	  was	  covered	  in	  addition	  for	  all	  patients	  (excluding	  29833).	  However,	  no	  sequence	  alterations	  were	  found.	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3.5.3	  FZD4	  screening	  	  Frizzled	   4	   (FZD4)	   was	   the	   second	   gene	   after	   NDP	   (Chen	   et	   al.,	   1993)	   that	   has	   been	  associated	  with	   FEVR	   (Robitaille	   et	   al.,	   2002).	   In	   contrast	   to	  NDP,	   mutations	   in	   FZD4	  follow	  a	  dominant	  mode	  of	  inheritance.	  After	  the	  discovery	  of	  a	  similar	  ocular	  phenotype	  in	  Ndph	   and	   Fzd4	   ko	  mice,	   it	   has	   been	   been	   shown	   that	   FZD4	   acts	   as	   a	   receptor	   for	  norrin	   (Xu	   and	  Wang	   et	   al.,	   2004).	   This	   common	   involvement	   in	   the	   same	  molecular	  pathway	  could	  explain	  the	  high	  phenotypic	  overlap	  between	  patients	  with	  mutations	  in	  either	  NDP	  or	  FZD4.	  Therefore,	  patients	  diagnosed	  with	  ND	  or	  CD	  who	  were	  negative	   for	  mutations	   in	   the	  
NDP	  gene	  were	  screened	  for	  alterations	  in	  FZD4	  (Figure	  90).	  Exon	  1	  and	  the	  coding	  region	  of	  exon	  2,	  as	  well	  as	   the	   flanking	  parts	  of	   intron	  1	  were	  sequenced	  mainly	  (12	  of	  17	  patients:	  6	  females,	  7	  males,	  4	  of	  unknown	  gender)	  by	  Jurian	  Zürcher	  as	  part	  of	  his	  masterthesis.	  In	   addition,	   two	  miRNAs	   (miR-­‐31	   and	  miR-­‐184)	   that	   target	   the	   5.5kb	   3’UTR	   of	   FZD4	  have	   been	   shown	   to	   inhibit	   neovascularization	   (Shen	   et	   al.,	   2008).	   Since	  mutations	   in	  miRNA	   recognition	   sites	   have	   been	   discussed	   in	   association	   with	   human	   disease	  (Abelson	  et	  al.,	  2005;	  Clop	  et	  al.,	  2006;	  Sethupathy	  et	  al.,	  2007;	  Jensen	  et	  al.,	  2008),	  the	  two	  parts	   of	   the	  FZD4	   3’UTR	  harboring	   the	   recognition	   sites	   for	  miR-­‐31	   and	  miR-­‐184	  were	  also	  sequenced.	  	  
	  
Figure	  90	  FZD4	  is	  a	  2-­‐exon	  gene	  spanning	  9.71kb	  on	  chromosome	  11q14.2.	  It	  holds	  the	  information	  for	  a	  7,382	  bp	  transcript,	  which	  codes	  a	  537	  aa	  protein.	  (Source:	  www.ensembl.org)	  	  Three	  annotated	  sequence	  alterations	  were	  found	  in	  our	  patient	  group:	  A	  c.1614*2G>T	  exchange	  in	  patient	  22439,	  and	  the	  missense	  mutations	  c.97C>T	  (p.P33S)	  and	  c.502C>T	  (p.P168S)	   in	   the	   DNA	   of	   patient	   27118	   (Figure	   91).	   No	   variations	   were	   found	   in	   the	  3’UTR	  including	  the	  recognition	  sites	  for	  miR-­‐31	  and	  miR-­‐184.	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Figure	   91	   Electropherograms	   showing	   the	   3	   heterozygous	   FZD4	   nucleotide	   variations	   found	   in	   the	  patient	  group.	  (A)	  SNP	  rs61749246	  (c.1614*2G>T)	  observed	  in	  patient	  22439.	  (B)	  The	  c.97C>T	  mutation	  causing	  the	  p.P33S	  substitution	  in	  patient	  27118.	  (C)	  The	  c.502C>T	  (p.P168S;	  rs61735303)	  substitution	  in	  patient	  27118.	  (Source:	  Masterthesis	  Jurian	  Zürcher,	  2007)	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The	  nucleotide	  exchange	   in	   the	  3’-­‐UTR	  was	  predicted	  as	   a	   SNP	   (rs61749246)	  with	   an	  estimated	  allele	   frequency	  of	   the	  T	   allele	   of	   2%	   in	  whites	   (Toomes	  et	   al.,	   2004a).	  The	  p.P33S	  substitution	  was	  discussed	  as	  pathogenic	  (CM050619;	  MacDonald	  et	  al.,	  2006),	  while	   the	   p.P168S	   substitution	   (rs61735303)	   was	   described	   as	   a	   rare	   (<0.3%),	   but	  benign	  variant	  (Toomes	  et	  al.,	  2004).	  	  Patient	   27118,	   harboring	   the	   p.P33S	   and	   p.P168S	   variants,	   is	   a	   preterm	   delivery	   to	  opthalmologically	   healthy	   parents.	   She	   was	   born	   with	   a	   gestational	   age	   of	   about	   30	  weeks,	  a	  birth	  weight	  of	  1500g,	  and	  received	  oxygen	  supplementation	  for	  ~6	  hours.	  She	  had	  low	  visual	  acuity	  in	  both	  eyes	  since	  early	  childhood.	  At	  the	  last	  examination,	  she	  had	  no	  light	  perception	  on	  the	  left,	  and	  a	  visual	  acuity	  of	  1/25	  on	  her	  right	  eye.	  The	  left	  eye	  presented	   with	   microcornea	   and	   a	   shallow	   anterior	   chamber.	   An	   ophthalmoscopic	  examination	   performed	   by	   Dr.	   Charlotte	   Poloschek,	   Freiburg,	   Germany,	   revealed	  exudative	  retinal	  detachment	  with	  massive	  lipid	  exudation	  in	  both	  eyes.	  A	  vascularized	  (pseudo-­‐)tumor	  was	  present	  at	   the	  6	  o’clock	  position	   in	   the	  right	  eye,	  which	  has	  been	  removed	   after	   cryotherapy.	   Incontinentia	   pigmentii	   was	   excluded	   by	   dermatologic	  examination,	  and	  the	  examining	  physicians	  excluded	  ROP,	  FEVR,	  and	  ND	  due	  to	  the	  lack	  of	  typical	  temporal	  dragging,	  finally	  diagnosing	  Coats’	  disease.	  Two	  cousins	  had	  retinal	  detachments.	   Unfortunately,	   the	   patient	   and	   her	   family	  were	   not	   available	   for	   further	  examinations	  after	  the	  molecular	  diagnosis.	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3.5.4	  LRP5	  screening	  	  Mutations	   in	   the	   low	  density	   lipoprotein	  receptor-­‐related	  protein	  5	   (LRP5),	   the	  norrin	  co-­‐receptor	   to	  FZD4	  (Xu	  and	  Wang	  et	  al.,	  2004),	  have	  also	  been	  associated	  with	  FEVR	  (Toomes	   et	   al.,	   2004).	   In	   contrast	   to	   FZD4,	   mutations	   in	   LRP5	   are	   mainly	   inherited	  recessively,	   although	  dominant	  mutations	   have	  been	   also	   reported	   (Gong	   et	   al.,	   2001;	  Toomes	   et	   al.,	   2004).	   After	  mutations	   in	  NDP	   and	  FZD4	  have	   been	   excluded,	  Walther	  Hänseler	   performed	   the	   screening	   of	   the	   remaining	   patient	   DNAs	   during	   his	  masterthesis	  under	  my	  supervision.	  All	   23	   exons	   and	   flanking	   intronic	   regions	   of	   the	   only	   known	   transcript	  (ENST00000294304;	   Figure	   92)	   were	   sequenced	   from	   DNAs	   from	   14	   patients	   (5	  females,	  5	  males,	  and	  4	  patients	  with	  unknown	  gender).	  	  
	  
	  
Figure	  92	  The	  LRP5	  gene	  is	  located	  on	  11q13.2	  spanning	  136.63kb.	  The	  5,124	  bp	  transcript	  is	  organized	  in	  23	  exons	  and	  codes	  for	  a	  1,615	  aa	  protein.	  (Source:	  www.ensembl.org)	  
	  Four	  so	  far	  undescribed	  sequence	  variants	  were	  found.	  A	  patient	  diagnosed	  with	  Coats‘	  disease	  (#28786;	  Figure	  93)	  was	  found	  to	  harbor	  a	  p.T672M	  (c.2015C>T;	  Figure	  94	  A)	  amino	  acid	  exchange,	  which	  is	  a	  position	  highly	  conserved	  among	  vertebrates.	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Figure	  93	  Ocular	  presentation	  of	  patient	  28786,	  a	  girl	  diagnosed	  with	  CD.	  (A)	  The	  left	  eye	  was	  marked	  by	  a	   central	   lesion	   surrounded	   by	   exudates	   and	   retinal	   folds	  with	   papillary	   adherence.	   The	   right	   eye	  was	  clinically	  unsuspicious.	  (B)	  Leakage	  of	  fluorescein	  at	  the	  macular	  lesion.	  	  (C,	  D)	  Fundus	  (C)	  and	  fluorescein	  angiography	  (FLA;	  D)	  of	  a	  normal	  eye	  of	  the	  patient’s	  mother.	  (E,	  F)	  Optical	  coherence	  tomography	  (OCT)	  of	   the	   lesion	   in	   the	   patient’s	   left	   eye	   revealed	   an	   enormous	   deformation	   of	   the	   retina	   and	   extended	  subretinal	   exudates.	   The	   green	   line	   in	   the	   funduscopic	   picture	   (E)	   indicates	   the	   plane	   of	   section	   of	   the	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corresponding	   OCT	   presented	   in	   (F).	   (Pictures	   taken	   by	   Dr.	   Charlotte	   Poloschek,	   Department	   of	  Ophthalmology,	  University	  of	  Freiburg,	  Freiburg,	  Germany)	  	  
  
  
Figure	  94	  Electropherograms	  of	  so	  far	  undescribed	  heterozygous	  LRP5	  DNA	  sequence	  variations	  in	  our	  patient	  group.	  (A)	  A	  c.2015C>T	  missense	  mutation	  (p.T672M)	  was	   found	   in	  patient	  28786.	  (B)	  A	  silent	  mutation	   in	   exon	  10,	   c.2178C>T,	  was	   found	   in	  patient	  24536.	   (C)	   The	   intronic	   variation	   c.3427+10C>T	  (intron	  11)	  was	  found	  in	  patient	  27116.	  (D)	  A	  variation	  in	  intron	  17,	  c.3764-­‐30G>A,	  was	  found	  in	  patient	  24536.	  	  (Source:	  Masterthesis	  Hänseler,	  2008)	  	  The	  mutation	  was	   absent	   in	   384	   control	   alleles.	   The	   amino	   acid	   exchange	   lies	   in	   the	  third	   β-­‐propeller	   of	   the	   extracellular	   domain	   of	   LRP5	   in	   the	   binding	   site	   of	   DKK,	   an	  endogenous	  inhibitor	  of	  Wnt-­‐signaling	  (reviewed	  by	  Balemans	  and	  van	  Hul,	  2007).	  The	  mutation	  thus	  could	   imply	  a	   functional	  change	  of	  LRP5	  that	  strengthens	  the	  affinity	  to	  DKK,	  thereby	  explaining	  an	  NDP-­‐related	  phenotype.	  Pathogenicity	  was	  analyzed	  in	  silico	  with	   the	   prediction	   programs	   SIFT	   (http://blocks.fhcrc.org/sift/SIFT.html)	   and	  PolyPhen	  (http://coot.embl.de/PolyPhen).	  SIFT	  predicted	  the	  amino	  acid	  exchange	  to	  be	  marginally	   tolerable,	   while	   PolyPhen	   predicted	   the	   p.T672M	  mutation	   to	   be	   possibly	  damaging	  (Masterthesis	  Hänseler,	  2008).	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However,	   the	  mutation	  was	   also	   found	   to	   be	   heterozygous	   in	   the	   patient’s	   unaffected	  mother	  as	  well	  as	  her	  two	  so	  far	  unaffected	  younger	  siblings	  (Figure	  95).	  This	  would	  be	  consistent	   with	   the	   expected	   recessive	   mode	   of	   inheritance.	   Due	   to	   the	   lack	   of	   a	  homozygous	   mutation	   in	   the	   patient,	   the	   clinical	   picture	   could	   be	   explained	   with	   a	  second,	  somatic	  mutation	  only	  in	  the	  affected	  eye,	  similar	  to	  the	  NDP	  mutation	  described	  by	  Black	  et	  al.,	  1999.	   	  
	  	  
Figure	   95	   Pedigree	   of	   the	   CD	   patient	   28786,	   showing	   the	   electropherograms	   for	   the	   newly	   identified	  c.2015C>T	  (p.T672M)	  mutation.	  The	  variation	  is	  heterozygous	  in	  the	  patient,	  but	  as	  well	  in	  her	  unaffected	  mother	  and	  her	  two	  siblings.	  (Source:	  Masterthesis	  Hänseler,	  2008)	  	  The	   three	  other	  variations	  are	  all	   silent	   (Figure	  94	  B-­‐D).	  Only	  one	   is	  exonic,	   the	  other	  two	   lie	   in	   intronic	   regions.	  Effects	  on	  common	  splice	  sites	  could	  be	  excluded.	  Variants	  c.2178C>T	  and	  c.3427+10C>T	  were	  not	  found	  in	  384	  control	  alleles,	  c.3764-­‐30G>A	  was	  found	  in	  3	  alleles.	  (Masterthesis	  Hänseler,	  2008)	  The	  exonic	  mutation	  (c.2178C>T;	  Figure	  94	  B)	  was	  checked	  in-­silico	  for	  effects	  on	  exonic	  splice	   enhancers/silencers	   with	   the	   programs	   ESEfinder	   (http://rulai.cshl.edu/cgi-­‐bin/tools/ESE3/esefinder.cgi?process=home),	   PESXs	   (http://cubweb.biology.	  columbia.edu/pesx/),	   and	   ESRsearch	   (http://ast.bioinfo.tau.ac.il/ESR.htm).	   ESRsearch	  could	  localize	  four	  splicing	  regulatory	  motifs	  involving	  the	  C	  allele	  that	  do	  not	  recognize	  the	   T	   allele,	   but	   also	   two	   binding	   sequences	   that	   are	   present	   only	   with	   the	   T	   allele	  (Figure	  96).	  	  	  
	  
Figure	  96	  Results	   from	  the	  ESRsearch	  analysis	   for	  exonic	  splice	  regulatory	  elements	   (ESR).	  The	  c.2178	  position	   is	   framed	  and	   the	   respective	   allele	   is	   highlighted	   in	   green.	  When	   the	   c.2178C	  allele	   is	   present,	  four	  putative	  ESR	  were	  predicted	  to	  bind,	  while	  those	  four	  would	  not	  recognize	  the	  c.2178T	  allele.	  Instead,	  two	   other	   putative	   ESR	   were	   predicted	   to	   recognize	   the	   c.2178T	   allele.	   (modified	   after	   data	   from	  
http://ast.bioinfo.tau.ac.il/ESR.htm)	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In	   addition,	   eleven	   known	   single	   nucleotide	   polymorphisms	   (SNPs)	   were	   found	  (Masterthesis	   Hänseler,	   2008).	   One	   of	   them	   presented	   with	   a	   significant	   differential	  allele	   frequency	   in	   our	   patient	   group	   in	   comparison	   to	   the	   frequency	   found	   in	   the	  HAPMAP	   database	   (rs4988320;	   Table	   42),	   suggesting	   it	   as	   risk-­‐factor	   for	   the	  development	   of	   an	   FEVR-­‐like	   phenotype.	   However,	   this	   conclusion	   has	   to	   be	   treated	  with	  care,	  because	  the	  occurrence	  of	  the	  homozygous	  risk	  allele	  would	  be	  several	  orders	  of	   magnitude	   higher	   than	   the	   occurrence	   of	   the	   disease.	   Nonetheless,	   the	   SNP	   could	  modify	   other	   genetic	   or	   environmental	   factors	   (e.g.	   premature	   birth)	   that	   have	   an	  influence	  on	  the	  severity	  of	  the	  disease.	  	  
Allele frequency of the LRP5 SNP 
Exon SNP Base substitution Database patients Odds ratio Lower limit Upper limit 
Ex7 rs4988320 c.1413-50G>A 0.96 0.82 5.33 1.33 21.41 
	  
Table	   42	   Allele	   frequency	   for	   LRP5	   SNP	   rs4988320.	   Frequencies	   are	   given	   for	   the	   ancestral	   allele.	  Frequency	  data	   for	  rs4988320	  originates	   from	  the	  CSHL-­‐HAPMAP-­‐CEU	  cohort	  (102	  alleles).	  Our	  patient	  group	  consisted	  of	  28	  alleles.	  Data	  was	  retrieved	  from	  www.ncbi.nlm.nih.gov.	  Odds	  ratios	  were	  calculated	  with	   a	   web-­‐based	   tool	   (http://faculty.vassar.edu/lowry/odds2x2.html).	   (data	   taken	   from:	  Masterthesis	  Hänseler,	  2008) 	  	  
3.5.5	  LRP5L	  screening	  	  Low	   density	   lipoprotein	   receptor-­‐related	   protein	   5-­‐like	   (LRP5L)	   first	   came	   to	   my	  attention	  during	   the	  screening	  of	  LRP5,	  because	  PCR	  primer	  pairs	  designed	   to	  amplify	  fragments	  of	  LRP5	  also	  produced	  amplicons	  of	  LRP5L	  due	  to	  its	  high	  homology.	  LRP5L	  is	  located	  on	  chromosome	  22q11.23	  and	  encodes	   for	  a	  252aa	  protein	  (Figure	  97)	   that	   is	  highly	   similar	   to	   the	   second	   β-­‐propeller	   domain	   of	   LRP5.	   Since	   this	   a	   domain	   where	  many	   OPPG	   mutations	   cluster	   (Balemans	   and	   van	   Hul,	   2007),	   I	   wondered	   whether	  mutations	  in	  LRP5L	  could	  contribute	  to	  an	  FEVR-­‐like	  phenotype.	  Further	  indication	  for	  a	  possible	   role	   came	   from	   a	   poster	   presented	   at	   the	   annual	   ARVO	   (Association	   for	  Research	   in	   Vision	   and	   Ophthalmology)	   meeting	   in	   2008	   (Gilmour	   et	   al.,	   2009).	   It	  described	  a	  patient	  with	  DiGeorge	  sequence	  due	  to	  a	  deletion	  on	  chromosome	  22q11.2	  who	  in	  addition	  presented	  with	  an	  FEVR-­‐like	  ocular	  phenotype.	  At	  this	  time	  point,	  it	  was	  unclear	  whether	   the	  deletion	   included	   the	  LRP5L	   locus,	   so	  Walther	  Hänseler	   screened	  the	  CDS-­‐containing	  part	  and	  flanking	  intronic	  regions	  of	  this	  gene	  as	  well.	  	  No	  unknown	  sequence	  variants	  were	  observed	   in	  13	  patients	   (the	   same	  patients	  who	  were	   screened	   for	   LRP5	   mutations,	   but	   without	   #29550).	   Four	   annotated	   SNPs	  were	  found;	  for	  two	  of	  them,	  allele	  frequency	  data	  were	  available	  for	  comparison.	  The	   allele	   frequency	   of	   SNP	   rs9624807,	   a	   silent	   mutation	   in	   exon	   2	   (c.339C>T),	   was	  significantly	  higher	  in	  the	  patient	  group,	  and	  had	  a	  calculated	  odds	  ratio	  of	  18.42	  (Table	  43).	   Further	   in	   silico	   analysis	  with	   the	   ESRsearch	   tool	   revealed	   the	   creation	   of	   a	   new	  binding	  site	  for	  a	  putative	  exonic	  splice	  regulatory	  element	  as	  result	  of	  the	  C>T	  exchange	  (Figure	  98).	  











Figure	   97	  On	   chromosome	   22q11.23,	   a	   gene	  with	   high	   homology	   to	  LRP5	   is	   located,	   termed	  LRP5L.	   4	  transcripts	  of	  the	  gene	  are	  known.	  (A)	  The	  longest	  consists	  of	  3,602	  bp,	  is	  organized	  in	  4	  exons	  and	  spans	  a	   genomic	   region	   of	   11.14kb	   (ENST00000215872).	   Screening	   was	   established	   to	   sequence	   the	   CDS	   of	  these	   4	   exons.	   (B-­D)	   However,	   the	   three	   other	   transcripts	   (ENST00000444995, ENST00000402859, ENST00000402785)	  span	  a	  larger	  genomic	  region	  and	  include	  untranslated	  5’-­‐exons.	  All	  encode	  a	  252	  aa	  protein,	  with	  the	  exception	  of	  (B),	  which	  encodes	  a	  shorter	  224	  aa	  product.	  (Source:	  www.ensembl.org)	  	  	  
Allele frequency of the LRP5L SNP 
Exon SNP Base substitution Database patients Odds ratio Lower limit Upper limit 
Ex2 rs9624807 c.339C>T (p.R113R) 0.98 0.73 18.42 3.55 95.56 
	  
Table	  43	  Allele	  frequencies	  for	  the	  LRP5L	  SNP	  rs9624807.	  Frequencies	  are	  given	  for	  the	  ancestral	  allele.	  Frequency	  data	  originates	  from	  the	  CSHL-­‐HAPMAP-­‐CEU	  cohort	  (102	  alleles).	  Our	  patient	  group	  consisted	  of	  26	  alleles.	  Data	  were	   retrieved	   from	  www.ncbi.nlm.nih.gov.	  Odds	   ratios	  were	   calculated	  with	  a	  web-­‐based	   tool	   (http://faculty.vassar.edu/lowry/odds2x2.html).	   (data	   taken	   from:	   Masterthesis	   Hänseler,	  2008)	  	  	  
	  
Figure	   98	   Results	   from	   the	   ESRsearch	   for	   exonic	   splice	   regulatory	   sequences.	   The	   c.339	   position	   is	  framed	   and	   the	   respective	   allele	   is	   highlighted	   in	   green.	  When	   the	   c.339C	   allele	   is	   present,	   no	  putative	  ESRs	  	  bind	  to	  the	  sequence.	  Instead,	  a	  new	  recognition	  site	  for	  one	  putative	  ESR	  was	  predicted	  when	  the	  c.339T	  allele	  was	  analyzed.	  (modified	  after	  data	  from	  http://ast.bioinfo.tau.ac.il/ESR.htm) 	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3.5.6	  PLVAP	  screening	  	  The	  plasmalemma	  vesicle	  associated	  protein	  (PLVAP)	  probably	  is	  the	  best	  characterized	  and	  most	  promising	  candidate	  gene	  of	  this	  thesis.	  Its	  mRNA	  expression	  was	  increased	  in	  the	   microarray	   experiment	   (Table	   40),	   and	   retinal	   expression	   was	   shown	   to	   be	  increased	   throughout	   postnatal	   retinal	   development	   from	   p5	   to	   p21	   (Figure	   52	   A),	  especially	  at	  the	  more	  advanced	  stages.	  It	  likely	  mediates	  one	  of	  the	  hallmark	  features	  of	  ND	  and	  probably	  other	  EVRs:	  blood	  vessel	  leakiness.	  Since	  it	  is	  differentially	  expressed	  already	  early	   in	  development,	   I	  hypothesized	   that	   it	   could	  be	  a	  direct	   target	  of	  Norrin	  (Schäfer	   et	   al.,	   2009).	   Further,	   ectopic	   expression	   in	   the	   retinal	   vasculature	   could	   be	  shown	  by	  immunohistochemistry	  (Figure	  53).	  A	  possible	  mode	  of	  action	  for	  Norrin,	  besides	  transcriptional	  regulation	  via	  the	  Wnt/β-­‐catenin	  pathway,	  might	  be	  a	  direct	  modulation	  of	  the	  microtubule	  cytoskeleton	  (Salinas,	  2007)	   or	   Plvap	   itself.	   This	   led	  me	   to	   hypothesize	   that	   transient	   Plvap	   expression	   and	  fenestration	  occur	  during	  maturation	  of	  the	  retinal	  vasculature	  and	  that	  Norrin	  signaling	  is	  possibly	  required	  for	   its	  suppression.	  Mutations	   in	  PLVAP	  thus	  may	  affect	  sprouting	  angiogenesis	   as	  well	   as	   the	   formation	   and	  maintenance	   of	   the	   blood-­‐retina-­‐	   or	   blood-­‐brain-­‐barrier,	  and	  therefore	  could	  mimic	  or	  modify	  the	  ocular	  effect	  of	  NDP	  mutations.	  All	   6	   exons	   and	   the	   flanking	   intronic	   regions	   of	   the	   PLVAP	   gene	   (Figure	   99)	   were	  sequenced	  from	  DNAs	  of	  13	  patients	  (3	  females,	  6	  males,	  and	  4	  patients	  with	  unknown	  gender).	  No	  new	  or	  unannotated	  SNPs	  or	  mutations	  were	  found	  in	  the	  screening.	  	  
	  
Figure	  99	  The	  transcript	  of	  the	  PLVAP	  gene	  (ENST00000252590)	  consists	  of	  6	  exons	  and	  has	  a	  length	  of	  2,298bp.	   The	   CDS	   codes	   for	   442aa	   and	   starts	   in	   exon	   1.	   PLVAP	   is	   located	   on	   chromosome	   19p13.11.	  (Source:	  www.ensembl.org)	  	  However,	   three	   silent,	   annotated	   SNPs	  were	   observed.	   The	   first	   one	   (rs10417806)	   is	  located	  in	  exon	  1,	  44	  bases	  upstream	  of	  the	  ATG	  in	  the	  5’-­‐UTR.	  A	  thymidine	  is	  replaced	  by	   a	   guanine.	   This	   polymorphism	   was	   found	   heterozygously	   in	   patients	   25160	   and	  27110	  (Figure	  117	  in	  the	  appendix).	  The	  second	  SNP	  (ENSSNP5758645),	  a	  guanine	  to	  adenosine	  substitution,	  is	  situated	  37	  nucleotides	   upstream	   of	   exon	   6	   in	   intron	   5.	   This	   sequence	   variation	   is	   present	  heterozygously	   in	  5	  patients:	   22439,	   24536,	   25160,	   27110,	   and	  27116	   (Figure	  118	   in	  the	  appendix).	  The	  third	  SNP	  is	  rs7259703,	  which	  has	  been	  found	  in	  patients	  27113	  and	  27735.	  It	  is	  a	  cytosine	  to	  thymine	  substitution	  and	  located	  329	  bp	  into	  the	  3’-­‐UTR	  (Figure	  119	  in	  the	  appendix).	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A	  comparison	  with	  allele	  frequency	  data	  from	  the	  HAPMAP	  project	  for	  rs10417806	  and	  rs7259703	   (www.hapmap.org)	   showed	   no	   significant	   differences	   with	   the	   examined	  patient	  group	  (Table	  44).	  No	  allele	  frequencies	  were	  available	  for	  ENSSNP5758645.	  	  	  
SNP Nuc Change AA Change Exon 
Exon 
position SNP freq database Genotype frequencies 
             
T/T T/G G/G  
rel. abs. rel. abs. rel. abs.  
0.846 11.0 0.154 2.0 0.000 0.0 patients 
rs10417806 c.-44T>G 5'-UTR 1 19 CSHL-HAPMAP:HapMap-CEU 
0.793 10.3 0.172 2.2 0.034 0.4 expected 
             
G/G G/A A/A  
rel. abs. rel. abs. rel. abs.  
0.615 8.0 0.385 5 0.000 0.0 patients 
ENSSNP5758645 c.1322-37G>A Intron 5 6 -37 none 
na na na na na na expected 
             
C/C C/T T/T  
rel. abs. rel. abs. rel. abs.  
0.846 11.0 0.154 2 0.000 0.0 patients 
rs7259703 c.*329C>T 3'-UTR 6 386 CSHL-HAPMAP:HapMap-CEU 
0.967 12.6 0.033 0.4 0.000 0.0 expected 
	  
Table	   44	   PLVAP	   SNPs	   found	   in	   the	   patient	   screening.	   Genotype	   frequencies	   are	   given	   in	   relative	   and	  absolute	   values.	   No	   significant	   differences	   to	   frequencies	   published	   in	   databases,	  when	   available,	  were	  found.	  dbSNP128.	  na:	  not	  available	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3.5.7	  LMO2	  screening	  	  LIM	  domain	  only	  protein	  2,	  or	  Rhombotin-­‐2	  (LMO2),	  was	  not	  on	  the	  list	  of	  differentially	  expressed	   transcripts	   generated	   from	   the	   microarray	   experiment,	   nor	   was	   its	  expression	   analyzed	   by	   other	   methods	   in	   this	   study.	   However,	   some	   other	   evidence	  suggested	  LMO2	  as	  promising	  candidate	  gene	  for	  mutation	  screening.	  First,	  a	  new	  locus	  for	  ad	  FEVR	  has	  been	  described	  on	  chromosome	  11p12-­‐13	  (Downey	  et	  al.,	  2001).	  The	  linkage	   interval	  was	  determined	   to	  a	  14cM	  region,	  with	  a	  maximum	  LOD	  score	  of	  6.6,	  and	  the	  locus	  was	  termed	  „EVR3“.	  One	  of	  the	  genes	  in	  this	  interval	  possibly	  relevant	  to	  FEVR	  is	  LMO2.	  It	  is	  a	  transcription	  factor	  that	  affects	  angiogenesis	  and	  is	  likely	  involved	  in	  Wnt-­‐signaling	   (Yamada	   et	   al.,	   2000).	   Like	  NDP	   and	  FZD4,	   two	   of	   the	   known	   FEVR-­‐associated	   genes,	   LMO2	   is	   expressed	   in	   the	   retina	   and	   inner	   ear,	   two	   of	   the	   organs	  affected	   in	  ND	   (Deng	  et	   al.,	   2006).	  Further,	   in	   silico	   analysis	   suggested	   that	  NDP	   has	  a	  binding	   site	   for	   LMO2	   (Katoh	   and	   Katoh,	   2005).	   Conservation	   on	   transcript	   level	   to	  mouse	   Lmo2	   is	   96%	   and	   thus	   the	   ko	   mouse	   model	   could	   be	   instrumental	   to	   the	  understanding	   of	   its	   function.	   Lmo2	   is	   a	   nuclear	   protein	   expressed	   in	   the	   erythroid	  lineage	   in	   vivo	   that	   is	   essential	   for	   erythroid	   development	   in	   mice.	   The	   homozygous	  









Figure	  100	  LMO2,	   located	  on	   chromosome	  11p13,	  has	  4	  known	   transcripts.	   (A)	  The	   longest	   transcript	  (ENST00000257818)	  consists	  of	  6	  exons	  and	  has	  a	  length	  of	  2,291bp.	  The	  CDS	  codes	  for	  227aa	  and	  starts	  in	   exon	   4.	   (B-­D)	   The	   three	   other	   transcripts	   lack	   at	   least	   the	   first	   two	   exons	   and	   have	   a	   shorter	   CDS.	  (Source:	  www.ensembl.org)	  	  All	   6	   exons	   and	   the	   flanking	   intronic	   regions	   of	   the	  LMO2	   gene	  were	   sequenced	   from	  DNAs	  from	  13	  patients	  (3	  females,	  6	  males,	  and	  4	  patients	  with	  unknown	  gender).	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Analysis	   of	   the	   sequence	   data	   revealed	   five	   annotated	   SNPs	   (Table	   45).	   The	   first,	  rs2273799,	   is	  an	  adenine	  to	  guanine	  substitution	   in	  the	  5’-­‐UTR	  (exon	  1;	  c.-­‐796A>G).	   It	  was	   found	   in	   a	   heterozygous	   state	   in	   DNAs	   from	   patients	   25160,	   25649,	   27116,	   and	  27735.	   It	   was	   homozygous	   in	   patients	   22439,	   24536,	   and	   27111	   (Figure	   120	   in	   the	  appendix).	  A	  second	  one	  (rs11032432)	  was	  found	  at	  position	  c.-­‐425C>G,	  also	  in	  the	  5'-­‐UTR.	  It	  is	  located	  in	  exon	  3,	  and	  was	  present	  heterozygously	  in	  6	  patients:	  22439,	  25160,	  25649,	   27111,	   27112,	   and	   27188.	   Patients	   24165,	   27110,	   27116,	   and	   27735	   were	  homozygous	   (Figure	  121	   in	   the	   appendix).	   SNP	   rs2038602,	   a	   c.111T>C	   exchange	   that	  has	   no	   effect	   on	   protein	   level	   (p.I37I),	  was	   found	   in	   6	   patients	   22439,	   25160,	   25659,	  27111,	   27112,	   and	   27188	   in	   a	   heterozygous	   state.	   4	   patients	   (24165,	   27110,	   27116,	  27735)	   were	   homozygous	   (Figure	   122	   in	   the	   appendix).	   Six	   patients	   were	   further	  heterozygous	   for	   another	   silent	   SNP,	   rs3740617,	   which	   is	   a	   c.363A>G	   substitution	  (p.K121K):	  22439,	  25160,	  25649,	  27111,	  27112,	  and	  27188.	  The	  variation	  was	  present	  homozygously	   in	  patients	  24536,	  27113,	  and	  28931	  (Figure	  123	  in	  the	  appendix).	  The	  last	  LMO2	  SNP	   found	   in	   the	  patient	  group	  was	  rs3740616.	   It	   is	  an	  adenine	   to	   thymine	  exchange	   in	   the	  3’-­‐UTR	  (c.*483A>T).	  Four	  patients	  were	  heterozygous	   (25649,	  27111,	  27112,	  27116),	  patient	  27110	  was	  homozygous	  (Figure	  124	  in	  the	  appendix).	  For	   four	   of	   the	   five	   SNPs,	   allele	   frequency	   data	   were	   available.	   A	   comparison	   with	  frequency	   data	   of	   the	   patient	   group	   (www.hapmap.org)	   showed	   no	   significant	  differences	  (Table	  45),	  and	  all	  variants	  appear	  to	  be	  common.	  No	  frequency	  data	  were	  available	  for	  rs11032432.	  No	  new	  or	  unannotated	  SNP	  or	  mutation	  was	  found	  in	  the	  screening.	  
SNP Nuc Change AA Change Exon 
Exon 
position SNP freq database Genotype frequencies 
             
A/A A/G G/G  
rel. abs. rel. abs. rel. abs.  
0.462 6 0.308 4.0 0.231 3.0 patients 
rs2273799 c.-796A>G 5'-UTR 1 269 CSHL-HAPMAP:HapMap-CEU 
0.267 3.5 0.500 6.5 0.233 3.0 expected 
             
C/C C/G G/G  
rel. abs. rel. abs. rel. abs.  
0.231 3.0 0.462 6.0 0.308 4.0 patients 
rs11032432 c.-425C>G 5'-UTR 3 177 none 
na na na na na na expected 
             
T/T T/C C/C  
rel. abs. rel. abs. rel. abs.  
0.231 3.0 0.462 6.0 0.308 4.0 patients 
rs2038602 c.111T>C p.I37I 5 70 CSHL-HAPMAP:HapMap-CEU 
0.233 3.0 0.533 6.9 0.233 3.0 expected 
             
G/G G/A A/A  
rel. abs. rel. abs. rel. abs.  
0.308 4.0 0.462 6.0 0.231 3.0 patients 
rs3740617 c.363A>G p.K121K 6 106 CSHL-HAPMAP:HapMap-CEU 
0.267 3.5 0.500 6.5 0.233 3.0 expected 
             
A/A A/T T/T  
rel. abs. rel. abs. rel. abs.  
0.615 8 0.308 4 0.077 1 patients 
rs3740616 c.*483A>T 3'-UTR 6 226 CSHL-HAPMAP:HapMap-CEU 
0.483 6.3 0.517 6.7 0.017 0.2 expected 
	  
Table	   45	   LMO2	   SNPs	   found	   in	   the	   patient	   screening.	   Genotype	   frequencies	   are	   given	   in	   relative	   and	  absolute	  values.	  dbSNP128.	  na:	  not	  available	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3.5.8	  SLC38A5	  screening	  	  The	  solute	  carrier	  Slc38a5	  was	  the	  transcript	  with	  the	  most	  decreased	  expression	  in	  the	  microarray	   experiment	   (Table	   40),	   and	   retinal	   expression	   was	   shown	   to	   be	   reduced	  throughout	   postnatal	   retinal	   development	   from	   p5	   to	   p21	   (Figure	   52	   B).	   It	   therefore	  could	  be	  a	  direct	  target	  of	  Norrin.	  Slc38a5,	  a	  neutral	   	  amino	  acid	  transporter,	  has	  been	  shown	  to	  be	  an	  important	  glutamine	  transporter	  in	  the	  retina	  (Umapathy	  et	  al.,	  2005),	  and	  was	  also	  found	  in	  astrocytes	  of	  the	  cerebellum	  (Cubelos	  et	  al.,	  2005).	  Therefore,	   it	  could	   also	   mediate	   norrin	   function	   in	   the	   brain,	   and	   may	   contribute	   to	   the	   mental	  retardation	   phenotype	   of	   ND	   patients.	   Evidence	   for	   this	   hypothesis	   came	   from	   the	  report	   of	   a	  microdeletion	   including	  SLC38A5	   and	   the	  neighboring	  FTSJ1	   that	  has	  been	  found	   in	   three	   brothers	   with	   moderate	   to	   severe	   mental	   retardation	   (Froyen	   et	   al.,	  2007).	   Further	   experiments	   lead	   to	   the	   discovery	   that	   Slc38a5	   expression	   is	   also	  reduced	  in	  the	  cerebellum	  of	  Ndph	  ko	  mice	  (Figure	  58;	  Hänseler,	  Masterthesis,	  2008).	  Since	  NDP	   and	  SLC38A5	   are	   both	   located	   on	   the	  X-­‐chromosome	   and	   are	   separated	  by	  only	   4.5cM	   (Figure	   101),	   variations	   in	   both	   genes	   are	   likely	   to	   cosegregate	   within	   a	  familiy.	   It	   thus	  seems	  possible	   that	  SLC38A5	   could	  act	  as	  a	  modifier	   for	  NDP	  mediated	  function.	  	  
	  
Figure	   101	   The	   loci	   of	  NDP	   and	   SLC38A5	   are	   only	   separated	   by	   4.5cM	   on	   the	   human	   X-­‐chromosome.	  (Source:	  www.ensembl.org)	  	  All	  16	  exons	  and	   the	   flanking	   intronic	   regions	  of	   the	  SLC38A5	   gene	   (Figure	  102)	  were	  sequenced	   from	  DNAs	   from	  a	   total	  of	  22	  patients	   (8	   females,	  10	  males,	  and	  4	  patients	  with	  unknown	  gender).	  Because	   it	  was	  hypothesized	   that	  variations	   in	  SLC38A5	   could	  modify	   the	   outcome	  or	   severity	   of	   the	   disease,	  DNAs	   from	  patients	  who	   already	   have	  been	  diagnosed	  with	  mutations	  in	  the	  established	  genes	  NDP	  (5),	  FZD4	  (1),	  and	  LRP5	  (1)	  were	  included.	  The	  screening	  was	  performed	  by	  Karin	  Schläpfer	  under	  my	  supervision	  during	  her	  one-­‐month	  internship	  at	  the	  Institute	  of	  Medical	  Genetics.	  	  	  
	  
Figure	  102	  The	  longest	  transcript	  of	  the	  SLC38A5	  gene	  (ENST00000376876)	  consists	  of	  16	  exons	  and	  has	  a	   length	  of	  2,654bp.	  The	  CDS	  codes	   for	  472aa	  and	  starts	   in	  exon	  2.	  SLC38A5	   is	   located	  on	  chromosome	  Xp11.23.	  (Source:	  www.ensembl.org)	  	  Analysis	  of	  the	  sequence	  data	  from	  the	  22	  patient	  DNAs	  revealed	  two	  annotated	  SNPs.	  The	   first	   one	   (rs2293953)	   is	   situated	   in	   intron	   2,	   43	   bases	   upstream	   of	   exon	   3.	   A	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thymidine	   is	   replaced	   by	   a	   cytosine.	   This	   polymorphism	   was	   found	   in	   five	   patients:	  Individuals	   22777,	   24165,	   27110	   and	   28786	   are	   heterozygous	   for	   this	   SNP,	   whereas	  27188	   is	   hemizygous	   (Figure	   125	   in	   the	   appendix).	   The	   second	   SNP	   (rs17281188)	   is	  located	  at	  position	  35	  of	  exon	  16.	  Also	  in	  this	  case,	  there	  is	  a	  cytosine	  nucleotide	  instead	  of	  a	  thymidine.	  As	  a	  result,	  there	  is	  a	  replacement	  of	  a	  methionine	  residue	  by	  a	  threonine	  in	   the	   protein.	   This	   sequence	   variation	   is	   present	   heterozygously	   in	   patients	   number	  22777	  and	  28786	  (Figure	  126	  in	  the	  appendix).	  A	  comparison	  with	  allele	  frequency	  data	  from	   the	   HAPMAP	   project	   (www.hapmap.org)	   showed	   no	   significant	   differences	  with	  the	  examined	  patient	  group	  (Table	  46)	  that	  would	  have	  indicated	  a	  possible	  risk	  factor.	  	  
SNP Nuc Change AA Change Exon 
Exon 
position SNP freq database Allele frequencies 
           
T C  
rel. abs. rel. abs.  
0.769 20.0 0.231 6.0 patients 
rs2293953 c.-44T>C Intron 2 2 -43 CSHL-HAPMAP:HapMap-CEU 
0.809 21.0 0.191 5.0 expected 
           
T C  
rel. abs. rel. abs.  
0.923 24.0 0.077 2.0 patients 
rs17281188 c.1352T>C p.M451T 16 35 CSHL-HAPMAP:HapMap-CEU 
0.942 24.5 0.058 1.5 expected 
	  
Table	   46	   SLC38A5	   SNPs	   found	   in	   the	   patient	   screening.	   Allele	   frequencies	   are	   given	   in	   relative	   and	  absolute	  values.	  Since	  SLC38A5	  is	  located	  on	  the	  X-­‐chromosome,	  only	  allele	  frequencies	  are	  given.	  A	  total	  of	  18	  patients	  were	  examined,	  8	  females	  and	  10	  males	  (26	  alleles).	  4	  additional	  patients	  (27111,	  27112,	  27113,	  27116)	  were	  of	  unknown	  gender	  and	   thus	  were	  excluded	   from	  the	   frequency	  calculation.	  Allele	  frequencies	  were	  retrieved	  from	  the	  SNP	  database	  version	  dbSNP128	  (www.ensembl.org).	  	  	  Besides	   the	   two	   annotated	   SNPs,	   one	   so	   far	   not	   reported	   change	   in	   the	   sequence	   of	  
SLC38A5	   was	   found	   in	   a	   single	   patient	   (25649).	   A	   guanine	   residue	   was	   replaced	  hemizygously	  by	  an	  adenine	  at	  position	  772	  of	  exon	  1	  (c.-­‐73G>A)	  (Figure	  103).	  	  	  	  
	  	  
Figure	  103	  Electropherogram	  from	  the	  sequence	  analysis	  of	  SLC38A5	  from	  patient	  25649.	  Instead	  of	  both	  a	  forward	  and	  a	  reverse	  sequence,	  the	  amplicon	  was	  sequenced	  twice	  in	  the	  reverse	  direction,	  because	  the	  forward	  read	  yielded	  no	  usable	  data.	  Due	  to	  this,	  the	  c.-­‐73G>A	  substitution	  is	  depicted	  as	  an	  G>T	  in	  this	  electropherogram.	  Numbers	  indicate	  the	  position	  inside	  exon	  1,	  which	  is	  upstream	  of	  the	  translation	  start.	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To	   predict	   a	   possible	   effect	   of	   this	   nucleotide	   exchange,	   in	   silico	   analysis	   with	   the	  ESRsearch	   tool	  was	  performed.	  The	  pESR	  predicted	   to	   bind	   the	   c.-­‐73G	   sequence	  does	  not	  recognize	  the	  mutatated	  c.-­‐73A	  allele.	  Instead,	  the	  base	  change	  creates	  a	  recognition	  site	  for	  three	  other	  pESRs	  (Figure	  104).	  	  
	  
Figure	   104	   Results	   from	   the	   ESRsearch	   for	   exonic	   splice	   regulatory	   sequences.	   The	   c.-­‐73	   position	   is	  framed	   and	   the	   respective	   allele	   is	   highlighted	   in	   green.	   When	   the	   c.-­‐73G	   allele	   is	   present,	   only	   one	  putative	  ESR	   	  binds	   to	   the	  sequence.	  This	  pESR	   is	  not	  predicted	   to	  bind	   the	  c.-­‐73A	  allele.	   Instead,	   three	  other	   recognition	   sites	   for	   putative	   ESRs	   were	   predicted.	   (modified	   after	   data	   from	  
http://ast.bioinfo.tau.ac.il/ESR.htm)	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3.6	  Recombinant	  protein	  expression	  in	  yeast	  	  High	  amounts	  of	  protein	  are	  required	  for	  functional	  and	  structural	  analyses,	  typically	  in	  the	  milligrams	  range.	  In	  order	  to	  obtain	  pure	  protein	  in	  sufficient	  quantity,	  cell	  culture	  systems	   are	   used	   for	   recombinant	   protein	   expression.	   The	   bacterium	  Escherichia	   coli	  represents	  an	  adequate	  means	  for	  fast	  and	  cheap	  expression	  of	  high	  amounts	  of	  protein.	  However,	   since	   it	   is	   a	   prokaryotic	   organism,	   it	   lacks	   the	   post-­‐translational	   processing	  machinery	  of	  mammalian	  cells.	  Thus	  it	  is	  highly	  possible	  that	  the	  produced	  protein	  is	  not	  biologically	  functional,	  since	  e.g.	  it	  has	  not	  been	  folded	  or	  glycosylated	  correctly.	  On	  the	  other	   hand,	   correct	   post-­‐translational	   modification	   is	   ensured	   when	   mammalian,	   e.g.	  HEK293	  or	  COS-­‐7	  cell	  lines	  are	  applied.	  Yet,	  these	  cell	  lines	  hardly	  qualify	  as	  expression	  systems	  for	  high	  quantities,	  and	  are	  rather	  slow	  and	  expensive.	  One	  possible	  intermediate	  solution	  is	  the	  appliance	  of	  a	  yeast	  system.	  The	  yeast	  Pichia	  
pastoris	   is	   comparable	   to	  E.	   coli	   in	   respect	   to	  ease-­‐of-­‐use,	   speed	  and	  costs,	  but	   carries	  eukaryotic	   features	   like	   glycosylation	   and	   facilitation	   of	   disulphide-­‐bonds,	   which	  enables	  correct	  protein	   folding.	   In	   the	  course	  of	  my	  PhD	   thesis,	   I	  used	   this	  expression	  system	   to	   generate	   four	   different	   variants	   of	   norrin	   protein	   and	   aimed	   to	   obtain	   high	  quantities	   in	   collaboration	   with	   Kurt	   Ballmer,	   Rolf	   Jaussi,	   Suzanne	   Kronenberg,	   and	  Thomas	  Schleier	  from	  the	  Paul-­‐Scherrer-­‐Institute	  in	  Villigen,	  Switzerland,	  and	  my	  fellow	  PhD	  student	  Lucas	  Mohn	  from	  the	  Institute	  of	  Medical	  Genetics	  in	  Schwerzenbach.	  Four	  different	  norrin	  constructs	  were	  used:	  The	  wild	  type	  and	  a	  C95R	  variant,	  which	  is	  a	  copy	  of	  a	  human	  pathogenic	  mutation,	  with	  either	  tags	  at	  the	  N-­‐	  or	  C-­‐terminus	  (Figure	  43;	   Figure	   44).	   The	   secreted	   protein	   should	   consist	   of	   275/232	   amino	   acids	   (C-­‐/N-­‐terminal	   tagged).	  After	   secretion	   into	   the	  medium,	  most	  of	   the	  α-­‐factor	   signal	  peptide	  (89aa)	  should	  be	  cleaved	  from	  the	  protein	  at	  the	  Kex2	  site,	  which	  results	  into	  a	  186/133	  aa	   (C-­‐/N-­‐terminal	   tagged)	  mature	  NDP	  protein.	  The	   expected	  molecular	  weight	   of	   the	  monomer	  is	  ~21/17kDa	  (C-­‐/N-­‐terminal	  tagged).	  	  
3.6.1	  Expression	  control	  in	  cultures	  with	  a	  volume	  of	  50ml	  Before	   high	   quantity	   production	   of	   protein	   was	   attempted,	   an	   expression	   control	  experiment	  with	  a	  medium	  volume	  of	  50ml	  was	  conducted.	  The	  yeast	  cells	  were	  grown	  for	  24h	  and	  subsequently	   induced	   to	  express	  recombinant	  norrin	  with	  methanol	   for	  4	  days.	  Every	  12	  hours	  a	  500µl	  sample	  was	  taken	  from	  the	  cell	  medium.	  To	   determine	   the	  Pichia	   clone	  which	   expresses	  most	   recombinant	   protein,	   a	  Western	  blot	  was	   performed	  with	   15µl	   of	   the	   cell	  medium	   after	   4	   days	   of	  methanol-­‐induction	  (Figure	  105).	  The	  proteins	  were	   separated	  on	  a	  12%	  SDS	  polyacrylamide	  gel,	   and	   the	  blot	  was	  incubated	  with	  a	  monoclonal	  anti-­‐c-­‐myc	  antibody.	  A	  double-­‐band	  in	  the	  range	  of	   the	   expected	  monomeric	   size	   (~21kDa)	   could	  be	  detected	   in	   the	   supernatant	   of	   all	  clones	   with	   C-­‐terminal	   tagged	   constructs.	   Judging	   from	   the	   intensity	   of	   the	   detected	  bands,	  clones	  no.	  223.2	  (wt)	  and	  224.2	  (C95R)	  expressed	  the	  most	  protein.	  In	  contrast,	  a	  possible	  monomeric	  band	  at	  ~17kDa	  could	  not	  (or	  only	  very	  marginally)	  be	   detected	   in	   the	   supernatants	   of	   the	   clones	   with	   N-­‐terminal	   tagged	   constructs.	  However,	  several	  other	  bands	  of	  higher	  molecular	  weight	  could	  be	  observed.	  Although	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the	  gel	  was	  run	  under	  reducing	  conditions	  and	  no	  polymers	  were	  expected,	  a	  band	  at	  the	  size	  of	  a	  possible	  dimer	  (~34kDa)	  appeared	  in	  all	  clones.	  	  	  
 
 
	  	  	  	  A	   	  	  	  	  B	  
Figure	  105	  Western	  blots	  with	   supernatant	   from	  all	   tested	  clones	  after	  4d	  of	  expression	   induction	   (t4)	  were	  stained	  with	  c-­‐myc	  (1:500)	  and	  a	  secondary	  anti-­‐mouse-­‐IgG-­‐HRP	  (1:2000)	  antibody.	  (A)	  A	  double-­‐band	  in	  the	  range	  of	  the	  expected	  size	  (~21kDa)	  of	  the	  recombinant	  norrin	  protein	  could	  be	  detected	  in	  the	   supernatant	   of	   all	   clones	   with	   C-­‐terminal	   tagged	   constructs.	   Strongest	   expression	   was	   detected	   in	  clones	  223.2	   (wt)	  and	  224.2	   (C95R).	  (B)	  Many	  unspecific	  bands	  were	  detected	   in	   the	  supernatant	   from	  clones	   containing	   the	   N-­‐terminal	   tagged	   constructs.	   Only	   a	   hint	   of	   a	   band	   could	   be	   detected	   at	   the	  expected	  size	  of	  ~17kDa	  (see	  clone	  226.4).	  The	  membrane	  on	  the	  left	  (A)	  has	  been	  exposed	  for	  30min,	  the	  one	  on	  the	  right	  (B)	  for	  40min.	  BMMY:	  protein	  expression	  medium	  (negative	  control);	  #1811:	  molecular	  weight	  ladder.	  	  To	  determine	  the	  optimal	  culture	  time,	  a	  Western	  blot	  was	  performed	  with	  supernatant	  from	  8	  different	  time	  points	  after	  induction	  (Figure	  106).	  Intensity	  of	  the	  putative	  norrin	  band	   increased	   over	   time,	   reaching	   a	   maximum	   after	   4	   days	   (t4).	   Thus,	   it	   seems	  advisable	  to	   incubate	  the	  cultures	  at	   least	   for	  this	  period.	  Further,	  accumulation	  of	   the	  protein	  in	  the	  medium	  indicates	  that	  it	  is	  produced	  and	  secreted	  by	  the	  cells	  as	  expected.	  Interestingly,	  the	  wt	  and	  C95R	  bands	  both	  appeared	  with	  a	  weak	  smear/double-­‐band	  on	  the	  blot	  presented	  in	  Figure	  105.	  In	  contrast,	  there	  was	  only	  a	  single	  sharp	  wt	  band	  on	  the	   blot	   in	   Figure	   106,	   while	   the	   C95R	   variant	   appeared	   as	   a	   double	   band	   on	   a	   blot	  processed	  at	  the	  the	  same	  time.	  Supernatants	   (t4)	   from	   the	   high	   expressing	   clones	   223.2	   (wt)	   and	   224.2	   (C95R)	  were	  concentrated	  with	  filter	  columns	  by	  factor	  20.	  An	  SDS-­‐PAGE	  was	  conducted	  with	  15µl	  of	  the	   concentrated	   protein,	   and	   run	   under	   reducing	   (β-­‐mercaptoethanol)	   and	   non-­‐reducing	   conditions.	   Since	   the	   cysteine	   at	   position	   95	   has	   been	   suggested	   to	   be	  responsible	   for	  homodimerization	  of	   the	  protein	  (Meitinger	  et	  al.,	  1993),	   I	  expected	  to	  see	   bands	   at	   different	   molecular	   weights	   (monomer:	   ~21kDa;	   dimer:	   ~42kDa).	  However,	  no	  difference	  could	  be	  observed	  (Figure	  107).	  This	  is	  in	  contrast	  to	  a	  similar	  experiment	  with	  recombinant	  protein	   from	  HEK	  cells	   (p.55;	  Masterthesis	  Lucas	  Mohn,	  2007),	  where	  it	  could	  be	  shown	  that	  the	  C95R	  variant	  does	  not	  form	  the	  putative	  dimer.	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  A	  expected	  size	  of	  the	  monomer:	  ~21kDa	   	  	  	  	  	  	  B	  expected	  size	  of	  the	  monomer:	  ~21kDa	  
Figure	  106	  Western	  blots	  with	  supernatants	  from	  the	  C-­‐terminal	  tagged	  clones	  223.2	  (wt;	  A)	  and	  224.2	  (C95R;	  B).	  Medium	   samples	   from	  8	  different	   induction	   time	  points	  were	   loaded.	   The	  membranes	  were	  stained	   with	   c-­‐myc	   (1:500)	   and	   a	   secondary	   anti-­‐mouse-­‐IgG-­‐HRP	   (1:2000)	   antibody.	   Intensity	   of	   the	  stained	  protein	  bands	   in	   the	   size	   range	  of	  ~21kDa	   increased	  over	   time.	  Noteworthy,	   the	  putative	  C95R	  protein	   appeared	   as	   a	   double-­‐band,	   whereas	   the	   wt	   variant	   only	   produced	   a	   single	   band.	   #1811:	  molecular	  weight	  ladder.	  
	  
Figure	   107	  Western	   blot	  with	   concentrated	   protein	   from	   the	   t4	   supernatants	   of	   the	   C-­‐terminal	   tagged	  clones	  223.2	  (wt)	  and	  224.2	  (C95R).	  The	  samples	  were	  run	  under	  reducing	  (β-­‐mercaptoethanol)	  and	  non-­‐reducing	  conditions.	  Under	  reducing	  conditions,	  a	  band	  at	  ~21kDa	  was	  detected,	  and	  a	  weak	  double-­‐band	  of	   approximately	   twice	   the	   size.	   Under	   non-­‐reducing	   conditions,	   the	   double-­‐band	   at	  ~42kDa	   appeared	  much	   stronger,	   and	   no	   band	   at	  ~21kDa	  was	   observed.	   The	   banding	   pattern	   seemed	   to	   be	   comparable	  between	   both	   norrin	   variants	   (wt	   and	   C95R).	   The	   membrane	   was	   stained	   with	   c-­‐myc	   (1:500)	   and	   a	  secondary	  anti-­‐mouse-­‐IgG-­‐HRP	  (1:2000)	  antibody.	  BMMY:	  protein	  expression	  medium	  (negative	  control);	  
#1811:	  molecular	  weight	  ladder.	  
	  
3.6.2	  Expression	  in	  cultures	  with	  a	  volume	  of	  200ml	  In	  a	  next	  step,	  Thomas	  Schleier	  conducted	  expression	  in	  a	  larger,	  200ml	  volume	  culture	  at	  the	  Paul-­‐Scherrer-­‐Institute.	  C-­‐terminal	  tagged	  clones	  no.	  223.2	  (wt)	  and	  224.2	  (C95R)	  were	  used.	  Expected	  size	  of	  the	  recombinant	  norrin:	  21	  kDa	  (30	  kDa,	  if	  the	  α-­‐Factor	  has	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not	  been	  removed).	  Per	  lane,	  20µl	  of	  200ml	  medium	  were	  loaded	  on	  the	  SDS-­‐PAGE	  gel,	  and	  silver	  and	  Coomassie	  staining,	  as	  well	  as	  an	  α-­‐myc	  Western	  Blot	  were	  performed.	  Distinct	  bands	  were	  visible	  on	  both	  the	  Coomassie-­‐gel	  and	  the	  Western	  blot;	  the	  longer	  the	  MeOH-­‐induction	  time,	  the	  more	  intensive	  the	  bands	  (Figure	  108).	  This	  indicates	  that	  the	  detected	  protein	  accumulated	  in	  the	  medium	  over	  time.	  Two	  bands	  were	  detected:	  a	  double	  band	  slightly	  bigger	  than	  11kDa,	  and	  a	  (double-­‐)band	  of	  ~42	  kDa.	  The	  gels	  were	  run	   under	   reducing	   conditions,	   but	   arithmetically,	   this	   40kDa	   band	   could	   be	   a	   norrin	  dimer.	  The	   smaller,	  ~11kDa	  band	  could	  be	  norrin	  degradation	  product	   containing	   the	  myc-­‐tag;	   however,	   no	   additional	   KEX2	   recognition	   site	   is	   present	   in	   the	   construct	  sequence	  that	  could	  explain	  further	  cleavage.	  	  
	   	  
A	  Coomassie-­‐gel	   B	  	  α-­‐myc	  Western	  blot	  
Figure	  108	  Coomassie-­‐gel	  (A)	  and	  corresponding	  α-­‐myc	  Western	  blot	  (B)	  run	  under	  reducing	  conditions	  show	  two	  bands	  at	  >11kDa	  and	  ~42kDa	  that	  increase	  with	  MeOH	  induction	  time.	  C-­‐terminal	  tagged	  clones	  223.2	  (wt)	  and	  224.2	  (C95R)	  were	  used.	  
	   	  
A	   Silver	   staining	   of	   an	   SDS-­‐PAGE	   run	   under	  	  	  	  	  	  	  reducing	  conditions	   B	   	   Silver	   staining	   of	   an	   SDS-­‐PAGE	   run	   under	   non	  	  	  	  	  	  	  	  reducing	  conditions	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Figure	  109	  Silver	  gels	  and	  extracted	  bands	  that	  were	  analyzed	  by	  mass	  spectrometry.	  Only	  R.5	  and	  R.6	  yielded	  a	  sufficient	  amount	  for	  analysis,	  but	  were	  not	  identical	  to	  norrin.	  	  However,	  the	  bands	  visible	  on	  the	  Coomassie-­‐stained	  gel	  or	  the	  Western	  blot	  could	  not	  be	  easily	  detected	  by	  silver	  staining.	  Seven	  bands	  that	  could	  correspond	  to	  these	  bands	  (highlighted	   in	   Figure	   109)	   were	   isolated;	   protein	   was	   extracted	   and	   subsequently	  analyzed	   by	  mass-­‐spectrometry	   at	   the	   protein	   service	   lab	   of	   the	   FGCZ.	   For	   all	   bands	  besides	  R.5	  and	  R.6	   the	  MS	  analysis	  did	  not	  allow	   identification,	  probably	  because	   the	  sample	   amount	   was	   below	   the	   detection	   limit.	   Bands	   R.5	   and	   R.6	   are	   likely	   due	   to	  chitosanase	   (Q9ALZ1),	   a	   protein	   of	   bacterial	   origin.	   Thus,	   MS	   confirmation	   of	   norrin	  could	  not	  be	  achieved	  so	  far.	  	  
	   	  
A	   FPLC	   chromatogram	   of	   IMAC	   purified	   223.2	   wt	  	  	  	  	  	  	  medium	   B	   FPLC	   chromatogram	   of	   IMAC	   purified	   224.2	  	  	  	  	  	  	  	  C95R	  medium	  
	   	  
C	   Western	   blot	   against	   α-­‐myc	   with	   223.2	   wt	  	  	  	  	  	  	  	  fractions	  A1-­‐A10	  from	  (A)	   D	   Western	   blot	   against	   α-­‐myc	   with	   224.2	   C95R	  	  	  	  	  	  	  	  fractions	  B3-­‐C7	  from	  (B)	  
Figure	   110	   FPLC	   chromatograms	   of	   IMAC	   purified	   wt	   (A)	   and	   C95R	   (B)	   media	   and	   corresponding	  Western	  blots	  under	  reducing	  conditions	  (C,	  D).	  FPLC	  chromatograms	  provided	  by	  Thomas	  Schleier	  (PSI).	  Western	  blots	  conducted	  by	  Lucas	  Mohn.	  Another	  200ml	  medium	  from	  a	  second	  expression	  round	  conducted	  at	  the	  PSI	  was	  IMAC	  (immobilized	  metal	   ion	  affinity	  chromatography)	  purified	  on	  nickel	  columns	  and	  FPLC	  (fast	   protein	   liquid	   chromatography)	   fractionated	   in	   2ml	   samples	   (Figure	   110).	   Ten	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fractions	   for	   each	   the	   wt	   (223.2)	   and	   C95R	   (224.2)	   media	   that	   cover	   the	   respective	  protein	  peak	  (Figure	  110	  A,	  B)	  were	  separated	  on	  an	  SDS-­‐PAGE	  and	  stained	  with	  an	  α-­‐myc	  antibody	  (Western	  blots	   in	  Figure	  110	  C,	  D).	  All	  separated	  fractions	  of	  the	  wt	  and	  the	  C95R	  clones	  yielded	  a	  band	  of	  ~42kDa,	  which	  is	  the	  size	  of	  a	  possible	  norrin	  dimer.	  Intensity	   of	   these	   bands	   correlated	   with	   the	   peak	   height	   of	   the	   corresponding	   FPLC	  chromatogram	   fractions.	  No	   smaller	  band	  at	   >11kDa,	  which	  has	  been	  observed	   in	   the	  earlier	  experiments,	  was	  visible.	   If	   such	  a	  product,	  which	  may	  be	  some	   form	  of	  norrin	  degradation	   product,	   was	   initially	   present,	   it	   was	   possibly	   removed	   during	   the	  purification	  process	  due	  to	  its	  small	  size.	  Fractions	  were	  collected	  on	  a	  96-­‐well	  plate	  and	  unfortunately,	  some	  of	   them	  spilled	  over	  and	  mixed	  with	  each	  other.	  Therefore,	   it	  was	  not	  possible	  to	  allocate	  the	  results	   from	  the	  Western	  blots	  to	  the	  chromatograms	  with	  certainty,	   and	   worst,	   wt	   and	   C95R	   protein	   fractions	   can	   not	   be	   used	   for	   further	  experiments	  due	  to	  their	  unknown	  purity.	  Curiously,	   although	   both	  Western	   blots	  with	   protein	   extracts	   from	   the	   200ml	   volume	  cultures	  were	  run	  under	  reducing	  conditions	  (Figure	  108;	  Figure	  110),	  only	  the	  putative	  norrin	   dimer	   bands	   were	   detected.	   In	   contrast,	   none	   of	   the	   expected	   ~21kDa	  monomeric	   bands,	  which	   have	   been	   observed	   in	   the	   50ml	   expression	   control	   (Figure	  105;	  Figure	  106;	  Figure	  107),	  were	  visible.	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Figure	   112	   Putative	  Ndph-­‐ko	   allele.	  Most	   of	  Ndph	   exon	   2	   (yellow),	   including	   the	   entire	   CDS,	   has	   been	  replaced	  by	  a	  reverse	  oriented	  neomycin	  resistance	  cassette	  (green;	  Berger	  et	  al.,	  1996;	  sequenced	  only	  in	  flanking	   regions).	  Primer	  binding	   sites	   for	   the	  genotyping	  PCR	  are	   indicated.	   In	   contrast	   to	   the	  original	  sequence,	  an	  71	  bp	  insertion	  is	  present.	  	  
 
 





size	  wild	  type	   179	   180	   527	  bp	  knockout	   179	   177	   271	  bp	  knockout	   178	   180	   204	  bp	  knockout	   178	   180	   133	  bp	   
Figure	   111	   Ndph	   genotyping	   PCR.	   4	   different	  products	   can	   be	   observed:	   1	   from	   the	   wt	   allele,	  and	  2	  or	  3	   from	  the	  ko	  allele.	  All	  3	  or	  4	  bands	   in	  one	  sample	  indicate	  heterozygosity.	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4.	  Discussion	  
	  In	   this	   study,	   I	   aimed	   to	   identify	  differences	   in	   gene	  expression	   in	  brain	   and	   retina	  of	  norrin	   knockout	   mice,	   a	   mouse	   model	   for	   Norrie	   disease,	   to	   further	   elucidate	   the	  sequence	  of	  pathogenic	  events	  leading	  to	  the	  disease.	  I	  further	  aimed	  to	  find	  supporting	  evidence	   for	  norrin’s	  hypothesized	  role	  as	   transcriptional	  regulator	  of	  so	   far	  unknown	  target	  genes.	  Since	  such	  downstream	  genes	  are	  ideal	  candidates	  for	  contributing	  to	  ND	  or	  allelic	  diseases,	  a	  mutation	  screen	  was	  performed	  in	  patients	  who	  were	  negative	  for	  alterations	  in	  the	  three	  known,	  EVR-­‐related	  genes	  NDP,	  FZD4,	  and	  LRP5.	  	  
4.1	  Differential	  expression	  in	  Ndph	  ko	  mice	  	  
4.1.1	  Analyses	  of	  the	  brain	  
4.1.1.1	  Impaired	  vasculature	  in	  the	  cerebellum	  	  Vascular	  anomalies	  and	  subsequent	  hypoxia	  seem	  to	  be	  the	  common	  feature	  in	  the	  eye	  of	  patients	  harboring	  mutations	   in	  NDP,	  FZD4,	   and	  LRP5.	   Since	  patients	  with	  NDP	   and	  
LRP5	  mutations	  also	  show	  neurological	  symptoms,	  and	  brain	  anomalies	  were	  described	  in	   the	   Fzd4-­/-­	   mouse,	   the	   Ndph	   ko	   mouse	   was	   investigated	   with	   regard	   to	   cerebral	  vascular	   defects	   that	   might	   explain	   the	   observed	   mental	   impairments	   in	   patients.	  Transcript	   levels	  of	  the	  three	  EVR-­‐associated	  genes	  Ndph,	  Fzd4,	  and	  Lrp5,	  as	  well	  as	  of	  three	  hypoxia-­‐regulated	  angiogenic	  factors	  (Vegfa,	  Itgrb3,	  Tie1)	  were	  investigated	  in	  six	  different	  brain	  regions	  (cerebellum,	  cortex,	  hippocampus,	  olfactory	  bulb,	  pituitary	  gland	  and	  brain	  stem)	  of	  6-­‐8-­‐month-­‐old	  Ndph	  wt	  and	  ko	  mice.	  No	  significant	  differences	  were	  found	  between	  Ndph	  wt	  and	  ko	  mice	  (Figure	  45;	  Figure	  46).	  Nonetheless,	  reduced	  vessel	  density	  was	  found	  in	  the	  white	  matter	  of	  the	  Ndph	  ko	  cerebellum	  (Figure	  48;	  Figure	  49).	  Concordantly,	   expression	   of	  Ndph	   and	  Fzd4	  was	   highest	   in	   the	  wt	   cerebellum	   (Figure	  45),	   substantiating	   that	   an	   Ndph/Fzd4-­‐mediated	   signal	   involved	   in	   vascular	  development	  of	  the	  cerebellum	  could	  be	  associated	  with	  mental	  impairment	  in	  patients.	  	  Interestingly,	   while	   no	   ND	   patients	   were	   reported	   with	   cerebral	   vascular	   anomalies,	  reduced	  development	  of	  the	  CNS	  deep	  venous	  system	  in	  favor	  of	  a	  prominent	  superficial	  venous	   plexus	  was	   described	   in	   a	   Coats’	   patient	   (Robitaille	   et	   al.,	   1996).	   However,	   in	  contrast	  to	  the	  Fzd4-­/-­	  mouse	  (Wang	  et	  al.,	  2001),	  no	  reduction	  of	  Purkinje	  or	  granular	  cells	  was	  noted	  in	  the	  Ndph	  ko	  (Figure	  47).	  The	  more	  severe	  phenotype	  in	  the	  Fzd4-­/-­	  ko	  could	  indicate	  that	  ligands	  other	  than	  norrin	  might	  also	  be	  involved	  in	  the	  development	  of	  the	  cerebellar	  vasculature,	  which	  can	  in	  part	  compensate	  the	  loss	  of	  Ndph	   in	  the	  ko.	  Such	  a	  compensatory	  action	  of	  Wnt-­‐ligands	  has	  been	  suggested	   for	  axonal	  growth	  and	  synaptogenesis	  of	  cerebellar	  mossy	  ﬁbers	  as	  they	  ﬁnd	  their	  granule	  cell	   targets	  (Lucas	  and	  Salinas,	  1997;	  Hall	  et	  al.,	  2000).	  The	  lack	  of	  mental	  impairment	  in	  patients	  harboring	  
FZD4	   mutations	   (typically	   diagnosed	   as	   ad-­‐FEVR	   patients)	   might	   be	   due	   to	   their	  dominant	  nature	  in	  humans.	  So	  far,	  only	  one	  homozygous	  FZD4	  case	  was	  reported,	  but	  in	  contrast	  to	  the	  mouse	  model,	  no	  extraocular	  symptoms	  were	  observed	  (Kondo	  et	  al.,	  2007;	  Kondo,	  personal	  communication),	  maybe	  because	  the	  FZD4	  mutation	  (p.R417Q)	  is	  only	  hypomorphic,	  and	  not	  a	  complete	  loss-­‐of-­‐function	  as	  in	  the	  ko	  mouse.	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4.1.1.2	  Differential	  cerebellar	  expression	  of	  the	  glutamine	  transporter	  Slc38a5	  After	   global	   transcript	   analysis	   of	   the	   Ndph	   ko	   retina	   revealed	   the	   glial	   amino	   acid	  transporter	   Slc38a5	   to	   be	   lower	   expressed	   (Figure	   52),	   mRNA	   levels	   were	   also	  investigated	  in	  the	  brain,	  where	  it	  has	  already	  been	  found	  abundantly	  in	  astrocytic	  end	  feet	   (Cubelos	   et	   al.,	   2005).	   No	   differences	  were	   detected	   in	   adult	   brains,	   but	   reduced	  expression	   of	   Slc38a5	   was	   found	   in	   the	   cerebellum	   of	   p21	  Ndph	   ko	  mice	   (Figure	   58;	  Hänseler,	  Masterthesis,	  2008),	  the	  region	  where	  Ndph	   is	  expressed	  the	  most	  among	  all	  investigated	  wt	  brain	  regions	  (Table	  36).	  Antibody-­‐staining	  of	  cryosections	  appeared	  to	  be	  stronger	  in	  sections	  from	  norrin	  wt	  mice,	  and	  was	  most	  intense	  around	  the	  Purkinje	  cells	   (Figure	   59).	   This	   correlates	   with	   the	   finding	   that	   Slc38a5	   has	   been	   located	   to	  Bergmann	  glia	  (Cubelos	  et	  al.,	  2005).	  Their	  cell	  somata	  are	   located	   in	   the	  Purkinje	  cell	  layer,	  and	  their	  processes	  expand	  into	  the	  molecular	  layer,	  ensheating	  parallel	  fiber	  cell	  terminals	  and	  synapses	  of	  Purkinje	  cells	  with	  climbing	  fibers.	  Both	  climbing	  fibers	  and	  parallel	  fibers	  excitate	  Purkinje	  cells	  using	  glutamate	  (or	  aspartate)	  as	  neurotransmitter.	  Since	  Slc38a5	  has	  been	  reported	  as	  an	   important	  glutamine	   transporter	   (Umapathy	  et	  al.,	  2005),	  reduced	  expression	  in	  the	  Ndph	  ko	  cerebellum	  could	  hint	  to	  another	  possible	  pathogenic	  mechanism	   in	   the	   brain	   that	   could	   explain	   the	  mental	   impairments	   in	  ND	  patients.	  Based	  on	  the	  published	  localization	  of	  Slc38a5	  in	  Bergmann	  glia	  and	  our	  own	  observations,	  it	  is	  tempting	  to	  speculate	  that	  Norrin	  induces	  expression	  of	  Slc38a5	  in	  the	  retina	  and	  cerebellum,	  and	  that	   lack	  of	  norrin	   leads	  to	  reduced	  levels	  of	   the	  glutamine	  transporter	  in	  these	  tissues.	  Glutamate/glutamine	  homeostasis	  would	  be	  disturbed,	  and	  excitatory	   signaling	   of	   granule	   cells	   and	   climbing	   fibers	   on	   Purkinje	   cells	   would	   be	  impaired.	   Since	   this	   neuronal	   network	   is	   primarily	   involved	   in	   fine-­‐tuning	   of	   motor	  control	   and	   learning,	   altered	   signaling	   could	   induce	  a	   cerebellar	  ataxia-­‐like	  phenotype	  similar	   to	   that	   reported	   in	  Fzd4-­/-­	  mice.	   Cerebellar	   anomalies,	   however,	   are	   harder	   to	  associate	  with	  the	  mental	  disabilities	  typically	  seen	  in	  ND	  patients,	  like	  autistic	  features,	  cognitive	   impairment	   (low	   IQ	   to	   severe	   MR),	   seizures,	   or	   developmental	   delay.	  Nonetheless,	  cerebellar	  ataxia	  has	  been	  described	  in	  several	  CD	  patients	  (Tolmie	  et	  al.,	  1988;	  Révész	  et	  al.,	  1992;	  Goutieres	  et	  al.,	  1999).	  
4.1.1.3	  Synopsis	  In	  summary,	  investigation	  of	  the	  Ndph	  ko	  brain	  added	  further	  evidence	  to	  the	  hypothesis	  that	   the	   unifying	   feature	   of	   all	   observed	   symptoms	   in	   eye,	   ear,	   brain,	   female	  reproductive	   system,	   and	   peripheral	   venous	   system	   is	   a	   defect	   in	   angiogenesis.	   In	  addition,	  differential	  expression	  of	  a	  glutamine	  transporter	  in	  cerebellar	  glia	  cells	  could	  indicate	  impaired	  synaptic	  transmission	  in	  and	  function	  of	  cerebellar	  motor	  circuits.	  	  	  
4.1.2	  Analyses	  of	  the	  retina	  Consistent	  with	  data	  obtained	  from	  other	  developmental	  stages	  (Luhmann	  et	  al.,	  2005a),	  examination	   of	   the	   p7	  Ndph	   knockout	  mice	   showed	   insufficient	   retinal	   capillarization	  and	  lack	  of	  deep	  vessel	  formation.	  Vascular	  permeability	  has	  not	  been	  observed	  only	  in	  later,	   nearly	   adult	   stages,	   but	   was	   noted	   throughout	   development,	   as	   indicated	   by	  elevated	  mRNA	   and	   protein	   expression	   data	   for	   Plvap.	   Although	   norrin’s	   hypothetical	  role	  as	  a	  transcriptional	  regulator	  of	  Wnt/β-­‐catenin	  target	  genes	  was	  not	  obvious	  from	  the	  array	  experiment,	  I	  was	  able	  to	  substantiate	  the	  finding	  that	  Norrin	  is	  important	  for	  retinal	   angiogenesis.	   Several	   genes	   probably	   implicated	   in	   blood	   vessel	   development	  that	  may	  be	  transcriptionally	  regulated	  by	  Norrin	  were	  identified.	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4.1.2.1	  Possible	  implications	  of	  microarray-­‐detected	  differentially	  expressed	  genes	  Differential	   expression	   of	   five	   genes	   that	   were	   conspicuous	   in	   the	   microarray	  experiment	  could	  be	  confirmed	  by	  qRT-­‐PCR.	  Since	  the	  role	  of	  these	  five	  genes	  has	  been	  discussed	  extensively	  in	  the	  IOVS	  publication,	  I	  just	  want	  to	  give	  a	  short	  summary	  in	  the	  following	  paragraph,	  extended	  by	  a	  few	  additional	  arguments.	  Three	   genes	   showed	   a	   decreased	   expression	   in	   the	   ko:	   the	   neutral	   amino	   acid	  transporter	   Slc38a5	   (24x	   less),	   apolipoprotein	   D	   (ApoD;	   2.4x	   less),	   and	   angiotensin	   II	  receptor-­‐like	  1	  (Agtrl1;	  2x	   less).	   Increased	  expression	  was	  found	  for	  the	  plasmalemma	  vesicle	  associated	  protein	  (Plvap;	  4.2x	  higher)	  and	  adrenomedullin	  (Adm;	  2.7x	  higher).	  
Slc38a5	  and	  Plvap	  mRNA	  expression	  in	  addition	  was	  shown	  to	  be	  significantly	  different	  not	  only	  at	  p7,	  but	  also	  at	  p5,	  p10,	  p15,	  and	  p21.	  Differences	  were	  especially	  apparent	  in	  the	  retinal	  cryosections	  stained	  with	  an	  antibody	  against	  Plvap.	  
4.1.2.1.1	  Plasmalemma	  vesicle	  associated	  protein	  (Plvap)	  The	   experimental	   results	   suggested	   an	   early	   involvement	   of	   plasmalemma	   vesicle-­‐associated	  protein	  (Plvap)	  in	  the	  pathogenesis	  of	  NDP-­‐related	  retinopathies.	  It	  remains	  to	   be	   shown	   whether	   a	   possible	   mode	   of	   action	   for	   Norrin,	   besides	   transcriptional	  regulation	   via	   the	   Wnt/β-­‐catenin	   pathway,	   might	   be	   a	   direct	   modulation	   of	   the	  microtubule	  cytoskeleton	  (Salinas,	  2007)	  or	  Plvap	  itself.	  Regardless	  the	  exact	  molecular	  function,	   I	  hypothesized	   that	   transient	  Plvap	  expression	  and	   fenestration	  occur	  during	  maturation	  of	  the	  retinal	  vasculature	  and	  that	  Norrin	  signaling	  is	  possibly	  required	  for	  its	  suppression.	  Norrin	  thus	  may	  be	  involved	  in	  sprouting	  angiogenesis	  as	  well	  as	  in	  the	  formation	   and	   maintenance	   of	   the	   blood-­‐retina-­‐	   or	   blood-­‐brain-­‐barrier.	   Interestingly,	  Plvap	  expression	  appeared	  especially	  prominent	  in	  veins	  (Figure	  55),	  which	  correlates	  with	   the	   finding	   that	  deeper	  networks	   start	   to	  develop	   from	  veins	  and	  capillaries,	  but	  not	  arteries	  (Fruttiger,	  2007).	  
4.1.2.1.2	  Solute	  carrier	  family	  38,	  member	  5	  (Slc38a5)	  The	  role	  of	  solute	  carrier	  family	  38,	  member	  5	  (Slc38a5)	  is	  less	  clear.	  Slc38a5	  has	  been	  reported	   to	   be	   a	   main	   glutamine	   transporter	   in	   retinal	   Müller	   cells	   (system	   N2)	  (Umapathy	   et	   al.,	   2005),	   and	   therefore	  may	  play	   an	   important	   role	   in	   neuronal	   signal	  transduction	   through	   regulation	   of	   the	   glutamate/glutamine	   household.	   Its	   decreased	  expression	   in	   Ndphy/-­	   mice	   (Figure	   52)	   may	   indicate	   an	   involvement	   of	   Norrin	   in	  neuronal	  differentiation	  or	  synaptogenesis,	  which	  would	  correlate	  with	  the	  reduced	  ERG	  activity	  found	  in	  the	  inner	  retina	  (Berger	  et	  al.,	  1996;	  Rüther	  et	  al.,	  1997).	  Another	  role	  could	  be	  impaired	  communication	  between	  Müller	  cells	  and	  developing	  retinal	  vessels,	  for	  which	  they	  serve	  as	  guidance	  structures	  (Fruttiger,	  2007).	  
4.1.2.1.3	  Angiotensin	  II	  receptor-­‐like	  1	  (Agtrl1)	  Angiotensin	  II	  receptor-­‐like	  1	  (Agtrl1),	  or	  apelin	  receptor	  (APLNR),	  has	  been	  described	  as	  venous	  marker	  (Saint-­‐Geniez	  et	  al.,	  2003)	   that	   is	   important	   for	  retinal	  angiogenesis	  (Kasai	  et	  al.,	  2004).	  The	  2-­‐fold	  decreased	  expression	  in	  the	  p7	  Ndph	  ko	  retina	  (Figure	  63	  A)	  coincides	  with	  the	  observed	  impaired	  vascular	  development,	  but	  could	  merely	  reflect	  reduced	   vessel	   density	   or,	   considering	   the	   venous/capillary	   nature	   of	   the	   deep	   vessel	  system	   (Fruttiger,	   2007),	   a	   lack	   of	   development	   of	   this	   particular	   network.	   The	   last	  consideration	   probably	   is	   more	   likely,	   because	   no	   significant	   expression	   differences	  were	   found	   in	   the	   p5	   retina.	   Upon	   binding	   of	   its	   ligand	   apelin,	   Agtrl1	   signals	   via	   the	  ERK1/2	  MAPK-­‐pathway	  (Bai	  et	  al.,	  2008).	  Like	  FZD4	  and	  LRP5,	  AGTRL1	  is	  located	  on	  the	  proximal	  part	  of	  the	  long	  arm	  of	  chromosome	  11	  (11q12).	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4.1.2.1.4	  Apolipoprotein	  D	  (ApoD)	  In	   contrast,	   transcript	   levels	  of	   apolipoprotein	  D	   (ApoD)	  were	  not	  only	   reduced	  at	  p7,	  but	  also	  at	  p5	   (Figure	  61).	   It	   could	  be	   implicated	   in	   the	  observed	  angiogenic	  defect	  of	  
Ndphy/-­	  mice,	  because	  ApoD	  has	  been	  reported	  to	  stimulate	  proliferation	  and	  migration	  of	  vascular	   smooth	  muscle	   cells	   (Leung	  et	   al.,	   2004),	  probably	   through	  suppression	  of	  Pdgf-­‐bb-­‐mediated	   proliferation	   through	   inhibition	   of	   ERK1/2	   nuclear	   translocation	  (Sarjeant	  et	  al.,	  2003).	  A	  possible	  functional	  relationship	  between	  norrin	  and	  ApoD	  could	  further	   be	   indicated	   by	   co-­‐expression	   of	   these	   two	   genes	   in	   disease-­‐affected	   organs.	  Besides	   the	   retina,	   APOD	   has	   been	   shown	   to	   be	   upregulated	   in	   human	   endometrium	  during	  implantation	  (Kao	  et	  al.,	  2002),	  a	  process	  that	  is	  disturbed	  in	  female	  homozygous	  norrin	   knockout	   mice	   (Luhmann	   et	   al.,	   2005b).	   Further,	   ApoD	   expression	   was	   also	  reported	   in	   the	   inner	   ear,	   another	   affected	   organ	   in	  Norrie	   disease	   patients	   and	  mice	  (Rehm	   et	   al.,	   2002),	   where	   it	   has	   been	   suggested	   to	   be	   implicated	   in	   cochlear	   fluid	  homeostasis	  (Hildebrand	  et	  al.,	  2005).	  	  
4.1.2.1.5	  Adrenomedullin	  (Adm)	  Adrenomedullin	  (Adm)	  is	  a	  hypoxia	  induced	  vasodilating	  peptide	  (Ogita	  et	  al.,	  2001)	  that	  has	  been	  suggested	  to	  be	  vascular	  protective	  (Ando	  and	  Fujita,	  2003).	  In	  addition	  to	  p7,	  
Adm	  transcript	  expression	  was	  elevated	  even	  more	  in	  the	  Ndph	  ko	  retina	  at	  p21	  (Figure	  63	  B).	  This	  finding	  correlates	  with	  the	  observation	  that	  adrenomedullin	  inhibits	  vascular	  remodeling	  (Matsui	  et	  al.,	  2004).	  Although	  high	  Adm	   levels	  at	  p21	  could	  be	  a	  result	  of	  retinal	  hypoxia,	  it	  is	  tempting	  to	  speculate	  that	  norrin-­‐mediated	  enhanced	  expression	  of	  
Adm	   causes	   the	  defects	   in	  retinal	  vascularization	  due	   to	   its	  anti-­‐angiogenic	  properties.	  Like	  Agtrl1,	  ApoD,	  and	  Plvap,	  Adm	  seems	  to	  be	   involved	  in	  MAPK-­‐signaling,	  because	   it	  has	   been	   found	   to	   act	   as	   a	   survival	   factor	   in	   osteoblastic	   cells	   via	   a	   CGRP1	  receptor/MEK-­‐ERK	   pathway	   (Uzan	   et	   al.,	   2008).	   The	   genes	   for	   the	   CGRP1-­‐receptor	  (CALCA)	  and	  ADM	  itself	  are	  located	  on	  chromosome	  11p15.	  	  
4.1.2.2	  Further	  genes	  possibly	  involved	  in	  the	  pathogenesis	  of	  ND	  The	  microarray	  experiment	  provided	  additional	  candidate	  genes	  that	  could	  be	  involved	  in	   ND	   pathogenesis.	   They	   appeared	   on	   the	   list	   of	   differentially	   expressed	   transcripts	  (Table	   40)	   or	   at	   least	   on	   the	   complete	   list	   without	   multiple	   testing	   correction	  (appendix),	   but	   could	   not	   be	   verified	   by	   qRT-­‐PCR.	   The	   discrepancy	   between	   the	  microarray	   and	   the	   qRT-­‐PCR	   results	   most	   likely	   has	   various	   reasons.	   Besides	   the	  technical	  differences	  of	  the	  experimental	  setup,	  microarray	  calculation	  procedures	  that	  transform	   raw	  data	   into	   expression	   estimates	   are	   distinct	   and	   vary	   depending	   on	   the	  platform,	   laboratory,	   and	   researchers	   involved	   (Gyorffy	   et	   al.,	   2009).	   Background	  correction,	  normalization,	  and	  summarization	  of	  multiple	  probes	  are	  typically	  combined	  in	   a	   preprocessing	   algorithm	   that	   is	   intended	   to	   standardize	   analyses.	   But	   each	  algorithm	   is	   based	   on	   its	   own	   set	   of	   assumptions,	   and	   no	   gold	   standard	   can	   be	  formulated	  for	  experimental	  research.	  The	  same,	  maybe	  in	  a	  lesser	  extent,	  applies	  to	  the	  analysis	   of	   qRT-­‐PCR	   data	   (Skern	   et	   al.,	   2005).	   Here,	   in	   addition,	   selection	   of	   the	  appropriate	  reference	  gene	  is	  of	  critical	  importance	  (Radonić	  et	  al.,	  2004).	  Depending	  on	  the	  nature	  of	   the	  expected	  data,	   each	   researcher	  has	   to	  decide	  which	  analysis	  method	  might	   be	   best	   suited	   for	   his/her	   experimental	   setup.	   Thus,	   conclusions	   from	   gene	  expression	  experiments	  are	  substantially	  influenced	  by	  the	  chosen	  set	  of	  algorithms.	  To	  make	  biological	   sense	  out	  of	   a	   set	  of	  numbers,	   it	   is	   good	  practice	   to	  use	   two	  different	  methods	  to	  estimate	  the	  significance	  of	  an	  experimental	  finding	  (Imbeaud	  et	  al.,	  2005).	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For	  this	  reason,	  I	  aimed	  to	  validate	  the	  microarray	  findings	  by	  qRT-­‐PCR.	  Data	  that	  could	  be	   confirmed	   was	   treated	   as	   more	   reliable,	   but	   that	   does	   not	   exclude	   biological	  significance	  for	  genes	  that	  only	  emerged	  in	  one	  experiment.	  Thus,	  it	  might	  be	  interesting	  to	  analyze	  their	  role	  in	  future	  research.	  
4.1.2.2.1	  Claudin	  5	  (Cldn5)	  Claudin	   5	   (Cldn5)	   plays	   a	   major	   role	   in	   tight	   junction-­‐specific	   obliteration	   of	   the	  intercellular	  space	  in	  CNS	  endothelial	  cells	  (Nitta	  et	  al.,	  2003).	  Thus,	  reduced	  expression	  of	  Cldn5,	  in	  addition	  to	  elevated	  expression	  of	  Plvap,	  could	  explain	  leakiness	  of	  vessels	  in	  the	  Ndph	   ko.	   However,	   differences	   at	   the	   transcript	   level	   as	   determined	   by	   qRT-­‐PCR	  were	  not	  significant,	  although	  a	  trend	  to	  reduced	  expression	  could	  be	  observed	  (Figure	  63	  C).	  
4.1.2.2.2	  ATP-­‐binding	  cassette,	  sub-­‐family	  B	  (MDR/TAP),	  member	  1A	  (Abcb1a)	  Differential	   expression	  of	  ATP-­‐binding	   cassette,	   sub-­‐family	  B	   (MDR/TAP),	  member	  1A	  (Abcb1a)	  could	  not	  be	  confirmed	  by	  qRT-­‐PCR	  (Figure	  64),	  but	  it	  was	  the	  second-­‐lowest	  differentially	   expressed	   gene	   in	   the	   microarray	   experiment	   (down	   4.9x).	   It	   has	   been	  shown	   to	   be	   Wnt-­‐regulated	   (Wielenga	   et	   al.,	   1999).	   It	   is	   a	   cell-­‐surface	   glycoprotein	  involved	  in	  cell-­‐cell	   interactions,	  cell	  adhesion	  and	  migration,	  plays	  a	  major	  role	   in	  the	  blood-­‐brain	  barrier	  and	  permeability	  for	  certain	  drugs	  (Schinkel	  et	  al.,	  1994),	  can	  bind	  to	  matrix	  metalloproteinases,	  and	  is	  involved	  in	  tumour	  development	  (Comerford	  et	  al.,	  2002).	   Thus,	   reduced	   expression	   in	   the	   Ndph	   ko	   retina	   would	   be	   consistent	   with	   a	  possible	  Wnt-­‐mediated	  regulation	  through	  norrin,	  which	  could	  be	  involved	  in	  enhanced	  vascular	  permeability	  and	  reduced	  angiogenic	  activity.	  
4.1.2.2.3	  Von	  Willebrand	  factor	  (Vwf)	  Von	   Willebrand	   factor	   homolog	   (Vwf)	   is	   expressed	   in	   platelets	   that	   could	   induce	  capillary	   sprouting	   of	   microvascular	   endothelial	   cells	   (Rhee	   et	   al.,	   2004).	   Reduced	  expression	   in	   the	  Ndph	   ko	   retina	   could	   indicate	   reduced	   amounts	   of	   platelets	   in	   the	  retinal	  vasculature,	  or	  the	  missing	  ability	  of	  platelets	  to	  bind	  to	  angiogenic	  sprouting	  tips	  (Kisucka	  et	  al.,	  2006),	  and	  thus	  account	  for	  reduced	  vascular	  development	  in	  the	  Ndph	  ko	  mouse.	  However,	  the	  indicated	  reduced	  expression	  could	  not	  be	  confirmed	  by	  qRT-­‐PCR	  (Figure	  64).	  	  
4.1.2.3	  Analysis	  of	  neuronal	  markers	  in	  the	  retina	  Most	   data	   from	   the	   analysis	   of	   the	   norrin	   ko	   mouse	   support	   the	   hypothesis	   that	  impairment	  of	  the	  retinal	  vascular	  development	  is	  the	  first	  pathogenic	  event,	  and	  effects	  on	  the	  neural	  retina	  occur	  only	  secondarily	  (Luhmann	  et	  al.	  2005a;	  this	  work).	  If	  Norrin	  in	  the	  first	  place	  is	  essential	  for	  the	  development	  of	  the	  retinal	  vasculature,	  the	  Ndph	  ko	  mouse	   could	   serve	   as	   a	   model	   to	   investigate	   neuronal	   development	   under	   hypoxic	  conditions.	  However,	  norrin	  has	  also	  been	  suggested	  to	  have	  a	  direct	  neurotrophic	  effect	  (Ohlmann	   et	   al.,	   2005).	   Therefore,	   if	   further	  data	  would	   indicate	   early	   involvement	   of	  norrin	   in	   neuronal	   differentiation,	   maturation,	   or	   migration,	   the	   hypothesis	   of	   an	  initially	  impaired	  vessel	  development	  would	  have	  to	  be	  reevaluated.	  Based	  on	  the	  analyses	  of	  several	  neuronal	  markers	  (Islet-­‐1,	  beta-­‐tubulin,	  neurofilament	  150kDa,	   ChAT,	   PKC-­‐α,	   calbindin	   28kd,	   SNAP	   25,	   synaptophysin),	   no	   differences	  were	  found	  in	  the	  p5	  Ndph	  ko	  retina,	  supporting	  the	  hypothesis	  that	  neuronal	  changes	  occur	  secondarily	   to	  vascular	   changes.	  At	   later	   stages,	   alterations	  of	   the	   retinal	  morphology,	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especially	   in	   the	   ganglion	   cell	   layer,	   seemed	   to	   correlate	   with	   tissue	   invasion	   by	  pathognomonic	   retinal	   vessels	   (Figure	   76	   C)	   in	   accordance	   with	   previously	   reported	  findings	  (Berger	  et	  al.,	  1996).	  Background	  staining	  of	  the	  plexiform	  layers	  appeared	  to	  be	  higher	   in	   the	  ko	   retinas,	  possibly	  due	   to	   increased	  permeability	   and	   leakage	  of	   the	  vasculature,	  and	  thus	  presence	  of	  IgGs	  in	  those	  areas.	  We	  observed	  a	  trend	  to	  reduced	  numbers	   of	   ganglion	   cells,	   similar	   to	   previous	   observations	   (Richter	   et	   al.,	   1998).	  Neuronal	   damage	  was	   indicated	   by	   a	   reduced	   protein	   level	   of	   the	  RGC	  marker	   islet-­‐1	  (Isl-­1)	   at	   p21,	   and	   an	   altered	   protein	   expression	   of	   synaptophysin	   (Syp)	   (Figure	   68;	  Figure	  70).	  However,	  these	  changes	  were	  not	  present	  on	  mRNA	  level	  (Figure	  69;	  Figure	  72).	   In	   contrast,	  mRNA	   transcript	   levels	  of	   the	   solute	   carrier	  Slc38a5	  were	   reduced	   in	  the	  ko	  during	   the	  whole	  postnatal	   retinal	  development	   (Figure	  52),	  but	  no	  differences	  were	  found	  in	  immunohistochemically	  stained	  cryosections	  (Figure	  57).	  
	  
4.1.2.3.1	  Islet-­‐1	  (Isl-­‐1)	  Islet-­‐1	  (Isl-­1)	  is	  a	  transcription	  factor	  under	  the	  control	  of	  Wnt/β-­‐catenin	  signaling	  that	  has	  been	  shown	  to	  be	  involved	  in	  proliferation	  and	  survival	  of	  cardiac	  progenitor	  cells	  (Lin	   et	   al.,	   2007).	   It	   is	   also	   indispensable	   for	   retinal	   neuron	   differentiation,	   as	   a	  conditional	   loss	   of	   Isl-­1	   led	   to	   significant	   reductions	   of	   mature	   ON-­‐	   and	   OFF-­‐bipolar	  (>76%),	  cholinergic	  amacrine	  (93%),	  and	  ganglion	  (71%)	  cells	  (Elshatory	  et	  al.,	  2007).	  Thus,	   it	   could	   be	   hypothesized	   that	   Isl-­1	   is	   under	   transcriptional	   control	   of	  
Ndph/Fzd4/Lrp5-­‐signaling,	   and	   that	   lack	   of	   this	   signaling	   in	   ND	   patients	   leads	   to	  impaired	   maturation	   of	   bipolar	   and	   amacrince	   cells,	   as	   well	   as	   reduced	   viability	   of	  retinal	  ganglion	  cells.	  Lack	  of	  Isl-­‐1	  immunoreactivity	  in	  the	  retina	  of	  p21	  Ndph	  ko	  mice	  supports	  this	  hypothesis,	  as	  well	  as	  the	  possibly	  reduced	  staining	  in	  p5	  Ndph	  ko	  bipolar	  cells,	  hinting	  to	  a	  function	  of	  norrin	  in	  the	  differentiation	  and	  survival	  of	  neuronal	  cells	  in	  agreement	  with	  its	  proposed	  neurotrophic	  function	  (Ohlmann	  et	  al.,	  2005).	  However,	  the	   detected	   staining	   differences	   at	   p5	   could	   be	   only	   due	   to	   the	   center-­‐to-­‐periphery	  gradient	  of	  retinal	  neuronal	  differentiation,	  or	  a	  slightly	  different	  developmental	  stage	  of	  the	   investigated	   animals.	   Also	   opposing	   the	   possible	   involvement	   of	   Isl-­1	   in	   the	  pathogenesis	  of	  ND	   is	   the	   finding	  of	   similar	  expression	   in	  wt	  and	  ko	  on	   the	   transcript	  level	  at	  p5	  and	  p21	  (Figure	  72).	  	  
4.1.2.3.2	  Synaptophysin	  (Syp)	  Synaptophysin	   (Syp)	   is	   one	   of	   the	   most	   abundantly	   expressed	   proteins	   in	   synaptic	  vesicles	   (Calhoun	   et	   al.,	   1996),	   and	   is	   thought	   to	   negatively	   modify	   the	   release	   of	  synaptic	  vesicles	   through	  binding	   to	   synaptobrevin	   (Syb)	   (Edelmann	  et	  al.,	   1995).	  The	  retinal	  staining	  pattern	  of	  synaptophysin	  differed	  between	  Ndph	  wt	  and	  ko,	  especially	  at	  p21	  (Figure	  68).	  A	   typical	  pattern	  of	  small	  spots	  was	  visible	   in	   the	  plexiform	   layers	  of	  the	  wild	  type,	  indicating	  numerous	  synapses.	  In	  the	  knockout,	  labeling	  was	  weaker	  and	  more	  diffuse.	   In	   the	  samples	   from	  p5	  animals,	  only	  very	   faint	  staining	  was	  detected	   in	  the	   wt,	   and	   no	   immunoreactivity	   for	   Syp	   could	   be	   observed	   in	   the	   ko.	   However,	   no	  significant	  differences	  in	  mRNA	  expression	  could	  be	  detected	  at	  either	  p5	  or	  p21	  (Figure	  69).	  Analysis	  of	  a	  Syp	  knockout	  mouse	  revealed	   that	  behavior	  and	  appearance	  of	  mice	  lacking	   Syp	   was	   indistinguishable	   from	   that	   of	   their	   wild	   type	   litter	   mates	   and	   that	  synaptic	   transmission	  was	  normal	  with	  no	  detectable	  changes	   in	  synaptic	  plasticity	  or	  the	   probability	   of	   release	   (McMahon	   et	   al.,	   1996).	   This	   implied	   that	   the	   function	   of	  synaptophysin	   is	   redundant	   or	   has	   only	   a	   subtle	   effect	   on	   synpatic	   vesicle	   release.	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Nonetheless,	  synaptophysin	  was	  upregulated	  198-­‐fold	  in	  the	  rat	  retina	  after	  optic	  nerve	  transection	   (Piri	   et	   al.,	   2006),	   and	   has	   recently	   been	   associated	   with	   mild	   mental	  retardation	   and	   occasional	   seizures	   (Tarpey	   et	   al.,	   2009).	   Besides	   its	   role	   in	   the	   CNS,	  synaptophysin	   has	   been	   suggested	   to	   be	   involved	   in	   intracellular	   transport	   and	   the	  release	   of	   hormones	   in	   the	   gastrointestinal	   tract,	   e.g.	   in	   serotonin-­‐producing	  enterochromaffin	   cells	   (Portela-­‐Gomes	   et	   al.,	   1999).	   Since	   SYP	   is	   located	   on	   the	   short	  arm	   of	   the	   X	   chromosome	   (Xp11.23-­‐p11.22),	   only	   about	   5cM	   from	   the	   NDP	   locus,	  mutations	  are	  likely	  to	  co-­‐segregate	  with	  NDP	  mutations	  and	  could	  contribute	  to	  some	  of	  the	  interfamilial	  differences	  with	  regard	  to	  the	  severity	  of	  ND.	  Taken	   together,	   the	   cellular	   composition	   of	   the	   neural	   retina	   seems	   to	   be	   mainly	  unaffected	  in	  the	  Ndph	  ko	  mouse.	  All	  investigated	  cell	  types	  were	  similarly	  present	  in	  the	  ko	   retina,	   only	   the	   number	   of	   ganglion	   cells	   appears	   to	   decrease	   at	   p21,	   as	   has	   been	  previously	   reported	   (Richter	   et	   al.,	   1998).	   Evidence	   was	   provided	   that	   their	   function	  could	   be	   impaired,	   as	   demonstrated	   by	   an	   aberrant	   protein	   expression	   of	   islet-­‐1	   and	  synaptophysin,	   and	   different	   mRNA	   transcript	   levels	   for	   the	   glutamine-­‐transporter	  
Slc38a5.	   However,	   a	   conclusive	   statement	   about	   their	   role	   in	   ND	   and	   allelic	   diseases	  remains	  elusive.	  Future	  research	  could	  detect	  hypoxia-­‐induced	  impairment	   in	  synaptic	  transmission,	  which	  would	  correlate	  with	   the	  reduced	  ERG-­‐activity	  of	   the	   inner	  retina	  found	  in	  Ndph	  ko	  mice	  (Berger	  et	  al.,	  1996;	  Rüther	  et	  al.,	  1997).	  On	  the	  other	  side,	  based	  on	   the	   presented	   results,	   I	   would	   not	   exclude	   a	   primary	   role	   for	   Wnt-­‐signaling	  controlled	  decreased	  or	  ectopic	  expression	  of	  Isl-­1	  that	  could	  lead	  to	  a	  maturation	  defect	  and	   reduced	   viability	   of	   retinal	   neurons,	   or	   an	   important	   role	   of	   dysregulated	   Syp	  expression	  in	  the	  control	  of	  vascular	  development	  through	  impaired	  neuronal	  secretion	  of	  angiogenic	  factors.	  	  
4.1.2.4	  Differences	  in	  retinal	  miRNA	  expression	  Micro	   RNAs,	   in	   addition	   to	   messenger	   RNAs,	   present	   another	   level	   of	   gene	   activity	  regulation,	   which	   has	   been	   investigated	   only	   very	   limited	   so	   far.	   Recently,	   several	  miRNAs	  were	  found	  to	  be	  differently	  expressed	  in	  the	  retina	  under	  hypoxic	  conditions	  (Shen	  et	  al.,	  2008).	  Specifically,	  miR-­‐31,	  miR-­‐150,	  and	  miR-­‐184	  were	   lower	  expressed,	  and	   injection	   of	   pre-­‐miR-­‐31,	   pre-­‐miR-­‐150,	   or	   pre-­‐miR-­‐184	   reduced	   ischemia-­‐induced	  retinal	  neovascularization.	  Thus,	  the	  reported	  data	  suggested	  a	  crucial	  role	  for	  miRNAs	  in	  ocular	  vascular	  development.	  Since	  norrin	  is	  required	  for	  early	  angiogenic	  sprouting	  and	  the	  formation	  of	  deep	  retinal	  capillary	  networks,	  probably	   through	  transcriptional	  regulation	  of	   target	  genes	  via	   the	  Wnt/β-­‐catenin	   pathway,	   I	   investigated	   if	   lack	   of	   Norrin	   had	   an	   influence	   on	   the	  transcription	  of	  miRNAs	  that	  could	  be	  involved	  in	  retinal	  blood	  vessel	  development.	  	  Two	   developmental	   stages	   were	   investigated,	   p5	   and	   p21.	   No	   differences	   in	   global	  miRNA	  expression	  were	  found	  in	  the	  Ndph	  ko	  p5	  retina.	  At	  p21,	  12	  miRNAs	  exhibited	  a	  fold	   change	   over	   1.3	   (Figure	   66).	   Eight	   (66.6%)	   of	   the	   12	  miRNAs	  with	   a	   fold	   change	  greater	   than	   1.3	   were	   also	   described	   as	   differentially	   expressed	   in	   the	   hypoxic	   OIR	  retina	   in	   the	   study	   by	   Shen	   et	   al.	   (Figure	   113),	   although	   their	   fold	   change	   differences	  were	  generally	  higher	  (e.g.	  expression	  of	  the	  most	  decrased	  miRNA	  mmu-­‐miR-­‐184	  was	  11.3x	  down).	  One	  of	  those	  miRNAs	  (mmu-­‐miR-­‐211)	  was	  present	  in	  the	  opposite	  group,	  however	   (i.e.	   1.4-­‐fold	   reduced	   expression	   in	   the	   Ndph	   ko,	   but	   2-­‐fold	   increased	  expression	   in	  the	  OIR	  model).	  As	  expected,	  comparison	  of	   these	  data	  suggests	  that	   the	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Ndph	  ko	  retina	  is	  in	  a	  similar	  (presumably	  hypoxic)	  condition	  as	  in	  the	  OIR	  model.	  None	  of	   the	   three	  miRNAs	   that	   Shen	   et	   al.	   could	   prove	   to	   inhibit	   blood	   vessel	   development	  (mmu-­‐miR-­‐31,	   -­‐150,	   -­‐184)	  was	  differentially	  expressed	   in	   the	  p21	  Ndph	  ko	  retina,	  nor	  were	  mmu-­‐miR-­‐221/-­‐222,	  which	  were	   reported	   to	   inhibit	  HUVEC	  migration	   and	   tube	  formation	  (Poliseno	  et	  al.,	  2006).	  The	  fact	  that	  litter-­‐specific	  differences	  in	  p5	  retinal	  miRNA	  expression	  were	  bigger	  than	  
Ndph	  genotype-­‐specific	  differences	  implies	  that	  we	  could	  not	  detect	  a	  direct	  influence	  of	  norrin	   on	   the	   expression	   of	   miRNAs	   that	   could	   account	   for	   the	   impaired	   retinal	  development.	  Expression	  changes	  of	  miRNAs	   in	   later	   stages	  are	  probably	   the	   result	  of	  the	  hypoxic	  environment,	  as	  indicated	  by	  the	  high	  similarity	  of	  differentially	  expressed	  miRNAs	  in	  the	  p21	  norrin	  ko	  and	  the	  hypoxic	  OIR	  retina.	  	  
	  
Figure	  113	  Comparison	  between	  the	  12	  most	  differentially	  expressed	  miRNAs	  of	  the	  p21	  Ndph	  ko	  retina	  with	  the	  hypoxic	  retina	  described	  by	  Shen	  et	  al.,	  2008.	  Expression	  of	  7	  miRNAs	  was	  also	  different	  in	  their	  study	  (light	  blue),	  and	  one	  miRNA	  (miR-­‐211)	  was	  differentially	  expressed	  in	  the	  opposite	  direction:	  lower	  in	  the	  Ndph	  ko,	  but	  higher	  in	  their	  study	  (orange).	  The	  remaining	  4	  differentially	  expressed	  miRNAs	  were	  not	  mentioned	  in	  their	  study	  (dark	  blue).	  	  
4.1.2.4.1	  Possible	  effects	  on	  target	  genes	  A	  database	  search	  on	  39	  representatively	  selected,	  putative	  angiogenesis-­‐related	  genes	  revealed	   that	   18	   harbor	   a	   binding	   site	   for	   at	   least	   one	   of	   the	   miRNAs	   differentially	  expressed	   in	   the	   p21	  Ndph	   ko	   retina	   (Table	   41).	   Four	   genes	   (Igf1,	   Notch3,	   Dvl3,	   and	  
Slc38a5)	   are	   recognized	   by	   several	   miRNAs.	   The	   miRNA	   recognizing	   the	   most	   of	   the	  selected	  genes	  is	  mmu-­‐miR-­‐27a	  (5	  targets:	  Igf1,	  Cldn5,	  Dvl2,	  Notch2,	  and	  Notch4).	  Interestingly,	   none	   of	   these	   39	   genes	   is	   recognized	   by	   the	   miRNA	   with	   the	   highest	  differential	   expression:	  mmu-­‐miR-­‐322	   (2.2x).	   However,	   it	   is	   predicted	   to	   bind	   to	   880	  genes	  such	  as	  Chat,	  Dll1,	  Efna5,	  Epha7,	  Fgf8,	  Fgfr1,	  Icam1,	  Ifng,	  Igf1r,	  Lrp6,	  Pecam1,	  and	  
Timp4.	  The	   gene	   encoding	   the	   precursor	   of	  mmu-­‐miR-­‐322	   is	   situated	   34Mb	   from	   the	  
Ndph	  locus	  on	  chromosome	  X,	  which	  roughly	  correlates	  to	  a	  meiotic	  recombination	  rate	  of	  17%.	  Therefore,	   it	   is	   possible	   that	   two	  different	  mmu-­‐miR-­‐322	  alleles	  with	  varying	  expressivity	   simply	   co-­‐segregate	  with	   the	  Ndph	  wt	   and	   ko	   alleles,	   and	   the	   expression	  difference	  is	  the	  result	  of	  a	  different	  genetic	  background	  (wt:	  C57Bl/6	  vs.	  ko:	  129P2).	  Differential	  expression	  of	  miRNAs	  correlates	   to	  some	  extent	  with	  observed	  expression	  differences	   of	   target	   genes:	   For	   example,	   Angpt2	   and	   Kdr	   (VEGFR2)	   both	   have	   been	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described	  to	  be	  higher	  expressed	  in	  the	  p21	  Ndph	  ko	  retina	  (Luhmann	  et	  al.,	  2005a),	  and	  both	   are	   targeted	   by	   mmu-­‐miR-­‐129-­‐5p,	   which	   is	   lower	   expressed	   in	   the	   norrin	   ko.	  Additionally,	  Nrp1,	  the	  co-­‐receptor	  for	  Kdr,	  is	  also	  recognized	  by	  a	  miRNA	  with	  reduced	  expression	   (mmu-­‐miR-­‐375),	   which	   favors	   its	   increased	   expression.	   Angpt2,	   Kdr,	   and	  Nrp-­‐1	  all	  act	  simultaneously	  in	  angiogenic	  remodeling	  –	  a	  process	  that	  is	  impaired	  in	  the	  norrin	   ko	   (reviewed	   in	   Penn	   et	   al.,	   2008).	   On	   the	   other	   side,	   expression	   of	  Vegfa	   and	  
Itgav	   has	  been	   shown	   to	  be	   increased	   in	   the	  Ndph	   ko,	   but	   the	   corresponding	  miRNAs	  (mmu-­‐miR-­‐126-­‐3p	  and	  -­‐142-­‐3p,	  respectively)	  are	  also	  higher	  expressed.	  Thus,	  I	  would	  have	   expected	   them	   to	   have	   a	   negative	   effect	   on	   their	   target	   genes.	   Igf1	   and	  Dvl3	   are	  recognized	   both	   by	   miRNAs	   that	   are	   decreased	   and	   increased,	   making	   it	   difficult	   to	  predict	  a	  transcriptional	  effect.	  An	  interesting	  target	  gene	  is	  Slc38a5.	  Its	  expression	  has	  been	  shown	  to	  be	  significantly	  decreased	   in	   the	   norrin	   ko	   mouse	   by	   the	   microarray	   experiment	   (Table	   40)	   and	  following	  qRT-­‐PCRs	  (3-­‐fold	  at	  p21;	  Figure	  52).	  Strikingly,	   the	  recognizing	  miRNA	  miR-­‐210	  is	   increased	  at	  p21	  (Figure	  66),	  and	  thus	  could	  account	  for	  the	  reduced	  transcript	  amounts	  of	  Slc38a5.	  In	  addition,	  Slc38a5	  has	  predicted	  recognition	  sites	  for	  miR-­‐31	  and	  -­‐222.	  These	  miRNAs	  have	  been	  shown	  to	  reduce	  neovascularisation	  and	  tube	  formation,	  respectively,	   and	   thus	   deliver	   another	   hint	   that	   Slc38a5	   could	   be	   involved	   in	  angiogenesis.	  	  
4.1.2.4.2	  Synopsis	  Taken	   together,	  differential	   expression	  of	  miRNAs	   in	   the	  Ndph	  ko	   retina	  was	  detected	  with	   the	   microarray	   approach	   at	   p21,	   but	   not	   at	   p5.	   Although	   this	   does	   not	   exclude	  differences	   at	   p5	   (insufficient	   sensitivity	   of	   the	   approach,	   dilution	   effect	   through	  employment	  of	  a	  whole	  tissue,	  not	  a	  single	  cell	   type),	   it	  could	   indicate	  that	  differential	  expression	   of	   miRNAs	   is	   not	   a	   primary	   event	   in	   the	   pathogenesis	   of	   ND,	   but	   rather	  mirrors	  secondary	  changes	  like	  the	  establishment	  of	  chronic	  hypoxia.	  This	  conclusion	  is	  supported	  by	  the	  finding	  that	  eight	  (66.6%)	  of	  the	  12	  miRNAs	  with	  a	  fold	  change	  greater	  than	  1.3	  were	  also	  described	  as	  differentially	  expressed	  in	  the	  hypoxic	  retina	  of	  the	  OIR	  model	   (Shen	   et	   al.,	   2008).	   One	   of	   those	   miRNAs,	   mmu-­‐miR-­‐211,	   was	   differentially	  expressed	   in	   the	   opposite	   direction	   (Figure	   113),	   and	   thus	   represents	   an	   interesting	  candidate	   that	  might	   explain	   differences	   between	   the	   hypoxic	   retinas	   of	   the	   OIR	   and	  
Ndph	   ko	  mouse	  models.	   Transcript	   expression	   differences	   of	   some	   angiogenic	   factors	  (Slc38a5,	  Angpt2,	   and	  Kdr)	   could	  be	   correlated	  with	  differences	   in	  miRNA	  expression,	  while	   expression	   of	   others	   (Vegfa	  and	   Itgav)	  was	   opposite	   to	  what	   could	   be	   expected	  from	   differential	   expression	   of	   recognizing	   miRNAs.	   Nonetheless,	   experimental	  manipulation	  of	  e.g.	  miR-­‐27a	  could	  lead	  to	  further	  interesting	  insights	  into	  the	  molecular	  pathogenesis	  of	  ND,	  since	  it	  recognizes	  many	  angiogenic	  transcripts.	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4.2	  Norrin	  in	  pathways	  and	  pathogenesis	  
	  The	  microarray	  experiment	  suggested	  that	  all	  pathways	  that	  appear	  to	  be	  affected	  in	  the	  
Ndph	  knockout	  p7	  retina	  (Table	  39)	  are	  involved	  in	  angiogenesis:	  MAPK	  signaling,	  focal	  adhesion,	  Ca2+	  signaling,	  	  tight	  junction,	  and	  Wnt-­‐signaling.	  	  
4.2.1	  MAPK-­‐signaling	  The	  MAP-­‐Kinase	   pathway,	   which	   has	   been	   suggested	   to	   be	   the	  main	   VEGF-­‐mediating	  signaling	   cascade,	   and	   the	   phosphatidylinositol	   3-­‐kinase	   (PI3K)/Akt	   pathway	   are	  thought	   to	   induce	   endothelial	   cell	   survival	   and	   proliferation,	   mediate	   vascular	  permeability	   and	   vasodilation	   through	   nitric	   oxide	   (NO)	   generation	   and	   elevation	   of	  cytosolic	   Ca2+,	   and	   control	   angiogenesis	   through	   upregulation	   of	   matrix	  metalloproteinases	  and	  activation	  of	  focal	  adhesion	  kinase	  (Zachary	  and	  Gliki,	  2001;	  Wu	  et	   al.,	   1999).	   Further,	   a	   crosstalk	   to	   different	  Wnt-­‐signaling	   pathways	   involves	   either	  transcription	  of	  angiogenesis-­‐relevant	  genes	  such	  as	  VEGF	  (Zhang	  et	  al.,	  2001)	  or	  TEK	  (Masckauchan	  et	  al.,	  2006)	  or	  directly	  modifies	  the	  cytoskeleton,	  e.g.	  through	  PKC-­‐	  and	  Ca2+-­‐dependent	   regulation	   of	   tight	   junctions	   (Harhai	   and	   Antonetti,	   2004).	   Thus,	   the	  MAPK-­‐pathway	  seems	  to	  involve	  all	  signaling	  systems	  apparently	  affected	  in	  the	  norrin	  ko	  retina,	  and	  emphasizes	  a	  role	  for	  norrin	  in	  blood	  vessel	  development.	  Although	  4	  of	  the	   5	   verified	   differentially	   expressed	   genes	   presented	   in	   the	   IOVS	   publication	   (page	  114)	   appear	   to	   be	   involved	   in	   MAPK-­‐signaling	   (Adm,	   Agtrl1,	   ApoD,	   and	   Plvap),	   no	  difference	   in	  phosphorylation	  of	   the	  ERK1/2	  MAPK	   (and	   thus	  differential	   activity	  of	   a	  main	   MAPK-­‐pathway)	   was	   found	   in	   the	   p7	   Ndph	   ko	   retina	   (Figure	   65).	   Therefore,	  additional	   	   experiments	   are	   required	   to	   test	   the	   hypothesis.	   Because	   of	   the	   early	  developmental	  stage	  investigated	  here	  and	  the	  lack	  of	  neovascularization	  in	  later	  stages,	  I	  tend	  to	  consider	  a	  role	  of	  VEGF	  itself	  in	  the	  early	  pathogenesis	  of	  NDP-­‐related	  diseases	  rather	   unlikely	   and	   hypothesize	   whether	   Norrin	   instead	   might	   modulate	   the	   cellular	  response	  to	  VEGF.	  	  
4.2.2	  Wnt-­‐signaling	  
4.2.2.1	  Wnt-­‐signaling	  in	  the	  retina	  and	  brain	  of	  Ndphy/-­‐	  ko	  mice	  Norrin’s	  hypothetical	  role	  as	  a	   transcriptional	  regulator	  of	  Wnt/β-­‐catenin	   target	  genes	  was	   not	   obvious	   from	   the	   array	   experiment.	   The	   pathway	   analysis	   suggested	  involvement	  of	  Wnt-­‐signaling	  only	  at	  the	  5th	  position	  (Table	  39),	  and	  only	  one	  of	  the	  34	  genes	   (besides	   Ndph	   itself)	   listed	   among	   the	   most	   differentially	   regulated	   has	   been	  associated	  with	   it:	   adenomatosis	   polyposis	   coli	   downregulated	   1	   (Apcdd1)	   (Table	   40)	  (Takahashi	  et	  al.,	  2002).	  This	  does	  not	  necessarily	  mean	  that	  Norrin	   is	  not	  exerting	   its	  function	  over	  binding	   to	  Wnt-­‐receptors	  –	  but	   it	  may	   imply	   that	  Norrin	  does	  not	  work	  primarily	   as	   a	   transcriptional	   regulator	   via	   the	   canonical	   Wnt/β-­‐catenin	   signaling.	  However,	   this	   conclusion	   relies	  heavily	  on	   the	  number	  of	   currently	  known	  Wnt	   target	  genes,	  and	  on	  the	  assumption	  that	  this	  signaling	  actually	  occurs	  in	  p7	  retinae.	  Further,	  as	  two	   major	   angiogenesis-­‐related	   genes	   have	   been	   shown	   to	   be	   transcriptionally	  regulated	  by	  Wnt-­‐signaling,	  Tie-­2/Tek	   (Masckauchan	  et	  al.,	   2006)	  and	  Vegfa	   (Zhang	  et	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al.,	  2001),	   it	   is	  possible	   that	  Norrin	  has	  a	  direct	  role	   in	  controlling	  expression	  of	   these	  genes	  in	  a	  spatially	  and	  temporally	  restricted	  manner	  which	  was	  not	  detectable	  by	  the	  microarray	  approach.	  This	  also	  applies	   to	  expression	  of	   the	  norrin	  receptors	  Fzd4	  and	  
Lrp5,	  which	  was	  shown	  to	  be	  elevated	  in	  the	  Ndph	  ko	  retina	  at	  p15	  and	  p21,	  but	  not	  at	  p5	  or	  p10	  (Luhmann	  et	  al.,	  2005a).	  Besides	  transcriptional	  regulation,	  activation	  of	  Wnt-­‐signaling	   has	   been	   shown	   to	   also	   stabilize	   the	   microtubule	   cytoskeleton	   through	   a	  transcription-­‐independent	   pathway,	   as	   it	   becomes	   resistant	   to	   depolymerization	  through	  inhibition	  of	  Gsk3β	  (Ciani	  et	  al.,	  2004;	  Salinas	  et	  al.,	  2007).	  If	  Norrin	  acts	  as	  an	  activator	   of	   Wnt-­‐signaling,	   lack	   of	   Norrin	   could	   promote	   a	   higher	   susceptibility	   to	  depolymerization	   of	   the	   microtubule	   cytoskeleton	   and	   therefore	   might	   have	   a	   direct	  influence	  on	  cell	  migration.	  In	   addition	   to	   the	   published	   results,	   Wnt-­‐signaling	   was	   investigated	   in	   further	  experiments.	  The	  gene	  most	  differentially	  transcribed	  in	  the	  microarray	  experiment	  was	  
Slc38a5.	  To	  test	  the	  hypothesis	  that	  its	  reduced	  expression	  is	  caused	  by	  a	  lack	  of	  norrin	  and	  subsequently	  lack	  of	  canonical	  Wnt-­‐signaling,	  I	  investigated	  SLC38A5	  expression	  in	  HEK-­‐cells	   in	  response	   to	  LiCl	   treatment,	  a	  potent	  activator	  of	  Wnt/β-­‐catenin	  signaling.	  No	   significant	   effect	   was	   found	   on	   mRNA	   level	   (Figure	   80),	   but	   an	   interesting	   and	  reproducible	   finding	   was	   made	   on	   Western	   blots.	   The	   Slc38a5	   antibody	   labeled	   two	  bands,	  one	  band	  corresponding	  to	  the	  molecular	  weight	  of	  the	  monomer,	  and	  one	  band	  corresponding	   to	   a	   possible	   tetramer.	   Levels	   of	   the	  monomeric	   band	  were	   similar	   in	  protein	  extracts	  from	  treated	  and	  untreated	  HEK-­‐cells	  (Figure	  81)	  as	  well	  as	  from	  Ndph	  wt	  and	  ko	  retina	  (Figure	  56)	  and	  cerebellum	  (Figure	  60).	  However,	  the	  tetrameric	  band	  appeared	  to	  be	  more	  intense	  in	  the	  absence	  of	  Ndph	  (Figure	  56;	  Figure	  60),	  and	  weaker	  in	  LiCl-­‐treated,	  Wnt-­‐signaling	  activated	  cells	  (Figure	  81).	  This	  observation	  is	  in	  contrast	  to	  the	  reduced	  mRNA	  levels	  in	  the	  retina	  and	  cerebellum	  of	  Ndph	  ko	  mice,	  and	  does	  not	  explain	   the	   different	   appearance	   of	   the	   tetrameric	   band.	   Since	   Slc38a5	   is	   strongly	  expressed	  in	  glia	  in	  the	  CNS,	  it	  may	  be	  worthwile	  to	  repeat	  the	  experiment	  in	  a	  cell-­‐line	  of	   neuronal	   origin,	   where	   expression	   and	   regulation	   probably	   are	   more	   closely	  resembling	   the	   in	   vivo	   situation	   than	   HEK-­‐cells,	   which	   are	   derived	   from	   embryonic	  kidney	  tissue.	  The	  molecule	  central	  to	  canonical	  Wnt-­‐signaling,	  β-­‐catenin,	  was	  not	  differently	  active	  in	  the	   p7	  Ndphy/-­	   retina	   (Figure	   77),	   as	   determined	   by	  Western	   blots.	   Further,	   the	  Wnt-­‐specific	   transcription	   factors	  Tcf3	   and	  Tcf4	  were	  not	  differentially	  expressed	   in	   the	  ko	  during	  retinal	  development	  (Figure	  78).	  Expression	  of	  the	   lymphoid	  enhancer	  binding	  factor	  1	   (Lef1)	  was	  significantly	  reduced	  in	  the	  p15	  Ndph	  ko	  retina	  (Figure	  78	  B).	  It	  has	  been	  described	  as	  transcription	  factor	  in	  canonical	  Wnt-­‐signaling,	  whereas	  itself	  is	  negatively	  regulated	  by	  the	  same	  pathway	  in	  a	  negative	   feedback	   loop	   (Hovanes	   et	   al.,	   2001).	   This	   could	   be	   hinting	   at	   higher	   Wnt-­‐signaling	  activitiy	  at	  p15	  in	  the	  Ndph	  ko	  retina.	  Differences	  at	  p5,	  p10,	  and	  p21	  were	  not	  significant.	   Nonetheless,	   a	   trend	   could	   be	   observed	   of	   higher	   expression	   in	   the	   early	  stages	  (p5	  and	  p10),	  and	  lower	  expression	  in	  the	  later	  stages	  (p15	  and	  p21).	  The	  same	  trend	  was	  observed	  for	  Bmp4,	  a	  transforming	  growth	  factor-­‐β	  family	  member.	  Expression	   of	   Bmp4	   was	   more	   than	   four-­‐fold	   elevated	   in	   the	   p5	   ko	   retina,	   and	   was	  reduced	  two-­‐fold	  at	  p15	  (Figure	  78	  A).	  Although	  differences	  were	  not	  significant	  at	  p10	  and	   p21,	   these	   data	   also	   indicated	   two	   disease	   phases.	   This	   observation	   is	   consistent	  with	   the	   disease	   phases	   proposed	   by	   Luhmann	   et	   al.	   (Luhmann	   et	   al.,	   2005a).	   Since	  
Bmp4	  was	   shown	   to	   be	   upregulated	   in	   response	   to	   β-­‐catenin	   (Kim	   et	   al.,	   2002),	   in	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contrast	   to	   negative	   feedback	   on	  Lef1,	   it	   is	   not	   possible	   to	   draw	   a	   definite	   conclusion	  about	  Wnt-­‐signaling	   activity	   in	   the	  Ndph	   ko	   retina.	  While	   the	   Lef1	   expression	   profile	  suggests	  reduced	  Wnt-­‐signaling	  activity	  in	  the	  early	  phase,	  and	  enhanced	  activity	  in	  the	  late	  phase,	  it	  is	  exactly	  the	  opposite	  in	  regard	  to	  Bmp4	  expression.	  However,	  it	  has	  been	  shown	  that	  up-­‐	  or	  downregulation	  of	  canonical	  Wnt-­‐target	  genes	  depends	  on	  the	  type	  of	  transcription	   factors	   and	   the	   position	   of	   their	   binding	   sites	   (Logan	   and	  Nusse,	   2004).	  Thus,	  it	  is	  possible	  that	  β-­‐catenin	  activity	  is	  uniformly	  shifted	  in	  the	  Ndph	  ko	  retina,	  but	  that	  different	   transcription	   factors	  mediate	   an	  opposite	   effect	   on	   the	   two	   investigated	  target	  genes.	  Further,	  Bmp4	  regulation	  through	  β-­‐catenin	  provided	  a	  link	  between	  WNT	  and	  TGF-­‐β	  signaling	  pathways	  (Kim	  et	  al.,	  2002).	  My	  experimental	  data	  now	  add	  further	  support	   for	   WNT/TGF-­‐β	   crosstalk,	   because	   norrin	   has	   initially	   been	   described	   as	   a	  growth	   factor	   with	   high	   homology	   to	   TGF-­‐β	   (Meitinger	   et	   al.,	   1993)	   and	   apparently	  affects	  Bmp4	  expression	  via	  canonical	  Wnt-­‐signaling.	  	  
4.2.2.2	  The	  role	  of	  Wnt-­‐signaling	  in	  the	  regression	  of	  hyaloid	  vessels	  In	  this	  thesis,	  I	  also	  aimed	  to	  demonstrate	  altered	  Wnt-­‐signaling	  in	  Ndph	  ko	  mice	  in	  vivo.	  However,	   the	   used	   Wnt-­‐reporter	   mouse	   proved	   to	   be	   inadequate	   to	   detect	   Wnt-­‐signaling	  in	  the	  retina.	  In	  contrast,	  intense	  Wnt-­‐signaling	  was	  detected	  in	  the	  remaining	  hyaloid	  vasculature	  of	  Ndphy/-­	  mice	  (Figure	  82;	  Figure	  87).	  This	  is	  of	  particular	  interest,	  because	   it	   has	   been	   shown	   that	  macrophage-­‐mediated	   apoptosis	   of	   hyaloid	   vessels	   in	  the	  Lrp5-­/-­	  mouse	  failed	  (Kato	  et	  al.,	  2002),	  and	  that	  this	  defect	  correlates	  with	  missing	  Wnt-­‐signaling	  activity	  in	  hyaloid	  endothelial	  cells	  (Lobov	  et	  al.,	  2005).	  Persistent	  hyloid	  vessels	  and	  reduced	  levels	  of	  cell	  death	  were	  also	  found	  in	  Lef1	  deficient	  mice,	   further	  substantiating	  involvement	  of	  canonical	  Wnt-­‐signaling	  (Lobov	  et	  al.,	  2005).	  This	  report	  initially	   lead	   me	   to	   the	   hypothesis	   that	   hyaloid	   regression	   is	   dependent	   on	   norrin-­‐induced	  canonical	  Wnt-­‐signaling	  in	  endothelial	  cells	  through	  binding	  to	  Lrp5.	  However,	  two	  facts	  contradict	  this	  hypothesis:	  For	  one,	  macrophage-­‐associated	  Wnt7b	  was	  shown	  to	   be	   the	   necessary	   Lrp5-­‐ligand	   for	   Wnt-­‐induced	   regression	   of	   the	   hyaloid	   vessels	  (Lobov	  et	  al.,	  2005).	  And	  second,	  canonical	  Wnt-­‐signaling	  appeared	   to	  be	  active	   in	   the	  hyaloid	   vasculature	   of	   norrin-­‐deficient	  mice	   (Figure	   82;	   Figure	   87).	   But	   since	   hyaloid	  vessels	   persist	   in	   the	   Ndph	   ko,	   these	   data	   suggest	   that	   norrin	   is	   necessary	   for	   the	  regression	   of	   the	   hyaloid	   vasculature,	   but	   not	   via	   canonical	   Wnt-­‐signaling	   in	   hyaloid	  endothelial	   cells.	   One	   possible	   mode	   of	   function	   could	   be	   that	   norrin	   effects	   hyaloid	  vessels	   via	   a	   non-­‐canonical	   Wnt-­‐pathway,	   or	   that	   it	   has	   no	   direct	   function	   on	   the	  transient	  vitreal	  vasculature	  at	  all,	  causing	  the	  failed	  regression	  only	  indirectly	  through	  impaired	   development	   of	   the	   retinal	   vasculature.	   It	   would	   be	   interesting	   to	   further	  investigate	   norrin’s	   role	   in	   hyaloid	   regression,	   e.g.	   through	   transciptional	   analysis	   of	  
Wnt7b	  and	  Lrp5	  in	  the	  Ndph	  ko	  vitreous.	  	  
4.2.2.3	  Valproic	  acid:	  a	  modifier	  of	  Wnt-­‐signaling	  In	  one	  family	  with	  a	  mutation	  in	  FZD4	  (p.I114T),	  the	  mother	  of	  two	  boys	  suffering	  from	  a	  severe	   form	   of	   FEVR	   has	   been	   treated	   with	   valproic	   acid	   (VPA)	   during	   pregnancy	  (Robitaille	   et	   al.,	   2009).	   VPA	   is	   an	   epigenetic	   anticancer	   drug	   that	   targets	   chromatin	  through	   inhibition	  of	  histone	  deacetylases	   and	  DNA	  methyltransferases,	   and	   therefore	  unspecifically	   acts	   on	   most	   tumor	   types.	   Treatment	   with	   VPA	   evokes	   differential	  expression	  of	  hundreds	  of	  genes	  belonging	  to	  multiple	  pathways,	  and	  in	  high	  doses	  has	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been	   associated	   with	   neural	   tube	   defects	   and	   other	   major	   congenital	   malformations.	  Since	   it	   was	   also	   shown	   to	   up-­‐regulate	   genes	   involved	   in	   the	  Wnt-­‐pathway	   (Duenas-­‐Gonzales	   et	   al.,	   2008),	   it	   was	   speculated	   that	   valproic	   acid	   could	   be	   a	   modifier	   for	  mutations	   in	  FZD4	  and	  might	  account	   for	   the	  more	  severe	  phenotype	  (Robitaille	  et	  al.,	  2009).	  	  
4.2.2.4	  Wnt-­‐signaling	  in	  bone	  synthesis	  Reduced	  bone	  mass	  in	  Lrp5-­/-­	  mice	  has	  been	  found	  to	  be	  caused	  by	  a	  lack	  of	  osteoblast	  cells,	  which	   account	   for	   bone	   synthesis	   (Kato	   et	   al.,	   2002).	   Since	  Lrp5	   is	   expressed	   in	  osteoblasts	  and	  further	  has	  been	  shown	  to	  be	   involved	  in	  Wnt/β-­‐catenin	  signaling	  (Xu	  and	  Wang	   et	   al.,	   2004),	   it	   was	   hypothesized	   that	   Lrp5	   mutants	   cause	   impaired	  Wnt-­‐signaling	   in	   these	   cells,	   and	   OPPG	   and	   HBM	   were	   considered	   Wnt-­‐related	   diseases	  (Krishnan	  et	  al.,	  2006).	  However,	  osteoblast-­‐specific	  loss-­‐	  or	  gain-­‐of-­‐function	  mutations	  	  in	  β-­‐catenin	   did	   not	   affect	   bone	   formation	   (Glass	   et	   al.,	   2005).	   Concordantly,	   isolated	  
Lrp5-­/-­	  osteoblasts	  proliferated	  well	  ex	  vivo,	  indicating	  that	  Wnt-­‐signaling	  in	  osteoblasts	  is	  not	  the	  cause	  for	  the	  bone	  phenotype	  in	  Lrp5-­/-­	  mice	  and	  OPPG	  patients	  (Yadav	  et	  al.,	  2008).	   Based	   on	   these	   findings,	   Yadav	   and	   colleagues	   could	   show	   that	   LRP5	   instead	  controls	  bone	  formation	  by	  inhibiting	  serotonin	  synthesis	  in	  the	  duodenum	  (Figure	  114)	  (Yadav	  et	  al.,	  2008).	  	  
4.2.2.5	  Thoughts	  about	  Wnt-­‐related	  candidate	  genes	  for	  future	  investigations	  The	  presence	  of	  several	  genes	  involved	  in	  blinding	  disorders	  on	  the	  proximal	  portion	  of	  chromosome	   11q	   (FZD4,	   LRP5,	   BEST1)	   might	   indicate	   a	   hotspot	   for	   genes	   that	   are	  evolutionary	  and	   functionally	   linked,	  and	   it	   can	  be	  speculated	  about	   the	  emergence	  of	  further	   disease-­‐associated	   genes	   in	   this	   region.	  One	   such	   candidate	  would	   be	  WNT11,	  which	  has	  been	  shown	  to	  be	  important	  for	  eye	  development,	  and	  to	  interact	  with	  LRP5	  and	   Wnt-­‐signaling	   (Cavodeassi	   et	   al.,	   2005).	   Another	   one	   could	   be	   matrix	  metalloproteinase-­‐7	   (MMP7),	   which	   has	   been	   shown	   to	   be	   positively	   regulated	   by	  Wnt/β-­‐catenin	   signaling	   and	   is	   involved	   in	   degradation	   of	   the	   extracellular	   matrix	  during	  angiogenic	  remodeling	  and	   in	  cell	  migration	  (Brabletz	  et	  al.,	  1999;	  Crawford	  et	  al.,	   1999).	   It	   is	   also	   situated	   on	   the	   long	   arm	  of	   chromosome	  11,	   but	   a	   little	   bit	  more	  distal	  (11q22).	  Hypomorphic	  Wnt7b	  mutants	  were	  reported	  to	  display	  a	  PFV	  phenotype	  (Lobov	  et	  al.,	  2005),	  whereas	  Wnt7b	   null-­‐mutants	   die	   embryonically	   (Shu	   et	   al.,	   2002).	   In	   addition,	  homozygous	   Wnt7b	   hypomorphic	   mutans	   are	   infertile	   due	   to	   a	   defect	   in	   placental	  development	  (Parr	  et	  al.,	  2001),	  in	  agreement	  with	  the	  phenotype	  observed	  in	  Ndph	  ko	  mice	   (Luhmann	  et	  al.,	  2005b).	  Wnt7a/Wnt7b	   further	  have	  been	  shown	  to	  be	  essential	  for	   CNS	   vasculature	   development	   (Stenman	   et	   al.,	   2008).	   Thus,	   mutations	   in	  Wnt7b	  cause	   angiogenic	   defects	   in	   the	   same	   organs	   that	   are	   affected	   in	  Ndph	   ko	   mice,	   and	  represents	  another	  interesting	  candidate	  gene	  for	  future	  research.	  Wnt7b	   is	   located	  on	  22q13	  (outside	  the	  DiGeorge-­‐critical	  region).	  Vimentin	   (Vim)	   is	   a	   GFAP-­‐binding	  member	   of	   the	   intermediate	   filament	   family	   and	   is	  widely	  used	  as	  Müller	  cell	  marker	  (Lemmon	  and	  Rieser,	  1983).	  It	  has	  been	  proposed	  as	  direct	  target	  of	  β-­‐catenin/TCF	  (Gilles	  et	  al.,	  2003),	  although	  another	  report	  suggests	  it	  is	  involved	   in	   cell	   migration	   not	   via	   the	   canonical	   pathway	   (Katoh,	   2008).	   Further,	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mutations	  in	  VIM	  cause	  dominant,	  pulverant	  cataract	  (Müller	  et	  al.,	  2009),	  although	  Vim	  ko	  mice	  lack	  an	  obvious	  phenotype	  (Colucci-­‐Guyon	  et	  al.,	  1994).	  Unfortunately,	  staining	  of	  retinal	  cryosections	  gave	  no	  results,	  probably	  because	  the	  available	  antibody	  was	  no	  longer	  working.	  It’s	  role	  in	  NDP-­‐related	  diseases	  should	  nonetheless	  be	  investigated.	  
4.2.2.6	  Synopsis	  The	   hypothesized	   involvement	   of	   norrin	   in	   canonical	   Wnt-­‐signaling	   was	   not	   obvious	  from	  the	  global	  expression	  analysis	  (Table	  39),	  nor	  was	  the	  activity	  of	  the	  most	  central	  molecule,	   β-­‐catenin	   (Figure	   77),	   different	   in	   p7	   Ndph	   ko	   retinas.	   Further,	   two	   Wnt-­‐specific	  transcription	  factors	  (Tcf3,	  Tcf4)	  were	  not	  differentially	  expressed	  during	  retinal	  development	   (Figure	   78).	   Differential	   expression	   of	   Lef1	   and	   Bmp4	   suggested	   two	  diseases	  phases,	  an	  early	  (p5,	  p10)	  and	  a	  late	  (p15,	  p21)	  one	  (Figure	  78)	  in	  accordance	  with	   the	  previously	  proposed	  model	   (Luhmann	  et	  al.,	  2005a).	  However,	  although	  both	  genes	  were	   lower	   expressed	   at	   p15,	  Lef1	   has	   been	   reported	   to	   be	   repressed	   by	  Wnt-­‐signaling,	  whereas	   Bmp4	   has	   been	   found	   to	   be	   enhanced.	   Thus,	   a	   uniform	   conclusion	  about	   different	   activity	   of	   canonical	  Wnt-­‐signaling	   cannot	   be	  made.	   In	   contrast	   to	  my	  expectations,	   Wnt-­‐signaling	   was	   active	   in	   the	   hyaloid	   vasculature	   of	   Ndph	   ko	   mice	  (Figure	   82;	   Figure	   87),	   suggesting	   that	   vessel	   regression	   is	   not	   dependent	   on	   norrin-­‐induced	   Wnt-­‐signaling.	   However,	   differential	   Wnt-­‐activity	   in	   the	   retina,	   which	   could	  have	  elucidated	  norrin’s	  role	  in	  vivo,	  could	  not	  be	  investigated	  with	  the	  reporter	  mouse	  employed.	   Further	   genes	   involved	   in	   Wnt-­‐signaling	   and	   angiogenesis	   should	   be	  investigated	  in	  subsequent	  experiments.	  A	  recent	  report	  suggested	  that	  LRP5-­‐controlled	  repression	  of	  systemic	  serotonin	  levels	  appears	  to	  be	  the	  key	  to	  the	  bone	  phenotypes	  in	  OPPG	  and	  HBM	  (Yadav	  et	  al.,	  2008).	  It	  remains	  to	  be	  shown	  whether	  this	  control	   is	  mediated	  via	  the	  canonical	  Wnt-­‐pathway,	  and	  whether	   serotonin	   is	   also	   crucial	   for	   the	  development	   of	   the	   ocular	   phenotype	  of	  ND/FEVR/OPPG.	  	  
4.2.3	  Serotonin-­‐mediated	  signaling	  Serotonin	   (5-­‐HT;	   5-­‐hydroxytryptamine)	   is	   a	   monoamine	   neurotransmitter	   that	   is	  produced	  in	  enterochromaffin	  cells	  in	  the	  gut	  (80%-­‐90%	  of	  total	  5-­‐HT),	  and	  to	  a	  minor	  extent	  in	  serotonergic	  neurons	  in	  the	  CNS.	  Because	  5-­‐HT	  does	  not	  pass	  the	  blood-­‐brain-­‐barrier,	  two	  different	  functions	  and	  places	  of	  action	  have	  been	  postulated:	  one	  inside	  the	  CNS,	  and	  one	  outside.	  In	  the	  CNS,	  serotonin	  is	  involved	  in	  the	  control	  of	  mood	  and	  anger,	  and	  in	  the	  gut,	  it	  has	  been	  associated	  with	  the	  control	  of	  intestinal	  movements,	  amongst	  others	  (Purves,	  2004).	  Interestingly,	   high	   serotonin	   levels	   have	   frequently	   been	   observed	   in	   patients	   with	  osteoporosis	   and	   autism	   (Hediger	   et	   al.,	   2008),	   and	   patients	   with	   mood	   disorders	  chronically	   taking	   selective	   serotonin	   reuptake	   inhibitors	   (SSRIs)	   have	   been	   found	   to	  develop	   osteoporosis	   as	  well	   (Richards	   et	   al.,	   2007).	   Now	   recently,	  Lrp5	   expressed	   in	  enterochromaffin	  cells	  of	  the	  duodenum	  was	  shown	  to	  inhibit	  expression	  of	  tryptophan	  hydroxylase	  1	  (Tph1),	  the	  rate-­‐limiting	  enzyme	  involved	  in	  serotonin	  synthesis	  (Figure	  114)	   (Yadav	   et	   al.,	   2008).	   Serotonin	   secreted	   in	   the	   blood	   can	   bind	   to	   osteoblasts	  through	  its	  receptor	  Htr1b,	  which	  inhibits	  intracellular	  Creb	  and	  thus	  also	  proliferation	  of	  osteoblasts	  via	  reduced	  expression	  of	  CycD1.	  Although	  no	  bone	  phenotype	  has	  been	  reported	   in	   patients	   with	   mutations	   in	   NDP	   or	   FZD4,	   nor	   in	   the	   respective	   mouse	  
DISCUSSION	   205	  	  
	  
models,	   it	   may	   be	   worthwile	   to	   investigate	   the	   role	   of	   serotonin	   with	   regard	   to	   the	  development	   of	   the	   vascular	   anomalies	   and	   other	   symptoms	   found	   in	   EVR-­‐related	  diseases.	  While	  Lrp5	   in	   the	  gut	   is	  probably	   activated	  by	  another	   ligand	   than	  norrin,	   it	  cannot	  be	  excluded	   that	  norrin	  has	  an	   influence	  on	  serotonin	  homeostasis	   in	   the	   local	  retinal	   vasculature	  or	   in	   the	  CNS,	   although	   the	  authors	   state	   that	   the	  CNS	  analogue	  of	  
Tph1,	   Tph2,	   is	   not	   differentially	   expressed	   in	   the	   CNS	   of	   Lrp5-­/-­	   mice.	   However,	  differential	   protein	   expression	   of	   synaptophysin	   (Syp)	   was	   found	   in	   inner	   retinal	  neurons	  of	  the	  Ndph	  ko	  (Figure	  68).	  Since	  this	  protein	  has	  been	  suggested	  to	  be	  involved	  in	   the	   release	   of	   hormones,	   such	   as	   serotonin,	   in	   the	   gastrointestinal	   tract	   (Portela-­‐Gomes	  et	  al.,	  1999),	  it	  is	  tempting	  to	  speculate	  whether	  it	  excerts	  this	  function	  also	  in	  the	  retina.	  
	  
Figure	  114	  Model	  of	  the	  proposed	  function	  of	  LRP5	  in	  bone	  formation.	  Lrp5	  facilitates	  bone	  mass	  accrual	  through	   inhibition	   of	   expression	   of	   Tph1,	   the	   rate-­‐limiting	   enzyme	   for	   serotonin	   synthesis	   in	   the	  duodenum.	   Serotonin	   has	   been	   shown	   to	   reduce	   CycD1	   expression	   in	   and	   proliferation	   of	   osteoblasts	  through	  Htr1b	  mediated	  inhibition	  of	  Creb.	  (Source:	  Yadav	  et	  al.,	  2008)	  	  High	  serotonin	  levels	  caused	  by	  therapeutic	  drugs	  (SSRIs,	  MAO-­‐inhibitors)	  cause	  a	  wide	  spectrum	   of	   symptoms	   (reviewed	   by	   Boyer	   and	   Shannon,	   2005).	   Some	   of	   these	  symptoms	   may	   also	   be	   found	   in	   ND/OPPG-­‐related	   diseases,	   if	   investigated	   properly.	  Among	  them	  are,	  in	  addition	  to	  osteoporosis,	  myoclonic	  seizures,	  which	  have	  often	  been	  reported	   in	   conjunction	  with	  ND	  patients,	   and	  disseminated	   intravascular	   coagulation	  (DIC).	   DIC	   describes	   a	   condition	   where	   coagulation	   processes	   are	   pathologically	  activated.	  Small	  blood	  clods	   form	  inside	  the	  blood	  vessels,	   resulting	   in	   impaired	  organ	  perfusion	   (e.g.	   through	   microvascular	   thrombosis)	   and	   subsequent	   ischemia,	   while	  hemorrhages	  may	  be	  due	   to	   the	  consumption	  of	  all	  available	  coagulation	  proteins	  and	  platelets.	   Misbalance	   in	   the	   coagulation/fibrinolysis	   system	   may	   further	   activate	   the	  complement	  and	  kinin	  systems,	  contributing	  to	  increased	  vascular	  permeability.	  It	  has	  been	  shown	  that	  serotonin	  has	  no	  effect	  on	  healthy	  adult	  retinal	  blood	  vessels	  in	  monkeys,	  but	  that	  it	  elicits	  vasospasms	  in	  artherosclerotic	  vessels,	  leading	  to	  temporary	  complete	   occlusion	   or	   impaired	   blood	   flow	   (reviewed	   by	   Hayreh,	   1999).	   Thus,	   it	   is	  tempting	  to	  speculate	  that	  increased	  serum	  serotonin	  levels	  not	  only	  affect	  injured,	  but	  also	   developing	   vessels,	   and	   that	   5-­‐HT	  may	   also	   be	   related	   to	   the	   vascular	   anomalies	  found	   in	   patients	   harboring	  LRP5	  mutations,	   or	   even	   those	  with	  mutations	   in	  NDP	   or	  
FZD4.	  In	  addition,	  serotonin	  has	  been	  shown	  to	  cause	  transient	  cataracts	  in	  the	  rat	  eye,	  probably	   through	   decreased	   production	   of	   aqueous	   (Boerrigter	   et	   al.,	   1992),	   which	  resembles	   another	   symptom	   often	   described	   in	   ND/OPPG	   patients.	   An	   interesting	  sidenote	  may	  be	   the	  close	  genetic	   localization	  of	  NDP	  and	   the	  MAO	  genes,	  since	  MAOA	  catalyzes	  the	  breakdown	  of	  serotonin.	  Thus,	  co-­‐segregating	  mutations	  in	  MAOA	  may	  also	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lead	   to	   increased	   5-­‐HT	   levels,	   further	   contributing	   to	   the	   severity	   of	   homeostatic	  misbalance.	   Systemic	   and	   significant	   reduction	   in	   the	   activity	   of	   both	  MAO	   genes	   has	  been	  found	  in	  ND	  patients	  with	  an	  X-­‐chromosomal	  deletion,	  presumably	  including	  NDP,	  
MAOA	  and	  MAOB	  (Murphy	  et	  al.,	  1990).	  This	  correlated	  with	  markedly	   increased	  5-­‐HT	  levels	  in	  the	  plasma	  and	  cerebrospinal	  fluid	  of	  ND	  microdeletion	  patients	  (Collins	  et	  al.,	  1992).	   Interestingly,	   MAOA	   not	   only	   preferentially	   deaminates	   5-­‐HT,	   but	   also	  norepinephrine	  (NE).	  However,	  no	  changes	  in	  NE	  plasma	  levels	  were	  observed	  (Collins	  et	  al.,	  1992),	  which	  could	  be	  indicative	  of	  another	  cause	  for	  the	  elevated	  5-­‐HT	  levels,	  e.g.	  lack	  of	  or	  mutations	  in	  NDP.	  In	  addition,	  it	  already	  has	  been	  proposed	  that	  an	  imbalance	  between	   5-­‐HT	   activity	   and	   the	   activity	   of	   other	   neurotransmitters	   could	   account	   for	  cataplexy	  and	  REM	  sleep	  disturbances	  in	  ND	  patients	  (Vossler	  et	  al.,	  1996).	  However,	  no	  altered	  serotonin	   levels	  have	  been	  reported	   from	  ND	  patients	  with	  point	  mutations	   in	  the	  NDP	  gene	  so	  far.	  
4.2.3.1	  Synopsis	  Taken	  together,	  it	  has	  been	  shown	  that	  elevated	  serotonin	  serum	  levels	  account	  for	  the	  osteoporosis	   phenotype	   in	   the	   Lrp5-­/-­	   mouse	   (Yadav	   et	   al.,	   2008),	   and	   may	   also	  contribute	  to	  some	  neuronal	  phenotypes	  in	  ND	  patients	  (cataplexy,	  sleep	  disturbances)	  (Vossler	  et	  al.,	  1996).	  Althouh	  no	  bone	  phenotype	  has	  been	  reported	  in	  conjunction	  with	  
NDP	   or	   FZD4	   mutations,	   it	   seems	   very	   promising	   to	   me	   to	   investigate	   serotonin-­‐mediated	   signaling	   also	   in	   the	  Ndph	   knockout	   mice	   as	   well	   as	   in	   patients,	   especially	  because	  of	  the	  reported	  vascular	  effects	  of	  high	  serotonin	  levels.	  In	  contrast	  to	  the	  Lrp5-­/-­	  mouse,	  I	  expect	  that	  systemic	  5-­‐HT	  blood	  levels	  are	  not	  conspicuously	  altered,	  since	  no	  bone	   phenotype	   has	   been	   observed,	   but	   that	   local	   serotonin	   levels	   in	   the	   retina	   are	  elevated,	   possibly	   contributing	   to	   the	   developmental	   anomalies.	   If	   so,	   elevated	   5-­‐HT	  levels	   could	   be	   reduced	   by	   a	   tryptophan-­‐less	   diet	   or	   the	   administration	   of	  parachlorophenylalanine	  (pCPA)	  during	  ocular	  development	  (Yadav	  et	  al.,	  2008;	  Kubera	  et	   al.,	   2000).	   Interestingly,	   the	   gene	   for	   tryptophane	   hydroxylase	   1	   (TPH1),	   the	  serotonin-­‐synthesis	  rate	  limiting	  enzyme,	   is	   located	  on	  11p15.3-­‐14,	  only	  ~4cM	  outside	  the	   genomic	   region	   designated	   as	   EVR3	   (11p3;	   Downey	   et	   al.,	   2001),	   and	   thus	   could	  present	  another	  candidate	  gene	  for	  future	  mutation	  screenings.	  	  
4.3	  Production	  of	  recombinant	  norrin	  protein	  Production	  efforts	  of	  recombinant	  norrin	  in	  yeast	  cells	  resulted	  in	  a	  single	  40	  kDa	  band	  in	   200ml	   expression	   control	   setups	   that	   could	   correlate	  with	   a	   putative	   norrin	   dimer	  (Figure	   108).	   The	   21	   kDa	   monomeric	   band	   was	   only	   visible	   after	   50ml	   expression	  controls	  (Figure	  106;	  Figure	  107),	  maybe	  due	  to	  differences	  in	  cultivation	  conditions	  at	  the	   Institute	   of	   Medical	   Genetics	   and	   the	   Paul-­‐Scherrer-­‐Institute.	   Nonetheless,	   high	  amounts	   of	   recombinant	   norrin	   protein	   that	   could	   be	   used	   for	   functional	   assays	   or	  structural	   analyses	   should	   be	   easily	   obtained	   through	   additional	   expression	   rounds.	  However,	   the	   engineered	   protein	   still	   has	   to	   be	   confirmed	   by	  mass	   spectrometry	   and	  functional	   tests.	   The	   latter	   may	   be	   of	   special	   importance,	   because	   although	   Pichia	  
pastoris	   carries	   eukaryotic	   features	   like	   glycosylation	   and	   facilitation	   of	   disulphide-­‐bonds,	  it	  remains	  to	  be	  shown	  that	  the	  recombinant	  human	  protein	  is	  glycosylated	  and	  folded	   correctly.	   Such	   functional	   tests	   would	   include	   proliferation,	   migration,	   and	  endothelial-­‐tube-­‐formation	  assays,	   as	  well	   as	  pathway	  assays	  which	   include	  activation	  of	   luciferase	   reporters	   like	   the	   Wnt-­‐signaling-­‐controlled	   Super	   TOP-­‐FLASH	   (Xu	   and	  Wang	  et	  al.,	  2004).	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4.4	  Gene	  screening	  in	  patients	  	  A	   total	   of	   22	   patients	   with	   ND/FEVR-­‐like	   clinical	   presentation	   were	   screened	   for	  mutations	   in	  NDP,	   FZD4,	   and	   LRP5,	   and	   subsequently	   for	   mutations	   in	   the	   candidate	  genes	  LRP5L,	  LMO2,	  PLVAP,	  and	  SLC38A5.	  Different	  medical	  terms	  were	  used	  to	  describe	  the	   respective	   clinical	   entity,	   and	   for	   some	   patients,	   more	   than	   one	   diagnosis	   was	  suggested.	  In	  this	  respect,	  I	  like	  to	  cite	  Ulrich	  Kellner,	  who	  proposed:	  “When	  no	  genetic	  basis	   for	   the	   disease	   could	   be	   identified,	   the	   diagnosis	   should	   be	   „unclassified	  vitreoretinopathy	   (with	  or	  without	   syndromic	   features)“,	   rather	   than	  an	  enforced,	  but	  maybe	  misleading	  or	  wrong	  allocation	  to	  ND	  or	  a	  similar	  disease”	  (Kellner	  et	  al.,	  2004).	  In	  order	  to	  determine	  whether	  an	  annotated	  SNP	  found	  in	  the	  patient	  group	  is	  more	  or	  less	   frequent	   than	   it	   is	   in	   the	  average	  population,	   the	   frequency	  of	   the	  ancestral	  allele	  among	   the	   patients	   was	   calculated	   and	   compared	   with	   the	   allele	   frequency	   in	   the	  Caucasian	  European	  population	  (HapMap-­‐CEU	  database,	  dbSNP128,	  www.ensembl.org).	  It	   was	   assumed	   that	   most	   of	   our	   patients	   belong	   to	   this	   population,	   although	   ethnic	  origin	   of	   most	   individuals	   was	   unknown,	   and	   it	   cannot	   be	   excluded	   that	   some	   are	  members	  of	  other	  ethnic	  groups.	  This	  consideration	  should	  be	  kept	  in	  mind,	  because	  it	  may	   lead	   to	   false	   prediction	   of	   genetic	   risk	   factors.	   For	   most	   SNPs,	   only	   a	   minor	  difference	   was	   determined.	   Therefore,	   neither	   potential	   risk-­‐alleles	   nor	   protective	  alleles	  for	  Norrie	  disease	  were	  found.	  However,	  the	  size	  of	  our	  patient	  group	  is	  probably	  not	   sufficient	   to	   make	   statistically	   significant	   predictions	   concerning	   risk-­‐alleles	   or	  protective	  alleles.	  Therefore,	  even	  when	  a	  considerable	  difference	  between	  patients	  and	  average	  population	  was	   found,	   this	  could	  have	  occurred	  by	  chance.	  Of	  course,	  also	   the	  opposite	   is	   true:	   the	   existence	   of	   risk-­‐alleles	   and	   protective	   alleles	   for	   ND/EVR-­‐like	  phenotypes	  cannot	  be	  completely	  excluded,	  since	  allele	  frequencies	  could	  be	  similar	  due	  to	  coincidence.	  	  
4.4.1	  NDP	  screening	  No	  variations	  in	  addition	  to	  the	  five	  mutations	  detected	  prior	  to	  this	  study	  were	  found	  in	  the	  NDP	   gene,	   including	   its	   5’-­‐	   and	   3’-­‐UTRs.	   This	   implies	   that	   16	   out	   of	   22	   patients	  analyzed	   in	   this	   study	   were	   negative	   for	   mutations	   in	   NDP	   despite	   being	   clinically	  diagnosed	   as	   ND	   or	   CD	   patients	   (one	   patient	   was	   diagnosed	   with	   Eales’	   Disease).	  Regarding	  the	  variety	  of	  other	  diseases	  with	  similar	  ocular	  phenotypes	  and	  the	  relative	  rarity	  of	   the	  disease,	   it	   could	  be	  possible	   that	   false	  diagnosis	   is	   common.	  On	   the	  other	  hand,	   in	   the	   case	   of	   familial	   occurrence	   of	   the	   disease,	   involvement	   of	   other	   genes,	  especially	   of	   the	   already	   associated	  FZD4	   and	  LRP5,	   is	   highly	   likely.	   I	  was	   speculating	  that	  mutations	  in	  the	  3’-­‐UTR	  could	  also	  contribute	  to	  the	  disease,	  because	  this	  part	  of	  the	  gene	  was	   not	   routinely	   tested	   in	   our	   diagnostic	   division,	   and	  miRNA	   recognition	   site	  mutations	  in	  the	  3’UTR	  have	  been	  discussed	  in	  association	  with	  human	  disease	  (Abelson	  et	  al.,	  2005;	  Clop	  et	  al.,	  2006;	  Sethupathy	  et	  al.,	  2007;	   Jensen	  et	  al.,	  2008).	  However,	   it	  appears	   that	   no	   mutations	   in	   NDP	   have	   been	   missed	   in	   our	   patient	   group,	   and	   no	  evidence	  for	  involvement	  of	  miRNAs	  in	  the	  regulation	  of	  NDP-­‐associated	  diseases	  could	  be	  found.	  	  
208	   DISCUSSION	  	  
	  
4.4.2	  FZD4	  screening	  Exon	  1	  and	  the	  coding	  region	  of	  exon	  2	  were	  screened	  by	  Jurian	  Zürcher	  as	  part	  of	  his	  masterthesis	   (Masterthesis	   Zürcher,	   2007).	   Since	   two	   miRNAs	   shown	   to	   inhibit	  neovascularization	  (Shen	  et	  al.,	  2008)	  are	  predicted	  to	  bind	  to	  the	  FZD4	  3’-­‐UTR,	  the	  two	  parts	   harboring	   the	   recognition	   sites	   were	   sequenced	   additionally.	   However,	   no	  alterations	  were	  found	  in	  these	  regions	  of	  the	  3’-­‐UTR,	  leaving	  a	  possible	  involvement	  of	  miR-­‐31-­‐	  and	  miR-­‐184-­‐mediated	  regulation	  of	  FZD4	  in	  the	  pathogenesis	  of	  ND/EVR	  open.	  Two	   already	   described	   single	   nucleotide	   substitutions,	   c.97C>T	   (p.P33S;	   CM050619)	  and	   c.502C>T	   (p.P168S),	   were	   found	   in	   patient	   27118	   (Masterthesis	   Zürcher,	   2007).	  Although	   in	   silico	   analyses	   suggested	   a	   possibly	   pathogenic	   effect	   of	   the	   p.P168S	  variation,	   it	   has	   been	   described	   as	   a	   SNP	   before	   (Toomes	   et	   al.,	   2004).	   However,	   the	  particular	  control	  proband	  was	  not	  examined	  by	  fluorescein	  angiography,	  and	  could	  be	  an	   asymptomatic	   carrier.	   Both	   parents	   of	   patient	   27118	   were	   reported	   to	   be	  asymptomatic,	  and	  since	  mutations	   in	  FZD4	  have	  been	  described	  to	   follow	  a	  dominant	  mode	  of	  inheritance	  (Robitaille	  et	  al.,	  2009),	  incomplete	  penetrance	  has	  to	  be	  assumed	  in	  the	  parent	  who	  inherited	  the	  p.P33S	  mutation.	  A	   haplotype	   analysis	   of	   the	   two	   sequence	   variants	   p.P33S	   and	   p.P168S	   revealed	   that	  they	   are	   located	   on	   different	   chromosomes	   (Masterthesis	   Zürcher,	   2007),	   suggesting	  that	   they	   have	   been	   inherited	   from	   both	   parents.	   This	   facilitates	   the	   alternative	  hypothesis	   of	   compound	   heterozygousity	   in	   the	   patient	   and	   a	   recessive	   mode	   of	  inheritance.	   However,	   p.P33S	   and	   p.P168S	   have	   recently	   been	   found	   in	   several	   FEVR	  patients	  on	  the	  same	  allele	  that	  did	  not	  co-­‐segregate	  with	  FEVR	  (Boonstra	  et	  al.,	  2009).	  More	   family	   members	   of	   patient	   27118	   should	   be	   examined	   to	   prove	   or	   reject	   the	  hypothesis	   of	   a	   recessive	   or	   dominant	   mode	   (with	   incomplete	   penetrance)	   of	  inheritance	   of	   these	  FZD4	  mutations.	   Unfortunately,	   none	   of	   the	   family	  members	  was	  available	  for	  further	  examinations.	  	  This	  patient	  is	  a	  good	  example	  for	  the	  variety	  of	  diagnoses	  that	  are	  made	  in	  an	  attempt	  to	  describe	  the	  clinical	  entity.	  She	  was	  diagnosed	  with	  Coats’	  disease,	  although	  both	  eyes	  were	  affected,	  and	  had	  a	  history	  of	  preterm	  birth,	  which	  would	  have	  qualified	  for	  ROP.	  ND	   was	   considered,	   but	   rejected	   because	   of	   her	   gender,	   and	   our	   molecular	   analysis	  finally	  pointed	  to	  FEVR.	  	  
4.4.3	  LRP5	  screening	  An	  amino	  acid	  exchange	  at	  position	  p.T672M	  (c.2015C>T;	  Figure	  94	  A)	  was	  found	  in	  a	  CD	   patient	   (Masterthesis	   Hänseler,	   2008).	   The	   position	   is	   highly	   conserved	   among	  vertebrates,	   and	   the	   mutation	   was	   absent	   in	   374	   control	   alleles.	   The	   amino	   acid	  exchange	   is	   located	   in	   the	   third	  β-­‐propeller	  of	   the	  extracellular	  domain	  of	  LRP5	   in	   the	  binding	  site	  of	  DKK,	  an	  endogenous	  inhibitor	  of	  Wnt-­‐signaling.	  The	  mutation	  thus	  could	  imply	   a	   functional	   change	   of	   LRP5	   that	   strengthens	   the	   affinity	   to	   DKK,	   thereby	  explaining	  an	  NDP-­‐related	  ocular	  phenotype.	  Bone	  anomalies	  typical	  for	  OPPG	  were	  not	  observed	  in	  the	  patient	  and	  her	  family.	  However,	  no	  determination	  of	  bone	  density	  has	  been	  performed.	  The	  fact	  that	  the	  p.T672M	  mutation	  was	  also	  found	  to	  be	  heterozygous	  in	  the	  patient’s	  unaffected	   mother	   as	   well	   as	   her	   two	   so	   far	   unaffected	   younger	   siblings	   (Figure	   95)	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excludes	  a	  dominant	  phenotype	  of	  this	  mutation	  and	  leaves	  the	  clinical	  presentation	  of	  the	  patient	  unexplained.	  Most	  probably,	  a	  second	  somatic	  mutation	  in	  the	  affected	  eye,	  as	  it	  has	  been	  described	  for	  an	  NDP	  mutation	  found	  in	  a	  CD	  patient	  (Black	  et	  al.,	  1999),	  accounts	  for	  the	  clinical	  presentation.	  To	  clarify	  the	  pathogenic	  relevance	  of	  this	  mutation,	  screening	  of	  NDP,	  FZD4,	  and	  LRP5	  should	  be	  repeated	  with	  DNA	  from	  the	  affected	  eye,	  if	  it	  became	  available.	  This	  would	  be	  the	  first	  time	  that	  a	  case	  of	  Coats‘	  disease	  is	  associated	  with	  a	  mutation	  in	  LRP5.	  In	  addition	  to	  this	  amino	  acid	  exchange,	  one	  silent	  mutation	  (c.2178C>T)	  was	  found	  in	  patient	  24536.	  In	  silico	  analysis	  suggested	  a	  possible	  effect	  on	  splicing	  (Figure	  96)	  that	  should	  be	   investigated	  when	  RNA	  became	  available.	  Splice	  variants,	  which	  can	  also	  be	  affected	   by	   mutations	   in	   the	   intron,	   especially	   the	   exon	   flanking	   regions,	   are	   often	  expressed	   in	   a	   tissue	   specific	   manner.	   A	   mutation	   could	   favour	   the	   formation	   of	   a	  transcript	   normally	   not	   or	   only	   marginally	   expressed	   in	   a	   tissue	   that	   is	   otherwise	  specific	   for	   another	   isoform,	  or	  vice	  versa,	   abolish	  or	  diminish	  expression	  of	   a	   certain	  transcript.	  As	   a	   result,	   the	   ratios	  between	  different	   splice	  products	  would	  be	   affected,	  which	   might	   influence	   clinical	   phenotypes,	   such	   as	   those	   characteristic	   for	   Norrie	  disease.	  Further,	   one	   SNP	   in	   the	   patient	   group	   (rs4988320)	   showed	   a	   significantly	   different	  allele	   frequency	   in	   comparison	   to	   the	  HAPMAP	  database,	   suggesting	   it	   as	  a	   risk-­‐factor	  for	   the	   development	   of	   an	   CD-­‐like	   phenotype.	   This	   hypothesis	   would	   have	   to	   be	  supported	  by	  additional	  sequencing	  of	  patients,	  and	  should	  be	  tested	  also	  by	  differential	  splicing	  experiments.	  So	   far,	  almost	  only	  exonic	  mutations	  have	  been	   found	   in	  LRP5.	  Regarding	   the	  genomic	  size	   (136.63kb)	   and	   exon	   structure	   of	   LRP5	   (23	   exons),	   it	   appears	   promising	   to	  investigate	   the	   intronic	   regions	   through	  deep	  or	  next-­‐generation	   sequencing	   in	   future	  studies,	  and	  analyse	  differential	  splicing	   in	  RNA	  samples,	  since	  only	  one	  transcript	  has	  been	  annotated	  in	  the	  public	  databases	  of	  NCBI	  and	  Ensembl	  so	  far.	  	  
4.4.4	  LRP5L	  screening	  /	  22q11	  deletion	  syndromes	  Since	   no	   mutations	   have	   been	   observed	   in	   the	   LRP5L	   gene,	   no	   evidence	   for	   an	  association	  with	  ND/EVR	  was	  found.	  However,	   in	  silico	  analysis	  of	  a	  silent	  variation	   in	  exon	  2	  (c.339C>T;	  rs9624807)	  revealed	  the	  creation	  of	  a	  new	  binding	  site	  for	  a	  putative	  splice	  regulatory	  element	  (Figure	  98),	  which	  in	  addition	  to	  the	  significant	  higher	  allele	  frequency	  in	  the	  patient	  group	  (odds-­‐ratio	  18.42)	  indicates	  a	  possible	  risk-­‐factor.	  As	  has	  been	  discussed	  above,	  the	  pathogenic	  potential	  of	  this	  variation	  has	  to	  be	  confirmed	  by	  screening	   of	   additional	   patients,	   and	   investigation	   of	   differential	   splicing	   (if	   RNA	  was	  available).	  Recently,	   the	   case	   of	   the	   DiGeorge	   patient	   who	   presented	   with	   an	   FEVR-­‐like	   ocular	  phenotype,	  which	  was	  presented	  at	   the	  ARVO	  annual	  meeting	   in	  2008,	  was	  published	  (Gilmour	  et	  al.,	  2009).	  The	  authors	  adressed	  my	  hypothesis,	  and	  investigated	  LRP5L	  as	  possible	   candidate	   gene	   for	   FEVR.	   Allele	   loss	   studies	   demonstrated	   that	   it	   is	   situated	  >2.5Mb	   from	   the	   deletion	   on	   chromosome	   22	   that	   was	   linked	   to	   DiGeorge	   sequence.	  Although	  not	  deleted	   itself,	   there	   could	  be	  positional	   effects	   of	   regulatory	   elements	   in	  the	  proximity	  of	  LRP5L	   that	  might	  have	  been	  deleted.	  However,	   the	  authors	  point	  out	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that	  the	  longest	  range	  reported	  in	  a	  position	  effect	  mutation	  to	  date	  is	  1	  Mb,	  making	  this	  possibility	  rather	  unlikely	  (Kleinjan	  et	  al.,	  2005).	  On	  the	  other	  hand,	  another	  DiGeorge	  sequence	  case	  report	  has	  been	  published	  before,	  describing	  a	  patient	  with	  Coats’	  disease-­‐like	  phenotype	   (Scholz	   et	   al.,	   1997),	  who	  also	  harbors	  a	  chromosome	  22q11	  deletion	  (although	  of	  unreported	  extent).	  This	  case	  could	  support	   the	  hypothesis	   that	   among	   the	  ~40	  known	  genes	   typically	   involved	   in	  22q11	  deletions	   (reviewed	   by	   Shprintzen,	   2008),	   one	   gene	   contributes	   to	   an	   ND/FEVR	  phenotype.	  With	   regard	   to	   LRP5/LRP5L	   and	   ND/OPPG,	   I	   think	   it	   is	   noteworthy	   that	   DiGeorge	  patients	   often	   suffer	   from	   skeletal	   anomalies,	   mental	   retardation,	   and	   hearing	  disabilities	   (Shprintzen,	   2008).	   However,	   about	   180	   phenotypes	   for	   the	   typical	   3Mb	  22q11	  deletion	  have	  been	  described	  so	  far,	  and	  it	   is	  difficult	  to	  associate	  single	  clinical	  presentations	  with	  a	  certain	  gene.	  Several	  attempts	  have	  been	  made,	  the	  most	  noticable	  maybe	  concerning	  T-­‐box	  1	  (TBX1),	  a	  gene	  coding	  for	  a	   transcription	  factor	   involved	   in	  developmental	   processes	   that	   is	   always	   involved	   in	   22q11	  deletion	   syndromes.	   It	   has	  been	  shown	  that	  Tbx1	  interacts	  with	  Vegfa,	  and	  thus	  may	  represent	  an	  additional	  link	  to	  ND	  and	  allelic	  diseases	  (Stalmans	  et	  al.,	  2003).	  	  
4.4.5	  PLVAP	  screening	  No	  mutations	  or	  not	  annotated	  SNPs	  were	  found	  in	  the	  patient	  group,	  leaving	  a	  possible	  implication	   of	   PLVAP	   in	   ND	   or	   similar	   diseases	   open.	   Allele	   frequencies	   of	   the	   three	  annotated	  SNPs	  were	  in	  the	  expected	  range	  of	  the	  control	  population	  (Table	  44).	  Since	  
Plvap	  was	  higher	  expressed	  in	  the	  absence	  of	  functional	  norrin,	  it	  is	  difficult	  to	  speculate	  about	   possible	   pathogenic	   consequences	   of	  PLVAP	  mutations.	   A	  mere	   loss-­‐of-­‐function	  through	   deletions,	   frameshift,	   or	   nonsense	   mutations	   would	   result	   in	   lack	   of	   PLVAP	  protein,	  which	  has	  been	   shown	   to	  be	   important	   for	   the	   structure	   and	  development	  of	  endothelial	  fenestrae	  diaphragms	  (Figure	  115)	  (Stan	  et	  al.,	  1999).	  Endothelial	  fenestrae	  do	  not	  always	  contain	  a	  diaphragm,	  as	  has	  been	  shown	  in	  muscle	  capillaries,	  (Bearer	  and	  Orci,	  1985)	  but	  it	  is	  responsible	  for	  fenestrated	  capillary	  permeability.	  	  
	  
Figure	   115	   Electron	   microscopic	   image	   (120‘000x)	   of	   fenestral	   diaphragms	   on	   the	   etched	   surface	   of	  peritubular	   capillaries	   in	   the	   rat	   kidney	   cortex	   (luminal	   surface	   view).	   Plvap	   is	   thought	   to	   be	   the	  main	  constituent	  of	  the	  intertwining	  fibrils	  that	  compose	  the	  diaphragm	  (Stan	  et	  al.,	  1999).	  (Source:	  Bearer	  and	  Orci,	  1995).	  	  Thus,	   loss-­‐of-­‐function	  mutations	  do	  probably	  not	   lead	   to	  an	  ND-­‐like	  ocular	  phenotype,	  because	   the	   development	   of	   vessel	   leakiness	   should	   be	   impaired.	   However,	   as	   was	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discussed	   in	   the	   IOVS	   publication,	   transient	   expression	   of	   Plvap	   and	   fenestration	   of	  capillaries	   may	   be	   important	   for	   proper	   remodeling	   of	   the	   retinal	   vasculature.	  Therefore,	   lack	   of	   Plvap	   could	   contribute	   to	   impaired	   angiogenesis,	   and	   thus	  may	   be	  involved	   in	   the	   pathogenesis	   of	   the	   disease.	   Gain-­‐of-­‐function	   mutations	   or	   mutations	  leading	  to	  increased	  expression	  of	  PLVAP	  would	  mirror	  the	  situation	  found	  in	  the	  Ndph	  ko	  mouse,	  and	  in	  my	  opinion	  are	  more	  likely	  to	  induce	  a	  ND-­‐like	  phenotype.	  Therefore,	  it	  may	  be	  worthwhile	  to	  identify	  potential	  upstream	  regulatory	  regions	  of	  PLVAP,	  and	  to	  sequence	  those	  regions	  in	  our	  patient	  group.	  	  
4.4.6	  SLC38A5	  screening	  Two	  annotated	  SNPs	  with	  allele	  frequencies	  similar	  to	  the	  control	  population	  have	  been	  found	  in	  the	  SLC38A5	  screening,	  but	  no	  pathogenic	  amino	  acid	  exchanges.	  However,	  one	  new	   sequence	   variation	   was	   found	   in	   the	   5’-­‐UTR.	   Patient	   25649	   harbors	   a	   c.-­‐73G>A	  exchange	  that	  is	  not	  affecting	  the	  coding	  sequence.	  Instead,	  the	  base	  change	  could	  have	  occurred	  in	  a	  promoter	  element	  or	  a	  regulatory	  sequence,	  or	  affect	  the	  splice	  pattern.	  In	  
silico	  analysis	  predicted	  a	  change	  in	  putative	  exonic	  regulatory	  elements	  that	  can	  bind	  to	  the	   sequence	   (Figure	   104).	   Thus,	   the	   variation	   could	   affect	   splicing	   that	   should	   be	  investigated	  when	  RNA	  became	  available.	  Among	   the	   investigated	   genes,	   SLC38A5	   would	   be	   of	   particular	   interest,	   because	   it	   is	  only	  located	  4.5	  cM	  from	  the	  NDP	  locus	  on	  the	  short	  arm	  of	  the	  X-­‐chromosome	  (Figure	  116),	   and	   variations	   in	   both	   genes	   would	   co-­‐segregate	   with	   a	   high	   probability.	   This	  could	  explain	  some	  of	  the	  (interfamilial)	  phenotypic	  variability	  of	  the	  disease.	  	  
	  
Figure	  116	  The	   loci	  of	  Ndph/NDP	  and	  Slc38a5/SLC38A5	  are	  only	  separated	  by	  4.3cM	  and	  4.5cM	  on	  the	  murine	  and	  human	  X-­‐chromosome,	  respectively.	  Thus,	  cosegregation	  of	  the	  two	  alleles	  is	  highly	  likely.	  	  
4.4.7	  LMO2	  screening	  Although	  differential	  expression	  of	  LMO2	  was	  not	  investigated	  in	  this	  study,	  I	  selected	  it	  for	  patient	  screening	  for	  several	  reasons.	  For	  one,	  it	  is	  located	  in	  the	  linkage	  interval	  for	  EVR3	  on	  chromosome	  11p12-­‐13	  (Downey	  et	  al.,	  2001).	  Two,	  it	  has	  been	  associated	  with	  angiogenesis	   and	  Wnt-­‐signaling	   (Yamada	   et	   al.,	   2000).	   Three,	   it	   is	   expressed	   in	   retina	  and	   inner	   ear,	   two	   of	   the	   organs	   affected	   in	   ND	   (Deng	   et	   al.,	   2006).	   Four,	   in	   silico	  analyses	  predicted	  a	  binding	  site	  for	  NDP	  (Katoh	  and	  Katoh,	  2005).	  However,	  after	  sequencing	  of	  all	   six	  exons	  and	   flanking	   intronic	   regions,	  no	  mutations	  were	   found	   in	   the	  patient	  group.	  Allele	   frequencies	   for	   four	  of	   the	   five	  SNPs	  observed	  were	  similar	  to	  the	  database	  values,	  and	  for	  one	  SNP	  (rs11032432),	  no	  frequency	  data	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was	  available.	  This	   information	   should	  be	   retrieved	  by	   sequencing	  a	   cohort	  of	   control	  DNAs.	  	  
4.4.8	  Promising	  candidate	  genes	  for	  future	  genetic	  screening	  of	  ND/EVR	  patients	  In	   addition	   to	   genes	   that	   were	   shown	   to	   be	   differentially	   expressed	   or	   have	   been	  discussed	  above	  (MAOA,	  MMP7,	  TPH1,	  WNT7B,	  WNT11),	  following	  candidates	  should	  be	  considered	  for	  future	  research:	  
4.4.8.1	  Tissue	  inhibitor	  of	  metalloproteinases	  1	  (TIMP1)	  This	   gene	   is	   located	  within	   intron	   6	   of	   the	   synapsin	   I	   gene	   and	   is	   transcribed	   in	   the	  opposite	   direction	   at	   Xp11.3	   (~5	   cM	   from	  NDP).	   TIMP1	  was	   shown	   to	   inhibit	  matrix	  metalloproteinase	  (MMP)	  activity	  and	   thereby	  suppresses	  angiogenesis	   in	  vitro	  and	   in	  vivo	   (Johnson	   et	   al.,	   1994).	   Although	   two	   patients	   with	   ND	   and	   a	   submicroscopic	  deletion	  of	  Xp11.3-­‐11.2	  were	  found	  to	  retain	  the	  TIMP1	  gene	  (Gal	  et	  al.,	  1986),	  it	  should	  not	   be	   excluded	   as	   candidate,	   since	   two	   genes	   closely	   located	   two	   each	   other	   may	  interact	  functionally	  and	  can	  contribute	  to	  the	  same	  disease,	  as	  has	  been	  demonstrated	  by	  the	  adjacent	  genes	  FZD4	  and	  LRP5	  on	  chromosome	  11q.	  
4.4.8.2	  NF-­‐κ-­‐B	  essential	  modulator	  gene	  (NEMO/IKBKG)	  The	   NF-­‐kappa-­‐B	   essential	   modulator	   gene	   (NEMO/IKBKG)	   has	   been	   shown	   to	   cause	  incontinentia	  pigmenti	  (IP),	  which	  has	  an	  ocular	  phenotype	  very	  similar	  to	  ND	  (Smahi	  et	  al.,	   2000).	   Usually,	   familial	   mutations	   in	   NEMO/IKBKG	   cause	   extra-­‐ocular	   symptoms,	  especially	  and	  maybe	  best	  visible	  in	  the	  skin.	  But	  in	  the	  case	  of	  somatic	  mutations	  that	  only	  affect	  the	  eyes,	  mutations	  in	  NEMO/IKBKG	  could	  account	  for	  an	  ND-­‐like	  phenotype.	  Thus,	  NEMO/IKBKG	  should	  be	  considered	  as	  candidate	  gene	  for	  screening	  in	  ND/FEVR	  patients	  without	  mutations	  in	  NDP.	  
4.4.8.3	  Insulin-­‐like	  growth	  factor	  1	  (IGF-­‐1)	  Insulin-­‐like	  growth	  factor	  1	  (IGF-­1)	  has	  been	  shown	  to	  be	  necessary	  for	  ocular	  vascular	  development	  (Hellström	  et	  al.,	  2002),	  and	   low	  serum	  levels	  have	  been	  associated	  with	  ROP	  (Hellström	  et	  al.,	  2003).	  Further,	  growth	  failure,	  sensorineural	  deafness,	  and	  mental	  retardation	  were	  observed	  (Woods	  et	  al.,	  1996;	  Bonapace	  et	  al.,	  2003).	  In	  one	  family,	  a	  mutation	   in	   IGF-­1	   (p.V44M)	   additionally	   presented	   with	   bilateral	   cataract,	   shallow	  anterior	  chamber,	  and	  varying	  degrees	  of	  reduced	  bone	  density	  up	  to	  osteoporosis,	  all	  clinical	   features	   reminiscent	   of	   ND/OPPG	   (Walenkamp	   et	   al.,	   2005).	   However,	   no	  significant	  differences	  were	  found	  on	  transcript	  level	  in	  the	  Ndph	  ko	  retina	  (Luhmann	  et	  al.,	  2005a).	  
4.4.8.4	  Angiopoietin	  2	  (ANGPT-­‐2)	  Angiopoietin	   2	   is	   necessary	   for	   angiogenesis	   and	   vessel	   regression	   (Fruttiger,	   2007).	  	  Transcript	   levels	   are	   elevated	   during	   neovascularization	   and	   can	   also	   be	   found	   in	   the	  
Ndph	  ko	  retina	  at	  p15	  and	  p21	  (Luhmann	  et	  al.,	  2005a).	  High	   levels	  have	  further	  been	  observed	   in	   the	   vitreous	   of	   patients	   diagnosed	  with	   proliferative	   diabetic	   retinopathy	  (Watanabe	  et	  al.,	  2005).	  The	  Angpt-­2	  ko	  mouse	  is	  an	  ocular	  phenocopy	  of	  the	  Ndph	  ko	  mouse,	  presenting	  with	  delayed	  and	   incomplete	  development	  of	   the	  superficial	   retinal	  vasculature,	   lack	   of	   deep	   and	   intermediate	   networks,	   and	   lack	   of	   hyaloid	   vessel	  regression	  (Hackett	  et	  al.,	  2002).	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4.4.8.5	  Endothelial-­‐specific	  receptor	  tyrosine	  kinase	  (TEK/TIE2)	  TEK	   is	   a	   key	   protein	   for	   angiogenesis	   (Fruttiger,	   2007)	   that	   has	   been	   shown	   to	   be	  regulated	  by	  Wnt5a	  (Masckauchan	  et	  al.,	  2006)	  via	  non-­‐canonical	  Wnt-­‐signaling.	  Since	  expression	   of	   the	   Tie-­2	   mRNA	   in	   the	   p5	   Ndph	   ko	   retina	   is	   significantly	   reduced	  (Luhmann	   et	   al.,	   2005a),	   it	   is	   tempting	   to	   speculate	   if	   norrin	  might	   be	   involved	   in	   its	  regulation	  as	  well.	  	  	  
4.4.8.6	  Dickkopf	  2	  (DKK2)	  Dickkopf	  2	  (Dkk2)	  is	  an	  inhibitor	  of	  canonical	  Wnt-­‐signaling	  that	  has	  been	  shown	  to	  be	  a	  key	   regulator	   in	   corneal	   fate	   determination	   of	   the	   ocular	   surface	   epithelium	  (Mukhopadhyay	   et	   al.,	   2006).	   Dkk2	   ko	   mice	   present	   with	   opaque	   corneas,	   another	  feature	   frequently	   observed	   in	   ND	   patients.	   Mutations	   in	   DKK2	   could	   affect	  norrin/FZD4/LRP5	   signaling	   in	   the	   eye,	   and	   thus	   contribute	   to	   the	   severity	   of	   the	  disease.	  	  
4.4.9	  Synopsis	  Five	   of	   our	   22	   patients	   were	   previously	   found	   to	   harbor	   mutations	   in	   NDP	   (p.M1V,	  p.R74C,	  p.C110S,	  p.C128X,	  c.174+1G>T)	  (Table	  6).	  Of	  the	  remaining	  17	  patients,	  one	  had	  a	   mutation	   in	   FZD4	   (p.P33S),	   and	   one	   had	   a	   new	   heterozygous	   mutation	   in	   LRP5	  (p.T672M).	  15	  patients	  had	  no	  mutations	  in	  these	  three	  genes,	  but	  sequence	  analyses	  of	  
LRP5L,	  LMO2,	  PLVAP,	   and	   SLC38A5	   revealed	   no	   additional	   pathogenic	   variants.	   In	   the	  patient	   group,	   significant	   different	   allele	   frequencies	  were	   found	   for	   one	   SNP	   in	  LRP5	  (rs4988320)	   and	   one	   in	   LRP5L	   (rs9624807),	   which	   should	   be	   confirmed	   through	  additional	  screening	  of	  patients	  and	  analyzed	  with	  regard	  to	  differential	  splicing	  activity.	  One	  new	  sequence	  variant	  was	  found	  in	  exon	  1	  of	  SLC38A5,	  which	  has	  been	  predicted	  to	  possibly	   affect	   splicing	   also	   (c.-­‐73G>A).	   The	   absence	   of	   mutations	   in	   LRP5L,	   LMO2,	  
PLVAP,	   and	   SLC38A5	   in	   15	   patients	   does	   not	   implicate	   that	   these	   genes	   are	   not	   of	  importance	  for	  the	  pathogenesis	  of	  ND/EVR-­‐like	  diseases,	  and	  thus	  should	  nonetheless	  be	  considered	  as	  candidates	  for	  future	  screening	  efforts.	  In	  addition,	  several	  other	  genes	  should	  be	  included,	  such	  as	  ANGPT2,	  DKK2,	  IGF-­1,	  ISL1,	  IKBKG,	  MAOA,	  MMP7,	  SYP,	  TEK,	  
TIMP1,	  TPH1,	  WNT7B,	  and	  WNT11.	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Appendix	  
Primer	  sequences	  used	  in	  this	  work	  	  
ID Name Sequence 5´- 3´ 
54 LacZ1L20 GAT TTC CAT GTT GCC ACT CG 
55 LacZ1U20 TCG TCT GCT CAT CCA TGA CC 
56 M13 -20tg GTA AAA CGA CGG CCA GTG 
57 M13 rev GGA AAC AGC TAT GAC CAT G 
177 SL105 CTA TCG CCT TCT TGA CGA GTT 
178 SL106 GGC CTG GGT GGA GAG GCT TTT T 
179 SL107 GTA TTG CAT CCA TAT TTC TTG G 
180 SL108 CTC TCC ATC CCC TGA CAA GGA 
188 Sry fwd1 TTC AGC CCT ACA GCC ACA TGA 
189 Sry rev1 ATG TGG GTT CCT GTC CCA CTG 
196 GAPD fwd GAC CAC AGT CCA TGC CAT CAC T 
197 GAPD rev TCC ACC ACC CTG TTG CTG TAG 
198 Slc38a5 fwd CGA CCT TTG GAT ACC TCA CCT T 













TTG AAA ATC CGC GGG AGA G 
203 
mm 28S 
rRNA rev 1 











































































TTG AGC AGA AGA GCT GCT ACG T 
230 LacZ fwd ACA CAA ATC AGC GAT TTC CAT GT 
ID Name Sequence 5´- 3´ 
231 LacZ rev 









ACG GAA ACA CTC TTA TGT GCG 
234 Gata1 fwd CAG AAA ACA AGG AGG CGA AGG 













GGG GAC AAG TTT GTA CAA AAA 
AGC AGG CTT CCT GGT GCC GCG 
CGG CAG CAA AAC GGA CAG CTC 




GGG GAC CAC TTT GTA CAA GAA 
AGC TGG GTC GGA TCC GCG CGG 
CAC CAG GGA ATT GCA TTC CTC 




AGG ATC TGC ACC ATC ACC ATC 
ACC ATC TGG TGC CGC GCG GCA 





GGG GAC CAC TTT GTA CAA GAA 
AGC TGG GTC GGA TCC GCG CGG 
CAC CAG CTA TCA GGA ATT GCA 




GGG GAC AAG TTT GTA CAA AAA 
AGC AGG CTT CGA ACA AAA ACT 
CAT CTC AGA AGA GGA TCT GCA 
CCA TCA CCA TCA C 
282 AOX 5' GAC TGG TTC CAA TTG ACA AGC 
283 AOX 3' GCA AAT GGC ATT CTG ACA TCC 
284 
mm Isl-1 5' 
Exon 2 
AGG GAT GGG AAA ACC TAC TGT 
AAA 
285 
mm Isl-1 3' 
Exon 3 
AGT CGT TCT TGC TGA AGC CTA TG 
286 
mm Syp 5' 
Exon 3 
GAG TGC CCT CAA CAT CGA AGT C 
287 
mm Syp 3' 
Exon 4 























































CCG GTG TTT TAA CAA GCC CTC CT 
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ACG GCA GCA TTC ATT GTG TGG 































TCC GTG CCT CAG TTT CCC CAC 





























































































TTG AGG CAG GTA CAG AGG GAA 
GG 
428 FZD4-1-fwd CTG CTA CCC CCG ATG CTG 
































GGA ATC ATC TGC AGA ATA CCG 
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CAA ACT GGG GGT GTC TGC CAG 
476 27118 fwd GCC CAC ACA GCC ATC CAG AT 





































































































GGC AGA GTT TGC AAT GAG CC 





























































































































































ACA GAA GCC GAC AGC AGA ATG 
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AAT GTC CAA TAT CCA GCT CCA 
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Results	  from	  the	  whole	  genome	  cDNA	  microarray	  (p	  <0.01)	  	  
Increased Symbol Name Affymetrix ID 
3.06 Mdm2 Transformed mouse 3T3 cell double minute 2 1457929_at 
2.79 Wdr67 WD repeat domain 67 1442286_at 
2.47 Seh1l SEH1-like (S. cerevisiae) 1441857_x_at 
2.30 Fndc3a fibronectin type III domain containing 3A 1444482_at 
2.16 Prdm9 PR domain containing 9 1426107_at 
2.04 E330034G19Rik RIKEN cDNA E330034G19 gene 1433798_a_at 
2.03 Adm adrenomedullin 1447839_x_at 
2.00 Ifnb1 Interferon beta, fibroblast 1422305_at 
2.00 Lilrb4 leukocyte immunoglobulin-like receptor, subfamily B, member 4 1420394_s_at 
1.95 Arhgap10 Rho GTPase activating protein 10 1442967_at 
1.88 Iqsec2 IQ motif and Sec7 domain 2 1448063_at 
1.87 Lenep lens epithelial protein 1422309_a_at 
1.86 Plvap plasmalemma vesicle associated protein 1418090_at 
1.84 Foxp1 forkhead box P1 1446280_at 
1.81 Sc4mol sterol-C4-methyl oxidase-like 1459627_at 
1.81 A2m alpha-2-macroglobulin 1434719_at 
1.80 Klhl7 kelch-like 7 (Drosophila) 1459477_at 
1.80 Emp1 epithelial membrane protein 1 1416529_at 
1.79 Spsb1 splA/ryanodine receptor domain and SOCS box containing 1 1421474_a_at 
1.76 Sync syncoilin 1432350_at 
1.67 Acta2 actin, alpha 2, smooth muscle, aorta 1416454_s_at 
1.66  Mus musculus transcribed sequences 1457729_at 
1.65 Gfra2 glial cell line derived neurotrophic factor family receptor alpha 2 1459847_x_at 
1.65 Ganab alpha glucosidase 2, alpha neutral subunit 1437812_x_at 
1.65 Dync1li1 dynein cytoplasmic 1 light intermediate chain 1 1425953_at 
1.65 Car12 carbonic anyhydrase 12 1428485_at 
1.63 Maob monoamine oxidase B 1434354_at 
1.59 Ms4a6b membrane-spanning 4-domains, subfamily A, member 6B 1418826_at 
1.58 Prkag1 protein kinase, AMP-activated, gamma 1 non-catalytic subunit 1457803_at 
1.56 St13 suppression of tumorigenicity 13 1416851_at 
1.55 Xist inactive X specific transcripts 1436936_s_at 
1.55 Ndufa4l2 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4-like 2 1434905_at 
1.54 Thrsp thyroid hormone responsive SPOT14 homolog (Rattus) 1422973_a_at 
1.52 Arpp21 cyclic AMP-regulated phosphoprotein, 21 1442121_at 
1.52 Nr2c2 nuclear receptor subfamily 2, group C, member 2 1433379_at 
1.49 Kif26b kinesin family member 26B 1440990_at 
1.49 Hk2 hexokinase 2 1422612_at 
1.48 Ppfia2 protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 2 1445766_at 
1.47 2700054A10Rik Mus musculus 11 days embryo whole body cDNA, RIKEN full-length enriched library, clone:2700054A10 product:unknown EST, full insert sequence 1431223_at 
1.47 Tgfbi transforming growth factor, beta induced 1437463_x_at 
1.47 Ptchd2 patched domain containing 2 1440288_at 
1.46 D12Ertd647e ISG12a protein 1452956_a_at 
1.45 Rere arginine glutamic acid dipeptide (RE) repeats 1439159_at 
1.44 Mrpl15 mitochondrial ribosomal protein L15 1458612_at 
1.44 Map2k5 mitogen activated protein kinase kinase 5 1430180_at 
1.44 Obfc2a oligonucleotide/oligosaccharide-binding fold containing 2A  1460521_a_at 
1.44 RP23-376N23.4 predicted gene, OTTMUSG00000016611 1420318_at 
1.43 Myst2 MYST histone acetyltransferase 2 1447631_at 
1.43 Fbxw9 F-box and WD-40 domain protein 9 1425857_at 
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1.42 Ednrb endothelin receptor type B 1423594_a_at 
1.42 Ints7 integrator complex subunit 7 1443045_at 
1.42 Lsp1 lymphocyte specific 1 1417756_a_at 
1.40 Mt1 metallothionein 1 1422557_s_at 
1.40 Pfkp phosphofructokinase, platelet 1437759_at 
1.38 Slc25a40 solute carrier family 25, member 40 1458031_at 
1.38 Bnip3 BCL2/adenovirus E1B 19kDa-interacting protein 1, NIP3 1422470_at 
1.38 Trappc6a trafficking protein particle complex 6A 1460054_at 
1.36 AI452102 expressed sequence AI452102 1458459_a_at 
1.36 Gnl3 guanine nucleotide binding protein-like 3 (nucleolar) 1440766_at 
1.36 Kcnj3 potassium inwardly-rectifying channel, subfamily J, member 3 1421468_at 
1.36 Amot angiomotin 1425907_s_at 
1.35 Tacstd1 tumor-associated calcium signal transducer 1 1447899_x_at 
1.35 Sfrp4 secreted frizzled-related sequence protein 4 1451031_at 
1.35 Chst14 carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 14 1426866_at 
1.34 Arih2 ariadne homolog 2 (Drosophila) 1445934_at 
1.34 Sufu suppressor of fused homolog (Drosophila) 1420848_at 
1.33 H19 H19 fetal liver mRNA 1448194_a_at 
1.32 Pfkp phosphofructokinase, platelet 1416069_at 
1.30 A930016P21Rik RIKEN cDNA A930016P21 gene 1444686_at 
1.29 Slc19a2 solute carrier family 19 (thiamine transproter), member 2 1426117_a_at 
1.29 Pdk1 3-phosphoinositide dependent protein kinase-1 1423748_at 
1.28 Flrt1 fibronectin leucine rich transmembrane protein 1 1460041_at 
1.28 Ppp1r10 protein phosphatase 1, regulatory subunit 10 1430560_at 
1.27 Cops6 COP9 (constitutive photomorphogenic) homolog, subunit 6 (Arabidopsis thaliana) 1451367_at 
1.27 H2-Q7 histocompatibility 2, Q region locus 7 1418536_at 
1.27 Dmrtc1a DMRT-like family C1a 1431360_s_at 
1.26 Sirt1 sirtuin 1 (silent mating type information regulation 2, homolog) 1 (S. cerevisiae) 1458538_at 
1.26 Cenpo centromere protein O 1418542_s_at 
1.26 Mrps5 mitochondrial ribosomal protein S5 1435563_at 
1.26 Akap8l neighbor of A-kinase anchoring protein 95 1428814_at 
1.25 Ppih peptidyl prolyl isomerase H 1429832_at 
1.25 AL807384.5 RIKEN cDNA 1700030G11 gene 1439592_at 
1.25 Ptpdc1 protein tyrosine phosphatase domain containing 1 1435107_at 
1.24 Sec24d Sec24 related gene family, member D (S. cerevisiae) 1426972_at 
1.24 Zfp13 zinc finger protein 13 1435131_at 
1.24 Igf2 insulin-like growth factor 2 1448152_at 
1.24 Lrrc8d leucine rich repeat containing 8D 1447491_at 
1.24 Hnrpdl heterogeneous nuclear ribonucleoprotein D-like 1428225_s_at 
1.23 Loxl2 lysyl oxidase-like 2 1431004_at 
1.23  Mus musculus transcribed sequences 1458798_at 
1.23 0610037D15Rik RIKEN cDNA 0610037D15 gene 1453639_s_at 
1.23 2310056P07Rik family with sequence similarity 162, member A 1451385_at 
1.23 Pi4kb phosphatidylinositol 4-kinase, catalytic, beta polypeptide 1447950_at 
1.23 Vps13d vacuolar protein sorting 13 D (yeast) 1439187_at 
1.22 Atp9b ATPase, class II, type 9B 1460099_at 
1.21 Ndel1 nuclear distribution gene E-like homolog 1 (A. nidulans) 1424893_at 
1.20 Rasal2 RAS protein activator like 2 1436910_at 
1.20 Selenbp2 selenium binding protein 2 1417580_s_at 
1.20 Gpi1 phosphatidylinositol glycan anchor biosynthesis, class Q 1456909_at 
1.19 Gins3 GINS complex subunit 3 (Psf3 homolog) 1429149_at 
1.18 Pnpla8 patatin-like phospholipase domain containing 8 1442416_at 
1.18 Lba1 lupus brain antigen 1 1429276_at 
1.18 Ccnt2 cyclin T2 1427088_at 
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1.16 Siat9 sialyltransferase 9 (CMP-NeuAc:lactosylceramide alpha-2,3-sialyltransferase) 1449198_a_at 
1.15 EG245190 predicted gene, EG245190 1455739_at 
1.15 Seh1l SEH1-like (S. cerevisiae) 1420386_at 
1.15 Xrcc1 X-ray repair complementing defective repair in Chinese hamster cells 1 1416587_a_at 
1.15 Elmo2 engulfment and cell motility 2, ced-12 homolog (C. elegans) 1436011_at 
1.14 Pgk1 phosphoglycerate kinase 1 1417864_at 
1.13 Zfp50 zinc finger protein 50 1453175_at 
1.12 Nedd4l neural precursor cell expressed, developmentally down-regulated gene 4-like 1423269_a_at 
1.11 Pomgnt1 protein O-linked mannose beta1,2-N-acetylglucosaminyltransferase 1426618_a_at 
1.08 Ift172 intraflagellar transport 172 homolog (Chlamydomonas) 1423068_at 	  
Decreased Symbol Name Affymetrix ID 
14.03 Slc38a5 SN2; C81234 1454622_at 
4.88 Abcb1a ATP-binding cassette, sub-family B (MDR/TAP), member 1A 1419758_at 
2.82 Rps10 ribosomal protein S10 1439374_x_at 
2.72 4833411O04Rik 4833411O04Rik 1447914_x_at 
2.57  Mus musculus 10 day old male pancreas cDNA, RIKEN full-length enriched library, clone:1810021B22 product:unknown EST, full insert sequence 1440350_at 
2.44 Mfsd2 major facilitator superfamily domain containing 2 1428223_at 
2.24 Nutf2 nuclear transport factor 2 1447440_at 
2.13 Aass aminoadipate-semialdehyde synthase 1423523_at 
2.06 Apod apolipoprotein D 1416371_at 
2.05 Centd3 centaurin, delta 3 1419833_s_at 
2.03 Cldn5 claudin 5 1417839_at 
2.02 Vwf Von Willebrand factor homolog 1435386_at 
2.01 Ndph Norrie disease homolog 1449251_at 
1.92 Agtrl1 angiotensin receptor-like 1  1438651_a_at 
1.89 6230424C14Rik Mus musculus adult male cecum cDNA, RIKEN full-length enriched library, clone:9130410H17 product:unknown EST, full insert sequence 1441972_at 
1.88 2310015A05Rik RIKEN cDNA 2310015A05 gene 1436104_a_at 
1.85 6330409D20Rik RIKEN cDNA 6330409D20 gene 1430098_at 
1.85 Plekhh1 pleckstrin homology domain containing, family H (with MyTH4 domain) member 1 1435053_s_at 
1.79 6720489N17Rik RIKEN cDNA 6720489N17 gene 1440869_x_at 
1.76 Zf206 Mus musculus similar to zinc finger protein 206 (LOC332221), mRNA 1438787_at 
1.74 Abcc9 ATP-binding cassette, sub-family C (CFTR/MRP), member 9 1435752_s_at 
1.72 Eltd1 EGF, latrophilin seven transmembrane domain containing 1 1418059_at 
1.67 Ets1 E26 avian leukemia oncogene 1, 5' domain 1452163_at 
1.67 Vwa1 von Willebrand factor A domain containing 1 1426399_at 
1.66 Apcdd1 adenomatosis polyposis coli down-regulated 1 1418383_at 
1.66  Mus musculus transcribed sequences 1443322_at 
1.62 Slc7a1 Solute carrier family 7 (cationic amino acid transporter, y+ system), member 1 1454992_at 
1.61 Gpr123 G protein-coupled receptor 123 (Secretin family) 1459750_s_at 
1.60 9630027E11 Mus musculus 16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630027E11 product:unknown EST, full insert sequence 1440177_at 
1.60 Osmr oncostatin M receptor 1418674_at 
1.59 AI851453 Mus musculus adult male diencephalon cDNA, RIKEN full-length enriched library, clone:9330115I17 product:unclassifiable, full insert sequence 1441815_at 
1.56 5330430P22Rik RIKEN cDNA 2310066I18 gene 1453832_at 
1.56 Gpr23 G protein-coupled receptor 23 1439665_at 
1.55 Gpr22 G protein-coupled receptor 22 1434673_at 
1.55 Sema3e sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3E 1419717_at 
1.55 Ccl9 chemokine (C-C motif) ligand 9 1417936_at 
1.54 A930033C23Rik RIKEN cDNA A930033C23 gene 1431490_at 
1.53 Mobkl2c MOB1, Mps One Binder kinase activator-like 2C (yeast) 1459919_a_at 
1.52 Alox5ap arachidonate 5-lipoxygenase activating protein 1452016_at 
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1.52 5730508B09Rik RIKEN cDNA 5730508B09 gene 1447100_s_at 
1.51 Serpinb6a serine (or cysteine) proteinase inhibitor, clade B, member 6a 1436189_at 
1.51 Mmp15 matrix metalloproteinase 15 1437462_x_at 
1.51 Col25a1 collagen, type XXV, alpha 1 1438540_at 
1.51 Lect1 leukocyte cell derived chemotaxin 1 1460258_at 
1.50 Cit citron kinase 1455609_at 
1.50 1500009L16Rik Mus musculus adult male cerebellum cDNA, RIKEN full-length enriched library, clone:1500009L16 product:hypothetical protein, full insert sequence 1452840_at 
1.49  Mus musculus transcribed sequence with strong similarity to protein sp:P00722 (E. coli) BGAL_ECOLI Beta-galactosidase (Lactase) 1447922_at 
1.48 Kirrel3 kin of IRRE like 3 (Drosophila) 1431402_at 
1.48 Cyhr1 cysteine and histidine rich 1 1419284_at 
1.47 Tacr3 tachykinin receptor 3 1450278_at 
1.47 Agtrl1 angiotensin receptor-like 1 1423037_at 
1.46 Slco2b1 solute carrier organic anion transporter family, member 2b1 1433933_s_at 
1.46 BC022687 Uncharacterized protein C14orf79 homolog 1451533_at 
1.46 Myo1b myosin IB 1447364_x_at 
1.45 Sh3d1B SH3 domain protein 1B 1446735_at 
1.45 Paxip1 PAX interacting (with transcription-activation domain) protein 1 1434363_x_at 
1.45  Mus musculus transcribed sequence with strong similarity to protein sp:P00722 (E. coli) BGAL_ECOLI Beta-galactosidase (Lactase) 1440271_at 
1.44  Mus musculus transcribed sequences 1439816_at 
1.44 Pigc phosphatidylinositol glycan, classC 1424190_at 
1.44 Mff mitochondrial fission factor 1457371_at 
1.44  Mus musculus LOC386430 (LOC386430), mRNA 1443871_at 
1.43 Rnaseh2c ribonuclease H2, subunit C 1435733_x_at 
1.43 9030624J02Rik RIKEN cDNA 9030624J02 gene 1426695_at 
1.43 Adcy7 adenylate cyclase 7 1450065_at 
1.42 Gimap8 GTPase, IMAP family member 8 1456061_at 
1.42 1700012H17Rik family with sequence similarity 110, member B 1440359_at 
1.42 Ramp2 receptor (calcitonin) activity modifying protein 2 1418187_at 
1.42 Pdlim5 PDZ and LIM domain 5 1422862_at 
1.42 Itm2a integral membrane protein 2A 1423608_at 
1.41 B430007K19Rik Mus musculus 16 days neonate heart cDNA, RIKEN full-length enriched library, clone:D830033F17 product:unknown EST, full insert sequence 1440038_at 
1.41 Apcdd1 adenomatosis polyposis coli down-regulated 1 1454822_x_at 
1.41 Dnase2a deoxyribonuclease II alpha 1448986_x_at 
1.41 Wee1 wee 1 homolog (S. pombe) 1416774_at 
1.40 Zbtb33 zinc finger and BTB domain containing 33 1456596_at 
1.40 Sepp1 selenoprotein P, plasma, 1 1452141_a_at 
1.40 Phf2 PHD finger protein 2 1421067_a_at 
1.39  Mus musculus, Similar to sodium channel, voltage-gated, type I, alpha polypeptide, clone IMAGE:5361050, mRNA 1441728_at 
1.39 Eltd1 EGF, latrophilin seven transmembrane domain containing 1 1418058_at 
1.38 Atp5g1 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit c (subunit 9), isoform 1 1444874_at 
1.38 Myt1 myelin transcription factor 1 1439365_at 
1.38 Cyb5r3 cytochrome b5 reductase 3 1456554_at 
1.38 Pgr progesterone receptor 1439527_at 
1.38 Aifm2 apoptosis-inducing factor, mitochondrion-associated 2 1431143_x_at 
1.37 H2afz H2A histone family, member Z 1456032_x_at 
1.37  Mus musculus transcribed sequence with weak  similarity to protein ref:NP_081764.1 (M.musculus)  RIKEN cDNA 5730493B19 [Mus musculus] 1442387_at 
1.36 Eraf erythroid associated factor 1449077_at 
1.36 Traf3ip3 TRAF3 interacting protein 3 1457267_at 
1.36 Dpyd dihydropyrimidine dehydrogenase 1427946_s_at 
1.36 Tha1 threonine aldolase 1 1428780_at 
1.35 4930404N11Rik Mus musculus similar to hypothetical protein MGC20700 (LOC216175), mRNA 1434263_at 
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1.35 Magel2 melanoma antigen, family L, 2 1417217_at 
1.35 2410002O22Rik RIKEN cDNA 2410002O22 gene 1453332_at 
1.34 Rag1 recombination activating gene 1 1450680_at 
1.34 Mettl7a1 methyltransferase like 7A1 1434151_at 
1.34 Smad7 MAD homolog 7 (Drosophila) 1423389_at 
1.34 Tmem168 transmembrane protein 168 1451133_s_at 
1.34 Bcl11a B-cell CLL/lymphoma 11A (zinc finger protein) 1426552_a_at 
1.34 Tmhs tetraspan transmembrane protein, hair cell stereocilia 1429266_at 
1.34 Slc7a1 solute carrier family 7 1454991_at 
1.34 Taok2 TAO kinase 2 1438208_at 
1.33 Mrps24 mitochondrial ribosomal protein S24 1438563_s_at 
1.33 Egfr epidermal growth factor receptor 1424932_at 
1.33 Pard6b par-6 (partitioning defective 6) homolog beta (C. elegans) 1423174_a_at 
1.32 Spin2 spindlin family, member 2 1455297_at 
1.32 Zfp148 zinc finger protein 148 1436217_at 
1.32 Dhx30 DEAH (Asp-Glu-Ala-His) box polypeptide 30 1438832_x_at 
1.32 Ppm1a protein phosphatase 1A, magnesium dependent, alpha isoform 1417221_at 
1.32 2810410L24Rik 
Mus musculus 10, 11 days embryo whole body cDNA, RIKEN full-length 
enriched library, clone:2810410L24 product:unknown EST, full insert 
sequence 
1429510_at 
1.32 Suv39h2 suppressor of variegation 3-9 homolog 2 (Drosophila) 1433996_at 
1.32 Sdk2 sidekick homolog 2 (chicken) 1457333_at 
1.31  Mus musculus transcribed sequences 1458920_at 
1.31 Chchd7 coiled-coil-helix-coiled-coil-helix domain containing 7 1454640_at 
1.31 Pkn1 protein kinase C-like 1 1436851_at 
1.31 3830431G21Rik hypothetical protein 3830431G21 1436035_at 
1.31 Alg1 asparagine-linked glycosylation 1 homolog (yeast, beta-1,4-mannosyltransferase) 1451368_at 
1.31 AI447490 RIKEN cDNA A130022J15 gene 1433671_at 
1.31 Cart cocaine and amphetamine regulated transcript 1422825_at 
1.31 Nfkbia nuclear factor of kappa light chain gene enhancer in B-cells inhibitor, alpha 1449731_s_at 
1.31 Fkbp1b FK506 binding protein 1b 1449429_at 
1.30 Epha3 Eph receptor A3 1425575_at 
1.30 D430047L21Rik Mus musculus transcribed sequences 1435590_at 
1.30 Gpr124 G protein-coupled receptor 124 1418379_s_at 
1.30 Zbtb8a zinc finger and BTB domain containing 8a 1452063_at 
1.30 Rad51ap1 RAD51 associated protein 1 1448899_s_at 
1.30 Lrrc4 leucine rich repeat containing 4 1435832_at 
1.30 Gart phosphoribosylglycinamide formyltransferase 1424436_at 
1.30 Rfc4 replication factor C (activator 1) 4 1424321_at 
1.30  Mus musculus transcribed sequences 1455147_at 
1.30 2410003K15Rik RIKEN cDNA 2410003K15 gene 1428495_at 
1.30 Lsm5 LSM5 homolog, U6 small nuclear RNA associated (S. cerevisiae) 1418656_at 
1.30 1700066J24Rik RIKEN cDNA 1700066J24 gene 1436150_at 
1.29 Smpd4 sphingomyelin phosphodiesterase 4 1429530_a_at 
1.29 Rbpms RNA binding protein gene with multiple splicing 1429359_s_at 
1.29 Dgkz diacylglycerol kinase zeta 1426738_at 
1.29 Nptx1 neuronal pentraxin 1 1434877_at 
1.29 Clmn calmin 1439117_at 
1.29 Sema4a sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4A 1438934_x_at 
1.29 Zfp580 zinc finger protein 580 1429634_at 
1.29 Smarcd1 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 1 1448913_at 
1.29 Atp5sl ATP5S-like 1416775_at 
1.28 9430008C03Rik RIKEN cDNA 9430008C03 gene 1434574_at 
1.28 4632433K11Rik RIKEN cDNA 4632433K11 gene 1438689_at 
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1.28 Slc40a1 solute carrier family 40 (iron-regulated transporter), member 1 1448566_at 
1.28 Rgmb RGM domain family, member B 1442811_at 
1.28 1110038B12Rik RIKEN cDNA 1110038B12 gene 1441081_a_at 
1.28 Ddx1 DEAD (Asp-Glu-Ala-Asp) box polypeptide 1 1440816_x_at 
1.28 4930471M23Rik RIKEN cDNA 4930471M23 gene 1426220_at 
1.28 Mtrr 5-methyltetrahydrofolate-homocysteine methyltransferase reductase 1452110_at 
1.28 Chchd6 coiled-coil-helix-coiled-coil-helix domain containing 6 1438659_x_at 
1.28 Suclg2 succinate-Coenzyme A ligase, GDP-forming, beta subunit 1435841_s_at 
1.28  Foxk2 forkhead box K2 1428353_at 
1.27  Mus musculus transcribed sequences 1440378_at 
1.27 Riok2 RIO kinase 2 (yeast) 1436684_a_at 
1.27 Tmem51 transmembrane protein 51 1424383_at 
1.27 Tcfap2e transcription factor AP-2, epsilon 1435205_at 
1.27 Glul glutamate-ammonia ligase (glutamine synthase) 1426236_a_at 
1.27 3300001P08Rik RIKEN cDNA 3300001P08 1444677_at 
1.27 Cep68 centrosomal protein 68 1441340_at 
1.27 Nrsn2 neurensin 2 1434640_at 
1.27 Zic3 zinc finger protein of the cerebellum 3 1423424_at 
1.27 Stmn3 stathmin-like 3 1460181_at 
1.27 Ccdc45 coiled-coil domain containing 45 1436620_at 
1.27 Rab11fip4 RAB11 family interacting protein 4 (class II) 1434156_at 
1.27 Nup210 nucleoporin 210 1417585_at 
1.27 Nmd3 NMD3 homolog (S. cerevisiae) 1448133_at 
1.27 Ano8 anoctamin 8 1437895_at 
1.27 Slain2 SLAIN motif family, member 2 1427024_at 
1.27 9430016H08Rik RIKEN cDNA 9430016H08 gene 1424075_at 
1.26 Nmnat NMN adenylyltransferase; nicotinamide mononucleotide adenylyl transferase 1429819_at 
1.26 Osbpl1a oxysterol binding protein-like 1A 1416823_a_at 
1.26 Rnf138 ring finger protein 138 1419368_a_at 
1.26 Strn4 striatin, calmodulin binding protein 4 1426209_at 
1.26 Cd2ap CD2-associated protein 1455310_at 
1.26 Blzf1 basic leucine zipper nuclear factor 1 1442164_at 
1.26 Ccdc123 coiled-coil domain containing 123 1421949_a_at 
1.26 Rab14 RAB14, member RAS oncogene family 1419244_a_at 
1.26 Rex3 reduced expression 3 1448595_a_at 
1.26 Rab11b RAB11B, member RAS oncogene family 1439508_at 
1.25 Slc25a20 solute carrier family 25 (mitochondrial carnitine/acylcarnitine translocase), member 20 1423109_s_at 
1.25 Rab4a RAB4A, member RAS oncogene family 1418341_at 
1.25 Zc3h10 zinc finger CCCH type containing 10 1417833_at 
1.25 AW121567 Transmembrane protein FAM155A 1435138_at 
1.25 Zfp191 zinc finger protein 191 1430651_s_at 
1.25 Tmem185b transmembrane protein 185B 1452093_at 
1.25 Myo18a myosin XVIIIa 1451422_at 
1.25 Dusp4 dual specificity phosphatase 4 1428834_at 
1.25 Crlz1 charged amino acid rich leucine zipper 1 1417583_a_at 
1.25 Tmco7 transmembrane and coiled-coil domains 7 1458249_at 
1.25 Sfrs15 splicing factor, arginine/serine-rich 15 1427333_s_at 
1.25 D11Bwg0517e Fox-1 homolog C 1456149_at 
1.25 1700012H17Rik family with sequence similarity 110, member B 1437150_at 
1.24 Rhbdd3 rhomboid domain containing 3 1454719_at 
1.24 5730437N04Rik RIKEN cDNA 4933402O15 gene 1453591_at 
1.24 Hdac9 histone deacetylase 9 1434572_at 
1.24 Tcof1 Treacher Collins Franceschetti syndrome 1, homolog 1423601_s_at 
1.24 Shfdg1 split hand/foot deleted gene 1 1418574_a_at 
1.24 Kdelc2 KDEL (Lys-Asp-Glu-Leu) containing 2 1453071_s_at 
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1.24 Shisa2 shisa homolog 2 (Xenopus laevis) 1423852_at 
1.24 Ipo9 importin 9 1439481_at 
1.24 6530403A03Rik RIKEN cDNA 6530403A03 gene 1425319_s_at 
1.23 Tanc2 tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 2 1435078_at 
1.23 Sh3bp5 calpain 7 1421923_at 
1.23 Ppp1r14a protein phosphatase 1, regulatory (inhibitor) subunit 14A 1418086_at 
1.23 Ablim3 actin binding LIM protein family, member 3 1434013_at 
1.23 Zfp354a zinc finger protein 354A 1420390_s_at 
1.23 Mrpl9 mitochondrial ribosomal protein L9 1437749_s_at 
1.23 4921537I17Rik Mus musculus adult male testis cDNA, RIKEN full-length enriched library, clone:4921537I17 product:unknown EST, full insert sequence 1431259_at 
1.23 Evi5l ecotropic viral integration site 5 like 1430510_at 
1.23 Otop3 otopetrin 3 1429036_at 
1.23 0610010K14Rik RIKEN cDNA 0610010K14 gene 1428679_s_at 
1.23 Commd1 COMM domain containing 1 1424121_at 
1.23 Grb14 growth factor receptor bound protein 14 1417673_at 
1.23 Fxc1 fractured callus expressed transcript 1 1448887_x_at 
1.23 4921504N20Rik --- 1440778_x_at 
1.23 Mrpl52 mitochondrial ribosomal protein L52 1415762_x_at 
1.22 6720467C03Rik RIKEN cDNA 6720467C03 gene 1451570_a_at 
1.22 Syt7 synaptotagmin VII 1439633_at 
1.22 Mtdh Metadherin 1434882_at 
1.22 Pprc1 peroxisome proliferative activated receptor, gamma, coactivator-related 1 1426381_at 
1.22 Arpp19 cAMP-regulated phosphoprotein 19 1422608_at 
1.22 Dhx9 DEAH (Asp-Glu-Ala-His) box polypeptide 9 1451770_s_at 
1.22 Ash1l ash1 (absent, small, or homeotic)-like (Drosophila) 1450072_at 
1.22 Pfdn1 prefoldin 1 1417026_at 
1.22 Tomm20 translocase of outer mitochondrial membrane 20 homolog (yeast) 1455357_x_at 
1.22 Sec62 SEC62 homolog (S. cerevisiae) 1454697_at 
1.22 Evi2a ecotropic viral integration site 2a 1450241_a_at 
1.22 2310009B15Rik Mus musculus adult male tongue cDNA, RIKEN full-length enriched library, clone:2310009B15 product:unknown EST, full insert sequence 1435776_at 
1.22 Sept6 septin 6 1420877_at 
1.22 Cdh13 cadherin 13 1454015_a_at 
1.22 Lmbr1l limb region 1 like 1451165_at 
1.22 Daam1 dishevelled associated activator of morphogenesis 1 1458662_at 
1.22 Wtap Wilms' tumour 1-associating protein 1454805_at 
1.22 Atpaf1 ATP synthase mitochondrial F1 complex assembly factor 1 1434934_at 
1.22 Ndufb6 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6 1434056_a_at 
1.22 Arrdc4 arrestin domain containing 4 1424759_at 
1.22 Srp14 signal recognition particle 14 1454615_x_at 
1.22 Cdc42ep3 CDC42 effector protein (Rho GTPase binding) 3 1450700_at 
1.22 Psmg2 proteasome (prosome, macropain) assembly chaperone 2 1448212_at 
1.22 Rex3 reduced expression 3 1428209_at 
1.22  Mus musculus transcribed sequences 1457141_at 
1.22 Rpl27 ribosomal protein L27 1448217_a_at 
1.22 Efna2 ephrin A2 1444606_at 
1.22 Dkc1 dyskeratosis congenita 1, dyskerin homolog (human) 1438016_at 
1.22 B4galt6 UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 6 1435758_at 
1.22 Cmc1 COX assembly mitochondrial protein homolog (S. cerevisiae) 1431510_s_at 
1.22 Trim8 tripartite motif protein 8 1418577_at 
1.21 Zrf2 zuotin related factor 2 1448794_s_at 
1.21 Psmc3ip proteasome (prosome, macropain) 26S subunit, ATPase 3, interacting protein 1425271_at 
1.21 Mrps36 mitochondrial ribosomal protein S36 1423242_at 
1.21 Slc35a4 solute carrier family 35, member A4 1456013_x_at 
1.21 Rps24 ribosomal protein S24 1453362_x_at 
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1.21 Usp6nl USP6 N-terminal like 1440883_at 
1.21 Pan3 PAN3 polyA specific ribonuclease subunit homolog (S. cerevisiae) 1428768_at 
1.21 Sat1 spermidine/spermine N1-acetyl transferase 1 1420502_at 
1.21 1500019G21Rik RIKEN cDNA 1500019G21 gene 1416894_at 
1.21 Ppfibp1 PTPRF interacting protein, binding protein 1 (liprin beta 1) 1452759_s_at 
1.21 4930430E16Rik family with sequence similarity 161, member A 1443569_at 
1.21 Bms1l BMS1-like, ribosome assembly protein (yeast) 1433636_at 
1.21 Ndufs5 NADH dehydrogenase (ubiquinone) Fe-S protein 5 1416495_s_at 
1.21 Fkbp8 FK506 binding protein 8 1416113_at 
1.21 Tbca tubulin cofactor a 1456205_x_at 
1.21 Angel2 angel homolog 2 (Drosophila) 1448360_s_at 
1.21 Cox17 cytochrome c oxidase, subunit XVII assembly protein homolog (yeast) 1434435_s_at 
1.21 2810002O09Rik family with sequence similarity 123, member B 1439565_at 
1.21 Cog1 component of oligomeric golgi complex 1 1433774_x_at 
1.21 Tctex1 t-complex testis expressed 1 1428116_a_at 
1.21 3110009E18Rik RIKEN cDNA 3110009E18 gene 1428023_at 
1.21 Nef3 neurofilament 3, medium 1422520_at 
1.21 Shfdg1 split hand/foot deleted gene 1 1418575_at 
1.21 Cetn3 centrin 3 1417239_at 
1.20 A230106M20Rik RIKEN cDNA A230106M20 gene 1458997_at 
1.20 1200016B10Rik RIKEN cDNA 1200016B10 gene 1452859_at 
1.20 Rpl37 ribosomal protein L37 1438291_x_at 
1.20 D11Bwg0517e Fox-1 homolog C 1436450_at 
1.20 Vav3 vav 3 oncogene 1417123_at 
1.20 Snrpe small nuclear ribonucleoprotein E 1451294_s_at 
1.20 Tspan2 tetraspanin 2 1424567_at 
1.20 Wdr31 WD repeat domain 31 1459664_at 
1.20 Giyd2 GIY-YIG domain containing 2 1454082_a_at 
1.20 Hdac2 histone deacetylase 2 1449080_at 
1.20 Scamp2 secretory carrier membrane protein 2 1448404_at 
1.20 Stx1a syntaxin 1A (brain) 1437390_x_at 
1.20 D2Bwg1335e DNL-type zinc finger protein 1435528_at 
1.20 Abl1 c-abl oncogene 1, receptor tyrosine kinase 1423999_at 
1.20 Ndufb5 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5 1417102_a_at 
1.20 Mrpl12 mitochondrial ribosomal protein L12 1452048_at 
1.20 Gtf3c5 general transcription factor IIIC, polypeptide 5 1423998_at 
1.20 Epc1 enhancer of polycomb homolog 1 (Drosophila) 1440742_at 
1.20 Rpl37 ribosomal protein L37 1434872_x_at 
1.20 2310005N03Rik RIKEN cDNA 2310005N03 gene 1428619_at 
1.20 Csnk1e casein kinase 1, epsilon 1417175_at 
1.20 Dcun1d5 DCN1, defective in cullin neddylation 1, domain containing 5 (S. cerevisiae) 1432271_a_at 
1.20 6330416L07Rik RIKEN cDNA 6330416L07 gene 1425085_at 
1.20 Cdk4 cyclin-dependent kinase 4 1422439_a_at 
1.20 Rpl22 ribosomal protein L22 1416603_at 
1.20 Ncl nucleolin 1415772_at 
1.20 A130090K04Rik RIKEN cDNA A130090K04 gene 1439808_at 
1.20 4930420K17Rik RIKEN cDNA 4930420K17 gene 1436337_at 
1.20 Dut deoxyuridine triphosphatase 1419270_a_at 
1.20 Rps12 ribosomal protein S12 1416453_x_at 
1.19 Rgl1 ral guanine nucleotide dissociation stimulator,-like 1 1449124_at 
1.19 Irak1 interleukin-1 receptor-associated kinase 1 1448668_a_at 
1.19 Pawr PRKC, apoptosis, WT1, regulator 1426910_at 
1.19 Atp6ap2 ATPase, H+ transporting, lysosomal accessory protein 2 1423662_at 
1.19 Crmp1 collapsin response mediator protein 1 1448289_at 
1.19 Tmem85 transmembrane protein 85 Gene 1438369_x_at 
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1.19 Saps1 SAPS domain family, member 1 1436306_at 
1.19 Thtpa thiamine triphosphatase 1433436_s_at 
1.19 Rbm18 RIKEN cDNA 2010004P11 gene 1420608_at 
1.19 Kdelr1 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 1 1460211_a_at 
1.19 Ubxn2b UBX domain protein 2B 1449122_at 
1.19 Wdr9 WD repeat domain 9 1433955_at 
1.19 Tmco1 transmembrane and coiled-coil domains 1 1423759_a_at 
1.19 5530601H04Rik Mus musculus 0 day neonate kidney cDNA, RIKEN full-length enriched library, clone:D630033M22 product:hypothetical protein, full insert sequence 1452750_at 
1.19 Rps24 ribosomal protein S24 1428530_x_at 
1.19 Srd5a2l steroid 5 alpha-reductase 2-like 1423574_s_at 
1.19 Cycs cytochrome c, somatic 1422484_at 
1.19 Cnot6 CCR4-NOT transcription complex, subunit 6 1418273_a_at 
1.19 Snrpd1 small nuclear ribonucleoprotein D1 1416336_s_at 
1.19 Dbi diazepam binding inhibitor 1455976_x_at 
1.19 Wdr77 WD repeat domain 77 1434552_at 
1.19 2810002N01Rik RIKEN cDNA 2810002N01 gene 1429248_at 
1.19 Crym crystallin, mu 1416776_at 
1.19 1110003E01Rik RIKEN cDNA 1110003E01 gene 1416767_a_at 
1.19 6430571L13Rik RIKEN cDNA 6430571L13 gene 1458456_x_at 
1.19 2810002D19Rik RIKEN cDNA 2810002D19 gene 1452312_at 
1.19 A630054L15Rik family with sequence similarity 116, member A 1451568_at 
1.19 Ebf1 early B-cell factor 1 1448293_at 
1.19 Rps7 ribosomal protein S7 1435593_x_at 
1.19 Smo smoothened homolog (Drosophila) 1427049_s_at 
1.19 Klhdc2 kelch domain containing 2 1460678_at 
1.19 Zdhhc24 zinc finger, DHHC domain containing 24 1452719_at 
1.19 Mdc1 mediator of DNA damage checkpoint 1 1434837_at 
1.19 AI428479 Mus musculus transcribed sequences 1434422_at 
1.19 Pkia protein kinase inhibitor, alpha 1420859_at 
1.19 Mbd3 methyl-CpG binding domain protein 3 1417728_at 
1.18 Ppil6 sphingomyelin phosphodiesterase 2, neutral 1453310_at 
1.18 Fbxl10 F-box and leucine-rich repeat protein 10 1452198_at 
1.18 Sesn1 sestrin 1 1433711_s_at 
1.18 2310022M17Rik RIKEN cDNA 2310022M17 gene 1428293_at 
1.18 Zfp91 zinc finger protein 91 1426326_at 
1.18 Nsmce1 non-SMC element 1 homolog (S. cerevisiae) 1455927_x_at 
1.18 Vps29 vacuolar protein sorting 29 (S. pombe) 1417660_s_at 
1.18 Stoml1 stomatin-like 1 1452738_at 
1.18 Rps27l ribosomal protein S27-like 1435429_x_at 
1.18 Sec63 SEC63-like (S. cerevisiae) 1424924_at 
1.18 Rbbp7 Mus musculus transcribed sequences 1456227_x_at 
1.18 Pmvk phosphomevalonate kinase 1427893_a_at 
1.18 Hint1 histidine triad nucleotide binding protein 1424018_at 
1.18 Brp44 brain protein 44 1423833_a_at 
1.18 Nfe2l2 nuclear, factor, erythroid derived 2, like 2 1416543_at 
1.18 Magoh mago-nashi homolog, proliferation-associated (Drosophila) 1416212_at 
1.18 Ell elongation factor RNA polymerase II 1460643_at 
1.18 Cacnb3 calcium channel, voltage-dependent, beta 3 subunit 1448656_at 
1.18 1110054O05Rik RIKEN cDNA 1110054O05 gene 1429242_at 
1.18 Mark2 MAP/microtubule affinity-regulating kinase 2 1415952_at 
1.18 Gabpa GA repeat binding protein, alpha 1450664_at 
1.18 Enoph1 enolase-phosphatase 1 1423705_at 
1.18 Cobra1 cofactor of BRCA1 1421292_a_at 
1.18 Mast1 RIKEN cDNA 9430008B02 gene 1449423_at 
1.18 Mrpl44 mitochondrial ribosomal protein L44 1437391_x_at 
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1.18 Sdccag33 serologically defined colon cancer antigen 33 1427233_at 
1.18 2900092E17Rik RIKEN cDNA 2900092E17 gene 1424014_at 
1.18 Siat7d sialyltransferase 7 ((alpha-N-acetylneuraminyl 2,3-betagalactosyl-1,3)-N-acetyl galactosaminide alpha-2,6-sialyltransferase) D 1418074_at 
1.18 Nfia nuclear factor I/A 1456087_at 
1.18 Rdbp RD RNA-binding protein 1450705_at 
1.18 Ube2f predicted gene, EG432649 1450275_x_at 
1.18 1110002B05Rik RIKEN cDNA 1110002B05 gene 1448388_a_at 
1.18 Prickle4 prickle homolog 4 (Drosophila) 1437336_x_at 
1.18 St5 suppression of tumorigenicity 5 1428372_at 
1.18 Stk24 FERM, RhoGEF (Arhgef) and pleckstrin domain protein 1 (chondrocyte-derived) 1426248_at 
1.17 Nfib nuclear factor I/B 1454834_at 
1.17 Sort1 sortilin 1 1423363_at 
1.17 Ihpk1 inositol hexaphosphate kinase 1 1422969_s_at 
1.17 Dirc2 disrupted in renal carcinoma 2 (human) 1454654_at 
1.17 Tarsl2 threonyl-tRNA synthetase-like 2 1434738_at 
1.17 AC139040.8 40S ribosomal protein S12 1433432_x_at 
1.17 Ube2e2 ubiquitin-conjugating enzyme E2E 2 (UBC4/5 homolog, yeast) 1424358_at 
1.17 Gp1bb glycoprotein Ib, beta polypeptide 1422977_at 
1.17 Zfp36l1 zinc finger protein 36, C3H type-like 1 1422528_a_at 
1.17 Khdrbs1 KH domain containing, RNA binding, signal transduction associated 1 1418629_a_at 
1.17 Ctbp1 C-terminal binding protein 1 1415702_a_at 
1.17 Ly6e lymphocyte antigen 6 complex, locus E 1453304_s_at 
1.17 Aptx aprataxin 1450921_at 
1.17 Mafb v-maf musculoaponeurotic fibrosarcoma oncogene family, protein B (avian) 1435335_a_at 
1.17 Med9 mediator of RNA polymerase II transcription, subunit 9 homolog (yeast) 1419377_at 
1.17 Sox2 SRY-box containing gene 2 1416967_at 
1.17 Rps10 ribosomal protein S10 1438723_a_at 
1.17 Ankrd17 ankyrin repeat domain 17 1436775_a_at 
1.17 BC017158 UPF0420 protein C16orf58 homolog 1424812_at 
1.17 Cdc26 cell division cycle 26 1423987_at 
1.17 Tfpt transmembrane channel-like gene family 4 1418064_at 
1.17 Spin spindlin 1415794_a_at 
1.17 Sf3a2 splicing factor 3a, subunit 2 1455546_s_at 
1.17 U2af1-rs2 U2 small nuclear ribonucleoprotein auxiliary factor (U2AF) 1, related sequence 2 1442154_at 
1.17 Zfp513 zinc finger protein 513 1437483_at 
1.17 Gpkow G patch domain and KOW motifs 1434344_at 
1.17 Ccdc90b coiled-coil domain containing 90B 1428505_at 
1.17 Rbm28 RNA binding motif protein 28 1426513_at 
1.17 Rpl21 ribosomal protein L21 1455767_x_at 
1.17 1500001M20Rik RIKEN cDNA 1500001M20 gene 1428684_at 
1.17 Eif1b eukaryotic translation initiation factor 1B 1428272_at 
1.17 Rabl4 RAB, member of RAS oncogene family-like 4 1424648_at 
1.17 Znhit2 zinc finger, HIT domain containing 2 1416651_at 
1.17 Psma6 proteasome (prosome, macropain) subunit, alpha type 6 1416506_at 
1.17 Gcsh glycine cleavage system protein H (aminomethyl carrier) 1432164_a_at 
1.17 Tysnd1 trypsin domain containing 1 1428689_at 
1.17 Gatc glutamyl-tRNA(Gln) amidotransferase, subunit C homolog (bacterial) 1425211_at 
1.17 Echdc1 enoyl Coenzyme A hydratase domain containing 1 1425001_at 
1.17 Nck2 non-catalytic region of tyrosine kinase adaptor protein 2 1416796_at 
1.16 Jund1 Jun proto-oncogene related gene d1 1449117_at 
1.16 Wdr48 WD repeat domain 48 1443836_x_at 
1.16 Hsdl2 hydroxysteroid dehydrogenase like 2 1426856_at 
1.16 Ddx26 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 26 1423275_at 
1.16 Yy1 YY1 transcription factor 1422570_at 
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1.16 Ssb Sjogren syndrome antigen B 1416421_a_at 
1.16 L3mbtl3 l(3)mbt-like 3 (Drosophila) 1454882_at 
1.16 Ube2a ubiquitin-conjugating enzyme E2A, RAD6 homolog (S. cerevisiae) 1417609_at 
1.16 Rpl22 ribosomal protein L22 1453118_s_at 
1.16 Wdr32 WD repeat domain 32 1438727_at 
1.16 AI316807 Uncharacterized protein C8orf40 homolog 1438199_at 
1.16 Vapb vesicle-associated membrane protein, associated protein B and C 1436079_s_at 
1.16 Rps10 ribosomal protein S10 1434854_a_at 
1.16 Kif16b kinesin family member 16B 1429062_at 
1.16 Ptch1 patched homolog 1 1428853_at 
1.16 Prr6 proline-rich polypeptide 6 1428706_at 
1.16 Lrrc42 leucine rich repeat containing 42 1424049_at 
1.16 E130012K09 hypothetical protein E130012K09 1457737_at 
1.16 Hint1 histidine triad nucleotide binding protein 1424017_a_at 
1.16 AC121926.3 Mitochondrial import inner membrane translocase subunit Tim16 (Mitochondria-associated granulocyte macrophage CSF-signaling molecule) 1416765_s_at 
1.16 Rragc Ras-related GTP binding C 1415749_a_at 
1.16 Ndufv2 NADH dehydrogenase (ubiquinone) flavoprotein 2 1452692_a_at 
1.16 Ube2v1 ubiquitin-conjugating enzyme E2 variant 1 1444523_s_at 
1.16 Gats opposite strand transcription unit to Stag3 1437252_at 
1.16 Rab11b RAB11B, member RAS oncogene family 1435253_at 
1.16 Bclaf1 BCL2-associated transcription factor 1 1428844_a_at 
1.16 Ndufa1 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1 1422241_a_at 
1.16 Mkrn2 makorin, ring finger protein, 2 1417935_at 
1.16 Mosc2 MOCO sulphurase C-terminal domain containing 2 1416766_at 
1.16 Txn1 thioredoxin 1 1416119_at 
1.16 Znhit1 zinc finger, HIT domain containing 1 1451745_a_at 
1.16 Rab9 RAB9, member RAS oncogene family 1448391_at 
1.16 Ncoa6 nuclear receptor coactivator 6 1423374_at 
1.16 Yeats4 YEATS domain containing 4 1423105_a_at 
1.15 Poldip3 polymerase (DNA-directed), delta interacting protein 3 1437335_x_at 
1.15 Arhgap21 Rho GTPase activating protein 21 1428369_s_at 
1.15 Tomm7 translocase of outer mitochondrial membrane 7 homolog (yeast) 1428214_at 
1.15 Myst4 MYST histone acetyltransferase (monocytic leukemia) 4 1423508_at 
1.15 Ubxn1 UBX domain protein 1 1436342_a_at 
1.15 Rps21 ribosomal protein S21 1430288_x_at 
1.15 Zipro1 zinc finger proliferation 1 1420095_s_at 
1.15 Rps20 ribosomal protein S20 1456436_x_at 
1.15 Cox5a cytochrome c oxidase, subunit Va 1448153_at 
1.15 Ndufs6 NADH dehydrogenase (ubiquinone) Fe-S protein 6 1433603_at 
1.15 Sfrs10 splicing factor, arginine/serine-rich 10 (transformer 2 homolog, Drosophila) 1427432_a_at 
1.15 Gcn5l2 GCN5 general control of amino acid synthesis-like 2 (yeast) 1426783_at 
1.15 Sui1-rs1 suppressor of initiator codon mutations, related sequence 1 (S. cerevisiae) 1423799_at 
1.15 Rnf220 ring finger protein 220 1415717_at 
1.15 Ube2a ubiquitin-conjugating enzyme E2A, RAD6 homolog (S. cerevisiae) 1448772_at 
1.15 Mfhas1 malignant fibrous histiocytoma amplified sequence 1 1429005_at 
1.15 Ndufb10 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 10 1428322_a_at 
1.15 Tcf12 transcription factor 12 1427670_a_at 
1.15 Ssbp3 single-stranded DNA binding protein 3 1425940_a_at 
1.15 Hagh hydroxyacyl glutathione hydrolase 1424172_at 
1.15 Ndufb9 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 9 1452184_at 
1.15 Prss12 protease, serine, 12 neurotrypsin (motopsin) 1447896_s_at 
1.15 BC023814 UPF0431 protein C1orf66 homolog 1433961_at 
1.15 Phip pleckstrin homology domain interacting protein 1429004_at 
1.15 6330403K07Rik RIKEN cDNA 6330403K07 gene 1426766_at 
1.15 Setd8 SET domain containing (lysine methyltransferase) 8 1426406_at 
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1.15 Cnp1 cyclic nucleotide phosphodiesterase 1 1418980_a_at 
1.15 Mrpl52 mitochondrial ribosomal protein L52 1460701_a_at 
1.15 Ndufb6 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6 1434057_at 
1.15 6430548M08Rik RIKEN cDNA 6430548M08 gene 1425637_at 
1.15 Myo1c myosin IC 1419649_s_at 
1.15 Zfyve20 zinc finger, FYVE domain containing 20 1456754_at 
1.15 Ndufb2 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2 1448483_a_at 
1.15 Hmgcs1 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 1433445_x_at 
1.15 Rps10 ribosomal protein S10 1456497_x_at 
1.15 Zfp715 zinc finger protein 715 1434461_at 
1.15 March5 membrane-associated ring finger (C3HC4) 5 1428843_at 
1.15 Polr2i polymerase (RNA) II (DNA directed) polypeptide I 1428494_a_at 
1.15 Sdbcag84 serologically defined breast cancer antigen 84 1423548_s_at 
1.15 Ptprf protein tyrosine phosphatase, receptor type, F 1420842_at 
1.14 Bcap37 B-cell receptor-associated protein 37 1455713_x_at 
1.14 Pi4k2a phosphatidylinositol 4-kinase type 2 alpha 1454605_a_at 
1.14 Rpl18 
Mus musculus transcribed sequence with weak  similarity to protein 
ref:NP_000970.1 (H.sapiens)  ribosomal protein L18; 60S ribosomal protein 
L18 [Homo sapiens] 
1436699_x_at 
1.14 Ube1dc1 ubiquitin-activating enzyme E1-domain containing 1 1435247_at 
1.14 Skiip SKI interacting protein 1429002_at 
1.14 Mrpl30 mitochondrial ribosomal protein L30 1423857_at 
1.14 Ranbp9 RAN binding protein 9 1422736_at 
1.14 Tnpo3 transportin 3 1419950_s_at 
1.14 Gkap1 G kinase anchoring protein 1 1417594_at 
1.14 Rab6 RAB6, member RAS oncogene family 1448304_a_at 
1.14 Eif4el3 eukaryotic translation initiation factor 4E like 3 1435803_a_at 
1.14 Apoe apolipoprotein E 1432466_a_at 
1.14 1600027N09Rik RIKEN cDNA 1600027N09 gene 1428366_at 
1.14 Acsl5 fatty acid Coenzyme A ligase, long chain 5 1428082_at 
1.14 Syap1 synapse associated protein 1 1416472_at 
1.14 Mtch1 mitochondrial carrier homolog 1 (C. elegans) 1460718_s_at 
1.14 Socs7 Nck, Ash and phospholipase C binding protein 1455402_at 
1.14 Thoc7 THO complex 7 homolog (Drosophila) 1448461_a_at 
1.14 Med10 mediator of RNA polymerase II transcription, subunit 10 homolog (NUT2, S. cerevisiae) 1448295_at 
1.14 Limch1 LIM and calponin homology domains 1 1435106_at 
1.14 Dlat dihydrolipoamide S-acetyltransferase (E2 component of pyruvate dehydrogenase complex) 1426264_at 
1.14 Blcap bladder cancer associated protein homolog (human) 1420631_a_at 
1.14 Faim Fas apoptotic inhibitory molecule 1418029_at 
1.14 Chmp4b chromatin modifying protein 4B 1451988_s_at 
1.14 Ppp1r2 protein phosphatase 1, regulatory (inhibitor) subunit 2 1448684_at 
1.14 Kpnb1 karyopherin (importin) beta 1 1448526_at 
1.14 Ppp2r2c protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), gamma isoform 1438671_at 
1.14 Sept2 septin 2 1435985_at 
1.14 Kif3c kinesin family member 3C 1434947_at 
1.14 Eif2ak1 eukaryotic translation initiation factor 2 alpha kinase 1 1421901_at 
1.14 Tubg1 tubulin, gamma 1 1417144_at 
1.14 Atp5j2 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit f, isoform 2 1416269_at 
1.14 Mdm4 transformed mouse 3T3 cell double minute 4 1460542_s_at 
1.14 Rbm27 RNA binding motif protein 27 1456058_at 
1.14 Serbp1 Serpine1 mRNA binding protein 1 1441501_at 
1.14 Samhd1 SAM domain and HD domain, 1 1434438_at 
1.14 1600002H07Rik RIKEN cDNA 1600002H07 gene 1428832_at 
1.14 Tmem70 transmembrane protein 70 1424541_at 
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1.14 Cygb cytoglobin 1423630_at 
1.14 Tce4 T-complex expressed gene 4 1420326_s_at 
1.14 Rpl36 ribosomal protein L36 1416519_at 
1.14 Tubb3 tubulin, beta 3 1415978_at 
1.14 Podxl2 podocalyxin-like 2 1455622_at 
1.14 Cxxc5 RIKEN cDNA 4930415K17 gene 1448960_at 
1.14 Igfbp4 insulin-like growth factor binding protein 4 1437405_a_at 
1.14 Rpl13a ribosomal protein L13a 1435873_a_at 
1.14 Nutf2 nuclear transport factor 2 1434367_s_at 
1.14 Ndufs7 NADH dehydrogenase (ubiquinone) Fe-S protein 7 1424313_a_at 
1.14 Ncbp2 nuclear cap binding protein subunit 2 1423045_at 
1.14 Dia1 diaphorase 1 (NADH) 1422186_s_at 
1.14 Mettl9 methyltransferase like 9 1417710_at 
1.14 Qser1 glutamine and serine rich 1 1452331_s_at 
1.14 Ptdss2 phosphatidylserine synthase 2 1450354_a_at 
1.14 Neurod4 neurogenic differentiation 4 1436694_s_at 
1.14 Ssbp3 single-stranded DNA binding protein 3 1427917_s_at 
1.14 Fads1 fatty acid desaturase 1 1423680_at 
1.14 Ube2l3 ubiquitin-conjugating enzyme E2L 3 1417908_s_at 
1.14 Atp5j ATP synthase, H+ transporting, mitochondrial F0 complex, subunit F 1416143_at 
1.14 1700029F09Rik RIKEN cDNA 1700029F09 gene 1428593_at 
1.14 Dnajc9 DnaJ (Hsp40) homolog, subfamily C, member 9 1426473_at 
1.13 Drap1 Dr1 associated protein 1 (negative cofactor 2 alpha) 1451676_at 
1.13 Kcnh2 potassium voltage-gated channel, subfamily H (eag-related), member 2 1449544_a_at 
1.13 Clp1 cardiac lineage protein 1 1419359_at 
1.13 Fbxo8 F-box only protein 8 1418510_s_at 
1.13 Rabac1 Rab acceptor 1 (prenylated) 1427773_a_at 
1.13 Grcc10 gene rich cluster, C10 gene 1416522_a_at 
1.13 Nipsnap3a nipsnap homolog 3A (C. elegans) 1448967_at 
1.13 Ndufb5 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5 1448589_at 
1.13 Lysmd2 LysM, putative peptidoglycan-binding, domain containing 2 1428626_at 
1.13 1810063B07Rik RIKEN cDNA 1810063B07 gene 1427905_at 
1.13 Dnajc14 DnaJ (Hsp40) homolog, subfamily C, member 14 1426553_at 
1.13 Wbscr18 Williams-Beuren syndrome chromosome region 18 homolog (human) 1418081_at 
1.13 Msh6 mutS homolog 6 (E. coli) 1416915_at 
1.13 Rnf153 membrane-associated ring finger (C3HC4) 5 1452925_a_at 
1.13 Atp5k ATP synthase, H+ transporting, mitochondrial F1F0 complex, subunit e 1434053_x_at 
1.13 Caml calcium modulating ligand 1417842_at 
1.13 Rpl35a ribosomal protein L35a 1417317_s_at 
1.13 Tm4sf8 transmembrane 4 superfamily member 8 1416009_at 
1.13 2610204K03Rik Sec24 related gene family, member C (S. cerevisiae) 1452147_at 
1.13 Tomm7 translocase of outer mitochondrial membrane 7 homolog (yeast) 1428215_x_at 
1.13 Hnrpr heterogeneous nuclear ribonucleoprotein R 1427129_a_at 
1.13 Ube2m ubiquitin C, related sequence 2 1424345_s_at 
1.13 Thy1 thymus cell antigen 1, theta 1423135_at 
1.13 Banf1 barrier to autointegration factor 1 1421082_s_at 
1.13 Tce1 T-complex expressed gene 1 1417891_at 
1.13 Stat3 signal transducer and activator of transcription 3 1460700_at 
1.13 Sf3b2 splicing factor 3b, subunit 2 1433461_at 
1.13 Calm2 calmodulin 3 1422414_a_at 
1.13 6330500D04Rik RIKEN cDNA 6330500D04 gene 1460555_at 
1.13 Tctn2 tectonic family member 2 1423224_at 
1.13 Ptp4a2 protein tyrosine phosphatase 4a2 1420613_at 
1.13 Ccdc12 coiled-coil domain containing 12 1419803_s_at 
1.13 Ppm1g protein phosphatase 1G (formerly 2C), magnesium-dependent, gamma isoform 1416792_at 
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1.12 AC140307.3 NAT11_MOUSE Isoform 2 of Q8VE10 1452120_at 
1.12 Ppp3cb protein phosphatase 3, catalytic subunit, beta isoform 1428473_at 
1.12 Fbxo3 F-box only protein 3 1423491_at 
1.12 Ptbp2 polypyrimidine tract binding protein 2 1423470_at 
1.12 Sca10 spinocerebellar ataxia 10 homolog (human) 1422576_at 
1.12 Hras1 Harvey rat sarcoma virus oncogene 1 1422407_s_at 
1.12 Dek DEK oncogene (DNA binding) 1452659_at 
1.12 Nnp1 novel nuclear protein 1 1427720_a_at 
1.12 Trib2 tribbles homolog 2 (Drosophila) 1426640_s_at 
1.12 Xpo7 exportin 7 1415682_at 
1.12 Trpc4ap transient receptor potential cation channel, subfamily C, member 4 associated protein 1460720_at 
1.12 Clta clathrin, light polypeptide (Lca) 1434540_a_at 
1.12 C230096C10Rik RIKEN cDNA C230096C10 gene 1434021_at 
1.12 Lrrc47 leucine rich repeat containing 47 1428451_at 
1.12 Smn survival motor neuron 1426596_a_at 
1.12 Hpcal1 hippocalcin-like 1 1448812_at 
1.12 Hnrpab heterogeneous nuclear ribonucleoprotein A/B 1448144_at 
1.12 Rnps1 ribonucleic acid binding protein S1 1438267_x_at 
1.12 Brsk2 BR serine/threonine kinase 2 1431826_a_at 
1.12 Rtn1 reticulon 1 1429761_at 
1.12 Dus3l dihydrouridine synthase 3-like (S. cerevisiae) 1424066_at 
1.12 Acas2 acetyl-Coenzyme A synthetase 2 (ADP forming) 1422479_at 
1.12 Fbxo13 F-box only protein 13 1452860_at 
1.12 Limk2 LIM motif-containing protein kinase 2 1452060_a_at 
1.12 Rps8 ribosomal protein S8 1437610_x_at 
1.12 Actr1b ARP1 actin-related protein 1 homolog B (yeast) 1426403_at 
1.12 Hspa9a heat shock protein, A 1418504_at 
1.12 Tmem132a transmembrane protein 132A 1416845_at 
1.12 Rps16 ribosomal protein S16 1416404_s_at 
1.12 Npdc1 neural proliferation, differentiation and control gene 1 1415919_at 
1.12 Fkbp1a FK506 binding protein 1a 1448184_at 
1.12 D030012E24Rik RIKEN cDNA D030012E24 gene 1436747_at 
1.12 Dgkd diacylglycerol kinase, delta 1433564_at 
1.12 Chmp2a chromatin modifying protein 2A 1425591_a_at 
1.12 Dnaja2 DnaJ (Hsp40) homolog, subfamily A, member 2 1417183_at 
1.12 Rps8 ribosomal protein S8 1455319_x_at 
1.12 Map1lc3a microtubule-associated protein 1 light chain 3 alpha 1451290_at 
1.12 Pdcd2l programmed cell death 2-like 1426845_at 
1.12 Odag GATA zinc finger domain containing 1 1425599_a_at 
1.12 Bax Bcl2-associated X protein 1416837_at 
1.12 Npm1 nucleophosmin 1 1415839_a_at 
1.12 Rps6 ribosomal protein S6 1454620_x_at 
1.12 Ctdp1 CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) phosphatase, subunit 1 1452697_at 
1.12 Kctd3 potassium channel tetramerisation domain containing 3 1436811_at 
1.12 Mll5 serine/arginine-rich protein specific kinase 2 1434704_at 
1.12 Ube2d2 ubiquitin-conjugating enzyme E2D 2 1416477_at 
1.12 Hmgb3 high mobility group box 3 1416155_at 
1.11 Wbscr1 Williams-Beuren syndrome chromosome region 1 homolog (human) 1438554_x_at 
1.11 Ppp1r1a protein phosphatase 1, regulatory (inhibitor) subunit 1A 1422605_at 
1.11 Rpl35 ribosomal protein L35 1455950_x_at 
1.11 Nutf2 nuclear transport factor 2 1449017_at 
1.11 Rpl14 ribosomal protein L14 1436688_x_at 
1.11 Rpl14 ribosomal protein L14 1433688_x_at 
1.11 Rpl21 ribosomal protein L21 1429077_x_at 
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1.11 Gnaq guanine nucleotide binding protein, alpha q polypeptide 1428938_at 
1.11 Ppp4r1 protein phosphatase 4, regulatory subunit 1 1424294_at 
1.11 Ddx39 DEAD (Asp-Glu-Ala-Asp) box polypeptide 39 1455814_x_at 
1.11 Psma3 proteasome (prosome, macropain) subunit, alpha type 3 1448442_a_at 
1.11 Cs citrate synthase 1450667_a_at 
1.11 Atp5a1 ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit, isoform 1 1449710_s_at 
1.11 Bat1a HLA-B-associated transcript 1A 1448221_at 
1.11 Prdx1 peroxiredoxin 1 1436691_x_at 
1.11 Nat5 N-acetyltransferase 5 (ARD1 homolog, S. cerevisiae) 1418244_at 
1.11 Dnajc12 DnaJ (Hsp40) homolog, subfamily C, member 12 1417441_at 
1.11 Cdc42ep4 CDC42 effector protein (Rho GTPase binding) 4 1416511_a_at 
1.11 Smad1 MAD homolog 1 (Drosophila) 1459843_s_at 
1.11 Ndufa12 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 12 1455806_x_at 
1.11 Pcbp4 poly(rC) binding protein 4 1449055_x_at 
1.11 Tceb2 serine/arginine repetitive matrix 2 1436949_a_at 
1.11 Rpl17 ribosomal protein L17 1435791_x_at 
1.11 Srm spermidine synthase 1421260_a_at 
1.11 Snx25 sorting nexin 25 1455020_at 
1.11 Pcnxl3 pecanex-like 3 (Drosophila) 1451328_at 
1.11 Rpl36al ribosomal protein L36a-like 1448697_s_at 
1.11 AC132435.3 coiled-coil domain containing 6 1428311_at 
1.11 Aof2 amine oxidase (flavin containing) domain 2 1426762_s_at 
1.11 Bnip2 BCL2/adenovirus E1B 19kDa-interacting protein 1, NIP2 1422490_at 
1.11 Sin3a transcriptional regulator, SIN3A (yeast) 1419101_at 
1.11 Wdr5 WD repeat domain 5 1416581_at 
1.11 Sgta small glutamine-rich tetratricopeptide repeat (TPR)-containing, alpha 1451067_at 
1.11 Arhgef12 Rho guanine nucleotide exchange factor (GEF) 12 1423902_s_at 
1.11 Snx3 sorting nexin 3 1422480_at 
1.11 Maged1 melanoma antigen, family D, 1 1450062_a_at 
1.11 Cox4i1 cytochrome c oxidase subunit IV isoform 1 1448322_a_at 
1.11 Rpl31 ribosomal protein L31 1436924_x_at 
1.11 Pak1ip1 glycerophosphodiester phosphodiesterase domain containing 1 1423766_at 
1.10 Vps26b vacuolar protein sorting 26 homolog B (yeast) 1453762_at 
1.10 Dbi diazepam binding inhibitor 1433991_x_at 
1.10 Ran Mus musculus transcribed sequence with strong similarity to protein pdb:1I2M (H.sapiens) A Chain A, Ran-Rcc1-So4 Complex 1433569_x_at 
1.10 Chgb chromogranin B 1415885_at 
1.10 Ncl nucleolin 1415771_at 
1.10 Ndufv2 NADH dehydrogenase (ubiquinone) flavoprotein 2 1438159_x_at 
1.10 Egflam EGF-like, fibronectin type III and laminin G domains 1434647_at 
1.10 Ptgr2 prostaglandin reductase 2 1433503_at 
1.10 Tceb1 transcription elongation factor B (SIII), polypeptide 1 1427914_a_at 
1.10 Fbxo9 f-box only protein 9 1417480_at 
1.10 Ubl1 ubiquitin-like 1 1456349_x_at 
1.10 Copb2 coatomer protein complex, subunit beta 2 (beta prime) 1456175_a_at 
1.10 Cbx5 chromobox homolog 5 (Drosophila HP1a) 1454636_at 
1.10 Fkbp3 FK506 binding protein 3 1416859_at 
1.10 Trappc1 trafficking protein particle complex 1 1436019_a_at 
1.10 Tssc4 tumor-suppressing subchromosomal transferable fragment 4 1427661_a_at 
1.10 Fh1 fumarate hydratase 1 1424828_a_at 
1.10 Rpl35 ribosomal protein L35 1454856_x_at 
1.10 2700081O15Rik RIKEN cDNA 2700081O15 gene 1437291_at 
1.10 BC002199 cDNA sequence BC002199 1426234_s_at 
1.10 B230219D22Rik RIKEN cDNA B230219D22 gene 1424005_at 
1.10 Actr10 ARP10 actin-related protein 10 homolog  (S. cerevisiae) 1417157_at 
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1.10 D330038O06Rik RIKEN cDNA D330038O06 gene 1455334_at 
1.10 Sfrs4 splicing factor, arginine/serine-rich 4 (SRp75) 1448778_at 
1.10 Centg2 centaurin, gamma 2 1437394_at 
1.10 Cln3 ceroid lipofuscinosis, neuronal 3, juvenile (Batten, Spielmeyer-Vogt disease) 1417551_at 
1.10 Trspap1 tRNA selenocysteine associated protein 1 1428747_at 
1.10 Mapt microtubule-associated protein tau 1424719_a_at 
1.10 Prdx2 peroxiredoxin 2 1418506_a_at 
1.10 Vdac3 voltage-dependent anion channel 3 1416175_a_at 
1.10 Lrrc40 leucine rich repeat containing 40 1448720_at 
1.10 2900010M23Rik RIKEN cDNA 2900010M23 gene 1448685_at 
1.10 Snrpb small nuclear ribonucleoprotein B 1437193_s_at 
1.10 Sdccag8 serologically defined colon cancer antigen 8 1435260_at 
1.10 Pnrc1 proline-rich nuclear receptor coactivator 1 1433668_at 
1.10 6720456B07Rik RIKEN cDNA 6720456B07 gene 1423188_a_at 
1.09 Np15 nuclear protein 15.6 1455911_x_at 
1.09 Rpl29 ribosomal protein L29 1454627_a_at 
1.09 Rpl18 ribosomal protein L18 1437005_a_at 
1.09 Akirin2 akirin 2 1428237_at 
1.09 Pofut2 protein O-fucosyltransferase 2 1416573_at 
1.09 Ppp1ca protein phosphatase 1, catalytic subunit, alpha isoform 1460165_at 
1.09 Sltm SAFB-like, transcription modulator 1424452_at 
1.09 Rbmxrt RNA binding motif protein, X chromosome retrogene 1416177_at 
1.09 Usp7 ubiquitin specific protease 7 1454948_at 
1.09 Gcap14 granule cell antiserum positive 14 1452223_s_at 
1.09 Fliih flightless I homolog (Drosophila) 1448189_a_at 
1.09 Ndufa12 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 12 1433513_x_at 
1.09 Unc45a unc-45 homolog A (C. elegans) 1415866_at 
1.09 Actr3 ARP3 actin-related protein 3 homolog (yeast) 1452051_at 
1.09 Tprgl transformation related protein 63 regulated like 1451172_at 
1.09 Wdr61 WD repeat domain 61 1448102_a_at 
1.09 Ubqln4 ubiquilin 4 1448691_at 
1.09 Thap4 THAP domain containing 4 1424052_at 
1.09 Gosr2 golgi SNAP receptor complex member 2 1419371_s_at 
1.09 Ifrg15 interferon alpha responsive gene 1418115_s_at 
1.09 Rpl24 ribosomal protein L24 1460201_a_at 
1.09 Zfp90 zinc finger protein 90 1449126_at 
1.08 Leo1 Leo1, Paf1/RNA polymerase II complex component, homolog (S. cerevisiae) 1455293_at 
1.08 Gnb2 guanine nucleotide binding protein, beta 2 1450623_at 
1.08 Mast2 microtubule associated testis specific serine/threonine protein kinase 1417324_at 
1.08 Atp5k ATP synthase, H+ transporting, mitochondrial F1F0 complex, subunit e 1422525_at 
1.08 Rps6kb1 ribosomal protein S6 kinase, polypeptide 1 1460705_at 
1.08 Ttll1 tubulin tyrosine ligase-like 1 1426427_at 
1.08 Akt1 thymoma viral proto-oncogene 1 1425711_a_at 
1.08 Rpl19 ribosomal protein L19 1416219_at 
1.08 Bms1l BMS1 homolog, ribosome assembly protein (yeast) 1447679_s_at 
1.08 Tmem178 transmembrane protein 178 1429175_at 
1.08 Prr13 proline rich 13 1423686_a_at 
1.08 Wbp5 WW domain binding protein 5 1451230_a_at 
1.08 2700060E02Rik RIKEN cDNA 2700060E02 gene 1448238_at 
1.08 Cops7a COP9 (constitutive photomorphogenic) homolog, subunit 7a (Arabidopsis thaliana) 1429078_a_at 
1.08 Gpsn2 short coiled-coil protein 1416352_s_at 
1.08 Larp5 La ribonucleoprotein domain family, member 5 1434597_at 
1.07 Klhdc3 kelch domain containing 3 1454747_a_at 
1.07 Htatip HIV-1 tat interactive protein, homolog (human) 1433980_at 
1.07 Eif4g2 eukaryotic translation initiation factor 4, gamma 2 1428362_at 
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1.07 Rpl31 ribosomal protein L31 1428212_x_at 
1.07 Dhx15 DEAH (Asp-Glu-Ala-His) box polypeptide 15 1416145_at 
1.07 Ndst1 N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 1 1460436_at 
1.07 Secisbp2 SECIS binding protein 2 1428497_at 
1.07 Slc39a6 solute carrier family 39 (metal ion transporter), member 6 1424674_at 
1.07 Actr8 ARP8 actin-related protein 8 homolog (S. cerevisiae) 1423385_at 
1.07 Rab14 RAB14, member RAS oncogene family 1415686_at 
1.07 D0HXS9928E DNA segment, human DXS9928E 1419516_at 
1.06 Kctd20 potassium channel tetramerisation domain containing 20 1416323_at 
1.06 Stox2 storkhead box 2 1447624_s_at 
1.06 Chn1 chimerin (chimaerin) 1 1420545_a_at 
1.06 Acin1 apoptotic chromatin condensation inducer in the nucleus 1416568_a_at 
1.06 Clns1a chloride channel, nucleotide-sensitive, 1A 1436935_x_at 
1.06 Gtf2i general transcription factor II I 1425628_a_at 
1.05 Prkrir protein-kinase, interferon-inducible double stranded RNA dependent inhibitor, repressor of (P58 repressor) 1426482_at 	  	  











Figure	   118	   Electropherograms	   from	   the	   PLVAP	   sequence	   analysis	   showing	   SNP	   ENSSNP5758645.	  Patients	  22439,	  24536,	  25160,	  27110,	  and	  27116	  are	  heterozygous	  for	  the	  c.1322-­‐37G>A	  exchange.	  























Figure	   121	   Electropherograms	   showing	   SNP	   rs11032432	   in	   the	   LMO2	   gene.	   Patients	   22439,	   25160,	  25649,	  27111,	  27112,	  and	  27188	  are	  heterozygous	  for	  the	  c.-­‐425C>G	  substitution,	  patients	  24165,	  27110,	  27116,	  and	  27735	  are	  homozygous.	  	  	  	  
   
  






Figure	  122	  Electropherograms	   from	  the	  LMO2	   sequence	  analysis	  showing	  SNP	  rs2038602.	  Six	  patients	  are	   heterozygous	   for	   the	   c.111T>C	   (p.I37I)	   substitution	   (22439,	   25160,	   25659,	   27111,	   27112,	   27188),	  four	  patients	  are	  homozygous	  (24165,	  27110,	  27116,	  27735).	  	  	  
  








Figure	  123	  LMO2	  electropherograms	  revealed	  patients	  22439,	  25160,	  25649,	  27111,	  27112,	  and	  27188	  harbor	  the	  SNP	  rs3740617	  in	  a	  heterozygous	  fashion,	  patients	  24536,	  27113,	  and	  28931	  are	  homozygous	  gor	  this	  c.363A>G	  (p.K121K)	  variation.	  








Figure	  124	  Electropherograms	  from	  the	  LMO2	  sequence	  analysis	  showed	  heterozygous	  occurence	  of	  SNP	  rs3740616	   in	   patients	   25649,	   27111,	   27112,	   and	   27116,	   while	   patient	   27110	   is	   homozygous	   for	   the	  c.*483A>T	  substitution.	  








Figure	  125	  Electropherograms	   from	   the	  SLC38A5	   sequence	   analysis	   showing	   SNP	   rs2293953.	   Patients	  22777,	   24165,	   27110,	   and	   28786	   are	   heterozygous,	   patient	   27188	   is	   hemizygous	   for	   the	   c.-­‐44T>C	  exchange.	  	  
  
	  
Figure	  126	  Electropherograms	  from	  the	  SLC38A5	  sequence	  analysis	  showing	  SNP	  rs17281188.	  Patients	  22777	  and	  28786	  are	  heterozygous	  for	  the	  c.1352T>C	  exchange.	  Numbers	  indicate	  position	  in	  exon	  16.	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